WO2011149492A1 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Google Patents

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Download PDF

Info

Publication number
WO2011149492A1
WO2011149492A1 PCT/US2010/057587 US2010057587W WO2011149492A1 WO 2011149492 A1 WO2011149492 A1 WO 2011149492A1 US 2010057587 W US2010057587 W US 2010057587W WO 2011149492 A1 WO2011149492 A1 WO 2011149492A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
methyl
pyrrolo
yloxy
piperazin
Prior art date
Application number
PCT/US2010/057587
Other languages
French (fr)
Inventor
Milan Bruncko
Hong Ding
George Doherty
Steven Elmore
Lisa Hasvold
Laura Hexamer
Aaron R. Kunzer
Xiaohong Song
Andrew J. Souers
Gerard Sullivan
Zhi-Fu Tao
Gary T. Wang
Le Wang
Xilu Wang
Michael Wendt
Robert Mantei
Todd M. Hansen
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43836533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011149492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ603463A priority Critical patent/NZ603463A/en
Priority to SI201031000T priority patent/SI2576546T1/en
Priority to CA2799280A priority patent/CA2799280A1/en
Priority to DK10784398.9T priority patent/DK2576546T3/en
Priority to AU2010354083A priority patent/AU2010354083B2/en
Priority to RU2012156844/04A priority patent/RU2554346C2/en
Priority to PL10784398T priority patent/PL2576546T3/en
Priority to MEP-2015-156A priority patent/ME02215B/en
Priority to UAA201214904A priority patent/UA107706C2/en
Priority to SG2012084745A priority patent/SG185638A1/en
Priority to BR112012029923A priority patent/BR112012029923A2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to ES10784398.9T priority patent/ES2546135T3/en
Priority to EP10784398.9A priority patent/EP2576546B1/en
Priority to KR1020127033726A priority patent/KR101725114B1/en
Priority to CN201080068177.5A priority patent/CN103153993B/en
Priority to RS20150643A priority patent/RS54289B1/en
Priority to JP2013512589A priority patent/JP5667695B2/en
Priority to MX2012013708A priority patent/MX350726B/en
Publication of WO2011149492A1 publication Critical patent/WO2011149492A1/en
Priority to IL223070A priority patent/IL223070A/en
Priority to ZA2012/08832A priority patent/ZA201208832B/en
Priority to HK13111276.7A priority patent/HK1183866A1/en
Priority to HRP20150925TT priority patent/HRP20150925T1/en
Priority to SM201600015T priority patent/SMT201600015B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention pertains to compounds which inhibit the activity of Bcl-2
  • anti-apoptotic proteins compositions containing the compounds, and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed.
  • Anti-apoptotic Bcl-2 proteins are associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins.
  • Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.
  • Bcl-2 proteins in bladder cancer brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/037911, published as WO 2005/049594.
  • a 1 is N or C(A 2 );
  • Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 , C(0)R 17 , C(0)OR 17 , SR 17 , S0 2 R 17 , NH 2 , NHR 17 , N(R 17 ) 2 , NHC(0)R 17 , C(0)NH 2 ,
  • E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSO Z NHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ OzNHR 1 , ⁇ 80 2 ⁇ ( ⁇ ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or A 2 and B 1 , together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ NHR 1 , NR 1 S0 2 N(R 1 ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ OzNHR 1 , ⁇ 80 2 ⁇ ( ⁇ ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
  • G 1 is H, or C(0)OR
  • R is alkyl
  • R 1 is R 2 , R 3 , R 4 or R 5 ;
  • R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
  • R 2 is phenyl, which is unfused or fused with R 2A ;
  • R 2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 3 is heteroaryl, which is unfused or fused with R 3A ;
  • R 3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 4A ;
  • R 4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0
  • R 6 is C 2 -C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N 3 , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
  • R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
  • R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
  • R 7 is R 8 , R 9 , R 10 or R u ;
  • R 8 is phenyl, which is unfused or fused with R 8A ;
  • R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 9 is heteroaryl, which is unfused or fused with R 9A ;
  • R 9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 10A ;
  • R 10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 , NHS(0) 2 R 12 , NR 12 S(0) 2 R 12 , NHC(0)OR 12 , NR 12 C(0)OR 12 , NHC(0)NH 2 , NHC(0)NHR 12 , NHC(0)N(R 12 ) 2 , NR 12 C(0)NHR 12 , NR 12 C(0)N(R 12 ) 2 , C(0)NH 2 , C(0)NHR 12 , C(0)N(R 12 ) 2 , C(0)NHOH, C(0)NHOR 12 , C(0)NHS0 2 R
  • R 12 is R 13 , R 14 , R 15 or R 16 ;
  • R 13 is phenyl, which is unfused or fused with R 13A ;
  • R 13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 14 is heteroaryl, which is unfused or fused with R 14A ;
  • R 14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R 15A ;
  • R 15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 16 is alkyl, alkenyl or alkynyl
  • R 17 is R 18 , R 19 , R 20 or R 21 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 19 is heteroaryl, which is unfused or fused with R 19A ;
  • R 19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R 20A ;
  • R 20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 ,
  • R 22 is R 23 , R 24 or R 25 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 24 is heteroarene, which is unfused or fused with R 24A ;
  • R 24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 25A ;
  • R 25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Z 2 is R 28 , R 29 or R 30 ;
  • Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
  • Z 12A is C 2 -C 6 -alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
  • L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
  • R 26 is phenylene, which is unfused or fused with R 26A ;
  • R 26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 27 is heteroarylene, which is unfused or fused with R 27A ;
  • R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 28 is phenylene, which is unfused or fused with R 28 A ;
  • R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 29 is heteroarylene, which is unfused or fused with R 29A ;
  • R 29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R 30A ;
  • R 30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 37 is a bond or R 37A
  • R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 , NHC(0)R 37B , NR 37B C(0)R 37B , NHS(0) 2 R 37B , NR 37B S(0) 2 R 37B , NHC(0)OR 37B ,
  • NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H, C(0)OH, C(N)NH 2 , C(N)NHR 37B , C(N)N(R 37B ) 2 , CNOH, CNOCH 3 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , N
  • R 37B is alkyl, alkenyl, alkynyl, or R 37C ;
  • R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
  • Z 3 is R 38 , R 39 or R 40 ;
  • R 38 is phenyl, which is unfused or fused with R 38A ;
  • R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene
  • R 39 is heteroaryl, which is unfused or fused with R 39A ;
  • R 39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 40A ;
  • R 40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 26 and R 27 are substituted (i.e., if Z 1A and Z 2A are absent) or further substituted (i.e., if Z 1A and Z 2A are present) with R 41 , OR 41 , SR 41 ,
  • C(0)NHOR 41 C(0)NHS0 2 R 41 , C(0)NR 41 S0 2 R 41 , S0 2 NHR 41 , S0 2 N(R 41 ) 2 , C(N)NHR 41 , or C(N)N(R 41 ) 2 ;
  • R 41 is heteroaryl, which is fused with R 43A ;
  • R 43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused or fused with benzene, heteroarene or R 43B ;
  • R 43B is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 ,and R 40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 , OC(0)R 57 , OC(0)OR 57 , NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , NHC(0)NH 2 , NHC(0)NHR 57 , NHC(0)N(R 57 ) 2 , NR 57 C(0)N(R 57 ) 2 , C(0)NH 2 , C(0)
  • R 57A is spiroalkyl, or spiroheteroalkyl
  • R 57 is R 58 , R 59 , R 60 or R 61 ;
  • R 58 is phenyl, which is unfused or fused with R 58A ;
  • R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 59 is heteroaryl, which is unfused or fused with R 59A ; R 59A
  • R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 60A ;
  • R 60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 , CO(0)R 62 , OC(0)R 62 , OC(0)OR 62 , NH 2 , NHR 62 , N(R 62 ) 2 , NHC(0)R 62 , NR 62 C(0)R 62 , NHS(0) 2 R 62 , NR 62 S(0) 2 R 62 , NHC(0)OR 62 , NR 62 C(0)OR 62 , NHC(0)NH 2 , NHC(0)NHR 62 , NHC(0)N(R 62 ) 2 , NR 62 C(0)N(R 62 ) 2 , C(0)NH 2 , C(0)NHR 62 , C(0)N(R 62 ) 2 , C(0)
  • R 62 is R 63 , R 64 , R 65 or R 66 ;
  • R 63 is phenyl, which is unfused or fused with R 63A ;
  • R 63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 64 is heteroaryl, which is unfused or fused with R 64A ;
  • R 64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R 65A ;
  • R 65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N(R 67 ) 2 , C(0)
  • RR 67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, ppihenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl
  • R , R , R , R , R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 , NR 68 C(0)OR 68 , NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 , NR b T(0)N(f 2 , C(0)NH 2 , C
  • R 68 is R 69 , R 70 , R 71 or R 72 ;
  • R 69 is phenyl, which is unfused or fused with R 69A ;
  • R 69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 70 is heteroaryl, which is unfused or fused with R 70A ;
  • R 70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 71A ;
  • R 71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 ,
  • R 73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
  • Another embodiment of this invention pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (II)
  • n 0, 1, 2, or 3;
  • a 1 is N or C(A 2 );
  • Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 ,
  • E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • N(CH 3 )S0 2 N(CH 3 )R 1 F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or A 2 and B 1 , together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ NHR 1 , NR 1 S0 2 N(R 1 ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ OzNHR 1 , ⁇ 80 2 ⁇ ( ⁇ ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
  • R 1 is R 2 , R 3 , R 4 or R 5 ;
  • R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
  • R 2 is phenyl, which is unfused or fused with R 2A ;
  • R 2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 3 is heteroaryl, which is unfused or fused with R 3A ;
  • R 3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 4A ;
  • R 4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R , NHC(0)OR / , SO2NH2, S0 2 NHR ⁇ S0 2 N(R') 2 , NHC(0)NH 2 , NHC(0)NHR , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 7 , OH, (O), C(0)OH, N 3 , CN,
  • R 6 is C 2 -C 5 -spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
  • R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
  • R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
  • R 7 is R 8 , R 9 , R 10 or R u ;
  • R 8 is phenyl, which is unfused or fused with R 8A ;
  • R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 9 is heteroaryl, which is unfused or fused with R 9A ;
  • R 9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 10A ;
  • R 10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 ,
  • R 12 is R 13 , R 14 , R 15 or R 16 ;
  • R 13 is phenyl, which is unfused or fused with R 13A ;
  • R 13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 14 is heteroaryl, which is unfused or fused with R 14A ;
  • R 14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R 15A ;
  • R 15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 16 is alkyl, alkenyl or alkynyl
  • R 17 is R 18 , R 19 , R 20 or R 21 ;
  • R 18 is phenyl, which is unfused or fused with R 18A ;
  • R 18 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 19 is heteroaryl, which is unfused or fused with R 19A ;
  • R 19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R 20A ;
  • R 20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 , NHS(0) 2 R 22 , NR 22 S(0) 2 R 22 , NHC(0)OR 22 , NR 22 C(0)OR 22 , NHC(0)NH 2 , NHC(0)NHR 22 , NHC(0)N(R 22 ) 2 , NR 22 C(0)NHR 22 , NR 22 C(0)N(R 22 ) 2 , C(0)NH 2 , C(0)NHR 22 , C(0)N(R 22 ) 2 , C(0)NHOH, C(0)NHOR 22 , C(0)NHS0 2 R
  • R 22 is R 23 , R 24 or R 25 ;
  • R 23 is phenyl, which is unfused or fused with R 23A ;
  • R 23A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 24 is heteroarene, which is unfused or fused with R 24A ;
  • R 24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 25A ;
  • R 25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Z 2 is R 28 , R 29 or R 30 ;
  • L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
  • R 28 is phenylene, which is unfused or fused with R 28 A ;
  • R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 29 is heteroarylene, which is unfused or fused with R 29A ;
  • R 29A is benzer
  • R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R 30A ;
  • R 30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 37 is a bond or R 37A
  • R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 ,
  • NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H,
  • R 37B is alkyl, alkenyl, alkynyl, or R 37C ;
  • R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
  • Z 3 is R 38 , R 39 or R 40 ;
  • R 38 is phenyl, which is unfused or fused with R 38A ;
  • R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 39 is heteroaryl, which is unfused or fused with R 39A ;
  • R 39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 40A ;
  • R 40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 ,and R 40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 , OC(0)R 57 , OC(0)OR 57 , NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , NHC(0)NH 2 , NHC(0)NHR 57 , NHC(0)N(R 57 ) 2 , NR 57 C(0)N(R 57 ) 2 , C(0)NH 2 , C(0)
  • R 57A is spiroalkyl or heterospiroalkyl
  • R 57 is R 58 , R 59 , R 60 or R 61 ;
  • R 58 is phenyl, which is unfused or fused with R 58A ;
  • R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 59 is heteroaryl, which is unfused or fused with R 59A ;
  • R 59A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 60A ;
  • R 60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 , CO(0)R 62 , OC(0)R 62 , OC(0)OR 62 , NH 2 , NHR 62 , N(R 62 ) 2 , NHC(0)R 62 , NR 62 C(0)R 62 ,
  • R 62 is R 63 , R 64 , R 65 or R 66 ;
  • R 63 is phenyl, which is unfused or fused with R 63A ;
  • R 63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 64 is heteroaryl, which is unfused or fused with R 64A ;
  • R 64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 65 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 65A ;
  • R 65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N(R 67 ) 2 , C(0)NH 2
  • R 67 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R 57A , R 58 , R 59 , R 60 , R 63 , R 64 , R 65 , and R 67 are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 , NR 68 C(0)OR 68 , NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 ,
  • R 68 is R 69 , R 70 , R 71 or R 72 ;
  • R 69 is phenyl, which is unfused or fused with R 69A ;
  • R 69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 70 is heteroaryl, which is unfused or fused with R 70A ;
  • R 70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 71A ;
  • R 71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 , NHS(0) 2 R 73 , NR 73 S(0) 2 R 73 , NHC(0)OR 73 , NR 73 C(0)OR 73 , NHC(0)NH 2 , NHC(0)NHR 73 , NHC(0)N(R 73 ) 2 , NR 73 C(0)NHR 73 , NR 73 C(0)N(R 73 ) 2 , C(0)NH 2 , C(0)NHR 73 , C(0)N
  • R 73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
  • Another embodiment pertains to compounds of Formula (I) wherein A 1 is N or C(A 2 ); A 2 is H; and G 1 is H.
  • Another embodiment pertains to compounds of Formula (I) wherein A 1 is N or C(A 2 );
  • a 2 is H; G 1 is H; and B 1 is NHR 1 .
  • a 1 is N or C(A 2 ); A 2 is H; G 1 is H; B 1 is NHR 1 ; and D 1 is H.
  • a 1 is N or C(A 2 ); A 2 is H; G 1 is H; B 1 is NHR 1 ; D 1 is H; and E 1 is H.
  • a 1 is N or C(A 2 ); A 2 is H; G 1 is H; B 1 is NHR 1 ; D 1 is H; E 1 is H; and Y 1 is N0 2 .
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-( ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ⁇ sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound Trans-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-( ⁇ 4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitrophenyl ⁇ sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound Cis-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-[(4- ⁇ [(4- methoxycyclohexyl)methyl] amino ⁇ -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound Trans-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-[(4- ⁇ [(4- methoxycyclohexyl)methyl] amino ⁇ -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-( ⁇ 4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy] -3 -nitrophenyl ⁇ sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N- [(4- ⁇ [(trans-4-hydroxy-4- methy Icy clohexyl)methyl] amino ⁇ -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-[(4- ⁇ [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino ⁇ -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound N-[(5-chloro-6- ⁇ [4-fluoro-l-(oxetan- 3-yl)piperidin-4-yl]methoxy ⁇ pyridin-3-yl)sulfonyl]-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound N-( ⁇ 5-bromo-6-[(l-tetrahydro-2H- pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl ⁇ sulfonyl)-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N-[(4- ⁇ [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino ⁇ -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-N- ⁇ [4-( ⁇ 3 -[cyclopropyl(oxetan-3 - yl)amino]propyl ⁇ amino)-3-nitrophenyl]sulfonyl ⁇ -2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-5-methoxy- 5-methylcyclohex- 1 -en-1 -yl]methyl ⁇ piperazin- 1 -yl)-N-( ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ⁇ sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 - yl)-N- [(4- ⁇ [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino ⁇ -3 -nitrophenyl)sulfonyl] -2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-[(4- ⁇ [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino ⁇ -3 -nitrophenyl)sulf
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(5 -chloro-6- ⁇ [ 1 -(cy anomethy l)piperidin-4-yl]methoxy ⁇ pyridin-3 -yl)sulfonyl] - 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl ⁇ piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 - yl)-N- [(4- ⁇ [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino ⁇ -3 -nitrophenyl)sulfonyl] -2-
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin-l -yl)-N- ⁇ [4-( ⁇ 3-[cyclopropyl(oxetan-3- yl)amino]propyl ⁇ amino)-3-nitrophenyl]sulfonyl ⁇ -2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 - yl)-N- ⁇ [3 -nitro-4-( ⁇ [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yljmethyl ⁇ amino)phenyl]sulfonyl ⁇ -2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 - yl)-N- ⁇ [3 -nitro-4-( ⁇ [(3R)- 1 -tetrahydro-2H-pyr
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 - yl)-N- [(3 -nitro-4- ⁇ [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino ⁇ phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
  • Another embodiment pertains to the compound N-[(5-chloro-6- ⁇ [l- (cyanomethyl)piperidin-4-yl]methoxy ⁇ pyridin-3-yl)sulfonyl]-4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(4- ⁇ [(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino ⁇ -3 - nitrophenyl)sulfonyl] -4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl ⁇ piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- ⁇ [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-( ⁇ 4-[(4- methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl ⁇ sulfonyl)-2-
  • Another embodiment pertains to the compound 4-(4- ⁇ [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl ⁇ piperazin- 1 -yl)-N-( ⁇ 4-[(4-methoxytetrahydro-2H-pyran- 4-yl)methoxy]-3-nitrophenyl ⁇ sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
  • Another embodiment pertains to a composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (I) or Formula (II).
  • Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or Formula (II).
  • Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I) or Formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
  • variable moiety herein may be the same or different as another specific embodiment having the same identifier.
  • alkenyl as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond.
  • C x -C y alkenyl means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond containing x to y carbon atoms.
  • C3-C6 alkenyl means an alkenyl group containing 3-6 carbon atoms.
  • alkenyl include, but are not limited to, buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkenylene means a divalent group derived from a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-carbon double bond.
  • C x -C y alkenylene means a divalent group derived from a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing x to y carbon atoms.
  • alkyl as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms.
  • Cx-C y alkyl means a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms.
  • Ci-C 6 alkyl means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n- hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylene means a divalent group derived from a straight or branched, saturated hydrocarbon chain of 1 to 10 carbon atoms, for example, of 1 to 4 carbon atoms.
  • Cx-C y alkylene means a divalent group derived from a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms.
  • C 2 -C 6 alkylene means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms.
  • alkylene examples include, but are not limited to, -CH 2 -, -CH 2 CH 2 -, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH 2 CH(CH 3 )CH 2 -.
  • alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • C x -C y alkynyl means a straight or branched chain hydrocarbon group containing from x to y carbon atoms.
  • C 3 -C 6 alkynyl means a straight or branched chain hydrocarbon group containing from 3 to 6 carbon atoms and containing at least one carbon- carbon triple bond.
  • Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • alkynylene means a divalent radical derived from a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • aryl as used herein, means phenyl.
  • cyclic moiety means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkylene, cycloalkene, cycloalkenyl, cycloalkenylene, cycloalkyne, cycloalkynyl, cycloalkynylene, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and spiroalkyl.
  • cycloalkylene or cycloalkyl or “cycloalkane” as used herein, means a monocyclic or bridged hydrocarbon ring system.
  • the monocyclic cycloalkyl is a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the monocyclic ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non- adjacent carbon atoms of the ring system. Representative examples of such bridged cycloalkyl ring systems include, but are not limited to, bicyclo[3.1.1]heptane,
  • the monocyclic and bridged cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system.
  • cycloalkenylene or "cycloalkenyl” or “cycloalkene” as used herein, means a monocyclic or a bridged hydrocarbon ring system.
  • the monocyclic cycloalkenyl has four to ten carbon atoms and zero heteroatoms.
  • the four-membered ring systems have one double bond, the five-or six-membered ring systems have one or two double bonds, the seven- or eight-membered ring systems have one, two, or three double bonds, and the nine- or ten-membered rings have one, two, three, or four double bonds.
  • monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • the monocyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
  • Representative examples of the bridged cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene.
  • cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
  • cycloalkyne or "cycloalkynyl,” or “cycloalkynylene,” as used herein, means a monocyclic or a bridged hydrocarbon ring system.
  • the monocyclic cycloalkynyl has eight or more carbon atoms, zero heteroatoms, and one or more triple bonds.
  • the monocyclic cycloalkynyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
  • the monocyclic and bridged cycloalkynyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
  • heteroaryl or “heteroarylene,” as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more than one independently selected nitrogen, oxygen or sulfur atom.
  • the heteroarenes of this invention are connected through any adjacent atoms in the ring, provided that proper valences are maintained.
  • heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-l-yl), isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g.
  • pyridin-4-yl pyridin-2-yl, pyridin-3-yl
  • pyridazinyl pyrimidinyl
  • pyrazinyl pyrazolyl
  • pyrrolyl tetrazolyl
  • thiadiazolyl 1,3-thiazolyl
  • thienyl including, but not limited thereto, thien-2-yl, thien-3-yl
  • triazolyl including, but not limited thereto, thien-2-yl, thien-3-yl
  • triazolyl triazinyl.
  • heterocycloalkane or “heterocycloalkyl,” or “heterocycloalkylene,” as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and zero double bonds.
  • heterocycloalkane are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings.
  • the nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized.
  • Representative examples of heterocycloalkane groups include, but are not limited to, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, dioxolanyl, tetrahydrofuranyl, thiomorpholinyl, 1 ,4-dioxanyl, tetrahydrothienyl,
  • tetrahydrothiopyranyl oxetanyl, piperazinyl, imidazolidinyl, azetidine, azepanyl, aziridinyl, diazepanyl, dithiolanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, oxadiazolidinyl, oxazolidinyl, pyrazolidinyl, tetrahydrothienyl, thiadiazolidinyl, thiazolidinyl,
  • heterocycloalkene or “heterocycloalkenyl,” or “heterocycloalkenylene,” as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and one or more double bonds.
  • the monocyclic and bridged heterocycloalkene are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings.
  • the nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized.
  • heterocycloalkene groups include, but are not limited to, 1,4,5,6-tetrahydropyridazinyl, 1,2,3,6-tetrahydropyridinyl, dihydropyranyl, imidazolinyl, isothiazolinyl, oxadiazolinyl, isoxazolinyl, oxazolinyl, pyranyl, pyrazolinyl, pyrrolinyl, thiadiazolinyl, thiazolinyl, and thiopyranyl.
  • phenyl as used herein, means a monovalent radical formed by removal of a hydrogen atom from benzene.
  • phenylene as used herein, means a divalent radical formed by removal of a hydrogen atom from phenyl.
  • spiroalkyl means alkylene, both ends of which are attached to the same carbon atom and is exemplified by C2-spiroalkyl, C3-spiroalkyl, C 4 -spiroalkyl, Cs-spiroalkyl, C6-spiroalkyl, C 7 -spiroalkyl, Cs-spiroalkyl, C9-spiroalkyl and the like.
  • spiroheteroalkyl means spiroalkyl having one or two CH 2 moieties replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties unreplaced or replaced with N.
  • spiroheteroalkenyl means spiroalkenyl having one or two CH 2 moieties replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties unreplaced or replaced with N and also means spiroalkenyl having one or two CH 2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH and one or two CH moieties replaced with N.
  • C2-C5-spiroalkyl means C 2 -spiroalkyl, C 3 -spiroalkyl, C 4 -spiroalkyl, and Cs-spiroalkyl.
  • C 2 -spiroalkyl means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
  • C 3 -spiroalkyl means prop-l,3-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
  • C 4 -spiroalkyl means but-l,4-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
  • Cs-spiroalkyl means pent-l,5-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
  • C6-spiroalkyl means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH 2 moiety.
  • NH protecting group means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl,
  • ortho-bromobenzyloxycarbonyl chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3 ,4-dimethoxybenzyl-oxycarbonyl,
  • C(0)OH protecting group means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para- methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro- ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl
  • OH or SH protecting group means benzyloxycarbonyl, 4- nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1 , 1 -dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl,
  • Geometric isomers may exist in the present compounds.
  • Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term “Z” represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules.
  • the compounds of this invention may also exist as a mixture of "E” and "Z” isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration.
  • the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system.
  • Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuration.
  • C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760 See C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.
  • Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R” and “S” are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10.
  • Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%.
  • this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers. Isotope Enriched or Labeled Compounds
  • Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature.
  • Isotopes can be radioactive or non- radioactive isotopes.
  • Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur,
  • fluorine, chlorine, and iodine include, but are not limited to, H, H, C, C, N, O, P,
  • the isotope-labeled compounds contain deuterium ( 2 H), tritium ( 3 H) or 14 C isotopes.
  • Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope- labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope- labeled reagent for a non-labeled reagent.
  • compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D 2 S0 4 /D 2 0.
  • a deuteric acid such as D 2 S0 4 /D 2 0.
  • the isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays.
  • Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)).
  • Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.,
  • non-radio active isotope containing drugs such as deuterated drugs called “heavy drugs”
  • Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment.
  • Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.
  • Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
  • Suitable groups for A 1 , B 1 , D 1 , E 1 , G 1 , Y 1 , L 1 , Z 1A , Z 2A , Z 1 , Z 2 , and Z 3 in compounds of Formula (I) are independently selected.
  • the described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention.
  • embodiments for any of A 1 , B 1 , D 1 , Z 2 , and Z 3 can be combined with embodiments defined for any other of A 1 , B 1 , D 1 , E 1 , G 1 , Y 1 , L 1 , Z 1A , Z 2A , Z 1 , Z 2 , and Z 3 .
  • One embodiment of this invention therefore, pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds havin Formula (I)
  • a 1 is N or C(A 2 );
  • Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 ,
  • E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and NHC(0)OR 1 , NR ⁇ CC OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , S0 2 N( 1 ) 2 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2, N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ OzNHR 1 , ⁇ 80 2 ⁇ ( ⁇ ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
  • G 1 is H, or C(0)OR
  • R is alkyl
  • R 1 is R 2 , R 3 , R 4 or R 5 ;
  • R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
  • R 2 is phenyl, which is unfused or fused with R 2A ;
  • R 2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 3 is heteroaryl, which is unfused or fused with R 3A ;
  • R 3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 4A ;
  • R 4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 7 , OH, (O), C(0)OH
  • R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
  • R 6C is aziridin- 1 -yl, azetidin- 1 -yl, pyrrolidin- 1 -yl or piperidin- 1 -yl, each having one
  • R 7 is R 8 , R 9 , R 10 or R u ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 9 is heteroaryl, which is unfused or fused with R 9A ;
  • R 9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 10A ;
  • R 10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 ,
  • R 12 is R 13 , R 14 , R 15 or R 16 ;
  • R 13 is phenyl, which is unfused or fused with R 13A ;
  • R 13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 14 is heteroaryl, which is unfused or fused with R 14A ;
  • R 14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R 15A ;
  • R 15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 16 is alkyl, alkenyl or alkynyl
  • R 17 is R 18 , R 19 , R 20 or R 21 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 19 is heteroaryl, which is unfused or fused with R 19A ;
  • R 19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R 20A ;
  • R 20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 , NHS(0) 2 R 22 , NR 22 S(0) 2 R 22 , NHC(0)OR 22 , NR 22 C(0)OR 22 , NHC(0)NH 2 , NHC(0)NHR 22 , NHC(0)N(R 22 ) 2 , NR 22 C(0)NHR 22 , NR 22 C(0)N(R 22 ) 2 , C(0)NH 2 , C(0)NHR 22 , C(0)N(R 22 ) 2 , C(0)NHOH, C(0)NHOR 22 , C(0)NHS0 2 R
  • R 22 is R 23 , R 24 or R 25 ;
  • R 23 is phenyl, which is unfused or fused with R 23A ;
  • R 23A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 24 is heteroarene, which is unfused or fused with R 24A ;
  • R 24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 25A ;
  • R 25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Z 2 is R 28 , R 29 or R 30 ;
  • Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
  • Z 12A is C 2 -C 6 -alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
  • L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
  • R 26 is phenylene, which is unfused or fused with R 26A ;
  • R 26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 27 is heteroarylene, which is unfused or fused with R 27A ;
  • R 27A is benzer
  • R 28 is phenylene, which is unfused or fused with R 28 A ;
  • R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 29 is heteroarylene, which is unfused or fused with R 29A ;
  • R 29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R 30A ;
  • R 30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 37 is a bond or R 37A
  • R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 ,
  • NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H,
  • R 37B is alkyl, alkenyl, alkynyl, or R 37C ;
  • R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
  • Z 3 is R 38 , R 39 or R 40 ;
  • R 38 is phenyl, which is unfused or fused with R 38A ;
  • R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 39 is heteroaryl, which is unfused or fused with R 39A ;
  • R 39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfus seedd oorr f fuusseedd wwiitthh RR 40A ;; RR 40A iiss bbee:nzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 26 and R 27 are substituted (i.e., if Z 1A and Z 2A are absent) or further substituted (i.e., if Z 1A and Z 2A are present) with R 41 , OR 41 , SR 41 ,
  • R 41 is heteroaryl, which is fused with R 43A ;
  • R 43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused or fused with
  • R 43B is cycloalkane, cycloalkene, heterocycloalkane or
  • R 40 ,and R 40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 , OC(0)R 57 , OC(0)OR 57 , NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , 5 NHC(0)NH 2 , NHC(0)NHR 57 , NHC(0)N(R 57 ) 2 , NR 57 C(0)NHR 57 , NR 57 C(0)N(R 57 ) 2 ,
  • R 57A is spiroalkyl, or spiroheteroalkyl
  • R 57 is R 58 , R 59 , R 60 or R 61 ;
  • R 58 is phenyl, which is unfused or fused with R 58A ;
  • R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 59 is heteroaryl, which is unfused or fused with R 59A ;
  • R 59A is benzene, heteroarene,5 cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 60A ;
  • R 60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one0 or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 ,
  • R 62 is R 63 , R 64 , R 65 or R 66 ;
  • R 63 is phenyl, which is unfused or fused with R 63A ;
  • R 63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 64 is heteroaryl, which is unfused or fused with R 64A ;
  • R 64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 65 is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R 65A ;
  • R 65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N(R 67 ) 2 , C(0)
  • RR 67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, pphi enyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R 57A , R 58 , R 59 , R 60 , R 63 , R M , R M , and R' are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 , NR 68 C(0)OR 68 , NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 ,
  • R 68 is R 69 , R 70 , R 71 or R 72 ;
  • R 69 is phenyl, which is unfused or fused with R 69A ;
  • R 69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 70 is heteroaryl, which is unfused or fused with R 70A ;
  • R 70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene
  • R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 71A ;
  • R 71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 , NHS(0) 2 R 73 , NR 73 S(0) 2 R 73 , NHC(0)OR 73 , NR 73 C(0)OR 73 , NHC(0)NH 2 , NHC(0)NHR 73 , NHC(0)N(R 73 ) 2 , NR 73 C(0)NHR 73 , NR 73 C(0)N(R 73 ) 2 , C(0)NH 2 , C(0)NHR 73 , C(0)N
  • R 73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
  • Another embodiment of this invention pertains to compounds of Formula (I), wherein
  • a 1 is N or C(A 2 );
  • Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 ,
  • E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , C(NH)N(R 1 ) 2 NHS0 2 NHR 1 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ OzNHR 1 , NR ⁇ OzNiR ⁇ z, C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
  • G 1 is H, or C(0)OR
  • R is alkyl
  • R 1 is R 2 , R 3 , R 4 or R 5 ;
  • R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
  • R 2 is phenyl, which is unfused or fused with R 2A ;
  • R 2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 3 is heteroaryl, which is unfused or fused with R 3A ;
  • R 3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 4A ;
  • R 4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 7 , OH, (O), C(0)OH
  • R 6 is C 2 -C 5 -spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N , CN, CF 3 , CF 2 CF 3 , F, CI, Br, I, NH 2 , NH(CH 3 ) or N(CH 3 ) 2 ;
  • R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
  • R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
  • R 7 is R 8 , R 9 , R 10 or R u ;
  • R 8 is phenyl, which is unfused or fused with R 8A ;
  • R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 9 is heteroaryl, which is unfused or fused with R 9A ;
  • R 9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 10A ;
  • R 10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 , NHS(0) 2 R 12 , NR 12 S(0) 2 R 12 , NHC(0)OR 12 , NR 12 C(0)OR 12 , NHC(0)NH 2 , NHC(0)NHR 12 , NHC(0)N(R 12 ) 2 , NR 12 C(0)NHR 12 , NR 12 C(0)N(R 12 ) 2 , C(0)NH 2 , C(0)NHR 12 , C(0)N(R 12 ) 2 , C(0)NHOH, C(0)NHOR 12 , C(0)NHS0 2 R
  • R 12 is R 13 , R 14 , R 15 or R 16 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 14 is heteroaryl, which is unfused or fused with R 14A ;
  • R 14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R 15A ;
  • R 15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 16 is alkyl, alkenyl or alkynyl
  • R 17 is R 18 , R 19 , R 20 or R 21 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 19 is heteroaryl, which is unfused or fused with R 19A ;
  • R 19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R 20A ;
  • R 20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 , NHS(0) 2 R 22 , NR 22 S(0) 2 R 22 , NHC(0)OR 22 , NR 22 C(0)OR 22 , NHC(0)NH 2 , NHC(0)NHR 22 , NHC(0)N(R 22 ) 2 , NR 22 C(0)NHR 22 , NR 22 C(0)N(R 22 ) 2 , C(0)NH 2 , C(0)NHR 22 , C(0)N(R 22 ) 2 , C(0)NHOH, C(0)NHOR 22 , C(0)NHS0 2 R
  • R 22 is R 23 , R 24 or R 25 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 24 is heteroarene, which is unfused or fused with R 24A ;
  • R 24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 25A ;
  • R 25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Z 2 is R 28 , R 29 or R 30 ; Z and Z are both absent or are taken together to form C3 ⁇ 4, CH 2 CH 2 or Z ; Z 12A is C 2 -C 6 -alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
  • L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,
  • R 26 is phenylene, which is unfused or fused with R 26A ;
  • R 26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 27 is heteroarylene, which is unfused or fused with R 27A ;
  • R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 28 is phenylene, which is unfused or fused with R 28 A ;
  • R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 29 is heteroarylene, which is unfused or fused with R 29A ;
  • R 29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R 30A ;
  • R 30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 37 is a bond or R 37A
  • R 37A is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R 37B , S0 2 R 37B , C(0)R 37B , CO(0)R 37B , OC(0)R 37B , OC(0)OR 37B , NH 2 , NHR 37B , N(R 37B ) 2 , NHC(0)R 37B , NR 37B C(0)R 37B , NHS(0) 2 R 37B , NR 37B S(0) 2 R 37B , NHC(0)OR 37B ,
  • NR 37B C(0)OR 37B NHC(0)NH 2 , NHC(0)NHR 37B , NHC(0)N(R 37B ) 2 , NR 37B C(0)NHR 37B , NR 37B C(0)N(R 37B ) 2 , C(0)NH 2 , C(0)NHR 37B , C(0)N(R 37B ) 2 , C(0)NHOH, C(0)NHOR 37B , C(0)NHS0 2 R 37B , C(0)NR 37B S0 2 R 37B , S0 2 NH 2 , S0 2 NHR 37B , S0 2 N(R 37B ) 2 , C(0)H,
  • R 37B is alkyl, alkenyl, alkynyl, or R 37C ;
  • R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
  • Z 3 is R 38 , R 39 or R 40 ;
  • R 38 is phenyl, which is unfused or fused with R 38A ;
  • R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 39 is heteroaryl, which is unfused or fused with R 39A ;
  • R 39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfus seedd oorr f fuusseedd wwiitthh RR 40A ;; RR 40A iiss bbeenrzene, heteroarene, cycloalkane, cycloalkene heterocycloalkane or heterocycloalkene;
  • R 26 and R 27 are substituted (i.e., if Z 1A and Z 2A are absent) or further substituted (i.e., if Z 1A and Z 2A are present) with R 41 , OR 41 , SR 41 , S(0)R 41 , S0 2 R 41 , C(0)R 41 , CO(0)R 41 , OC(0)R 41 , OC(0)OR 41 , NHR 41 , N(R 41 ) 2 , NHC(0)R 41 , NR 41 C(0)R 41 , NHS(0) 2 R 41 , NR 41 S(0) 2 R 41 , NHC(0)OR 41 , NR 41 C(0)OR 41 , NHC(0)NHR 41 , NHC(0)N(R 41 ) 2 , NR 41 C(0)N(R 41 ) 2 , NR 41 C(0)N(R 41 ) 2 , C(0)NHR 41 , C(0)N(R 41 ) 2 , C(0)N(R 41 ) 2 ,
  • C(0)NHOR 41 C(0)NHS0 2 R 41 , C(0)NR 41 S0 2 R 41 , S0 2 NHR 41 , S0 2 N(R 41 ) 2 , C(N)NHR 41 , or C(N)N(R 41 ) 2 ;
  • R 41 is heteroaryl, which is fused with R 43A ;
  • R 43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused;
  • R 40 ,and R 40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R 57A , R 57 , OR 57 , SR 57 , S(0)R 57 , S0 2 R 57 , C(0)R 57 , CO(0)R 57 , OC(0)R 57 , OC(0)OR 57 , NH 2 , NHR 57 , N(R 57 ) 2 , NHC(0)R 57 , NR 57 C(0)R 57 , NHS(0) 2 R 57 , NR 57 S(0) 2 R 57 , NHC(0)OR 57 , NR 57 C(0)OR 57 , NHC(0)NH 2 , NHC(0)NHR 57 , NHC(0)N(R 57 ) 2 , NR 57 C(0)N(R 57 ) 2 , C(0)NH 2 , C(0)
  • R 57A is spiroalkyl, or spiroheteroalkyl
  • R 57 is R 58 , R 59 , R 60 or R 61 ;
  • R 58 is phenyl, which is unfused or fused with R 58A ;
  • R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 59 is heteroaryl, which is unfused or fused with R 59A ; R 59A
  • R 60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 60A ;
  • R 60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 62 , OR 62 , SR 62 , S(0)R 62 , S0 2 R 62 , C(0)R 62 , CO(0)R 62 , OC(0)R 62 , OC(0)OR 62 , NH 2 , NHR 62 , N(R 62 ) 2 , NHC(0)R 62 , NR 62 C(0)R 62 , NHS(0) 2 R 62 , NR 62 S(0) 2 R 62 , NHC(0)OR 62 , NR 62 C(0)OR 62 , NHC(0)NH 2 , NHC(0)NHR 62 , NHC(0)N(R 62 ) 2 , NR 62 C(0)N(R 62 ) 2 , C(0)NH 2 , C(0)NHR 62 , C(0)N(R 62 ) 2 , C(0)
  • R 62 is R 63 , R 64 , R 65 or R 66 ;
  • R 63 is phenyl, which is unfused or fused with R 63A ;
  • R 63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 64 is heteroaryl, which is unfused or fused with R 64A ;
  • R 64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 65A ;
  • R 65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 67 , OR 67 , SR 67 , S(0)R 67 , S0 2 R 67 , C(0)R 67 , CO(0)R 67 , OC(0)R 67 , OC(0)OR 67 , NH 2 , NHR 67 , N(R 67 ) 2 , NHC(0)R 67 , NR 67 C(0)R 67 , NHS(0) 2 R 67 , NR 67 S(0) 2 R 67 , NHC(0)OR 67 , NR 67 C(0)OR 67 , NHC(0)NH 2 , NHC(0)NHR 67 , NHC(0)N(R 67 ) 2 , NR 67 C(0)N(R 67 ) 2 , C(0)NH 2 , C(0)NHR 67 , C(0)N(R 67 ) 2 , C(0)
  • RR 67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, ppihenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl
  • R , R , R , R , R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected R 68 , OR 68 , SR 68 , S(0)R 68 , S0 2 R 68 , C(0)R 68 , CO(0)R 68 , OC(0)R 68 , OC(0)OR 68 , NH 2 , NHR 68 , N(R 68 ) 2 , NHC(0)R 68 , NR 68 C(0)R 68 , NHS(0) 2 R 68 , NR 68 S(0) 2 R 68 , NHC(0)OR 68 , NR 68 C(0)OR 68 , NHC(0)NH 2 , NHC(0)NHR 68 , NHC(0)N(R 68 ) 2 , NR 68 C(0)NHR 68 , NR b T(0)N(f 2 , C(0)NH 2 , C
  • R 68 is R 69 , R 70 , R 71 or R 72 ;
  • R 69 is phenyl, which is unfused or fused with R 69A ;
  • R 69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 70 is heteroaryl, which is unfused or fused with R 70A ;
  • R 70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 71A ;
  • R 71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 73 , OR 73 , SR 73 , S(0)R 73 , S0 2 R 73 , C(0)R 73 , CO(0)R 73 , OC(0)R 73 , OC(0)OR 73 , NH 2 , NHR 73 , N(R 73 ) 2 , NHC(0)R 73 , NR 73 C(0)R 73 ,
  • R 73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
  • R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH 2 , C(0)NH 2 , C(0)NHOH, S0 2 NH 2 , CF 3 , CF 2 CF 3 , C(0)H, C(0)OH, C(N)NH 2 , OH, (O), CN, N 3 , N0 2 , CF 3 , CF 2 CF 3 , OCF 3 , OCF 2 CF 3 , F, CI, Br or I.
  • Another embodiment of this invention pertains to compounds of Formula (I), wherein
  • a 1 is N or C(A 2 );
  • Y 1 is H, CN, N0 2 , C(0)OH, F, CI, Br, I, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , R 17 , OR 17 , C(0)R 17 , C(0)OR 17 , SR 17 , S0 2 R 17 , NH 2 , NHR 17 , N(R 17 ) 2 , NHC(0)R 17 , C(0)NH 2 ,
  • E 1 and Y 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Y 1 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ; or
  • a 2 and B 1 together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 ,
  • a 2 and D 1 together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • NHC(0)OR 1 NR 1 C(0)OR 1 , NHC(0)NH 2 , NHC(0)NHR 1 , NHC(0)N(R 1 ) 2 , NR 1 C(0)NHR 1 , NR 1 C(0)N(R 1 ) 2 , S0 2 NH 2 , SOzNHR 1 , NHSOzNHR 1 , NHS0 2 N(R 1 ) 2 , NR ⁇ NHR 1 , NR 1 S0 2 N(R 1 ) 2 , C(0)NHNOH, C(0)NHNOR 1 ,
  • C(0)NHS0 2 R 1 C(NH)NH 2 , NHS0 2 N(CH 3 )R 1 , N(CH 3 )S0 2 N(CH 3 )R 1 , F, CI, Br, I, CN, N0 2 N 3 , OH, C(0)H, CHNOH, CH(NOCH 3 ), CF 3 , C(0)OH, C(0)NH 2 or C(0)OR 1A ;
  • G 1 is H, or C(0)OR
  • R is alkyl
  • R 1 is R 2 , R 3 , R 4 or R 5 ;
  • R 1A is cycloalkyl, cycloalkenyl or cycloalkynyl
  • R 2 is phenyl, which is unfused or fused with R 2A ;
  • R 2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 3 is heteroaryl, which is unfused or fused with R 3A ;
  • R 3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 4A ;
  • R 4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 6 , NC(R 6A )(R 6B ), R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , NHR 7 , N(R 7 ) 2 , C(0)R 7 , C(0)NH 2 , C(0)NHR 7 , C(0)N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS0 2 R 7 , NHC(0)OR 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , NHC(0)NH 2 , NHC(0)NHR 7 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NH 2 , NHC(0)CH(CH 3 )NHC(0)CH(CH 3 )NHR 7 , OH, (O), C(0)OH
  • R 6 is C 2 -C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N 3 ,
  • R 6A and R 6B are independently selected alkyl or, together with the N to which they are attached, R 6C ;
  • R 6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH 2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH 3 , S, S(O), S0 2 or NH;
  • R 7 is R 8 , R 9 , R 10 or R u ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 9 is heteroaryl, which is unfused or fused with R 9A ;
  • R 9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 10A ;
  • R 10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 12 , OR 12 , SR 12 , S(0)R 12 , S0 2 R 12 , C(0)R 12 , CO(0)R 12 , OC(0)R 12 , OC(0)OR 12 , NH 2 , NHR 12 , N(R 12 ) 2 , NHC(0)R 12 , NR 12 C(0)R 12 , NHS(0) 2 R 12 , NR 12 S(0) 2 R 12 , NHC(0)OR 12 , NR 12 C(0)OR 12
  • R 12 is R 13 , R 14 , R 15 or R 16 ;
  • R 13 is phenyl, which is unfused or fused with R 13A ;
  • R 13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 14 is heteroaryl, which is unfused or fused with R 14A ;
  • R 14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R 15A ;
  • R 15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 16 is alkyl, alkenyl or alkynyl
  • R 17 is R 18 , R 19 , R 20 or R 21 ;
  • R 18 is phenyl, which is unfused or fused with R 18A ;
  • R 18 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 19 is heteroaryl, which is unfused or fused with R 19A ;
  • R 19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R 20A ;
  • R 20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R 22 , OR 22 , SR 22 , S(0)R 22 , S0 2 R 22 , C(0)R 22 , CO(0)R 22 , OC(0)R 22 , OC(0)OR 22 , NH 2 , NHR 22 , N(R 22 ) 2 , NHC(0)R 22 , NR 22 C(0)R 22 , NHS(0) 2 R 22 , NR 22 S(0) 2 R 22 , NHC(0)OR 22 , NR 22 C(0)OR 22 , NHC(0)NH 2 , NHC(0)NHR 22 , NHC(0)N(R 22 ) 2 , NR 22 C(0)NHR 22 , NR 22 C(0)N(R 22 ) 2 , C(0)NH 2 , C(0)NHR 22 , C(0)N(R 22 ) 2 , C(0)NHOH, C(0)NHOR 22 , C(0)NHS0 2 R
  • R 22 is R 23 , R 24 or R 25 ;
  • R is phenyl, which is unfused or fused with R ;
  • R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 24 is heteroarene, which is unfused or fused with R 24A ;
  • R 24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • R 25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R 25A ;
  • R 25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
  • Z 2 is R 28 , R 29 or R 30 ;
  • Z 1A and Z 2A are both absent or are taken together to form CH 2 , CH 2 CH 2 or Z 12A ;
  • Z 12A is C 2 -C6-alkylene having one or two CH 2 moieties replaced by NH, N(CH 3 ), S, S(O) or S0 2 ;
  • L 1 is a R 37 , OR 37 , SR 37 , S(0)R 37 , S0 2 R 37 , C(0)R 37 , CO(0)R 37 , OC(0)R 37 ,

Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Description

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND
IMMUNE AND AUTOIMMUNE DISEASES
This application is a continuation-in-part of U.S. Patent Application Serial No.
12/787,682, filed May 26, 2010, which claims priority to United States Provisional
Application Serial No. 61/181,203 filed May 26, 2009, both of which are incorporated by reference in their entirety.
FIELD OF THE INVENTION
This invention pertains to compounds which inhibit the activity of Bcl-2
anti-apoptotic proteins, compositions containing the compounds, and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed.
BACKGROUND OF THE INVENTION
Anti-apoptotic Bcl-2 proteins are associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins.
Overexpression of Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.
Involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/037911, published as WO 2005/049594.
Involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. Involvement of Bcl-2 proteins in arthritis is disclosed in commonly- owned United States Provisional Patent Application Serial No. 60/988,479. Involvement of Bcl-2 proteins in bone marrow transplant rejection is disclosed in commonly-owned United States Patent Application Serial No. 11/941,196. SUMMARY OF THE INVENTION
One embodiment of this invention, therefore, pertains to compounds or
therapeutically acceptable salts, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds havin Formula (I)
Figure imgf000003_0001
(I),
wherein
A1 is N or C(A2);
NHR1, N(R1)2,
Figure imgf000003_0002
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000003_0003
C(NH)N(R1)2
Figure imgf000003_0004
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000003_0005
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000003_0006
C(NH)N(R1)2
Figure imgf000003_0007
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000003_0008
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000003_0009
C(NH)N(R1)2
Figure imgf000003_0010
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; NHR1, N(R1)2,
Figure imgf000004_0001
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000004_0002
C(NH)N(R1)2
Figure imgf000004_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2,
C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
)R1,
Figure imgf000004_0004
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000004_0005
NHSOZNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000004_0006
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000004_0007
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^, NHSOzR1, NR^OzR1, NHSOzNHR1, NHS02N(R1)2, NR^O^HR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000004_0008
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000005_0001
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000005_0002
NHSOzNHR1, NHS02N(R1)2, NR^NHR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000005_0003
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000005_0004
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000005_0005
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000005_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2, NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
R 8 is phenyl, which is unfused or fused with R 8A ; R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12, NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR12, NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
18 18A 18 A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22,
NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22, NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
23 23A 23A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
z s R26 or R27;
Z2 is R28, R29 or R30;
Z1A and Z2A are both absent or are taken together to form CH2, CH2CH2 or Z12A; Z12A is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(O) or S02; L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37,
OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH,
S02NHR37, C(N)NH, or C(N)NHR37;
R26 is phenylene, which is unfused or fused with R26A; R26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 27 is heteroarylene, which is unfused or fused with R 27A ; R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2, NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B, NHC(0)OR37B,
NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl;
Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene
R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R40A; R40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the moieties represented by R26 and R27 are substituted (i.e., if Z1A and Z2A are absent) or further substituted (i.e., if Z1A and Z2A are present) with R41, OR41 , SR41,
S(0)R41, S02R41, C(0)R41, CO(0)R41, OC(0)R41, OC(0)OR41, NHR41, N(R41)2, NHC(0)R41, NR41C(0)R41, NHS(0)2R41, NR41S(0)2R41, NHC(0)OR41, NR41C(0)OR41, NHC(0)NHR41, NHC(0)N(R41)2, NR41C(0)NHR41, NR41C(0)N(R41)2, C(0)NHR41, C(0)N(R41)2,
C(0)NHOR41, C(0)NHS02R41, C(0)NR41S02R41, S02NHR41, S02N(R41)2, C(N)NHR41, or C(N)N(R41)2;
R41 is heteroaryl, which is fused with R43A; R43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused or fused with benzene, heteroarene or R43B; R43B is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A,
Tj lO D 10A D 13 D 13A D 14 D 14A D 1 5 D 15A D 18 D 18A D 19 D 19A Ό 20 D 20A D 23 D 23A D 24 D 24A , , , , , , , , , , , , , , , , , ,
D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A D 30 D 30A D 37B D 38 D 38A D 39 D 39A
, , , , , , , , , , , , , , , , ,
R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57, NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57,
C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2,
C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI , Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A
cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62, NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62, NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67, NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67,
S02N(R67)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH,
(O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents
RR67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, ppihenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl
wherein the cyclic moieties represented by R , R , R , R , R , R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68, NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2, NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68, NRbT(0)N(f 2, C(0)NH2, C(0)NHR , C(0)N(Rb8)2, C(0)NHOH, C(0)NHOR , C(0)NHS02R68, C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73,
NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73, NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
Another embodiment of this invention pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (II)
Figure imgf000012_0001
(Π),
or a therapeutically acceptable salt thereof, wherein
R is as described for substituents on
n is 0, 1, 2, or 3;
A1 is N or C(A2);
NHR1, N(R1)2,
Figure imgf000012_0002
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000012_0003
C(NH)N(R1)2
Figure imgf000012_0004
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
R1, N(R1)2,
Figure imgf000012_0005
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000012_0006
C(NH)N(R1)2
Figure imgf000012_0007
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000012_0008
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000012_0009
C(NH)N( 1)2 NHSO2NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000013_0001
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000013_0002
C(NH)N(R1)2
Figure imgf000013_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17,
C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2,
C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000013_0004
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000013_0005
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000013_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000013_0007
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000013_0008
NHSOZNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000013_0009
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000014_0001
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000014_0002
NHSOzNHR1, NHS02N(R1)2, NR^NHR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000014_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000014_0004
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000014_0005
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000014_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2, NHC(0)R7, NR7C(0)R7, NHS02R , NHC(0)OR/, SO2NH2, S02NHR\ S02N(R')2, NHC(0)NH2, NHC(0)NHR , NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N , CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
R 8 is phenyl, which is unfused or fused with R 8A ; R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12,
NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR12, NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl; R17 is R18, R19, R20 or R21;
R 18 is phenyl, which is unfused or fused with R 18A ; R 18 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22, NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
R 23 is phenyl, which is unfused or fused with R 23A ; R 23A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
Z2 is R28, R29 or R30;
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37,
OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH,
S02NHR37, C(N)NH, or C(N)NHR37;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzer
heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2,
NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B, NHC(0)OR37B,
NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H,
C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl;
Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R40A; R40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A,
Tj lO D 10A D 13 D 13A D 14 D 14A D 15 D 15A D 18 D 18A D 19 D 19A D 20 D 20A D 23 D 23A D 24 D 24A , , , , , , , , , , , , , , , , , ,
D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A D 30 D 30A D 37B D 38 D 38A D 39 D 39A
, , , , , , , , , , , , , , , , ,
R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57, NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57, C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2,
C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R57A is spiroalkyl or heterospiroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62,
NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62, NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R65 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67, NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67, S02N(Rb /)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR , C(N)N(Rb /)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents;
R67 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
wherein the cyclic moieties represented by R57A, R58, R59, R60, R63, R64, R65, and R67 are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68, NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2, NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68,
NR68C(0)N(R68)2, C(0)NH2, C(0)NHR68, C(0)N(R68)2, C(0)NHOH, C(0)NHOR68,
C(0)NHS02R68, C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73, NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73, NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
Another embodiment pertains to compounds of Formula (I) wherein A1 is N or C(A2); A2 is H; and G1 is H.
Another embodiment pertains to compounds of Formula (I) wherein A1 is N or C(A2);
A2 is H; G1 is H; and B1 is NHR1.
Another embodiment pertains to compounds of Formula (I) wherein A1 is N or C(A2); A2 is H; G1 is H; B1 is NHR1; and D1 is H.
Another embodiment pertains to compounds of Formula (I) wherein A1 is N or C(A2); A2 is H; G1 is H; B1 is NHR1; D1 is H; and E1 is H.
Another embodiment pertains to compounds of Formula (I) wherein A1 is N or C(A2); A2 is H; G1 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({4-[(3-morpholin-4- ylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-(2- naphthylsulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl} piperazin- 1 -yl)-N- { [3 - nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-({3- nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-
N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N- { [3 -(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - (trifluoromethyl)phenyl]sulfonyl}benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-
N-( {4- [( 1 -methylpiperidin-4-yl)amino] -3 -[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
5-({[4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfony l)-2-(tetrahydro-2H-pyran-4- y lmethoxy Nicotinamide ;
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [2-(2-methoxyethoxy)ethy 1] sulfonyl} -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyri yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dm^
yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- {[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (morpholin-3 -ylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(methylsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1 -yljmethyl} piperazin- 1 -y l)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yl
oxy)benzamide;
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -morpholin-4-ylcyclohexyl)methy 1] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3 -yl)methoxy]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(4-tetrahydro-2H-pyran-4-ylmorpholin-3-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidothiomorpholin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,3S)-3-morpholin-4-ylcyclopentyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(tetrahydrofuran-3 -ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[cis-3-fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydrofuran-3 -ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(cyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoropiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl]amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2-methoxyethyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethoxy} -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclobutylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydrofuran-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yljmethyl } amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxy-2,2-dimethylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpiperidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(l-acetylpyrrolidin-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyljsulfonyl } -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3 S)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} methyl)amino]-3 -nitropheny 1} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitropheny l)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-oxetan-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3-nitrophenyl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
(l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3S)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({ [cis-3 -morpholin-4-ylcyclopentyl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {4- [(methylsulfonyl)amino] cyclohexyl } amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -cyclopropylpiperidin-4-yl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-oxetan-3-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(Z)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({4-[(lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methyl-5 -oxopyrrolidin-3 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2 ]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2 ]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3-dien-l-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl} pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2-y^
b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2 b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-l- carboxylate;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4- (morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyr
yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3-
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -isopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {[1 -(cyanomethyl)piperidin-3-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(5 -chloro-6- { [(3R)- 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yl] amino } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro- 6-sulfanyl)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- (lH-pyrrolo[2,3-£]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l ,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(oxetan-3 -yl)piperazin- 1 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[4-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(3R)-tetrahydrofuran-3 -ylamino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4,4-difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-( {4- [( 1 -tert-butylpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]pheny 1} sulfony l)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)m
{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(oxetan-3 -yl)azetidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4 (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4-fluoro-l-methylpiperi
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-( {3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- (trifluoromethyl)phenyl}sulfonyl)benzamide;
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-( {3-chloro-4-[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6-
{ [ 1 -( 1 ,3 -difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy } -5 -(trifluoromethyl)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3-methylpiperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3 -yl] sulfonyl} benzamide;
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperidin- 1 -yl)-N- { [3 - chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcy clohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate;
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)amino]methyl} -N- ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3 - nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-[(3-chloro-4- {[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( lH-pyrrolo [2,3 - £]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4- {[9-(4- chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N- {[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3- yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide;
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
N- [(5 -chloro-6- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin-
2-yl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljniethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcycloliex- 1 -en- 1 -yljniethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -bis(fluoromethyl)cyclohex- 1 -en- 1 -yljniethyl} piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6- [(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] ( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl} sulfonyl)amino} methyl pivalate;
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] ( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl} sulfonyl)amino} methyl butyrate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}cyclohexanecarboxylate;
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylic acid;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide;
N-({5-chloro-6-[(2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine- 1-carboxamide;
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 - b]pyridin-5-yl]sulfonyl}benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 -b]pyridin-5 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} phenyl)- 4-methoxypiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-cyanopiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-hydroxy-4-methylpiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(methoxymethyl)piperidine- 1 -carboxamide;
N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(morpholin-4-yl)piperidine- 1 -carboxamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(5-chloro-6-{[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)cyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-chlorophenyl)-l-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)carbamoyl] -3 -( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)phenyl} piperazin- 1 -yl)methyl] cyclohex-3 -ene- 1 -carboxylic acid;
N- [(5 -chloro-6- {[l-(oxetan-3 -yl)piperidin-4-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-
¾]pyridin-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound Cis-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof. Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound N-[(5-chloro-6-{[4-fluoro-l-(oxetan- 3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound N-({5-bromo-6-[(l-tetrahydro-2H- pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [4-( {3 -[cyclopropyl(oxetan-3 - yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-5-methoxy- 5-methylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N- { [4-( {3 - [cy clopropyl(oxetan-3 -yl)amino]propyl} amino)-3 - nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a
pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(5 -chloro-6- { [ 1 -(cy anomethy l)piperidin-4-yl]methoxy } pyridin-3 -yl)sulfonyl] - 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-
(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-N- {[4-( {3-[cyclopropyl(oxetan-3- yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- { [3 -nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yljmethyl} amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-
{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(4- methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-
5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof. Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(3 -nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{ [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound N-[(5-chloro-6-{[l- (cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino } -3 - nitrophenyl)sulfonyl] -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4- methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-methoxytetrahydro-2H-pyran- 4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to a composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (I) or Formula (II).
Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or Formula (II).
Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I) or Formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
DETAILED DESCRIPTION OF THE INVENTION
Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
It is meant to be understood that proper valences are maintained for all moieties and combinations thereof, that monovalent moieties having more than one atom are drawn from left to right and are attached through their left ends, and that divalent moieties are also drawn from left to right.
It is also meant to be understood that a specific embodiment of a variable moiety herein may be the same or different as another specific embodiment having the same identifier.
The term "alkenyl" as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond. The term "Cx-Cy alkenyl" means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond containing x to y carbon atoms. The term "C3-C6 alkenyl" means an alkenyl group containing 3-6 carbon atoms. Representative examples of alkenyl include, but are not limited to, buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
The term "alkenylene" means a divalent group derived from a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-carbon double bond. The term "Cx-Cy alkenylene" means a divalent group derived from a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing x to y carbon atoms. Representative examples of alkenylene include, but are not limited to, -CH=CH- and -CH2CH=CH-.
The term "alkyl" as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term "Cx-Cy alkyl" means a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "Ci-C6 alkyl" means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n- hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
The term "alkylene" means a divalent group derived from a straight or branched, saturated hydrocarbon chain of 1 to 10 carbon atoms, for example, of 1 to 4 carbon atoms. The term "Cx-Cy alkylene" means a divalent group derived from a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "C2-C6 alkylene" means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms.
Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-.
The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term "Cx-Cy alkynyl" means a straight or branched chain hydrocarbon group containing from x to y carbon atoms. For example "C3-C6 alkynyl" means a straight or branched chain hydrocarbon group containing from 3 to 6 carbon atoms and containing at least one carbon- carbon triple bond. Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term "alkynylene," as used herein, means a divalent radical derived from a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
The term "aryl" as used herein, means phenyl.
The term "cyclic moiety," as used herein, means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkylene, cycloalkene, cycloalkenyl, cycloalkenylene, cycloalkyne, cycloalkynyl, cycloalkynylene, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and spiroalkyl.
The term "cycloalkylene" or cycloalkyl" or "cycloalkane" as used herein, means a monocyclic or bridged hydrocarbon ring system. The monocyclic cycloalkyl is a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The monocyclic ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non- adjacent carbon atoms of the ring system. Representative examples of such bridged cycloalkyl ring systems include, but are not limited to, bicyclo[3.1.1]heptane,
bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.03'7]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.13'7]decane (adamantane). The monocyclic and bridged cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system.
The term "cycloalkenylene," or "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkenyl has four to ten carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five-or six-membered ring systems have one or two double bonds, the seven- or eight-membered ring systems have one, two, or three double bonds, and the nine- or ten-membered rings have one, two, three, or four double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The monocyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Representative examples of the bridged cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene. The monocyclic and bridged
cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
The term "cycloalkyne," or "cycloalkynyl," or "cycloalkynylene," as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkynyl has eight or more carbon atoms, zero heteroatoms, and one or more triple bonds. The monocyclic cycloalkynyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. The monocyclic and bridged cycloalkynyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems.
The term "heteroarene," or "heteroaryl," or "heteroarylene," as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more than one independently selected nitrogen, oxygen or sulfur atom. The heteroarenes of this invention are connected through any adjacent atoms in the ring, provided that proper valences are maintained. Representative examples of heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-l-yl), isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g. pyridin-4-yl, pyridin-2-yl, pyridin-3-yl), pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl (including, but not limited thereto, thien-2-yl, thien-3-yl), triazolyl, and triazinyl.
The term "heterocycloalkane," or "heterocycloalkyl," or "heterocycloalkylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and zero double bonds. The monocyclic and bridged
heterocycloalkane are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkane groups include, but are not limited to, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, dioxolanyl, tetrahydrofuranyl, thiomorpholinyl, 1 ,4-dioxanyl, tetrahydrothienyl,
tetrahydrothiopyranyl, oxetanyl, piperazinyl, imidazolidinyl, azetidine, azepanyl, aziridinyl, diazepanyl, dithiolanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, oxadiazolidinyl, oxazolidinyl, pyrazolidinyl, tetrahydrothienyl, thiadiazolidinyl, thiazolidinyl,
thiomorpholinyl, trithianyl, and trithianyl.
The term "heterocycloalkene," or "heterocycloalkenyl," or "heterocycloalkenylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and one or more double bonds. The monocyclic and bridged heterocycloalkene are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkene groups include, but are not limited to, 1,4,5,6-tetrahydropyridazinyl, 1,2,3,6-tetrahydropyridinyl, dihydropyranyl, imidazolinyl, isothiazolinyl, oxadiazolinyl, isoxazolinyl, oxazolinyl, pyranyl, pyrazolinyl, pyrrolinyl, thiadiazolinyl, thiazolinyl, and thiopyranyl. The term "phenyl," as used herein, means a monovalent radical formed by removal of a hydrogen atom from benzene.
The term "phenylene," as used herein, means a divalent radical formed by removal of a hydrogen atom from phenyl.
The term "spiroalkyl," as used herein, means alkylene, both ends of which are attached to the same carbon atom and is exemplified by C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl, Cs-spiroalkyl, C6-spiroalkyl, C7-spiroalkyl, Cs-spiroalkyl, C9-spiroalkyl and the like.
The term "spiroheteroalkyl," as used herein, means spiroalkyl having one or two CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH and one or two CH moieties unreplaced or replaced with N.
The term "spiroheteroalkenyl," as used herein, means spiroalkenyl having one or two CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH and one or two CH moieties unreplaced or replaced with N and also means spiroalkenyl having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH and one or two CH moieties replaced with N.
The term "C2-C5-spiroalkyl," as used herein, means C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl, and Cs-spiroalkyl.
The term "C2-spiroalkyl," as used herein, means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety.
The term "C3-spiroalkyl," as used herein, means prop-l,3-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety.
The term "C4-spiroalkyl," as used herein, means but-l,4-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety.
The term "Cs-spiroalkyl," as used herein, means pent-l,5-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety.
The term "C6-spiroalkyl," as used herein, means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "NH protecting group," as used herein, means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl,
ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3 ,4-dimethoxybenzyl-oxycarbonyl,
4-(phenylazo)benzyloxycarbonyl, 2-furfuryl-oxycarbonyl, diphenylmethoxycarbonyl, 1,1- dimethylpropoxy-carbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1- adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, triphenylmethyl, 2- nitrophenylthio, methanesulfonyl, para-toluenesulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-l-naphthyl- methylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene,
2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopentylidene,
2-acetylcyclohexylidene, 3,3-dimethyl-5-oxycyclo-hexylidene, diphenylphosphoryl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-l,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl, and triphenylsilyl.
The term "C(0)OH protecting group," as used herein, means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para- methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro- ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, l,l-dimethyl-2-propenyl, 3-methyl- 3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert- butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and
tert-buty lmethoxypheny lsily 1.
The term "OH or SH protecting group," as used herein, means benzyloxycarbonyl, 4- nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1 , 1 -dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl,
diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2- (trimethylsilyl)ethoxycarbonyl, 2-(phenylsulfonyl)ethoxycarbonyl, 2- (triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1 -adamantyloxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, S-benzylthiocarbonyl, 4-ethoxy-l-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl,
2,2,2-trichloroethyl, 2-trimethylsilylethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl.
Compounds
Geometric isomers may exist in the present compounds. Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term "E" represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term "Z" represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules. The compounds of this invention may also exist as a mixture of "E" and "Z" isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration. Furthermore, the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system. Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuration. For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.
Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R" and "S" are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers. Isotope Enriched or Labeled Compounds
Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non- radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur,
2 3 13 14 15 18 32 fluorine, chlorine, and iodine include, but are not limited to, H, H, C, C, N, O, P,
35 18 36 125
S, F, CI, and I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
In another embodiment, the isotope-labeled compounds contain deuterium (2H), tritium (3H) or 14C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope- labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope- labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2S04/D20. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al, Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al, Org Lett, 5(7), 963 (2003); PCT publications
WO1997010223, WO2005099353, WO1995007271, WO2006008754; US Patent Nos.
7538189; 7534814; 7531685; 7528131; 7521421; 7514068; 7511013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, the methods are hereby incorporated by reference.
The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.,
Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al, J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol, 77, 79-88 (1999).
In addition, non-radio active isotope containing drugs, such as deuterated drugs called "heavy drugs," can be used for the treatment of diseases and conditions related to Bcl-2 activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201 : 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in "Dosimetry & Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134;
Diabetes Metab. 23: 251 (1997)).
Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
Suitable groups for A1, B1, D1, E1, G1, Y1, L1, Z1A, Z2A, Z1, Z2, and Z3 in compounds of Formula (I) are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of A1, B1, D1,
Figure imgf000068_0001
Z2, and Z3 can be combined with embodiments defined for any other of A1, B1, D1, E1, G1, Y1, L1, Z1A, Z2A, Z1, Z2, and Z3. One embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds havin Formula (I)
Figure imgf000069_0001
(I),
wherein
A1 is N or C(A2);
NHR1, N(R1)2,
Figure imgf000069_0002
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, S02NHR1, S02N(R1)2,
NR1S02N(R1)2, C(0)N
Figure imgf000069_0003
C(NH)N(R1)2
Figure imgf000069_0004
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000069_0005
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000069_0006
C(NH)N(R1)2
Figure imgf000069_0007
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000069_0008
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000069_0009
C(NH)N(R1)2
Figure imgf000069_0010
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
R1, N(R1)2,
Figure imgf000069_0011
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SO2NHR1, S02N(R1)2, NHSO2R1, R1S02R1, NHSO2NHR1, HS02N(R1)2, NR^OzNHR1,
Figure imgf000070_0001
C(NH)N(R1)2 NHSO2NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17,
C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2,
C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000070_0002
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, SO2NH2, SO2NHR1, SO^R1^, NHSO2R1, NR^OzR1, NHSO2NHR1, NHSOzN R1^, NR1S02NHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000070_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000070_0004
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000070_0005
NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000070_0006
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000070_0007
NHC(0)OR1, NR^CC OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, S02N( 1)2,
Figure imgf000071_0001
NHS02N(R1)2, NR1S02NH
C(0)NHS02R1, C(NH)NH2,
Figure imgf000071_0002
2N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000071_0003
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000071_0004
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000071_0005
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2, NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin- 1 -yl, azetidin- 1 -yl, pyrrolidin- 1 -yl or piperidin- 1 -yl, each having one
CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
8 8A 8A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12,
CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12,
NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR12,
NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12,
S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH,
(O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
18 18A 18 A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22, NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
R 23 is phenyl, which is unfused or fused with R 23A ; R 23A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
z s R26 or R27;
Z2 is R28, R29 or R30;
Z1A and Z2A are both absent or are taken together to form CH2, CH2CH2 or Z12A; Z12A is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(O) or S02;
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37,
OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH,
S02NHR37, C(N)NH, or C(N)NHR37;
R26 is phenylene, which is unfused or fused with R26A; R26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 27 is heteroarylene, which is unfused or fused with R 27A ; R 27A is benzer
heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2,
NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B, NHC(0)OR37B,
NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H,
C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl;
Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfus seedd oorr f fuusseedd wwiitthh RR40A;; RR40A iiss bbee:nzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the moieties represented by R26 and R27 are substituted (i.e., if Z1A and Z2A are absent) or further substituted (i.e., if Z1A and Z2A are present) with R41, OR41 , SR41,
S(0)R41, S02R41, C(0)R41, CO(0)R41, OC(0)R41, OC(0)OR41, NHR41, N(R41)2, NHC(0)R41, NR41C(0)R41, NHS(0)2R41, NR41S(0)2R41, NHC(0)OR41, NR41C(0)OR41, NHC(0)NHR41, NHC(0)N(R41)2, NR41C(0)NHR41, NR41C(0)N(R41)2, C(0)NHR41, C(0)N(R41)2, C(0)NHOR41, C(0)NHS02R41, C(0)NR41S02R41, S02NHR41, S02N(R41)2, C(N)NHR41, or C(N)N(R41)2;
R41 is heteroaryl, which is fused with R43A; R43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused or fused with
5 benzene, heteroarene or R43B; R43B is cycloalkane, cycloalkene, heterocycloalkane or
heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A,
Tj lO D 10A D 13 D 13A D 14 D 14A D 1 5 D 15A D 18 D 18A D 19 D 19A Ό 20 D 20A D 23 D 23A D 24 D 24A , , , , , , , , , , , , , , , , , ,Π D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A D 30 D 30A D 37B D 38 D 38A D 39 D 39AU , , , , , , , , , , , , , , , , ,
R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57, 5 NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2,
C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57,
C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2,
C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
0 R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A is benzene, heteroarene,5 cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one0 or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62,
CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62, NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62, NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R65 is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67, NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67, S02N(R67)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH,
(O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents
RR67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, pphi enyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
wherein the cyclic moieties represented by R57A, R58, R59, R60, R63, RM, RM, and R' are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68, NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2, NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68,
NR68C(0)N(R68)2, C(0)NH2, C(0)NHR68, C(0)N(R68)2, C(0)NHOH, C(0)NHOR68, C(0)NHS02R68, C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73, NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73, NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
Another embodiment of this invention pertains to compounds of Formula (I), wherein
A1 is N or C(A2);
NHR1, N(R1)2,
Figure imgf000077_0001
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000077_0002
C(NH)N(R1)2
Figure imgf000077_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000077_0004
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000077_0005
C(NH)N(R1)2
Figure imgf000077_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; NHR1, N(R1)2,
Figure imgf000078_0001
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, S02NHR1, S02N(R1)2,
NR1S02N(R1)2, C(0)N
Figure imgf000078_0002
C(NH)N(R1)2
Figure imgf000078_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000078_0004
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000078_0005
C(NH)N(R1)2
Figure imgf000078_0006
NHS02N(CH3)R1,_N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17,
C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2,
C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000078_0007
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^, NHSOzR1, NR^OzR1, NHSOzNHR1, NHS02N(R1)2, NR^O^HR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000078_0008
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000078_0009
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, SO2NH2, SO2NHR1, S02N( 1)2, NHSO2R1, R1S02R1, NHSO2NHR1, NHSO^R1)* NR^OzNHR1, NR^O^R1)* C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000079_0001
C(NH)N(R1)2 NHS02NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000079_0002
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, S02NHR1, S02N(R1)2,
Figure imgf000079_0003
NR1S02R1, NHS02NHR1, NHS02N(R1)2, NR1S02NHR1, NR^O^R1)* C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000079_0004
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000079_0005
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000079_0006
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, NR^OzNiR^z, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000079_0007
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2, NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N , CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
R 8 is phenyl, which is unfused or fused with R 8A ; R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12, NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR12, NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16; R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
18 18A 18 A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22, NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
23 23A 23A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
z s R26 or R27;
Z2 is R28, R29 or R30; Z and Z are both absent or are taken together to form C¾, CH2CH2 or Z ; Z12A is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(O) or S02;
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37,
OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH,
SO2NHR37, C(N)NH, or C(N)NHR37;
R26 is phenylene, which is unfused or fused with R26A; R26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 27 is heteroarylene, which is unfused or fused with R 27A ; R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2, NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B, NHC(0)OR37B,
NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H,
C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl;
Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfus seedd oorr f fuusseedd wwiitthh RR40A ;; RR40A iiss bbeenrzene, heteroarene, cycloalkane, cycloalkene heterocycloalkane or heterocycloalkene;
wherein the moieties represented by R26 and R27 are substituted (i.e., if Z1A and Z2A are absent) or further substituted (i.e., if Z1A and Z2A are present) with R41, OR41 , SR41, S(0)R41, S02R41, C(0)R41, CO(0)R41, OC(0)R41, OC(0)OR41, NHR41, N(R41)2, NHC(0)R41, NR41C(0)R41, NHS(0)2R41, NR41S(0)2R41, NHC(0)OR41, NR41C(0)OR41, NHC(0)NHR41, NHC(0)N(R41)2, NR41C(0)NHR41, NR41C(0)N(R41)2, C(0)NHR41, C(0)N(R41)2,
C(0)NHOR41, C(0)NHS02R41, C(0)NR41S02R41, S02NHR41, S02N(R41)2, C(N)NHR41, or C(N)N(R41)2;
R41 is heteroaryl, which is fused with R43A; R43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A,
Tj lO D 10A D 13 D 13A D 14 D 14A D 1 5 D 15A D 18 D 18A D 19 D 19A Ό 20 D 20A D 23 D 23A D 24 D 24A , , , , , , , , , , , , , , , , , ,
D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A D 30 D 30A D 37B D 38 D 38A D 39 D 39A
, , , , , , , , , , , , , , , , ,
R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57, NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57,
C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2,
C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A
cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62, NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62, NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67, NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67,
S02N(R67)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH,
(O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents
RR67 iiss aallkkyyll,, aallkkeennyyll,, aallkkyynnyyll,, ppihenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl
wherein the cyclic moieties represented by R , R , R , R , R , R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68, NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2, NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68, NRbT(0)N(f 2, C(0)NH2, C(0)NHR , C(0)N(Rb8)2, C(0)NHOH, C(0)NHOR , C(0)NHS02R68, C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73,
NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73, NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
Another embodiment of this invention pertains to compounds of Formula (I), wherein
A1 is N or C(A2);
R1, N(R1)2,
Figure imgf000085_0001
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000085_0002
C(NH)N( 1)2 NHSO2NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000086_0001
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000086_0002
C(NH)N(R1)2 NHS02NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000086_0003
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000086_0004
C(NH)N(R1)2 NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000086_0006
R1,
NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000086_0007
C(NH)N(R1)2
Figure imgf000086_0008
NHS02N(CH3)R1,_N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2,
C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000086_0009
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000086_0010
NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1, C(0)NHS02R1, C(NH)NH2, C^FfjNHR1, C(NH)N(R1)2 NHS02NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
C(0)R1,
Figure imgf000087_0001
)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000087_0002
NHSOzNHR1, NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000087_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000087_0004
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2,
Figure imgf000087_0005
NHS02N(R1)2, NR^OzNHR1, Ν^802Ν(^)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000087_0006
N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000087_0007
NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000087_0008
NHSOzNHR1, NHS02N(R1)2, NR^NHR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1,
C(0)NHS02R1, C(NH)NH2,
Figure imgf000087_0009
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2, NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3,
CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin-l-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
8 8A 8A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12, NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR12, NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
R 18 is phenyl, which is unfused or fused with R 18A ; R 18 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22, NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25; R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
z s R26 or R27;
Z2 is R28, R29 or R30;
Z1A and Z2A are both absent or are taken together to form CH2, CH2CH2 or Z12A;
Z12A is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(O) or S02;
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37,
OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH,
S02NHR37, C(N)NH, or C(N)NHR37;
R26 is phenylene, which is unfused or fused with R26A; R26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 27 is heteroarylene, which is unfused or fused with R 27A ; R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(0)R37 S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2, NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B, NHC(0)OR37B,
NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR3' NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR; C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR , C(N)N(Ri /H)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl;
Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfus seedd oorr f fuusseedd wwiitthh RR40A;; RR40A iiss bbee:nzene, heteroarene, cycloalkane, cycloalkene heterocycloalkane or heterocycloalkene;
wherein the moieties represented by R26 and R27 are substituted (i.e., if Z1A and Z2A are absent) or further substituted (i.e., if Z1A and Z2A are present) with R41, OR41 , SR41,
S(0)R41, S02R41, C(0)R41, CO(0)R41, OC(0)R41, OC(0)OR41, NHR41, N(R41)2, NHC(0)R41, NR41C(0)R41, NHS(0)2R41, NR41S(0)2R41, NHC(0)OR41, NR41C(0)OR41, NHC(0)NHR41, NHC(0)N(R41)2, NR41C(0)NHR41, NR41C(0)N(R41)2, C(0)NHR41, C(0)N(R41)2,
C(0)NHOR41, C(0)NHS02R41, C(0)NR41S02R41, S02NHR41, S02N(R41)2, C(N)NHR41, or C(N)N(R41)2;
R41 is heteroaryl, which is fused with R43A; R43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is fused with benzene, heteroarene or R43B; R43B is cycloalkane, cycloalkene, heterocycloalkane or
heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A,
Tj lO D 10A D 13 D 13A D 14 D 14A D 1 5 D 15A D 18 D 18A D 19 D 19A Ό 20 D 20A D 23 D 23A D 24 D 24A , , , , , , , , , , , , , , , , , ,
D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A D 30 D 30A D 37B D 38 D 38A D 39 D 39A
, , , , , , , , , , , , , , , , ,
R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57, NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57, C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2,
C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62,
NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62, NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R65 is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67, NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67, S02N(Rb /)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR , C(N)N(Rb /)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents;
R67 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
wherein the cyclic moieties represented by R57A, R58, R59, R60, R63, R64, R65, and R67 are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68, NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2, NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68,
NR68C(0)N(R68)2, C(0)NH2, C(0)NHR68, C(0)N(R68)2, C(0)NHOH, C(0)NHOR68,
C(0)NHS02R68, C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73, NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73, NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
In one embodiment of Formula (I), A1 is N; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H, F, CI, Br, or I; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; and G1 is H.
In one embodiment of Formula (I), B1 is R1, OR1, NHR1,
Figure imgf000094_0001
F, CI, Br, or I. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is OR1; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is R1; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is NHR1; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is OR1; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is R1; and G1 is H.
In one embodiment of Formula (I), D1 is H or CI. In another embodiment of Formula
(I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is OR1; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is CI; D1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is R1; D1 is H; and G1 is H.
In one embodiment of Formula (I), E1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; D1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is CI; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is R1; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is NHR1; E1 is H; D1 is CI; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is OR1; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is CI; D1 is H; E1 is H; and G1 is H. In another embodiment of Formula (I), A1 is N; B1 is R1; D1 is H; E1 is H; and G1 is H.
In one embodiment of Formula (I), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2. In another embodiment of Formula (I), Y1 is H. In another embodiment of Formula (I), Y1 is CN. In another embodiment of Formula (I), Y1 is F, CI, Br, or I. In another embodiment of Formula (I), Y1 is CF3. In another embodiment of Formula (I), Y1 is SR17. In another embodiment of Formula (I), Y1 is OR17. In another embodiment of Formula (I), Y1 is N02. In another embodiment of Formula (I), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (I), Y1 is S02R17; wherein R17 is alkyl. In another embodiment of Formula (I), Y1 is R17; wherein R17 is alkynyl. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is N02. In another embodiment of Formula (I), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is N02 or S02R17;
wherein R17 is alkyl or alkynyl. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is N02. In another embodiment of Formula (I), A1 is N; B1 is NHR1; D1 is H; E1 is H; G1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F.
In one embodiment of Formula (I), G1 is H; A1 is N or C(A2); and A2 is H. In another embodiment of Formula (I), G1 is H; A1 is N or C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (I), G1 is H; A1 is N or C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (I), G1 is H; A1 is N or C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (I), G1 is H; A1 is N or C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02.
In one embodiment of Formula (I), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (I), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (I), A1 is C(A2); A2, G1, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (I), A1 is C(A2); A2, G1, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene. In one embodiment of Formula (I), R1 is R4 or R5. In one embodiment of Formula (I), R1 is R4. In one embodiment of Formula (I), R1 is R5. In one embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (I), R1 is R4; and R4 is heterocycloalkyl.
In one embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (I), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (I), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is
57 57 61 61 cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R )2; R is R ; and R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with R 62 ; R 62 is R 65 ; and R 65 is cycloalkyl. In another embodiment of Formula (I), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl.
In one embodiment of Formula (I), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (I), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (I), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (I), R1 is R4; R4 is heterocycloalkyl; wherein the
heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (I), R1 is R4; R4 is heterocycloalkyl; wherein the
heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (I), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57" ; R 57" is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (I), R1 is R4; R4 is heterocycloalkyl; wherein the
heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR57; R57 is R61; R61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (I), R1 is R5; and R5 is alkyl which is unsubstituted or substituted. In one embodiment of Formula (I), R1 is R5; and R5 is alkyl which is
unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (I), R1 is R5; and R5 is alkyl which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (I), R7 is R8, R9, R10 or R11 which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R7 is R8 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R7 is R9 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R7 is R10 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R7 is R11 which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (I), R8 is phenyl which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (I), R9 is heteroaryl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (I), RIO is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is heterocycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is cycloalkyl which is
unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is cycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R10 is heterocycloalkyl which is fused with R10A; and R10A is heteroarene. In another embodiment of Formula (I), R10 is 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl.
In one embodiment of Formula (I), R11 is alkyl, alkenyl or alkynyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R11 is alkyl. In another embodiment of Formula (I), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (I), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (I), R11 is alkyl; which is substituted with OR 12 , R 12 is R 16 ; and R 16 is alkyl. In another embodiment of Formula (I), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (I), R11 is alkyl; which is substituted with R12; R12 is R14; and R14 is heteroaryl.
In one embodiment of Formula (I), A1 is N or C(A2);
A2 is H, F, Br, I, or CI;
B1 is R1, OR1, NHR1,
Figure imgf000098_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI;
E is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R4 or R5;
R4 is cycloalkyl, or heterocycloalkyl; R5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R7, OR7, NHR7, N(R7)2, CN, OH, F, CI, Br or I;
R7 is R8, R9, R10, or R11;
R8 is phenyl;
R9 is heteroaryl;
R10 is cycloalkyl, cycloalkenyl, or heterocycloalkyl; each of which is unfused or fused with R10A, R10A is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12or CF3;
R12 is R14 or R16;
R14 is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R22 is R25;
R25 is heterocycloalkyl;
Z1 is R26;
Z2 is R30;
Z1A and Z2A are both absent;
L1 is a R 37.
R26 is phenylene;
R30 is heterocycloalkylene;
R37 is R37A;
R37Ais alkylene;
Z3 is R38, or R40;
R38 is phenyl;
R40 is cycloalkyl, cycloalkenyl, or heterocycloalkenyl;
wherein the moiety represented by R26 is substituted with OR41;
R41 is heteroaryl, which is fused with R43A; R43A is heteroarene; which is unfused or fused with benzene;
wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, R25, R30, R38, and R40 are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH, OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R59, R60 or R61;
R58 is phenyl;
R59 is heteroaryl;
R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to compounds having Formula (I), which are 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({4-[(3-morpholin-4- ylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin- 1 -yl)-N-( {4-[(l -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide;
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-[(3-pyrrolidin-l - ylpropyl)amino]phenyl}sulfonyl)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-(2- naphthylsulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [3 - nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N- { [3 -(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - (trifluoromethyl)phenyl]sulfonyl}benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4- (4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dih^
N-( {4- [( 1 -methylpiperidin-4-yl)amino] -3 -[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
5- ({[4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfony l)-2-(tetrahydro-2H-pyran-4- y lmethoxy Nicotinamide ;
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [2-(2-methoxyethoxy)ethy 1] sulfonyl} -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-di ydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (morpholin-3 -ylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(methylsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yl
oxy)benzamide;
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2 b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin^ 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -morpholin-4-ylcyclohexyl)methy 1] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(4-tetrahydro-2H-pyran-4-ylmorpholin-3-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidothiomorpholin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,3S)-3-morpholin-4-ylcyclopentyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(tetrahydrofuran-3 -ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[cis-3-fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydrofuran-3 -ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-5 ,5 -dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(cyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoropiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl]amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2-methoxyethyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yl]methoxy } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclobutylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydrofuran-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yljmethyl } amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxy-2,2-dimethylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpiperidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{ [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -ylo
xy)benzamide;
- I l l - 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpyrrolidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl } -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3 S)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} methyl)amino]-3 -nitrophenyl} sulfonyl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitropheny l)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-oxetan-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3-nitrophenyl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{ [4-(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3S)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({ [cis-3 -morpholin-4-ylcyclopentyl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {4- [(methylsulfonyl)amino] cyclohexyl } amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -cyclopropylpiperidin-4-yl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-oxetan-3-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(Z)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-({4-[(l S,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l ,3-dien-l-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {[4-(N,N-dimethylglycyl)morpholin-2 -yljmethyl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[ b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-l- carboxylate;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4-
(morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyr
yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[(3R)-l-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3-
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzami 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -isopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5- yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(5 -chloro-6- { [(3R)- 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yl] amino } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro- 6-sulfanyl)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- (lH-pyrrolo[2,3-£]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l ,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(oxetan-3 -yl)piperazin- 1 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[4-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(3R)-tetrahydrofuran-3 -ylamino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4,4-difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; N-( {4- [( 1 -tert-butylpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]pheny 1} sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2 ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(oxetan-3 -yl)azetidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-m
2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4-fluoro-l-methylpiperi
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-( {3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-
(trifluoromethyl)phenyl}sulfonyl)benzamide; N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-( {3-chloro-4-[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- {[3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; N-[(5-chloro-6- {[ 1 -(2,2-difluoroethyl)-4- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- { [ 1 -( 1 ,3 -difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy } -5 -(trifluoromethyl)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3-methylpiperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(i pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperidin- 1 -yl)-N- { [3 - chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin- 5-yloxy)benzamide;
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcy clohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate; 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)amino]methyl} -N- ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3 - nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4- {[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( lH-pyrrolo [2,3 - £]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fiuorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4- {[9-(4- chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3- yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl} -N-ethyl-N-methylmorpholine-4- carboxamide;
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
N-[(5-chloro-6-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)amino]methyl} -N-ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -bis(fluoromethyl)cyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-({3-chloro-4-[(trans-4-hydroxy-4-me
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6- [(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] ( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl} sulfonyl)amino} methyl pivalate;
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)amino} methyl butyrate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6-
{ [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-
(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4- carboxamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
({[4-(methoxymethyl)cyclohexyl]methyl}amm^
b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}cyclohexanecarboxylate;
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylic acid;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-
(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide; N-({5-chloro-6-[(2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine- 1-carboxamide;
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 - b]pyridin-5-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 -b]pyridin-5 -yl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-methoxypiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} phenyl)- 4-cyanopiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-hydroxy-4-methylpiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(methoxymethyl)piperidine- 1 -carboxamide; N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(morpholin-4-yl)piperidine- 1 -carboxamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)cyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-chlorophenyl)-l-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)carbamoyl] -3 -( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)phenyl} piperazin- 1 -yl)methyl] cyclohex-3 -ene- 1 -carboxylic acid;
N- [(5 -chloro-6- {[l-(oxetan-3 -yl)piperidin-4-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- ¾]pyridin-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof. Still another embodiment pertains to Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-N-( {4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Still another embodiment pertains to Cis-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Still another embodiment pertains to Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Still another embodiment pertains to 4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
Another embodiment pertains to the compound N-[(5-chloro-6- {[4-fluoro-l-(oxetan- 3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-[4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} (2Hg)piperazin- 1 -yl]-N-( {3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-¾]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound N-({5-bromo-6-[(l-tetrahydro-2H- pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {3-[cyclopropyl(oxetan-3- yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-5-methoxy- 5-methylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a
pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(5 -chloro-6- { [ 1 -(cy anomethy l)piperidin-4-yl]methoxy } pyridin-3 -yl)sulfonyl] - 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-N- {[4-( {3-[cyclopropyl(oxetan-3- yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-N- { [3 -nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(4- methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(3 -nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound N-[(5-chloro-6-{[l- (cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Still another embodiment pertains to compounds having Formula (I) or Formula (II), which are N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino } -3 - nitrophenyl)sulfonyl] -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin-l -yl)-N-( {4-[(4- methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
Another embodiment pertains to the compound 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-methoxytetrahydro-2H-pyran- 4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention provides compounds of Formula (II)
Figure imgf000140_0001
(II)
and therapeutically acceptable salts, and metabolites thereof,
wherein A 1 , B1 , D1 , E1 , Y1 , Z2% L1 , and V 3 are as described herein for Formula (II); n is 0, 1, 2, or 3; describing the number of substituents on Z1; and R100 is as described for substituents on R26.
In one embodiment of Formula (II), n is 0 or 1. In another embodiment of Formula
(II), n is 0.
In one embodiment of Formula (II), A1 is N. In another embodiment of Formula (II), A1 is C(A2). In another embodiment of Formula (II), A1 is C(A2); and A2 is H, F, CI, Br, or I. In another embodiment of Formula (II), A1 is C(A2); and A2 is H.
In one embodiment of Formula (II), B1 is R1, OR1, NHR1,
Figure imgf000140_0002
F, CI, Br, or I.
In another embodiment of Formula (II), A1 is C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (II), A1 is C(A2); A2 is H; and B1 is OR1. In another embodiment of Formula (II), A1 is C(A2); A2 is H; and B1 is CI. In another embodiment of Formula (II), A1 is C(A2); A2 is H; and B1 is R1. In another embodiment of Formula (II), A1 is N; and B1 is NHR1. In another embodiment of Formula (II), A1 is N; and B1 is OR1. In another embodiment of Formula (II), A1 is N; and B1 is CI. In another embodiment of Formula (II), A1 is Nj and B s R1.
In one embodiment of Formula (II), D1 is H or CI. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is CI. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is OR1; and D1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is CI; and D1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is R1; and D1 is H. In another embodiment of Formula (II), A1 is N; B1 is NHR1; and D1 is H. In another embodiment of Formula (II), A1 is N; B1 is NHR1; and D1 is CI. In another embodiment of Formula (II), A1 is N; B1 is OR1; and D1 is H. In another embodiment of Formula (II), A1 is N; B1 is CI; and D1 is H. In another embodiment of Formula (II), A1 is N; B1 is R1; and D1 is H.
In one embodiment of Formula (II), E1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is N; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is N; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (II), A1 is N; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is N; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (II), A1 is N; B1 is R1; D1 is H; and E1 is H.
In one embodiment of Formula (II), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2. In another embodiment of Formula (II), Y1 is H. In another embodiment of Formula (II), Y1 is CN. In another embodiment of Formula (II), Y1 is F, CI, Br, or I. In another embodiment of Formula (II), Y1 is CF3. In another embodiment of Formula (II), Y1 is SR17. In another embodiment of Formula (II), Y1 is OR17. In another embodiment of Formula (II), Y1 is N02. In another embodiment of Formula (II), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (II), Y1 is S02R 17 ; wherein R 17 is alky 1. In another embodiment of Formula (II), Y 1 is R17 ; wherein R 17 is alkynyl. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (II), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (II), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (II), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (II), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In one embodiment of Formula (II), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (II), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (II), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (II), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene.
In one embodiment of Formula (II), R1 is R4 or R5. In one embodiment of Formula (II R S R4. In one embodiment of Formula (II), R1 is R5. In one embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (II), R1 is R4; and R4 is heterocycloalkyl.
In one embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (II), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (II), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is
57 57 61 61 cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R )2; R is R ; and R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with 62 62 65 65
R ; R is R ; and R is cycloalkyl. In another embodiment of Formula (II), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl.
In one embodiment of Formula (II), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (II), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (II), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (II), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (II), R1 is R4; R4 is heterocycloalkyl; wherein the
heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (II), R1 is R4; R4 is
heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (II), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (II), R1 is R5; and R5 is alkyl which is unsubstituted or substituted. In one embodiment of Formula (II), R1 is R5; and R5 is alkyl which is
unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (II), R1 is R5; and R5 is alkyl which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (II), R7 is R8, R9, R10 or R11 which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R7 is R8 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R7 is R9 which is unsubstituted or substituted as defined herein. In another embodiment of
Formula (II), R7 is R10 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R7 is R11 which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (II), R8 is phenyl which is unsubstituted or substituted as defined herein. In one embodiment of Formula (II), R9 is heteroaryl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (II), RIO is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is heterocycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is tetrahydro furanyl,
tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R10 is heterocycloalkyl; which is fused with R10A; and R10A is heteroarene. In another embodiment of Formula (II), R10 is 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl.
In one embodiment of Formula (II), R11 is alkyl, alkenyl or alkynyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R11 is alkyl. In another embodiment of Formula (II), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (II), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (II), R11 is alkyl; which is substituted with OR 12 ; R 12 is R 16 ; and R 16 is alkyl. In another embodiment of Formula (II), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (II), R11 is alkyl; which is substituted with R12; R12 is R14; and R14 is heteroaryl.
In one embodiment of Formula (II),
n is 0;
A1 is N or C(A2);
A2 is H, F, Br, I, or CI;
B1 is R1, OR1, NHR1,
Figure imgf000144_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI; E1 is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
R1 is R4 or R5;
R4 is cycloalkyl, or heterocycloalkyl;
R5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R7, OR7, NHR7, N(R7)2, CN, OH, F, CI, Br or I;
R7 is R8, R9, R10, or Ru;
R8 is phenyl;
R9 is heteroaryl;
R10 is cycloalkyl, cycloalkenyl, or heterocycloalkyl; each of which is unfused or fused with R10A, R10A is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12or CF3;
R12 is R14 or R16;
R14 is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R is heterocycloalkyl;
Z2 is R30;
Z and Z are both absent;
T L 1 i ·s a r R> 37 ;
R30 is heterocycloalkylene;
37 · n 37A.
R3 is R'
R37A is alkylene;
Z3 is R38, or R40;
R is phenyl;
R40 is cycloalkyl, cycloalkenyl, or heterocycloalkenyl; wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, R25, R30, R38, and R40 are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH, OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R60 or R61;
R58 is phenyl;
R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to compounds having Formula (II), which are 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({4-[(3-morpholin-4- ylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-(2- naphthylsulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-
N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N- { [3 -(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - (trifluoromethyl)phenyl]sulfonyl}benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4- (4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-( {4- [( 1 -methylpiperidin-4-yl)amino] -3 -[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
5- ({[4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfony l)-2-(tetrahydro-2H-pyran-4- y lmethoxy)nicotinamide ; N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [2-(2-methoxyethoxy)ethy 1] sulfonyl} -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- morpholin-4-ylcyclohexyl)amino]-3-nito
yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- {[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (morpholin-3 -ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(methylsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yl
oxy)benzamide;
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -morpholin-4-ylcyclohexyl)methy 1] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[4-(dicyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3 -yl)methoxy]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(4-tetrahydro-2H-pyran-4-ylmorpholin-3-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidothiomorpholin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,3S)-3-morpholin-4-ylcyclopentyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(tetrahydrofuran-3 -ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[cis-3-fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydrofuran-3 -ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide; 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5 yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl]amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2-methoxyethyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yl]methoxy } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclobutylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydrofuran-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yljmethyl } amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxy-2,2-dimethylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(4- { [( 1 -acetylpiperidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -ylo
xy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpyrrolidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyljsulfonyl } -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3 S)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} methyl)amino]-3 -nitropheny 1} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitropheny l)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(l^ pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-oxetan-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3-nitrophenyl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4-
[(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
(l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3S)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[cis-3-morpholin-4-ylcyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {4- [(methylsulfonyl)amino] cyclohexyl } amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -cyclopropylpiperidin-4-yl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-oxetan-3-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(Z)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({4-[(l S,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methyl-5 -oxopyrrolidin-3 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l ,3-dien-l-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {[4-(N,N-dimethylglycyl)morpholin-2 -yljmethyl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-l- carboxylate;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4- (morpholin-4-yl)piperidin-l-yl]-3-m
yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3-
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-isopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(5-chloro-6- {[(3R)-l-(l ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro- 6-sulfanyl)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l ,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(oxetan-3 -yl)piperazin- 1 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[4-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(3R)-tetrahydrofuran-3 -ylamino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4,4-difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-( {4- [( 1 -tert-butylpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]pheny 1} sulfony l)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(oxetan-3 -yl)azetidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({3-nitro-4-[(tetrahydro-
2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4-fluoro-l-methylpiperi
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-( {3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- (trifluoromethyl)phenyl}sulfonyl)benzamide;
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-( {3-chloro-4-[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- { [ 1 -( 1 ,3 -difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy } -5 -(trifluoromethyl)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3-methylpiperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3 -yl] sulfonyl} benzamide; N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperidin- 1 -yl)-N- { [3 - chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcy clohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate;
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)amino]methyl} -N- ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3 - nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4- {[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( lH-pyrrolo [2,3 - £]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fiuorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4- {[9-(4- chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2R)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N- {[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3- yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide;
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
N- [(5 -chloro-6- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-5 ,5 -bis(fluoromethyl)cyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6- [(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}cyclohexanecarboxylate;
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylic acid;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide;
N-({5-chloro-6-[(2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine- 1-carboxamide;
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 - b]pyridin-5-yl]sulfonyl}benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 -b]pyridin-5 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} phenyl)- 4-methoxypiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-cyanopiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-hydroxy-4-methylpiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(methoxymethyl)piperidine- 1 -carboxamide;
N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(morpholin-4-yl)piperidine- 1 -carboxamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)cyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4-chlorophenyl)-l-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)carbamoyl] -3 -( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)phenyl} piperazin- 1 -yl)methyl] cyclohex-3 -ene- 1 -carboxylic acid;
N- [(5 -chloro-6- {[l-(oxetan-3 -yl)piperidin-4-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- ¾]pyridin-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
In another aspect, the present invention provides compounds of Formula (III)
Figure imgf000181_0001
wherein A1, B1, D1, E1, and Y1 are as described herein for Formula (I); R is as described for substituents on R26 ; n is 0, 1, 2, or 3; R is as described for substituents on R30; is 0, 1, 2, 3, 4, 5, or 6: R is as described for substituents on R40; q is 0, 1, 2, 3, 4, 5, or 6; R103 is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.
In one embodiment of Formula (III), n, p, r, and q are each 0.
In one embodiment of Formula (III), A1 is N. In another embodiment of Formula (III), A1 is C(A2). In another embodiment of Formula (III), A1 is C(A2); and A2 is H, F, CI, Br, or I. In another embodiment of Formula (III), A1 is C(A2); and A2 is H.
In one embodiment of Formula (III), B1 is R1, OR1, NHR1,
Figure imgf000182_0001
F, CI, Br, or I. In another embodiment of Formula (III), A1 is C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (III), A1 is C(A2); A2 is H; and B1 is OR1. In another embodiment of Formula (III), A1 is C(A2); A2 is H; and B1 is CI. In another embodiment of Formula (III), A1 is C(A2); A2 is H; and B1 is R1. In another embodiment of Formula (III), A1 is N; and B1 is NHR1. In another embodiment of Formula (III), A1 is N; and B1 is OR1. In another embodiment of Formula (III), A1 is N; and B1 is CI. In another embodiment of Formula (III), A1 is Nj and B s R1.
In one embodiment of Formula (III), D1 is H or CI. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is CI. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is OR1; and D1 is H. In another embodiment of
Formula (III), A1 is C(A2); A2 is H; B1 is CI; and D1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is R1; and D1 is H. In another embodiment of Formula (III), A1 is N; B1 is NHR1; and D1 is H. In another embodiment of Formula (III), A1 is N; B1 is NHR1; and D1 is CI. In another embodiment of Formula (III), A1 is N; B1 is OR1; and D1 is H. In another embodiment of Formula (III), A1 is N; B1 is CI; and D1 is H. In another embodiment of Formula (III), A1 is N; B1 is R1; and D1 is H.
In one embodiment of Formula (III), E1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; and D1 is CI. In another
embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is N; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is N; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (III), A1 is N; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is N; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (III), A1 is N; B1 is R1; D1 is H; and E1 is H.
In one embodiment of Formula (III), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2. In another embodiment of Formula (III), Y1 is H. In another embodiment of Formula (III), Y1 is CN. In another embodiment of Formula (III), Y1 is F, CI, Br, or I. In another embodiment of Formula (III), Y1 is CF3. In another embodiment of Formula (III), Y1 is SR17. In another embodiment of Formula (III), Y1 is OR17. In another embodiment of Formula (III), Y1 is N02. In another embodiment of Formula (III), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (III), Y is
S02R 17 ; wherein R 17 is alky 1. In another embodiment of Formula (III), Y 1 is R 17 ; wherein R 17 is alkynyl. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (III), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (III), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (III), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (III), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F.
In one embodiment of Formula (III), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (III), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (III), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (III), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene.
In one embodiment of Formula (III), R1 is R4 or R5. In one embodiment of Formula (III), R1 is R4. In one embodiment of Formula (III), R1 is R5. In one embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (III), R1 is R4; and R4 is heterocycloalkyl. In one embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (III), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (III), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is
57 57 61 61 cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R )2; R is R ; and R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with R 62 ; R 62 is R 65 ; and R 65 is cycloalkyl. In another embodiment of Formula (III), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein
57 57 61 61
the cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl.
In one embodiment of Formula (III), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (III), R1 is R4; and R4 is heterocycloalkyl;
wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (III), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (III), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (III), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (III), R1 is R4; R4 is
heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (III), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (III), R1 is R5; and R5 is alkyl which is unsubstituted or substituted. In one embodiment of Formula (III), R1 is R5; and R5 is alkyl which is unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (III), R1 is R5; and R5 is alkyl which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (III), R7 is R8, R9, R10 or R11 which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R7 is R8 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R7 is R9 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R7 is R10 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R7 is R11 which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (III), R8 is phenyl which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (III), R9 is heteroaryl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (III), R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is heterocycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is tetrahydro furanyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R10 is heterocycloalkyl which is fused with R10A; and R10A is heteroarene. In another embodiment of Formula (III), R10 is 5,6,7,8-tetrahydroimidazo[l ,2-a]pyridinyl.
In one embodiment of Formula (III), R11 is alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R11 is alkyl. In another embodiment of Formula (III), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (III), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (III), R11 is alkyl; which is substituted with OR 12 ; R 12 is R 16 ; and R 16 is alkyl. In another embodiment of Formula (III), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (III), R11 is alkyl; which is substituted with R12; R12 is R14; and R14 is heteroaryl.
In one embodiment of Formula (III),
n, p, r, and q are each 0;
A1 is N or C(A2);
A2 is H, F, Br, I, or CI;
B1 is R1, OR1, NHR1,
Figure imgf000186_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI;
E1 is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or
Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
R1 is R4 or R5;
R4 is cycloalkyl, or heterocycloalkyl;
R5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R7, OR7, NHR7, N(R7)2, CN, OH, F, CI, Br or I;
R7 is R8, R9, R10, or R11;
R8 is phenyl;
R9 is heteroaryl; R10 is cycloalkyl, cycloalkenyl, or heterocycloalkyl; each of which is unfused or fused with R10A, R10A is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12or CF3;
R12 is R14 or R16;
R14 is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R22 is R25;
R25 is heterocycloalkyl;
wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, and
R25 , are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH, OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R60 or R61;
R58 is phenyl;
R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to compounds having Formula (III), which are 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2 -methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-(2- naphthylsulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [3 - nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-
[(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N- { [3 -(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
5-({[4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfony l)-2-(tetrahydro-2H-pyran-4- y lmethoxy)nicotinamide ;
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [2-(2-methoxyethoxy)ethy 1] sulfonyl} -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
(morpholin-3 -ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(methylsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yl
oxy)benzamide;
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrro b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amin^
5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -morpholin-4-ylcyclohexyl)methy 1] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3 -yl)methoxy]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methoxy]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidothiomorpholin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,3S)-3-morpholin-4-ylcyclopentyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(tetrahydrofuran-3 -ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[cis-3-fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydrofuran-3 -ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl]sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(cyclopropylamino)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoropiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl]amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-methoxyethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yl]methoxy } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclobutylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydrofuran-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -cyclopropylpyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yljmethyl } amino)phenyl] sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxy-2,2-dimethylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(l-acetylpiperidin-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 -[2-fiuoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -ylo
xy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methy lsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpyrrolidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl } -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3 S)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} methyl)amino]-3 -nitrophenyl} sulfonyl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitropheny l)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-oxetan-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3-nitrophenyl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{ [4-(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3S)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({ [cis-3 -morpholin-4-ylcyclopentyl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {4- [(methylsulfonyl)amino] cyclohexyl } amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1 -cyclopropylpiperidin-4-yl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro-l-tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-oxetan-3-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(Z)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-({4-[(l S,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin-1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {[4-(N,N-dimethylglycyl)morpholin-2 -yljmethyl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2 -yljmethyl} amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2, 3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-l- carboxylate;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4- (morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyr
yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3-
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -isopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(5 -chloro-6- { [(3R)- 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yl] amino } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro- 6-sulfanyl)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l ,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(oxetan-3 -yl)piperazin- 1 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- {[4-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [(3R)-tetrahydrofuran-3 -ylamino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4,4-difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-( {4- [( 1 -tert-butylpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]pheny 1} sulfony l)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ( { [4-(oxetan-3 -yl)morpholin-2-yl]methyl} amino)-3 -
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(oxetan-3 -yl)azetidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(4-fluoro-l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; N- [(5 -chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy} pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluoro-l-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- { [ 1 -( 1 ,3 -difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy } -5 -(trifluoromethyl)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3 -yl] sulfonyl} benzamide;
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcy clohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate;
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)amino]methyl} -N- ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3- yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide;
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
N- [(5 -chloro-6- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } pyridin-3 -yl)sulfonyl] -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin-
2-yl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(cis- 1 -fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6- [(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6-
{ [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-
(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4- carboxamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-
({[4-(methoxymethyl)cyclohexyl]methyl}amm^
b]pyridin-5 -yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}cyclohexanecarboxylate;
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}cyclohexanecarboxylic acid;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-
(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide;
N-({5-chloro-6-[(2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine- 1-carboxamide; N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 - b]pyridin-5-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 -b]pyridin-5 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-methoxypiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-cyanopiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-hydroxy-4-methylpiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(methoxymethyl)piperidine- 1 -carboxamide;
N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-(morpholin-4-yl)piperidine- 1 -carboxamide; N- [(5 -chloro-6- { [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- { [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[l-(oxetan-3 -yl)piperidin-4-yl]methoxy} pyridin-3 -yl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-
£]pyridin-5-yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
In another as ect, the present invention provides compounds of Formula (IV)
Figure imgf000218_0001
(IV);
and therapeutically acceptable salts, and metabolites thereof, wherein A1, B1, D1, E1, and Y1 are as described herein for Formula (I); R is as described for substituents on n is 0, 1, 2, or 3: R is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5, or 6; R104 is as described for substituents on R38; s is 0, 1, 2, 3, 4, 5, or 6; R103 is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.
In one embodiment of Formula (IV), n, p, r, and s are each 0. In one embodiment of Formula (IV), A1 is N. In another embodiment of Formula (IV), A1 is C(A2). In another embodiment of Formula (IV), A1 is C(A2); and A2 is H, F, CI, Br, or I. In another embodiment of Formula (IV), A1 is C(A2); and A2 is H.
In one embodiment of Formula (IV), B1 is R1, OR1, NHR1,
Figure imgf000219_0001
F, CI, Br, or I. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; and B1 is OR1. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; and B1 is CI. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; and B1 is R1. In another embodiment of Formula (IV), A1 is N; and B1 is NHR1. In another embodiment of Formula (IV), A1 is N; and B1 is OR1. In another embodiment of Formula (IV), A1 is N; and B1 is CI. In another embodiment of Formula (IV), A1 is Nj and B s R1.
In one embodiment of Formula (IV), D1 is H or CI. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is CI. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is OR1; and D1 is H. In another embodiment of
Formula (IV), A1 is C(A2); A2 is H; B1 is CI; and D1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is R1; and D1 is H. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; and D1 is H. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; and D1 is CI. In another embodiment of Formula (IV), A1 is N; B1 is OR1; and D1 is H. In another embodiment of Formula (IV), A1 is N; B1 is CI; and D1 is H. In another embodiment of Formula (IV), A1 is N; B1 is R1; and D1 is H.
In one embodiment of Formula (IV), E1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; and D1 is CI. In another
embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (IV), A1 is N; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is N; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (IV), A1 is N; B1 is R1; D1 is H; and E1 is H.
In one embodiment of Formula (IV), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2. In another embodiment of Formula (IV), Y1 is H. In another embodiment of Formula (IV), Y1 is CN. In another embodiment of Formula (IV), Y1 is F, CI, Br, or I. In another embodiment of Formula (IV), Y1 is CF3. In another embodiment of Formula (IV), Y1 is SR17. In another embodiment of Formula (IV), Y1 is OR17. In another embodiment of Formula (IV), Y1 is N02. In another embodiment of Formula (IV), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (IV), Y1 is
S02R 17 ; wherein R 17 is alky 1. In another embodiment of Formula (IV), Y 1 is R17 ; wherein R 17 is alkynyl. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (IV), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (IV), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F.
In one embodiment of Formula (IV), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (IV), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (IV), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (IV), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene.
In one embodiment of Formula (IV), R1 is R4 or R5. In one embodiment of Formula (IV^ R S R4. In one embodiment of Formula (IV), R1 is R5. In one embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (IV), R1 is R4; and R4 is heterocycloalkyl.
In one embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (IV), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (IV), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is
57 57 61 61 cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R )2; R is R ; and R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with R 62 , R 62 is R 65 ; and R 65 is cycloalkyl. In another embodiment of Formula (IV), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein
57 57 61 61
the cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl
In one embodiment of Formula (IV), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (IV), R1 is R4; and R4 is heterocycloalkyl;
wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (IV), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (IV), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (IV), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (IV), R1 is R4; R4 is
heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (IV), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR 57" ; R 57" is R 61 ; R 61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (IV), R1 is R5; and R5 is alkyl; which is unsubstituted or substituted. In one embodiment of Formula (IV), R1 is R5; and R5 is alkyl; which is unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (IV), R1 is R5; and R5 is alkyl; which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (IV), R7 is R8, R9, R10 or R11 which are unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R7 is R8 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R7 is R9 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R7 is R10 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R7 is R11 which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (IV), R8 is phenyl which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (IV), R9 is heteroaryl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (IV), R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is heterocycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is tetrahydro furanyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R10 is heterocycloalkyl; which is fused with R ; and R is heteroarene. In another embodiment of Formula (IV), R10 is 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl.
In one embodiment of Formula (IV), R11 is alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R11 is alkyl. In another embodiment of Formula (IV), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IV), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (IV), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (IV), R11 is alkyl; which is substituted with OR 12 ; R 12 is R 16 ; and R 16 is alkyl. In another embodiment of Formula (IV), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (IV), R11 is alkyl; which is substituted with R12, R12 is R14, and R14 is heteroaryl.
In one embodiment of Formula (IV),
n, p, r, and s are each 0;
A1 is N or C(A2);
A2 is H, F, Br, I, or CI;
B1 is R1, OR1, NHR1,
Figure imgf000223_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI;
E is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or
Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
R1 is R4 or R5;
R4 is cycloalkyl, or heterocycloalkyl;
5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two
Figure imgf000223_0002
with R , R1UA is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of indepe R12, OR12or CF3;
Figure imgf000223_0003
R is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R22 is R25;
R25 is heterocycloalkyl;
wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, and
R25 , are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH, OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R60 or R61;
R58 is phenyl;
R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to compounds having Formula (IV), which are 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({4-[(3-morpholin-4- ylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
In another aspect, the present invention provides compounds of Formula (V)
Figure imgf000225_0001
and therapeutically acceptable salts, and metabolites thereof,
wherein A1, B1, D1, E1, and Y1 are as described herein for Formula (I); R is as described for substituents on R26 ; n is 0, 1, 2, or 3; R is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5, or 6: R is as described for substituents on R40; t is 0, 1, 2, 3, or 4; R103 is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.
In one embodiment of Formula (V), n, p, r, and t are each 0.
In one embodiment of Formula (V), A1 is N. In another embodiment of Formula (V), A1 is C(A2). In another embodiment of Formula (V), A1 is C(A2); and A2 is H, F, CI, Br, or I. In another embodiment of Formula (V), A1 is C(A2); and A2 is H.
In one embodiment of Formula (V), B1 is R1, OR1, NHR1, NHC(0)R1, F, CI, Br, or I. In another embodiment of Formula (V), A1 is C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (V), A1 is C(A2); A2 is H; and B1 is OR1. In another embodiment of Formula (V), A1 is C(A2); A2 is H; and B1 is CI. In another embodiment of Formula (V), A1 is C(A2); A2 is H; and B1 is R1. In another embodiment of Formula (V), A1 is N; and B1 is NHR1. In another embodiment of Formula (V), A1 is N; and B1 is OR1. In another embodiment of Formula (V), A1 is N; and B1 is CI. In another embodiment of Formula (V), A1 is Nj and B s R1.
In one embodiment of Formula (V), D1 is H or CI. In another embodiment of
Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is CI. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is OR1; and D1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is CI; and D1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is R1; and D1 is H. In another embodiment of Formula (V), A1 is N; B1 is NHR1; and D1 is H. In another embodiment of Formula (V), A1 is N; B1 is NHR1; and D1 is CI. In another embodiment of Formula (V), A1 is N; B1 is OR1; and D1 is H. In another embodiment of Formula (V), A1 is N; B1 is CI; and D1 is H. In another embodiment of Formula (V), A1 is N; B1 is R1; and D1 is H.
In one embodiment of Formula (V), E1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of
Formula (V), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is N; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is N; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (V), A1 is N; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is N; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (V), A1 is N; B1 is R1; D1 is H; and E1 is H.
In one embodiment of Formula (V), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2. In another embodiment of Formula (V), Y1 is H. In another embodiment of Formula (V), Y1 is CN. In another embodiment of Formula (V), Y1 is F, CI, Br, or I. In another embodiment of Formula (V), Y1 is CF3. In another embodiment of Formula (V), Y1 is SR17. In another embodiment of Formula (V), Y1 is OR17. In another embodiment of Formula (V), Y1 is N02. In another embodiment of Formula (V), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (V), Y is
S02R 17 ; wherein R 17 is alky 1. In another embodiment of Formula (V), Y 1 is R 17 ; wherein R 17 is alkynyl. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (V), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (V), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (V), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (V), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F.
In one embodiment of Formula (V), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (V), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (V), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (V), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene.
In one embodiment of Formula (V), R1 is R4 or R5. In one embodiment of Formula
(V^ R S R4. In one embodiment of Formula (V), R1 is R5. In one embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (V), R1 is R4; and R4 is heterocycloalkyl.
In one embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (V), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (V), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with 57" 57" 61 and 61
N(R )2; R is R ; R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the 57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with R 62 ; R 62 is R 65 ; and R 65 is cycloalkyl. In another embodiment of Formula (V), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the
57" 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl.
In one embodiment of Formula (V), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (V), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (V), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (V), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (V), R1 is R4; R4 is heterocycloalkyl; wherein the
heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (V), R1 is R4; R4 is
heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (V), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (V), R1 is R5; and R5 is alkyl which is unsubstituted or substituted. In one embodiment of Formula (V), R1 is R5; and R5 is alkyl which is
unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (V), R1 is R5; and R5 is alkyl which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (V), R7 is R8, R9, R10 or R11 which are unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R7 is R8 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R7 is R9 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R7 is R10 which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R7 is R11 which is unsubstituted or substituted as defined herein. In one embodiment of Formula (V), R8 is phenyl which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (V), R9 is heteroaryl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (V), R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is heterocycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is tetrahydro furanyl,
tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R10 is heterocycloalkyl which is fused with R10A; and R10A is heteroarene. In another embodiment of Formula (V), R10 is 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl.
In one embodiment of Formula (V), R11 is alkyl, alkenyl or alkynyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R11 is alkyl. In another embodiment of Formula (V), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (V), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (V), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (V), R11 is alkyl; which is substituted with OR 12 ; R 12 is R 16 ; and R 16 is alkyl. In another embodiment of Formula (V), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (V), R11 is alkyl; which is substituted with R12; R12 is R14; and R14 is heteroaryl.
In one embodiment of Formula (V),
n, p, r, and t are each 0;
A1 is N or C(A2);
A2 is H, F, Br, I, or CI; B1 is R1, OR1, NHR1,
Figure imgf000230_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI;
E1 is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or
Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
R1 is R4 or R5;
R4 is cycloalkyl, or heterocycloalkyl;
R5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R7, OR7, NHR7, N(R7)2, CN, OH, F, CI, Br or I;
R7 is R8, R9, R10, or R11;
R8 is phenyl;
R9 is heteroaryl;
R10 is cycloalkyl, cycloalkenyl, or heterocycloalkyl; each of which is unfused or fused with R10A, R10A is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12or CF3;
R12 is R14 or R16;
R14 is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R22 is R25;
R25 is heterocycloalkyl;
wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, and R25 , are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH, OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl;
R57 is R58, R60 or R61;
R58 is phenyl; R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to a compound having Formula (V), which is 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzam
ide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benza
mide; 4-(4-{[4-(4-chlorophenyl)-6,6-dime
2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 -
(trifluoromethy l)pheny 1] sul
fonyl}benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3 - [(trifluoromethyl)sulfonyl]
phenyl} sulfonyl)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyri
din-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2 pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
In another aspect, the present invention provides compounds of Formula (VI)
Figure imgf000233_0001
(VI);
and therapeutically acceptable salts, and metabolites thereof,
wherein A1, B1, D1, E1, and Y1 are as described herein for Formula (I); R is as described for substituents on R26 ; n is 0, 1, 2, or 3; R is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5, or 6: R is as described for substituents on R40; q is 0, 1, 2, 3, 4, 5, or 6; R103 is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.
In one embodiment of Formula (VI), n, p, r, and q are each 0.
In one embodiment of Formula (VI), A1 is N. In another embodiment of Formula (VI), A1 is C(A2). In another embodiment of Formula (VI), A1 is C(A2); and A2 is H, F, CI, Br, or I. In another embodiment of Formula (VI), A1 is C(A2); and A2 is H.
In one embodiment of Formula (VI), B1 is R1, OR1, NHR1,
Figure imgf000233_0002
F, CI, Br, or I. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; and B1 is NHR1. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; and B1 is OR1. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; and B1 is CI. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; and B1 is R1. In another embodiment of Formula (VI), A1 is N; and B1 is NHR1. In another embodiment of Formula (VI), A1 is N; and B1 is OR1. In another embodiment of Formula (VI), A1 is N; and B1 is CI. In another embodiment of Formula (VI), A1 is Nj and B s R1.
In one embodiment of Formula (VI), D1 is H or CI. In another embodiment of
Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; and D1 is CI. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is OR1; and D1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is CI; and D1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is R1; and D1 is H. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; and D1 is H. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; and D1 is CI. In another embodiment of Formula (VI), A1 is N; B1 is OR1; and D1 is H. In another embodiment of Formula (VI), A1 is N; B1 is CI; and D1 is H. In another embodiment of Formula (VI), A1 is N; B1 is R1; and D1 is H.
In one embodiment of Formula (VI), E1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; E1 is H; and D1 is CI. In another
embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is R1; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; E1 is H; and D1 is CI. In another embodiment of Formula (VI), A1 is N; B1 is OR1; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is N; B1 is CI; D1 is H; and E1 is H. In another embodiment of Formula (VI), A1 is N; B1 is R1; D1 is H; and E1 is H.
In one embodiment of Formula (VI), Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17,
SR17, S02R17, or C(0)NH2. In another embodiment of Formula (VI), Y1 is H. In another embodiment of Formula (VI), Y1 is CN. In another embodiment of Formula (VI), Y1 is F, CI, Br, or I. In another embodiment of Formula (VI), Y1 is CF3. In another embodiment of Formula (VI), Y1 is SR17. In another embodiment of Formula (VI), Y1 is OR17. In another embodiment of Formula (VI), Y1 is N02. In another embodiment of Formula (VI), Y1 is S02R17; wherein R17 is as defined herein. In another embodiment of Formula (VI), Y1 is
S02R 17 ; wherein R 17 is alky 1. In another embodiment of Formula (VI), Y 1 is R17 ; wherein R 17 is alkynyl. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (VI), A1 is C(A2); A2 is H; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02 or S02R17; wherein R17 is alkyl or alkynyl. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is N02. In another embodiment of Formula (VI), A1 is N; B1 is NHR1; D1 is H; E1 is H; and Y1 is S02R17; wherein R17 is alkyl substituted with three F.
In one embodiment of Formula (IV), Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (IV), Y1 and B1, together with the atoms to which they are attached, are heteroarene. In another embodiment of Formula (IV), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are benzene. In another embodiment of Formula (IV), A1 is C(A2); A2, E1, and D1 are independently selected H; and Y1 and B1, together with the atoms to which they are attached, are heteroarene.
In one embodiment of Formula (VI), R1 is R4 or R5. In one embodiment of Formula
(VI^ R S R4. In one embodiment of Formula (VI), R1 is R5. In one embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl. In one embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl or heterocycloalkyl. In one embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl. In one embodiment of Formula (VI), R1 is R4; and R4 is heterocycloalkyl.
In one embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with R57 or N(R57)2. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; and R57 is R60. In another embodiment of Formula (VI), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; and R60 is heterocycloalkyl. In another embodiment of Formula (VI), R1 is R4; R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl;
wherein the heterocycloalkyl ring is morpholinyl. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R57)2. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R57)2. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with 57" 57" 61 and 61
N(R )2; R is R ; R is alkyl which is unsubstituted or substituted with R62. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the 57 57 61 61
cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is unsubstituted or substituted with R 62 ; R 62 is R 65 ; and R 65 is cycloalkyl. In another embodiment of Formula (VI), R1 is R4; and R4 is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein
57" 57 61 61
the cyclohexyl ring is substituted with R ; R is R ; and R is alkyl which is substituted with R62; R62 is R65; and R65 is cyclopropyl.
In one embodiment of Formula (VI), R1 is R4; and R4 is heterocycloalkyl; wherein R4 is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (VI), R1 is R4; and R4 is heterocycloalkyl;
wherein the heterocycloalkyl ring is substituted with R57. In another embodiment of Formula (VI), R1 is R4; and R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the heterocycloalkyl ring is substituted with R57; and R57 is R60 or R61. In another embodiment of Formula (VI), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60 or R61; R60 is heterocycloalkyl; and R61 is alkyl. In another embodiment of Formula (VI), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R57; R57 is R60; R60 is heterocycloalkyl; wherein the heterocycloalkyl is tetrahydropyranyl. In another embodiment of Formula (VI), R1 is R4; R4 is
heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with R 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl. In another embodiment of Formula (VI), R1 is R4; R4 is heterocycloalkyl; wherein the heterocycloalkyl ring is piperdinyl or piperizinyl; and wherein the piperdinyl or piperizinyl ring is substituted with C(0)OR 57 ; R 57 is R 61 ; R 61 is alkyl; and the alkyl is methyl.
In one embodiment of Formula (VI), R1 is R5; and R5 is alkyl which is unsubstituted or substituted. In one embodiment of Formula (VI), R1 is R5; and R5 is alkyl which is unsubstituted or substituted with R7, OR7, OH, CN, or F. In another embodiment of Formula (VI), R1 is R5; and R5 is alkyl which is substituted with R7, OR7, NHR7, or N(R7)2.
In one embodiment of Formula (VI), R7 is R8, R9, R10 or R11; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R7 is R8; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R7 is R9; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R7 is R10; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R7 is R11; which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (VI), R8 is phenyl; which is unsubstituted or substituted as defined herein.
In one embodiment of Formula (VI), R9 is heteroaryl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R9 is furanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R9 is furanyl; which is unsubstituted.
In one embodiment of Formula (VI), R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is heterocycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is tetrahydro furanyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxetanyl, piperdinyl, or pyrrolidinyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is tetrahydropyranyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is morpholinyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is cycloalkyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is cyclohexyl, cyclopropyl, cyclobutyl, or bicyclo[2.2.1]heptanyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R10 is heterocycloalkyl; which is fused with R10A; and R10A is heteroarene. In another embodiment of Formula (VI), R10 is 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl.
In one embodiment of Formula (VI), R11 is alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R11 is alkyl. In another embodiment of Formula (VI), R11 is methyl; which is unsubstituted or substituted as defined herein. In another embodiment of Formula (VI), R11 is alkyl; which is substituted as defined herein. In another embodiment of Formula (VI), R11 is alkyl; which is substituted with R12, OR12, or CF3. In another embodiment of Formula (VI), R11 is alkyl; which is substituted with OR 12 ; R 12 is R 16 ; and R 16 is alkyl. In another embodiment of
Formula (VI), R11 is alkyl; which is substituted with CF3. In another embodiment of Formula (VI), R11 is alkyl; which is substituted with R12; R12 is R14; and R14 is heteroaryl.
In one embodiment of Formula (VI),
n, p, r, and q are each 0; A1 is N or C(A2);
A2 is H, F, Br, I, or CI;
B1 is R1, OR1, NHR1,
Figure imgf000238_0001
F, Br, I or CI;
D1 is H, F, Br, I, or CI;
E1 is H; and
Y1 is H, CN, N02, F, CI, Br, I, CF3, R17, OR17, SR17, S02R17, or C(0)NH2; or
Y1 and B1, together with the atoms to which they are attached, are benzene, heteroarene, or heterocycloalkene; and
A2, D1, and E1 are independently selected H;
R^S R R5;
R4 is cycloalkyl, or heterocycloalkyl;
R5 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R7, OR7, NHR7, N(R7)2, CN, OH, F, CI, Br or I;
R7 is R8, R9, R10, or R11;
R8 is phenyl;
R9 is heteroaryl;
R10 is cycloalkyl, cycloalkenyl, or heterocycloalkyl; each of which is unfused or fused with R10A, R10A is heteroarene;
R11 is alkyl each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12or CF3;
R12 is R14 or R16;
R14 is heteroaryl;
R16 is alkyl;
R17 is R21;
R21 is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, F, CI, Br or I;
R22 is R25;
R25 is heterocycloalkyl;
wherein the cyclic moieties represented by Y1 and B1 together, R4, R8, R10, R10A, and R25, are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, S02R57, C(0)R57, CO(0)R57,C(0)N(R57)2, NH2, NHR57, N(R57)2, NHC(0)R57, NHS(0)2R57, C(0)OH,
OH, CN, (O), F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl; R57 is R58, R60 or R61;
R58 is phenyl;
R60 is cycloalkyl, or heterocycloalkyl;
R61 is alkyl which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, N(R62)2, C(0)OH, OH, CN, F, CI, Br or I;
R62 is R65, or R66;
R65 is cycloalkyl, or heterocycloalkyl;
R66 is alkyl which is unsubstituted or substituted with OR67;
R67 is alkyl;
wherein the cyclic moieties represented by R57A, R58, and R60 are unsubstituted or substituted with one or two or three or four of independently selected R68, (O), F, CI, Br or I;
R68 is R71 or R72;
R71 is heterocycloalkyl; and
R72 is alkyl, which is unsubstituted or substituted with one or two F.
Still another embodiment pertains to a compound having Formula (VI), which is
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof.
Pharmaceutical Compositions, Combination Therapies, Methods of Treatment, and
Administration
Another embodiment comprises pharmaceutical compositions comprising a compound having Formula (I) and an excipient.
Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I). Still another embodiment comprises methods of treating autoimmune disease in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I).
Still another embodiment pertains to compositions for treating diseases during which anti-apoptotic Bcl-2 proteins are expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).
Still another embodiment pertains to methods of treating disease in a patient during which anti-apoptotic Bcl-2 proteins are expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).
Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).
Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).
Still another embodiment pertains to compositions for treating diseases during which are expressed anti-apoptotic Bcl-2 proteins, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
Still another embodiment pertains to methods of treating disease in a patient during which are expressed anti-apoptotic Bcl-2 proteins, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with anti-apoptotic Bcl-2 proteins.
Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with expression of anti-apoptotic Bcl-2 proteins.
Compounds having Formula (I) may exist as acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during isolation or following
purification of the compounds. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate,
thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate salts of the compounds are contemplated as being embraced by this invention. Basic addition salts of the compounds are those derived from the reaction of the compounds with the hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium.
The compounds having Formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally or vaginally.
Therapeutically effective amounts of compounds having Formula (I) depend on the recipient of the treatment, the disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered. The amount of a compound of this invention having Formula (I) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.
Compounds having Formula (I) may be administered with or without an excipient. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.
Excipients for preparation of compositions comprising a compound having Formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil,
cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium
carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth,
tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof.
Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S. P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.
Compounds having Formula (I) are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, other apoptosis promoters (for example, Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNA's, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal
anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteosome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, and the like, and in combination with one or more of these agents .
BiTE antibodies are bi-specific antibodies that direct T-cells to attack cancer cells by simultaneously binding the two cells. The T-cell then attacks the target cancer cell.
Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like. Without being limited by theory, one of the mechanisms by which T-cells elicit apoptosis of the target cancer cell is by exocytosis of cytolytic granule components, which include perforin and granzyme B. In this regard, Bcl-2 has been shown to attenuate the induction of apoptosis by both perforin and granzyme B. These data suggest that inhibition of Bcl-2 could enhance the cytotoxic effects elicited by T-cells when targeted to cancer cells (V.R. Sutton, D.L. Vaux and J.A. Trapani, J. of Immunology 1997, 158 (12), 5783).
SiR As are molecules having endogenous RNA bases or chemically modified nucleotides. The modifications do not abolish cellular activity, but rather impart increased stability and/or increased cellular potency. Examples of chemical modifications include phosphorothioate groups, 2'-deoxynucleotide, 2'-OCH3-containing ribonucleotides, 2'-F- ribonucleotides, 2'-methoxyethyl ribonucleotides, combinations thereof and the like. The siRNA can have varying lengths (e.g., 10-200 bps) and structures (e.g., hairpins,
single/double strands, bulges, nicks/gaps, mismatches) and are processed in cells to provide active gene silencing. A double-stranded siRNA (dsRNA) can have the same number of nucleotides on each strand (blunt ends) or asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be present on the sense and/or the antisense strand, as well as present on the 5'- and/ or the 3 '-ends of a given strand. For example, siRNAs targeting Mcl-1 have been shown to enhance the activity of ABT-263, (i.e., N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl- 1 -cyclohex- 1 -en- 1 -yl)methyl)piperazin- 1 -yl)benzoyl)-4-((( 1 R)-3 -(morpholin-4-y 1)- 1 -
((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide) or ABT-737 (i.e., N-(4-(4-((4'-chloro(l,r-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4- ((( 1 R)-3 -(dimethylamino)- 1 -((phenylsulfanyl)methyl)propyl)amino)-3 - nitrobenzenesulfonamide) in multiple tumor cell lines (Tse et. al, Cancer Research 2008, 68(9), 3421 and references therein).
Multivalent binding proteins are binding proteins comprising two or more antigen binding sites. Multivalent binding proteins are engineered to have the three or more antigen binding sites and are generally not naturally occurring antibodies. The term "multispecific binding protein" means a binding protein capable of binding two or more related or unrelated targets. Dual variable domain (DVD) binding proteins are tetravalent or multivalent binding proteins binding proteins comprising two or more antigen binding sites. Such DVDs may be monospecific (i.e., capable of binding one antigen) or multispecific (i.e., capable of binding two or more antigens). DVD binding proteins comprising two heavy chain DVD
polypeptides and two light chain DVD polypeptides are referred to as DVD Ig's. Each half of a DVD Ig comprises a heavy chain DVD polypeptide, a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.
Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone,
bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, rofosfamide and the like.
Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.
Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethynyl-l-P -D-ribofuranosylimidazole-4- carboxamide), enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or in
combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea,
ALKERAN® (melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed,
Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.
Antivirals include ritonavir, hydroxychloroquine and the like.
Aurora kinase inhibitors include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific kinase inhibitors and pan- Aurora kinase inhibitors and the like.
Bcl-2 protein inhibitors include AT-101 ((-)gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2 -targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4'- chloro( 1 , 1 '-biphenyl)-2-yl)methyl)piperazin- 1 -yl)benzoyl)-4-((( 1 R)-3 -(dimethylamino)- 1 - ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2- (4-chlorophenyl)-5 ,5 -dimethyl- 1 -cyclohex- 1 -en- 1 -yl)methyl)piperazin- 1 -yl)benzoyl)-4- ((( 1 R)-3 -(morpholin-4-yl)- 1 -((phenylsulfanyl)methy l)propyl)amino)-3 - ((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.
Bcr-Abl kinase inhibitors include DASATINIB® (BMS-354825), GLEEVEC®
(imatinib) and the like.
CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.
COX-2 inhibitors include ABT-963 , ARCOXI A® (etoricoxib), BEXTRA®
(valdecoxib), BMS347070, CELEBREX® (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-l-(4- sulfamoylphenyl-lH-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067,
SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.
EGFR inhibitors include ABX-EGF, anti-EGFR immuno liposomes, EGF-vaccine,
EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib),
TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.
ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK- 165 ,
GW-572016 (ionafarnib), GW-282974, EKB-569, PI- 166, dHER2 (HER2 vaccine),
APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.
Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.
HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (human recombinant antibody to HSP-90), NCS-683664, PU24FC1, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.
Inhibitors of inhibitors of apoptosis proteins include HGS1029, GDC-0145, GDC-
0152, LCL-161, LBW-242 and the like.
Antibody drug conjugates include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DMl, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.
Kinesin inhibitors include Eg5 inhibitors such as AZD4877, ARRY-520; CENPE inhibitors such as GSK923295A and the like.
JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and INCBO 18424 and the like.
MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.
mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI-103, PP242, PP30, Torin 1 and the like.
Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (difiunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN®
(naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO®
(oxaprozin) and the like.
PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.
Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin and the like.
Polo-like kinase inhibitors include BI-2536 and the like.
Phosphoinositide-3 kinase (PI3K) inhibitors include wortmannin, LY294002, XL- 147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.
Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.
VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788,
ANGIOZYME™ (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals
(Boulder, CO.) and Chiron, (Emeryville, CA)) , axitinib (AG- 13736), AZD-2171,
CP-547,632, IM-862, MACUGEN (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunitinib, SU- 11248), VEGF trap, ZACTIMA™ (vandetanib, ZD-6474) and the like. Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or
MYOCET® (liposomal doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (valrubicin), zinostatin and the like.
Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.
Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT- 1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGFlR-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250),
RITUXAN® (rituximab), ticilimumab, trastuzimab, CD20 antibodies types I and II and the like.
Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMA™ (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol),
MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA® (finasteride), rilostane,
SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), VANTAS® (Histrelin implant), VETORYL® (trilostane or modrastane), ZOLADEX®
(fosrelin, goserelin) and the like.
Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol
(KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like.
PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG- 014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.
Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like. Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.
Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma- la, ACTIMMUNE® (interferon gamma- lb) or interferon gamma-nl, combinations thereof and the like. Other agents include ALFAFERONE® ,(IFN-a), BAM- 002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab),
CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFGl), PROVENGE® (sipuleucel-T), sargaramostim, sizofilan, teceleukin, THERACYS® (Bacillus Calmette- Guerin), ubenimex, VIRULIZIN® (immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF- 10 (Tetrachlorodecaoxide (TCDO)),
PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like.
Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include krestin, lentinan, sizofiran, picibanil PF- 3512676 (CpG-8954), ubenimex and the like.
Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.
Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL®
(mercaptopurine) .
Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4- hydroxyphenyl)amino)pyridin-3 -yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone,
XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.
Ubiquitin ligase inhibitors include MDM2 inhibitors, such as nutlins, NEDD8 inhibitors such as MLN4924 and the like. Compounds of this invention can also be used as radiosensitizers that enhance the efficacy of radiotherapy. Examples of radiotherapy include external beam radiotherapy, teletherapy, brachytherapy and sealed, unsealed source radiotherapy and the like.
Additionally, compounds having Formula (I) may be combined with other chemotherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN® (Ad5CMV-p53 vaccine), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly Lpoly C12U, a synthetic RNA), APTOSYN® (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (l-methyl-3,17-dione-androsta-l,4- diene), AVAGE® (tazarotene), AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX® (human papillomavirus vaccine), CHOP® (C: CYTOXAN® (cyclophosphamide); H:
ADRIAMYCIN® (hydroxy doxorubicin); O: Vincristine (ONCOVIN®); P: prednisone), CYPAT™ (cyproterone acetate), combrestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a His- Ala linker to human epidermal growth factor) or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6- dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE® (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EPO906 (epithilone B), GARDASIL® (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), GASTRIMMUNE®, GENASENSE® , GMK
(ganglioside conjugate vaccine), GVAX® (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-a, interferon-γ, JUNO VAN™ or MEPACT™ (mifamurtide), lonafarnib, 5, 10-methylenetetrahydro folate, miltefosine
(hexadecylphosphocholine), NEOVASTAT®(AE-941 ), NEUTREXIN® (trimetrexate glucuronate), NIPENT® (pentostatin), ONCONASE® (a ribonuclease enzyme),
ONCOPHAGE® (melanoma vaccine treatment), ONCOVAX® (IL-2 Vaccine),
ORATHECIN™ (rubitecan), OSIDEM® (antibody-based cell drug), OVAREX® MAb (murine monoclonal antibody), paclitaxel, PANDIMEX™ (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB® (catumaxomab), REVLIMID®
(lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), TAXOPREXIN® (DHA-paclitaxel), TELCYTA® (canfosfamide, TLK286), temilifene, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn- KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFERADE™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-a), TRACLEER® or ZAVESCA® (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN® (motexafm gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS® (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), ZOMETA® (zolendronic acid), zorubicin and the like.
Data
Determination of the utility of compounds having Formula (I) as binders to and inhibitors of anti-apoptotic Bcl-2 proteins was performed using the Time Resolved- Fluorescence Resonance Energy Transfer (TR-FRET) Assay. Tb-anti-GST antibody was purchased from Invitrogen (Catalog No. PV4216).
Probe Synthesis
All reagents were used as obtained from the vendor unless otherwise specified.
Peptide synthesis reagents including diisopropylethylamine (DIEA), dichloromethane (DCM), N-methylpyrrolidone (NMP), 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU), N-hydroxybenzotriazole (HOBt) and piperidine were obtained from Applied Biosystems, Inc. (ABI), Foster City, CA or American Bioanalytical, Natick, MA. Preloaded 9-Fluorenylmethyloxycarbonyl (Fmoc) amino acid cartridges (Fmoc-Ala- OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Phe-OH, Fmoc- Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met- OH, Fmoc-Asn(Trt)-OH, Fmoc-Pro-OH, Fmor-Gln(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH) were obtained from ABI or Anaspec, San Jose, CA. The peptide synthesis resin (Fmoc-Rink amide MBHA resin) and Fmoc-Lys(Mtt)-OH were obtained from Novabiochem, San Diego, CA. Single-isomer 6-carboxyfluorescein succinimidyl ester (6-FAM-NHS) was obtained from Anaspec. Trifluoroacetic acid (TFA) was obtained from Oakwood Products, West Columbia, SC. Thioanisole, phenol, triisopropylsilane (TIS), 3,6-dioxa-l,8-octanedithiol (DODT) and isopropanol were obtained from Aldrich Chemical Co., Milwaukee, WI.
Matrix-assisted laser desorption ionization mass-spectra (MALDI-MS) were recorded on an Applied Biosystems Voyager DE-PRO MS). Electrospray mass-spectra (ESI-MS) were recorded on Finnigan SSQ7000 (Finnigan Corp., San Jose, CA) in both positive and negative ion mode.
General Procedure For Solid-Phase Peptide Synthesis (SPPS) Peptides were synthesized with, at most, 250 μιηοΐ preloaded Wang resin/vessel on an ABI 433 A peptide synthesizer using 250 μιηοΐ scale Fastmoc™ coupling cycles. Preloaded cartridges containing 1 mmol standard Fmoc-amino acids, except for the position of attachment of the fluorophore, where 1 mmol Fmoc-Lys(Mtt)-OH was placed in the cartridge, were used with conductivity feedback monitoring. N-terminal acetylation was accomplished by using 1 mmol acetic acid in a cartridge under standard coupling conditions.
Removal Of 4-Methyltrityl (Mtt) From Lysine
The resin from the synthesizer was washed thrice with DCM and kept wet. 150 mL of 95:4: 1 dichloromethane:triisopropylsilane:trifluoroacetic acid was flowed through the resin bed over 30 minutes. The mixture turned deep yellow then faded to pale yellow. 100 mL of DMF was flowed through the bed over 15 minutes. The resin was then washed thrice with DMF and filtered. Ninhydrin tests showed a strong signal for primary amine.
Resin Labeling With 6-Carboxyfluorescein-NHS (6-FAM-NHS) The resin was treated with 2 equivalents 6-FAM-NHS in 1% DIEA/DMF and stirred or shaken at ambient temperature overnight. When complete, the resin was drained, washed thrice with DMF, thrice with (1 x DCM and 1 x methanol) and dried to provide an orange resin that was negative by ninhydrin test.
General Procedure For Cleavage And Deprotection Of Resin-Bound Peptide Peptides were cleaved from the resin by shaking for 3 hours at ambient temperature in a cleavage cocktail consisting of 80% TFA, 5% water, 5% thioanisole, 5% phenol, 2.5% TIS, and 2.5% EDT (1 mL/0.1 g resin). The resin was removed by filtration and rinsing twice with TFA. The TFA was evaporated from the filtrates, and product was precipitated with ether (10 mL/0.1 g resin), recovered by centrifugation, washed twice with ether (10 mL/0.1 g resin) and dried to give the crude peptide.
General Procedure For Purification Of Peptides
The crude peptides were purified on a Gilson preparative HPLC system running Unipoint® analysis software (Gilson, Inc., Middleton, WI) on a radial compression column containing two 25 x 100 mm segments packed with Delta-Pak™ C18 15 μιη particles with 100 A pore size and eluted with one of the gradient methods listed below. One to two milliliters of crude peptide solution (10 mg/mL in 90% DMSO/water) was purified per injection. The peaks containing the product(s) from each run were pooled and lyophilized. All preparative runs were run at 20 mL/min with eluents as buffer A: 0.1% TFA-water and buffer B: acetonitrile.
General Procedure For Analytical HPLC
Analytical HPLC was performed on a Hewlett-Packard 1200 series system with a diode-array detector and a Hewlett-Packard 1046A fluorescence detector running HPLC 3D ChemStation software version A.03.04 (Hewlett-Packard. Palo Alto, CA) on a 4.6 x 250 mm YMC column packed with ODS-AQ 5 μιη particles with a 120 A pore size and eluted with one of the gradient methods listed below after preequilibrating at the starting conditions for 7 minutes. Eluents were buffer A: 0.1% TFA-water and buffer B: acetonitrile. The flow rate for all gradients was 1 mL/min.
F-Bak: Peptide Probe Acetyl-(SEQ ID NO: 1 )GQ VGRQL AIIGDK(6-F AM)-(SEQ ID NO:
2)INR-NH2
Fmoc-Rink amide MBHA resin was extended using the general peptide synthesis procedure to provide the protected resin-bound peptide (1.020 g). The Mtt group was removed, labeled with 6-FAM-NHS and cleaved and deprotected as described hereinabove to provide the crude product as an orange solid (0.37 g). This product was purified by RP- HPLC. Fractions across the main peak were tested by analytical RP-HPLC, and the pure fractions were isolated and lyophilized, with the major peak providing the title compound (0.0802 g) as a yellow solid; MALDI-MS m/z = 2137.1 [(M+H)+].
Alternative Synthesis of Peptide Probe F-Bak: Acetyl-(SEQ ID NO:
1 )GQ VGPvQLAIIGDK(6-F AM)-(SEQ ID NO:2)INR-NH2 The protected peptide was assembled on 0.25 mmol Fmoc-Rink amide MBHA resin (Novabiochem) on an Applied Biosystems 433 A automated peptide synthesizer running Fastmoc™ coupling cycles using pre-loaded 1 mmol amino acid cartridges, except for the fluorescein(6-FAM)-labeled lysine, where 1 mmol Fmoc-Lys(4-methyltrityl) was weighed into the cartridge. The N-terminal acetyl group was incorporated by putting 1 mmol acetic acid in a cartridge and coupling as described hereinabove. Selective removal of the 4- methyltrityl group was accomplished with a solution of 95:4: 1 DCM:TIS:TFA (v/v/v) flowed through the resin over 15 minutes, followed by quenching with a flow of dimethylformamide. Single-isomer 6-carboxyfluorescein-NHS was reacted with the lysine side-chain in 1% DIEA in DMF and confirmed complete by ninhydrin testing. The peptide was cleaved from the resin and side-chains deprotected by treating with 80:5:5:5:2.5:2.5 TF A/water/phenol/ thioanisole/triisopropylsilane: 3,6-dioxa-l,8-octanedithiol (v/v/v/v/v/v), and the crude peptide was recovered by precipitation with diethyl ether. The crude peptide was purified by reverse- phase high-performance liquid chromatography, and its purity and identity were confirmed by analytical reverse-phase high-performance liquid chromatography and matrix-assisted laser-desorption mass-spectrometry (m/z = 2137.1 ((M+H)+)).
Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) Assay
Representative compounds were serially diluted in dimethyl sulfoxide (DMSO) starting at 50 μΜ (2x starting concentration; 10% DMSO) and 10 were transferred into a 384-well plate. Then 10
Figure imgf000254_0001
of a protein/probe/antibody mix was added to each well at final concentrations listed in TABLE 1. The samples are then mixed on a shaker for 1 minute and incubated for an additional 3 hours at room temperature. For each assay, the probe/antibody and protein/probe/antibody were included on each assay plate as negative and positive controls, respectively. Fluorescence was measured on the Envision (Perkin Elmer) using a 340/35 nm excitation filter and 520/525 (F-Bak peptide) and 495/510 nm (Tb-labeled anti- Histidine antibody) emission filters. Dissociation constants (Κ;) are shown in TABLE 2 below and were determined using Wang's equation (Wang Z.-X., An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360: 111-4).
TABLE 1. Protein, Probe And Antibody Used For TR-FRET Assays
Figure imgf000254_0002
6-FAM = 6- carboxyfluorescein.; Tb = terbium; GST = glutathione S-transferase
The samples were then mixed on a shaker for 1 minute and incubated for an additional 3 hours at room temperature. For each assay, the probe/antibody and
protein/probe/antibody were included on each assay plate as negative and positive controls, respectively. Fluorescence was measured on the Envision (Perkin Elmer) using a 340/35 nm excitation filter and 520/525 (F-Bak peptide) and 495/510 nm (Tb-labeled anti-Histidine antibody) emission filters. Inhibition constants (Kj) for compounds according to the invention are shown in TABLE 2 below. Where the K; for a compound is represented as "<" (less than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for Bcl-2) is lower than the limit of detection of the assay used. Inhibition constants were determined using Wang's equation (Wang Zx,. An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360: 111-4).
TABLE 2. TR-FRET Bcl-2 Binding K; (μΜ)
Figure imgf000255_0001
25 < 0.000010 227 < 0.000010
26 0.000011 228 0.026761
27 0.000134 229 0.002109
28 < 0.000010 230 0.000031
29 < 0.000010 231 0.000770
30 < 0.000010 232 0.001631
31 < 0.000010 233 0.001654
32 < 0.000010 234 0.000115
33 < 0.000010 235 0.000023
34 0.00001 236 0.000033
35 < 0.000010 237 0.000024
36 0.000017 238 < 0.000010
37 < 0.000010 239 0.000026
38 0.0003 240 < 0.000010
39 0.000012 241 < 0.000010
40 < 0.000010 242 0.000057
41 < 0.000010 243 0.000546
42 0.000439 244 0.000281
43 0.000012 245 0.000015
44 < 0.000010 246 0.000144
45 < 0.000010 247 0.000019
46 0.000935 248 0.000029
47 < 0.000010 250 0.000412
48 < 0.000010 251 0.000571
49 0.000074 252 < 0.000010
50 0.000021 253 0.000052
51 < 0.000010 254 < 0.000010
52 0.000114 255 < 0.000010
53 < 0.000010 256 < 0.000010
54 0.002071 257 0.000052
55 < 0.000010 258 < 0.000010
56 0.000037 259 < 0.000010 57 0.000063 260 0.000016
58 < 0.000010 261 0.000134
59 0.000203 262 < 0.000010
60 < 0.000010 263 0.000156
61 0.000091 264 0.000036
62 < 0.000010 265 < 0.000010
63 < 0.000010 266 < 0.000010
64 < 0.000010 267 0.000035
65 < 0.000010 268 < 0.000010
66 < 0.000010 269 0.000016
67 < 0.000010 270 < 0.000010
68 0.000012 271 0.000039
69 0.001157 272 0.000031
70 0.003964 273 0.000035
71 0.00001 274 0.000040
72 < 0.000010 275 < 0.000010
73 < 0.000010 276 < 0.000010
74 0.000029 277 < 0.000010
75 < 0.000010 278 0.000252
76 0.000196 279 0.000035
77 0.000213 280 0.000071
78 < 0.000010 281 0.000145
79 < 0.000010 282 < 0.000010
80 < 0.000010 283 < 0.000010
81 < 0.000010 284 0.000024
82 0.000328 285 < 0.000010
83 0.000071 286 < 0.000010
84 0.000123 287 0.000081
85 0.000391 288 0.000251
86 0.000498 289 0.000090
87 0.000618 290 < 0.000010
88 0.000672 291 < 0.000010 89 0.000073 292 0.000190
90 0.000013 293 0.000093
91 0.000487 294 0.000046
92 0.000128 295 < 0.000010
93 0.003461 296 0.000512
94 0.000678 297 0.000174
95 0.000014 298 < 0.000010
96 0.000014 299 0.000039
97 0.000017 300 0.001627
98 < 0.000010 301 0.002065
99 0.000233 302 0.000332
100 < 0.000010 303 0.000044
101 0.000021 304 Nd
102 0.000094 305 0.000033
103 < 0.000010 306 0.002067
104 0.000016 307 0.000130
105 < 0.000010 308 0.000141
106 0.000895 309 0.000023
107 0.000035 310 0.000165
108 < 0.000010 311 < 0.000010
109 0.000127 312 < 0.000010
110 0.000557 313 0.001102
111 < 0.000010 314 0.000042
112 < 0.000010 315 0.000052
113 < 0.000010 316 0.000601
114 < 0.000010 317 < 0.000010
115 < 0.000010 318 < 0.000010
116 < 0.000010 319 < 0.000010
117 < 0.000010 320 < 0.000010
118 < 0.000010 321 < 0.000010
119 < 0.000010 322 < 0.000010
120 < 0.000010 323 0.000104 121 < 0.000010 324 < 0.000010
122 < 0.000010 325 < 0.000010
123 < 0.000010 326 < 0.000010
124 < 0.000010 327 < 0.000010
125 < 0.000010 328 < 0.000010
126 < 0.000010 329 0.000030
127 < 0.000010 330 < 0.000010
128 < 0.000010 331 0.001086
129 0.000002 332 0.000621
130 < 0.000010 333 0.000511
131 < 0.000010 334 0.000572
132 < 0.000010 335 0.000150
133 < 0.000010 336 0.000198
134 < 0.000010 337 < 0.000010
135 < 0.000010 338 0.000013
136 < 0.000010 339 0.000036
137 < 0.000010 340 < 0.000010
138 < 0.000010 341 < 0.000010
139 < 0.000010 342 < 0.000010
140 < 0.000010 343 < 0.000010
141 < 0.000010 344 < 0.000010
142 0.00013 345 < 0.000010
143 < 0.000010 346 0.000042
144 < 0.000010 347 0.000013
145 < 0.000010 348 0.000034
146 < 0.000010 349 0.000023
147 < 0.000010 350 < 0.000010
148 < 0.000010 351 < 0.000010
149 < 0.000010 352 0.000014
150 < 0.000010 353 < 0.000010
151 0.000017 354 0.000010
152 < 0.000010 355 0.000014
Figure imgf000260_0001
_.8£/.£0/OlOZSil/I3d Z6t6H/nOZ OAV 185 0.000022
388 0.000812
186 0.000047
389 0.000774
187 0.00008
390 < 0.000010
188 < 0.000010
391 < 0.000010
189 0.000018
392 0.000171
190 0.000026
393 0.000263
191 < 0.000010
394 0.000132
192 < 0.000010
395 0.000257
193 < 0.000010
396 0.000014
194 < 0.000010
397 0.000041
195 < 0.000010
398 0.000149
196 < 0.000010
399 < 0.000010
197 < 0.000010
400 0.000031
198 < 0.000010
401 < 0.000010
199 < 0.000010
402 < 0.000010
200 < 0.000010
403 < 0.000010
201 0.000014
404 < 0.000010
202 < 0.000010
nd = not c etermined
The inhibition constant (Kj) is the dissociation constant of an enzyme-inhibitor complex or a protein/small molecule complex, wherein the small molecule is inhibiting binding of one protein to another protein or peptide. So a large K; value indicates a low binding affinity and a small K; value indicates a high binding affinity.
TABLE 2 shows inhibition constants for the inhibition of a Bak BH3 peptide probe to Bcl-2 protein and indicate that compounds according to the invention have high binding affinities for anti-apoptotic Bcl-2 protein. The compounds are therefore expected to have utility in treatment of diseases during which anti-apoptotic Bcl-2 protein is expressed.
RS4;11 Cell Viability Assay
The acute lymphoblastic leukemia (ALL) cell line RS4;11 was used as the primary human cell line to assess the cellular activity of Bcl-2 selective agents in vitro and their efficacy in vivo. Previous studies have shown by BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, that RS4;11 cells were highly dependant on BCL-2 for survival and sensitive to the Bcl-2 family member inhibitor ABT-737 (Blood, 2008, Vol. I l l, 2300-2309). The prevalence of Bcl-2 complexed to the proapoptotic BH3 protein Bim in RS4;11 suggests that these cells are "primed" or more susceptible to cell death by antagonism of the antiapoptotic protein Bcl-2 for which they depend on for survival.
RS4;11 cells were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 10% FBS, 1 mM sodium pyruvate, 2 mM HEPES, 1% penicillin/streptomycin (Invitrogen), 4.5 g/L glucose and maintained at 37 C containing 5% CO2. To test for the cellular activity of compounds in vitro, cells were treated at 50,000 cells per well in 96-well microtiter plates in the presence of 10% human serum for 48 hours in a humidified chamber with 5% C02. Cell cytotoxicity EC50 values were assessed using CellTiter Glo (Promega) according to the manufacturer's recommendations. The EC50 values were determined as a percentage of viable cells following treatment compared to the untreated control cells.
Table 3. RS4;11 EC50 Values (μΜ)
Figure imgf000262_0001
19 0.465 221 0.094771
20 0.191 222 > 1
21 0.062 223 0.18208
22 0.085 224 0.013887
23 0.045 225 0.56001
24 0.00983 226 0.1178
25 0.007 227 0.0073566
26 0.05888 228 > 1
27 0.33237 229 > 1
28 0.0419 230 0.052821
29 0.02047 231 0.52301
30 0.01529 232 > 1
31 0.01565 233 > 1
32 0.08147 234 0.13532
33 0.00711 235 0.03232
34 0.00748 236 0.04292
35 0.29147 237 0.05316
36 0.18137 238 0.10303
37 0.00118 239 0.023699
38 3.5092 240 0.017266
39 0.01974 241 0.11377
40 0.09974 242 0.22275
41 0.05801 243 0.80718
42 0.53412 244 0.79378
43 0.27208 245 0.083614
44 0.05309 246 0.40218
45 0.00992 247 0.092976
46 > 5 248 0.099588
47 0.03265 250 > 1
48 0.00333 251 0.91782
49 0.35161 252 0.003475
50 0.31264 253 0.049586 51 0.02308 254 0.019908
52 0.19964 255 0.009004
53 0.06674 256 0.017997
54 1.9158 257 0.026002
55 0.0132 258 0.00055345
56 0.08654 259 0.00038795
57 0.42611 260 0.0054323
58 > 5 261 0.18366
59 0.7215 262 0.016346
60 0.05948 263 > 1
61 0.18337 264 0.68866
62 0.02506 265 0.0071718
63 0.00751 266 0.0072924
64 0.00025 267 0.06944
65 0.00025 268 0.048792
66 0.01893 269 0.0072346
67 0.04954 270 0.0025216
68 0.10846 271 0.43657
69 1.7243 272 0.84006
70 > 5 273 0.20925
71 0.09165 274 0.21418
72 0.00751 275 0.14303
73 0.02369 276 0.0035006
74 0.057 277 0.0081845
75 0.01509 278 0.79393
76 0.51131 279 0.22492
77 0.76196 280 0.45923
78 0.01252 281 0.65371
79 0.0649 282 0.032187
80 0.06863 283 0.013096
81 0.04814 284 0.16213
82 0.68383 285 0.057413 83 0.197 286 0.034464
84 0.158 287 0.59312
85 1.95 288 0.39042
86 1.02 289 0.6687
87 1.18 290 0.10663
88 0.447 291 0.016079
89 0.06446 292 0.88938
90 0.06299 293 0.28715
91 0.18296 294 0.12525
92 0.08089 295 0.014803
93 > 5 296 0.76869
94 1.6946 297 0.59157
95 0.02954 298 0.070305
96 0.04356 299 0.067981
97 0.05557 300 0.76334
98 0.0229 301 > 1
99 1.3923 302 0.38106
100 0.13666 303 0.04776
101 0.2991 304 0.29755
102 0.62178 305 0.032539
103 0.03917 306 0.55348
104 0.07125 307 0.12767
105 0.05357 308 0.257
106 0.82639 309 0.052421
107 0.06117 310 > 1
108 0.02407 311 0.035835
109 0.18339 312 0.016178
110 0.53638 313 > 1
111 0.01451 314 0.66006
112 0.02063 315 0.21027
113 0.00136 316 > 1
114 0.01078 317 0.013313 115 0.01184 318 0.011566
116 0.02853 319 0.0044972
117 0.0182 320 0.050974
118 0.01294 321 0.0188
119 0.01138 322 0.012367
120 0.00147 323 0.71689
121 0.05972 324 0.0045254
122 0.00185 325 0.012319
123 0.00333 326 0.023133
124 0.21224 327 0.0027224
125 0.00838 328 0.0098808
126 0.05359 329 0.42369
127 0.00975 330 0.0097843
128 0.00589 331 0.92638
129 0.01484 332 0.45738
130 0.01059 333 0.46292
131 0.01266 334 > 1
132 0.02209 335 0.26951
133 0.03186 336 0.35134
134 0.00251 337 0.001759
135 0.00237 338 0.003399
136 0.00296 339 0.45016
137 0.01272 340 0.05646
138 0.00152 341 0.031652
139 0.01681 342 0.050891
140 0.01275 343 0.12664
141 0.02044 344 0.0066616
142 0.34531 345 0.0092536
143 0.01914 346 0.19003
144 0.0212 347 0.018849
145 0.004 348 0.050263
146 0.01916 349 0.023086 147 0.02618 350 0.0058378
148 0.00938 351 0.0020618
149 0.01347 352 0.0011961
150 0.05103 353 0.0050512
151 0.03372 354 0.053231
152 0.02037 355 0.018771
153 0.01723 356 0.026623
154 0.02647 357 0.013235
155 0.59421 358 0.0038131
156 0.00805 359 0.0059243
157 0.01086 360 0.0098968
158 0.01793 361 0.00053755
159 0.01179 362 0.031726
160 0.08363 363 0.02643
161 0.03465 364 0.011244
162 0.01297 365 0.0030168
163 0.00432 366 0.016548
164 0.01476 367 nd
165 0.0051 368 nd
166 0.01185 369 0.0079974
167 0.00093 370 nd
168 0.08867 371 0.007165
169 0.07626 372 nd
170 0.12515 373 nd
171 0.05272 374 0.015475
172 0.02053 375 0.56013
173 0.00516 376 0.008765
174 0.12621 377 0.002377
175 > 1 378 0.006764
176 0.13353
379 0.019371
177 0.15936
380 0.13375
178 0.20234
381 0.0014055 179 0.04273
382 0.026976
180 0.0118
383 0.012436
181 0.10612
384 > 1
182 0.1234
385 0.13251
183 0.01753
386 0.0083796
184 0.02323
387 0.91091
185 0.02747
388 > 1
186 0.06443
389 0.73345
187 0.21494
390 0.0050612
188 0.01638
391 0.008412
189 0.14397
392 > 1
190 0.55068
393 > 1
191 0.00691
394 0.46138
192 0.00241
395 > 1
193 0.00076
396 0.084052
194 0.00819
397 0.11285
195 0.00207
398 0.54754
196 0.00172
399 0.12748
197 0.0125
400 0.064041
198 0.03619
401 0.026563
199 0.00506
402 0.010064
200 0.01099
403 0.034024
201 0.59132
404 > 1
202 0.0438
nd = not determined
TABLE 3 shows the utility of compounds having Formula I to functionally inhibit anti-apoptotic Bcl-2 protein in a cellular context. The acute lymphoblastic leukemia (ALL) cell line RS4;11 has been shown by BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, to be highly dependant on Bcl-2 for survival and is sensitive to the Bcl-2 family member inhibitor ABT-737 (Blood, 2008, Vol. I l l, 2300-2309). The ability of compounds to kill RS4;11 cells is a direct measure of the compounds ability to inhibit anti-apoptotic Bcl-2 protein function. Compounds of Formula I are very effective in killing RS4;11 cells as demonstrated by low EC50 values. Compounds taught in U.S. Patent Application No. 12/631404, entitled "BCL-2- SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES," filed on December 4, 2009, have utility for the treatment of various cancers and auto-immune diseases due to their activity against Bcl-2 family proteins, and more specifically Bcl-2. These compounds bind to Bcl-2 with high affinity in a FRET based assay described in 12/631404. The administration of a one or more of these compounds to cells that are dependant on Bcl-2 or Bcl-2 family proteins for survival, such as the RS4: 11 B-cell leukemia human tumor cell line, results in apoptosis, also known as programmed cell death. The amount of apoptosis caused by administration of the compound is represented by the EC50 in the cell viability assay, which is a measure of the number of living cells after administration of compound.
TABLE 4 identifies certain compounds (described below in Examples in 19, 20, 23 and 92 and described more fully in 12/631404, the disclosure of which is incorporated herein by reference) with the various substituents being defined by R, X and Y as set forth. As can be seen from TABLE 4, these compounds exhibit a trend of increasing binding affinity (Kj) for Bcl-2 with increasing levels of apoptosis, or cell death, in the Bcl-2 dependant tumor cell line RS4; 11. On this basis, the inventors expect that compounds with even greater affinity towards Bcl-2 than those compounds shown in Table 4 will exhibit a similar trend, potentially eliciting even greater levels of apoptosis, when administered to cells dependent on Bcl-2 for survival.
Table 4. Selected compounds in US Patent Application No. 12/631404
Figure imgf000269_0001
Figure imgf000270_0001
To t s en , n ng a n ty an ce u ar act v ty or compoun s accor ng to present invention were compared with structurally similar indole compounds. In particular, the compounds of the present invention, in which a nitrogen is contained at a specific position within the heteroarene fused to the heteroaryl ring were compared with the corresponding indole compounds, which latter compounds lack only the specific nitrogen substitution included in the compounds of the present invention.
As can be seen in TABLE 5, compounds of the present invention having the specific nitrogen substitutions shown (i.e., compounds of Examples 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 15, 16, and 17, where Z = N) in fact achieve relatively greater levels of apoptosis when administered to cells that depend on Bcl-2 for survival and have increased affinity towards Bcl-2 relative to the corresponding structural analogs lacking the specific nitrogen substitution (i.e., compounds of Examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93, and 94, respectively, where Z = C, taught in 9696USL2, the disclosure of which is incorporated herein by reference) .
Specifically, the seventh column of TABLE 5 compares binding affinity of compounds of the present invention (the compound identified by the designated substituents in the uppermost row in each pair of rows set apart by blank rows) to corresponding compounds lacking the described nitrogen substitution. In each comparison, compounds of the present application (upper row of each pair of rows separated by a blank row) bind Bcl-2 with greater affinity to Bcl-2 than the corresponding analogs (lower row of each pair of rows separated by a blank row).
Further, column 8 of TABLE 5 compares the amount of apoptosis in the Bcl-2 dependant RS4;11 cell line achieved using compounds of the present invention (again the compound identified by the designated substituents in the uppermost row in each pair of rows set apart by blank rows) to that achieved using compounds of Examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93, and 94, where Z = C . In each comparison, compounds of the present invention (upper row of each pair of rows separated by a blank row) achieve greater extent of apoptosis in Bcl-2 dependent RS4;11 cells than the corresponding analogs (lower row of each pair of rows separated by a blank row).
The increase in binding affinity between the compounds of the present invention and corresponding analogs ranges from 2.7x to greater than lOOx, and the increased potency in RS4;11 cells ranges from a 1.65x increase to greater than lOx increase.
As detailed below, a specific substitution of a nitrogen atom for a carbon atom leads to unexpected increase in binding affinity to antiapoptotic Bcl-2 and increase in potency in cell viability assays assessing apoptosis in Bcl-2 dependent cell lines.
This invention therefore comprises a series of compounds that demonstrate unexpected properties with respect to their binding to and inhibiting the activity of antiapoptotic Bcl-2 protein to a significantly greater extent than corresponding analog compounds.
TABLE 5. Direct comparison of compounds of the present invention with corresponding analogs.
Figure imgf000271_0001
Figure imgf000272_0001
(6) NH N02 5a N 0.000018 0.035
(91) NH N02 5a C 0.000487 0.183
(9) NH N02 5a N < 0.00001 0.015
(19) NH N02 5a C 0.000226 0.465
(10) NH N02 N < 0.00001 0.052
(20) NH N02 5a C 0.000181 0.191
(11) NH N02 5a N 0.000016 0.014
(21) NH N02 5a C 0.000912 0.062
(12) 0 N02 5a N < 0.00001 0.035
(92) 0 N02 5a C 0.000128 0.081 (13) NH N02 5a N < 0.00001 0.023
(22) NH N02 5a C 0.000291 0.085
(15) NH N02 5a N < 0.00001 0.013
(23) NH N02 5a C 0.000083 0.045
(16) NH S02CF3 5a N 0.000219 1.210
(93) NH S02CF3 5a C 0.035 > 5.000
(17) NH S02CF3 N 0.000090 0.475
(94) NH S02CF3 5a C 0.000678 1.690
More specifically, compounds of the present invention contain a substitution pattern shown in the diagram below.
Figure imgf000274_0001
Other compounds that contain isomeric ring systems to that shown above, such as those rings systems containing a nitrogen adjacent to the oxygenated carbon within the ring, as shown below, are compromised by instability. -
Figure imgf000275_0001
Specifically, this was discovered by the inventors in the following compound preparation. The intermediate structure F, that directly precedes the final product of the unstable compound, was prepared according to the route below. All intermediates A-F were stable and isolable using techniques known to those skilled in the art.
Figure imgf000275_0002
Intermediate F, shown in the scheme above, was reacted with intermediate G using standard coupling conditions that are known to those skilled in the art. The reaction mixture was analyzed via HPLC/MS to monitor the formation of a peak corresponding to the compound H. While this peak formed within hours of initiating the reaction below, the peak progressively disappeared during workup and chromatography, until it no longer was present. The lack of stability of the putative compound originates from the position of the nitrogen within the fused ring-system described above. This position, which is adjacent to the oxygen- bearing carbon in the 5-substituted-lH-pyrrolo[2,3-c]pyridine ring system shown below and described above makes the compound H unstable.
Figure imgf000276_0001
It is expected that a compound containing the fused 5 -substituted- lH-pyrrolo [3,2- b]pyridine ring system below would be similarly unstable, since the position of the nitrogen is adjacent to the oxygen-bearing carbon within the ring.
Figure imgf000276_0002
Therefore, compounds with the 5-substituted-lH-pyrrolo[2,3-b]pyridines are preferred over the isomeric compounds.
It is expected that, because compounds having Formula (I) bind to Bcl-2, they would also have utility as binders to anti-apoptotic proteins having close structural homology to Bcl- 2, such as, for example, anti-apoptotic BC1-XL, Bcl-w, Mcl-1 and Bfl-l/Al proteins.
Involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/037911, published as WO 2005/049594.
Involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418.
Involvement of Bcl-2 proteins in arthritis is disclosed in commonly-owned United States Provisional Patent Application Serial No. 60/988,479. Involvement of Bcl-2 proteins in bone marrow transplant rejection is disclosed in commonly-owned United States Patent Application Serial No. 11/941,196.
Overexpression of Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system. Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer),
lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like.
It is also expected that compounds having Formula (I) would inhibit growth of cells expressing Bcl-2 proteins derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous system, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like.
Autoimmune disorders include acquired immunodeficiency disease syndrome (AIDS), autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia, acute or chronic immune disease associated with organ transplantation, Addison's disease, allergic diseases, alopecia, alopecia areata, atheromatous disease/arteriosclerosis, atherosclerosis, arthritis (including osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis and reactive arthritis), autoimmune bullous disease, abetalipoprotemia, acquired immunodeficiency-related diseases, acute immune disease associated with organ transplantation, acquired acrocyanosis, acute and chronic parasitic or infectious processes, acute pancreatitis, acute renal failure, acute rheumatic fever, acute transverse myelitis, adenocarcinomas, aerial ectopic beats, adult
(acute) respiratory distress syndrome, AIDS dementia complex, alcoholic cirrhosis, alcohol- induced liver injury, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allergy and asthma, allograft rejection, alpha-1- antitrypsin deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, angina pectoris, ankylosing spondylitis associated lung disease, anterior horn cell degeneration, antibody mediated cytotoxicity, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, arthropathy, asthenia, asthma, ataxia, atopic allergy, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, atrophic autoimmune hypothyroidism, autoimmune haemo lytic anaemia, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), autoimmune mediated hypoglycaemia, autoimmune neutropaenia, autoimmune thrombocytopaenia, autoimmune thyroid disease, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bronchiolitis obliterans, bundle branch block, burns, cachexia, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chlamydia, choleosatatis, chronic alcoholism, chronic active hepatitis, chronic fatigue syndrome, chronic immune disease associated with organ transplantation, chronic eosinophilic pneumonia, chronic inflammatory pathologies, chronic mucocutaneous candidiasis, chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, common varied
immunodeficiency (common variable hypogammaglobulinemia), conjunctivitis, connective tissue disease associated interstitial lung disease, contact dermatitis, Coombs positive haemo lytic anaemia, cor pulmonale, Creutzfeldt- Jakob disease, cryptogenic autoimmune hepatitis, cryptogenic fibrosing alveolitis, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Crohn's disease, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, scleroderma, dermatologic conditions,
dermatomyositis/polymyositis associated lung disease, diabetes, diabetic arteriosclerotic disease, diabetes mellitus, Diffuse Lewy body disease, dilated cardiomyopathy, dilated congestive cardiomyopathy, discoid lupus erythematosus, disorders of the basal ganglia, disseminated intravascular coagulation, Down's Syndrome in middle age, drug-induced interstitial lung disease, drug-induced hepatitis, drug-induced movement disorders induced by drugs which block CNS dopamine, receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, enteropathic synovitis, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, female infertility, fibrosis, fibrotic lung disease, fungal sepsis, gas gangrene, gastric ulcer, giant cell arteritis, glomerular nephritis, glomerulonephritides, Goodpasture's syndrome, goitrous autoimmune hypothyroidism (Hashimoto's disease), gouty arthritis, graft rejection of any organ or tissue, graft versus host disease, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, group B streptococci (GBS) infection, Grave's disease, haemosiderosis associated lung disease, hairy cell leukemia, hairy cell leukemia, Hallerrorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hematopoietic malignancies (leukemia and lymphoma), hemolytic anemia, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, Henoch-Schoenlein purpurea, Hepatitis A, Hepatitis B, Hepatitis C, HIV infection/HIV neuropathy, Hodgkin's disease, hypoparathyroidism, Huntington's chorea, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hyperthyroidism, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic leucopaenia, idiopathic pulmonary fibrosis, idiopathic thrombocytopaenia, idiosyncratic liver disease, infantile spinal muscular atrophy, infectious diseases, inflammation of the aorta, inflammatory bowel disease, insulin dependent diabetes mellitus, interstitial pneumonitis, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile pernicious anaemia, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, Kawasaki's disease, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, linear IgA disease, lipidema, liver transplant rejection, Lyme disease, lymphederma, lymphocytic infiltrative lung disease, malaria, male infertility idiopathic or NOS, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, microscopic vasculitis of the kidneys, migraine headache, mitochondrial multisystem disorder, mixed connective tissue disease, mixed connective tissue disease associated lung disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine -Thomas Shi-Drager and Machado-Joseph), myalgic encephalitis/Royal Free Disease, myasthenia gravis, microscopic vasculitis of the kidneys, mycobacterium avium intracellulare, mycobacterium tuberculosis, myelodyplastic syndrome, myocardial infarction, myocardial ischemic disorders,
nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, nephrotic syndrome, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, Non-alcoholic Steatohepatitis, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, organ transplant rejection, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoarthrosis, osteoporosis, ovarian failure, pancreas transplant rejection, parasitic diseases, parathyroid transplant rejection, Parkinson's disease, pelvic inflammatory disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, perennial rhinitis, pericardial disease, peripheral atherlosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, phacogenic uveitis, Pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, postinfectious interstitial lung disease, premature ovarian failure, primary biliary cirrhosis, primary sclerosing hepatitis, primary myxoedema, primary pulmonary hypertension, primary sclerosing cholangitis, primary vasculitis,
Progressive supranucleo Palsy, psoriasis, psoriasis type 1, psoriasis type 2, psoriatic arthropathy, pulmonary hypertension secondary to connective tissue disease, pulmonary manifestation of polyarteritis nodosa, post-inflammatory interstitial lung disease, radiation fibrosis, radiation therapy, Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease, regular narrow QRS tachycardia, Reiter's disease, renal disease NOS, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, rheumatoid arthritis associated interstitial lung disease, rheumatoid spondylitis, sarcoidosis, Schmidt's syndrome,
scleroderma, senile chorea, Senile Dementia of Lewy body type, sepsis syndrome, septic shock, seronegative arthropathies, shock, sickle cell anemia, Sjogren's disease associated lung disease, Sjorgren's syndrome, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, sperm autoimmunity, multiple sclerosis (all subtypes), spinal ataxia, spinocerebellar degenerations, spondyloarthopathy, sporadic, polyglandular deficiency type I, sporadic polyglandular deficiency type II, Still's disease, streptococcal myositis, stroke, structural lesions of the cerebellum, Subacute sclerosing panencephalitis, sympathetic ophthalmia, Syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic lupus erythematosus-associated lung disease, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, T-cell or FAB ALL,
Takayasu's disease/arteritis, Telangiectasia, Th2 Type and Thl Type mediated diseases, thromboangitis obliterans, thrombocytopenia, thyroiditis, toxicity, toxic shock syndrome, transplants, trauma/hemorrhage, type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), type B insulin resistance with acanthosis nigricans, type III hypersensitivity reactions, type IV hypersensitivity, ulcerative colitic arthropathy, ulcerative colitis, unstable angina, uremia, urosepsis, urticaria, uveitis, valvular heart diseases, varicose veins, vasculitis, vasculitic diffuse lung disease, venous diseases, venous thrombosis, ventricular fibrillation, vitiligo acute liver disease, viral and fungal infections, vital encephalitis/aseptic meningitis, vital- associated hemaphagocytic syndrome, Wegener's granulomatosis, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, yersinia and salmonella-associated arthropathy and the like.
Schemes and Experimentals The following abbreviations have the meanings indicated. ADDP means l,l'-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2C03, and K2S04; 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means
tert-butoxycarbonyl; (DHQD)2PHAL means hydroquinidine 1 ,4-phthalazinediyl diethyl ether; DBU means l,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means Ν,Ν-dimethylformamide; dmpe means 1 ,2-bis(dimethylphosphino)ethane;
DMSO means dimethylsulfoxide; dppb means l,4-bis(diphenylphosphino)-butane; dppe means l,2-bis(diphenylphosphino)ethane; dppf means 1 , l'-bis(diphenylphosphino)ferrocene; dppm means l,l-bis(diphenylphosphino)methane; EDAC HC1 means l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means
fluorenylmethoxycarbonyl; HATU means 0-(7-azabenzotriazol-l-yl)-N,N'N'N'- tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine.
The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.
SCHEME 1
Figure imgf000282_0001
Compounds of Formula (4) can be prepared as shown in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I), which are representative of the compounds of the present invention. Compounds of Formula (1) wherein R is alkyl, can be converted to compounds of Formula (2) using Z3L1MgX1, wherein X1 is a halide, in a solvent such as but not limited to ether or tetrahydrofuran. Compounds of Formula (3) can be prepared from compounds of Formula (2) using a strong base such as NaH and R57X2, wherein X2 is a halide and R57 is as described herein. Compounds of Formula (3), when treated with aqueous NaOH or LiOH, will provide compounds of Formula (4).
SCHEME 2
Figure imgf000283_0001
As shown in SCHEME 2, compounds of Formula (5) can be reacted with compounds of Formula (6) and a reducing agent to provide compounds of Formula (7). Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium
triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofuran, and dichloromethane or mixtures thereof. Compounds of Formula (8) can be prepared from compounds of Formula (7) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
SCHEME 3
Figure imgf000283_0002
Compounds of Formula (9), when reacted with a compound a Formula (10) wherein X is a halide or triflate, and a base will provide a compound of Formula (11). Bases useful in the reaction include triethylamine, diisopropylethylamine and the like. Compounds of Formula (13), wherein Y is as described herein for substituents on Z3, can be prepared from compounds of Formula (11) and compounds of Formula (12) using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (14) can be prepared from compounds of Formula (13) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
Figure imgf000284_0001
(20) (21 )
As shown in SCHEME 4, compounds of Formula (17) can be prepared from compounds of Formula (15) and compounds of Formula (16), wherein R is alkyl and R38 is as described herein, using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (17) can be reduced to compounds of Formula (18) using a reducing agent such as L1AIH4 in a solvent such as but not limited to diethyl ether or THF. Compounds of Formula (19) can be prepared from compounds of
Formula (18) using Dess-Martin periodinane or Swern oxidation conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (19) can be reacted with a compound of Formula (5) and a reducing agent to provide compounds of
Formula (20). Examples of reducing agents include sodium borohydride, sodium
cyanoborohydride, sodium triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofuran, 1 ,2-dichloroethane, and dichloromethane or mixtures thereof. Compounds of Formula (21) can be prepared from compounds of Formula (20) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
SCHEME 5
Figure imgf000285_0001
As shown in SCHEME 5, compounds of Formula (22), wherein Ris alkyl, may be converted to compounds of Formula (23) by reacting the former, wherein X1 is CI, Br, I, or CF3SO3-, and compounds of Formula R41-OH and a catalyst, with or without a first base. Examples of catalysts include copper(I) trifluoromethanesulfonate toluene complex, PdCl2, Pd(OAc)2, and Pd2(dba)3. Examples of first bases include triethylamine, N,N- diisopropylethylamine, Cs2C03, Na2C03, K3P04, and mixtures thereof.
Compounds of Formula (22) may also be converted to compounds of Formula (23) by reacting the former, when X1 is CI, F, or N02, and compounds of Formula R41-OH with a first base. Examples of first bases include triethylamine, N,N-diisopropylethylamine, Cs2C03, Na2C03, K3P04, and mixtures thereof.
SCHEME 6
Figure imgf000286_0001
Compounds of Formula (18) can be reacted with mesyl chloride and a base such as but not limited to triethylamine, followed by N-t-butoxycarbonylpiperazine, to provide compounds of Formula (24). Compounds of Formula (25) can be prepared by reacting compounds of Formula (24) with triethylsilane and trifluoroacetic acid. Compounds of Formula (25) can be reacted with compounds of Formula (26) and HK2P04 to provide compounds of Formula (27) in a solvent such as but not limited to dimethylsulfoxide.
Compounds of Formula (28) can be prepared from compounds of Formula (27) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
Figure imgf000286_0002
As shown in SCHEME 7, compounds of Formula (1) can be reacted with an appropriate triphenylphosphonium bromide of Formula (29) and a base such as but not limited to sodium hydride or n-butyllithium to provide compounds of Formula (30). The reaction is typically performed in a solvent such as THF or DMSO. Compounds of Formula (31) can be prepared from compounds of Formula (30) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
SCHEME 8
Figure imgf000287_0001
As shown in SCHEME 8, compounds of Formula (32), which can be prepared as described herein, may be converted to compounds of Formula (33) by reacting the former with ammonia. Compounds of Formula (33) may be converted to compounds of Formula (I) by reacting the former and compounds of Formula (4), (8), (14), (21), (28), (31), or (38) and a coupling agent, with or without a first base. Examples of coupling agents include l-ethyl-3- [3-(dimethylamino)propyl]-carbodiimide hydrochloride, Ι,Γ-carbonyldiimidazole, and benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate. Examples of first bases include triethylamine, Ν,Ν-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.
SCHEME 9
Figure imgf000287_0002
Compounds of Formula (33), prepared as described in SCHEME 8, may also be converted to compounds of Formula (I) by reacting the former and compounds of Formula
(34) and a first base. Examples of first bases include but are not limited to sodium hydride, triethylamine, Ν,Ν-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.
Figure imgf000288_0001
(37) (38)
As shown in SCHEME 10, compounds of Formula (35), wherein L is a bond, alkyl, O, S, S(O), S(0)2, NH, etc., can be reacted with compounds of Formula (36), to provide compounds of Formula (37). The reaction is typically performed at elevated temperatures in a solvent such as but not limited to dimethylsulfoxide, and may require the use of a base such as but not limited to potassium phosphate, potassium carbonate, and the like. Compounds of Formula (38) can be prepared from compounds of Formula (37) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I).
SCHEME 1
Figure imgf000288_0002
Compounds of Formula (39), wherein Y is as described herein for substituents on Z , can be prepared from compounds of Formula (39 A) wherein X is a halide or triflate, and Y- B(OH)2 using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (39) can be reacted with tert-butyl piperazine-l-carboxylate and a reducing agent such as sodium triacetoxyborohydride to provide compounds of Formula (40). The reaction is typically performed in a solvent such as but not limited to methylene chloride. Compounds of Formula (41) can be prepared from compounds of Formula (40) by reacting the latter with R57X, wherein X is a halide, and NaH in a solvent such as Ν,Ν-dimethylformamide, and then the resulting material can be treated with triethylsilane and trifluoroacetic acid in dichloromethane. Compounds of Formula (41) can be used as described in Scheme 10 wherein LJ-Z3 is as shown in Formula (41).
SCHEME 12
Figure imgf000289_0001
(42) (43)
As shown in SCHEME 12, substituted piperazin-2-ones wherein R57 is alkyl, can be reacted with compounds of Formula (6) and a reducing agent such as sodium
triacetoxyborohydride in dichloromethane to provide compounds of Formula (42).
Compounds of Formula (42) can be reduced to compounds of Formula (43) using a reducing agent such as but not limited to lithium aluminum hydride in a solvent such as but not limited to tetrahydrofuran. Compounds of Formula (43) can be used as described in Scheme 10 wherein Lx-Z3 is as shown in Formula (43).
The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. The exemplified compounds were named using ACD/ChemSketch Version 5.06 (05 June 2001, Advanced Chemistry Development Inc., Toronto, Ontario),
ACD/ChemSketch Version 12.01 (13 May 2009), Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA).
Intermediates were named using ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA).
EXAMPLE 1
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 1A
tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)piperazine- 1 -carboxylate 4'-Chlorobiphenyl-2-carboxaldehyde (4.1 g), tert-butyl piperazine-1 -carboxylate (4.23 g), and sodium triacetoxyborohydride (5.61 g) in CH2C12 (60 mL) were stirred for 24 hours. The reaction was quenched with methanol and poured into ether. The solution was washed with water and brine, concentrated, and chromatographed on silica gel with 2-25% ethyl acetate/hexanes.
EXAMPLE IB
l-((4'-chlorobiphenyl-2-yl)methyl)piperazine
EXAMPLE 1A (3.0 g) and triethylsilane (1 mL) were stirred in CH2C12 (30 mL) and trifluoroacetic acid (30 mL) for 2 hours, and the reaction was concentrated, and then taken up in ether and concentrated again. The material was taken up in dichloromethane (200 mL) and NaHC03 solution (100 mL), and partitioned. The organic layer was dried over Na2S04, and condensed to give the title compound.
EXAMPLE 1C
tert-butyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin- 1 -yl)-2-fluorobenzoate Tert-butyl 4-bromo-2-fluorobenzoate (14.0 g), EXAMPLE IB (16.05 g), Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(0))(1.40 g), 2-(di-tert-butylphosphino)biphenyl (1.82 g), and K3PO4 (16.2 g) were stirred in 1,2-dimethoxyethane (300 mL) at 80°C for 24 hours. The reaction was cooled and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE ID
tert-butyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin- 1 -yl)benzoate
lH-Pyrrolo[2,3-B]pyridine-5-ol (167 mg), EXAMPLE 1C (500 mg), and Cs2C03 (508 mg) were stirred in dimethylsulfoxide (5 mL) at 130°C for 24 hours. The mixture was cooled, diluted with ethyl acetate, washed thee times with water, and brine, and dried (Na2S04), filtered and concentrated. The crude product was chromatographed on silica gel with 25% ethyl acetate/hexanes.
EXAMPLE IE
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l- yl)benzoic acid EXAMPLE ID (200 mg) and triethylsilane (1 mL) were stirred in dichloromethane (15 mL) and trifluoroacetic acid (15 mL) for 1 hour. The mixture was concentrated, taken up in ethyl acetate, washed twice with NaH2P04, and brine, and dried (Na2S04), filtered and concentrated.
EXAMPLE IF
3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonamide (2.18 g), l-(tetrahydropyran-4-yl)methylamine (1.14 g), and triethylamine (1 g) were stirred in tetrahydrofuran (30 mL) for 24 hours. The solution was diluted with ethyl acetate, washed with NaH2P04 solution and brine, and dried (Na2S04), filtered and concentrated. The product was triturated from ethyl acetate.
EXAMPLE 1G
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE IE (115 mg), EXAMPLE IF (67 mg), l-ethyl-3-[3- (dimethylamino)propyl]-carbodiimide hydrochloride (82 mg), and 4-dimethylaminopyridine (26 mg) were stirred in CH2C12 (3 mL) for 24 hours. The reaction was cooled and
chromatographed on silica gel with 0-5% methanol/ethyl acetate. 1H NMR (300MHz, dimethylsulfoxide-de) δ 11.48 (brs, 1H), 8.34 (br s, 1H), 8.31 (m, 1H), 7.90 (d, 1H), 7.68 (m, 1H), 7.58 (m, 2H), 7.46 (m, 4H), 7.35 (m, 2H), 7.21 (dd, 1H), 6.76 (m, 4H), 6.28
(m, 2H), 3.02 (m, 2H), 2.89 (m, 4H), 2.80 (m, 4H), 2.40 (m, 3H), 1.59 (m, 2H), 1.25 (m, 4H), 0.87 (m, 2H).
EXAMPLE 2
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-( {4-[(3-morpholin-4- ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 2A
4-(3 -morpholinopropylamino)-3 -nitrobenzenesulfonamide This EXAMPLE was prepared by substituting 3-(N-morpholinyl)-propylamine for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 2B
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-( {4-[(3-morpholin-4- ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 2 A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.60 (brs, IH), 8.60 (m, IH), 8.43 (d, IH), 7.94 (d, IH), 7.64 (m, 2H), 7.54 (d, IH), 7.45 (m, 4H), 7.33 (m, 2H), 7.23 (dd, IH), 6.96 (d, IH), 6.85 (m, 2H), 6.32 (d, IH), 6.26 (d, IH), 3.60 (m, 4H), 3.10 (m, 4H), 3.05 (m, 10H), 2.40 (m, 2H), 2.33 (m, 2H), 1.77 (m, 2H). EXAMPLE 3
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 3A
methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoroacetic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product.
EXAMPLE 3B
methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarboxylate
EXAMPLE 3 A (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2: 1 dimethoxy ethane /methanol (600 mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product. EXAMPLE 3C
(2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 3B (53.8 g) and ether (400 mL), was added methanol (25 mL) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN HC1 with ice-cooling. The mixture was diluted with water and extracted with ether (3x 100 mL). The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes.
EXAMPLE 3D
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine- 1 - carboxylate
Mesyl Chloride (7.5 mL) was added via syringe to EXAMPLE 3C (29.3 g) and triethylamine (30 mL) in CH2C12 (500 mL) at 0°C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE 3E
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine EXAMPLE 3D (1 g) was stirred in dichloromethane (10 mL), trifluoroacetic acid (10 mL), and triethylsilane (1 mL) for 1 hour. The mixture was concentrated, taken up in a mixture of dichloromethane (100 mL) and saturated aqueous Na2C03 solution (20 mL) and stirred for 10 minutes. The layers were separated, and the organic layer was dried over Na2S04, filtered, and concentrated to give the product.
EXAMPLE 3F
5-bromo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine To a mixture of 5-bromo-lH-pyrrolo[2,3-b]pyridine (15.4 g) in tetrahydrofuran (250 mL) was added 1M lithium hexamethyldisilazide in tetrahydrofuran (86 mL), and after 10 minutes, TIPS-Cl (triisopropylchlorosilane ) (18.2 mL) was added. The mixture was stirred at room temperature for 24 hours. The reaction was diluted with ether, and the resulting solution was washed twice with water. The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10% ethyl acetate/hexanes.
EXAMPLE 3G
l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-5-ol
To a mixture of EXAMPLE 3F (24.3 g) in tetrahydrofuran (500 mL) at -78°C was added 2.5M BuLi (30.3 mL). After 2 minutes, trimethylborate (11.5 mL) was added, and the mixture was allowed to warm to room temperature over 1 hour. The reaction was poured into water, extracted thee times with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was taken up in tetrahydrofuran (200 mL) at 0°C, and 1M NaOH (69 mL) was added, followed by 30% H202 (8.43 mL), and the solution was stirred for 1 hour. Na2S203 (10 g) was added, and the pH was adjusted to 4-5 with
concentrated HC1 and solid NaH2P04. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2S04), filtered, and
concentrated. The crude product was chromatographed on silica gel with 5-25% ethyl acetate/hexanes.
EXAMPLE 3H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 3G (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and K3P04
(9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes. EXAMPLE 31
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate A mixture of EXAMPLE 3H (1.55 g), EXAMPLE 3E (2.42 g), and HK2P04 (1.42 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed with 3x 1M NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50% ethyl acetate/hexanes. EXAMPLE 3J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
EXAMPLE 31 (200 mg) in dioxane (10 mL) and 1M NaOH (6 mL) at 50°C was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product.
EXAMPLE 3K
tert-butyl 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-ylcarbamate
Tert-butyl piperidin-4-ylcarbamate (45.00 g, 225 mmol) and dihydro-2H-pyran- 4(3H)-one (24.74 g, 247 mmol) were added to dichloromethane (1000 mL). Sodium triacetoxyborohydride (61.90 g, 292 mmol) was added, and the solution was stirred at room temperature for 16 hours. The solution was extracted with 1M sodium hydroxide and dried over anhydrous sodium sulfate. The solution was filtered and concentrated and purified by flash column chromatography on silica gel with 10% methanol (in dichloromethane) increasing to 20% methanol (in dichloromethane).
EXAMPLE 3L
1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-amine dihydrochloride
A solution of EXAMPLE 3K (52.57 g, 185 mmol) in dichloromethane (900 mL) was treated with 4M aqueous HC1 (462 mL), and the solution was mixed vigorously at room temperature for 16 hours. Solvent was removed under vacuum to give crude product as the dihydrochloride salt, which was used without further purification.
EXAMPLE 3M
3 -nitro-4-( 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)benzenesulfonamide EXAMPLE 3L (22.12 g, 86 mmol) was added to 1,4-dioxane (300 mL) and water (43 mL). Triethylamine (43.6 mL, 31.6 g, 313 mmol) was added, and the mixture was stirred at room temperature until EXAMPLE 3L had completely dissolved. 4-chloro-3- nitrobenzenesulfonamide was added and the mixture was heated at 90°C for 16 hours. The mixture was cooled, and the solvents were removed under vacuum. 10%> methanol (in dichloromethane) was added and the solution was stirred vigorously at room temperature until a fine suspension was obtained. The solid was isolated by vacuum filtration and washed with dichloromethane to give pure product.
EXAMPLE 3N
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 3M for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.65 (brs, IH), 8.53 (br s, IH), 8.18 (m, IH), 8.00 (br s, IH), 7.63 (m, IH), 7.49 (m, 3H), 7.34 (d, 2H), 7.12 (m, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.37 (d, IH), 6.20 (d, IH), 3.95 (m, 2H), 3.05 (m, 10H), 2.73 (m, 4H), 2.17 (m, 10H), 1.95 (m, 2H), 1.80 (m, 2H), 1.63 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 4
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 4A
4-( 1 -methylpiperidin-4-ylamino)-3 -nitrobenzenesulfonamide
This EXAMPLE was prepared by substituting 4-amino-N-methylpiperidine for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 4B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 4A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-de) δ 11.65 (brs, IH), 8.55 (br s, IH), 8.17 (m, IH), 8.02 (d, IH), 7.85
(dd, IH), 7.51 (m, 3H), 7.35 (m, 2H), 7.18 (dd, IH), 7.05 (d, 2H), 6.68 (dd, IH), 6.38 (d, IH), 6.20 (d, IH), 3.90 (m, IH), 3.09 (m, 8H), 2.77 (m, 2H), 2.05-2.30 (m, 10H), 1.95 (s, 3H), 1.39 (t, 2H), 1.24 (m, 2H), 0.93 (s, 6H). EXAMPLE 5
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 5A
3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide A mixture of 4-fluoro-3-nitrobenzenesulfonamide (2.18 g), l-(tetrahydropyran-4- yl)methylamine (1.14 g), and triethylamine (1 g) in tetrahydrofuran (30 mL) were stirred overnight, neutralized with concentrated HCl and concentrated. The residue was suspended in ethyl acetate and the precipitates were collected, washed with water and dried to provide the title compound.
EXAMPLE 5B
methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate
To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoroacetic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product.
EXAMPLE 5C
methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarboxylate EXAMPLE 5B (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2: 1 dimethoxy ethane /methanol (600 mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product. EXAMPLE 5D
(2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 5C (53.8 g) and ether (400 mL), was added methanol (25 mL) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN HC1 with ice-cooling. The mixture was diluted with water and extracted with ether (3x 100 mL). The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes.
EXAMPLE 5E
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine- 1 - carboxylate
Mesyl Chloride (7.5 mL) was added via syringe to EXAMPLE 5D (29.3 g) and triethylamine (30 mL) in CH2C12 (500 mL) at 0°C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE 5F
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine EXAMPLE 5E (200 mg) and triethylsilane (1 mL) were stirred in dichloromethane (15 mL) and trifluoroacetic acid (15 mL) for 1 hour. The mixture was concentrated, taken up in ethyl acetate, washed twice with NaH2P04, and brine, and dried (Na2S04), filtered and concentrated.
EXAMPLE 5G
5-bromo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine To a mixture of 5-bromo-lH-pyrrolo[2,3-b]pyridine (15.4 g) in tetrahydrofuran (250 mL) was added 1M lithium hexamethyldisilazide in tetrahydrofuran (86 mL), and after 10 minutes, TIPS-Cl (triisopropylchlorosilane ) (18.2 mL) was added. The mixture was stirred at room temperature for 24 hours. The reaction was diluted with ether, and the resulting solution was washed twice with water. The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 5H
l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-5-ol
To a mixture of EXAMPLE 5G (24.3 g) in tetrahydrofuran (500 mL) at -78°C was added 2.5M BuLi (30.3 mL). After 2 minutes, trimethylborate (11.5 mL) was added, and the mixture was allowed to warm to room temperature over 1 hour. The reaction was poured into water, extracted thee times with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was taken up in tetrahydrofuran (200 mL) at 0°C, and 1M NaOH (69 mL) was added, followed by 30% H202 (8.43 mL), and the solution was stirred for 1 hour. Na2S203 (10 g) was added, and the pH was adjusted to 4-5 with
concentrated HC1 and solid NaH2P04. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2S04), filtered, and
concentrated. The crude product was chromatographed on silica gel with 5-25% ethyl acetate/hexanes.
EXAMPLE 51
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 5H (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and K3P04 (9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes.
EXAMPLE 5J
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate
A mixture of EXAMPLE 51 (1.55 g), EXAMPLE 5F (2.42 g), and HK2P04 (1.42 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed with 3x 1M NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50% ethyl acetate/hexanes.
EXAMPLE 5K
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid EXAMPLE 5J (200 mg) in dioxane (10 mL) and 1M NaOH (6 mL) at 50UC was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product.
EXAMPLE 5L
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 5K (3.39 g), EXAMPLE 5A (1.87 g), l-ethyl-3-[3- (dimethylamino)propyl]-carbodiimide hydrochloride (2.39 g), and 4-dimethylaminopyridine (1.09 g) were stirred in CH2C12 (40 mL) for 24 hours. The reaction was cooled and chromatographed on silica gel with 25-100% ethyl acetate/hexanes, then 10% methanol/ethyl acetate with 1% acetic acid,o give the product (1.62 g, 32%) as a white solid. 1H NMR (300MHz, dimethylsulfoxide-d6) 11.65 (brs, 1H), 8.55 (br s, 1H), 8.04 (d, 1H), 7.89 (dd, 1H), 7.51 (m, 3H), 7.33 (d, 2H), 7.08 (m, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (d, 1H), 6.19 (d, 1H), 3.84 (m, 1H), 3.30 (m, 4H), 3.07 (m, 4H), 2.73(m, 2H), 2.18 (m, 6H), 1.95 (m, 2H), 1.61 (dd, 2H), 1.38 (m, 2H), 1.24 (m, 4H), 0.92 (s, 6H).
EXAMPLE 6
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 6A
4-(4-methy lpiperazin- 1 -ylamino)-3 -nitrobenzenesulfonamide A 50 mL round-bottomed flask was charged with 4-chloro-3- nitrobenzenesulfonamide (1 g, 4.23 mmol), 4-methylpiperazin-l -amine dihydrochloride (1 g, 5.32 mmol), and N^N^^^-tetramethylethane-l^-diamine (3 mL, 20.01 mmol) in dioxane (10 mL). The reaction mixture was refluxed for 12 hours. After this time, the reaction mixture was cooled to room temperature, the salt filtered off via a Buchner funnel, and the solvent removed in vacuo. The crude product was added to a silica gel column (Analogix, SF65- 200g) and purified by eluting with 0-5% methanol in dichloromethane. EXAMPLE 6B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 6A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-de) δ 11.65 (brs, IH), 9.09 (br s, IH), 8.47 (d, IH), 8.24 (dd, IH), 7.99 (d, IH), 7.50 (m, 4H), 7.34 (d, 2H), 7.04 (d, 2H), 6.64 (dd, IH), 6.35 (d, IH), 6.20 (d, IH), 3.04 (m, 4H), 2.89 (m, 4H), 2.73 (m, 2H), 2.34 (s, 3H), 2.17 (m, 6H), 1.95 (br s, 2H), 1.38 (t, 2H), 1.05 (m, 4H), 0.93 (s, 6H).
EXAMPLE 7
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N-( {4- [( 1 -methylpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzamide
EXAMPLE 7A
ethyl 2-(9H-carbazol-4-yloxy)-4-fluorobenzoate
This EXAMPLE was prepared by substituting ethyl 2,4-difluorobenzoate for methyl 2,4-difluorobenzoate and 4-hydroxycarbazole for EXAMPLE 3G in EXAMPLE 3H.
EXAMPLE 7B
ethyl 2-(9H-carbazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 - enyl)methyl)piperazin- 1 -yl)benzoate
This EXAMPLE was prepared by substituting EXAMPLE 7A for EXAMPLE 3H in EXAMPLE 31.
EXAMPLE 7C
2-(9H-carbazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 7B for EXAMPLE 31 in EXAMPLE 3 J, except here upon completion of the reaction, water and 2N HCl were added to adjust the pH to 2, and the HCl salt of the product was extracted using CHCI3/CH3OH.
EXAMPLE 7D
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N-( {4- [( 1 -methylpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 7C for EXAMPLE IE and EXAMPLE 4 A for EXAMPLE IF in EXAMPLE 1G, except here the purification was done by preparative HPLC using a CI 8 column, 250 x 50 mm, 10μ, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a
bistrifluoroacetate salt. 1H NMR (300 MHz, dimethylsulfoxide -de) δ 11.82 (br s, IH), 11.40 (s, IH), 9.70, 9.40 (both v br s, total 2H), 8.40 (d, IH), 8.10 (br d, IH), 7.90 (br d, IH), 7.72 (dd, IH), 7.60 (d, IH), 7.48 (d, IH), 7.38 (m, 3H), 7.22 (m, 2H), 7.07 (m, 4H), 6.78 (dd, IH), 6.43 (dd, IH), 6.19 (s, IH), 3.97 (m, IH), 3.80 (m, 2H), 3.60, 3.30, 3.10, 2.80 (all br m, total 11H), 2.20, 2.10, 2.00 (all br m, total 8H), 1.78 (m, 2H), 1.42 (m, 2H), 1.25 (m, 2H), 0.92 (s, 6H).
EXAMPLE 8
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l -yl)-N-( {3-nitro-4-[(3-pyrrolidin- 1 - ylpropyl)amino]phenyl}sulfonyl)benzamide
EXAMPLE 8A
3 -nitro-4-(3 -(pyrrolidin- 1 -yl)propylamino)benzenesulfonamide
This EXAMPLE was prepared by substituting 3-(pyrrolidin-l-yl)propan-l -amine for l-(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 8B
2-(9H-carbazol-4-yloxy)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l -yl)-N-( {3-nitro-4-[(3-pyrrolidin- 1 - ylpropyl)amino]phenyl}sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 7C for EXAMPLE IE and EXAMPLE 8 A for EXAMPLE IF in EXAMPLE 1G, except here the purification was done by preparative HPLC using a CI 8 column, 250 x 50 mm, 10μ, and eluting with a gradient of 20-100% CH3CN vs. 0.1%) trifluoroacetic acid in water, giving the product as a bistrifluoroacetate salt.. 1H NMR (300 MHz, dimethylsulfoxide -de) δ 11.80 (br s, IH), 11.42 (s, IH), 9.50, 9.25 (both v br s, total 2H), 8.58 (br t, IH), 8.43 (d, IH), 7.91 ( d, IH), 7.72 ( dd, IH), 7.60 (d, IH), 7.50 (d, IH), 7.38 (m, 3H), 7.23 (m, 2H), 7.07 (m, 3H), 6.93 (d, IH), 6.78 (dd, IH), 6.44 (dd, IH), 6.18 (s, IH), 3.70, 3.60, 3.20. 3.00 (all br m, total 18H), 2.18 (br m, 2H), 2.00-180 (envelope, 8H), 1.42 (m, 2H), 0.92 (s, 6H).
EXAMPLE 9
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 9A
Trans-tert-butyl 4-morpholinocyclohexylcarbamate A solution of tert-butyl-4-aminocyclohexylcarbamate (20.32 g, 95 mmol), bis(2- bromoethyl) ether (14.30 ml, 114 mmol) and triethylamine (33.0 ml, 237 mmol) in N,N- dimethylformamide (200 ml) was stirred for 16 hours at 70 °C. The reaction mixture was cooled down to room temperature, concentrated and the product was extracted with ethyl acetate. The organic layer was washed with sodium carbonate solution (15%> aq.), dried and concentrated. The product was used in next step without purification.
EXAMPLE 9B
Trans-4-morpholinocyclohexanamine dihydrochloride To a solution of trans-tert-butyl-4-morpholinocyclohexylcarbamate (19.2 g, 67.5 mmol) in dichloromethane (100 ml) was added HC1 (100 ml, 400 mmol) (4M in dioxane) and the reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was diluted with ether and solid salt was filtered off, and dried in an oven.
EXAMPLE 9C
Trans-4-(4-morpholinocyclohexylamino)-3-nitrobenzenesulfonamide A solution of trans-4-morpholinocyclohexanamine dihydrochloride (5 g, 19.44 mmol), 4-fluoro-3-nitrobenzenesulfonamide (4.32 g, 19.63 mmol) and triethylamine (20 ml, 143 mmol) in tetrahydrofuran (60 ml) was stirred for 16 hours at room temperature. The solid product was filtered off, washed with tetrahydrofuran, ether, dichloromethane (3 x) and dried under vacuum.
EXAMPLE 9D
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 9C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.61 (brs, 1H), 8.49 (br s, 1H), 8.12 (m, 1H), 7.99 (br s, 1H), 7.71 (m, 1H), 7.50 (m, 3H), 7.35 (d, 2H), 7.04 (d, 2H), 7.01 (m, 1H), 6.65 (dd, 1H), 6.36 (d, 1H), 6.21 (d, 1H), 3.60 (m, 4H), 3.04 (m, 4H), 2.73 (m, 2H), 2.57 (m, 2H), 2.42 (m, 1H), 2.18 (m, 6H), 2.05 (m, 2H), 1.95 (m, 2H), 1.90 (m, 2H), 1.38 (m, 6H), 1.15 (m, 3H), 0.92 (s, 6H).
EXAMPLE 10
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 10A
4-(2-methoxyethylamino)-3-nitrobenzenesulfonamide This EXAMPLE was prepared by substituting 2-methoxyethylamine for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 10B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 10A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.65 (brs, 1H), 8.58-8.49 (m, 1H), 8.55 (d, 1H), 8.03 (d, 1H), 7.79 (m, 1H), 7.49 (m, 3H), 7.34 (m, 2H), 7.06 (m, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.38 (m, 1H), 6.20 (d, 1H), 3.61-3.51 (m, 4H), 3.31 (s, 3H), 3.07 (m, 4H), 2.74 (m, 2H), 2.17 (m, 6H), 1.95 (br s, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 11
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 11 A
(S)-3 -nitro-4-((tetrahydro-2H-pyran-3 -yl)methylamino)benzenesulfonamide and
(R)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide This EXAMPLE was prepared by substituting (tetrahydro-2H-pyran-3- yl)methanamine for l-(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 11B
(S)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide The racemic mixture of EXAMPLE 11A was resolved by chiral SFC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in C02 over 15 minutes (oven temperature: 40°C; flow rate: 40 mL/minute) to provide the title compound.
EXAMPLE l lC
(R)-3 -nitro-4-((tetrahydro-2H-pyran-3 -yl)methylamino)benzenesulfonamide
The racemic mixture of EXAMPLE 11A was resolved by chiral SFC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in C02 over 15 minutes (oven temperature: 40°C; flow rate: 40 mL/minute) to provide the title compound. EXAMPLE 11D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
To a mixture of EXAMPLE 3J (59.8 mg, 0.105 mmol), EXAMPLE 1 IB (33mg,
0.105 mmol) and N,N-dimethylpyridin-4-amine (38.4 mg, 0.314 mmol) in dichloromethane (5 ml) was added l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (24.07 mg, 0.13 mmol). The reaction mixture was stirred at room temperature overnight and concentrated. The residue was purified by reverse phase HPLC on a CI 8 column using a gradient of 40-60% acetonitrile/0.1% trifluoroacetic acid in water to give the title compound as the trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (6 ml) and washed with 50% aqueous NaHC03. The organic layer was dried over anhydrous Na2SC"4 and concentrated to give the title compound. 1H NMR (500 MHz, dimethylsulfoxide -d6) δ 11.68 (s, 1 H), 11.40 (s, br, 1 H), 8.53 - 8.58 (m, 2 H), 8.04 (d, 1 H), 7.80 (dd, 1 H), 7.47 - 7.54 (m, 3 H), 7.34 (d, 2 H), 7.02 - 7.09 (m, 3 H), 6.67 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.79 (dd, 1 H), 3.69 - 3.73 (m, 1 H), 3.22 - 3.37 (m, 3 H), 3.16 - 3.21 (m, 1 H), 3.07 (s, 4 H), 2.74 (s, 2 H), 2.09 - 2.24 (m, 6 H), 1.95 (s, 2 H), 1.86 - 1.93 (m, 1 H), 1.79 - 1.85 (m, 1 H), 1.58 - 1.64 (m, 1 H), 1.42 - 1.51 (m, 1 H), 1.38 (t, 2 H), 1.25 - 1.34 (m, 1 H), 0.92 (s, 6 H).
EXAMPLE 12
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 12A
4-((l,4-dioxan-2-yl)methoxy)-3-nitrobenzenesulfonamide (l,4-Dioxan-2-yl)methanol (380 mg, 3.22 mmol) in tetrahydrofuran (30 ml) was treated with sodium hydride (60%) (245 mg, 6.13 mmol) at room temperature for 30 minutes. The reaction mixture was cooled in an ice bath and 4-fluoro-3-nitrobenzenesulfonamide (675 mg, 3.06 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours and another portion of sodium hydride (60%>) (245 mg, 6.13 mmol) was added. The reaction mixture was stirred overnight and quenched with ice water (3 ml). The cloudy mixture was filtered and the filtrate was concentrated. The residue was triturated with methanol to give the title compound.
EXAMPLE 12B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 12A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide -de) δ 11.67 (s, 1 H), 11.42 (s, br, 1 H), 8.34 (s, 1 H), 8.03 (d, 2 H), 7.48 - 7.55 (m, 3 H), 7.41 (d, 1 H), 7.35 (d, 2 H), 7.04 (d, 2 H), 6.67 (dd, 1 H), 6.39 (dd, 1 H), 6.21 (d, 1 H), 4.20 - 4.28 (m, 2 H), 3.85 - 3.91 (m, 1 H), 3.82 (dd, 1 H), 3.74 - 3.78 (m, 1 H), 3.59 - 3.69 (m, 2 H), 3.41 - 3.51 (m, 2 H), 3.05 - 3.17 (m, 4 H), 2.83 (s, br, 2 H), 2.27 (s, br, 4 H), 2.15 (s, 2 H), 1.96 (s, 2 H), 1.39 (t, 2 H), 0.93 (s, 6 H).
EXAMPLE 13
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 11C in place of EXAMPLE 1 IB. The proton NMR spectra of EXAMPLE 13 and
EXAMPLE 1 ID are identical. 1H NMR (500 MHz, dimethylsulfoxide -de) δ 11.68 (s, 1 H), 11.40 (s, br, 1 H), 8.53 - 8.58 (m, 2 H), 8.04 (d, 1 H), 7.80 (dd, 1 H), 7.47 - 7.54 (m, 3 H), 7.34 (d, 2 H), 7.02 - 7.09 (m, 3 H), 6.67 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.79 (dd, 1 H), 3.69 - 3.73 (m, 1 H), 3.22 - 3.37 (m, 3 H), 3.16 - 3.21 (m, 1 H), 3.07 (s, 4 H), 2.74 (s, 2 H), 2.09 - 2.24 (m, 6 H), 1.95 (s, 2 H), 1.86 - 1.93 (m, 1 H), 1.79 - 1.85 (m, 1 H), 1.58 - 1.64 (m, 1 H), 1.42 - 1.51 (m, 1 H), 1.38 (t, 2 H), 1.25 - 1.34 (m, 1 H), 0.92 (s, 6 H). EXAMPLE 14
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-(2- naphthylsulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared as described in EXAMPLE 1 ID using naphthalene- 2-sulfonamide (47 mg, 0.227 mmol) in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 11.82 (s, 1 H), 11.69 (s, 1 H), 8.51 (s, 1 H), 8.08 (d, 1 H), 8.05 (d, 1 H), 7.97 (dd, 2 H), 7.82 (dd, 1 H), 7.66 - 7.71 (m, 1 H), 7.63 (t, 1 H), 7.54 (d, 1 H), 7.47 - 7.52 (m, 2 H), 7.34 (d, 2 H), 7.04 (d, 2 H), 6.65 (dd, 1 H), 6.39 (dd, 1 H), 6.18 (s, 1 H), 3.04 (s, 4 H), 2.72 (s, 2 H), 2.10 - 2.20 (m, 6 H), 1.95 (s, 2 H), 1.38 (t, 2 H), 0.92 (s, 6 H).
EXAMPLE 15
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 15A
methyl 6,6-dimethyl-4-oxotetrahydro-2H-pyran-3-carboxylate To a suspension of hexane-washed NaH (0.72 g, 60% in mineral oil) in
tetrahydrofuran (30 mL) was added a solution of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (2.0 g) in tetrahydrofuran (20mL). The suspension was stirred at room temperature for 30 minutes. The dimethylcarbonate (6.31 mL) was added dropwise by syringe. The mixture was heated to reflux for 4h. LC/MS showed the expected product as the major product. The mixture was acidified with 5% HCl and extracted with dichloromethane (100 mL x 3) and washed with water, brine and dried over Na2SC" . After evaporation, the crude product was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product.
EXAMPLE 15B
methyl 6,6-dimethyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydro-2H-pyran-3-carboxylate
To a cooled (0°C) stirring suspension of NaH (0.983 g, 60%> in mineral oil) in ether (50 mL) was added EXAMPLE 15A (3.2 g). The mixture was stirred at 0°C for 30 minutes before the addition of Tf20 (4.2 mL). The mixture was then stirred at room temperature overnight. The mixture was diluted with ether (200 mL) and washed with 5% HCl , water and brine. After drying over Na2SC"4, evaporation of solvent gave the crude product which was used in the next step without further purification.
EXAMPLE 15C
methyl 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carboxylate
To a solution of EXAMPLE 15B (2.88 g), 4-chlorophenylboronic acid (1.88 g) and Pd(Ph3P)4 (0.578 g) in toluene (40 mL) and ethanol (10 mL) was added 2N Na2C03 (10 mL). The mixture was stirred at reflux overnight. The mixture was diluted ether (300 mL) and washed with water, brine and dried over Na2S04. After evaporation of solvent, the residue was loaded on a column and eluted with 3% ethyl acetate in hexane to give the product.
EXAMPLE 15D
(4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methanol To a solution of EXAMPLE 15C (1.6 g) in ether (20 mL) was added LiAlH4 (1.2 g). The mixture was stirred for 4 hours. The mixture was acidified carefully with 5% HC1 and extracted with ethyl acetate (100 mL x 3) and washed with water, brine and dried over Na2S04. After concentration, the crude product was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product. EXAMPLE 15E
4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carbaldehyde
To a solution of oxalyl chloride (1.1 g) in dichloromethane (30 mL) at -78°C was added dimethylsulfoxide (6.12 mL). The mixture was stirred at the temperature for 30 minutes, and then a solution of EXAMPLE 15D (1.2 g) in dichloromethane (10 mL) was added . The mixture was stirred at -78°C for 2 hours before the addition of triethylamine (10 mL). The mixture was stirred overnight and the temperature was allowed to rise to room temperature. The mixture was diluted with ether (300 mL) and washed with water, brine and dried over Na2S04. Concentration of the solvent and column purification (5% ethyl acetate in hexane) gave the product.
EXAMPLE 15F
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(piperazin-l-yl)benzoate A mixture of EXAMPLE 3H (20.5 g) and piperazine (37.0 g) in dimethylsulfoxide (200 mL) was heated to 110°C for 24 hours, and the mixture was allowed to cool to room temperature. The mixture was poured into water (1 L), extracted thee times with
dichloromethane, and the combined extracts were washed with 2x water, and brine and filtered and concentrated to give the pure product.
EXAMPLE 15G
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6- dihydro-2H-pyran-3-yl)methyl)piperazin- 1 -yl)benzoate To a solution of EXAMPLE 15E (100 mg) and EXAMPLE 15F (177 mg) in dichloromethane (10 mL) was added sodium triacetoxyborohydride (154 mg). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with 2%NaOH, water and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated under vacuum. The residue was loaded on a column and eluted with 30% ethyl acetate in hexane to give the pure product.
EXAMPLE 15H
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3 -yl)methyl)piperazin- 1 -yl)benzoic acid
To a solution of EXAMPLE 15G (254 mg) in tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) was added LiOH H20 (126mg). The mixture was stirred overnight. The mixture was then neutralized with 5% HC1 and diluted with ethyl acetate (200 mL). After washing with brine, it was dried over Na2S04. Filtration and evaporation of solvent gave the product.
EXAMPLE 151
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G, substituting
EXAMPLE IE with EXAMPLE 15H. 1H NMR (300 MHz, dimethylsulfoxide -de) δ 11.68 (br s, 1H), 11.42 (s, 1H), 8.60 (m, 1H), 8.57 (d, 1H), 8.05(d, 1H), 7.80 (dd, 1H), 7.48-7.54 (m, 3H), 7.38 (d, 2H), 7.12 (m, 3H), 6.68 (dd, 1H), 6.40 (dd, 1H), 6.20 (s, 1H), 4.1 l(s, 2H), 3.85(m, 2H), 3.27(m, 6H), 3.07 (m, 2H), 2.84 (m, 2H), 2.14 (m, 5H), 1.92(m, 1H), 1.42 (m, 2H), 1.24(m, 2H), 1.10 (s, 6H).
EXAMPLE 16
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino]-3-[(trifluorom
b]pyridin-5 -yloxy)benzamide
EXAMPLE 16A
4-(2-methoxyethylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide
4-Fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide (1.536 g, 5 mmol), 2- methoxyethanamine (0.376 g, 5mmol ), and triethylamine (1.939 g, 15 mmol) in anhydrous tetrahydrofuran (30 mL) solution was heated at 55°C for 3 hours. The solution was diluted with ethyl acetate, washed with water and brine, and dried (Na2S04), filtered and the filtrate was concentrated. The crude material was used in the next step without further purification.
EXAMPLE 16B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 16A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400MHz,
dimethylsulfoxide-de) δ 11.67 (brs, 1H), 8.14 (m 1H), 8.03 (d, 1H), 7.91 (d, 1H), 7.50 (m, 3H), 7.34 (d, 2H), 7.19 (s, 1H), 7.04 (m, 3H), 6.67 (dd, 1H), 6.39 (m, 1H), 6.19 (d, 1H), 3.51 (m, 4H), 3.28 (s, 3H), 3.06 (m, 4H), 2.75 (m, 2H), 2.17 (m, 6H), 1.95 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 17
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide EXAMPLE 17A
4-((tetrahydro-2H-pyran-4-yl)methylamino)-3-(trifluoromethylsulfonyl)benzenesulfonami This EXAMPLE was prepared by substituting l-(tetrahydropyran-4-yl)methylamine for 2-methoxyethanamine in EXAMPLE 16A.
EXAMPLE 17B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and
EXAMPLE 17A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400MHz,
dimethylsulfoxide-de) δ 11.70 (brs, 1H), 8.15 (m 1H), 8.04 (d, 1H), 7.92 (d, 1H), 7.51 (m, 3H), 7.34 (d, 2H), 7.19 (s, 1H), 7.05 (m, 3H), 6.68 (dd, 1H), 6.40 (m, 1H), 6.18 (d, 1H), 3.85 (m, 2H), 3,25 (m, 4H), 3.07 (m, 4H), 2.77 (m, 2H), 2.17 (m, 6H), 1.95 (m, 2H), 1.84 (m,l H), 1.54 (m, 2H), 1.39(t, 2H), 1.24 (m, 2H), 0.93 (s, 6H).
EXAMPLE 18
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide
EXAMPLE 18A
methyl 2-(lH-indol-5-yloxy)-4-fluorobenzoate
A mixture of 5-hydroxyindole (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and K3PO4 (9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes.
EXAMPLE 18B
methyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoate A mixture of EXAMPLE 18A (1.7 g), EXAMPLE 3E (1.8 g), and HK2P04 (1.21 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed with 3x 1M NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50% ethyl acetate/hexanes.
EXAMPLE 18C
2-( 1 H-indol-5 -yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 - enyl)methyl)piperazin- 1 -yl)benzoic acid
EXAMPLE 18B (200 mg) in dioxane (10 mL) and 1M NaOH (6 mL) at 50°C was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product.
EXAMPLE 18D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID by replacing EXAMPLE 3 J with EXAMPLE 18C, and EXAMPLE IF for EXAMPLE 1 IB. 1H NMR (300MHz, dimethylsulfoxide-de) δ 11.18 (s, 2H), 8.59-8.64 (m, 2H), 7.80 (dd, 1H), 7.52 (d, 1H), 7.39-7.42 (m, 2H), 7.33 (d, 2H), 7.16 (d, 1H), 7.10 (d,lH), 7.03 (d, 2H), 6.8 (dd, 1H), 6.65 (dd, 1H), 6.40 )s, 1H), 6.14 (d, 1H), 3.85 (dd, 2H), 3.24-3.32 (m, 4H), 3.03 (s, 3H), 2.73 (s, 2H), 2.12-2.17 (m, 5H), 1.68-1.94 (m, 3H), 1.61 (d, 2H), 1.37 (t, 2H), 1.24-1.27 (m, 2H), 0.92 (s, 6H).
EXAMPLE 19
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID by replacing EXAMPLE 1 IB with EXAMPLE 9B and EXAMPLE 3 J with EXAMPLE 18C. 1H NMR (500 MHz, pyridine- 5) δ 12.29 (s, 1H), 9.29 (d, J=2.1 Hz, 1H), 8.37 (d, J=7.6 Hz, 1H), 8.32 (dd, J=9.3, 2.3 Hz, IH), 8.18 (d, J=8.8 Hz, IH), 7.52 - 7.57 (m, 2H), 7.39 - 7.47 (m, 3H), 7.10 (dd, J=8.7, 2.3 Hz, IH), 7.05 - 7.08 (m, 2H), 6.90 (d, J=9.5 Hz, IH), 6.74 (dd, J=9.0, 2.3 Hz, IH), 6.59 - 6.63 (m, IH), 6.55 (d, J=2.4 Hz, IH), 3.72 - 3.78 (m, 4H), 3.33 - 3.43 (m, IH), 2.99 - 3.09 (m, 4H), 2.76 (s, 2H), 2.46 - 2.54 (m, 4H), 2.16 - 2.29 (m, 3H), 2.09 - 2.14 (m, 4H), 2.05 (d, J=l 1.9 Hz, 2H), 1.97 (d, J=1.8 Hz, 2H), 1.87 (d, J=l 1.6 Hz, 2H), 1.19 - 1.42 (m, 6H), 0.93 (s, 6H).
EXAMPLE 20
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5-yloxy)-N-( {4-[(2-methoxyethyl)amino]-3-nitrophenyl} sulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID by replacing EXAMPLE 1 IB with EXAMPLE 10A and EXAMPLE 3J with EXAMPLE 18C. 1H NMR (400 MHz, dimethylsulfoxide - d6) δ 11.20 (br. s, IH) 11.15 (s, IH) 8.59 (m, 2H) 7.81 (dd, IH) 7.50 (d, IH) 7.36 (m, 4H) 7.08 (m, 4H) 6.85 (dd, IH) 6.65 (dd, IH) 6.38 (m, IH) 6.14 (m, IH) 3.58 (m, 4H) 3.30 (s, 3H) 3.03 (m, 4H) 2.73 (s, 2H) 2.15 (m, 6H) 1.96 (s, 2H) 1.38 (t, 2H) 0.92 (s, 6H)
EXAMPLE 21
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3- ylmethyl] amino } phenyl)sulfonyl]benzamide
The title compound was prepared as described in EXAMPLE 1 ID by replacing EXAMPLE 3J with EXAMPLE 18C. 1H NMR (400 MHz, dimethylsulfoxide -d6) δ 11.17 (s, 2 H), 8.53 - 8.65 (m, 2 H), 7.80 (d, 1 H), 7.51 (d, 1 H), 7.38 - 7.44 (m, 2 H), 7.33 (d, 2 H), 7.15 (s, 1 H), 7.02 - 7.09 (m, 3 H), 6.82 - 6.92 (m, 1 H), 6.65 (d, 1 H), 6.39 (s, 1 H), 6.14 (s, 1 H), 3.68 - 3.82 (m, 2 H), 3.22 - 3.32 (m, 2 H), 3.13 - 3.22 (m, 1 H), 3.03 (s, 4 H), 2.72 (s, 2 H), 2.09 - 2.23 (m, 6 H), 1.78 - 1.98 (m, 4 H), 1.56 - 1.66 (m, 1 H), 1.43 - 1.51 (m, 1 H), 1.37 (t, 2 H), 1.22 - 1.33 (m, 1 H), 0.92 (s, 6 H). EXAMPLE 22
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N- [(3 -nitro-4- { [(3R)-tetrahydro-2H-pyran-3 - ylmethyl] amino } phenyl)sulfonyl]benzamide The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 11C in place of EXAMPLE 1 IB, and EXAMPLE 18C in place of EXAMPLE 3 J. 1H NMR (400 MHz, dimethylsulfoxide -de) δ 11.17 (s, 2 H), 8.53 - 8.65 (m, 2 H), 7.80 (d, 1 H), 7.51 (d, 1 H), 7.38 - 7.44 (m, 2 H), 7.33 (d, 2 H), 7.15 (s, 1 H), 7.02 - 7.09 (m, 3 H), 6.82 - 6.92 (m, 1 H), 6.65 (d, 1 H), 6.39 (s, 1 H), 6.14 (s, 1 H), 3.68 - 3.82 (m, 2 H), 3.22 - 3.32 (m, 2 H), 3.13 - 3.22 (m, 1 H), 3.03 (s, 4 H), 2.72 (s, 2 H), 2.09 - 2.23 (m, 6 H), 1.78 - 1.98 (m, 4 H), 1.56 - 1.66 (m, 1 H), 1.43 - 1.51 (m, 1 H), 1.37 (t, 2 H), 1.22 - 1.33 (m, 1 H), 0.92 (s, 6 H).
EXAMPLE 23
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide
EXAMPLE 23A
methyl 2-( 1 H-indol-5 -yloxy)-4-(piperazin- 1 -yl)benzoate The title compound was prepared as described in EXAMPLE 15F by replacing EXAMPLE 3H with EXAMPLE 18A.
EXAMPLE 23B
methyl 2-(lH-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-
3 -yl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared as described in EXAMPLE 15G by replacing EXAMPLE 15F with EXAMPLE 23 A.
EXAMPLE 23C
2-(lH-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared as described in EXAMPLE 15H by replacing
EXAMPLE 15G with EXAMPLE 23B. EXAMPLE 23D
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)^
2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID by replacing
EXAMPLE 1 IB with EXAMPLE IF, and EXAMPLE 3J with EXAMPLE 23C. 1H NMR (400 MHz, dimethyl sul f oxide -d6) δ 11.20 (br s, 1H), 11.17(s, 1H), 8.63 (t, 1 H), 8.59 (d, 1 H), 7.79 (dd, 1 H), 7.51 (d, 1 H), 7.36 (m, 3 H), 7.13 (m, 2 H), 6.86 (dd, 1 H), 6.66 (dd, 1 H), 6.39 (s, 1 H), 6.15 (d, 1 H), 4.10 (s, 2 H), 3.85 (m, 3 H), 3.50 (m, 2 H), 3.42 (m, 2 H), 3.24 (m, 4 H), 3.02 (m, 4 H), 2.82 (m, 2 H), 2.16 (m, 2 H), 1.61 (m, 3 H), 1.25 (m, 4 H), 1.17 (s, 6 H).
EXAMPLE 24
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 24A
3-nitro-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide (Tetrahydro-2H-pyran-4-yl)methanol (2.0 g) in tetrahydrofuran (20 mL) was treated with 60% NaH (1.377 g). The solution was stirred for 20 minutes at the room temperature. To this solution was added 4-fluoro-3-nitrobenzenesulfonamide (2.84 g) portion-wise. The reaction was stirred for another 2 hours. The mixture was poured into water, neutralized with 10% HC1, and extracted with ethyl acetate thee times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified with flash column chromatography on silica gel eluting with 20-60% ethyl acetate in hexanes.
EXAMPLE 24B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 24A for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.33 (s, IH), 8.00-8.02 (m, 2H), 7.50-7.53 (m, 3H), 7.34-7.36 (m, 3H), 7.04 (d, 2H), 6.67 (dd, IH), 6.38 (d, IH), 6.21 (s, IH), 4.06 (d, 2H), 3.88 (dd, 2H), 3.08 (s, 4H), 2.80 (s, 2H), 2.25 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.63-1.66 (m, 2H), 1.52-1.55 (m, 1 H), 1.33-1.40 (m, 4H), 0.92 (s, 6H).
EXAMPLE 25
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 25A
4-((l,4-dioxan-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared as described in EXAMPLE IF using (l,4-dioxan-2- yl)methanamine in place of (tetrahydropyran-4-yl)methanamine.
EXAMPLE 25B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 ,4-dioxan-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 25A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 11.38 (s, IH), 8.53 - 8.59 (m, 2H), 8.03 (d, IH), 7.81 (dd, IH), 7.46 - 7.54 (m, 3H), 7.34 (d, 2H), 7.09 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.38 (dd, IH), 6.19 (d, IH), 3.75 - 3.86 (m, 3H), 3.58 - 3.68 (m, 2H), 3.45 - 3.52 (m, 2H), 3.35 - 3.43 (m, 2H), 3.07 (s, 4H), 2.75 (s, 2H), 2.17 (d, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H)
EXAMPLE 26
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 26A
3-nitro-4-(2,2,2-trifluoroethylamino)benzenesulfonamide The title compound was prepared by substituting 2,2,2-trifluoroethanamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 26B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2,2,2-trifluoroethyl)am
yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 26A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.48 (s, IH), 8.40 (m, 2H), 7.90 (d, IH), 7.71 (dd, IH), 7.59 (d, IH), 7.40 (t, IH), 7.34 (d, 2H), 7.25 (d, IH), 7.06 (m, 3H), 6.61 (dd, IH), 6.26 (m, 2H), 4.32 (m, 2H), 3.00 (m, 4H), 2.73 (s, 2H), 2.19 (m, 6H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 27
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 27A
3 -nitro-4-(3 ,3 ,3 -trifluoropropylamino)benzenesulfonamide The title compound was prepared by substituting 3,3,3-trifluoropropan-l-amine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 27B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 27A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.47 (s, IH), 8.37 (d, IH), 8.29 (m, IH), 7.89 (d, IH), 7.61 (m, 2H), 7.39 (t, IH), 7.35 (d, 2H), 7.22 (d, IH), 7.05 (d, 2H), 6.75 (d, IH), 6.62 (dd, IH), 6.27 (m, 2H), 3.59 (q, 2H), 3.00 (m, 4H), 2.73 (s, 2H), 2.66 (m, 2H), 2.18 (m, 6H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (m, 6H). EXAMPLE 28
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 28A
(S)-4-((l,4-dioxan-2-yl)methoxy)-3-nitrobenzenesulfonamide The racemic mixture of EXAMPLE 12A was resolved on a SFC chiral AD column to provide the title compound.
EXAMPLE 28B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE
28A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 2H), 8.35 (s, 1H), 8.03 (d, 2H), 7.48 - 7.57 (m, 3H), 7.42 (d, 1H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.21 (s, 1H), 4.19 - 4.30 (m, 2H), 3.85 - 3.92 (m, 1H), 3.73 - 3.85 (m, 2H), 3.58 - 3.70 (m, 2H), 3.40 - 3.52 (m, 2H), 3.10 (s, 4H), 2.85 (s, 2H), 2.18 - 2.39 (m, 3H), 2.15 (s, 2H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 29
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 29A
Cz5-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonamide (1.098 g) and EXAMPLE 34A (1 g) in tetrahydrofuran (20 mL) was treated with N,N-diisopropylethylamine (0.871 mL) overnight. The reaction mixture was concentrated and the residue was purified by reverse phase chromatography, eluted with 40-55% acetonitrile in 0.1% trifluoroacetic acid in water over 25 min to give the cis isomer EXAMPLE 29A and trans isomer EXAMPLE 34B. EXAMPLE 29B
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 29A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 11.36 (s, 1H), 8.53 - 8.63 (m, 2H), 8.04 (d, 1H), 7.79 (dd, 1H), 7.47 - 7.56 (m, 3H), 7.34 (d, 2H), 7.00 - 7.12 (m, 3H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 3.37 (s, 1H), 3.26 (t, 2H), 3.20 (s, 3H), 3.07 (s, 4H), 2.75 (s, 2H), 2.17 (d, 6H), 1.95 (s, 2H), 1.81 (dd, 2H), 1.64 - 1.74 (m, 1H), 1.48 (dd, 2H), 1.23 - 1.42 (m, 6H), 0.92 (s, 6H).
EXAMPLE 30
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 30A
(R)-4-((l,4-dioxan-2-yl)methoxy)-3-nitrobenzenesulfonamide The racemic mixture of EXAMPLE 12A was resolved on a SFC chiral AD column to provide the title compound.
EXAMPLE 30B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 30A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 2H), 8.35 (s, 1H), 8.03 (d, 2H), 7.48 - 7.57 (m, 3H), 7.42 (d, 1H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.21 (s, 1H), 4.19 - 4.30 (m, 2H), 3.85 - 3.92 (m, 1H), 3.73 - 3.85 (m, 2H), 3.58 - 3.70 (m, 2H), 3.40 - 3.52 (m, 2H), 3.10 (s, 4H), 2.85 (s, 2H), 2.18 - 2.39 (m, 3H), 2.15 (s, 2H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 31
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl) N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 25 A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 11.46 (m, IH), 8.54 (m, 2H),
8.45 (m, IH), 8.03 (d, IH), 7.83 (m, 2H), 7.50 (m, 3H), 7.34 (m, 3H), 7.12 (m, 2H), 6.68 (dd, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.11 (s, 2H), 3.79 (m, 4H), 3.51 (m, 6H), 3.05 (m, 4H), 2.17 (m, 3H), 1.17 (s, 6H). EXAMPLE 32
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [4-( 1 ,4-dioxan-2-ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 12A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.37 (d, IH), 8.03 (m, 2H), 7.50 (m, 3H), 7.37 (d, 2H), 7.13 (d, 2H), 6.68 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.25 (m, 2H), 4.12 (s, 2H), 3.84 (m, 3H), 3.63 (m, 2H), 3.45 (m, 2H), 3.06 (m, 4H), 2.86 (m, 2H), 2.24 (m, 6H), 1.20 (m, 6H).
EXAMPLE 33
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing
EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 9C, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.63 (s, IH), 8.51 (d, IH), 8.15 (d, IH), 8.01 (d, IH), 7.76 (dd, IH), 7.48 (m, 3H), 7.38 (d, 2H), 7.13 (d, 2H), 7.06 (d, IH), 6.66 (dd, IH), 6.36 (dd, IH), 6.21 (d, IH), 4.11 (s, 2H), 3.63 (m, 5H), 3.05 (m, 4H), 2.83 (s, 2H), 2.64 (m, 4H), 2.17 (m, 6H), 2.05 (m, 2H), 1.91 (s, 2H), 1.43 (m, 6H), 1.17 (m, 6H).
EXAMPLE 34
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 34A
(4-methoxycyclohexyl)methanamine
(4-Methoxyphenyl)methanamine (1 g, 1.29 mmol) in ethanol (10 ml) was treated with 5% Rh-Al203 (99.8 mg, 0.048 mmol) under H2 atmosphere (500 psi) at 50°C for 16 hours. Additional 5% Rh-Al203 (0.4 g) was added. The resulting mixture was stirred under H2 atmosphere (500 psi) at 60°C for 2 hours. The insoluble material was filtered off and the filtrate was concentrated to provide a mixture of cis and trans product as an oil, which was used in the next step without further purification.
EXAMPLE 34B
Trans-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide
4-Fluoro-3-nitrobenzenesulfonamide (1.098 g) and EXAMPLE 34A (1 g) in tetrahydrofuran (20 mL) was treated with N,N-diisopropylethylamine (0.871 mL) overnight. The reaction mixture was concentrated and the residue was purified by reverse phase chromatography, and was eluted with 40-55% acetonitrile in 0.1% trifluoroacetic acid in water over 25 minutes.
EXAMPLE 34C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 34B in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1 H), 11.37 (s, 1 H), 8.52 - 8.62 (m, 2 H), 8.04 (d, 1 H), 7.79 (dd, 1 H), 7.47 - 7.55 (m, 3 H), 7.34 (d, 2 H), 7.02 - 7.09 (m, 3 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.21 - 3.27 (m, 5 H), 3.02 - 3.12 (m, 5 H), 2.75 (s, 2 H), 2.20 (s, 4 H), 2.14 (s, 2 H), 1.93 - 2.04 (m, 4 H), 1.79 (d, 2 H), 1.55 - 1.65 (m, 1 H), 1.38 (t, 2 H), 0.97 - 1.12 (m, 4 H), 0.92 (s, 6 H).
EXAMPLE 35
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 36C, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.65 (s, 1H), 8.78 (s, 1H), 8.58 (s, 1H), 8.00 (d, 1H), 7.51 (m, 3H), 7.38 (d, 2H), 7.14 (d, 2H), 6.68 (dd, 1H), 6.37 (dd, 1H), 6.23 (d, 1H), 4.31 (d, 2H), 4.13 (s, 2H), 3.88 (dd, 2H), 3.11 (m, 5H), 2.16 (m, 6H), 1.65 (m, 2H), 1.35 (m, 2H), 1.19 (s, 6H). EXAMPLE 36
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 36A
5 -Bromo-6-chloropyridine-3 -sulfonyl chloride (8.2 g) in methanol (20 mL) was cooled to 0 °C. To this solution was added 7N NH3 in methanol (80 mL). The reaction mixture was stirred overnight. The solvent was removed at low temperature, and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate thee times. The combined organic layers were washed with brine, dried (MgS04), filtered, and concentrated. The solid was purified by flash column chromatography on silica gel using 20-100% ethyl acetate in hexanes to give the title compound.
EXAMPLE 36B
The title compound was prepared by substituting EXAMPLE 36A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A. EXAMPLE 36C
A mixture of EXAMPLE 36B (0.702 g), dicyanozinc (0.129 g), and
tetrakis(triphenylphosphine)palladium(0) (0.231 g) in N,N-dimethylformamide (2 mL) was degassed via vacuum/nitrogen cycle thee times. The reaction mixture was heated at 120 °C for 3 hours. After cooling, it was poured into water and extracted with ethyl acetate thee times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified with flash column chromatography on silica gel eluting with 20%-60% ethyl acetate in hexanes to give the title compound. EXAMPLE 36D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) 5 11.56 (s, 1H), 8.66 (s, 1H), 8.44 (s, 1H), 7.94 (d, 1H), 7.55 (d, 1H), 7.44 (t, 1H), 7.34-7.35 (m, 3H), 7.04 (d, 2H), 6.65 (dd, 1H), 6.32 (s, 1H), 6.24 (s, 1H), 4.26 (d, 2H), 3.86 (dd, 2H), 3.10 (s, 4H), 2.75 (s, 2H), 2.31-2.35 (m, 2H), 2.01-2.05 (m, 1H), 2.15 (s, 2H), 1.96 (s, 2H), 1.63-1.66 (m, 2H), 1.33-1.40 (m, 4H), 0.92 (s, 6H).
EXAMPLE 37
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 37A
l,6-dioxaspiro[2.5]octane-2-carbonitrile
A mixture of tetrahydropyran-4-one (10 mL) and chloroacetonitrile (6.4 mL) in tert- butanol (10 mL) was stirred for 10 minutes. To this solution was added a solution of potassium tert-butoxide (12.11 g) in 200 mL of tert-butanol at room temperature over 40 minutes. The reaction mixture was stirred for 16 hours, diluted with water and quenched slowly with 1 N HCl. The solvent was partially removed by rotary evaporation. It was then extracted with ether (5x 200 mL). The combined extracts was washed with brine, dried over MgS04, filtered, and the filtrate was concentrated and purified by flash chromatography on silica with 3:7 to 1 : 1 ethyl acetate :hexanes to provide the title compound.
EXAMPLE 37B
2-(4-fluorotetrahydro-2H-pyran-4-yl)-2-hydroxyacetonitrile
EXAMPLE 37A (11.5 g) in dichloromethane (40 mL) in a polypropylene bottle was treated with 70% hydrogen fluoride-pyridine (10.4 mL) dropwise at 0 °C. The solution was allowed to warm to room temperature over 3 hours, and stirred for an additional 1.5 hours. The reaction mixture was diluted with ethyl acetate (200 mL) and poured into saturated aqueous NaHC03. Additional solid NaHC03 was used carefully until bubbling ceased. The organic layer was isolated, and the aqueous layer was extracted with additional ethyl acetate three times (150 mL each). The combined organic layers were washed with 5% HC1 (50 mL each, twice), brine, dried over MgS04, filtered and concentrated to give the desired product which was used directly in the next step.
EXAMPLE 37C
(4-fluorotetrahydro-2H-pyran-4-yl)methanol
EXAMPLE 37B (11.7 g, 74 mmol) in 2-propanol (150 mL) and water (37.5 mL) was cooled to 0 °C. To this solution was added NaBH4 (4.20 g, 111 mmol). The solution was stirred and allowed to warm to room temperature over 3 hours. It was quenched with acetone, and stirred for another 1 hour. The clear liquid was separated from solid by decanting. Additional ethyl acetate (2x 100 mL) was used to wash the solid, and the mixture was decanted. The combined organic solutions were concentrated. The residue was purified by flash chromatography, eluting with 1 : 1 ethyl acetate :hexanes to provide the title compound.
EXAMPLE 37D
4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 37C for (tetrahydro-2H- pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 37E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 37D in place of EXAMPLE 1 IB. 1H NMR (dimethylsulfoxide-d6). 11.64 (s, 2H), 8.33 (s, 1H), 8.00-8.01 (m, 2H), 7.39-7.57 (m, 4H), 7.33 (d, J = 8.24 Hz, 2H), 7.03 (d, J = 8.54 Hz, 2H), 6.65 (dd, J = 9, 1.98 Hz, 1H), 6.37-6.38 (m, 1H), 6.19 (d, J = 1.53 Hz, 1H), 4.35 (d, J = 20.75 Hz, 2H), 3.74-3.78 (m, 2H), 3.55-3.60 (m, 2H), 3.07 (br, 4H), 2.80 (br, 2H), 2.25 (br, 4H), 2.13 (br, 2H), 1.81-1.94 (m, 6H), 1.38 (t, J = 6.26 Hz, 2H), 0.91 (s, 6H).
EXAMPLE 38
N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 38A
3-cyano-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting 3-cyano-4- fluorobenzenesulfonamide for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24 A.
EXAMPLE 38B
5-sulfamoyl-2-((tetrahydro-2H-pyran-4-yl)methoxy)benzamide To a solution of EXAMPLE 38A (0.455 g) in ethanol (3 mL) and tetrahydrofuran (1 mL) was added hydrogen peroxide (30% in water, 2 mL) followed by 1 N aqueous NaOH (1.024 ml) and heated to 35°C for 3 hours. The reaction was poured into dichloromethane (50 mL) and IN aqueous HC1 (25 mL). The aqueous layer was extracted with
dichloromethane (3 x 50 mL). The precipitate contained in the combined organic layers was collected by filtration to give the title compound.
EXAMPLE 38C
N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 38B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.79 - 11.70 (m, 1H), 11.66 - 11.54 (m, 1H), 9.29 - 9.08 (m, 1H), 8.27 (d, 1H), 8.08 (d, 1H), 7.97 - 7.90 (m, 1H), 7.76 - 7.72 (m, 1H), 7.62 (s, 1H), 7.54 (s, 1H), 7.50 (d, 1H), 7.39 (d, 1H), 7.23 (d, 1H), 7.08 (d, 1H), 6.74 - 6.67 (m, 1H), 6.44 (s, 1H), 6.22 (s, 1H), 4.03 (d, 6H), 3.74 - 3.52 (m, 4H), 3.33 (s, 4H), 3.11 - 2.90 (m, 2H), 2.01 (s, 4H), 1.79 - 1.58 (m, 2H), 1.24 (s, 5H), 0.94 (s, 6H).
EXAMPLE 39
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 39A
Cis-tert-butyl-4-morpholinocyclohexylcarbamate
To a solution of morpholine (4.08 g) and tert-butyl 4-oxocyclohexylcarbamate (10 g) stirred for 24 hours at room temperature in titanium (IV) isopropoxide (27.5 mL), methanol (10 mL) was added followed by careful addition of sodium borohydride (3.55 g). The reaction mixture was quenched with water/NaOH solution, extracted with ether, dried over magnesium sulfate, filtered, and concentrated. The product was separated from the trans isomer and purified by flash chromatography (silica gel, 50% - 100% acetone in hexanes) to provide the title compound.
EXAMPLE 39B
cis-4-morpholinocyclohexanamine bis(2,2,2-trifluoroacetate) To a solution of EXAMPLE 39A (2.43 g) in dichloromethane (15 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred for 16 hours at room
temperature. The reaction mixture was concentrated and the crude product was used without purification.
EXAMPLE 39C
4-(cis-4-morpholinocyclohexylamino)-3-nitrobenzenesulfonamide A solution of EXAMPLE 39B (0.40 g), 4-fiuoro-3-nitrobenzenesulfonamide (0.478 g) and triethylamine (2 mL) in tetrahydrofuran (10 mL) was stirred for 3 days at room temperature. The reaction mixture was concentrated and purified by flash chromatography (silica gel, 0-30% methanol / dichloromethane) providing the product.
EXAMPLE 39D
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 39C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.30 (d, IH), 8.64 (d, IH), 8.43 (d, IH), 8.38 (dd, IH), 8.11 (d, IH), 7.67 (t, 2H), 7.44 (d, 2H), 7.06 (d, 2H), 6.91 (d, IH), 6.74 (dd, IH), 6.48 - 6.55 (m, 2H), 3.65 - 3.73 (m, 5H), 3.02 - 3.09 (m, 4H), 2.76 (s, 2H), 2.41 - 2.48 (m, 4H), 2.25 (t, 2H), 2.09 - 2.16 (m, 5H), 1.97 (s, 2H), 1.77 - 1.86 (m, 2H), 1.55 - 1.63 (m, 6H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 40
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 40A
5, 6-dichloropyridine-3 -sulfonamide
The title compound was prepared by substituting 5,6-dichloropyridine-3-sulfonyl chloride for 5 -bromo-6-chloropyridine-3 -sulfonyl chloride in EXAMPLE 36 A.
EXAMPLE 40B
5-chloro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A. EXAMPLE 40C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 40B for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.52 (s, IH), 8.39 (d, IH), 8.03 (d, IH), 7.54 (d, IH), 7.52 (d, IH), 7.50 (dd, IH), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.39 (m, IH), 6.21 (d, IH), 4.25 (d, 2H), 3.87 (dd, 2H), 3.30 (m, 2H), 3.10 (v br s, 4H), 2.90 (v br s, 2H), 2.35 (v br s, 4H), 2.17 (br m, 2H), 2.05 (m, IH), 1.96 (s, 2H), 1.64 (d, 2H), 1.40 (t, 2H), 1.35 (ddd, 2H), 0.93 (s, 6H).
EXAMPLE 41
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 15H for EXAMPLE 3 J and EXAMPLE 40B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-de) δ 11.68 (s, IH), 8.55 (d, IH), 8.41 (d, IH), 8.04 (d, IH), 7.54 (m, 2H), 7.50 (dd, IH), 7.38 (d, 2H), 7.14 (d, 2H), 6.68 (dd, IH), 6.40 (m, IH), 6.20 (d, IH), 4.25 (d, 2H), 4.12 (s, 2H), 3.87 (dd, 2H), 3.30 (m, 2H), 3.10 (v br s, 4H), 2.90 (v br s, 2H), 2.27 (v br s, 4H), 2.17 (br m, 2H), 2.05 (m, IH), 1.96 (s, 2H), 1.64 (d, 2H), 1.35 (ddd, 2H), 0.97 (s, 6H).
EXAMPLE 42
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-
(trifluoromethyl)phenyl]sulfonyl}benzamide
EXAMPLE 42A
4-((tetrahydro-2H-pyran-4-yl)methylamino)-3-(trifluoromethyl)benzenesulfonamide A mixture of 4-fluoro-3-(trifluoromethyl)benzenesulfonamide (1.056 g), (tetrahydro- 2H-pyran-4-yl)methanamine (0.5 g) and N,N-diisopropylethylamine (1.68 g) in anhydrous dimethylsulfoxide ( 15 mL) solution was heated at 90°C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound.
EXAMPLE 42B
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 -
(trifluoromethyl)phenyl]sulfonyl}benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 42A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.73 (s, 1H), 11.25 (s, 1H), 8.08 (d, 1H), 7.89 (d, 1H), 7.77 (m, 1H), 7.61 (d, 1H), 7.51 (m, 2H), 7.37 (d, 2H), 7.13 (d, 2H), 6.88 (d, 1H), 6.67 (dd, 1H), 6.53 (m, 1H), 6.43 (m, 1H), 6.15 (d, 1H), 4.11 (s, 2H), 3.82 (dd, 2H), 3.19 (m, 5H), 3.05 (m, 4H), 2.82 (s, 2H), 2.20 (m, 7H), 1.85 (m, 1H), 1.56 (m, 2H), 1.18 (s, 6H). EXAMPLE 43
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 17A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 11.48 (m, 1H), 8.16 (d, 1H), 8.05 (d, 1H), 7.92 (dd, 1H), 7.52 (m, 3H), 7.37 (d, 2H), 7.27 (m, 1H), 7.11 (m, 3H), 6.68 (dd, 1H), 6.41 (dd, 1H), 6.18 (d, 1H), 4.11 (s, 2H), 3.84 (dd, 2H), 3.25 (m, 4H), 3.07 (m, 4H), 2.84 (m, 2H), 2.23 (m, 5H), 1.84 (m, 1H), 1.55 (m, 2H), 1.25 (m, 3H), 1.18 (s, 6H).
EXAMPLE 44
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-
1 -yl)-N-( {4-[(4-morpholin-4-ylcyclohexyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 44A
Trans-4-(4-morpholinocyclohexylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared as described in EXAMPLE 16A by replacing 2- methoxyethanamine with EXAMPLE 9B.
EXAMPLE 44B
Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-
1 -yl)-N-( {4-[(4-morpholin-4-ylcyclohexyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 44A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.62 (s, IH), 8.08 (s, IH), 8.00 (d, IH), 7.85 (d, IH), 7.47 (m, 3H), 7.38 (d, 2H), 7.14 (d, 2H), 6.98 (d, IH), 6.65 (dd, IH), 6.55 (m, IH), 6.37 (m, IH), 6.21 (d, IH), 4.12 (s, 2H), 3.54 (m, 6H), 3.04 (m, 4H), 2.83 (s, 2H), 2.57 (m, 3H), 2.24 (m, 6H), 1.91 (m, 5H), 1.34 (m, 4H), 1.20 (s, 6H). EXAMPLE 45
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 45A
4-(l-methylpiperidin-4-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared as described in EXAMPLE 16A by replacing 2- methoxyethanamine with l-methyl-4-aminopiperidine. EXAMPLE 45B
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-({4-[(l-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 45A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.59 (s, IH), 8.10 (s, IH), 7.98 (d, IH), 7.90 (dd, IH), 7.49 (m, 3H), 7.39 (m, 3H), 7.14 (d, 2H), 7.02 (d, IH), 6.65 (dd, 2H), 6.36 (dd, IH), 6.22 (d, 1H), 4.12 (s, 2H), 3.75 (m, 1H), 3.16 (m, 4H), 2.98 (m, 5H), 2.88 (m, 5H), 2.67 (s, 2H), 2.22 (m, 6H), 1.68 (m, 1H), 1.18 (s, 6H).
EXAMPLE 46
5 -( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2-(tetrahydro-2H-pyran-4- ylmethoxy Nicotinamide
5-sulfamoyl-2-((tetrahydro-2H-pyran-4-yl)methoxy)nicotinamide To EXAMPLE 36C (0.025 g) in ethanol (1 mL) and tetrahydrofuran (1 mL) was added hydrogen peroxide (30% in water, 0.5 mL) followed by 1M aqueous sodium hydroxide (0.056 ml) then another 1 mL of tetrahydrofuran. The reaction was heated to 45°C for 2 hours, cooled, quenched with IN aqueous HC1 (5 mL), and the product extracted into dichloromethane (10 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated to give the title compound.
EXAMPLE 46B
5 -( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2-(tetrahydro-2H-pyran-4- ylmethoxy Nicotinamide
The title compound was prepared by substituting EXAMPLE 46 A for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, CDC13) δ 10.31 - 10.09 (m, 1H), 9.09 (s, 2H), 8.93 - 8.81 (m, 1H), 8.28 - 8.18 (m, 1H), 8.03 - 7.87 (m, 1H), 7.77 - 7.68 (m, 1H), 7.59 - 7.51 (m, 1H), 7.48 - 7.41 (m, 1H), 6.91 (d, 2H), 6.59 - 6.48 (m, 2H), 5.97 (s, 2H), 4.50 (d, 2H), 4.08 - 3.98 (m, 2H), 3.45 (s, 4H), 3.13 - 2.99 (m, 4H), 2.82 - 2.68 (m, 2H), 2.19 (s, 4H), 1.86 (s, 5H), 1.61 - 1.35 (m, 4H), 0.94 (s, 6H).
EXAMPLE 47
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
EXAMPLE 47A
5-bromo-6-((l-methylpiperidin-4-yl)methoxy)pyridine-3-sulfonamide To (l-methylpiperidin-4-yl)methanol (0.109 g) in tetrahydrofuran (2 mL) was added sodium hydride (0.136 g). After 30 minutes, EXAMPLE 36A (0.230 g) was added as a solution in tetrahydrofuran (1 mL) and the reaction was heated to 50°C. After 4 hours, the reaction was cooled, poured into water (10 mL) and dichloromethane (50 mL), and the pH was adjusted to pH~8. The aqueous layer was extracted with dichloromethane (3 x 50 mL), and the organic layers were combined, washed with brine (30 mL), dried over magnesium sulfate, filtered, and concentrated to give the title compound.
EXAMPLE 47B
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 47 A for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.51 (s, 1H), 8.35 (d, 1H), 8.17 (d, 1H), 7.93 (d, 1H), 7.60 (d, 1H), 7.44 - 7.40 (m, 1H), 7.33 (dd, 3H), 7.05 (d, 2H), 6.61 (d, 1H), 6.31 (dd, 1H), 6.24 (s, 1H), 4.25 (d, 2H), 3.40 (s, 4H), 3.01 (s, 4H), 2.73 (d, J= 8.2, 5H), 2.20 (s, 6H), 1.93 (d, 4H), 1.54 (s, 1H), 1.39 (s, 2H), 1.24 (s, 2H), 0.93 (s, 6H).
EXAMPLE 48
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 48A
4-(( 1 -methylpiperidin-4-yl)methoxy)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting (l-methylpiperidin-4-yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 48B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 48 A for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.54 (s, 1H), 8.17 (s, 1H), 7.92 (s, 1H), 7.87 - 7.77 (m, 1H), 7.58 (d, 1H), 7.43 (s, 1H), 7.40 - 7.00 (m, 7H), 6.70 - 6.56 (m, 1H), 6.31 (s, 1H), 6.24 (s, 1H), 4.05 (s, 2H), 3.46 - 3.33 (m, 2H), 3.02 (s, 6H), 2.72 (d, 5H), 2.21 (s, 6H), 1.96 (s, 5H), 1.70 - 1.48 (m, 2H), 1.39 (s, 2H), 0.93 (s, 6H).
EXAMPLE 49
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 49A
6-((l , 4-dioxan-2-yl)methoxy)-5-bromopyridine-3 -sulfonamide The title compound was prepared by substituting (1, 4-dioxan-2-yl)methanol for
(tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 36A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 49B
6-((l ,4-dioxan-2-yl)methoxy)-5-cyanopyridine-3 -sulfonamide
The title compound was prepared by substituting EXAMPLE 49A for EXAMPLE 36B in EXAMPLE 36C.
EXAMPLE 49C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 49B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) 5 11.50 (s, 1H), 8.60 (s, 1H), 8.40 (s, 1H), 7.91 (d, 1H), 7.58 (d, 1H), 7.42 (t, 1H), 7.35 (d, 2H), 7.28 (s, 1H), 7.06 (d, 2H), 6.64 (dd, 1H), 6.29 (m, 2H), 4.40 (d, 2H), 3.90 (m, 1H), 3.79 (m, 2H), 3.63 (m, 2H), 3.46 (m, 4H), 3.07 (s, 4H), 2.85 (m, 2H), 2.34 (m, 4H), 2.16 (m, 2H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 50
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 49A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) 511.60 (s, 1H), 8.46 (s, 1H), 8.27 (s, 1H), 7.99 (d, 1H), 7.56 (d, 1H), 7.46 (m, 2H), 7.35 (d, 2H), 7.05 (d, 2H), 6.65 (dd, 1H), 6.36 (dd, 1H), 6.22 (d, 1H), 4.34 (m, 2H), 3.88 (m, 1H), 3.79 (m, 2H), 3.63 (m, 2H), 3.46 (m, 2H), 3.06 (s, 4H), 2.81 (s, 2H), 2.26 (m, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.38 (m, 2H), 0.93 (s, 6H).
EXAMPLE 51
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4 [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 51A
The title compound was prepared as described in EXAMPLE 12A by replacing (1,4 dioxan-2-yl)methanol with (2,2-dimethyltetrahydro-2H-pyran-4-yl)methanol.
EXAMPLE 5 IB
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 51 A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 2H), 8.35 (s, 2H), 8.03 (d, 4H), 7.47 - 7.58 (m, 6H), 7.31 - 7.42 (m, 6H), 7.04 (d, 4H), 6.68 (dd, 2H), 6.40 (s, 2H), 6.20 (d, 2H), 3.96 - 4.09 (m, 2H), 3.54 - 3.68 (m, 2H), 3.09 (s, 4H), 2.83 (s, 2H), 2.09 - 2.37 (m, 7H), 1.96 (s, 2H), 1.55 - 1.69 (m, 2H), 1.39 (t, 2H), 1.19 (m, 8H), 0.92 (s, 6H). EXAMPLE 52
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 52A
3-cyano-4-fluorobenzenesulfonamide
3-Cyano-4-fluorobenzene-l-sulfonyl chloride (1.1 g) in 1,4-dioxane (10 mL) at 0 °C was treated dropwise with a 7 M ammonia solution in methanol (3.57 mL) and stirred for 30 minutes. A small amount of solid was removed by filtration and discarded. The filtrate was concentrated, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and triturated with diethyl ether to give the product.
EXAMPLE 52B
3 -cyano-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide
The title compound was prepared by substituting EXAMPLE 52A for 4-chloro-3- nitrobenzenesulfonamide and (tetrahydro-2H-pyran-4-yl)methanamine for 4- methylpiperazin-1 -amine dihydrochloride in EXAMPLE 6A. EXAMPLE 52C
3-chloro-5-cyano-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide EXAMPLE 52B (0.148 g) in acetonitrile (5 mL) was treated with N- chlorosuccinimide (0.080 g), heated at 60 °C for 3 hours and filtered to remove a small amount of solid. The filtrate was concentrated and chromatographed on silica gel with 3- 15% ethyl acetate in dichloromethane as eluent. The obtained solid was slurried in water, filtered, rinsed with additional water and dried under vacuum to give the product.
EXAMPLE 52D
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 52C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.70 (s, 1H), 11.41 (br s, IH), 8.07 (d, IH), 7.89 (s, 2H), 7.61 (m, IH), 7.53 (m, 2H), 7.35 (d, 2H), 7.18 (m, IH), 7.05 (d, 2H), 6.69 (m, IH), 6.42 (dd, IH), 6.18 (dd, IH), 3.83 (m, 2H), 3.55 (t, 2H), 3.23 (m, 3H), 3.06 (m, 4H), 2.15 (m, 4H), 1.92 (m, 4H), 1.60 (m, 2H), 1.40 (m, 2H), 1.19 (m, 4H), 0.93 (s, 6H).
EXAMPLE 53
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 53A
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and 4-chloro-3-nitrobenzenesulfonamide for EXAMPLE IF in EXAMPLE 1G.
EXAMPLE 53B
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
A 5 mL round-bottomed flask was charged with EXAMPLE 53A (120 mg), 1- acetylpiperidin-4-amine (28 mg), and triethylamine (0.064 mL) in dioxane (2 ml). The reaction mixture was heated to 90°C for 24 hours. The reaction mixture was cooled to room temperature, and added to a silica gel column and purified by eluting with 0-5% methanol in dichloromethane. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.66 (br s, IH), 8.65 (d, IH), 8.24 (d, IH), 8.03 (d, IH), 7.83 (dd, IH), 7.54-7.46 (m, 3H), 7.35 (d, 2H), 7.19 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (m, IH), 6.20 (d, IH), 4.28 (d, IH), 3.97-3.75 (m, 2H), 3.07 (br s, 4H), 2.87-2.70 (m, 4H), 2.29-2.10 (m, 6H), 2.02 (s, 3H), 2.00-1.89 (m, 4H), 1.66-1.54 (m, 2H), 1.39 (t, 2H), 0.92 (s, 6H). EXAMPLE 54
N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 54A
2-chloro-5-fluoro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting 2-chloro-4,5- difluorobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide and (tetrahydro-2H- pyran-4-yl)methanamine for 4-methylpiperazin-l -amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 54
N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 54A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.76 (s, IH), 11.31 (s, IH), 8.08 (d, IH), 7.69 (d, IH), 7.60 (d, IH), 7.55 (m, 2H), 7.34 (d, 2H), 7.04 (d, 2H), 6.90 (s, IH), 6.84 (d, IH), 6.69 (dd, IH), 6.45 (dd, IH), 6.13 (d, IH), 3.82 (dd, 2H), 3.24 (t, 2H), 3.05 (m, 6H), 2.73 (s, 2H), 2.14 (m, 6H), 1.95 (s, 2H), 1.81 (m, IH), 1.61 (m, 2H), 1.38 (t, 2H), 1.17 (m, 2H), 0.92 (s, 6H).
EXAMPLE 55
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 2A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.66 (br s, IH), 8.75 (t, IH), 8.54 (d, IH), 8.03 (d, IH), 7.79 (dd, IH), 7.54-7.48 (m, 3H), 7.35 (d, 2H), 7.08-7.02 (m, 3H), 6.67 (dd, IH), 6.38 (m, IH), 6.20 (d, 1H), 3.61 (t, 4H), 3.43 (q, 2H), 3.29 (m, 2H), 3.06 (br s, 4H), 2.73 (br s, 2H), 2.47 (br s, 4H), 2.18 (m, 6H), 1.95 (br s, 2H), 1.80 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 56
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 56A
5-bromo-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 37C for tetrahydro-2H- pyran-4-yl)methanol and EXAMPLE 36A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 56B
The title compound was prepared by substituting EXAMPLE 56A for EXAMPLE EXAMPLE 36C.
EXAMPLE 56C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 56B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.58 (s, 1H), 8.70 (s, 1H), 8.51 (s, 1H), 7.96 (d, 1H), 7.57 (d, 1H), 7.45 (t, 1H), 7.35-7.37 (m, 3H), 7.06 (d, 2H), 6.67 (dd, 1H), 6.33 (d, 1H), 6.26 (s, 1H), 4.56 (d, 2H), 3.76-3.80 (s, 2H), 3.56- 3.62 (m, 2H), 3.01-3.10 (m, 4H), 2.14-2.18 (m, 2H), 1.96 (s, 2H), 1.80-1.87 (m, 4H), 1.41 (t, 2H), 0.93 (s, 6H). EXAMPLE 57
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide EXAMPLE 57A
5 -bromo-6-(2-morpholinoethoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting 2-morpholinoethanol for tetrahydro- 2H-pyran-4-yl)methanol and EXAMPLE 36A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 57B
5-cyano-6-(2-morpholinoethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 57A for EXAMPLE
36A in EXAMPLE 36B.
EXAMPLE 57C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 57B for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.56 (s, IH), 8.64 (s, IH), 8.41 (s, IH), 7.92 (d, IH), 7.58 (d, IH), 7.44 (t, IH), 7.36 (d, 2H), 7.31 (s, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.31 (d, IH), 6.27 (d, IH), 4.59 (t, 2H), 3.59 (s, 4H), 3.08 (s, 4H), 2.89 (s, 2H), 2.65 (s, 4H), 2.16-2.18 (m, 2H), 1.97 (s, 2H), 1.41 (t, 2H), 0.93 (s, 6H).
EXAMPLE 58
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 58A
3-chloro-4-(2-(2-methoxyethoxy)ethylthio)benzenesulfonamide In a 25 mL microwave tube was added sodium hydride (0.6 g) in terahydrofuran (10 mL) to give a suspension. 2-(2-Methoxyethoxy)ethanethiol (1 g) was added slowly. After stirring for 30 minutes, 3-chloro-4-fluorobenzenesulfonamide (1.54 g) dissolved in 10 mL tetrahydrofuran was added slowly. The mixture was heated at 110°C for 30 minutes in a Biotage Initiator microwave reactor. Water was added, the product was extracted with ether (20 mL x3), dried over Na2S04, filtered, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on silica eluting with 0- 25% ethyl acetate in hexane.
EXAMPLE 58B
3-chloro-4-(2-(2-methoxyethoxy)ethylsulfonyl)benzenesulfonamide EXAMPLE 58A (0.15 g) was suspended in acetic acid (3 mL). Peracetic acid (0.4 mL) was added slowly. The mixture was stirred at room temperature overnight, then poured into Na2S203 solution, and the product precipitated. After filtration and washing with water, the product was dried under vacuum.
EXAMPLE 58C
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 58B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.52 (s, 1H), 7.92 (d, 1H), 7.84 (m, 2H), 7.68 (m, 1H), 7.62 (d, 1H), 7.42 (t, 1H), 7.35 (d, 2H), 7.29 (m, 1H), 7.05 (d, 2H), 6.62 (dd, 1H), 6.32 (m, 1H), 6.26 (d, 1H), 3.74 (t, 2H), 3.68 (t, 2H), 3.24 (m, 2H), 3.06 (m, 5H), 3.01 (m, 4H), 2.74 (s, 2H), 2.19 (m, 6H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 59
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
EXAMPLE 59A
4-(2-(2-methoxyethoxy)ethylthio)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-nitrobenzenesulfonamide for 3-chloro-4-fluorobenzenesulfonamide in EXAMPLE 58 A.
EXAMPLE 59B
4-(2-(2-methoxyethoxy)ethylsulfonyl)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 59A for EXAMPLE 58A in EXAMPLE 58B.
EXAMPLE 59C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 59B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.51 (s, 1H), 8.17 (m, 1H), 7.94 (m, 3H), 7.64 (d, 1H), 7.42 (m, 1H), 7.35 (d, 2H), 7.28 (d, 1H), 7.05 (d, 2H), 6.62 (m, 1H), 6.28 (m, 2H), 3.83 (m, 4H), 3.16 (m, 2H), 3.08 (s, 3H), 3.01 (m, 4H), 2.73 (s, 2H), 2.18 (m, 6H), 1.96 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H)
EXAMPLE 60
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 60A
Trans-4-(4-aminocyclohexyloxy)-3-nitrobenzenesulfonamide To a solution of tert-butyl 4-hydroxycyclohexylcarbamate (0.250 g) in
tetrahydrofuran (5 mL) was added sodium hydride (0.186 g). After stirring for 15 minutes, 4- fluoro-3-nitrobenzenesulfonamide (0.256 g) was added as a solution in tetrahydrofuran (1 mL). The reaction was heated to 60°C for 1.5 hours, cooled, and poured into a mixture of dichloromethane (100 mL) and water (25 ml). The aqueous layer was adjusted to pH~4 with IN aqueous HC1 and the organic layer was separated, washed with brine (50 ml), dried over magnesium sulfate, filtered, and concentrated. The residue was loaded onto silica gel (GraceResolv 40 g) and eluted using a gradient of 0.5% to 7.5% methanol/dichloromethane over 30 minutes. This solid was treated with HC1 (4.0M in dioxane, 5 ml) at room temperature for 1 hour and concentrated to give the title compound.
EXAMPLE 60B
4-(trans-4-morpholinocyclohexyloxy)-3 -nitrobenzenesulfonamide
To EXAMPLE 60A (0.220 g) and l-bromo-2-(2-bromoethoxy)ethane (0.177 g) in N,N-dimethylformamide (3 mL) was added triethylamine (0.338 ml) and the reaction heated to 70°C for 5 hours. The reaction was cooled and the resulting precipitate was removed by filtration. The reaction was concentrated and loaded onto silica gel and was eluted using a gradient of 0.5% to 7.5% methanol/dichloromethane to give the title compound.
EXAMPLE 60C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 60B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.62 (s, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.96 - 7.88 (m, 1H), 7.54 (d, 1H), 7.48 (s, 2H), 7.34 (d, 3H), 7.04 (d, 2H), 6.72 - 6.58 (m, 1H), 6.37 (s, 1H), 6.21 (s, 1H), 4.69 - 4.47 (m, 1H), 3.66 (s, 4H), 3.05 (s, 4H), 2.76 (s, 6H), 2.22 (s, 9H), 1.96 (s, 4H), 1.39 (s, 6H), 0.92 (s, 6H).
EXAMPLE 61
N-( {5-bromo-6-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl} sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 61 A
5 -bromo-6-( 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)pyridine-3 -sulfonamide A mixture of EXAMPLE 36A (1.0 g), EXAMPLE 3L (0.95 g) and triethylamine
(3.08 mL) in anhydrous dioxane (20 mL) was heated at 110°C overnight. The organic solvent was removed under vacuum. The residue was purified with flash column chromatography on silica gel eluting with 2%-8% methanol/dichloromethane to give the title compound. EXAMPLE 6 IB
N-( {5-bromo-6-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl} sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 61 A for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.59 (s, IH), 8.35 (s, IH), 8.00 (s, 2H), 7.55 (d, IH), 7.46 (m, 2H), 7.34 (d, 2H), 7.04 (d, 2H), 6.63 (dd, IH), 6.49 (m, IH), 6.36 (s, IH), 6.20 (s, IH), 4.05 (m, IH), 3.94 (d, 2H), 3.28 (m, 6H), 3.01 (s, 4H), 2.72 (s, 2H), 2.16 (m, 6H), 1.93 (m, 4H), 1.80 (m, 4H), 1.57 (m, 2H), 1.38 (t, 2H), 1.17 (t, 2H), 0.90 (s, 6H).
EXAMPLE 62
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 62A
4-(2-cyanoethylamino)-3-nitrobenzenesulfonamide
The title compound was prepared by substituting 3-aminopropanenitrile for
EXAMPLE 39B in EXAMPLE 39C.
EXAMPLE 62B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(2-cyanoethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 62A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (501 MHz, pyridine-d5) δ 13.04 (s, IH), 9.24 (d, IH), 9.04 (t, IH), 8.43 (d, IH), 8.38 (dd, IH), 8.13 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (ddd, 2H), 7.07 (ddd, 2H), 7.02 (d, IH), 6.76 (dd, IH), 6.55 (d, IH), 6.48 (dd, IH), 3.83 (q, 2H), 3.07 (d, 4H), 2.98 (t, 2H), 2.77 (s, 2H), 2.26 (s, 2H), 2.11 - 2.17 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 63
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dm
yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2 b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 15H for EXAMPLE 3 J and EXAMPLE 39C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (501 MHz, pyridine d5) δ 13.09 (s, IH), 9.30 (d, IH), 8.64 (d, IH), 8.43 (d, IH), 8.38 (dd, IH), 8.10 (d, IH), 7.68 (dt, 2H), 7.46 (ddd, 2H), 7.12 (ddd, 2H), 6.91 (d, IH), 6.72 (dd, IH), 6.51 (dd, IH), 6.49 (d, IH), 5.69 (s, 2H), 4.40 (s, 2H), 3.69 - 3.73 (m, 4H), 3.68 (s, IH), 2.95 - 3.02 (m, 4H), 2.84 (s, 2H), 2.40 - 2.46 (m, 4H), 2.21 (s, 2H), 2.08 - 2.15 (m, 5H), 1.76 - 1.84 (m, 2H), 1.55 - 1.63 (m, 6H), 1.29 (s, 6H).
EXAMPLE 64
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl} 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 64A
tert-butyl (trans)-4-(bis(cyclopropylmethyl)amino)cyclohexylcarbamate The title compound was prepared by substituting cyclopropanecarbaldehyde for 4'- chlorobiphenyl-2-carboxaldehyde and tert-butyl (trans)-4-aminocyclohexylcarbamate for tert butyl piperazine-l-carboxylate in EXAMPLE 1A.
EXAMPLE 64B
(trans)-N1,N1-bis(cyclopropylmethyl)cyclohexane-l,4-diamine dihydrochloride To a solution of EXAMPLE 64 A (1.4 g) in dichloromethane (10 ml) was added hydrogen chloride (10 ml, 4M in dioxane) and the reaction was stirred for 16 hours at room temperature. The reaction mixture was diluted with ether and pure product was filtered off.
EXAMPLE 64C
Trans-4-(4-(bis(cyclopropylmethyl)amino)cyclohexylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 64B for EXAMPLE 39B in EXAMPLE 39C. EXAMPLE 64D
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 64C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.30 (d, IH), 8.44 (d, IH), 8.41 (dd, IH), 8.37 (d, IH), 8.12 (d, IH), 7.67 (d, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 7.00 (d, IH), 6.75 (dd, IH), 6.53 (d, IH), 6.49 (dd, IH), 3.36 - 3.43 (m, IH), 3.02 - 3.09 (m, 4H), 2.87 - 2.94 (m, IH), 2.77 (s, 2H), 2.47 (d, 4H), 2.25 (t, 2H), 2.11 - 2.16 (m, 4H), 2.08 (d, 2H), 1.97 (s, 2H), 1.84 (d, 2H), 1.39 (t, 2H), 1.26 - 1.35 (m, 4H), 0.90 - 0.98 (m, 8H), 0.50 - 0.56 (m, 4H), 0.18 - 0.23 (m, 4H).
EXAMPLE 65
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 65A
4-((l-methylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-aminomethyl-l -methyl piperidine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 65B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 65 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, dichloromethane-d2) δ 9.57 (bs, IH), 8.78 (d, IH), 8.41 (d, IH), 8.14 (d, IH), 7.90 (m, 2H), 7.64 (d, IH), 7.45 (d, IH), 7.23 (d, 2H), 6.95 (d, 2H), 6.76 (d, IH), 6.59 (dd, IH), 6.51 (d, IH), 6.09 (d, IH), 3.21 (m, 2H), 3.08 (m, 4H), 3.02 (m, 2H), 2.74 (s, 2H), 2.33 (s, 3H), 2.21-2.17 (m, 6H), 2.16-2.02 (m, 3H), 1.97 (br.s, 2H), 1.78 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H).
EXAMPLE 66
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 66A
tert-butyl 3-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate
"The title compound was prepared by substituting tert-butyl 3- (aminomethyl)morpholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine in
EXAMPLE IF. EXAMPLE 66B
tert-butyl 3-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 66 A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE IF, with the exception that the product was purified on a silica gel column eluted with 4% methanol in dichloromethane.
EXAMPLE 66C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-3 -ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
A solution of EXAMPLE 66B in 50% trifluoroacetic acid and dichloromethane mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated and the residue was purified on a reverse phase HPLC using a gradient of 20-80% acetonitrile in water containing 10 mM ammonium acetate. 1H NMR (500MHz, dimethylsulfoxide-de) δ 11.61 (s, IH), 8.52 (bs, IH), 8.49 (d, IH), 7.98 (d, IH), 7.78 (d, IH), 7.54 (d, IH), 7.46 (s, IH), 7.42 (s, IH), 7.34 (d, 2H), 7.04 (m, 3H), 6.65 (dd, IH), 6.34 (s, IH), 6.21 (d, IH), 3.89 (d, IH), 3.76 (d, IH), 3.55-3.46 (m, 2H), 3.40-3.35 (m, 4H), 3.04 (m, 4H),2.91 (t, IH), 2.73 (s, 2H), 2.20-2.12 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 67
4-(4-{[4-(4-chlorophenyl)-6,6-dime
N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 15H and EXAMPLE 6A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.58 (s, IH), 9.04 (s, IH), 8.44 (d, IH), 7.97 (d, IH), 7.76 (dd, IH), 7.49 (m, 4H), 7.38 (d, 2H), 7.14 (d, 2H), 6.64 (dd, IH), 6.34 (d, IH), 6.21 (d, IH), 4.12 (s, 2H), 3.03 (m, 6H), 2.85 (m, 5H), 2.29 (m, 4H), 2.18 (m, 6H), 1.20 (s, 6H).
EXAMPLE 68
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 68A
4-morpholinobut-2-yn- 1 -ol
To a solution of morpholine (4.36 g) in toluene (15 mL) was added 4-chlorobut-2-yn- l-ol (2.09 g) in toluene (5 mL). The solution was stirred at 85 °C for 3 hours. After cooling, the solid was filtered off. The filtrate was subjected to vacuum distillation to give the pure title compound.
EXAMPLE 68B
4-(4-morpholinobut-2-ynyloxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 68A for (tetrahydi pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 68C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-morpholin-4-ylbut-2-ynyl)oxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 68B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.68 (s, 1H), 8.36 (s, 1H), 8.08 (d, 1H), 8.03 (d, 1H), 7.47-7.53 (m, 4H), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, 1H), 6.40 (dd, 1H), 6.20 (d, 1H), 5.15 (s, 2H), 3.52-3.55 (m, 4H), 3.09 (s, 4H), 2.84 (br s, 2H), 2.23-2.40 (m, 6H), 2.12-2.18 (m, 2H), 1.96 (s, 2H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 69
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 69A
6-((tetrahydro-2H-pyran-4-yl)methoxy)-5-((triisopropylsilyl)ethynyl)pyridine-3-sulfonamide
EXAMPLE 36B (0.176 g), bis(triphenylphosphine)palladium(II) chloride (0.176 g), copper(I) iodide (0.010 g), N,N-dimethylacetamide (2.5 mL) and triethylamine (0.105 mL) were combined, flushed with nitrogen and stirred for 2 minutes. (Triisopropylsilyl)acetylene (0.135 mL) was added and the reaction mixture was flushed with nitrogen again, heated at 60 °C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 10-30% ethyl acetate in hexanes as the eluent to give the product.
EXAMPLE 69B
5-ethynyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 69 A (0.205 g) in tetrahydrofuran (3 mL) at ambient temperature was treated with tetrabutyl ammonium fluoride (1 M in tetrahydrofuran, 0.906 mL) and stirred at ambient temperature for 4 hours. Additional tetrabutyl ammonium fluoride (1 M in tetrahydrofuran, 1.8 mL) was added and the mixture was heated at 40 °C for 45 minutes. Solid tetrabutyl ammonium fluoride (0.253 g) was added and heating was continued for 30 minutes. The reaction mixture was concentrated and then chromatographed on silica gel using 0-2% methanol in dichloromethane as the eluent to give the product.
EXAMPLE 69
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 69B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 11.41 (s, 1H), 8.58 (d, 1H), 8.19 (d, 1H), 8.05 (d, 1H), 7.53 (m, 3H), 7.35 (d, 2H), 7.04 (d, 2H),
6.67 (dd, 1H), 6.41 (dd, 1H), 6.18 (d, 1H), 4.56 (s, 1H), 4.24 (d, 2H), 3.87 (dd, 2H), 3.38 (m, 3H), 3.07 (m, 4H), 2.86 (m, 2H), 2.29 (m, 5H), 2.04 (m, 3H), 1.64 (dd, 2H), 1.34 (m, 4H), 0.93 (s, 6H). EXAMPLE 70
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 70A
4-amino-3-cyanobenzenesulfonamide
3 -Cyano-4-fluorobenzene-l -sulfonyl chloride (1.1 g) was dissolved in dioxane (4 mL). The solution was cooled to 0°C and 7 mL of an ammonia (7N in methanol) solution was added. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature for 24 hours. After concentration of the reaction mixture, the crude material was purified by flash chromatography eluting with a gradient of 30-100% ethyl acetate/hexanes.
EXAMPLE 70B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-amino-3-cyanophenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 70 A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE 1G. EXAMPLE 70C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-amino-3-carbamoylphenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzamide To a solution of EXAMPLE 70B (90 mg) in ethanol (2 mL) was added
tetrahydrofuran (2 mL), hydrogen peroxide (30%, 1 mL) and 1M sodium hydroxide solution (0.48 mL), followed by an additional 2 mL of tetrahydrofuran. The reaction was heated to 45°C for 30 minutes, cooled, and then quenched with 5% HC1 solution and extracted twice with dichloromethane. The extracts were combined and concentrated to obtain the product.
EXAMPLE 70D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide EXAMPLE 70C (80 mg) was combined with trimethyl orthoformate (2.3 mL) and trifluoroacetic acid (0.03 mL) and the resulting solution was stirred at room temperature for 4 hours. The mixture was purified by flash chromatography, eluting with a gradient of 3-10% methanol/dichloromethane. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 12.61 (s, 1H), 11.71 (s, 1H), 8.65 (d, 1H), 8.24 (s, 1H), 8.17 (dd, 1H), 8.04 (m, 1H), 7.73 (d, 1H), 7.57 (d, 1H), 7.51 (m, 2H), 7.39 (d, 2H), 7.07 (d, 2H), 6.70 (dd, 1H), 6.40 (m, 1H), 6.24 (br s, 1H), 3.61 (m, 6H), 3.03 (m, 2H), 2.75 (m, 2H), 2.17 (m, 2H), 2.01 (m, 2H), 1.44 (m, 2H), 0.94 (s, 6H).
EXAMPLE 71
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 71 A
8-chlorospiro[4.5]dec-7-ene-7-carbaldehyde
To a solution of N,N-dimethylformamide (2.81 mL) in dichloromethane (40 mL) was added dropwise POCl3 (2.78 mL) at 0°C. The reaction mixture was warmed up to room temperature and spiro[4.5]decan-8-one (3.95 g) in dichloromethane ( 5 mL) was added dropwise. The mixture was stirred overnight. The reaction was quenched with cold aqueous sodium acetate and the resulting mixture was extracted with ether and the organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 7 IB
8-(4-chlorophenyl)spiro [4.5] dec-7-ene-7-carbaldehyde
To a suspension of EXAMPLE 71 A (3 g) in water (50 mL) was added 4- chlorophenylboronic acid (2.83 g), tetrabutylammonium (4.87 g), potassium carbonate (6.26 g) and palladium(II) acetate (0.169 g). The reaction mixture was stirred at 45°C for 5 hours and extracted with dichloromethane. The organic layer was concentrated and the residue was loaded onto a silica gel column, and eluted with 5-20% ethyl acetate in hexane to give the title compound.
EXAMPLE 71C
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((8-(4-chlorophenyl)spiro[4.5]dec-7-en-7- yl)methyl)piperazin- 1 -yl)benzoate
To a solution of EXAMPLE 7 IB (274 mg) in dichloroethane (3.5 mL) was added EXAMPLE 15F (387 mg) and sodium triacetoxyborohydride (317 mg). The reaction mixture was stirred overnight. Sodium cyanoborohydride (37.6 mg) was added and the resulting mixture stirred overnight. The reaction was quenched with water and diluted with dichloromethane. The mixture was washed with water extensively and the organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 7 ID
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((8-(4-chlorophenyl)spiro[4.5]dec-7-en-7- yl)methyl)piperazin-l-yl)benzoic acid
The title compound was prepared as described in EXAMPLE 3 J using EXAMPLE 71C in place of EXAMPLE 31.
EXAMPLE 7 IE
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 7 ID and EXAMPLE 9C in place of EXAMPLE 3 J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.64 (s, IH), 8.51 (s, IH), 8.15 (d, IH), 8.01 (d, IH), 7.76 (d, IH), 7.44 - 7.53 (m, 3H), 7.34 (d, 2H), 7.07 (d, 3H), 6.66 (dd, IH), 6.37 (dd, IH), 6.20 (d, IH), 3.50 - 3.70 (m, 5H), 3.04 (s, 4H), 2.55 - 2.76 (m, 5H), 2.34 - 2.39 (m, IH), 2.20 (d, 6H), 2.03 (s, 4H), 1.91 (s, 2H), 1.61 (q, 4H), 1.51 (t, 2H), 1.36 - 1.46 (m, 8H).
EXAMPLE 72
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l- yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 15H and 29A in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 11.69 (s, IH), 11.45 (s, IH), 8.59 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.79 (dd, IH), 7.54 (d, IH), 7.47 - 7.52 (m, 2H), 7.37 (d, 2H), 7.13 (d, 2H), 7.08 (d, IH), 6.68 (dd, IH), 6.35 - 6.42 (m, IH), 6.19 (d, IH), 4.11 (s, 2H), 3.37 (s, IH), 3.26 (t, 2H), 3.20 (s, 3H), 3.07 (s, 4H), 2.83 (s, 2H), 2.17 (d, 6H), 1.81 (dd, 2H), 1.64 - 1.73 (m, IH), 1.48 (dd, 2H), 1.23 - 1.41 (m, 4H), 1.18 (s, 6H). EXAMPLE 73
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 71D and EXAMPLE 37D in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.37 (s, IH), 7.98 - 8.11 (m, 2H), 4.38 (d, 2H), 3.74 - 3.82 (m, 2H), 3.54 - 3.64 (m, 2H), 3.44 (s, IH), 3.08 (s, 3H), 2.58 - 2.89 (m, 2H), 2.13 - 2.35 (m, 4H), 2.04 (s, 2H), 1.78 - 1.93 (m, 4H), 1.57 - 1.65 (m, 4H), 1.52 (t, 2H), 1.36 - 1.47 (m, 4H). EXAMPLE 74
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 71D and EXAMPLE 34B in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.39 (s, IH), 8.58 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.79 (dd, IH), 7.47 - 7.55 (m, 3H), 7.34 (d, 2H), 7.07 (d, 3H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.25 (t, 2H), 3.22 (s, 3H), 3.06 (s, 5H), 2.71 (s, 2H), 2.21 (s, 6H), 1.94 - 2.06 (m, 4H), 1.79 (d, 2H), 1.57 - 1.65 (m, 5H), 1.51 (t, 2H), 1.39 (t, 4H), 0.95 - 1.11 (m, 4H).
EXAMPLE 75
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 75A
methyl 5 ,5 -dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate The title compound was prepared by substituting 4,4-dimethyl-2- methoxycarbonylcyclohexanone for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in
EXAMPLE 3A.
EXAMPLE 75B
methyl 2-(4-chlorophenyl)-5,5-dimethylcyclohex-l -enecarboxylate The title compound was prepared by substituting EXAMPLE 75 A for EXAMPLE 3 A in EXAMPLE 3B.
EXAMPLE 75C
(2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methanol The title compound was prepared by substituting EXAMPLE 75B for EXAMPLE 3B in EXAMPLE 3C. EXAMPLE 75D
2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enecarbaldehyde To a solution of EXAMPLE 75 C (2.8 g) in dichloromethane (50 mL) was added Dess-Martin Periodinane (5.68 g). The reaction mixture was stirred at room temperature for 3 hours and diluted with ether and washed with 5% NaOH and brine. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by flash
chromatography using 20% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 75E
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared by replacing 4'-chlorobiphenyl-2-carboxaldehyde with EXAMPLE 75D and tert-butyl piperazine-l-carboxylate with EXAMPLE 15F in EXAMPLE 1A.
EXAMPLE 75F
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared as described in EXAMPLE 15H by replacing EXAMPLE 15G with EXAMPLE 75E.
EXAMPLE 75G
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 75F and EXAMPLE IF in place of EXAMPLE 3 J and EXAMPLE 1 IB, respectively. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.38 (s, IH), 8.60 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.80 (dd, IH), 7.47 - 7.55 (m, 3H), 7.31 - 7.36 (m, 2H), 7.05 - 7.13 (m, 3H), 6.68 (dd, IH), 6.39 (dd, IH), 6.18 (d, IH), 3.85 (dd, 2H), 3.22 - 3.31 (m, 4H), 3.07 (s, 4H), 2.67 - 2.78 (m, 2H), 2.19 (s, 6H), 1.82 - 1.98 (m, 3H), 1.56 - 1.66 (m, 2H), 1.39 (t, 2H), 1.17 - 1.33 (m, 3H), 0.93 (s, 6H). EXAMPLE 76
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 75F and EXAMPLE 36C in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.62 (s, 1H), 8.73 (s, 1H), 8.52 (s, 1H), 7.98 (d, 1H), 7.56 (d, 1H), 7.45 - 7.51 (m, 1H), 7.43 (s, 1H), 7.37 (d, 2H), 7.10 (d, 2H), 6.68 (dd, 1H), 6.35 (dd, 1H), 6.25 (s, 1H), 4.29 (d, 2H), 3.88 (dd, 2H), 3.12 (d, 4H), 2.21 (s, 2H), 2.00 - 2.11 (m, 1H), 1.95 (s, 2H), 1.64 (dd, 2H), 1.27 - 1.46 (m, 4H), 0.95 (s, 6 H)
EXAMPLE 77
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate
EXAMPLE 77A
tert-butyl 3-((2-nitro-4-sulfamoylphenoxy)methyl)morpholine-4-carboxylate The title compound was prepared as described in EXAMPLE 12A by replacing (1,4- dioxan-2-yl)methanol with tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate.
EXAMPLE 77B
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl}morpholine-4-carboxylate
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 77A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.36 (s, 1H), 8.01 - 8.11 (m, 2H), 7.47 - 7.61 (m, 4H), 7.35 (d, 2H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (d, 1H), 6.20 (s, 1H), 4.41 - 4.52 (m, 2H), 4.15 - 4.28 (m, 1H), 3.59 - 3.95 (m, 3H), 3.51 (d, 1H), 3.34 - 3.43 (m, 1H), 3.10 (s, 5H), 2.84 (s, 2H), 2.28 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.20 - 1.45 (m, 12H), 0.92 (s, 6H). EXAMPLE 78
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (morpholin-3 -ylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 77B (100 mg) in dichloromethane (10 mL) at 0°C was treated with trifluoroacetic acid (5 mL) for 20 minutes. The reaction mixture was concentrated. The residue was purified by reverse phase HPLC on a CI 8 column using a gradient of 35-60% acetonitrile in 0.1% trifluoroacetic acid water to give the title compound as a trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (10 mL) and washed with 50%) aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04 and
concentrated to give the title compound. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.56 (s, IH), 8.23 (d, IH), 7.94 (d, IH), 7.90 (dd, IH), 7.57 (d, IH), 7.42 - 7.46 (m, IH), 7.31 - 7.37 (m, 3H), 7.25 (d, IH), 7.01 - 7.09 (m, 2H), 6.64 (dd, IH), 6.29 - 6.37 (m, IH), 6.24 (d, IH), 4.17 - 4.31 (m, 2H), 3.90 - 4.05 (m, IH), 3.77 - 3.85 (m, IH), 3.45 - 3.59 (m, 4H), 2.94 - 3.13 (m, 6H), 2.76 (s, 2H), 2.18 (d, 6H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 79
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 71D and EXAMPLE IF in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.38 (s, IH), 8.60 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.77 - 7.84 (m, IH), 7.45 - 7.56 (m, 3H), 7.34 (d, 2H), 7.04 - 7.13 (m, 3H), 6.68 (dd, IH), 6.39 (d, IH), 6.19 (d, IH), 3.85 (dd, 2H), 3.22 - 3.31 (m, 4H), 3.07 (s, 4H),
2.71 (s, 2H), 2.21 (s, 6H), 2.03 (s, 2H), 1.81 - 1.94 (m, IH), 1.56 - 1.68 (m, 6H), 1.51 (t, 2H), 1.34 - 1.45 (m, 4H), 1.20 - 1.33 (m, 2H). EXAMPLE 80
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(methy lsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting l-(methylsulfonyl)piperidin-4-amine for l-acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.67 (br s, 1H), 8.57 (d, 1H), 8.25 (d, 1H), 8.04 (d, 1H), 7.83 (dd, 1H), 7.54-7.46 (m, 3H), 7.35 (d, 2H), 7.17 (d, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (m, 1H), 6.20 (d, 1H), 3.80 (m, 1H), 3.57 (m, 2H), 3.08 (br s, 4H), 2.95 (td, 2H), 2.92 (s, 3H), 2.85-2.72 (m, 2H), 2.30-2.10 (m, 6H), 2.07-1.93 (m, 4H), 1.70 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 81
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 81 A
1 , 1 -Dioxotetrahydro-2H-thiopyran-4-amine
N-Benzyl-l,l-dioxotetrahydro-2H-thiopyran-4-amine (2.00 g) was added to ethanol (40 mL) in a pressure bottle. Palladium hydroxide on carbon (0.587 g,) was added and the solution was stirred under 30 psi of hydrogen at room temperature for 2 hours. The mixture was filtered though a nylon membrane and the solvent was removed under vacuum.
EXAMPLE 8 IB
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 81 A for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.65 (br s, 1H), 8.55 (d, 1H), 8.25 (d, 1H), 8.03 (d, 1H), 7.86 (dd, 1H), 7.52-7.47 (m, 3H), 7.35 (d, 2H), 7.17 (d, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (m, 1H), 6.21 (d, 1H), 4.05 (m, 1H), 3.22-3.00 (m, 8H), 2.79 (br s, 2H), 2.31-2.11 (m, 10H), 1.96 (br s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 82
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and 4-chloro-3-nitrobenzenesulfonamide for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-de) δ 11.60 (br s, IH), 8.38 (br s, IH), 7.96 (d, IH), 7.91 (d, IH), 7.68 (d, IH), 7.58 (d, IH), 7.46 (t, IH), 7.39-7.35 (m, 3H), 7.07 (d, 2H), 6.67 (dd, IH), 6.34 (m, IH), 6.28 (d, IH), 3.31 (br s, 2H), 3.17 (br s, 8H), 2.18 (m, 2H), 1.98 (br s, 2H), 1.42 (t, 2H), 0.94 (s, 6H).
EXAMPLE 83
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 83A
3-Nitro-4-[l-(2,2,2-trifluoro-ethyl)-piperidin-4-ylamino]-benzenesulfonamide The title compound was prepared by substituting l-(2,2,2-trifluoroethyl)piperidin-4- amine hydrochloride for (tetrahydropyran-4-yl)methylamine in EXAMPLE 6A.
EXAMPLE 83B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 82A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-de) δ 11.66 (br s, IH), 8.56 (d, IH), 8.24 (d, IH), 8.04 (d, IH), 7.81 (dd, IH), 7.52 (dd, 2H), 7.48 (d, IH), 7.35 (d, 2H), 7.15 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.38 (m, IH), 6.20 (d, IH), 3.68 (m, IH), 3.22 (q, 2H), 3.07 (br s, 4H), 2.90 (m, 2H), 2.75 (br s, 2H), 2.29-2.12 (m, 8H), 1.97-1.86 (m, 4H), 1.63 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 84
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 84A
l-(tetrahydro-2H-pyran-4-yl)piperidin-4-ol
Piperidin-4-ol (7.8 g) and dihydro-2H-pyran-4(3H)-one (5.0 g) were dissolved in titanium(IV) isopropoxide (30 mL) and the reaction was stirred at room temperature overnight. Methanol (40 mL) was added and the reaction was cooled to 0°C. Then NaBH4 (3.8 g) was added in portions over one hour. After 2 hours IN aqueous NaOH was added, followed by ethyl acetate addition. After filtration though celite the layers were separated, the aqueous layer extracted with ethyl acetate, and the combined organic layers were dried over Na2S04. The crude was purified by column chromatography using dichloromethane having 5- 10% 7NNH3 in methanol.
EXAMPLE 84B
5 -bromo-6-( 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-yloxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 84A for (tetrahydro-2H- pyran-4-yl)methanol and EXAMPLE 36A for 4-fluoro-3-nitrobenzenesulfonamide in
EXAMPLE 24A.
EXAMPLE 84C
5 -cyano-6-( 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-yloxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 84B for EXAMPLE in EXAMPLE 36C. EXAMPLE 84D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 84C for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.50 (s, 1H), 8.60 (d, 1H), 8.37 (d, 1H), 7.90 (d, 1H), 7.60 (d, 1H), 7.42 (dd, 1H), 7.35 (d, 2H), 7.25 (d, 1H), 7.04 (d, 2H), 6.63 (dd, 1H), 6.28 (m, 1H), 6.24 (d, 1H), 5.30 (br s, 1H), 4.50 (d, 2H), 3.95 (dd, 2H), 3.30 (m, 5H), 3.02 (br s, 4H), 2.95 (br s, 2H), 2.24 (br s, 4H), 2.17 (br m, 4H), 1.96 (s, 2H), 1.90 (br m, 4H), 1.60 (br m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 85
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 85A
5-isopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide
EXAMPLE 36B (0.176 g), 2-dicyclohexylphosphino-2*,6'-dimethoxybiphenyl (0.041 g), and palladium(II) acetate (0.011 g) were combined in a 10 mL oven-dried flask.
Tetrahydrofuran (1 mL) was added and the mixture was flushed with nitrogen and stirred at ambient temperature for 5 minutes. 2-Propylzinc bromide solution (0.5 M in tetrahydrofuran) (1.5 mL) was added and stirring was continued under nitrogen overnight. Additional 2-2- dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.041 g) and palladium(II) acetate (0.011 g) were added. The mixture was flushed with nitrogen and stirred at ambient temperature for 5 minutes. 2- Propylzinc bromide solution (0.5 M in tetrahydrofuran) (1.5 mL) was added and stirring was continued under nitrogen for 2.5 days. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated, and chromatographed on silica gel with 0 to 3% methanol in CH2CI2 as the eluent. The obtained material was chromatographed on silica gel a second time with 10-40% ethyl acetate in CH2CI2 as the eluent, triturated with diethyl ether and dried under vacuum at 45 °C to give the product. EXAMPLE 85B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 85A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.70 (s, IH), 8.49 (m, IH), 8.04 (d, IH), 7.90 (m, IH), 7.57 (m, IH), 7.52 (t, IH), 7.48 (dd, IH), 7.34 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.41 (dd, IH), 6.17 (s, IH), 4.19 (m, 2H), 3.88 (m, 2H), 3.30 (m, 2H), 3.05 (m, 5H), 2.77 (s, 2H), 2.21 (s, 4H), 2.14 (s, 2H), 2.03 (m, IH), 1.95 (s, 2H), 1.64 (m, 2H), 1.34 (m, 4H), 1.12 (d, 6H), 0.92 (s, 6H).
EXAMPLE 86
N-( {3 -chloro-5 -fluoro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 86A
3-fluoro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting 3,4-difluorobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide and (tetrahydro-2H-pyran-4-yl)methanamine for 4- methylpiperazin-1 -amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 86B
3-chloro-5-fluoro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 86A for EXAMPLE 52B in EXAMPLE 52C.
EXAMPLE 86C
N-( {3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 86B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.72 (s, IH), 11.20 (s, IH), 8.08 (d, IH), 7.61 (m, 2H), 7.50 (m, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.68 (dd, IH), 6.42 (dd, IH), 6.16 (d, IH), 6.09 (m, IH), 3.81 (dd, 2H), 3.25 (m, 4H), 3.07 (m, 4H), 2.76 (s, 2H), 2.18 (m, 6H), 1.95 (s, 2H), 1.72 (m, IH), 1.53 (d, 2H), 1.38 (t, 2H), 1.16 (m, 2H), 0.92 (s, 6H). EXAMPLE 87
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -2-( 1 H-indol-5-yloxy)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl) benzamide EXAMPLE 87A
methyl 2-(lH-indol-5-yloxy)-4-fluorobenzoate
The title compound was prepared by substituting 5-hydroxyindole for
EXAMPLE 3G in EXAMPLE 3H.
EXAMPLE 87B
methyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared by substituting EXAMPLE 87A for
EXAMPLE 3H in EXAMPLE 31.
EXAMPLE 87C
2-( 1 H-indol-5 -yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 - enyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 87B for EXAMPLE 31 in EXAMPLE 3 J.
EXAMPLE 87D
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -2-( 1 H-indol-5 -yloxy)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 87C for EXAMPLE IE in EXAMPLE 1G, except here the crude was purified by preparative HPLC using a 250 x 50 mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.40 (br s, 1H), 11.17 (s, 1H), 9.50 (v br s, 1H), 8.61 (t, 1H), 8.57 (d, 1H), 7.77 (dd, 1H), 7.70 (br s, 1H), 7.50 (m, 5H), 7.36 (m, 5H), 7.10 (s, 1H), 7.08 (d, 1H), 6.83 (dd, 1H), 6.69 (dd, 1H), 6.37 (m, 1H), 6.21 (d, 1H), 4.30 (br s, 1H), 3.84 (dd, 2H), 3.70 (br s, 1H), 3.30 (m, 6H), 3.20, 2.95, 2.80 (all br s, total 6H), 1.86 (m, 1H), 1.60 (m, 2H), 1.25 (m, 2H). EXAMPLE 88
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -2-(lH-indol-5-yloxy)-N-({4-[(3- morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 87C for EXAMPLE IE and EXAMPLE 2 A for EXAMPLE IF in EXAMPLE 1G, except here the crude was purified by preparative HPLC using a 250 x 50 mm CI 8 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.40 (br s, 1H), 11.19 (s, 1H), 9.60 (v br s, 1H), 8.69 (t, 1H), 8.60 (d, 1H), 7.83 (dd, 1H), 7.65 (br s, 1H), 7.50 (m, 5H), 7.38 (m, 5H), 7.12 (m, 2H), 6.83 (dd, 1H), 6.69 (dd, 1H), 6.39 (m, 1H), 6.20 (d, 1H), 4.38 (br s, 1H), 4.00 (m, 2H), 3.80 (br s, 1H), 3.40 (m, 4H), 3.30-2.80 (envelope, 10H), 3.20 (m, 4H), 1.96 (m, 2H).
EXAMPLE 89
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N-( {3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide
This EXAMPLE was prepared by substituting EXAMPLE 87C for EXAMPLE IE and EXAMPLE 3M for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.15 (s, 1H), 8.56 (d, 1H), 8.20 (d, 1H), 7.84 (dd, 1H), 7.52 (d, 1H), 7.39 - 7.31 (m, 4H), 7.12 (d, 2H), 7.04 (d, 2H), 6.84 (dd, 1H), 6.65 (dd, 1H), 6.38 (t, 1H),
6.14 (d, 1H), 3.94 (m, 2H), 3.84 (m, 1H), 3.02 (m, 8H), 2.79 (m, 3H), 2.72 (s, 2H), 2.20-2.02 (m, 8H), 1.85 (m, 6H), 1.60 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 90
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 87C for EXAMPLE IE and EXAMPLE 4A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.08 (s, 1H), 8.51 (d, 1H), 8.13 (d, 1H), 7.78 (dd, 1H), 7.52 (d, 1H), 7.37 - 7.31 (m, 4H), 7.06 - 7.00 (m, 4H), 6.79 (dd, 1H), 6.59 (dd, 1H), 6.35 (t, 1H), 6.14 (d, 1H), 3.73 (m, 1H), 3.05 - 2.95 (m, 6H), 2.71 (s, 2H), 2.60 (m, 2H), 2.48 (s, 3H), 2.16 (m, 6H), 2.01 (m, 2H), 1.95 (s, 2H), 1.70 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 91
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N-( {4- [(4-methylpiperazin- 1 -yl)amino] -3 -nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 6 A for EXAMPLE 1 IB and EXAMPLE 87C for EXAMPLE 3J in EXAMPLE 1 ID. 1H NMR (500 MHz,
dimethylsulfoxide-de) δ 11.14 (s, IH), 9.18 (s, IH), 8.53 (d, IH), 7.84 (dd, IH), 7.56 (d, IH), 7.51 (d, IH), 7.39 (m, 2H), 7.33 (d, 2H), 7.12 (d, IH), 7.03 (d, 2H), 6.84 (dd, IH), 6.62 (dd, IH), 6.38 (m, IH), 6.13 (d, IH), 3.00 (m, 4H), 2.90 (m, 4H), 2.71 (s, 2H), 2.33 (s, 3H), 2.15 (m, 6H), 1.94 (s, 2H), 1.37 (t, 2H), 0.92 (s, 6H).
EXAMPLE 92
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-indol-5-yloxy)benzamide The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 87C and EXAMPLE 12A in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.16 (s, 2H), 8.39 (d, IH), 8.06 (dd, IH), 7.51 (d, IH), 7.38 - 7.43 (m, 3H), 7.34 (d, 2H), 7.15 (d, IH), 7.04 (d, 2H), 6.85 (dd, IH), 6.64 (dd, IH), 6.39 (s, IH), 6.15 (d, IH), 4.20 - 4.28 (m, 2H), 3.85 - 3.91 (m, IH), 3.82 (dd, IH), 3.74 - 3.78 (m, IH), 3.59 - 3.69 (m, 2H), 3.40 - 3.51 (m, 2H), 3.05 (s, 4H), 2.78 (s, 2H), 2.23 (s, 4H), 2.14 (s, 2H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 93
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 87C for EXAMPLE 3 J and EXAMPLE 16A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-de) δ 11.17 (s, IH), 8.18 (d, IH), 7.92 (dd, IH), 7.49 (d, IH), 7.40 (m, 2H), 7.33 (d, 2H), 7.26 (m, IH), 7.17 (d, IH), 7.04 (m, 3H), 6.86 (dd, IH), 6.65 (dd, IH), 6.40 (s, IH), 6.14 (d, IH), 3.51 (m, 4H), 3.28 (s, 3H), 3.03 (s, 4H), 2.74 (s, 2H), 2.16 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 94
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- indol-5 -yloxy)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 87C for EXAMPLE 3 J and EXAMPLE 17A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-de) δ 11.20 (s, 1H), 8.19 (d, 1H), 7.90 (dd, 1H), 7.53 (d, 1H), 7.40 (m, 4H), 7.33 (t, 1H), 7.17 (d, 1H), 7.07 (m, 3H), 6.86 (dd, 1H), 6.70 (dd, 1H), 6.41 (s, 1H), 6.21 (d, 1H), 3.84 (dd, 2H), 3.59 (m, 2H), 3.25 (m, 6H), 3.00 (m, 2H), 2.74 (s, 2H), 2.54 (m, 2H), 2.18 (s, 2H), 2.01 (s, 2H), 1.83 (m, 1H), 1.54 (m, 2H), 1.45 (t, 2H), 1.23 (m, 2H), 0.94 (s, 6H).
EXAMPLE 95
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-(l H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 95A
l-(l,3-difluoropropan-2-yl)piperidin-4-amine
Tert-butyl piperidin-4-ylcarbamate (0.212 g), l,3-difluoropropan-2-one (0.149 g) and sodium triacetoxyborohydride (0.337 g) were stirred together in dichloroethane at room temperature. After stirring overnight the reaction was quenched with water (10 mL) and extracted into dichloromethane (2 x 20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was treated with hydrogen chloride (4.0M in dioxane, 1.323 ml) for 1 hour to give the title compound as the HCl salt after concentration.
EXAMPLE 95B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({ 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl} -2-(l H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 95 A (0.057 g) and EXAMPLE 53 A (0.162 g) were suspended in dioxane (3 mL) and heated to 105°C overnight. The reaction was concentrated, loaded onto silica gel (GraceResolv 12 g) and eluted with a gradient of 0.5% to 4% methanol/dichloromethane. The product containing fractions were concentrated and loaded onto C18 (SF25-75g analogix column) and eluted using a gradient of 30% to 60%> acetonitrile/water. The product was partitioned between dichloromethane (20 mL) and saturated aqueous NaHC03 solution (20 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the title compound. 1H NMR (300 MHz, CDC13) δ 10.10 (s, 1H), 8.88 (d, 2H), 8.45 (d, 1H), 8.20 (s, 1H), 8.18 - 8.09 (m, 1H), 7.95 (d, 1H), 7.68 (d, 1H), 7.44 (s, 1H), 7.23 - 7.19 (m, 1H), 6.91 (d, 3H), 6.53 (d, 2H), 5.98 (d, 1H), 4.64 (dd, 4H), 3.68 - 3.50 (m, 1H), 3.01 (d, 6H), 2.72 (d, 4H), 2.19 (s, 11H), 1.69 (s, 2H), 1.41 (s, 2H), 0.94 (s, 6H).
EXAMPLE 96
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 96A
5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 37C for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 96B
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 96A for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.52 (s, 1H), 8.41 (s, 1H), 8.03 (d, 1H), 7.56 (d, 1H), 7.50 (m, 2H), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, 1H), 6.39 (m, 1H), 6.22 (s, 1H), 4.50 (d, 2H), 3.78 (m, 2H), 3.60 (m, 2H), 3.12 (v br s, 4H), 2.93 (v br s, 2H), 2.38 (v br s, 4H), 2.17 (br m, 2H), 1.96 (s, 2H), 1.86 (m, 4H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 97
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amm^
b]pyridin-5 -yloxy)benzamide
EXAMPLE 97A
tert-butyl 4-(2-nitro-4-sulfamoylphenylamino)piperidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl 4-aminopiperidine-l- carboxylate for 4-methylpiperazin-l -amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 97B
3-nitro-4-(piperidin-4-ylamino)benzenesulfonamide Tert-butyl 4-(2-nitro-4-sulfamoylphenylamino)piperidine- 1 -carboxylate was dissolved in dichloromethane (3 mL) and treated with IN HC1 in ether (4 mL). The reaction was stirred overnight then concentrated to give the title compound.
EXAMPLE 97C
4-(l-(2,2-difluoroethyl)piperidin-4-ylamino)-3-nitrobenzenesulfonamide 3-nitro-4-(piperidin-4-ylamino)benzenesulfonamide hydrochloride (0.1 OOg ), 1,1- difluoro-2-iodoethane (0.063 mL) and diisopropylamine (0.156 mL) were stirred together in N,N-dimethylformamide (3 ml) and heated to 85°C. The reaction was diluted with dichloromethane (50 mL) and washed with water (50 mL), brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. The residue was loaded onto silica gel (GraceResolve 12g) and eluted using a gradient of 0.5% methanol/dichloromethane to 3% methanol/dichloromethane over 30 minutes to give the title compound.
EXAMPLE 97D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[l-(2,2-difluoroethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 97B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-d6) δ 11.67 (s, IH), 11.54 - 11.27 (m, IH), 8.55 (d, IH), 8.24 (d, IH), 8.03 (d, IH), 7.81 (d, IH), 7.50 (dd, 3H), 7.34 (d, 2H), 7.13 (d, IH), 7.04 (d, 2H), 6.68 (d, IH), 6.38 (dd, IH), 6.15 (dt, 2H), 3.64 (s, IH), 3.07 (s, 4H), 2.79 (ddd, 6H), 2.41 (t, 2H), 2.17 (d, 6H), 1.92 (d, 4H), 1.61 (d, 2H), 1.38 (s, 2H), 0.92 (s, 6H).
EXAMPLE 98
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 53B by replacing 1- acetylpiperidin-4-amine with 4-amino-l-cyclopropylpiperidine. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.65 (s, IH), 8.54 (d, IH), 8.22 (d, IH), 8.02 (d, IH), 7.80 (dd, IH), 7.49 (m, 3H), 7.34 (d, 2H), 7.11 (d, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.38 (dd, IH), 6.19 (d, IH), 3.69 (m, IH), 3.06 (m, 4H), 2.92 (m, 2H), 2.74 (s, 2H), 2.23 (m, 7H), 1.93 (m, 5H), 1.77 (m, IH), 1.55 (m, 3H), 1.38 (t, 2H), 0.92 (s, 6H), 0.43 (m, 4H).
EXAMPLE 99
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -morpholin-4-ylcyclohexyl)methy 1] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 53B by replacing 1- acetylpiperidin-4-amine with l-(4-morpholino)cyclohexanemethylamine. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.70 (s, IH), 9.06 (s, IH), 8.59 (d, IH), 8.06 (d, IH), 7.83 (dd, IH), 7.57 (d, IH), 7.50 (m, 2H), 7.34 (m, 3H), 7.19 (d, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.41 (dd, IH), 6.17 (d, IH), 3.56 (m, 6H), 3.44 (m, 2H), 3.07 (m, 5H), 2.57 (m, 5H), 2.24 (m, 6H), 1.95 (s, 3H), 1.45 (m, 6H), 1.23 (m, 3H), 0.92 (s, 6H).
EXAMPLE 100
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 100A
Trans-tert-butyl-4-(dicyclopropylamino)cyclohexylcarbamate A suspension of trans-tert-butyl-4-aminocyclohexylcarbamate (1 g), molecular sieves 3A (1 g), acetic acid (2.67 ml), (l-ethoxycyclopropoxy)trimethysilane (3.74 ml) and sodium cyanoborohydride (0.880 g) in dry methanol (10 ml) was heated at reflux for 3 hours. The insolubles were filtered off, the resulting solution was basified with aqueous NaOH (6 M) to pH 14, and extracted with ether. The combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The residue was purified by flash chromatography (silica gel 80 g, 30 - 100% acetone/hexanes) to provide the title compound.
EXAMPLE 100B
(trans)-N1,N1-dicyclopropylcyclohexane- 1 ,4-diamine bis(2,2,2-trifluoroacetate)
The title compound was prepared by substituting EXAMPLE 100A for EXAMPLE 39A in EXAMPLE 39B.
EXAMPLE lOOC
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
A suspension of EXAMPLE 53A (0.14 g), EXAMPLE 100B (0.112 g) and N,N- diisopropylethylamine (0.310 mL) in dioxane (10 mL) was stirred for 3 days at 100 °C. Theproduct was concentrated and purified by RP HPLC(C8, 30% - 100% CH3CN/water/0.1% trifiuoroacetic acid). 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.28 (d, IH), 8.41 - 8.45 (m, 2H), 8.37 (d, IH), 8.12 (d, IH), 7.67 (d, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 7.01 (d, IH), 6.75 (dd, IH), 6.53 (d, IH), 6.48 - 6.51 (m, IH), 3.43 (ddd, IH), 3.03 - 3.09 (m, 4H), 2.72 - 2.79 (m, 3H), 2.22 - 2.28 (m, 2H), 2.11 - 2.16 (m, 4H), 2.10 (s, 2H), 2.00 - 2.05 (m, 2H), 1.97 (s, 2H), 1.89(s, IH), 1.86 (s, 3H), 1.62 - 1.71 (m, 2H), 1.39 (t, 2H), 1.19 - 1.29 (m, 2H), 0.93 (s, 6H), 0.48 (d, 8H).
EXAMPLE 101
4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 101 A
Ethyl 2-hydroxy-6,6-dimethylcyclohex- 1 -enecarboxylate Into a 500 mL flame dried round-bottomed flask was added copper(I) iodide (18 g) in ether (200 mL) to give a suspension. After cooling to -5°C, methyllithium (120 mL, 1.6M in ether) was added dropwise. After stirring at -5°C for 1 hour, 3-methylcyclohex-2-enone (5.15 mL) in 15 ml ether was added dropwise, and the mixture was stirred at -5°C for 1 hour. After cooling to -78°C, hexamethylphosphoramide (60 mL) was added dropwise. Ethyl carbonocyanidate (23.74 mL) was added. After stirring at -78 °C for 20 minutes, the mixture was warmed up to room temperature, and stirred for 1 hour. The mixture was poured into cold water, and the layers were separated. The aqueous layer was extracted with ether (3x 20 mL). The combined organic layers were washed with saturated aqueous NH4C1 (3x 20 mL), dried over Na2S04, filtered, and dried under vacuum. The crude product was added to a silica gel column and purified by eluting with 0-10% ethyl acetate in hexane.
EXAMPLE 101B
Ethyl 6,6-dimethyl-2-(trif uoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate Into a 500 mL round-bottomed flask was added hexane-washed sodium hydride (0.5 g) in dichloromethane (100 mL) to give a suspension. After cooling to -5 °C, EXAMPLE 101 A (2.0 g) was added. After stirring at -5 °C for 30 minutes, the mixture was cooled to - 78°C. Trifluoromethanesulfonic anhydride (2.2 mL) was added. The mixture was warmed to room temperature and stirred overnight. Water was added slowly to the mixture, the aqueous layer was then extracted by dichloromethane (2x 20 mL). The combined organic layers were washed with saturated NH4C1 and brine, dried over Na2S04, filtered, and concentrated.
EXAMPLE 101C
ethyl 2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -enecarboxylate Into a 25 mL microwave tube was added EXAMPLE 10 IB (2.9 g), 4- chlorophenylboronic acid (2.2 g), and tetrakis(triphenylphosphine)palladium (0.05 g) in 1,2- dimethoxyethane/methanol(2: l, 10 mL) to give a solution. Cesium fluoride (4 g) was then added. The reaction mixture was stirred at 150°C under (100W) in a Biotage Initiator microwave reactor for 30 minutes. After removing the solvents, water was added, and the mixture was extracted with ethyl acetate (2x). The combined organic layers were dried by MgS04. After filtering, the crude product was purified by reverse phase chromatography eluting with 50-100% acetonitrile/water with 0.1% trifluoroacetic acid. EXAMPLE 10 ID
(2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -enyl)methanol In a 100 mL round-bottomed flask was placed lithium aluminum hydride (1 g) in ether (20 mL) to give a suspension. EXAMPLE 101C (1 g) dissolved in ether (5 mL) was added slowly by syringe. The mixture was stirred at room temperature overnight. After cooling to 0°C, the reaction was quenched by water. Ether (2x 10 mL) was used to extract the product. The crude product was purified by flash chromatography on silica by eluting with 0- 15% ethyl acetate in hexane.
EXAMPLE 10 IE
Methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-6,6- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate To a 0°C solution of EXAMPLE 10 ID (0.43 g) in dichloromethane (5 mL) was added triethylamine (1 mL). Methanesulfonyl chloride (0.134 mL) was then added slowly. After 5 minutes, EXAMPLE 15F (0.61 g) was added. The mixture was stirred at room temperature overnight. The crude product was purified by flash chromatography on silica with 0 to 25% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 10 IF
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-6,6- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid In a 5 mL microwave tube was added lithium hydroxide hydrate (15 mg) and
EXAMPLE 10 IE (45 mg) in dioxane/water(2: l) (2 mL) to give a suspension. The mixture was heated to 130°C in a Biotage Initiator microwave reactor for 20 minutes. After cooling and neutralization by HCl, the crude product was added to a Prep HPLC column and was eluted with 20-80% acetonitrile/water with 0.1% trifluoroacetic acid.
EXAMPLE 101G
4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 10 IF for EXAMPLE 3 J and EXAMPLE IF for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 1 1.68 (s, 1H), 11.47 (s, 1H), 8.58 (m, 2H), 8.03 (m, 1H), 7.79 (m, 1H), 7.51 (m, 3H), 7.31 (d, 2H), 7.10 (m, 1H), 7.02 (d, 2H), 6.65 (m, 1H), 6.39 (m, 1H), 6.15 (m, 1H), 3.85 (m, 2H), 3.27 (m, 4H), 2.97 (m, 4H), 2.76 (s, 2H), 2.14 (m, 6H), 1.70 (m, 2H), 1.61 (m, 2H), 1.44 (m, 2H), 1.26 (m, 3H), 1.16 (m, 6H)
EXAMPLE 102
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 102 A
(4-ethylmorpholin-3-yl)methanol
Morpholin-3-ylmethanol (500 mg) and iodoethane (666 mg) in N,N- dimethylformamide was treated with K2CO3 (1.1 g) overnight. The reaction mixture 1 diluted with water and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 102B
5-bromo-6-((4-ethylmorpholin-3-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared as described in EXAMPLE 12A by replacing fluoro-3-nitrobenzenesulfonamide and (l,4-dioxan-2-yl)methanol with 5-bromo-6- fluoropyridine-3 -sulfonamide and EXAMPLE 102 A, respectively.
EXAMPLE 102C
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 102B in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.62 (s, 1H), 8.51 (s, 1H), 8.30 (s, 1H), 8.00 (d, 1H), 7.55 (d, 1H), 7.45 - 7.50 (m, 2H), 7.35 (d, 2H), 7.05 (d, 2H), 6.66 (dd, 1H), 6.37 (s, 1H), 6.21 (d, 1H), 4.58 (dd, 1H), 4.39 - 4.50 (m, 1H), 3.78 - 3.90 (m, 1H), 3.67 - 3.77 (m, 1H), 3.50 - 3.65 (m, 2H), 3.08 (s, 4H), 2.59 - 3.00 (m, 4H), 2.20 - 2.39 (m, 2H), 2.15 (s, 2H), 1.96 (s, 2H), 1.39 (t, 2H), 0.99 - 1.11 (m, 3H), 0.93 (s, 6H) EXAMPLE 103
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3 -yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 103 A
4-((4-ethylmorpholin-3 -yl)methoxy)-3 -nitrobenzenesulfonamide The title compound was prepared as described in EXAMPLE 12A by replacing (1,4- dioxan-2-yl)methanol with EXAMPLE 102A.
EXAMPLE 103B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-ethylmorpholin-3 -yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 103A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 8.33 (s, IH), 7.99 - 8.06 (m, 2H), 7.47 - 7.57 (m, 3H), 7.45 (d, IH), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.42 (dd, IH), 4.23 (dd, IH), 3.81 (d, IH), 3.69 (d, IH), 3.49 - 3.63 (m, 2H), 3.08 (s, 4H), 2.92 (s, IH), 2.81 (s, 4H), 2.54 (s, IH), 2.25 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.39 (t, 2H), 1.00 (t, 3H), 0.92 (s, 6H)
EXAMPLE 104
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(4-tetrahydro-2H-pyran-4-ylmorpholin-3-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 78 (20 mg) and dihydro-2H-pyran-4(3H)-one (10 mg) in dichloroethane (2 mL) was treated with NaCNB¾ (9.74 mg) overnight. Additional dihydro-2H-pyran- 4(3H)-one (20 mg) and titanium (IV) isoproxide (0.05 mL) were added. The resulting mixture was stirred at room temperature overnight and concentrated. The residue was purified by reverse phase HPLC on a CI 8 column using a gradient of 35-60% acetonitrile in 0.1% trifluoroacetic acid water to give the title compound as a trifluoroacetate salt. The trifluoro acetic acid salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHC03. The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.35 (s, IH), 8.04 (s, 2H), 7.44 - 7.58 (m, 4H), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.40 (s, IH), 6.20 (s, IH), 4.44 (s, IH), 4.28 (s, IH), 3.85 (d, 2H), 3.71 (d, IH), 3.61 (s, 3H), 3.20 - 3.29 (m, 2H), 3.08 (s, 5H), 2.54 - 2.96 (m, 5H), 2.06 - 2.42 (m, 5H), 1.96 (s, 2H), 1.77 (d, IH), 1.53 - 1.66 (m, IH), 1.29 - 1.51 (m, 4H), 0.92 (s, 6H)
EXAMPLE 105
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino} phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 105 A
(S)-tert-butyl 1 -(tetrahydro-2H-pyran-4-yl)piperidin-3 -ylcarbamate The title compound was prepared by substituting (S)-tert-butyl piperidin-3- ylcarbamate for tert-butyl piperazine-l-carboxylate and dihydro-2H-pyran-4(3H)-one for 4'- chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1 A.
EXAMPLE 105B
(S)- 1 -(tetrahydro-2H-pyran-4-yl)piperidin-3 -amine
The title compound was prepared by substituting EXAMPLE 105 A for EXAMPLE
1A in EXAMPLE IB.
EXAMPLE 105C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yl] amino} phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 105B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 8.68 (br s, IH), 8.54 (br s, IH), 8.02 (d, IH), 7.77 (m, IH), 7.50 (m, 3H), 7.34 (d, 2H), 7.03 (m, 3H), 6.67 (dd, IH), 6.38 (m, IH), 6.19 (d, IH), 3.98 (m, 2H), 3.90 (m, 2H), 3.52 (m, 2H), 3.09 (s, 2H), 3.05 (m, 4H), 2.77 (m, 2H), 2.60 (m, 2H), 2.16 (m, 6H), 1.95 (m, 2H), 1.65 (m, 5H), 1.50 (m, 3H), 1.38 (m, 2H), 0.94 (s, 6H). EXAMPLE 106
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 106 A
5-Bromo-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting (tetrahydro-2H-pyran-4- yl)methanamine for EXAMPLE 3L in EXAMPLE 61 A.
EXAMPLE 106B
5-cyano-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 106A for EXAMPLE 36B in EXAMPLE 36C.
EXAMPLE 106C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 106B for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.62 (s, IH), 8.55 (s, IH), 8.14 (s, IH), 8.01 (d, IH), 7.87 (s, IH), 7.56 (d, IH), 7.48 (d, 2H), 7.34 (d, 2H), 7.04 (d, 2H), 6.64 (m, IH), 6.37 (s, IH), 6.19 (d, IH), 3.81 (dd, 2H), 3.25 (m, 4H), 3.04 (s, 4H), 2.74 (s, 2H), 2.17 (m, 6H), 1.95 (s, 2H), 1.87 (m, IH), 1.53 (m, 2H), 1.37 (t, 2H), 1.18 (m, 2H), 0.91 (s, 6H).
EXAMPLE 107
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l,l-dioxidothiomorpholin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 107A
3-nitro-4-(4-aminothiomorpholine- 1 , 1 -dioxide)benzenesulfonamide The title compound was prepared by substituting 4-aminothiomorpho line- 1,1- dioxide for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 107B
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4- [( 1 , 1 -dioxidothiomorpholin-4-yl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 107A for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.64 (s, IH), 9.58 (s, IH), 8.50 (s, IH), 8.02 (d, IH), 7.78 (m, 2H), 7.50 (m, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.66 (dd, IH), 6.38 (s, IH), 6.19 (d, IH), 3.48 (m, 4H), 3.23 (m, 4H), 3.05 (s, 4H), 2.73 (d, 2H), 2.16 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 108
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 108 A
4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-(aminomethyl)tetrahydro-2H- -4-amine for (tetrahydro-2H-pyran-4-yl)methanamine in EXAMPLE IF.
EXAMPLE 108B
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 108 A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.55 (s, IH), 8.45 (s, 2H), 7.95 (d, IH), 7.75-7.77 (m, IH), 7.57 (d, 2H), 7.44 (s, IH), 7.34 (d, 2H), 7.09 (d, J = 8.85 Hz, IH), 7.05 (d, 2H), 6.69 (dd, IH), 6.33 (d, IH), 6.22 (d, IH), 3.59-3.71 (m, 6H), 3.01 (s, 4H), 2.73 (s, 2H), 2.15-2.19 (m, 6H), 1.95 (s, 2H), 1.71-1.74 (m, 2H), 1.59- 1.61 (m, IH), 1.38 (t, 2H), 0.93 (s, 6H). EXAMPLE 109
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3 b]pyridin-5 -yloxy)benzamide
EXAMPLE 109A
Trans-5-bromo-6-(4-morpholinocyclohexyloxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 9B for EXAMPLE 3L in EXAMPLE 61 A.
EXAMPLE 109B
Trans-5-cyano-6-(4-morpholinocyclohexylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 109A for EXAMPLE 36B in EXAMPLE 36C.
EXAMPLE 109C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 109B for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.59 (s, IH), 8.56 (d, IH), 8.13 (s, IH), 8.00 (d, IH), 7.55 (d, IH), 7.47 (m, 2H), 7.34 (d, 2H), 7.04 (d, 2H), 6.64 (dd, IH), 6.36 (d, IH), 6.19 (d, IH), 4.00 (m, IH), 3.65 (m, 4H), 3.28 (m, 4H), 3.03 (m, 4H), 2.73 (m, 4H), 2.16 (m, 6H), 1.90 (m, 6H), 1.40 (m, 6H), 0.93 (s, 6H).
EXAMPLE 110
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 52B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.71 (s, IH), 11.23 (s, IH), 8.08 (d, IH), 7.91 (d, IH), 7.74 (dd, IH), 7.60 (d, IH), 7.52 (m, 2H), 7.34 (m, 2H), 7.16 (s, 1H), 7.04 (m, 2H), 6.83 (d, 1H), 6.68 (dd, 1H), 6.43 (dd, 1H), 6.16 (d, 1H), 3.83 (dd, 2H), 3.23 (m, 2H), 3.12 (t, 2H), 3.06 (m, 4H), 2.73 (m, 2H), 2.15 (m, 6H), 1.95 (s, 2H), 1.82 (m, 1H), 1.58 (m, 2H), 1.38 (m, 2H), 1.18 (m, 2H), 0.92 (s, 6H).
EXAMPLE 111
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 111 A
benzyl (1 S,3R)-3-(tert-butoxycarbonylamino)cyclopentylcarbamate (lS,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid (1.03 g), diphenylphosphoryl azide (DPP A, 1.00 mL), triethylamine (0.929 mL), and benzyl alcohol (0.931 mL) were combined in toluene (10 mL) and stirred at 100°C for 24 hours. The solution was cooled and chromatographed on silica gel using 10% ethyl acetate/ hexanes to give the pure product.
EXAMPLE 11 IB
benzyl (1 S,3R)-3-aminocyclopentylcarbamate
The title compound was prepared by substituting EXAMPLE 111 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 111C
benzyl (1 S,3R)-3-morpholinocyclopentylcarbamate A solution of EXAMPLE 11 IB (400 mg), l-bromo-2-(2-bromoethoxy)ethane (0.246 mL), and triethylamine (0.595 mL) in N,N-dimethylformamide (6 mL) was stirred at 70°C for 24 hours. The solution was cooled and poured into ethyl acetate (200 mL). The solution was extracted with 3x water, washed with brine, concentrated, and chromatographed on silica gel using 10% methanol/ethyl acetate to give the pure product.
EXAMPLE H ID
( 1 S ,3R)-3 -morpholinocyclopentanamine EXAMPLE 111C (300 mg) and ethanol (20 ml) were added to wet 20% Pd(OH)2-C (60.0 mg) in a 50 mL pressure bottle and stirred for 8 hours at 30 psi. The mixture was filtered through a nylon membrane and condensed to give the product. EXAMPLE 11 IE
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE 1 E and EXAMPLE 111 D for EXAMPLE 1 F in EXAMPLE 1 G. 1H NMR
(dimethylsulfoxide-de) δ 11.65 (s, IH), 8.45 (d, IH), 8.28 (dd, IH), 7.97 (d, IH), 7.68 (d, IH), 7.52 (d, IH), 7.44 (d, 2H), 7.35 (d, 2H), 7.05 (d, 2H), 6.92 (dd, IH), 6.85 (dd, IH), 6.33 (s, IH), 6.22 (s, IH), 4.08 (m, IH), 3.60 (br s, 4H), 3.06 (br s, 4H), 2.73 (br s, 3H), 2.48 (m, 4H), 2.28 (m, IH), 2.18 (m, 6H), 2.07 (m, IH), 1.95 (s, 2H), 1.79 (m, 2H), 1.63 (m, 2H), 1.38 (t, 2H), 0.93 (s, 6H).
EXAMPLE 112
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 Pv,3 S)-3 -morpholin-4-ylcyclopentyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 112A
tert-butyl ( 1 R,3 S)-3 -aminocyclopentylcarbamate
The title compound was prepared by substituting EXAMPLE 111 A for EXAMPLE 111C in EXAMPLE 11 ID.
EXAMPLE 112B
tert-butyl ( 1 R,3 S)-3 -morpholinocyclopentylcarbamate The title compound was prepared by substituting EXAMPLE 112A for EXAMPLE 11 IB in EXAMPLE 111C.
EXAMPLE 112C
( 1 R,3 S)-3 -morpholinocyclopentanamine The title compound was prepared by substituting EXAMPLE 112B for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 112D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 Pv,3 S)-3 -morpholin-4-ylcyclopentyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 112C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (dimethylsulfoxide - d6) δ 11.35 (s, IH), 8.51 (d, IH), 8.44 (dd, IH), 8.00 (d, IH), 7.77 (d, IH), 7.50 (d, IH), 7.48 (s, 2H), 7.34 (d, 2H), 7.04 (d, 2H), 7.02 (dd, IH), 6.67 (dd, IH), 6.37 (dd, IH), 6.21 (d, IH), 4.11 (m, IH), 3.61 (br s, 4H), 3.06 (br s, 4H), 2.73 (br s, 3H), 2.50 (m, 4H), 2.28 (m, IH), 2.18 (m, 6H), 2.06 (m, IH), 1.95 (s, 2H), 1.77 (m, 2H), 1.66 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 113
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 113A
tert-butyl 2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting tert-butyl 2- (aminomethyl)morpholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine in
EXAMPLE IF.
EXAMPLE 113B
tert-butyl 2-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 113A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE 1G, with the exception that the product was purified on a silica gel column eluted with 4% methanol in dichloromethane. EXAMPLE 113C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(morpholin-2-ylmethyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 113B for EXAMPLE 66B in EXAMPLE 66C. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.60 (s, IH), 8.55 (br, s, IH), 8.51 (s, IH), 8.00 (d, IH), 7.80 (d, IH), 7.52 (d, IH), 7.49-7.46 (m, 2H), 7.34 (d, 2H), 7.07 (d, IH), 7.04(d, 2H), 6.66 (dd, IH), 6.36 (s, IH), 6.20 (d, IH), 4.00 (dd, IH), 3.91 (m, IH), 3.70 (t, IH), 3.60 (m, IH), 3.58 (m, IH), 3.32 (m, IH), 3.16 (d, IH), 3.05 (m, 4H), 2.98 (td, IH), 2.86 (t, IH), 2.73 (s, 2H), 2.20-2.12 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 114
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 114A
3-nitro-4-((tetrahydrofuran-3-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting 3-aminomethyl-tetrahydrofuran for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 114B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 114A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 11.42 (bs, IH), 8.63 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.80 (dd, IH), 7.53-7.48 (m, 3H), 7.34 (d, 2H), 7.10 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 3.82-3.79 (m, 1H),3.71 (t, IH), 3.62 (dd, IH), 3.50 (dd, IH), 3.38 (m, IH), 3.32 (m, IH), 3.07 (m, 4H), 2.76 (s, 2H), 2.58 (m, IH), 2.25-2.00 (m, 6H), 1.98 (m, IH), 1.95 (s, 2H), 1.65 (m, IH), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 115
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [cis-3 -fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 115A
Cis-tert-butyl 1 -(3 -fluorotetrahydro-2H-pyran-4-yl)piperidin-4-ylcarbamate The title compound was prepared as a racemate of the cis diastereomer by substituting tert-butyl piperidin-4-ylcarbamate for piperidin-4-ol and 3-fluorodihydro-2H-pyran-4(3H)- one (prepared by the method described in US2005/0101628A1) for dihydro-2H-pyran-4(3H)- one) in EXAMPLE 84A.
EXAMPLE 115B
Cis- 1 -(3 -fluorotetrahydro-2H-pyran-4-yl)piperidin-4-amine
EXAMPLE 115A (0.29 g) was dissolved in CH2C12 (9 mL), then 4NHC1 in dioxane (4 mL) was added and the reaction stirred at room temperature for 16 hours. The reaction was diluted with CH2C12 (30 mL), then 4N aqueous NaOH (5 mL) was added. After shaking and separating the layers the aqueous layer was saturated with solid NaCl and extracted with more CH2C12 (10 mL). The combined organic layers were dried over Na2S04. After filtration and concentration the amine was used with no further purification.
EXAMPLE 115C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [cis-3 -fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3 -nitrophenyl] sulfonyl} -2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 115B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.64 (s, 1H), 8.54 (d, 1H), 8.43 (br d, 1H), 8.03 (d, 1H), 7.80 (dd, 1H), 7.50 (m, 3H), 7.35 (d, 2H), 7.11 (d, 1H), 7.05 (d, 2H), 6.66 (dd, 1H), 6.38 ( m, 1H), 6.20 (d, 1H), 4.92 (d, 1H), 3.95 (m, 2H), 3.70 (v br m, 1H), 3.50, 3.40, 3.30 (all m, total 5H), 3.05, 3.00 (both v br m, total 5H), 2.74 (s, 2H), 2.55 (v br m, 1H), 2.18 (br m, 6H), 1.95 (m, 4H), 1.88 (ddd, 1H), 1.63 (v br m, 3H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 116
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 116A
1 -(tetrahydro-2H-pyran-4-yl)azetidin-3 -amine
Tert-butyl azetidin-3-ylcarbamate (0.46 g), dihydro-2H-pyran-4(3H)-one (0.29 g) and sodium triacetoxyborohydride (0.85 g) were stirred together in dichloromethane (5 mL) overnight. The reaction was poured into dichloromethane (50 mL) and saturated aqueous NaHC03 solution (25 mL). The organic layer was separated, washed with brine (25 mL), dried over Na2S04, filtered, and concentrated. Silica gel chromatography (GraceResolv 12 g) eluting with a gradient of 0.75% to 7.5% methanol/dichloromethane over 20 minutes gave the Boc-protected intermediate. Treatment with HCl (4.0M in dioxane, 2 mL) and methanol (1 mL) for 1 hour gave the title compound after concentration as the di-HCl salt.
EXAMPLE 116B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
A suspension of 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-chloro-3- nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazinl-yl)benzamide (0.180 g), l-(tetrahydro-2H-pyran-4-yl)azetidin-3- amine (0.078 g), and triethylamine (0.159 mL) in dioxane (2 mL) was degassed with nitrogen for 30 seconds then sealed. The reaction was heated to 110°C. After stirring for 16 hours, more triethylamine (10 equivalents total) and dimethylsulfoxide (1 mL) were added and the reaction stirred for an additional 18 hours at 110°C. The reaction was cooled, diluted with water (50 mL) and extracted with dichloromethane (2 x 150 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated. Silica gel chromatography
(GraceResolv 12 g) eluting with a gradient of 0.75% to 7.5% methanol/dichloromethane (Flow = 36 mL/minutes) gave the title compound. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.59 (s, 1H), 8.49 (d, 1H), 8.40 (s, 1H), 7.97 (d, 1H), 7.77 (s, 1H), 7.47 (dd, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.90 - 6.78 (m, 1H), 6.65 (d, 1H), 6.35 (s, 1H), 6.21 (s, 1H), 4.47 - 4.23 (m, 1H), 3.83 (s, 3H), 3.05 (s, 6H), 2.73 (s, 2H), 2.18 (s, 8H), 1.95 (s, 2H), 1.68 (s, 2H), 1.38 (s, 2H), 1.24 (s, 4H), 0.92 (s, 6H).
EXAMPLE 117
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydromran-3-ylazetidin-3-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 117A
1 -(tetrahydrofuran-3 -yl)azetidin-3 -amine
Tert-butyl azetidin-3-ylcarbamate (0.550 g), dihydrofuran-3(2H)-one (0.412 g) and sodium triacetoxyborohydride (1.015 g) were stirred together in dichloromethane (5 mL). After stirring overnight, the reaction was poured into saturated aqueous NaHC03 solution (25 mL) and extracted with dichloromethane (50 mL). The organic layer was washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel
chromatography (GraceResolv 12 g) eluting with a gradient of 0.5% to 7.5%
methanol/dichloromethane over 30 minutes gave tert-butyl 1 -(tetrahydrofuran-3 -yl)azetidin- 3-ylcarbamate. The resulting material was treated with HCl/dioxane for 1 hour, and then concentrated to give the title compound.
EXAMPLE 117B
3 -nitro-4-( 1 -(tetrahydrofuran-3 -yl)azetidin-3 -ylamino)benzenesulfonamide
4-Fluoro-3-nitrobenzenesulfonamide (0.084 g), 1 -(tetrahydrofuran-3 -yl)azetidin-3- amine
(0.090 g) and triethylamine (0.266 ml) in tetrahydrofuran (3 mL) was heated to 60°C. After stirring for 4 hours, the reaction was cooled, the tetrahydrofuran was removed and the residue was partitioned between dichloromethane (200 mL) and water (20 mL). The organic layer was separated, washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 117C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydromran-3-ylazetidin-3-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 117B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, CDC13) δ 10.39 - 9.79 (m, 1H), 9.17 (s, 1H), 8.87 (d, 1H), 8.51 (d, 1H), 8.15 (dd, 2H), 7.94 (d, 1H), 7.68 (d, 1H), 7.48 - 7.42 (m, 1H), 7.23 (d, 2H), 6.91 (d, 2H), 6.69 (d, 1H), 6.54 (dd, 2H), 5.99 (d, 1H), 4.29 (d, 1H), 4.01 - 3.73 (m, 4H), 3.66 (d, 2H), 3.08 (s, 6H), 2.76 (s, 2H), 2.21 (s, 6H), 2.03 - 1.83 (m, 3H), 1.64 (s, 2H), 1.42 (d, 2H), 0.93 (s, 6H).
EXAMPLE 118
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl]sulfonyl} - 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 118A
(R)-tert-butyl ( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl)methylcarbamate The title compound was prepared by substituting (S)-tert-butyl pyrrolidin-3- ylmethylcarbamate for tert-butyl piperazine-l-carboxylate and dihydro-2H-pyran-4(3H)-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 118B
(R)-( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl)methanamine The title compound was prepared by substituting EXAMPLE 118 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 118C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(3R)-l-tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl}amino)phenyl]sulfonyl}-
2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 118B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.57 (s, 1H), 8.59 (br s, 1H), 8.45 (br s, 1H), 8.02 (d, 1H), 7.95 (m, 1H), 7.71 (m, 1H), 7.56 (d, 1H), 7.45 (m, 1H), 7.35 (m, 3H), 7.05 (m, 2H), 6.90 (br s, 1H), 6.64 (d, 1H), 6.33 (m, 1H), 6.22 (m, 1H), 3.90 (m, 2H), 3.44 (m, 2H), 3.27 (m, 4H), 3.02 (m, 5H), 2.73 (m, 3H), 2.59 (m, 2H), 2.19 (m, 6H), 1.95 (m, 2H), 1.85 (m, 2H), 1.64 (m, 1H), 1.50 (m, 2H), 1.39 (m, 2H), 1.23 (m, 1H), 0.94 (s, 6H).
EXAMPLE 119
4-(4- { [2-(4-chlorophenyl)-5 ,5 -dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 75F and EXAMPLE 37D in place of EXAMPLE 3J and EXAMPLE 1 IB, respectively. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 8.39 (s, 1H), 8.08 (d, 1H), 8.04 (d, 1H), 7.41 - 7.59 (m, 4H), 7.35 (d, 2H), 7.08 (d, 2H), 6.68 (dd, 1H), 6.37 - 6.43 (m, 1H), 6.20 (s, 1H), 4.38 (d, 2H), 3.73 - 3.82 (m, 2H), 3.54 - 3.63 (m, 2H), 3.09 (s, 4H), 2.81 (s, 2H), 2.16 - 2.39 (m, 5H), 1.94 (s, 2H), 1.79 - 1.93 (m, 4H), 1.40 (t, 2H), 0.94 (s, 6H).
EXAMPLE 120
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide
EXAMPLE 120 A
Trans-4-(aminomethyl)cyclohexanol
Tert-butyl ((lr,4r)-4-hydroxycyclohexyl)methylcarbamate (1 g) in dichloromethane
(10 mL) was treated with trifluoroacetic acid (5 mL) at 0°C for 10 minutes and at room temperature for 30 minutes. The reaction mixture was concentrated and dried in vacuo to provide the title compound as a trifluoroacetic acid salt. EXAMPLE 120B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4-hydroxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide A mixture of EXAMPLE 53A (211 mg), EXAMPLE 120A (104 mg ) and N-ethyl-N- isopropylpropan-2-amine (0.3 mL) in dimethylsulfoxide (2 mL) was heated at 150°C in a Biotage Initiator microwave synthesizer for 1.5 hours and concentrated. The residue was purified by reverse phase HPLC on a CI 8 column using a gradient of 40-60% acetonitrile in 0.1% trifluoroacetic acid water to give the title compound as a trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (30 mL) and washed with 50%> aqueous NaHC03. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 11.69 (s, 1H), 11.41 (s, 1H), 8.61 (t, 1H), 8.53 - 8.58 (m, 1H), 8.04 (d, 1H), 7.76 - 7.83 (m, 1H), 7.47 - 7.56 (m, 3H), 7.34 (d, 2H), 7.07 - 7.11 (m, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 4.82 - 4.99 (m, 1H), 4.50 (d, 1H), 3.26 - 3.31 (m, 2H), 3.23 (t, 1H), 3.07 (s, 4H), 2.76 (s, 2H), 2.10 - 2.28 (m, 6H), 2.05 (dd, 1H), 1.95 (s, 2H), 1.84 (t, 2H), 1.52 - 1.76 (m, 2H), 1.41 - 1.51 (m, 1H), 1.38 (t, 2H), 0.95 - 1.25 (m, 4H), 0.92 (s, 6H) EXAMPLE 121
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide
EXAMPLE 121A
(4-methoxycyclohexyl)methanol
4-Methoxycyclohexanecarboxylic acid (7 g) in tetrahydrofuran (20 mL) was treated with 1 M (in tetrahydrofuran) borane-tetrahydrofuran complex (100 mL) overnight. The mixture was concentrated and the residue was dissolved in methanol (100 mL) and concentrated HC1 (10 mL). The resulting mixture was stirred for 1 hour and concentrated. The residue was dissolved in dichloromethane and washed with water. The organic layer was dried over Na2S04, filtered, and concentrated to give the title compound.
EXAMPLE 121B
4-((4-methoxycy clohexyl)methoxy)-3 -nitrobenzenesulfonamide
The title compound was prepared as described in EXAMPLE 12A by replacing (1,4- dioxan-2-yl)methanol with EXAMPLE 121 A. EXAMPLE 121 C
4-((cis-4-methoxycyclohexyl)methoxy)-3-nitrobenzenesulfonamide Separation of the cis and trans mixture of EXAMAPLE 12 IB on a reverse phase HPLC (gradient: 40-55% acetonitrile in 0.1% TFA in water over 25 minutes) provided the title compound.
EXAMPLE 12 ID
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4-methoxycyclohexyl)methoxy)-3 - nitrophenylsulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 121C in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.39 (s, IH), 8.34 (s, IH), 7.96 - 8.07 (m, 2H), 7.48 - 7.56 (m, 3H), 7.31 - 7.42 (m, 3H), 7.04 (d, 2H), 6.68 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.02 (d, 2H), 3.39 (s, IH), 3.20 (s, 3H), 3.09 (s, 4H), 2.82 (s, 2H), 2.09 - 2.34 (m, 6H), 1.96 (s, 2H), 1.78 - 1.86 (m, 3H), 1.54 (dd, 2H), 1.28 - 1.46 (m, 6H), 0.92 (s, 6H)
EXAMPLE 122
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 122 A
Cis-tert-butyl-4-(cyclopropylamino)cyclohexylcarbamate The title compound was prepared by substituting tert-butyl 4-oxocyclohexylcarbamate for 4'-chlorobiphenyl-2-carboxaldehyde and cyclopropylamine for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A.
EXAMPLE 122B
cis-N^cyclopropylcyclohexane- 1 ,4-diamine bis(2,2,2-trifluoroacetate) The title compound was prepared by substituting EXAMPLE 122 A for EXAMPLE
39A in EXAMPLE 39B. EXAMPLE 122C
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 122B for EXAMPLE 100B in EXAMPLE lOOC. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.28 (d, IH), 8.59 (d, IH), 8.44 (d, IH), 8.37 (dd, IH), 8.12 (d, IH), 7.67 (t, 2H), 7.43 (t, 2H), 7.07 (d, 2H), 6.90 (d, IH), 6.75 (dd, IH), 6.53 (d, IH), 6.50 (dd, IH), 3.56 - 3.63 (m, IH), 3.02 - 3.08 (m, 4H), 2.77 (s, 3H), 2.26 (t, 2H), 2.10 - 2.16 (m, 4H), 2.06 (ddd, IH), 1.97 (s, 2H), 1.74 - 1.82 (m, 2H), 1.61 - 1.71 (m, 5H), 1.39 (t, 2H), 0.93 (s, 6H), 0.39 - 0.44 (m, 4H).
EXAMPLE 123
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 123 A
Trans-tert-butyl-4-(tetrahydro-2H-pyran-4-ylamino)cyclohexylcarbamate The title compound was prepared by substituting trans-tert-butyl-4- aminocyclohexylcarbamate for tert-butyl piperazine-l-carboxylate and dihydro-2H-pyran- 4(3H)-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 123B
trans-N 1 -(tetrahydro-2H-pyran-4-yl)cyclohexane- 1 ,4-diamine bis(2,2,2-trifluoroacetate) The title compound was prepared by substituting EXAMPLE 123 A for EXAMPLE 39A in EXAMPLE 39B.
EXAMPLE 123C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 123B for EXAMPLE 100B in EXAMPLE lOOC. 1H NMR (500 MHz, pyridine-d5) δ 13.01 (s, IH), 9.28 (d, IH), 8.48 (d, IH), 8.38 (dd, IH), 8.32 (d, IH), 8.24 (d, IH), 7.67 - 7.69 (m, 2H), 7.44 (d, 2H), 7.08 (d, 2H), 6.91 (d, IH), 6.78 (dd, IH), 6.59 (d, IH), 6.48 (dd, IH), 4.01 (d, 2H), 3.44 - 3.49 (m, IH), 3.37 - 3.43 (m, 2H), 3.01 - 3.09 (m, 5H), 2.85 (t, IH), 2.78 (s, 2H), 2.27 (t, 2H), 2.13 - 2.18 (m, 4H), 2.05 (t, 4H), 1.97 (s, 2H), 1.93 (d, 2H), 1.52 - 1.60 (m, 2H), 1.44 - 1.50 (m, 2H), 1.39 (t, 2H), 1.25 - 1.34 (m, 2H), 0.94 (s, 6H).
EXAMPLE 124
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 124 A
Trans-4-morpholinocyclohexanol
Trans-4-Aminocyclohexanol (0.5 g), l-bromo-2-(2-bromoethoxy)ethane (1.07 g) and triethylamine (2.42 mL) were dissolved in anhydrous acetonitrile (20 mL). The reaction mixture was heated at 60°C overnight. The organic solvent was removed under vacuum. The residue was purified with flash column chromatography on silica gel eluting with 7%-10% methanol in dichloromethane to give the title compound.
EXAMPLE 124B
Trans-5-bromo-6-(4-morpholinocyclohexyloxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 124 A for (tetrahydro- 2H-pyran-4-yl)methanol and EXAMPLE 36A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 124C
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 124B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.56 (m, 2H), 8.03 (d, IH), 7.80 (m, IH), 7.50 (m, 3H), 7.34 (d, 2H), 7.12 (m, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.99 (m, IH), 3.67 (m, IH), 3.37 (m, 2H), 3.24 (m, 2H), 3.07 (m, 4H), 2.89 (m, IH), 2.71 (m, 2H), 2.16 (m, 6H), 1.96 (s, 3H), 1.80 (m, 4H), 1.38 (t, 2H), 1.27 (m, 2H), 0.92 (s, 6H).
EXAMPLE 125
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4- [(4-methoxycyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
EXAMPLE 125 A
4-(((trans)-4-methoxycyclohexyl)methoxy)-3-nitrobenzenesulfonamide Separation of the cis and trans mixture of EXAMAPLE 12 IB on a reverse phase HPLC provided the title compound.
EXAMPLE 125B
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4- [(4-methoxycyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 125A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.34 (s, IH), 7.96 - 8.09 (m, 2H), 7.51 (dd, 3H), 7.32 - 7.39 (m, 3H), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (dd, IH), 6.20 (d, IH), 4.02 (d, 2H), 3.24 (s, 3H), 3.00 - 3.15 (m, 5H), 2.83 (s, 2H), 2.09 - 2.36 (m, 6H), 2.03 (d, 2H), 1.96 (s, 2H), 1.77 - 1.86 (m, 2H), 1.73 (s, IH), 1.39 (t, 2H), 1.02 - 1.17 (m, 4H), 0.92 (s, 6H)
EXAMPLE 126
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylate
EXAMPLE 126 A
tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine- 1 -carboxylate 1-Tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.0 g) in tetrahydrofuran (5 niL) was treated with 1.0 N L1AIH4 in THF (2.54 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. Water (0.6 mL) was added to the reaction mixture drop-wise, followed by 2 N aqueous NaOH (0.2 mL). The reaction was stirred for another 1 hour. The solid was removed by filtration via a pack of Celite and washed with ethyl acetate. The filtrate was washed with brine, dried over MgSC^, filtered, and concentrated to give the product.
EXAMPLE 126B
tert-butyl 4-fluoro-4-((2-nitro-4-sulfamoylphenoxy)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 126 A for (tetrahydro-
2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 126C
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenoxy]methyl} -4-fluoropiperidine- 1 -carboxylateyl)oxy]benzamide
The title compound was prepared by substituting EXAMPLE 126B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.36 (s, 2H), 8.02-8.06 (m, 2H), 7.49-7.53 (m, 3H), 7.40 (d, IH), 7.35 (d, 2H), 7.04 (d, IH), 6.67 (dd, IH), 6.39 (dd, IH), 6.21 (d, IH), 4.36 (d, 2H), 3.83-3.85 (m, 2H), 3.09 (s, 4H), 2.33 (s, 2H), 2.27-2.32 (m, 4H), 2.13-2.16 (m, 2H), 1.96 (s, 2H), 1.83-1.92 (m, 2H), 1.67- 1.75 (m, 2H), 1.38-1.41 (m, 11H), 0.92 (s, 6H).
EXAMPLE 127
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 126C for
EXAMPLE 1A in EXAMPLE IB. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.50 (s, IH), 8.14 (d, IH), 7.90 (d, 2H), 7.80 (dd, IH), 7.60 (d, IH), 7.40 (t, IH), 7.35 (d, 2H), 7.25 (t, IH), 7.13 (d, IH), 7.05 (d, 2H), 6.61 (dd, IH), 6.30 (dd, IH), 6.26 (d, IH), 4.28 (d, 2H), 3.10- 3.13 (m, 2H), 2.91-3.00 (m, 6H), 2.73 (s, 2H), 1.96-2.02 (m, 4H), 1.77-1.89 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 128
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 128 A
tert-butyl 4-(tetrahydro-2H-pyran-4-yl)piperazine- 1 -carboxylate The title compound was prepared by substituting tert-butyl piperazine-1 -carboxylate for morpholine and dihydro-2H-pyran-4(3H)-one for tert-butyl 4-oxocyclohexylcarbamate in EXAMPLE 39A.
EXAMPLE 128B
1 -(tetrahydro-2H-pyran-4-yl)piperazine dihydrochloride To a solution of EXAMPLE 128 A (3.92 g) in ether was added HCl (25 ml, 2M in ether) and the reaction mixture was stirred for 16 hours at room temperature. The solid product was filtered off, dried and used in next step without further purification.
EXAMPLE 128C
Trans-tert-butyl-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl)cyclohexylcarbamate The title compound was prepared by substituting EXAMPLE 128B for morpholine in EXAMPLE 39A.
EXAMPLE 128D
trans-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin- 1 -yl)cyclohexanamine tris(2,2,2- trifluoroacetate)
The title compound was prepared by substituting EXAMPLE 128C for EXAMPLE 39A in EXAMPLE 39B.
EXAMPLE 128E
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 128D for EXAMPLE 100B in EXAMPLE lOOC. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, 1H), 9.28 - 9.32 (m, 1H), 8.44 (t, 1H), 8.34 - 8.39 (m, 2H), 8.10 - 8.14 (m, 1H), 7.66 - 7.69 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.92 (t, 1H), 6.73 - 6.77 (m, 1H), 6.52 - 6.55 (m, 1H), 6.49 - 6.52 (m, 1H), 3.99 - 4.06 (m, 2H), 3.29 - 3.36 (m, 2H), 3.03 - 3.09 (m, 4H), 2.77 (s, 2H), 2.62 (s, 8H), 2.24 - 2.29 (m, 3H), 2.10 - 2.16 (m, 5H), 2.05 (s, 2H), 1.97 (s, 2H), 1.92 (s, 2H), 1.70 (d, 2H), 1.57 (td, 2H), 1.34 - 1.43 (m, 4H), 1.20 - 1.30 (m, 2H), 0.93 (s, 6H).
EXAMPLE 129
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 129 A
(l-(l,3-difluoropropan-2-yl)piperidin-4-yl)methanol A suspension of piperidin-4-ylmethanol (0.250 g), sodium triacetoxyborohydride (0.690 g) and l,3-difluoropropan-2-one (0.245 g) were stirred together in dichloromethane. After stirring overnight the reaction was poured into saturated aqueous NaHC03 solution (10 mL) and stirred for 15 minutes. The reaction was extracted with dichloromethane (3 x 25 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (GraceResolv 12 g) eluting with a gradient of 0.75% to 3% methanol/dichloromethane gave the title compound.
EXAMPLE 129B
4-(( 1 -( 1 ,3 -difluoropropan-2-yl)piperidin-4-yl)methoxy)-3 -nitrobenzenesulfonamide To a solution of (l-(l,3-difluoropropan-2-yl)piperidin-4-yl)methanol (0.068 g) in tetrahydrofuran (1 mL) was added sodium hydride (0.056 g) and the reaction stirred for 30 minutes at room temperature. 4-Fluoro-3-nitrobenzenesulfonamide (0.077 g) was added in one portion and stirring was continued for 1 hour. The reaction was poured into water (20 mL) and extracted with dichloromethane. The pH of the aqueous layer was adjusted to pH~8 and it was extracted with dichloromethane (50 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 129C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 129B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.67 (s, IH), 11.47 - 10.98 (m, IH), 8.33 (d, IH), 8.03 (d, 2H), 7.50 (dd, 3H), 7.36 (t, 3H), 7.04 (d, 2H), 6.67 (d, IH), 6.39 (dd, IH), 6.20 (s, IH), 4.62 (dd, 4H), 4.06 (d, 2H), 3.18 - 2.71 (m, 11H), 2.20 (d, 6H), 1.96 (s, 2H), 1.73 (d, 3H), 1.35 (d, 4H), 0.92 (s, 6H).
EXAMPLE 130
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 130A
(R)-tert-butyl 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -ylcarbamate The title compound was prepared by substituting dihydro-2H-pyran-4(3H)-one for 4'- chlorobiphenyl-2-carboxaldehyde and (R)-tert-butyl pyrrolidin-3 -ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE 1A.
EXAMPLE 130B
(R)- 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -amine A solution of EXAMPLE 130A (550 mg) in dichloromethane (25 ml) was cooled in an ice bath under nitrogen. 2,2,2-Trifluoroacetic acid (8.333 ml) was added and the reaction was stirred for 2 hours. The product was obtained by concentration and high vacuum drying.
EXAMPLE 130C
(R)-3 -nitro-4-( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -ylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 130B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 130D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
To a solution of EXAMPLE 3 J (90 mg), EXAMPLE 130C (64.2 mg), triethylamine (0.077 ml), N,N-dimethylpyridin-4-amine (38.5 mg) in a mixture of dichloromethane (5 ml) and N,N-dimethylformamide (0.5 ml) was added N1-((ethylimino)methylene)-N3,N3- dimethylpropane-l,3-diamine, hydrochloric acid (60.4 mg) and the mixture was stirred 18 hours. This was concentrated on high vacuum and the crude was purified by reverse phase chromatography with ammonium acetate buffer / acetonitrile. IH NMR (500 MHz, pyridine- d5) δ 13.03 (s, IH), 9.27 (d, IH), 8.59 (d, IH), 8.43 (d, IH), 8.37 (dd, IH), 8.11 (d, IH), 7.65 - 7.67 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.88 (d, IH), 6.76 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.06 (m, IH), 3.98 (d, 2H), 3.35 (t, 2H), 3.07 (m, 4H), 2.73 - 2.80 (m, 4H), 2.68 - 2.72 (m, IH), 2.36 (q, IH), 2.11 - 2.30 (m, 9H), 1.97 (m, 2H), 1.62 - 1.71 (m, 3H), 1.48 - 1.58 (m, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 131
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 131 A
tert-butyl (3R)-l-(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting 2,2-dimethyldihydro-2H-pyran- 4(3H)-one for 4'-chlorobiphenyl-2-carboxaldehyde and (R)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE 1A.
EXAMPLE 13 IB
(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-amine The title compound was prepared by substituting EXAMPLE 131 A for EXAMPLE 130A in EXAMPLE 130B. EXAMPLE 131C
4-((3R)-(l-(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-ylamino)-3- nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 13 IB for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 13 ID
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 131C for EXAMPLE 130C in EXAMPLE 130D. IH NMR (500 MHz, pyridine-d5) δ 13.03 (d, IH), 9.28 (m, IH), 8.61 (m, IH), 8.44 (d, IH), 8.38 (dd, IH), 8.11 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.89 (m, IH), 6.76 (dd, IH), 6.54 (m, IH), 6.49 (m, IH), 4.08 (m, IH), 3.78 (m, IH), 3.61 (m, IH), 3.07 (m, 4H), 2.71 - 2.82 (m, 5H), 2.37 - 2.44 (m, 2H), 2.19 - 2.29 (m, 3H), 2.14 (m, 5H), 1.97 (s, 2H), 1.76 (m, IH), 1.66 (m, 2H), 1.32 - 1.49 (m, 4H), 1.28 (d, 3H), 1.20 (s, 3H), 0.94 (s, 6H).
EXAMPLE 132
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 132A
(S)-tert-butyl 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -ylcarbamate The title compound was prepared by substituting dihydro-2H-pyran-4(3H)-one for 4'- chlorobiphenyl-2-carboxaldehyde and (S)-tert-butyl pyrrolidin-3 -ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE 1A. EXAMPLE 132B
(S)- 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -amine The title compound was prepared by substituting EXAMPLE 132A for EXAMPLE in EXAMPLE 130B.
EXAMPLE 132C
(S)-3 -nitro-4-( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -ylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 132B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMMPLE 132D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3 nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 132C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.04 (m, IH), 9.27 (d, IH), 8.58 (d, IH), 8.43 (d, IH), 8.37 (dd, IH), 8.11 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.88 (d, IH), 6.75 (dd, IH), 6.54 (m, IH), 6.49 (m, IH), 4.06 (m, IH), 3.98 (d, 2H), 3.36 (t, 2H), 3.07 (m, 4H), 2.68 - 2.80 (m, 5H), 2.36 (m, IH), 2.09 - 2.29 (m, 9H), 1.97 (s, 2H), 1.62 - 1.72 (m, 3H), 1.48 - 1.60 (m, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 133
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4-
{ [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 133 A
tert-butyl (3S)-l-(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting 2,2-dimethyldihydro-2H-pyran- 4(3H)-one for 4'-chlorobiphenyl-2-carboxaldehyde and (S)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE 1A. EXAMPLE 133B
(3S)-l-(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-amine The title compound was prepared by substituting EXAMPLE 133 A for EXAMPLE 130A in EXAMPLE 130B.
EXAMPLE 133C
4-(3S)-(l-(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-ylamino)-3-nitro
benzenesulfonamide
The title compound was prepared by substituting EXAMPLE 133B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 133D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 133C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.03 (d, IH), 9.28 (m, IH), 8.61 (m, IH), 8.43 (d, IH), 8.38 (dd, IH), 8.11 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.89 (m, IH), 6.76 (dd, IH), 6.54 (m, IH), 6.49 (m, IH), 4.08 (m, IH), 3.78 (m, IH), 3.61 (m, IH), 3.07 (m, 4H), 2.71 - 2.82 (m, 5H), 2.37 - 2.44 (m, 2H), 2.19 - 2.29 (m, 3H), 2.14 (m, 5H), 1.97 (s, 2H), 1.76 (m, IH), 1.66 (m, 2H), 1.33 - 1.48 (m, 4H), 1.28 (d, 3H), 1.20 (s, 3H), 0.94 (s, 6H).
EXAMPLE 134
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 134A
4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide A solution of EXAMPLE 113A (0.8 g) in dichloromethane (10 mL) and
trifluoroacetic acid (10 mL) was stirred at room temperature for 2 hours. The solvents were evaporated and the residue triturated with diethyl ether. The resulting solid was dissolved in 5% aqueous sodium carbonate solution (20 mL). The solution was concentrated to dryness and the resulting solid was triturated with a solution of 10% methanol in dichloromethane several times. Evaporation of the organic solvents gave the title compound.
EXAMPLE 134B
4-((4-methylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 134A (158 mg) in anhydrous N,N-dimethylformamide (4 mL) was added sodium carbonate (64 mg) and methyl iodide (78 mg). After stirring overnight at room temperature, the mixture was evaporated to dryness. The crude product was then absorbed on silica gel (6 g) and purified on a silica gel column eluting with 10% methanol in dichloromethane to give the title compound.
EXAMPLE 134C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-methylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 134B for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.27 (d, IH), 8.87 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.11 (d, IH), 7.65 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.92 (m, 1H),3.86 (d, IH), 3.67 (dt, IH), 3.49-3.39 (m, 2H), 3.07 (m, 4H), 2.77 (s, 2H), 3.71 (m, IH), 2.49 (d, IH), 2.26 (m, 2H), 2.16 (s, 3H), 2.14 (m, 4H), 2.03 (dt, IH), 1.97 (s, 2H), 1.90 (t, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 135
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2-methoxyethyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 135 A
4-((4-(2-methoxyethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2-methoxyethyl bromide for methyl iodide in EXAMPLE 134B.
EXAMPLE 135B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2-methoxyethyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 135 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.98 (s, IH), 9.26 (d, IH), 8.88 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.93 (m, 1H),3.87 (d, IH), 3.70 (dt, IH), 3.51 (t, 2H), 3.48-3.38 (m, 2H), 3.27 (s, 3H), 3.07 (m, 4H), 2.95 (d, IH), 2.77 (s, 2H), 2.70 (m, IH), 2.57 (t, 2H), 2.27-2.07 (m, 8H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 136
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 136A
4-((4-acetylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting acetic anhydride for methyl iodide EXAMPLE 134B.
EXAMPLE 136B
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 136A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (s, IH), 8.85 (s, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.10 (d, IH), 7.65 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (dd, IH), 6.75 (dd, IH), 6.54 (s, IH), 6.48 (s, IH), 4.73 (dd, IH), 3.93-3.65 (m, 2H), 3.60-3.40 (m, 4H), 3.12 (m, IH), 3.07 (m, 4H), 2.77 (s, 2H), 2.70 (m, IH), 2.57 (t, 2H), 2.14 (s, 3H), 2.27-2.07 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 137
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethoxy } -3 -nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 137A
ethyl 4-fluorobut-2-enoate
Ethyl 2-fluoroacetate (21.0 g) in CH2C12 (200 mL) at -78 °C was treated dropwise over 45 min with a 1.0 M solution of diisobutylaluminum hydride in CH2C12 (200 mL) maintaining the internal temperature below -70 °C. Stirring was continued at -78 °C for 30 minutes and then (carbethoxymethylene)triphenylphosphorane (70.0 g) was added in one portion. The reaction mixture was allowed to slowly reach room temperature while stirring overnight. It was then quenched with methanol, filtered and concentrated to give the product as a mixture of isomers (E/Z = 3: 1).
EXAMPLE 137B
Trans-ethyl 1 -benzyl-4-(fluoromethyl)pyrrolidine-3-carboxylate A mixture of N-benzyl-l-methoxy-N-((trimethylsilyl)methyl)methanamine (4.5 g) and EXAMPLE 137A (2.5 g) in dichloromethane (50 mL) was cooled to 0 °C, treated dropwise with trifiuoroacetic acid (0.15 mL), stirred for 4 hours at 0 °C and neutralized with saturated aqueous Na2C03 solution. The mixture was poured into a separatory funnel and the layers separated. The organic layer was washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 0-20% ethyl acetate in hexanes as eluent to give both the cis and trans isomers of the product. Only the trans diastereomers were carried on in the following steps.
EXAMPLE 137C
Trans-ethyl 4-(fluoromethyl)pyrrolidine-3 -carboxylate EXAMPLE 137B (0.83 g) in ethanol (9 mL) was treated with 10% Pd/C (0.208 g) and ammonium formate (1.97 g), refluxed for 1.5 hours, concentrated, dissolved in
dichloromethane, filtered though a pad of celite rinsing with dichloromethane, and concentrated to give the product. EXAMPLE 137D
Trans- 1 -benzyl 3 -ethyl 4-(fluoromethyl)pyrrolidine-l ,3-dicarboxylate EXAMPLE 137C (0.44 g) in dioxane (4 mL) and water (4 mL) at 0 °C was treated sequentially with Na2C03 (0.89 g) and benzyl chloroformate (0.48 mL). The reaction mixture was stirred at 0 °C for 3 hours and was then allowed to slowly warm to room temperature over 1.5 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 10-25% ethyl acetate in hexanes as eluent to give the product.
EXAMPLE 137E
Trans- 1 -(benzyloxycarbonyl)-4-(fluoromethyl)pyrrolidine-3 -carboxylic acid The title compound was prepared by substituting EXAMPLE 137D for EXAMPLE 15G in EXAMPLE 15H.
EXAMPLE 137F
Trans-benzyl 3-(fluoromethyl)-4-(hydroxymethyl)pyrrolidine- 1 -carboxylate EXAMPLE 137E (0.563 g) in tetrahydrofuran (10 mL) at 0 °C was treated dropwise with a 1 M solution of borane in tetrahydrofuran (4 mL), stirred for 3 hours and then slowly quenched with saturated aqueous NH4C1 solution. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered and concentrated to give the product.
EXAMPLE 137G
Trans-benzyl 3 -(fluoromethyl)-4-((2-nitro-4-sulfamoylphenoxy)methyl)pyrrolidine- 1 - carboxylate
The title compound was prepared by substituting EXAMPLE 137F for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 137H
Trans-4-((4-(fluoromethyl)pyrrolidin-3-yl)methoxy)-3-nitrobenzenesulfonamide EXAMPLE 137G (0.232g) in acetic acid (2.5 ml) was treated with hydrobromic acid (33 wt % in acetic acid) (0.875 mL) at ambient temperature, stirred for 1 hour and concentrated. The product was free-based using a MEGA BE-SCX column with 1 : 1 GHkCb/methanol as eluent for the hydrobromic acid and acetic acid. The product was released from the column with 10% (7 M ammonia in methanol) in CH2CI2 as eluent.
EXAMPLE 1371
Trans-4-((4-(fluoromethyl)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yl)methoxy)-3 - nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 137H for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 137J
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethoxy } -3 -nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 1371 for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.35 (d, IH), 8.03 (m, 2H), 7.51 (m, 3H), 7.37 (m, 3H), 7.04 (m, 2H), 6.67 (dd, IH), 6.39 (dd, IH), 6.21 (d, IH), 4.45 (m, 6H), 4.21 (d, 2H), 3.62 (m, IH), 3.08 (m, 4H), 2.72 (m, 5H), 2.31 (m, 9H), 1.96 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 138
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 138A
(4-fluorotetrahydro-2H-pyran-4-yl)methyl methanesulfonate A mixture of EXAMPLE 37C (1.4 g), methanesulfonyl chloride (1.054 mL), triethylamine (2.99 mL), and 4-dimethylaminopyridine (0.051 g) in CH2CI2 (20 mL) was stirred at 0 °C for 2 hours, concentrated and chromatographed on silica gel eluting with 30% ethyl acetate in hexanes to give the product. EXAMPLE 138B
2-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)isoindoline-l,3-dione A mixture of EXAMPLE 138 A ( 1.8 g) and potassium phthalimide (2.356 g) in N,N- dimethylformamide (30 mL) was heated at 150 °C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel eluting with 30% ethyl acetate in hexanes to give the product.
EXAMPLE 138C
(4-fluorotetrahydro-2H-pyran-4-yl)methanamine
A mixture of EXAMPLE 138B (1.4 g) and hydrazine (1.548 mL) in ethanol (40 mL) was heated at 70 °C overnight, cooled to room temperature, slurried with CH2CI2 (200 mL) and the solid removed by filtration. The filtrate was concentrated and chromatographed on silica gel eluting with 100:5:1 ethyl acetate/methanol/NH4OH to give the product.
EXAMPLE 138D
4-((4-fluorotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide A mixture of 4-fluoro-3-nitrobenzenesulfonamide (0.44 g), EXAMPLE 138C (0.266 g), and triethylamine (1.11 mL) in tetrahydrofuran (10 mL) was heated at 70 °C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel eluting with 50% ethyl acetate in hexanes to give the product.
EXAMPLE 138E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 138D for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.62 (t, IH), 8.56 (d, IH), 8.04 (d, IH), 7.82 (dd, IH), 7.48-7.54 (m, 3H), 7.34 (d, 2H), 7.24 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.70-3.77 (m, 4H),
3.50-3.55 (m, 2H), 3.07 (s, 4H), 2.76 (s, 2H), 2.14-2.20 (m, 6H), 1.76-1.84 (m, 4H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 139
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 139A
tert-butyl 4-(4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)piperidine- 1 -carboxylate
The title compound was prepared as described in EXAMPLE 53B by replacing 1- acetylpiperidin-4-amine with 4-amino-piperidine-l-carboxylic acid tert-butyl ester.
EXAMPLE 139B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(piperidin-4-ylamino)phenylsulfonyl)benzamide To a cooled (0°C) solution of EXAMPLE 139A (960 mg) in dichloromethane (10 mL) was added dropwise trifluoroacetic acid (5 mL). The mixture was stirred at the temperature for 3 hours. Then, the mixture was concentrated under vacuum and the residue was dissolved in dichloromethane (200 mL) and washed with aqueous NaHC03 and brine. After drying over Na2S04, the mixture was filtered, and evaporation of the solvent from the filtrate gave the title compound.
EXAMPLE 139C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
To a solution of EXAMPLE 139B (120 mg) in tetrahydrofuran (3 mL) and acetic acid (1 mL) was added oxetan-3-one (50.8 mg) and MP-cyanoborohydride (2.15 mmol/g, 150 mg). The mixture was stirred at room temperature overnight. The mixture was filtered. The filtrate was concentrated and the residue was loaded on a silica gel cartridge and eluted with 5-10% 7N NH3 in methanol in dichloromethane to give the title compound. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.62 (s, 1H), 8.51 (d, 1H), 8.20 (d, 1H), 7.99 (d, 1H), 7.74 (m, 1H), 7.48 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H), 6.66 (dd, 1H), 6.36 (dd, 1H), 6.20 (d, 1H), 4.54 (t, 2H), 4.43 (t, 2H), 3.66 (m, 1H), 3.44 (m, 3H), 3.04 (m, 5H), 2.73 (s, 2H), 2.61 (m, 2H), 2.12 (m, 11H), 1.61 (m, 2H), 1.38 (t, 2H), 0.93 (m, 6H).
EXAMPLE 140
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclobutylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing oxetan-3-one with cyclobutanone. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.58 (s, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 7.97 (d, 1H), 7.74 (d, 1H), 7.53 (d, 1H), 7.45 (m, 1H), 7.36 (m, 3H), 7.02 (m, 3H), 6.64 (dd, 1H), 6.33 (m, 1H), 6.22 (d, 1H), 3.74 (m, 1H), 2.97 (m, 6H), 2.73 (s, 3H), 2.15 (m, 15H), 1.67 (m, 4H), 1.38 (t, 2H), 0.93 (s, 6H).
EXAMPLE 141
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing oxetan-3-one with 2,2-dimethyltetrahydropyran-4-one. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.60 (s, 1H), 8.50 (d, 1H), 8.15 (m, 1H), 7.99 (d, 1H), 7.78 (m, 1H), 7.62 (m, 1H), 7.47 (m, 3H), 7.34 (m, 3H), 7.05 (m, 3H), 6.65 (m, 2H), 6.35 (dd, 1H), 6.21 (d, 1H), 4.56 (d, 3H), 3.89 (m, 3H), 3.67 (m, 6H), 3.45 (m, 2H), 3.04 (m, 3H), 2.75 (m, 3H), 2.14 (m, 3H), 1.71 (m, 5H), 1.16 (s, 9H). EXAMPLE 142
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide EXAMPLE 142A
(S)-tert-butyl 1 -cyclopropylpyrrolidin-3 -ylcarbamate (S)-tert-butyl pyrrolidin-3 -ylcarbamate (415 mg), (1- ethoxycyclopropoxy)trimethylsilane (1.8 mL) and molecular sieves (500 mg) were combined in methanol (4.5 mL). Acetic acid (1.3 mL) was added, followed by sodium
cyanoborohydride (420 mg). The resulting mixture was heated to reflux for 4 hours.
Insoluble material was filtered off and reaction was made basic to pH 14 with addition of 6M aqueous NaOH solution. The solution was extracted three times with diethyl ether, and the combined extracts were dried over MgSC^, filtered and concentrated to obtain an oil, which was purified by flash chromatography, eluting first with 100% dichloromethane, followed by 5% methanol/dichloromethane and 10% methanol/dichloromethane.
EXAMPLE 142B
(S)- 1 -cyclopropylpyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 142 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 142C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -cyclopropylpyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 142B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.64 (s, 1H), 8.51 (m, 2H), 8.30 (m, 1H), 8.00 (br s, 1H), 7.77 (m, 1H), 7.49 (m, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.97 (br s, 1H), 6.67 (dd, 1H), 6.36 (m, 1H), 6.21 (m, 1H), 4.19 (m, 1H), 3.00 (m, 5H), 2.74 (m, 3H), 2.64 (m, 1H), 2.36 (m, 1H), 2.15 (m, 6H), 1.95 (s, 2H), 1.78 (br s, 1H), 1.68 (m, 1H), 1.38 (t, 2H), 1.23 (m, 1H), 0.92 (s, 6H), 0.39 (m, 4H). EXAMPLE 143
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-tetrahydrofuran-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing oxetan-3-one with 3-oxotetrahydrofuran. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.65 (s, 1H), 8.53 (d, 1H), 8.21 (m, 1H), 8.02 (m, 1H), 7.80 (dd, 1H), 7.49 (m, 3H), 7.34 (m, 3H), 7.05 (m, 3H), 6.67 (dd, 1H), 6.37 (m, 1H), 6.19 (d, 1H), 4.29 (m, 3H), 3.73 (m, 6H), 3.09 (m, 4H), 2.76 (m, 2H), 2.05 (m, 8H), 1.68 (m, 2H), 1.37 (m, 2H), 0.94 (s, 6H). EXAMPLE 144
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3Pv)- 1 -cyclopropylpyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 144 A
(R)-tert-butyl 1 -cyclopropylpyrrolidin-3 -ylcarbamate The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylcarbamate for (S)-tert-butyl pyrrolidin-3 -ylcarbamate in EXAMPLE 142A.
EXAMPLE 144B
(R)- 1 -cyclopropylpyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 144 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 144C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -cyclopropylpyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 144B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1H), 8.53 (d, 2H), 8.32 (d, 1H), 8.02 (d, 1H), 7.81 (m, 1H), 7.49 (m, 3H), 7.34 (d, 2H), 7.03 (m, 3H), 6.67 (dd, 1H), 6.37 (m, 1H), 6.20 (d, 1H), 4.21 (m, 1H), 3.00 (m, 5H), 2.74 (m, 3H), 2.64 (m, 1H), 2.36 (m, 1H), 2.15 (m, 6H), 1.95 (s, 2H), 1.74 (br s, 1H), 1.66 (m, 1H), 1.38 (t, 2H), 1.23 (m, 1H), 0.92 (s, 6H), 0.39 (m, 4H).
EXAMPLE 145
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl]methyl} amino)phenyl]sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide EXAMPLE 145 A
(S)-tert-butyl ( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl)methylcarbamate The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylmethylcarbamate for tert-butyl piperazine-l-carboxylate and dihydro-2H-pyran-4(3H)- for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 145B
(S)-( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 -yl)methanamine The title compound was prepared by substituting EXAMPLE 145 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 145C
(S)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(( 1 -(tetrahydro-2H-pyran-4-yl)pyrrolidin-3 - yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 145B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.58 (s, IH), 8.61 (br s, IH), 8.46 (s, IH), 7.96 (d, IH), 7.72 (m, IH), 7.54 (d, IH), 7.45 (t, IH), 7.37 (br s, 2H),7.34 (d, 2H), 7.04 (m, 2H), 6.94 (m, IH), 6.64 (dd, IH), 6.34 (m, IH), 6.22 (d, IH), 3.89 (m, 2H), 3.38 (m, 4H), 3.27 (m, 4H), 3.02 (m, 5H), 2.73 (s, 2H), 2.61 (m, IH), 2.18 (m, 6H), 2.05 (m, IH), 1.95 (m, 2H), 1.85 (m, 2H), 1.64 (m, IH), 1.50 (m, 2H), 1.38 (m, 2H), 0.94 (s, 6H).
EXAMPLE 146
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxy-2,2-dimethylpropyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 120B using 3-amino- 2,2-dimethylpropan-l-ol in place of EXAMPLE 120A. 1H NMR (500 MHz,
dimethylsulfoxide-de) δ 11.68 (s, IH), 11.35 (s, IH), 8.96 (t, IH), 8.56 (d, IH), 8.05 (d, IH), 7.79 (dd, IH), 7.46 - 7.56 (m, 3H), 7.34 (d, 2H), 7.10 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 5.10 (t, IH), 3.29 (d, IH), 3.24 (d, IH), 3.07 (s, 4H), 2.75 (s, 2H), 2.17 (d, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.93 (d, 12H). EXAMPLE 147
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methylsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 147 A
tert-butyl ( 1 -(methylsulfonyl)piperidin-3 -yl)methylcarbamate tert-Butyl piperidin-3-ylmethylcarbamate(500 mg) was dissolved in anhydrous dichloromethane (10 mL), and methanesulfonyl chloride (0.181 mL) was added followed by the addition of triethylamine (1.3 mL). The reaction mixture was stirred at room temperature overnight. The organic solvent was removed under vacuum. The residue was purified with flash column chromatography on silica gel eluting with 0-70% ethyl acetate in hexane to give the title compound.
EXAMPLE 147B
( 1 -(methylsulfonyl)piperidin-3 -yl)methanamine
EXAMPLE 147 A (400 mg) was suspended in 4N HC1 in dioxane (10 mL) followed by the addition of anhydrous methanol (1 mL). The clear solution was stirred at room temperature for 2 hours. The organic solvent was removed under vacuum. The solid residue was used in the next step without further purification.
EXAMPLE 147C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methylsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 53A (50 mg), EXAMPLE 147B (26 mg) and triethylamine (0.088 mL) were dissolved in anhydrous dioxane (lmL) and N,N-dimethylformamide (0.2 mL). The reaction vial was heated in a Biotage Initiator microwave reactor at 130°C for 25 minutes. The solvent was removed under vacuum. The residue was purified by reverse phase HPLC on a C 18 column using a gradient of 20-80% acetonitrile/0.1 % trifluoroacetic acid in water to give the title compound as the trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (6 mL) and washed with 50%> aqueous NaHC03. The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.65 (s, 1H), 8.56 (m, 2H), 8.03 (d, 1H), 7.80 (m, 1H), 7.50 (m, 3H), 7.35 (d, 2H), 7.12 (m, 1H), 7.04 (d, 2H), 6.67 (dd, 1H), 6.38 (dd, 1H), 6.19 (d, 1H), 3.52 (m, 1H), 3.40 (m, 2H), 3.06 (m, 4H), 2.84 (s, 3H), 2.75 (m, 2H), 2.75 (m, 4H), 2.58 (m, 1H), 2.16 (m, 6H), 1.95 (s, 3H), 1.76 (m, 2H), 1.52 (m, 1H), 1.37 (m, 2H), 0.92 (s, 6H).
EXAMPLE 148
N-[(4-{[(l-acetylpiperidin-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 148 A
tert-butyl (1 -acetylpiperidin-3-yl)methylcarbamate
The title compound was prepared by substituting acetyl chloride for methanesulfonyl chloride in EXAMPLE 147 A.
EXAMPLE 148B
1 -(3 -(aminomethyl)piperidin- 1 -yl)ethanone
The title compound was prepared by substituting EXAMPLE 148 A for EXAMPLE 147A in EXAMPLE 147B.
EXAMPLE 148C
N-[(4-{[(l-acetylpiperidin-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 148B for EXAMPLE 147B in EXAMPLE 147C. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.56 (m, 2H), 8.03 (d, 1H), 7.80 (m, 1H), 7.50 (m, 3H), 7.34 (d, 2H), 7.12 (m, 1H), 7.04 (d, 2H), 6.67 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 3.99 (m, 1H), 3.67 (m, 1H), 3.37 (m, 2H), 3.24 (m, 2H), 3.07 (m, 4H), 2.89 (m, 1H), 2.71 (m, 2H), 2.16 (m, 6H), 1.96 (s, 3H), 1.80 (m, 4H), 1.38 (t, 2H), 1.27 (m, 2H), 0.92 (s, 6H). EXAMPLE 149
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 149 A
(R)-tert-butyl 1 -(methylsulfonyl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperidin-3-ylmethylcarbamate in EXAMPLE 147 A.
EXAMPLE 149B
(R)- 1 -(methylsulfonyl)pyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 149 A for EXAMPLE in EXAMPLE 147B.
EXAMPLE 149C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 149B for EXAMPLE 147B in EXAMPLE 147C. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.65 (s, IH), 8.55 (d, IH), 8.29 (d, IH), 8.02 (d, IH), 7.86 (dd, IH), 7.49 (m, 3H), 7.33 (d, 2H), 7.17 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.41 (m, IH), 3.69 (m, IH), 3.39 (m, 3H), 3.06 (m, 4H), 2.97 (s, 3H), 2.76 (m, 2H), 2.27 (m, 8H), 1.93 (m, 2H), 1.54 (m, IH), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 150
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 150A
Ethyl 2-hydroxy-3,3-dimethylcyclohex-l-enecarboxylate Into a 500 mL round-bottomed flask was added diisopropylamine (3.5 mL) in ether (200 mL). After cooling to -30°C, butyllithium (16 mL) (1.6M in hexane) was added slowly. After stirring 30 minutes, the temperature was cooled to -5 °C. 2,2-Dimethylcyclohexanone (3 g) was added slowly. The mixture was warmed up to 0°C and stirred for 1 hour. After cooling to -5 °C, hexamethylphosphoramide (8 mL) and ethyl carbonocyanidate (2.5 mL) were added. After stirring at -5 °C for 20 minutes, and warming to room temperature, the reaction was stirred for 1 hour. The mixture was poured into cold water, and the layers were separated. The aqueous layer was extracted with ether (3x 20 mL). The combined the organic layers were washed with saturated aqueous NH4C1 (3x 20 mL). After drying over Na2S04, the mixture was filtered and the filtrate was concentrated. The crude product was purified by flash chromatography on silica with 0-10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 150B
Ethyl 3 ,3 -dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate The title compound was prepared by substituting EXAMPLE 150A for EXAMPLE 101A in EXAMPLE 101B.
EXAMPLE 150C
Ethyl 2-(4-chlorophenyl)-3,3-dimethylcyclohex-l -enecarboxylate The title compound was prepared by substituting EXAMPLE 150B for EXAMPLE 101B in EXAMPLE 101C.
EXAMPLE 150D
(2-(4-chlorophenyl)-3,3-dimethylcyclohex-l-enyl)methanol In a 200 mL round-bottomed flask was added EXAMPLE 150C (0.97 g) and lithium borohydride (0.47 g) in ether (20 mL) to give a suspension. Methanol (2.2 mL) was added slowly. The mixture was refluxed overnight. The reaction was then cooled, and methanol was added to quench the reaction. IN aqueous HC1 was then added until the pH<7, and ether (3x 30 mL) was used to extract the product. The combined organic layers were dried over Na2S04, filtered, and concentrated. The crude material was purified by flash chromatography on silica with 0-25% ethyl acetate in hexanes to provide the title compound. EXAMPLE 150E
2-(4-chlorophenyl)-3,3-dimethylcyclohex-l-enecarbaldehyde
Into a 100 mL round-bottomed flask was added EXAMPLE 150D (0.3 g) and Dess- Martin Periodinane (0.6 g) in dichloromethane (10 mL) to give a suspension. The mixture was stirred at room temperature overnight. After filtration, the mixture was washed with saturated aqueous NaHCC (2x 20 mL), dried over Na2S04, filtered, and concentrated. The crude product was purified by flash chromatography on silica with 0-25% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 150F
Methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-3,3- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 150E for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 15F for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A.
EXAMPLE 150G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-3,3- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 15 OF for EXAMPLE 101E in EXAMPLE 101F.
EXAMPLE 150H
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 150G for EXAMPLE 3 J and EXAMPLE IF for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethyl sulfoxide-de) δ 11.50 (s, 1H), 8.36 (m, 1H), 8.32 (m, 1H), 7.91 (d, 1H), 7.59 (m, 2H), 7.40 (t, 1H), 7.35 (d, 2H), 7.25 (m, 1H), 6.94 (d, 2H), 6.79 (d, 1H), 6.60 (m, 1H), 6.29 (m, 1H), 6.24 (d, 1H), 3.83 (m, 2H), 3.25 (m, 4H), 2.98 (m, 4H), 2.42 (s, 2H), 2.14 (m, 6H), 1.60 (m, 6H), 1.25 (m, 3H), 0.86 (s, 6H) EXAMPLE 151
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 151 A
1 -( 1 ,3 -difluoropropan-2-yl)azetidin-3 -amine
To a solution of tert-butyl azetidin-3-ylcarbamate (0.256 g) and l,3-difluoropropan-2- one (0.154 g) in dichloromethane (2 mL) was added sodium triacetoxyborohydride (0.473 g) and the reaction was allowed to stirred at room temperature. After 16 hours, the reaction was quenched with saturated NaHC03 solution (10 mL) and extracted into dichloromethane (25 mL). The organic layer was dried and concentrated. Silica gel chromatography
(GraceResolv 12 g) eluting with a gradient of 0.5% to 3.5% methanol/dichloromethane followed by treatment with HCl (4.0M in dioxane, 3 mL) and methanol (0.5 mL) for 2 hours gave the title compound after concentration.
EXAMPLE 15 IB
4-( 1 -( 1 ,3 -difluoropropan-2-yl)azetidin-3 -ylamino)-3 -nitrobenzenesulfonamide To a suspension of 4-chloro-3-nitrobenzenesulfonamide (0.225 g) and 1-(1,3- difluoropropan-2-yl)azetidin-3 -amine (0.193 g) in dioxane (5 mL) was added
diisopropylamine (0.832 mL). The reaction was sonicated and then heated to 100°C. After stirring overnight, the reaction was concentrated and loaded onto silica gel (GraceResolv 12 g) and eluted with a gradient of 0.5% to 3.5% methanol/dichloromethane to give the title compound.
EXAMPLE 151C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 15 IB for EXAMPLE
IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.66 (s, IH), 11.54 - 11.28 (m, IH), 8.54 (d, IH), 8.45 (s, IH), 8.01 (d, IH), 7.82 (d, IH), 7.48 (d, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.90 (d, IH), 6.67 (d, IH), 6.37 (s, 1H), 6.20 (s, 1H), 4.64 - 4.23 (m, 6H), 3.81 (s, 2H), 3.08 (s, 4H), 2.75 (s, 3H), 2.15 (s, 7H), 1.95 (s, 2H), 1.38 (s, 2H), 0.92 (s, 6H).
EXAMPLE 152
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methylsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 152A
tert-butyl (1 -(methylsulfonyl)pyrrolidin-3-yl)methylcarbamate The title compound was prepared by substituting tert-butyl pyrrolidin-3- ylmethylcarbamate for tert-butyl piperidin-3-ylmethylcarbamate in EXAMPLE 147 A.
EXAMPLE 152B
(l-(methylsulfonyl)pyrrolidin-3-yl)methanamine
The title compound was prepared by substituting EXAMPLE 152A for EXAMPLE 147A in EXAMPLE 147B.
EXAMPLE 152C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(methylsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 152B for EXAMPLE 147B in EXAMPLE 147C. 1H NMR (400MHz, dimethylsulfoxide-d6) 511.60 (s, 1H), 8.49 (m, 2H), 7.99 (s, 1H), 7.73 (m, 1H), 7.53 (d, 1H), 7.47 (s, 1H), 7.42 (m, 1H), 7.34 (d, 2H), 7.04 (m, 3H), 6.65 (m, 1H), 6.35 (s, 1H), 6.22 (s, 1H), 3.41 (m, 4H), 3.22 (m, 2H), 3.03 (m, 4H), 2.89 (s, 3H), 2.73 (m, 2H), 2.59 (m, 1H), 2.17 (m, 6H), 2.00 (m, 4H), 1.68 (m, 1H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 153
N-[(4- { [( 1 -acetylpyrrolidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
EXAMPLE 153 A
tert-butyl ( 1 -acetylpyrrolidin-3 -yl)methylcarbamate The title compound was prepared by substituting tert-butyl pyrrolidin-3- ylmethylcarbamate for tert-butyl piperidin-3-ylmethylcarbamate and acetyl chloride for methanesulfonyl chloride in EXAMPLE 147 A.
EXAMPLE 153B
1 -(3 -(aminomethyl)pyrrolidin- 1 -yl)ethanone
The title compound was prepared by substituting EXAMPLE 153 A for EXAMPLE 147A in EXAMPLE 147B.
EXAMPLE 153C
N-[(4-{[(l-acetylpyrrolidin-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 153B for EXAMPLE 147B in EXAMPLE 147C. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1H), 8.62 (m, 1H), 8.54 (s, 1H), 8.03 (m, 1H), 7.78 (d, 1H), 7.50 (m, 3H), 7.35 (t, 2H), 7.09 (s, 1H), 7.04 (d, 2H), 6.67 (dd, 1H), 6.37 (d, 1H), 6.20 (s, 1H), 3.56 (m, 1H), 3.42 (m, 4H), 3.43 (m, 4H), 3.23 (m, 1H), 3.07 (m, 4H), 2.74 (m, 2H), 2.16 (m, 6H), 1.93 (m, 5H), 1.38 (t, 2H), 0.93 (s, 6H).
EXAMPLE 154
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 154A
(R)-tert-butyl 1 -acetylpyrrolidin-3-ylcarbamate
The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperidin-3-ylmethylcarbamate and acetyl chloride for
methanesulfonyl chloride in EXAMPLE 147 A.
EXAMPLE 154B
(Pv)- 1 -(3 -aminopyrrolidin- 1 -yl)ethanone
The title compound was prepared by substituting EXAMPLE 154A for EXAMPLE in EXAMPLE 147B.
EXAMPLE 154C
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 154B for EXAMPLE 147B in EXAMPLE 147. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.61 (s, IH), 8.50 (s, IH), 8.17 (d, IH), 7.98 (s, IH), 7.78 (s, IH), 7.49 (m, 3H), 7.34 (d, 2H), 7.10 (m, IH), 7.04 (d, 2H), 6.66 (dd, IH), 6.35 (s, IH), 6.22 (s, IH), 4.34 (m, IH), 3.81 (m, IH), 3.58 (m, IH), 3.43 (m, IH), 3.05 (m, 4H), 2.74 (s, 2H), 2.19 (m, 9H), 1.96 (m, 5H), 1.38 (t, 2H), 0.94 (s, 6H).
EXAMPLE 155
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 120B using 3-methoxy- 2,2-dimethylpropan-l -amine in place of EXAMPLE 120A. 1H NMR (500 MHz,
dimethylsulfoxide-de) δ 11.69 (s, IH), 11.32 (s, IH), 8.92 (t, IH), 8.57 (d, IH), 8.04 (d, IH), 7.80 (dd, IH), 7.46 - 7.55 (m, 3H), 7.34 (d, 2H), 7.08 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.36 - 6.42 (m, IH), 6.19 (d, IH), 3.25 - 3.30 (m, 5H), 3.19 (s, 2H), 3.07 (s, 4H), 2.76 (s, 2H), 2.17 (d, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.96 (s, 6H), 0.92 (s, 6H). EXAMPLE 156
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3R)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-(l H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 156A
4-(((lR,3R)-3-hydroxycyclopentyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting (lR,3R)-3- hydroxy cyclopentyl)methylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 156B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 R,3R)-3-hydroxycyclopentyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-(l H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 156A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.05 (s, IH), 9.29 (s, IH), 8.62 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.10 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.85 (d, IH), 6.74 (dd, IH), 6.54 (s, IH), 6.49 (m, IH), 4.60 (m, IH), 3.19 (dd, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.70 (m, IH), 2.26 (t, 2H), 2.20-2.07 (m, 6H), 2.00 (m, IH), 1.97 (s, 2H), 1.90 (m, IH), 1.56 (m, IH), 1.39 (t, 2H), 1.34 (m, IH), 0.93 (s, 6H).
EXAMPLE 157
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMLE 157A
4-((( 1 S ,3 S)-3 -hydroxy cy clopentyl)methylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting (IS, 3S)-3- hydroxycyclopentyl)methylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 157B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lS,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 157A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.03 (s, IH), 9.29 (s, IH), 8.60 (t, IH), 8.44 (d, IH), 8.32 (dd, IH), 8.14 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.83 (d, IH), 6.75 (dd, IH), 6.55 (s, IH), 6.49 (m, IH), 4.60 (m, IH), 3.19 (dd, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.70 (m, IH), 2.26 (t, 2H), 2.20-2.07 (m, 6H), 2.00 (m, IH), 1.97 (s, 2H), 1.90 (m, IH), 1.56 (m, IH), 1.39 (t, 2H), 1.34 (m, IH), 0.93 (s, 6H).
EXAMPLE 158
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 S ,3Pv)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 158A
4-(((lS,3R)-3-hydroxycyclopentyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting (IS, 3R)-3- hydroxycyclopentyl)methylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 158B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [( 1 S ,3R)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 158A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.94 (s, IH), 9.25 (d, IH), 8.59 (t, IH), 8.48 (d, IH), 8.27 (m, 2H), 7.66 (m, 2H), 7.45 (d, 2H), 7.08 (d, 2H), 6.77 (dd, IH), 6.72 (d, IH), 6.60 (d, IH), 6.47 (m, IH), 4.53 (m, IH), 3.30 (m, 2H), 3.06 (m, 4H), 2.78 (s, 2H), 2.27 (m, 3H), 2.19-2.10 (m, 5H), 1.98 (m, 3H), 1.85-1.66 (m, 4H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 159
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 159A
4-((( 1 Pv,3 S)-3 -hydroxy eye lopentyl)methylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting (1R, 3S)-3- hydroxycyclopentyl)methylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 159B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(lR,3S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 158A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 9.28 (d, IH), 8.59 (t, IH), 8.44 (d, IH), 8.29 (d, IH), 8.13 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.08 (d, 2H), 6.82 (dd, IH), 6.74 (d, IH), 6.55 (d, IH), 6.48 (m, IH), 4.53 (m, IH), 3.34 (m, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.27 (m, 3H), 2.19-2.10 (m, 5H), 1.97 (m, 3H), 1.85-1.66 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 160
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting (S)-3-aminopiperidin-2-one for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.68 (br s, IH), 8.88 (d, IH), 8.57 (d, IH), 8.04 (d, IH), 7.95 (br s, IH), 7.83 (dd, IH), 7.55- 7.46 (m, 3H), 7.35 (d, 2H), 7.16 (d, IH), 7.05 (d, 2H), 6.68 (dd, IH), 6.38 (m, IH), 6.21 (d, IH), 4.41 (m, IH), 3.22 (m, 2H), 3.09 (br s, 4H), 2.78 (br s, 2H), 2.35-2.09 (m, 8H), 1.96 (br s, 2H), 1.86 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 161
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl} sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 161 A
tert-butyl 3-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)azetidine- 1 -carboxylate
EXAMPLE 82 (305 mg). tert-butyl 3 -(aminomethyl)azetidine-l -carboxylate (86 mg) and diisopropyl amine (0.202 mL) in dioxane (3 mL) were heated to 110°C. After stirring overnight, the reaction was concentrated. Silica gel chromatography (Reveleris, 12 g) eluting with a gradient of 0.5% to 3% methanol/dichloromethane (Flow = 36 ml/minute) gave the title compound.
EXAMPLE 161B
2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-(4-(azetidin-3 -ylmethylamino)-3 - nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzamide
To a solution of EXAMPLE 161 A (0.257 g) in dichloromethane (5 mL) was added trifluoroacetic acid (0.211 mL), After 30 minutes an additional 0.2 ml of trifluoroacetic acid was added. After 3 hours, the reaction was concentrated to give the title compound.
EXAMPLE 161C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl} sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
A solution of EXAMPLE 161B (0.118 g), sodium triacetoxyborohydride (0.035 g) and l,3-difluoropropan-2-one (0.012 g) were stirred together in dichloromethane (1 mL) overnight. The reaction was quenched with saturated aqueous NaHC03 solution (10 mL) and extracted into dichloromethane (30 mL). The organic layer was dried and concentrated. Silica gel chromatography (Reveleris 12 g) eluting with a gradient of 0.5% to 3.5%> methanol/dichloromethane over 30 minutes (Flow = 36 ml/min) gave the title compound. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 11.47 - 11.21 (m, 1H), 8.85 (s, 1H), 8.55 (d, IH), 8.03 (d, IH), 7.80 (dd, IH), 7.54 - 7.45 (m, 3H), 7.33 (s, 2H), 7.04 (d, 3H), 6.67 (d, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.43 (dt, 4H), 3.56 (t, 2H), 3.46 (s, 2H), 3.12 (m, 6H), 2.74 (m, 3H), 2.17 (m, 7H), 1.95 (s, 2H), 1.39 (d, 2H), 0.92 (s, 6H).
EXAMPLE 162
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting oxetan-3-one for 1,3- difluoropropan-2-one in EXAMPLE 161C. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 11.51 - 11.03 (m, IH), 8.81 (s, IH), 8.54 (d, IH), 8.02 (d, IH), 7.79 (dd, IH), 7.50 (dd, 3H), 7.34 (d, 2H), 7.04 (d, 3H), 6.67 (d, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.57 (s, 2H), 4.43 - 4.35 (m, 2H), 3.82 (s, IH), 3.59 (t, 2H), 3.44 (t, 2H), 3.20 (s, 2H), 3.06 (s, 4H), 2.73 (s, 3H), 2.18 (s, 6H), 1.95 (s, 2H), 1.39 (d, 2H), 0.92 (s, 6H).
EXAMPLE 163
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl]amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 163 A
tert-butyl 4-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl 4-
(aminomethyl)piperidine-l -carboxylate for l-acetylpiperidin-4-amine in EXAMPLE 53B.
EXAMPLE 163B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(piperidin-4- ylmethylamino)phenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 163 A for EXAMPLE 1A in EXAMPLE IB. EXAMPLE 163C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl]amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 163B for EXAMPLE 16 IB and oxetan-3 -one for l,3-difluoropropan-2-one in EXAMPLE 161C. 1H NMR
(500MHz, dimethylsulfoxide-de) δ 11.68 (s, IH), 8.60 (t, IH), 8.54 (d, IH), 8.03 (d, IH), 7.79 (dd, IH), 7.50 (m, 3H), 7.34 (d, 2H), 7.09 (d, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 4.55 (t, 2H), 4.46 (t, 2H), 3.52 (br s, IH), 3.28 (m, 2H), 3.17 (d, IH), 3.06 (m, 4H), 2.82 (m, 2H), 2.74 (m, 2H), 2.17 (m, 6H), 1.95 (m, 3H), 1.72 (m, 3H), 1.38 (t, 2H),
I .28 (m, 2H), 0.92 (s, 6H).
EXAMPLE 164
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXMAPLE 163B for (S)-tert-butyl pyrrolidin-3-ylcarbamate in EXAMPLE 142A. 1H NMR (500MHz, dimethylsulfoxide-d6) δ
I I .96 (br s, IH), 11.62 (br s, IH), 8.50 (m, 2H), 7.98 (d, IH), 7.72 (m, IH), 7.52 (d, IH), 7.45 (m, 2H), 7.34 (d, 2H), 7.04 (m, 2H), 6.94 (m, IH), 6.64 (dd, IH), 6.34 (m, IH), 6.22 (d, IH), 3.28 (m, 3H), 3.04 (m, 5H), 2.72 (s, 2H), 2.64 (m, IH), 2.64 (m, IH), 2.36 (m, IH), 2.16 (m, 7H), 1.95 (s, 2H), 1.68 (m, 3H), 1.38 (t, 2H), 1.18 (m, 3H), 0.94 (s, 6H), 0.35 (m, 3H).
EXAMPLE 165
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 165 A
4-((4-(2-fluoroethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2-fluoro-ethyl bromide for methyl iodide in EXAMPLE 134B. EXAMPLE 165B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2-fluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 165 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.87 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.92 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (dd, IH), 3.93 (m, IH), 4.63, 4.51(dt, 2H), 3.95-3.85 (m, 2H), 3.68 (dt, IH), 3.43-3.37 (m, 2H), 3.07 (m, 4H), 2.92 (d, IH), 2.77 (s, 2H), 2.65 (m, 2H), 2.59 (m, IH), 2.26 (m, 2H), 2.17-2.08 (m, 5H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 166
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(2,2-difluoroethyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 166A
4-((4-(2,2-difluoroethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2,2-difluoro-ethyl bromide for methyl iodide in EXAMPLE 134B.
EXAMPLE 166B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 166A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.01 (s, IH), 9.26 (d, IH), 8.86 (t, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.93 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 6.31, 6.20, 6.09 (tt, IH), 3.90 (m, IH), 3.85 (d, IH), 3.67 (dt, IH), 3.49-3.30 (m, 2H), 3.07 (m, 4H), 2.84 (d, IH), 2.82-2.75 (m, 4H), 2.69 (d, IH), 2.33 (dt, IH), 2.27-2.20 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 167
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -oxetan-3 -ylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 167A
4-((4-fiuoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 173 A for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 167B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -oxetan-3 -ylpiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 167A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.39 (s, IH), 8.09 (d, IH), 8.04 (d, IH), 7.52 (m, 4H), 7.35 (d, 2H), 7.05 (m, 2H), 6.68 (dd, IH), 6.40 (dd, IH), 6.20 (s, IH), 4.57 (t, 2H), 4.48 (m, 2H), 4.38 (d, 2H), 4.02 (m, IH), 3.63 (m, 2H), 3.08 (m, 4H), 2.74 (m, 4H), 2.17 (m, 6H), 1.88 (m, 6H), 1.40 (t, 2H), 0.93 (s, 6H).
EXAMPLE 168
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 168 A
(S)-methyl 4,4-difluoropyrrolidine-2-carboxylate
(S)-l -tert-butyl 2-methyl 4,4-difluoropyrrolidine-l,2-dicarboxylate (0.472 g) in CH2CI2 (1 mL) was treated with trifluoroacetic acid (1.4 mL), stirred at ambient temperature for 4 hours, and concentrated. The product was free-based using a MEGA BE-SCX column with 1 : 1 CH2Cl2/methanol as eluent for the trifluoroacetic acid. The product was released from the column with 5% (7 M ammonia in methanol) in CH2CI2 as eluent. EXAMPLE 168B
(S)-methyl 4,4-difluoro- 1 -(oxetan-3-yl)pyrrolidine-2-carboxylate The title compound was prepared by substituting EXAMPLE 168 A for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 168C
(S)-(4,4-difluoro- 1 -(oxetan-3-yl)pyrrolidin-2-yl)methanol EXAMPLE 168B (0.180 g) in tetrahydrofuran (3 mL) was treated sequentially with a solution of calcium chloride (0.245 g) in ethanol (3 mL) and NaBH4 (0.167 g) and then stirred at ambient temperature for 7 hours. The reaction was quenched with saturated aqueous NH4C1 solution and extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 50% ethyl acetate in hexanes as eluent to give the product.
EXAMPLE 168D
(S)-4-((4,4-difluoro-l-(oxetan-3-yl)pyrrolidin-2-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 168C for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 168E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(2S)-4,4-difluoro-l-oxetan-3-ylpyrrolidin-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 168D for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 8.38 (s, 1H), 8.06 (m, 2H), 7.49 (m, 4H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, 1H), 6.40 (m, 1H), 6.21 (s, 1H), 4.54 (m, 3H), 4.43 (t, 1H), 4.23 (m, 1H), 4.12 (m, 2H), 3.44 (m, 2H), 3.12 (m, 7H), 2.58 (m, 1H), 2.29 (m, 7H), 1.97 (s, 2H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 169
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 169A
tert-butyl 3-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)morpholine-4-carboxylate
The title compound was prepared as described in EXAMPLE 53B by replacing 1- acetylpiperidin-4-amine with tert-butyl 3-(aminomethyl)morpholine-4-carboxylate.
EXAMPLE 169B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(4-(morpholin-3 -ylmethylamino)-3 - nitrophenylsulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 139B by replacing EXAMPLE 139A with EXAMPLE 169A.
EXAMPLE 169C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing
EXAMPLE 139B and oxetan-3-one with EXAMPLE 169B and tetrahydropyran-4-one, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.77 (m, IH), 8.57 (d, IH), 8.05 (d, IH), 7.84 (dd, IH), 7.52 (m, 3H), 7.34 (m, 2H), 7.03 (m, 3H), 6.68 (dd, IH), 6.40 (dd, IH), 6.18 (d, IH), 3.86 (m, 2H), 3.72 (m, 2H), 3.11 (m, 6H), 2.74 (m, 4H), 2.20 (m, 6H), 1.95 (m, 3H), 1.51 (m, 7H), 0.92 (s, 6H). EXAMPLE 170
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing EXAMPLE 139B and oxetan-3-one with EXAMPLE 169B and cyclobutanone. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.68 (s, IH), 8.72 (s, IH), 8.57 (d, IH), 8.04 (d, IH), 7.84 (dd, IH), 7.52 (m, 3H), 7.34 (m, 3H), 7.03 (m, 4H), 6.67 (dd, IH), 6.39 (dd, IH), 6.18 (d, IH), 3.47 (m, 3H), 3.10 (m, 6H), 2.72 (m, 6H), 2.25 (m, 8H), 1.95 (m, 4H), 1.56 (m, 3H), 1.38 (m, 2H), 0.92 (s, 6H).
EXAMPLE 171
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 139C by replacing EXAMPLE 139B and oxetan-3-one with EXAMPLE 169B and 3-oxotetrahydrofuran, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.64 (s, IH), 8.66 (s, IH), 8.53 (d, IH), 8.01 (d, IH), 7.80 (d, IH), 7.50 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H), 6.98 (d, IH), 6.66 (dd, IH), 6.37 (d, IH), 6.19 (d, IH), 3.68 (m, 8H), 3.05 (m, 6H), 2.85 (m, 3H), 2.73 (s, 2H), 2.25 (m, 6H), 1.91 (m, 3H), 1.37 (m, 3H), 0.95 (m, 6H).
EXAMPLE 172
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3-nitrophenyl} sulfonyl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 163B for tert-butyl piperazine-l-carboxylate and l,3-difluoropropan-2-one for 4'-chlorobiphenyl-2- carboxaldehyde in EXAMPLE 1 A. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 11.40 (br s, IH), 8.57 (m, 2H), 8.03 (d, IH), 7.78 (d, IH), 7.50 (m, 3H), 7.34 (d, 2H), 7.07 (d, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.38 (m IH), 6.19 (d, IH), 4.63 (d, 2H), 4.53 (d, 2H), 3.28 (m, 2H), 3.07 (m, 4H), 2.89 (m, 2H), 2.74 (m, 2H), 2.40 (m, 2H), 2.16 (m, 6H), 1.95 (s, 2H), 1.67 (m, 3H), 1.38 (t, 2H), 1.23 (m, 3H), 0.94 (s, 6H).
EXAMPLE 173
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclopropyl-4-fiuoropiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 173 A
4-((4-fluoropiperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 126B for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 173B
4-(( 1 -cyclopropyl-4-fiuoropiperidin-4-yl)methoxy)-3 -nitrobenzenesulfonamide
To EXAMPLE 173 A (0.24 g) in methanol (3 mL) was added 3 A molecular sieves (0.1 g), followed sequentially by acetic acid (0.31 mL), (1- ethoxycyclopropoxy)trimethylsilane (0.64 mL), and sodium cyanoborohydride (0.148 g). The reaction was heated under reflux overnight. After cooling, the reaction mixture was loaded onto a silica gel column. After drying, the column was eluted with 100:2:0.2 ethyl acetate/methanol/NH4OH to give the title compound.
EXAMPLE 173 C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -cyclopropyl-4-fiuoropiperidin-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 173B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.65 (s, IH), 8.33 (s, IH), 8.01 (m, 2H), 7.53 (d, IH), 7.48-7.49 (m, 2H), 7.34-7.38 (m, 3H), 7.04 (d, 2H), 6.66 (dd, IH), 6.38 (dd, IH), 6.21 (d, IH), 4.32 (d, 2H), 3.70-3.77 (m, 2H), 3.07 (s, 4H), 2.92 (s, 2H), 2.80 (s, 2H), 2.58 (s, 2H), 2.25 (s, 4H), 2.13-2.16 (m 2H), 1.38 (t, 2H), 0.92 (s, 6H), 0.40-0.49 (m, 4H). EXAMPLE 174
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
A suspension of EXAMPLE 53 A (120 mg), (4-methoxyphenyl)methanamine (31 mg) and Hunig'sBase (0.159 mL) in dimethylsulfoxide (2 mL) was heated for 2 hours at 150 °C in a Biotage Initiator microwave reactor. The reaction mixture was diluted with methanol (2 mL) and purified by reverse phase HPLC (C8, 30% - 100% CH3CN/water/0.1%
trifiuoroacetic acid). 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.32 (d, IH), 9.17 (t, IH), 8.43 (d, IH), 8.28 (dd, IH), 8.08 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.38 (d, 2H), 7.07 (d, 2H), 6.97 - 7.02 (m, 2H), 6.90 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.49 (dd, IH), 4.55 (d, 2H), 3.68 (s, 3H), 3.03 - 3.09 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.10 - 2.17 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 175
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
The title compound was prepared by substituting (3- trifluoromethoxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.38 (t, IH), 9.31 (d, IH), 8.42 (d, IH), 8.28 (dd, IH), 8.08 (d, IH), 7.65 (ddd, 2H), 7.41 - 7.46 (m, 3H), 7.36 - 7.40 (m, 2H), 7.07 (d, 2H), 6.88 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.49 (d, IH), 4.73 (d, 2H), 3.02 - 3.08 (m, 4H), 2.77 (s, 2H), 2.22 - 2.28 (m, 2H), 2.09 - 2.16 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 176
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -methoxybenzyl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting (3-methoxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.27 - 9.32 (m, 2H), 8.42 (d, IH), 8.26 (dd, IH), 8.08 (d, IH), 7.64 - 7.67 (m, 2H), 7.44 (d, 2H), 7.32 (t, IH), 7.14 (s, IH), 7.04 - 7.09 (m, 3H), 6.88 - 6.94 (m, 2H), 6.74 (dd, IH), 6.52 (d, IH), 6.48 - 6.50 (m, IH), 4.64 (d, 2H), 3.68 (s, 3H), 3.03 - 3.09 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.10 - 2.18 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 177
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting (4- difluoromethoxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.32 (d, IH), 9.28 (t, IH), 8.42 (d, IH), 8.28 (dd, IH), 8.07 (d, IH), 7.66 (t, IH), 7.64 (d, IH), 7.58 (s, IH), 7.44 (s, 2H), 7.26 (s, IH), 7.25 (d, IH), 7.07 (d, 2H), 6.87 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.49 (dd, IH), 4.64 (d, 2H), 3.03 - 3.10 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.11 - 2.17 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 178
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- (l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting l,4-dioxa-spiro[4.5]dec-8-ylamine for l-acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.67 (br s, IH), 8.55 (d, IH), 8.26 (d, IH), 8.04 (d, IH), 7.81 (dd, IH), 7.54-7.46 (m, 3H), 7.35 (d, 2H), 7.15 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.38 (m, IH), 6.19 (d, IH), 3.89 (s, 4H), 3.78 (m, IH), 3.07 (br s, 4H), 2.78 (br s, 2H), 2.28-2.11 (m, 6H), 2.00-1.88 (m, 4H), 1.75-1.57 (m, 4H), 1.54-1.35 (m, 4H), 0.92 (s, 6H).
EXAMPLE 179
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 179A
tert-butyl trans-4-acetamidocyclohexylcarbamate
Tert-butyl (trans)-4-aminocyclohexylcarbamate (1.500 g) and triethylamine (2.93 mL, 2.125 g) were added to dichloromethane and stirred until the tert-butyl (trans)-4- aminocyclohexylcarbamate had dissolved completely. Acetyl chloride (0.577 g) was added slowly, and the solution was stirred at room temperature for 16 hours. The solvent was removed, and the residue taken up in ethyl acetate, washed with pH 4 buffer, washed with brine, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum.
EXAMPLE 179B
N-(trans-4-aminocyclohexyl)acetamide
The title compound was prepared by substituting EXAMPLE 179A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 179C
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 179B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.67 (br s, 1H), 8.55 (d, 1H), 8.20 (d, 1H), 8.04 (d, 1H), 7.82-7.76 (m, 2H), 7.53-7.46 (m, 3H), 7.35 (d, 2H), 7.16 (d, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (m, 1H), 6.19 (d, 1H), 3.57 (m, 2H), 3.07 (br s, 4H), 2.75 (br s, 2H), 2.28-2.10 (m, 6H), 2.03-1.94 (m, 4H), 1.83 (d, 2H), 1.80 (s, 3H), 1.55-1.24 (m, 6H), 0.92 (s, 6H).
EXAMPLE 180
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3Pv)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 180A
(R)-tert-butyl 1 -(2,2-difluoroethyl)pyrrolidin-3-ylcarbamate To a solution of (R)-tert-butyl pyrrolidin-3-ylcarbamate (500 mg) and l,l-difluoro-2- iodoethane (618 mg) in N,N-dimethylformamide (6 mL) was added N-ethyl-N- isopropylpropan-2-amine (1.403 ml) and the mixture was stirred at 70 °C for 72 hours. The reaction mixture was concentrated and the crude product was purified on silica gel with methanol / dichloromethane.
EXAMPLE 180B
(R)-l-(2,2-difluoroethyl)pyrrolidin-3-amine
To a solution of EXAMPLE 180A (525 mg) in a mixture of dichloromethane (3 mL) and methanol (4.0 mL) was added hydrogen chloride, 4M in dioxane (5.24 mL) and the reaction was stirred for 1.5 hours. The reaction was concentrated and the crude material was taken up in dichloromethane and the solvent evaporated, then taken up in ether and the solvent evaporated, and then dried on high vacuum. EXAMPLE 180C
(R)-4-(l-(2,2-difluoroethyl)pyrrolidin-3-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 180B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 180D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 180C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.02 (m, IH), 9.27 (d, IH), 8.55 (d, IH), 8.43 (d, IH), 8.35 (dd, IH), 8.10 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.83 (d, IH), 6.75 (dd, IH), 6.54 (m, IH), 6.48 (m, IH), 6.04 - 6.29 (m, IH), 4.06 (m, IH), 3.07 (m, 4H), 2.83 - 2.95 (m, 4H), 2.74 - 2.82 (m, 3H), 2.47 (m, IH), 2.09 - 2.30 (m, 8H), 1.97 (s, 2H), 1.67 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 181
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide EXAMPLE 181 A
(S)-tert-butyl 1 -(2-fluoroethyl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting l-fluoro-2-iodoethane for 1,1- difluoro-2-iodoetfiane and (S)-tert-butyl pyrrolidin-3-ylcarbamate for (R)-tert-butyl pyrrolidin-3-ylcarbamate in EXAMPLE 180A.
EXAMPLE 18 IB
(S)- 1 -(2-fluoroethyl)pyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 181 A for EXAMPLE 180A in EXAMPLE 180B.
EXAMPLE 181C
(S)-4-( 1 -(2-fluoroethyl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 18 IB for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 18 ID
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 181C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.00 (m, IH), 9.26 (d, IH), 8.56 (d, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.10 (d, IH), 7.63 - 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.82 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.60 (t, IH), 4.51 (t, IH), 4.05 (m, IH), 3.07 (m, 4H), 2.84 (m, IH), 2.66 - 2.79 (m, 6H), 2.39 (q, IH), 2.20 - 2.29 (m, 3H), 2.15 (m, 5H), 1.97 (s, 2H), 1.66 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 182
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 182A
(S)-tert-butyl 1 -(2,2-difluoroethyl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting (S)-tert-butyl pyrrolidin-3- ylcarbamate for (R)-tert-butyl pyrrolidin-3-ylcarbamate in EXAMPLE 180A.
EXAMPLE 182B
(S)- 1 -(2,2-difluoroethyl)pyrrolidin-3-amine
The title compound was prepared by substituting EXAMPLE 182A for EXAMPLE 180A in EXAMPLE 180B.
EXAMPLE 182C
(S)-4-(l-(2,2-difluoroethyl)pyrrolidin-3-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 182B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 182D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3 S)- 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 182C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.02 (m, IH), 9.27 (d, IH), 8.54 (d, IH), 8.43 (d, IH), 8.35 (dd, IH), 8.11 (d, IH), 7.64 - 7.68 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.82 (d, IH), 6.75 (dd, IH), 6.54 (m, IH), 6.48 (m, IH), 6.04 - 6.29 (m, IH), 4.06 (m, IH), 3.07 (m, 4H), 2.83 - 2.95 (m, 4H), 2.74 - 2.82 (m, 3H), 2.47 (m, IH), 2.09 - 2.30 (m, 8H), 1.97 (s, 2H), 1.67 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 183
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3Pv)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,b]pyridin-5 -yloxy)benzamide
EXAMPLE 183 A
(Pv)-tert-butyl 1 -(2-fluoroethyl)pyrrolidin-3-ylcarbamate The title compound was prepared by substituting l-fluoro-2-iodoethane for 1,1- difluoro-2-iodoethane in EXAMPLE 180A.
EXAMPLE 183B
(Pv)- 1 -(2-fluoroethyl)pyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 183 A for EXAMPLE 180A in EXAMPLE 180B.
EXAMPLE 183C
(Pv)-4-( 1 -(2-fluoroethyl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 183B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
ECAMPLE 183D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3Pv)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 183C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine- d5) δ 13.00 (m, 1H), 9.26 (d, 1H), 8.56 (d, 1H), 8.43 (d, 1H), 8.34 (dd, 1H), 8.10 (d, 1H), 7.63 - 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.83 (d, 1H), 6.75 (dd, 1H), 6.54 (d, 1H), 6.48 (m, 1H), 4.60 (t, 1H), 4.50 (t, 1H), 4.04 (m, 1H), 3.07 (m, 4H), 2.84 (m, 1H), 2.66 - 2.79 (m, 6H), 2.39 (q, 1H), 2.19 - 2.28 (m, 3H), 2.14 (m, 5H), 1.97 (s, 2H), 1.66 (m, 1H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 184
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 184A
(S)-tert-butyl 3 -((2-nitro-4-sulfamoylphenoxy)methyl)pyrrolidine- 1 -carboxylate To a solution of (S)-tert-butyl 3 -(hydroxymethyl)pyrrolidine-l -carboxylate (0.300 g) in tetrahydrofuran (5 mL) was added sodium hydride (0.238 g). After stirring for 15 minutes, 4-fluoro-3-nitrobenzenesulfonamide (0.295 g) was added and reaction stirred at room temperature. After 1 hour, the reaction was partitioned between water (25 mL) and dichloromethane (50 mL) and the reaction quenched with IN aqueous HC1 (5.96 mL). The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 12 g) eluting with a gradient of 0.2% to 2%
methanol/dichloromethane over 30 minutes (flow = 36 m/minute) gave the title compound.
EXAMPLE 184B
(S)-3 -nitro-4-(( 1 -(oxetan-3 -yl)pyrrolidin-3 -yl)methoxy)benzenesulfonamide To (S)-tert-butyl 3 -((2-nitro-4-sulfamoylphenoxy)methyl)pyrrolidine- 1 -carboxylate
(0.433 g) was added hydrogen chloride (4.0M in dioxane, 1.0 mL). After stirring for 1 hour, the reaction was concentrated and partitioned between dichloromethane (50 mL) and saturated aqueous NaHC03 solution (50 mL). The aqueous layer was separated and concentrated. The residue was triturated with methanol (100 mL), filtered and concentrated and treated with sodium cyanoborohyde (0.068 g) and cyclobutanone (0.078 g) and stirred overnight. The reaction was partitioned between dichloromethane (50 mL) and water (25 mL) and saturated aqueous NaHC03 (10 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 184C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 184B for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.64 (s, 1H), 11.45 - 11.01 (m, 1H), 8.30 (d, 1H), 7.98 (dd, 2H), 7.60 - 7.43 (m, 3H), 7.33 (t, 3H), 7.04 (d, 2H), 6.74 - 6.59 (m, 1H), 6.37 (dd, 1H), 6.21 (d, 1H), 4.49 (td, 2H), 4.33 (s, 1H), 4.13 (dd, 2H), 3.79 (s, 2H), 3.44 (dd, 2H), 3.07 (s, 4H), 2.74 (d, 6H), 2.19 (d, 6H), 1.98 (d, 2H), 1.74 - 1.52 (m, 1H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 185
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide The title compound was prepared by substituting (4-hydroxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 11.67 (bs, IH), 9.32 (d, IH), 9.14 (s, IH), 8.44 (d, IH), 8.28 (dd, IH), 8.09 (d, IH), 7.65 - 7.68 (m, 2H), 7.44 (d, 2H), 7.37 - 7.41 (m, 2H), 7.19 (s, 2H), 7.07 (d, 2H), 6.93 (d, IH), 6.75 (dd, IH), 6.53 (d, IH), 6.49 (dd, IH), 4.54 (d, 2H), 3.02 - 3.09 (m, 4H), 2.77 (s, 2H), 2.22 - 2.29 (m, 2H), 2.10 - 2.17 (m, 4H), 1.97 (d, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 186
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(3 -hydroxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting (3-hydroxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 11.67 (bs, IH), 9.27 - 9.32 (m, 2H), 8.43 (d, IH), 8.20 (dd, IH), 8.08 (d, IH), 7.66 (t, 2H), 7.44 (d, 2H), 7.33 (t, IH), 7.25 (s, IH), 7.13 (dd, IH), 7.07 (d, 2H), 6.98 (d, IH), 6.88 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.49 (dd, IH), 4.64 (d, 2H), 3.02 - 3.09 (m, 4H), 2.77 (s, 2H), 2.22 - 2.28 (m, 2H), 2.09 - 2.16 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 187
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(difluoromethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting (3- difluoromethoxyphenyl)methanamine for (4-methoxyphenyl)methanamine in EXAMPLE 174. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, IH), 9.34 (t, IH), 9.30 (d, IH), 8.42 (d,
IH), 8.26 (dd, IH), 8.08 (d, IH), 7.66 (ddd, 2H), 7.40 - 7.45 (m, 3H), 7.36 (t, IH), 7.27 - 7.30 (m, 2H), 7.19 (d, IH), 7.07 (d, 2H), 6.87 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.49 (dd, IH), 4.69 (d, 2H), 3.02 - 3.08 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.09 - 2.16 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 188
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[cis-3-morpholin-4-ylcyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 188A
Cis-methyl 3 -morpholinocyclopentanecarboxylate
The title compound was prepared by substituting methyl 3- oxocyclopentanecarboxylate for 4'-chlorobiphenyl-2-carboxaldehyde and morpholine for tert butyl piperazine-l-carboxylate in EXAMPLE 1A.
EXAMPLE 188B
Cis-3-morpholinocyclopentyl)methanol
The title compound was prepared by substituting EXAMPLE 188 A for EXAMPLE in EXAMPLE 101D.
EXAMPLE 188C
4-((Cis-3-morpholinocyclopentyl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 188B for (l,4-dioxan-2- yl)methanol in EXAMPLE 12 A.
EXAMPLE 188D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[cis-3-morpholin-4-ylcyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 188C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.57 (s, 1H), 8.17 (m, 1H), 7.94 (m, 1H), 7.82 (m, 1H), 7.56 (d, 1H), 7.44 (t, 1H), 7.34 (m, 3H), 7.16 (m, 1H), 7.05 (d, 2H), 6.64 (dd, 1H), 6.33 (m, 1H), 6.24 (d, 1H), 4.06 (m, 2H), 3.62 (m, 4H), 3.03 (m, 4H), 2.75 (s, 2H), 2.35 (m, 2H), 2.19 (m, 6H), 2.03 (m, 2H), 1.96 (s, 2H), 1.78 (m, 2H), 1.51 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H) EXAMPLE 189
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N { [4-( {4-[(methylsulfonyl)amino]cyclohexyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 189A
Trans-(4-Methanesulfonylamino-cyclohexyl)-carbamic acid tert-butyl ester The title compound was prepared by substituting methanesulfonyl chloride for acetyl chloride in EXAMPLE 179A.
EXAMPLE 189B
Trans-N-(4-Aminocyclohexyl)-methanesulfonamide The title compound was prepared by substituting EXAMPLE 189A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 189C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N { [4-( {4-[(methylsulfonyl)amino]cyclohexyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 189B for 1- acetylpiperidin-4-amine in EXAMPLE 53B. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.68 (br s, IH), 8.55 (d, IH), 8.18 (d, IH), 8.04 (d, IH), 7.84 (d, IH), 7.79 (dd, IH), 7.56- 7.47 (m, 3H), 7.34 (d, 2H), 7.16 (d, IH), 7.04 (d, 2H), 6.68 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 3.56 (m, IH), 3.17 (m, IH), 3.07 (br s, 4H), 2.93 (s, 3H), 2.75 (br s, 2H), 2.28-2.10 (m, 6H), 2.05-1.90 (m, 6H), 1.55-1.32 (m, 6H), 0.92 (s, 6H).
EXAMPLE 190
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 190A
4-( 1 -cyclopropylpiperidin-4-ylamino)-3 -(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared as described in EXAMPLE 17A by replacing (tetrahydropyran-4-yl)methylamine with 4-amino- 1 -cyclopropylpiperidine.
EXAMPLE 190B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1G by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE 3 J and EXAMPLE 190A, respectively. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 8.13 (d, IH), 8.02 (d, IH), 7.91 (m, IH), 7.48 (m, 3H), 7.34 (d, 2H), 7.04 (d, 2H), 6.67 (m, 2H), 6.38 (dd, IH), 6.19 (d, IH), 3.64 (m, IH), 3.13 (m, 5H), 2.73 (m, 5H), 2.22 (m, 6H), 1.92 (m, 5H), 1.70 (m, IH), 1.41 (m, 5H), 0.94 (s, 6H), 0.41 (m, 4H).
EXAMPLE 191
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 191 A
3 -nitro-4-(piperidin-4-ylmethoxy)benzenesulfonamide
To a solution of tert-butyl 4-(hydroxymethyl)piperidine-l-carboxylate (0.300 g) in tetrahydrofuran (5 mL) was added sodium hydride (0.223 g). After stirring for 15 minutes, 4- fluoro-3-nitrobenzenesulfonamide (0.276 g) was added and reaction stirred at room temperature. After 1 hour the reaction was partitioned between water (25 mL) and dichloromethane (50 mL) and the reaction quenched with IN aqueous HC1 (5.57 mL). The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated.
Treatment with HC1 (4.0M in dioxane, 2 mL) and methanol (2 mL) for 1 hour, followed by concentration, trituration with dichloromethane and filtration gave the title compound. EXAMPLE 191B
3 -nitro-4-(( 1 -(oxetan-3 -yl)piperidin-4-yl)methoxy)benzenesulfonamide To a suspension of 3-nitro-4-(piperidin-4-ylmethoxy)benzenesulfonamide (0.100 g) and cyclobutanone (0.030 g) in methanol (1 mL) was added sodium cyanoborohydride (0.027 g). After stirring overnight, the reaction was quenched with saturated NaHC03 (5 mL) and extracted into dichloromethane (2 x 10 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 191C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 19 IB for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.64 (s, 1H), 11.46 - 10.46 (m, 1H), 8.29 (s, 1H), 8.00 (d, 2H), 7.61 - 7.41 (m, 3H), 7.35 (d, 3H), 7.04 (d, 2H), 6.66 (d, 1H), 6.37 (s, 1H), 6.21 (s, 1H), 4.67 - 4.40 (m, 4H), 4.08 (d, 2H), 3.06 (s, 4H), 2.78 (s, 4H), 2.19 (m, 6H), 1.96 (s, 4H), 1.79 (m, 4H), 1.39 (s, 4H), 0.93 (s, 6H).
EXAMPLE 192
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 192 A
4-((4-fluoro- 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)methoxy)-3 - nitrobenzenesulfonamide
A mixture of EXAMPLE 173 A (0.4 g), dihydro-2H-pyran-4(3H)-one (0.179 g), sodium cyanoborohydride (0.112 g), and acetic acid (0.5 mL) in tetrahydrofuran (3 mL) was stirred overnight. The solvents were removed under reduced pressure. The residue was purified with flash column chromatography on silica gel eluting with 100:5:0.5 ethyl acetate/methanol/NH4OH to give the desired product.
EXAMPLE 192B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 192A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.58 (s, IH), 8.25 (s, IH), 7.96 (d, IH), 7.93 (d, IH), 7.57 (d, IH), 7.45 (t, IH), 7.34-7.37 (m, 3H),
7.26 (d, IH), 7.05 (d, 2H), 6.64 (dd, IH), 6.34 (dd, IH), 6.23 (d, IH), 4.34 (d, 2H), 3.93 (dd, 2H), 3.03 (s, 6H), 2.76 (s, 4H), 2.09-2.22 (m, 6H), 1.96 (s, 2H), 1.52-1.27 (m, 2H), 1.39 (t,
2H), 0.93 (s, 6H).
EXAMPLE 193
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 193 A
4-((4-fluoro- 1 -(tetrahydrofuran-3 -yl)piperidin-4-yl)methoxy)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting dihydrofuran-3(2H)-one for dihydro-2H-pyran-4(3H)-one in EXAMPLE 192A.
EXAMPLE 193B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- l-tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 193 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.63 (s, IH), 8.31 (s, IH), 7.99-8.00 (m, 2H), 7.54 (d, IH), 7.46-7.48 (m, 2H), 7.34-7.35 (m, 3H), 7.05 (d2H), 6.66 (dd, IH), 6.37 (dd, IH), 6.21 (d, IH), 4.34 (d, 2H), 3.76-3.83 (m, 3H), 3.62- 3.65 (m, 2H), 3.03 (s, 4H), 2.79 (s, 4H), 2.24 (s, 2H), 2.15 (s, 2H), 1.84-1.99 (m, 8H), 1.52-
1.27 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 194
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 194 A
4-((4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl)methoxy)-3 -nitrobenzenesulfonamide A mixture of EXAMPLE 173 A (0.4 g), methanesulfonyl chloride (0.113 g), and triethylamine (0.64 mL) in dichloromethane (5 mL) was stirred overnight. The reaction mixture was loaded onto a silica gel column and eluted with 100: 1 ethyl acetate :methanol to give the clean product.
EXAMPLE 194B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-fluoro- 1 -(methylsulfonyl)piperidin-4-yl]methoxy } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 194A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1H), 8.37 (s, 1H), 8.06 (d, 1H), 8.02 (d, 1H), 7.49-7.53 (m, 3H), 7.42 (d, 1H), 7.35 (d, 2H), 7.05 (d, 2H), 6.67 (dd, 1H), 6.38-6.39 (m, 1H), 6.21 (d, 1H), 4.40 (d, 2H), 3.51-3.54 (m, 2H), 3.09 (s, 4H), 2.96-3.01 (m, 4H), 2.92 (s, 3H), 2.82 (s, 2H), 2.25-2.34 (m, 4H), 2.13-2.16 (m, 6H), 2.01-2.07 (m, 2H0, 1.99 (s, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 195
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3R)- 1 -oxetan-3-ylpyrrolidin-3-yl]methyl} amino)phenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 195 A
(R)-tert-butyl 3-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)pyrrolidine- 1 -carboxylate
The title compound was prepared by substituting (R)-tert-butyl 3- (aminomethyl)pyrrolidine-l -carboxylate for l-acetylpiperidin-4-amine in EXAMPLE 53B. EXAMPLE 195B
(S)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(pyrrolidin-3 - ylmethylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 195 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 195C
(R)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(( 1 -(oxetan-3 -yl)pyrrolidin-3 - yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 195B for tert-butyl piperazine-l-carboxylate and oxetan-3 -one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A. 1H NMR (500MHz, dimethylsulfoxide-d6) 11.67 (s, IH), 8.81 (t, IH), 8.55 (d, IH), 8.02 (d, IH), 7.79 (dd, IH), 7.50 (m, 3H), 7.35 (m, 2H), 7.04 (m, 3H), 6.67 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 4.57 (m, 2H), 4.48 (m, 2H), 3.68 (m, 2H), 3.30 (m, 2H), 3.06 (m, 4H), 2.74 (m, 3H), 2.56 (m, 3H), 2.44 (m, IH), 2.18 (m, 5H), 1.95 (m, 3H), 1.58 (m, IH), 1.36 (m, 2H), 0.94 (s, 6H).
EXAMPLE 196
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4- [(4-hydroxycyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
EXAMPLE 196A
Trans-4-(4-(tert-butyldimethylsilyloxy)cyclohexyl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared as described in EXAMPLE 12A by replacing (1,4- dioxan-2-yl)methanol with trans-(4-(tert-butyldimethylsilyloxy)cyclohexyl)methanol (made according to the procedures in WO 2008/124878). EXAMPLE 196B
Trans-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-(((lr,4r)-4-(tert- butyldimethylsilyloxy)cyclohexyl)methoxy)-3-nitrophenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzamide The title compound was prepared as described in EXAMPLE 1G using EXAMPLE 196A in place of EXAMPLE IF and EXAMPLE 3J in place of EXAMPLE IE. EXAMPLE 196C
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4- [(4-hydroxycyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
EXAMPLE 196B (150 mg) in dichloromethane (5 mL) and methanol (2 mL) was treated with 10% aqueous HC1 (3 mL) for 1 hour and concentrated. The residue was purified by reverse phase HPLC on a CI 8 column using a gradient of 40-60% acetonitrile in 0.1% trifluoroacetic acid water to give the title compound as a trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (30 mL) and washed with 50%> aqueous NaHC03. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.69 (s, 1H), 11.27 (s, 1H), 8.34 (d, 1H), 7.95 - 8.08 (m, 2H), 7.47 - 7.55 (m, 3H), 7.32 - 7.40 (m, 3H), 7.01 - 7.07 (m, 2H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.20 (d, 1H), 4.54 (d, 1H), 3.96 - 4.06 (m, 2H), 3.10 (s, 4H), 2.84 (s, 2H), 2.05 - 2.39 (m, 6H), 1.96 (s, 2H), 1.46 - 1.93 (m, 5H), 1.39 (t, 2H), 0.98 - 1.29 (m, 4H), 0.92 (s, 6H)
EXAMPLE 197
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4- [3 -(dimethylamino)propoxy]benzyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 197A
3 -(4-(aminomethyl)phenoxy)-N,N-dimethylpropan- 1 -amine 4-(3-(Dimethylamino)propoxy)benzonitrile (300 mg) in methanol (20 mL) was treated with Raney nickel (wet, 1.5 g) under H2 (30 psi) for 4 hour. The insoluble material was filtered off and the filtrate was concentrated to provide the title compound.
EXAMPLE 197B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4- [3 -(dimethylamino)propoxy]benzyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
The title compound was prepared as described in EXAMPLE 120B using EXAMPLE 197A in place of EXAMPLE 120A. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.56 (s, 1H), 8.80 (t, 1H), 8.42 (d, 1H), 7.93 (d, 1H), 7.52 - 7.61 (m, 2H), 7.41 - 7.47 (m, 1H), 7.26 - 7.36 (m, 5H), 7.03 - 7.08 (m, 2H), 6.89 (d, 2H), 6.73 (d, IH), 6.61 (dd, IH), 6.31 (dd, IH), 6.22 (d, IH), 4.52 (d, 2H), 3.99 (t, 2H), 2.90 - 3.05 (m, 7H), 2.72 (s, 2H), 2.61 (s, 6H), 2.09 - 2.24 (m, 6H), 1.89 - 2.04 (m, 5H), 1.38 (t, 2H), 0.92 (s, 6H)
EXAMPLE 198
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 198 A
(4-(2-morpholinoethoxy)phenyl)methanamine
The title compound was prepared as described in EXAMPLE 197A using 4-(2- morpholinoethoxy)benzonitrile in place of 4-(3-(dimethylamino)propoxy)benzonitrile.
EXAMPLE 198B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(2-morpholin-4-ylethoxy)benzyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 120B using EXAMPLE 198 A in place of EXAMPLE 120A. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 1 1.69 (s, IH), 9.00 (t, IH), 8.56 (d, IH), 8.02 (d, IH), 7.72 (dd, IH), 7.46 - 7.54 (m, 3H), 7.27 - 7.36 (m, 4H), 7.01 - 7.07 (m, 2H), 6.89 - 6.95 (m, 3H), 6.66 (dd, IH), 6.38 (dd, IH), 6.18 (d, IH), 4.56 (d, 2H), 4.07 (t, 2H), 3.54 - 3.61 (m, 4H), 3.06 (s, 4H), 2.71 - 2.78 (m, 4H), 2.07 - 2.24 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 199
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 199A
4-[((E)-4-Hydroxy-adamantan-l-ylmethyl)-amino]-3-nitro-benzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonamide (0.5 g) and 5-(aminomethyl)adamantan-2-ol (0.6 g) in tetrahydrofuran (10 mL) were treated with triethylamine (1 mL) overnight. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC, eluting 40- 60% acetonitrile in 0.1 trif uoroacetic acid water to give two isomers, which were temporarily assigned as EXAMPLE 199 A and EXAMPLE 199B, respectively.
EXAMPLE 199B
4-[((Z)-4-Hydroxy-adamantan-l-ylmethyl)-amino]-3-nitro-benzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonamide (0.5 g) and 5-(aminomethyl)adamantan-2-ol (0.6 g) in tetrahydrofuran (10 mL) were treated with triethylamine (1 mL) overnight. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC, eluting 40- 60% acetonitrile in 0.1 trifluoroacetic acid water to give two isomers, which were temporarily assigned as EXAMPLE 199A and EXAMPLE 199B, respectively. EXAMPLE 199C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyljsulfonyl} -2-(l H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 199A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 1 1.68 (s, IH), 1 1.40 (s, IH), 8.55 (d, IH), 8.50 (t, IH), 8.03 (d, IH), 7.77 (dd, IH), 7.46 - 7.54 (m, 3H), 7.31 - 7.38 (m, 2H), 7.14 (d, IH), 7.01 - 7.06 (m, 2H), 6.68 (dd, IH), 6.38 (dd, IH), 6.19 (d, IH), 4.61 (d, IH), 3.63 (d, IH), 3.02 - 3.16 (m, 6H), 2.75 (s, 2H), 2.17 (d, 6H), 2.04 (d, 2H), 1.95 (s, 2H), 1.76 - 1.88 (m, 3H), 1.49 - 1.61 (m, 6H), 1.38 (t, 2H), 1.29 (d, 2H), 0.92 (s, 6H).
EXAMPLE 200
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {[(Z)-4-hydroxy- 1 -adamantyljmethyl} amino)-3-nitrophenyl]sulfonyl} -2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE
199B in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 1 1.39 (s, IH), 8.55 (d, IH), 8.51 (t, IH), 8.04 (d, IH), 7.77 (dd, IH), 7.46 - 7.55 (m, 3H), 7.31 - 7.37 (m, 2H), 7.14 (d, IH), 7.01 - 7.06 (m, 2H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 4.61 (d, IH), 3.61 (d, IH), 3.08 (d, 6H), 2.75 (s, 2H), 2.17 (d, 6H), 1.79 - 7H), 1.55 - 1.69 (m, 4H), 1.49 (s, 2H), 1.38 (t, 2H), 1.22 (d, 2H), 0.92 (s, 6H).
EXAMPLE 201
N-({4 (lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 201 A
4-((lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)-3-nitrobenzenesulfonamide The title compound was prepared as described in EXAMPLE 12A by replacing dioxan-2-yl)methanol with (lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethanol.
EXAMPLE 20 IB
N-({4-[(lS,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 201 A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.35 (d, IH), 7.95 - 8.10 (m, 2H), 7.47 - 7.58 (m, 3H), 7.30 - 7.45 (m, 3H), 7.04 (d, 2H), 6.68 (dd, IH), 6.40 (d, IH), 5.92 - 6.23 (m, 3H), 3.65 - 4.39 (m, 3H), 3.00 - 3.22 (m, 4H), 2.76 - 2.98 (m, 4H), 2.28 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.71 - 1.91 (m, IH), 1.33 - 1.47 (m, 3H), 1.20 - 1.32 (m, 2H), 0.92 (s, 6H), 0.50 - 0.66 (m, IH). EXAMPLE 202
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -methyl-5 -oxopyrrolidin-3 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 82 (140 mg) was dissolved in dioxane (3.0 mL), and 4-amino-l- methylpyrrolidin-2-one hydrochloride (30 mg) and triethylamine (0.100 mL) were added. The reaction mixture was heated at 110°C for 40 hours. The reaction was concentrated and the crude material was purified by preparative HPLC using a CI 8 column, 250 x 50 mm, 10μ, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHC03. The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. 1H NMR (400 MHz, dimethylsulfoxide- d6) δ 11.65 (s, 1H), 8.74 (d, 1H), 8.37 (br d, 1H), 8.02 (d, 1H), 7.83 (dd, 1H), 7.49 (m, 3H), 7.34 (d, 2H), 7.07 (d, 1H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.38 (m, 1H), 6.21 (d, 1H), 4.46 (m, 1H), 3.81 (dd, 1H), 3.38 (dd, 1H), 3.08 (br m, 4H), 2.82 (dd, 1H), 2.75 (s, 5H), 2.43 (dd, 1H), 2.21 (br m, 4H), 2.16 (br t, 2H), 1.95 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 203
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 203A
4-(((lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]heptan-2-yl)methoxy)-3- nitrobenzenesulfonamide
To a solution of EXAMPLE 201A (340 mg) in tetrahydrofuran (10 mL) and water (1 mL) was added N-methylmorpholine N-oxide (184 mg) and Os04 (2.5% in 2-methyl-2- propanol) (1.05 mL). The reaction mixture was stirred overnight and purified by reverse phase HPLC to provide two isomers, which were temporarily assigned as EXAMPLE 203 A and E AMPLE 203B, respectively.
EXAMPLE 203B
4-(((lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]heptan-2-yl)methoxy)-3- nitrobenzenesulfonamide
To a solution of EXAMPLE 201A (340 mg) in tetrahydrofuran (10 mL) and water (1 mL) was added N-methylmorpholine N-oxide (184 mg) and Os04 (2.5% in 2-methyl-2- propanol) (1.05 mL). The reaction mixture was stirred overnight and purified by reverse phase HPLC to provide two isomers, which were temporarily assigned as EXAMPLE 203 A and E AMPLE 203B, respectively. EXAMPLE 203C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 203A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.33 (s, IH), 7.97 - 8.07 (m, 2H), 7.48 - 7.55 (m, 3H), 7.41 (d, IH), 7.32 - 7.37 (m, 2H), 7.02 - 7.07 (m, 2H), 6.67 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.58 (dd, 2H), 4.07 - 4.19 (m, 2H), 3.82 (t, IH), 3.51 (t, IH), 3.09 (s, 4H), 2.81 (s, 2H), 2.09 - 2.34 (m, 8H), 2.04 - 2.09 (m, 2H), 1.93 - 2.01 (m, 3H), 1.62 - 1.77 (m, 2H), 1.39 (t, 2H), 1.11 (d, IH), 0.92 (s, 6H), 0.67 - 0.76 (m, IH).
EXAMPLE 204
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 203B in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.33 (s, IH), 7.98 - 8.07 (m, 2H), 7.49 - 7.54 (m, 3H), 7.41 (d, IH), 7.32 - 7.36 (m, 2H), 7.02 - 7.07 (m, 2H), 6.67 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.58 (dd, 2H), 4.13 (dd, 2H), 3.82 (t, IH), 3.51 (t, IH), 3.09 (s, 4H), 2.81 (s, 2H), 2.09 - 2.35 (m, 8H), 2.07 (s, 2H), 1.93 - 2.02 (m, 3H), 1.61 - 1.80 (m, 2H), 1.39 (t, 2H), 1.11 (d, IH), 0.92 (s, 6H), 0.66 - 0.78 (m, IH). EXAMPLE 205
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide EXAMPLE 205A
Methyl 1 ,4-dioxaspiro[4.5]decane-7-carboxylate
To a solution of trimethylsilyltrifluoromethanesulfonate (0.034 mL) in dry
dichloromethane (5 mL) was added 1 ,2-bis(trimethylsiloxy)ethane (4.55 mL) followed by methyl 3-oxocyclohexanecarboxylate (2.9 g). The reaction mixture was stirred for 3 hours at -78 °C. The reaction mixture was quenched with dry pyridine (0.5 mL), poured into saturated aqueous NaHC03, and extracted with ether. The ether layer was dried over Na2C03 / Na2S04. The reaction mixture was concentrated and purified by flash chromatography on silica with 5 to 30% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 205B
1 ,4-dioxaspiro [4.5] decan-7-ylmethanol
The title compound was prepared by substituting EXAMPLE 205 A for EXAMPLE in EXAMPLE 101D.
EXAMPLE 205C
3-nitro-4-((3-oxocyclohexyl)methoxy)benzenesulfonamide Into a 250 mL round-bottomed flask was added sodium hydride (0.5 g) in
tetrahydrofuran (10 mL) and then l,4-dioxaspiro[4.5]decan-7-ylmethanol (0.5 g) was added. After the mixture stirred at room temperature for 20 minutes, 4-fluoro-3- nitrobenzenesulfonamide (0.65 g) was added. The mixture was stirred at room temperature for overnight. Water (20 mL) was added slowly. The aqueous layer was extracted by dichloromethane (3x 20 mL). The combined organic layers were dried over Na2S04. After filtration, and concentration of the filtrate, the residue was purified by reverse phase chromatography, eluting with 30-60% acetonitrile in water with 0.1% trifluoroacetic acid.
EXAMPLE 205D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 205 C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.59 (s, 1H), 8.22 (s, 1H), 7.96 (d, 1H), 7.87 (m, 1H), 7.55 (d, 1H), 7.45 (t, 1H), 7.35 (m, 3H), 7.20 (m, 1H), 7.04 (d, 2H), 6.64 (dd, 1H), 6.34 (m, 1H), 6.23 (d, 1H), 4.07 (d, 2H), 3.04 (m, 4H), 2.76 (s, 2H), 2.35 (m, 2H), 2.20 (m, 8H), 1.96 (m, 4H), 1.58 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 206
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3-dien-l-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 206A
2-chloro-5,5-dimethylcyclohexa-l,3-dienecarbaldehyde In a 250 mL round-bottomed flask was added N,N-dimethylformamide (3.5 mL) in dichloromethane (30 mL), and the mixture was cooled to -10 °C. Phosphoryl trichloride (4 mL) was added dropwise, and the solution was warmed up to room temperature. 4,4- Dimethylcyclohex-2-enone (5.5 mL) was then added slowly, and the mixture was heated to reflux overnight. The reaction mixture was cooled and quenched with a 0°C solution of sodium acetate (25 g in 50 mL water). The aqueous layer was extracted with diethyl ether (200 mL x3). The combined organic layers were dried over Na2S04, filtered, and
concentrated to give the product.
EXAMPLE 206B
2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3-dienecarbaldehyde Into a 1 L round-bottomed flask was added EXAMPLE 206 A (6.8 g), 4- chlorophenylboronic acid (6.5 g), and palladium (II) acetate (0.2 g) in water (100 mL) to give a suspension. Potassium carbonate (15 g) and tetrabutylammonium bromide (10 g) were added. After degassing, the mixture was stirred at 45°C for 4 hours. After cooling and filtering though silica gel in a funnel, diethyl ether (4x 200mL) was used to extract the product. The combined organic layers were dried over Na2S04, and filtered. The filtrate was concentrated and purified by flash chromatography on silica with 0-10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 206C
Methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- dimethylcyclohexa- 1 ,3-dienyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 206B for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 15F for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A. EXAMPLE 206D
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3- dienyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 206C for EXAMPLE 101E in EXAMPLE 101F.
EXAMPLE 206E
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3-dien-l-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 206D for EXAMPLE 3 J and EXAMPLE IF for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 1 1.61 (s, IH), 8.49 (m, 2H), 7.99 (m, IH), 7.72 (m, IH), 7.53 (d, IH), 7.41 (m, 4H), 7.12 (d, 2H), 6.99 (m, IH), 6.66 (dd, IH), 6.35 (m, IH), 6.23 (d, IH), 5.74 (d, IH), 5.58 (d, IH), 3.84 (m, 2H), 3.26 (m, 4H), 3.06 (m, 4H), 2.88 (s, 2H), 2.24 (m, 6H), 1.61 (m, 2H), 1.26 (m, 3H), 1.00 (s, 6H).
EXAMPLE 207
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 207A
(R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-amine
The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl azetidin-3-ylcarbamate in EXAMPLE 151 A.
EXAMPLE 207B
(R)-4-( 1 -(1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 207A for EXAMPLE 151A in EXAMPLE 15 IB. EXAMPLE 207C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {(3R)- 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} -2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 207B for EXAMPLE
IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.67 (s, IH), 11.52 - 11.24 (m, IH), 8.55 (d, IH), 8.37 (d, IH), 8.03 (d, IH), 7.83 (dd, IH), 7.57 - 7.45 (m, 3H), 7.34 (d, 2H), 7.06 (t, 3H), 6.67 (d, IH), 6.38 (dd, IH), 6.20 (d, IH), 4.70 (d, 2H), 4.54 (d, 2H), 4.23 (s, IH), 3.11 - 2.87 (m, 7H), 2.74 (dd, 4H), 2.35 - 2.13 (m, 7H), 1.95 (s, 2H), 1.70 (s, IH), 1.39 (d, 2H), 0.92 (s, 6H).
EXAMPLE 208
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 208A
2-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-5-iodo-3-(trifluoromethyl)pyridine A mixture of EXAMPLE 37C (0.537 g), 5-iodo-3-(trifiuoromethyl)pyridin-2-ol (1.156 g), and triphenylphosphine (1.574 g) in tetrahydrofuran (20 mL) was cooled to 0 ° C. To this solution was added (E)-di-tert-butyl diazene-l,2-dicarboxylate (0.921 g). The reaction mixture was stirred overnight. The solvent was removed, and the residue was purified with column flash chromatography on silica gel eluting with 4: 1 hexanes/ethyl acetate to give the desired product.
EXAMPLE 208B
6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonamide EXAMPLE 207A (1.3 g) in tetrahydrofuran (10 mL) was cooled to -42 °C with a cold bath of CH3CN/dry ice. To this solution was added 2.0 M isopropylmagnesium chloride (1.6 mL) dropwise over 5 minutes. The reaction mixture was stirred for 30 minutes at -42 ° C, then allowed to warm to 0 ° C over 10 minutes. The reaction mixture was cooled again to -42 ° C, and S02 was bubbled though it for 10 minutes. The reaction mixture was stirred for another 30 minutes. To this solution was sulfuryl dichloride (0.433 g). On warming to room temperature, concentrated NH4OH (10 mL) was added and the reaction mixture was stirred for another 2 hours. The reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel eluting with 3 : 1 hexanes/ ethyl acetate to give the title compound.
EXAMPLE 208C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 208B for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.61 (s, 1H), 8.72 (s, 1H), 8.36 (s, 1H), 7.98 (d, 1H), 7.55 (d, 1H), 7.42-7.47 (m, 2H), 7.36 (d, 2H), 7.05 (d, 2H), 6.66 (dd, 1H), 6.35 (s, 1H), 6.23 (s, 1H), 4.56 (d, 2H), 3.75-3.79 (m, 2H), 3.56- 3.61 (m, 2H), 3.09 (s, 4H), 2.32-2.37 (m, 2H), 2.16(s, 2H), 1.97-1.99 (m, 2H), 1.79-1.86 (m, 4H), 1.40 (t, 2H), 0.93 (s, 6H).
EXAMPLE 209
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 209A
(S)-tert-butyl ( 1 -(oxetan-3 -yl)pyrrolidin-3 -yl)methylcarbamate The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylmethylcarbamate for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'- chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1 A.
EXAMPLE 209B
(S)-( 1 -(oxetan-3 -yl)pyrrolidin-3 -yl)methanamine
The title compound was prepared by substituting EXAMPLE 209A for (S)-l -tert- butyl 2-methyl 4,4-difluoropyrrolidine-l,2-dicarboxylate in EXAMPLE 168 A. EXAMPLE 209C
(S)-3-nitro-4-((l-(oxetan-3-yl)pyrrolidin-3-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-nitrobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide and EXAMPLE 209B for 4-methylpiperazin-l- amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 209D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 209C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.05 (s, IH), 9.30 (d, IH), 9.02 (t, IH), 8.42 (d, IH), 8.34 (dd, IH), 8.10 (d, IH), 7.67 (dd, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.82 (d, IH), 6.75 (m, IH), 6.52 (m, 2H), 4.82 (t, IH), 4.75 (t, IH), 4.67 (t, 2H), 3.57 (m, IH), 3.24 (t, 2H), 3.07 (m, 4H), 2.75 (m, 3H), 2.57 (dd, IH), 2.45 (s, IH), 2.36 (t, IH), 2.26 (s, 2H), 2.18 (m, 5H), 1.93 (m, 3H), 1.56 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 210
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 21 OA
(4-methoxycyclohexyl)methanol
The title compound was prepared by substituting 4-methoxycyclohexanecarboxylic acid for 1-tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate in EXAMPLE 126 A.
EXAMPLE 210B
Trans-5-chloro-6-((4-methoxycyclohexyl)methoxy)pyridine-3-sulfonamide
The title compound was prepared by substituting EXAMPLE 21 OA for tetrahydro- 2H-pyran-4-yl)methanol and EXAMPLE 40 A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A. EXAMPLE 2 IOC
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 2 IOC for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.50 (s, 1H), 8.17 (s, 1H), 8.02 (d, 1H), 7.49-7.54 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H),
6.67 (dd, J 1H), 6.39 (s, 1H), 6.21 (s, 1H), 4.20 (d, 2H), 3.23 (s, 3H), 3.06-3.09 (m, 4H), 2.15- 2.37 (m, 4H), 1.96-2.03 (m, 4H), 1.74-1.84 (m, 2H), 1.40 (t, 2H), 1.04-1.13 (m, 4H), 0.93 (s, 6H).
EXAMPLE 211
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 211 A
Cis-5-chloro-6-((4-methoxycyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was isolated as a by-product in the synthesis of EXAMPLE 210B.
EXAMPLE 21 IB
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 211 A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.51 (s, 1H), 8.17 (s, 1H), 8.03 (d, 1H), 7.49-7.54 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H),
6.68 (dd, 1H), 6.39 (s, 1H), 6.21 (s, 1H), 4.21 (d, 2H), 3.20 (s, 3H), 3.06 (s, 4H), 2.15-2.37 (m, 4H), 1.96 (s, 2H), 1.80-1.84 (m, 2H), 1.50-1.54 (m, 2H), 1.34-1.44 (m, 6H), 0.93 (s, 6H). EXAMPLE 212
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 212A
(S)-tert-butyl 1 -(oxetan-3 -yl)pyrrolidin-3 -ylcarbamate The title compound was prepared by substituting (S)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2- carboxaldehyde in EXAMPLE 1 A.
EXAMPLE 212B
(S)-l -(oxetan-3 -yl)pyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 212A for (S)-l -tert- butyl 2-methyl 4,4-difluoropyrrolidine-l,2-dicarboxylate in EXAMPLE 168 A.
EXAMPLE 212C
(S)-3-nitro-4-(l -(oxetan-3 -yl)pyrrolidin-3-ylamino)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-nitrobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide and EXAMPLE 212B for 4-methylpiperazin-l- amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 212D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 212C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.03 (s, IH), 9.27 (d, IH), 8.58 (d, IH), 8.42 (d, IH), 8.37 (dd, IH), 8.09 (d, IH), 7.67 (t, IH), 7.64 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.86 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (dd, IH), 4.67 (m, 4H), 4.09 (m, IH), 3.59 (m, IH), 3.07 (m, 4H), 2.77 (s, 2H), 2.69 (m, 2H), 2.62 (dd, IH), 2.28 (m, 4H), 2.14 (m, 4H), 1.97 (s, 2H), 1.68 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 213
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 213A
4-((4-(2-(2-methoxyethoxy)ethyl)morpholin-2-yl)m
The title compound was prepared by substituting 2-(2'-methoxyethoxy)ethyl bromide for methyl iodide in EXAMPLE 134B.
EXAMPLE 213B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 213A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.98 (s, IH), 9.26 (d, IH), 8.87 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.96-3.86 (m, 2H),3.72 (dd, IH), 3.67-3.61 (m, 4H), 3.51 (t, 2H), 3.48-3.38 (m, 2H), 3.28 (s, 3H), 3.07 (m, 4H), 2.95 (d, IH), 2.77 (s, 2H), 2.70 (m, IH), 2.60 (t, 2H), 2.30-2.05 (m, 8H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 214
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 214A
4-((4-(cyanomethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2-bromoacetonitrile for methyl iodide in EXAMPLE 134B. EXAMPLE 214B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 214A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.01 (s, IH), 9.26 (d, IH), 8.86 (t, IH), 8.43 (d, IH), 8.35 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.93 (m, 1H),3.87 (d, IH), 3.77 (s, 2H), 3.65 (dt, IH), 3.51-3.40 (m, 2H), 3.07 (m, 4H), 2.87 (d, IH), 2.77 (s, 2H), 2.60 (d, IH), 2.50 (m, IH), 2.38 (t, IH), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 215
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfo
pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 215A
4-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfo
The title compound was prepared by substituting 2-dimethylaminoacetyl chloride hydrochloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 215B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 215A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.27 (d, IH), 8.87 (bs, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.10 (dd, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (dd, IH), 6.75 (d, IH), 6.54 (s, IH), 6.48 (s, IH), 4.55 (dd, IH), 4.20 (dd, IH), 3.95-3.76 (m, 2H),3.60-3.40 (m, 3H),3.32 (dd, IH), 3.25-3.12 (m, 2H), 3.07 (m, 4H), 2.80 (m, IH), 2.77 (s, 2H), 2.26 (s, 6H), 2.23 (s, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 216
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid
EXAMPLE 216A
tert-butyl 2-(2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholino)acetate
The title compound was prepared by substituting tert-butyl 2-bromoacetate for methyl iodide in EXAMPLE 134B.
EXAMPLE 216B
tert-butyl 2-(2-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)methyl)morpholino)acetate
The title compound was prepared by substituting EXAMPLE 216A for EXAMPLE 130C in EXAMPLE 130D.
EXAMPLE 216C
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid The title compound was prepared by treating EXAMPLE 216B with 50%
trifluoroacetic acid in dichloromethane. 1H NMR (500MHz, pyridine-ds) δ 12.97 (s, IH), 9.26 (d, IH), 8.87 (t, IH), 8.43 (d, IH), 8.30 (dd, IH), 8.12 (d, IH), 7.69 (t, IH), 7.64 (d, IH), 7.43 (d, 2H), 7.08 (d, 2H), 6.88 (d, IH), 6.76 (dd, IH), 6.55 (d, IH), 6.47 (m, IH), 4.05-4.00 (m, 1H),3.91 (d, IH), 3.79 (dt, IH), 3.50 (s, 2H), 3.45 (m, 2H), 3.13 (d, IH), 3.07 (m, 4H), 2.88 (d, IH), 2.78 (s, 2H), 2.57 (dt, IH), 2.43 (t, IH), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 217
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2^
b]pyridin-5 -yloxy)benzamide
EXAMPLE 217A
The title compound was prepared by substituting EXAMPLE 134A for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 217B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 217A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.87 (t, IH), 8.44 (d, IH), 8.34 (dd, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.64 (m, 4H), 3.93 (m, 1H),3.89 (d, IH), 3.68 (dt, IH), 3.53-3.35 (m, 3H), 3.07 (m, 4H), 2.77 (s, 2H), 2.72 (d, IH), 2.44 (d, IH), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.85 (t, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 218
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 218A
4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 134A for EXAMPLE in EXAMPLE 173B. EXAMPLE 218B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 218 A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, 1H), 9.26 (d, 1H), 8.88 (t, 1H), 8.44 (d, 1H), 8.34 (dd, 1H), 8.12 (d, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (d, 1H), 6.75 (dd, 1H), 6.54 (d, 1H), 6.48 (m, 1H), 3.88 (d, 1H), 3.84-3.81 (m, 1H),3.59 (dt, 1H), 3.50-3.40 (m, 2H), 3.07 (m, 4H), 2.93 (d, 1H), 2.77 (s, 2H), 2.69 (d, 1H), 2.34 (dt, 1H), 2.26 (m, 2H), 2.21 (t, 1H), 2.14 (m, 4H), 1.97 (s, 2H), 1.58 (m, 1H), 1.39 (t, 2H), 0.94 (s, 6H), 0.45-0.39 (m, 4H).
EXAMPLE 219
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 219A
5-(methylthio)-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide A mixture of EXAMPLE 36B (0.1 g) and sodium methanethiolate (0.04 g) in N,N- dimethylformamide (2 mL) was heated at 80°C overnight. After cooling, the reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 10-50% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 219B
5-(methylsulfonyl)-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide A mixture of EXAMPLE 219A (0.15 g) and 75% meta-chloroperoxybenzoic acid
(0.217 g) in chloroform (4 mL) was stirred at room temperature. The reaction mixture was stirred overnight. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgSC^, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 10-50% ethyl acetate in hexanes to provide the title compound. EXAMPLE 219C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- (methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 219B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.65 (s, IH), 8.81 (s, IH), 8.55 (d, IH), 8.01 (d, IH), 7.55 (d, IH), 7.49-7.50 (m, 2H), 7.37 (d, 2H), 7.05 (d, 2H), 6.67 (dd, IH), 6.38 (dd, IH), 6.21 (d, IH), 4.36 (d, 2H), 3.88 (dd, 2H), 3.13 (s, 4H), 2.95 (s, 2H), 2.36-2.38 (m, 2H), 2.03-2.16 (m, 4H), 1.97 (s, 3H), 1.66-1.69 (m, 2H), 1.38-1.402 (m, 4H), 0.93 (s, 6H).
EXAMPLE 220
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 220A
4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3- (trifluoromethylsulfonyl)benzenesulfonamide
To a solution of EXAMPLE 37C (0.500 g) in tetrahydrofuran (5 mL) was added sodium hydride (0.596 g). Additional tetrahydrofuran (25 mL) was added and the mixture stirred for 30 minutes, then 4-fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide (1.145 g) was added as a solution in tetrahydrofuran (5 mL). After stirring for 2 hours, the reaction mixture was partioned between IN aqueous HC1 (50 mL) and dichloromethane (200 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. The resulting solid was chromatographed over silica gel (Reveleris 80g) eluting with a gradient of 0.5% to 7.5% methanol/dichloromethane over 30 minutes (flow = 40 mL/min) to provide the title compound. EXAMPLE 220B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 220A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.66 (s, IH), 8.42 (s, IH), 8.35 - 8.22 (m, IH), 8.01 (s, IH), 7.49 (d, 4H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (s, IH), 6.38 (s, IH), 6.21 (s, IH), 4.42 (d, 2H), 3.76 (s, 2H), 3.59 (s, 2H), 3.10 (s, 6H), 2.15 (s, 6H), 2.02 - 1.74 (m, 6H), 1.40 (s, 2H), 0.93 (s, 6H).
EXAMPLE 221
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 221 A
4-((4-methyltetrahydro-2H-pyran-4-yl)methoxy)-3-nitrobenzenesulfonamide
The title compound was prepared by substituting (4-methyltetrahydro-2H-pyran-4- yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 22 IB
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 221 A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.36 (s, IH), 8.04-8.06 (m, 2H), 7.50-7.53 (m, 3H), 7.41 (d, IH), 7.35 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.00 (s, 2H), 3.63-3.67 (m, 2H), 3.53-3.58 (m, 2H), 3.09 (s, 4H), 2.82 (s, 2H), 2.27 (s, 2H), 2.15 (s, 2H), 1.58-1.63 (m, 2H), 1.39 (t, 2H), 1.30-1.34 (m, 2H), 1.09 (s, 3H), 0.92 (s, 6H). EXAMPLE 222
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)piperazine- 1 - carboxylate
EXAMPLE 222A
ethyl 4-(2-nitro-4-sulfamoylphenyl)piperazine- 1 -carboxylate The title compound was prepared by substituting ethyl piperazine-1 -carboxylate for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 222B
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2 -nitrophenyl)piperazine- 1 - carboxylate
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 222A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 11.52 (br. s, IH), 8.08 (d, IH), 7.89 (d, IH), 7.59 (m, 2H), 7.43 (t, IH), 7.35 (d, 2H), 7.23 (d, IH), 7.05 (d, 2H), 6.94 (d, IH), 6.63 (dd, IH), 6.29 (m, 2H), 4.07 (q, 2H), 3.47 (m, 4H), 3.17 (d, 2H), 3.00 (m, 8H), 2.73 (s, 2H), 2.18 (m, 6H), 1.96 (s, 2H), 1.39 (t, 2H), 1.20 (t, 3H), 0.93 (s, 6H).
EXAMPLE 223
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4- (morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 223A
The title compound was prepared by substituting 4-(piperidin-4-yl)morpholine for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 223B
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[4- (morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyri^
yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 223A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (500 MHz, dimethylsulfoxide-de) δ 11.53 (br. s, IH), 8.05 (d, IH), 7.91 (d, IH), 7.58 (m, 2H), 7.43 (t, IH), 7.35 (d, 2H), 7.26 (d, IH), 7.05 (d, 2H), 6.91 (d, IH), 6.62 (dd, IH), 6.29 (m, 2H), 5.76 (s, IH), 3.57 (m, 4H), 3.20 (m, 2H), 3.01 (m, 4H), 2.80 (t, 2H), 2.73 (s, 2H), 2.47 (m, 4H), 2.32 (m, IH), 2.18 (m, 6H), 1.96 (m, 3H), 1.82 (m, 2H), 1.44 (m, 4H), 0.93 (s, 6H).
EXAMPLE 224
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 224A
(R)-tert-butyl 1 -(oxetan-3 -yl)pyrrolidin-3 -ylcarbamate The title compound was prepared by substituting (R)-tert-butyl pyrrolidin-3- ylcarbamate for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2- carboxaldehyde in EXAMPLE 1 A.
EXAMPLE 224B
(R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -amine
The title compound was prepared by substituting EXAMPLE 224A for (S)-l -tert- butyl 2-methyl 4,4-difluoropyrrolidine-l,2-dicarboxylate in EXAMPLE 168 A.
EXAMPLE 224C
(R)-3 -nitro-4-( 1 -(oxetan-3 -yl)pyrrolidin-3 -ylamino)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-nitrobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide and EXAMPLE 224B for 4-methylpiperazin-l- amine dihydrochloride in EXAMPLE 6A. XAMPLE224D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [(3R)- 1 -(oxetan-3 -yl)pyrrolidin-3 -yljamino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 224C for EXAMPLE
1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.03 (s, IH), 9.26 (d, IH), 8.57 (d, IH), 8.42 (d, IH), 8.36 (dd, IH), 8.09 (d, IH), 7.66 (m, IH), 7.64 (d, IH), 7.44 (m, 2H), 7.07 (m, 2H), 6.86 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (dd, IH), 4.67 (m, 4H), 3.58 (m, IH), 3.07 (m, 4H), 2.77 (m, 2H), 2.68 (m, 2H), 2.61 (m, IH), 2.28 (m, 4H), 2.14 (m, 4H), 1.97 (m, 2H), 1.67 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 225
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3-
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 225A
(Pv)-4-( 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -ylamino)-3 - (trifluoromethylsulfonyl)benzenesulfonamide
To EXAMPLE 207A (0.217 g) and 4-fluoro-3- (trifluoromethylsulfonyl)benzenesulfonamide (0.281 g) in tetrahydrofuran (5 mL) was added diisopropylethylamine (0.559 mL) and the reaction was allowed to stir at room temperature for 1 hour and was then heated to 50°C for 1 hour. The reaction was concentrated, the residue was loaded onto silica gel (Reveleris 40 g) and eluted with a gradient of 0.75% methanol/dichloromethane to 7.5% methanol/dichloromethane to provide the title compound.
EXAMPLE 225B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yljamino } -3 -
[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 225A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.69 (s, 1H), 11.52 - 11.23 (m, 1H), 8.17 (d, 1H), 8.04 (d, 1H), 7.95 (d, 1H), 7.54 (d, 1H), 7.53 - 7.50 (m, 1H), 7.48 (d, 1H), 7.34 (d, 2H), 7.10 - 6.97 (m, 4H), 6.67 (d, 1H), 6.40 (dd, 1H), 6.18 (d, 1H), 4.60 (dd, 4H), 4.20 (s, 1H), 3.11 - 2.63 (m, 12H), 2.19 (d, 6H), 1.95 (s, 2H), 1.58 (s, 1H), 1.40 (d, 2H), 0.92 (s, 6H).
EXAMPLE 226
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -isopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 226A
tert-butyl 4-(4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)piperidine- 1 -carboxylate
To a solution of EXAMPLE 82 (800 mg) and tert-butyl 4-aminopiperidine-l- carboxylate (203 mg) in dioxane (10 mL) was added Hunig's Base (1 mL). The mixture was stirred at 120°C overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with water, brine and dried over Na2SC"4. After filtration and evaporation of solvent, the residue was loaded on a silica gel cartridge and eluted with 3% methanol in dichloromethane to give the title compound.
EXAMPLE 226B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(piperidin-4-ylamino)phenylsulfonyl)benzamide To a solution of EXAMPLE 226 A (902 mg) in dichloromethane (10 mL) was added trifluoroacetic acid (5 mL). The mixture was stirred at room temperature for 3 hours. The mixture was concentrated under vacuum and co-concentrated with dichloromethane twice to afford the crude product which was used in the next step without further purification. EXAMPLE 226C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [( 1 -isopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide To a solution of EXAMPLE 226B (79 mg) in tetrahydrofuran (3 mL) and acetic acid (1 mL) was added acetone (54 mg) and MP-cyanoborohydride (150 mg, 2.25mmol/g). The mixture was stirred overnight. The mixture was filtered. The filtrate was concentrated and the residue was loaded on a silica gel cartridge and eluted with 5 to 10% 7N NH3 in methanol in dichloromethane to provide the title compound. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 12.09 (s, 1 H), 8.34 (m, 1 H), 7.93 (m, 2 H), 7.66 (m, 4 H), 7.35 (d, 2 H), 7.06 (d, 2 H), 6.89 (m, 1 H), 6.74 (dd, 1 H), 6.59 (dd, 1 H), 6.50 (d, 1 H), 3.11 (m, 6 H), 2.73 (m, 4 H), 2.26 (m, 9 H), 1.97 (s, 3 H), 1.40 (t, 2 H), 1.23 (s, 8 H), 0.94 (s, 6 H).
EXAMPLE 227
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 227A
1 -tert-butylpiperidin-4-amine
To a solution of l-tert-butylpiperidin-4-one (5.0 g) in methanol (100 mL) and water (10 mL) was added ammonium formate (20.3 g) and 0.5 g of Pd/C (10%>). The mixture was stirred overnight. The mixture was filtered and the filtrate was concentrated under vacuum and the residue was diluted with ethyl acetate (500 mL) and washed with water and brine. After drying over Na2S04 and filtration, the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 227B
4-( 1 -tert-butylpiperidin-4-ylamino)-3 -nitrobenzenesulfonamide
To a mixture of 4-fluoro-3 -nitrobenzenesulfonamide (2.2 g) and EXAMPLE 227 A (1.56 g) in tetrahydrofuran (20 mL) was added Hunig's Base (6 mL). The mixture was stirred for 3 days. The mixture was diluted with ethyl acetate (300 mL) and water (100 mL) and stirred until the solid disappeared into the solution. The layers were separated and the organic phase was washed with water and brine, dried over Na2S04, and filtered. The combined aqueous layers were extracted again with ethyl acetate and the combined organic phases were dried over Na2S04. After filtration, the solvent was evaporated to provide the title compound. EXAMPLE 227C
N-({4-[(l-tert-butylpiperidin-4-yl)am
4,4-dimethylcyclohex-l -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 227B for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.51 (s, 1 H), 8.43 (d, 1 H), 8.04 (m, 1 H), 7.93 (d, 1 H), 7.72 (m, 1 H), 7.56 (dd, 1 H), 7.42 (m, 1 H), 7.34 (m, 3 H), 7.05 (d, 2 H), 6.93 (dd, 1 H), 6.62 (dd, 1 H), 6.28 (m, 1 H), 3.04 (m, 6 H), 2.73 (s, 3 H), 2.25 (m, 9 H), 1.95 (s, 2 H), 1.68 (m, 2 H), 1.32 (m, 9 H), 0.93 (s, 6 H).
EXAMPLE 228
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 228A
tert-butyl 3-((2-nitro-4-sulfamoylphenylamino)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl 3- (aminomethyl)piperidine-l -carboxylate for (tetrahydropyran-4-yl)methylamine in
EXAMPLE IF.
EXAMPLE 228B
3 -nitro-4-(piperidin-3 -ylmethylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 228A for EXAMPLE 113 A in EXAMPLE 134A.
EXAMPLE 228C
4-((l-(2-methoxyethyl)piperidin-3-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 228B for EXAMPLE 134A and 2-methoxyethyl bromide for methyl iodide in EXAMPLE 134B. EXAMPLE 228D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(2-methoxyethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 228C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5, 90 °C) δ 12.40 (s, IH), 8.52 (s, IH), 8.43 (s, IH), 8.20 (m, 2H),7.95 (bs, IH), 7.80 (s, IH), 7.46 (d, IH), 7.36 (d, 2H), 7.07 (d, 2H), 7.05 (s, IH), 6.75 (d, IH), 6.59 (s, IH), 6.47 (s, IH), 3.65-3.50 (m, 5H),3.20 (s, 3H), 3.04 (m, 5H), 2.81 (s, 3H), 2.74 (m, IH), 2.24 (m, 7H), 2.06 (s, 2H), 2.00 (s, 2H), 1.75 (m, IH), 1.57 (m, 2H), 1.42 (t, 2H), 1.15 (m, IH), 0.95 (s, 6H).
EXAMPLE 229
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 229A
4-(( 1 -(cy anomethyl)piperidin-3 -yl)methylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 228B for EXAMPLE 134A and 2-bromoacetonitrile for methyl iodide in EXAMPLE 134B.
EXAMPLE 229B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 229A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.06 (s, IH), 9.03 (s, IH), 8.42 (s, IH), 8.30 (d, IH), 8.10 (d, IH), 7.68 (m, 2H), 7.44 (d, 2H), 7.08 (m, 3H), 6.99 (d, IH), 6.75 (d, IH), 6.51 (m, 2H), 3.78 (m, 2H), 3.43 (d, IH), 3.13 (m, IH), 3.04 (m, 4H), 2.76 (s, 2H), 2.71-2.65 (m, 3H), 2.52 (m, IH), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.84 (m, IH), 1.68 (m, IH), 1.50 (m, 2H), 1.39 (t, 2H), 1.07-0.99 (m, IH), 0.93 (s, 6H). EXAMPLE 230
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 230A
4-((4-fluoro- 1 -methylpiperidin-4-yl)methoxy)-3- (trifluoromethylsulfonyl)benzenesulfonamide
To a solution of (4-fluoro-l-methylpiperidin-4-yl)methanol (0.315 g) in
tetrahydrofuran (5 mL) was added sodium hydride (0.342 g). After stirring for 15 minutes, 4- fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide (0.658 g) was added as a solution in tetrahydrofuran (2 mL) followed by additional tetrahydrofuran (5 mL). After stirring for 1 hour, the reaction was poured in dichloromethane (50 mL) and water (25 mL) and the pH of the water layer was adjusted to 8. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The resulting oil was chromatographed over silica gel (Reveleris 40 g) eluting with a gradient of 1.0% to 10% 7N NH3 in methanol/dichloromethane over 20 minutes then maintaining 10% 7N NH3 in methanol/dichloromethane for 5 minutes (flow = 30 mL/min) to provide the title compound. EXAMPLE 230B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 230A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 1 1.63 - 11.57 (m, 1H), 8.40 - 8.36 (m, 1H), 8.28 - 8.17 (m, 1H), 7.97 (s, 1H), 7.53 (d, 1H), 7.50 - 7.32 (m, 5H), 7.05 (d, 1H), 7.05 (d, 1H), 6.68 - 6.61 (m, 1H), 6.35 (s, 1H), 6.22 (s, 1H), 4.55 - 4.40 (m, 2H), 3.06 (s, 8H), 2.79 (s, 4H), 2.06 (d, 13H), 1.39 (s, 2H), 0.93 (s, 6H).
EXAMPLE 231
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide EXAMPLE 231 A
(R)-5-chloro-6-(l-(l,3-difluoropropan-2-y^
To EXAMPLE 207A (0.051 g) and EXAMPLE 40A (0.049 g) in dioxane (5 mL) was added diisopropylethylamine (0.131 mL) and the reaction was heated to 75°C for 1 hour then 85°C for 2 days. The reaction was concentrated, loaded onto silica gel (Reveleris 12 g) and eluted with a gradient of 0.75% methanol/dichloromethane to 7.5%
methanol/dichloromethane to provide the title compound.
EXAMPLE 23 IB
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 231 A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.71 (s, 1H), 11.44 - 11.11 (m, 1H), 8.44 (d, 1H), 8.07 (d, 1H), 7.90 (d, 1H), 7.61 (d, 1H), 7.52 (dd, 2H), 7.34 (d, 2H), 7.19 (s, 1H), 7.04 (d, 2H), 6.67 (d, 1H), 6.42 (dd, 1H), 6.16 (s, 1H), 4.77 - 4.39 (m, 5H), 3.19 - 2.63 (m, HH), 2.19 (s, 7H), 1.91 (d, 3H), 1.38 (s, 2H), 0.92 (s, 6H).
EXAMPLE 232
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate
EXAMPLE 232A
tert-butyl 4-nitrosopiperazine-l -carboxylate
In a 500 mL round-bottomed flask, 6N aqueous HC1 (30 mL) was cooled to -10 °C, and tert-butyl piperazine-1 -carboxylate (10 g) was added. Sodium nitrite (4.5 g) dissolved in 35 ml water was added slowly. NaOH (10 g in 20 mL water) was used to neutralize the solution. Dichloromethane (3x 50 mL) was used to extract the product. After drying over Na2S04 and filtration, the solution was concentrated. The crude product was added to a silica gel column (Analogix, SF65-400 g,) and purified by eluting with 0-30%> ethyl acetate in hexane.
EXAMPLE 232B
tert-butyl 4-aminopiperazine- 1 -carboxylate In a 100 mL round-bottomed flask was added EXAMPLE 232A (0.15 g) and zinc (1 g) in water/methanol (1 : 1, 10 mL) to give a suspension. The mixture was cooled to 0°C. 12N Aqueous HC1 (2 ml) was added slowly, and the mixture was stirred at 0 °C for 30 minutes. 2N Aqueous NaOH solution was used to adjust the mixture to basic pH. The mixture was filtered, and extracted with ether (3x 30 mL). After drying over Na2S04, filtration, and concentration, the crude product was added to a silica gel column ( Analogix, SF15-12g,) and purified by eluting with 0-25% ethyl acetate in hexane.
EXAMPLE 232C
tert-butyl 4-(2-nitro-4-sulfamoylphenylamino)piperazine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 232B for 1- (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 232D
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]piperazine- 1 -carboxylate
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 232C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.47 (br. s, 1H), 8.86 (s, 1H), 8.34 (d, 1H), 7.90 (d, 1H), 7.59 (m, 2H), 7.36 (m, 4H), 7.23 (m, 1H), 7.05 (d, 2H), 6.61 (dd, 1H), 6.27 (m, 2H), 2.99 (m, 5H), 2.76 (m, 6H), 2.19 (m, 6H), 1.96 (s, 2H), 1.41 (m, 11H), 1.24 (m, 4H), 0.93 (s, 6H).
EXAMPLE 233
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro-lambda~6— sulfanyl)-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 233A
2-(5 -bromo-2-nitrophenyl)sulfur pentafluoride
To a solution of 3-bromophenylsulfur pentafluoride (2.18 g) in concentrated H2S04 (5 mL) was added KNO3 (780 mg). The mixture was stirred overnight. The mixture was diluted with diethyl ether (100 mL) and washed with water and brine. After drying over Na2S04 and filtration, the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 233B
2-(5-bromo-2-aminophenyl)sulfur pentafluoride
EXAMPLE 233A (6.4g) and tetrahydrofuran (300 mL) were added to Ra-Ni, (12.80 g) in a 50 mL pressure bottle and the mixture stirred for 2 hours at 30 psi and room temperature. The mixture was filtered though a nylon membrane and the filtrate was concentrated under vacuum to provide the title compound.
EXAMPLE 233C
4-bromo-2-pentafluorosulfanyl-N-(tetrahydro-2H-pyran-4-ylmethyl)aniline To a solution of EXAMPLE 233B (4.4 g) in methanol (50 mL) was added tetrahydro- 2H-pyran-4-carbaldehyde (1.68 g) and decaborane (1.1 g). The mixture was stirred and monitored by thin layer chromatography. More tetrahydro-2H-pyran-4-carbaldehyde (500 mg) was added to the stirring mixture to drive the reaction to completion. The reaction mixture was concentrated under vacuum and ethyl acetate (500 mL) and brine (200 mL) were added. The organic phase was dried over Na2S04. Filtration and evaporation of the solvent and flash chromatography (20% ethyl acetate in hexane) gave the title compound.
EXAMPLE 233D
4-thioacetoxy-2-pentafluorosulfanyl-N-(tetrahydro-2H-pyran-4-ylmethyl)aniline To a solution of EXAMPLE 233 C (456 mg) and potassium ethanethioate (197 mg) in dioxane (4 mL) was added tris(dibenzylideneacetone)dipalladium(0) (27 mg) and xantphos (33 mg) followed by N,N-diisopropylethylamine (0.5 mL). The mixture was purged with argon, sealed and stirred under microwave irradiation for 60 minutes at 120°C. The mixture was dissolved in ethyl acetate (300 mL) and water (100 mL). The organic phase was washed with brine and dried over Na2S04. Filtration and evaporation of the solvent followed by flash chromatography (20% ethyl acetate in hexane) provided the title compound.
EXAMPLE 233E
3-pentafluorosulfanyl-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenylsulfonamide N-chlorosuccinimide (527 mg) was added to a mixture of 2N aqueous HC1 (1.5 mL) and acetonitrile (12 mL) and then cooled to 0°C. A solution of EXAMPLE 233D (386 mg) in acetonitrile (3 mL) was added to the mixture which was then stirred at 0°C for 2 hours, and then diluted with ethyl acetate (300 mL) and washed with brine and dried over Na2S04. After filtration and evaporation of solvent, the residue was dissolved in isopropyl alcohol (20 mL) and cooled to 0°C with stirring. Then, ammonium hydroxide (cone. 10 mL) was added to mixture. After stirring for 2 hours, the mixture was concentrated under vacuum and the residue was added to ethyl acetate (400 mL) and water (150 mL). The organic layer was washed with brine and dried over Na2S04. After filtration and evaporation of solvent, the residue was purified by flash column ( 20% ethyl acetate in dichloromethane) to provide the title compound.
EXAMPLE 233F
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- (pentafluoro-lambda~6— sulfanyl)-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 233E for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.71 (s, 1 H), 11.33 (m, 1 H), 8.12 (m, 2 H), 7.72 (d, 1 H), 7.54 (m, 3 H), 7.33 (m, 2 H), 7.02 (m, 3 H), 6.67 (m, 2 H), 6.42 (m, 1 H), 6.16 (d, 1 H), 3.82 (m, 2 H), 3.21 (m, 4 H), 3.05 (m, 4 H), 2.73 (s, 2 H), 2.21 (m, 8 H), 1.97 (m, 3 H), 1.29 (m, 4 H), 0.92 (s, 6 H).
EXAMPLE 234
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 234A
4-vinyltetrahydro-2H-pyran-4-ol
Dihydro-2H-pyran-4(3H)-one (8.01 g) in anhydrous ethyl ether (50 mL) was treated with 1.0 M vinylmagnesium bromide (104 mL) over 20 minutes at 0 ° C. The reaction mixture was stirred at room temperature overnight. The reaction was quenched with saturated NH4C1, and the organic layer was separated. The aqueous layer was extracted with additional ethyl ether three times. The combined organic layers were washed with brine, dried, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 20% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 234B
4-methoxy-4-vinyltetrahydro-2H-pyran
To a solution of EXAMPLE 234A (9.4 g) in tetrahydrofuran (150 mL) was added 60 % sodium hydride (5.28 g) at 0°C portionwise. After the addition was complete, the solution was heated under reflux for three hours. After cooling, to this suspension was added dimethyl sulfate (8.41 mL) slowly. The solution was heated under reflux overnight, cooled to room temperature, and hydrolyzed with cool saturated aqueous NH4C1. After extraction with diethyl ether several times, the combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatograph on silica gel using 1-10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 234C
4-methoxytetrahydro-2H-pyran-4-carbaldehyde
EXAMPLE 234B (4.3 g) in tetrahydrofuran (200 mL) and water (67 mL) was treated with 4% osmium tetroxide in water (9.24 mL). To this solution was added potassium periodate (13.91 g) portionwise over 2 hours. The solution was stirred overnight at room temperature. Water was added to the mixture followed by repeat extractions with diethyl ether. The combined organic layers were dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 5-20%> ethyl acetate in hexanes to provide the title compound.
EXAMPLE 234D
(4-methoxytetrahydro-2H-pyran-4-yl)methanol
EXAMPLE 234C (1.8 g) in 2-propanol (28 mL) and water (7 mL) was cooled to 0 °C. To this solution was added sodium borohydride (0.709 g). The solution was stirred and allowed to warm to room temperature over 3 hours. The reaction was quenched with acetone, and stirred for another 1 hour. The clear liquid was separated from solid by decanting.
Additional ethyl acetate was used to wash the solid, and was the mixture was decanted. The combined organic solutions were concentrated. The residue was purified by flash
chromatography on silica gel eluting 1 : 1 ethyl acetate: hexane to provide the title compound. EXAMPLE 234E
4-((4-methoxytetrahydro-2H-pyran-4-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 234D for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 234F
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 234E for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 8.36 (s, IH), 8.04-8.07 (m, 2H), 7.50-7.53 (m, 3H), 7.45 (d, IH), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, IH), 6.40 (dd, IH), 6.20 (d, IH), 4.21 (s, 2H), 3.65-3.67 (m, 2H), 3.53-3.56 (m, 2H), 3.19 (s, 3H), 3.10 (s, 4H), 2.86 (s, 2H), 2.30 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.61- 1.74 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 235
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l,3-difiuoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 235A
(R)-tert-butyl 3-(2-nitro-4-sulfamoylphenoxy)pyrrolidine- 1 -carboxylate The title compound was prepared by substituting (R)-tert-butyl 3-hydroxypyrrolidine- 1 -carboxylate for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 235B
(R)-tert-butyl 3-(4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenoxy pyrrolidine- 1 -carboxylate
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 235A for EXAMPLE IF in EXAMPLE 1G. EXAMPLE 235C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
To a solution of EXAMPLE 235B (0.230 g) in dichloromethane (3 mL) was added trifluoroacetic acid (0.377 mL). After stirring for 4 hours, the reaction was concentrated then dissolved in dichloromethane (3 mL) and treated with l,3-difluoropropan-2-one (0.028 g) followed by sodium triacetoxyborohydride (0.078 g). After stirring for 4 hours, the reaction was quenched by the addition of saturated aqueous NaHC03 and dichloromethane (5 mL). The reaction was diluted with dichloromethane (250 mL) and saturated aqueous NaHC03 (100 mL) was added. The organic layer was separated, washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated. Trituration with acetonitrile gave the title compound. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.67 (s, 1H), 8.34 (s, 1H), 8.03 (s, 2H), 7.52 (d, 3H), 7.35 (d, 3H), 7.04 (d, 2H), 6.75 - 6.60 (m, 1H), 6.40 (s, 1H), 6.20 (s, 1H), 5.17 - 5.06 (m, 1H), 4.60 (d, 4H), 2.98 (d, 12H), 2.37 - 2.02 (m, 6H), 1.96 (s, 3H), 1.39 (s, 2H), 0.93 (s, 6H).
EXAMPLE 236
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[4-(oxetan-3-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
EXAMPLE 236A
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(piperazin- 1 -ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 232D for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 236B
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(oxetan-3 -yl)piperazin- 1 -yljamino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 236 A for tert-butyl piperazine-l-carboxylate and oxetan-3-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.67 (br. s, IH), 9.20 (s, IH), 8.53 (d, IH), 8.04 (d, IH), 7.83 (dd, IH), 7.53 (m, 4H), 7.34 (d, 2H), 7.04 (d, 2H), 6.67 (dd, IH), 6.39 (m, IH), 6.18 (d, IH), 4.55 (t, 2H), 4.44 (t, 2H), 3.47 (m, IH), 3.06 (m, 4H), 2.88 (m, 4H), 2.74 (m, 4H), 2.09 (m, 11H), 1.38 (t, 2H), 0.91 (s, 6H).
EXAMPLE 237
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4- { [4-(tetrahydro-2H-pyran-4-yl)piperazin- 1 -yljamino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 236 A for tert-butyl piperazine-l-carboxylate and dihydro-2H-pyran-4(3H)-one for 4'-chlorobiphenyl-2- carboxaldehyde in EXAMPLE 1A. 1H NMR (400 MHz, pyridine-d5) δ 13.05 (br. s, IH), 9.27 (d, IH), 9.23 (s, IH), 8.44 (m, 2H), 8.12 (d, IH), 7.68 (m, 3H), 7.44 (m, 2H), 7.06 (m, 2H), 6.75 (dd, IH), 6.51 (m, 2H), 4.02 (m, 2H), 3.31 (m, 2H), 3.06 (m, 4H), 2.91 (m, 5H), 2.76 (s, 2H), 2.38 (m, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.65 (m, 2H), 1.39 (m, 7H), 0.93 (s, 6H).
EXAMPLE 238
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 238 A
(R)-3 -nitro-4-(tetrahydrofuran-3 -ylamino)benzenesulfonamide The title compound was prepared by substituting (R)-tetrahydrofuran-3 -amine for 4- methylpiperazin-1 -amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 238B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 238 A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.59 (s, 1H), 8.47 (d, 1H), 8.19 (m, 2H), 7.97 (d, 1H), 7.74 (m, 1H), 7.52 (d, 1H), 7.46 (t, 1H), 7.34 (m, 2H), 7.05 (m, 2H), 6.96 (d, 1H), 6.89 (d, 1H), 6.65 (dd, 1H), 6.33 (m, 1H), 6.22 (d, 1H), 4.31 (m, 1H), 3.92 (m, 1H), 3.87 (m, 1H), 3.76 (m, 1H), 3.69 (m, 1H), 3.04 (m, 4H), 2.73 (m, 2H), 2.33 (m, 1H), 2.18 (m, 6H), 1.95 (m, 2H), 1.88 (m, 1H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 239
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 239A
tert-butyl (4,4-difluorocyclohexyl)methylcarbamate
Tert-butyl (4-oxocyclohexyl)methylcarbamate (5 g) and diethylaminosulfur trifluoride (7.45 g) were stirred in dichloromethane (100 mL) for 24 hours. The mixture was quenched with pH 7 buffer (100 mL), and poured into ether (400 mL). The resulting solution was separated, and the organic layer was washed twice with water, and once with brine, and then concentrated to give the crude product and fiuoroolefin by-product in a 3 :2 ratio. The crude material was taken up in tetrahydrofuran (70 mL) and water (30 mL), and N- methylmorpholine-N-oxide (1.75 g), and Os04 (2.5 wt % solution in t-butanol) were added, and the mixture was stirred for 24 hours. Na2S2C"3 (10 g) was then added, and the mixture was stirred for 30 minutes. The mixture was then diluted with ether (300 mL), and the resulting solution was separated, and rinsed twice with water, and once with brine, and concentrated. The crude product was chromatographed on silica gel using 5-10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 239B
(4,4-difluorocyclohexyl)methanamine
A solution of EXAMPLE 239A (3 g) in dichloromethane (35 mL), trifluoroacetic acid (15 mL), and triethylsilane (1 mL) was stirred for 2 hours. The solution was concentrated, then concentrated from toluene, and left on high vacuum for 24 hours. The semi-solid was taken up in ether/hexane and filtered to provide the title compound as its trifluoroacetic acid salt. EXAMPLE 239C
4-((4,4-difluorocyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 239B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 239D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 239C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 12.40 (s, IH), 11.61 (br s, IH), 8.53 (m, IH), 8.50 (d, IH), 7.99 (d, IH), 7.73 (d, IH), 7.49 (m, 2H), 7.32 (d, 2H), 7.04 (d, 2H), 7.00 (d, IH), 6.65 (d, IH), 6.32 (s, IH), 6.21 (s, IH), 3.37 (m, 4H), 3.06 (m, 4H), 2.73 (m, 2H), 2.18 (m, 4H), 1.97 (m, 4H), 1.81 (m, 4H), 1.38 (m, 2H), 1.20 (m, 4H), 0.92 (s, 6H).
EXAMPLE 240
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 240A
4-( 1 -tert-butylpiperidin-4-ylamino)-3 -(trifluoromethylsulfonyl)benzenesulfonamide To a mixture of 4-fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide (307 mg) and EXAMPLE 227 A (156 mg) in tetrahydrofuran (4 mL) was added Hunig's Base (1 mL). The mixture was stirred for 3 days. The mixture was diluted with ethyl acetate (300 mL) and water (100 mL) and stirred until the solid disappeared into the solution. The layers were separated and the organic phase was washed with water, brine and dried over Na2S04. After filtration, the combined aqueous layers were extracted again with ethyl acetate and the combined organic phase was dried over Na2S04. After filtration, the solvent was evaporated to provide the title compound. EXAMPLE 240B
N-( {4- [( 1 -tert-butylpiperidin-4-yl)am
(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 240A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.53 (s, 1 H), 8.04 (s, 1 H), 7.94 (d, 1 H), 7.86 (m, 1 H), 7.55 (d, 2 H), 7.44 (d, 1 H), 7.33 (m, 3 H), 7.05 (d, 2 H), 6.92 (m, 1 H), 6.62 (dd, 1 H), 6.43 (m, 1 H), 6.29 (d, 2 H), 3.79 (m, 1 H), 3.05 (m, 6 H), 2.73 (s, 3 H), 2.19 (m, 8 H), 1.96 (s, 3 H), 1.27 (m, 12 H), 0.92 (s, 6 H).
EXAMPLE 241
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 241 A
tert-butyl 2-((4-sulfamoyl-2-(trifluoromethylsulfonyl)phenylamino)methyl)morpholine carboxylate
The title compound was prepared by substituting tert-butyl 2-
(aminomethyl)morpholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine and 4- fluoro-3 -(trifluoromethy lsulfonyl)benzenesulfonamide for 4-fluoro-3 - nitrobenzenesulfonamide in EXAMPLE IF. EXAMPLE 24 IB
tert-butyl 2-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- (trifluoromethylsulfonyl)phenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 241 A for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. EXAMPLE 241C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(4-(morpholin-2-ylmethylamino)-3- (trifluoromethylsulfonyl)phenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 24 IB for EXAMPLE
1A in EXAMPLE IB.
EXAMPLE 24 ID
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- ({[4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)-3-
[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 241C for tert-butyl piperazine-l-carboxylate and oxetan-3-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.15 (d, IH), 8.04 (d, IH), 7.92 (dd, IH), 7.54 (d, IH), 7.51 (t, IH), 7.48 (d, IH), 7.34 (d, 2H), 7.25 (m,
IH), 7.04 (m, 3H), 6.68 (dd, IH), 6.41 (m, IH), 6.19 (d, IH), 4.54 (t, 2H), 4.43 (m, 2H), 3.85 (m, IH), 3.69 (m, IH), 3.52 (m, IH), 3.48 (m, IH), 3.39 (m, 2H), 3.07 (m, 4H), 2.77 (br s, 2H), 2.69 (d, IH), 2.56 (d, IH), 2.21 (br s, 4H), 2.15 (t, 2H), 1.94 (m, 3H), 1.76 (t, IH), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 242
N-[(5-chloro-6-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 242A
5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 138D. EXAMPLE 242B
N-[(5-chloro-6-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 242A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.71 (s, IH), 8.41 (d, IH), 8.07 (d, IH), 7.93 (d, IH), 7.60 (d, IH), 7.51-7.53 (m, 2H), 7.40 (s, IH), 7.33-7.35 (m, 2H), 7.03-7.05 (m, 2H), 6.68 (dd, IH), 6.42 (dd, IH), 6.16 (d, IH), 3.77 (d, IH), 3.69-3.71 (m, 3H), 3.48-3.53 (m, 2H), 3.07 (s, 4H), 2.76 (s, 2H), 2.14-2.20 (m, 6H),1.96 (s, 2H), 1.65-1.76 (m, 4H), 1.38 (t, 2H), 0.93 (s, 6H).
EXAMPLE 243
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 243A
5-chloro-6-(l-cyclopropylpiperidin-4-ylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-chloro-3- nitrobenzenesulfonamide, l-cyclopropylpiperidin-4-amine for 4-methylpiperazin-l -amine dihydrochloride and Hunig's base for N^N^^^-tetramethylethane-l^-diamine in
EXAMPLE 6A.
EXAMPLE 243B
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 243 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.67 (s, IH), 8.40 (d, IH), 8.05 (d, IH), 7.88 (d, IH), 7.56 (d, IH), 7.50 (m, 2H), 7.34 (d, 2H), 7.03 (d, 2H), 6.97 (br d, IH), 6.66 (dd, IH), 6.40 (m, IH), 6.16 (d, IH), 4.04 (m, IH), 3.03 (br m, 6H), 2.73 (s, 2H), 2.42 (br m, 2H), 2.18 (br m, 6H), 1.95 (s, 2H), 1.80 (m, 3H), 1.62 (m , 2H), 1.38 (t, 2H), 0.91 (s, 6H), 0.47 (m, 2H), 0.40 (br m, 2H). EXAMPLE 244
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)m
{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 244A
(S)-tert-butyl 2-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)morpholine-4-carboxylate The title compound was prepared by substituting (S)-tert-butyl 2-(hydroxymethyl)- morpholine-4-carboxylate fortetrahydro-2H-pyran-4-yl-methanol and EXAMPLE 40A for 4- fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24 A.
EXAMPLE 244B
(S)-5 -chloro-6-(morp ho lin-2-ylmethoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 244A for EXAMPLE 113 A in EXAMPLE 134A.
EXAMPLE 244C
(S)-5-chloro-6-((4-(cyanomethyl)morpholin-2-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 244B for EXAMPLE 134A and 2-bromoacetonitrile for methyl iodide in EXAMPLE 134B.
EXAMPLE 244D
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 244C for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.99 (s, 1H), 9.09 (d, 1H), 8.70 (d, 1H), 8.42 (d, 1H), 8.12 (d, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.75 (dd, 1H), 6.53 (d, 1H), 6.48 (m, 1H), 4.55 (dd, 1H),4.43 (dd, 1H), 4.05 (m, 1H), 3.85 (d, 1H), 3.76 (s, 2H), 3.63 (dt, 1H), 3.06 (m, 4H), 2.91 (d, 1H), 2.77 (s, 2H), 2.58 (d, 1H), 2.51-2.44 (m, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 245
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 245A
(S)-5-chloro-6-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methoxy)pyridine-3- sulfonamide
The title compound was prepared by substituting EXAMPLE 244B for EXAMPLE 134A and 2-(dimethylamino)acetyl chloride hydrochloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 245B
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 245 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, 1H), 9.09 (d, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 8.11 (t, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.76 (s, 1H), 6.54 (s, 1H), 6.49 (s, 1H), 4.85-4.46 (m, 3H),4.45-3.87 (m, 3H), 3.50 (m, 1H), 3.37 (dd, 1H), 3.21 (m, 2H), 3.07 (m, 4H), 2.86 (t, 1H), 2.77 (s, 2H), 2.27 (m, 8H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 246
N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 246A
(R)-tert-butyl 2-((3 -chloro-5 -sulfamoylpyridin-2-yloxy)methyl)morpholine-4-carboxylate The title compound was prepared by substituting (R)-tert-butyl 2-(hydroxymethyl)- morpholine-4-carboxylate for tetrahydro-2H-pyran-4-yl-methanol and EXAMPLE 40A for 4- fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24 A.
EXAMPLE 246B (R)-5-chloro-6-(morpholin-2-ylmethoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 246A for EXAMPLE 113A in EXAMPLE 134A.
EXAMPLE 246C
(R)-5-chloro-6-((4-(cyanomethyl)morpholin-2-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 246B for EXAMPLE 134A and 2-bromoacetonitrile for methyl iodide in EXAMPLE 134B.
EXAMPLE 246D
N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 246C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.99 (s, IH), 9.09 (d, IH), 8.70 (d, IH), 8.42 (d, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.75 (dd, IH), 6.53 (d, IH), 6.48 (m, IH), 4.55 (dd, 1H),4.43 (dd, IH), 4.05 (m, IH), 3.85 (d, IH), 3.76 (s, 2H), 3.63 (dt, IH), 3.06 (m, 4H), 2.91 (d, IH), 2.77 (s, 2H), 2.58 (d, IH), 2.51-2.44 (m, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 247
N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 247A
(R)-5-chloro-6-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methoxy)pyridine-3- sulfonamide
The title compound was prepared by substituting EXAMPLE 246B for EXAMPLE 134A and 2-(dimethylamino)acetyl chloride hydrochloride for methyl iodide in EXAMPLE 134B. EXAMPLE 247B
N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 247A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, 1H), 9.09 (d, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 8.11 (t, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.76 (s, 1H), 6.54 (s, 1H), 6.49 (s, 1H), 4.85-4.46 (m, 3H),4.45-3.87 (m, 3H), 3.50 (m, 1H), 3.37 (dd, 1H), 3.21 (m, 2H), 3.07 (m, 4H), 2.86 (t, 1H), 2.77 (s, 2H), 2.27 (m, 8H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 248
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 248A
5-bromo-3-fluoro-2-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine
The title compound was prepared by substituting 5-bromo-2,3-difluoropyridine for 4- fluoro-3-nitrobenzenesulfonamide and EXAMPLE 37C for (tetrahydro-2H-pyran-4- yl)methanol in EXAMPLE 24A.
EXAMPLE 248B
tert-butyl 5 -fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3 -ylcarbamate EXAMPLE 248A (0.308 g), tert-butyl carbamate (0.141 g), palladium(II) acetate
(0.011 g), Xantphos (0.043 g) and cesium carbonate (0.489 g) were combined with dioxane (5.0 mL) in a 20-mL vial equipped with a magnetic stir bar. The vial was flushed with nitrogen, capped and stirred at 100°C overnight. Additional palladium(II) acetate (0.011 g), Xantphos (0.043 g) and tert-butyl carbamate (0.141 g) were added and heating was continued at 100°C for 8 hours. The cooled reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 7-25% ethyl acetate in hexanes as the eluent. EXAMPLE 248C
5 -fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3 -sulfonyl chloride Under ice-cooling, thionyl chloride (1.563 mL) was added dropwise over 20 minutes to water (9 mL). The mixture was stirred for 12 hours to give a S02-containing solution. Separately, EXAMPLE 248B (0.295 g) was added to a mixture of 1,4-dioxane (3.2 mL) and concentrated HC1 (8 mL) at 0°C. After stirring for 15 minutes, a solution of sodium nitrite (0.065 g) in water (2 mL) was added dropwise and stirring was continued at 0°C for 3 hours. Copper(I) chloride (0.042 g) and then the freshly prepared solution of diazotized material were added sequentially to the previously prepared S02-containing solution. The resulting solution was stirred for 30 minutes and then extracted with ethyl acetate (2 x 125 mL). The combined extracts were dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 5% ethyl acetate in hexanes as the eluent.
EXAMPLE 248D
5 -fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3 -sulfonamide
EXAMPLE 248C (0.08 g) in isopropanol (2 mL) at 0°C was treated with ammonium hydroxide (1.697 mL), stirred overnight and then concentrated to dryness. The obtained solid was slurried in water, filtered, rinsed with water and dried under high vacuum to provide the title compound.
EXAMPLE 248E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 248D for EXAMPLE
1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.05 (s, IH), 9.03 (d, IH), 8.44 (dd, IH), 8.41 (d, IH), 8.10 (d, IH), 7.67 (m, IH), 7.65 (d, IH), 7.44 (m, 2H), 7.07 (m, 2H), 6.77 (dd, IH), 6.53 (d, IH), 6.49 (dd, IH), 4.55 (d, 2H), 3.80 (m, 4H), 3.08 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.88 (m, 4H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 250
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 250A
5 -chloro-6-((3 -methyloxetan-3 -yl)methoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting (3 -methyloxetan-3 -yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 250B
N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 25 OA for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.05 (s, 1H), 9.22 (d, 1H), 8.51 (d, 1H), 8.42 (d, 1H), 8.09 (d, 1H), 7.66 (t, 2H), 7.43 - 7.46 (m, 2H), 7.04 - 7.09 (m, 2H), 6.75 (dd, 1H), 6.45 - 6.54 (m, 2H), 4.47 (s, 2H), 3.81 - 3.84 (m, 2H), 3.74 (d, 2H), 3.03 - 3.11 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.10 - 2.17 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 1.16 (s, 3H), 0.94 (s, 6H).
EXAMPLE 251
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 251 A
5-bromo-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting (4-fluorotetrahydro-2H-pyran-4- yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and 5-bromo-6-chloropyridine-3- sulfonamide for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24 A. EXAMPLE 25 IB
6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide To a suspension of 5-bromo-6-((4-fluorotetrahydro-2H-pyran-4- yl)methoxy)pyridine-3-sulfonamide (200 mg) and cyclohexene (0.549 mL) in ethyl acetate (10 mL) was added 10% palladium on carbon (57.6 mg). The suspension was stirred for 60 minutes at 120°C. The reaction mixture was filtered and concentrated. The product was purified by reverse-phase flash chromatography (CI 8, 150g, 10%- 100%
acetonitrile/H20/trifluoroacetic acid 0.1%). EXAMPLE 251C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(4-f uorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 25 IB for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.06 (s, 1H), 9.29 (d, 1H), 8.50 (dd, 1H), 8.41 (d, 1H), 8.07 (d, 1H), 7.66 - 7.70 (m, 1H), 7.64 (d, 1H), 7.44 (d, 2H), 7.07 (d, 2H), 6.84 (d, 1H), 6.75 (dd, 1H), 6.52 (d, 1H), 6.49 (dd, 1H), 4.50 (d, 2H), 3.81 - 3.89 (m, 2H), 3.70 - 3.81 (m, 2H), 3.02 - 3.12 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.10 - 2.18 (m, 4H), 1.97 (s, 2H), 1.77 - 1.94 (m, 4H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 252
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 252A
tert-butyl (4-(l,3-difluoropropan-2-yl)morpholin-2-yl)methylcarbamate The title compound was prepared by substituting l,3-difluoropropan-2-one for 4'- chlorobiphenyl-2-carboxaldehyde and tert-butyl morpholin-2-ylmethylcarbamate for tert- butyl piperazine-l-carboxylate in EXAMPLE 1A.
EXAMPLE 252B
(4-( 1 ,3 -difluoropropan-2-yl)morpholin-2-yl)methanamine A solution of EXAMPLE 252A (538 mg) in dioxane (4 mL) was treated with 4.0M HCl in dioxane solution (1.8 mL). The reaction was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum and used without further purification.
EXAMPLE 252C
4-((4-(l,3-difluoropropan-2-yl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 252B for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 252D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 252C for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.64 (s, 1H), 8.59 (t, 1H), 8.57 (d, 1H), 8.04 (d, 1H), 7.83 (dd, 1H), 7.51 (m, 3H), 7.33 (d, 2H), 7.07 (d, 1H), 7.03 (d, 2H), 6.66 (dd, 1H), 6.39 (m, 1H), 6.19 (d, 1H), 4.69 (t, 2H), 4.57 (t, 2H), 3.85 (m, 1H), 3.70 (m, 1H), 3.52 (m, 2H), 3.41 (m, 2H), 3.07 (br s, 4H), 2.91 (d, 1H), 2.74 (m, 3H), 2.59 (m, 1H), 2.43 (m, 1H), 2.20 (m, 4H), 2.15 (m, 2H), 1.95 (br s, 2H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 253
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 253A
tert-butyl 4-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl 4- (hydroxymethyl)piperidine-l -carboxylate for tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 40 A for 4-fiuoro-3-nitrobenzenesulfonamide in EXAMPLE 24 A. EXAMPLE 253B
5 -chloro-6-(piperidin-4-ylmethoxy)pyridine-3 -sulfonamide ditrifluoroacetic acid The title compound was prepared by substituting EXAMPLE 253 A for EXAMPLE 39A in EXAMPLE 39B.
EXAMPLE 253C
5-chloro-6-((l-(cyanomethyl)piperidin-4-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 253B (0.061 g), 2-chloroacetonitrile (0.017 g), sodium carbonate (0.025 g) and Ν,Ν-dimethylformamide (1 mL) were combined in a 4-mL vial and heated at 60°C overnight. The cooled reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered and concentrated. The concentrate was chromato graphed on silica gel with 2-10% methanol in CH2C12 as the eluent.
EXAMPLE 253D
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 253C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400 MHz, pyridine- d5) δ 13.04 (s, 1H), 9.14 (d, 1H), 8.41 (d, 1H), 8.10 (d, 1H), 7.66 (t, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.74 (dd, 1H), 6.50 (m, 2H), 4.18 (d, 2H), 3.64 (s, 2H), 3.05 (s, 4H), 2.77 (m, 4H), 2.24 (m, 4H), 2.13 (m, 4H), 1.97 (s, 2H), 1.69 (m, 3H), 1.41 (m, 4H), 0.93 (s, 6H).
EXAMPLE 254
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({(3R)-l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 254A
(R)-tert-butyl 3 -(2-nitro-4-sulfamoylphenylamino)pyrrolidine- 1 -carboxylate
The title compound was prepared by substituting (R)-tert-butyl 3-aminopyrrolidine-l- carboxylate for l-(tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 254B
(R)-3 -nitro-4-(pyrrolidin-3 -ylamino)benzenesufonamide The title compound was prepared by substituting EXAMPLE 254A for EXAMPLE 113A in EXAMPLE 134A.
EXAMPLE 254C
(Pv)-4-( 1 -(2-(2-methoxyethoxy)ethyl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesufonamide To a solution of (R)-3-nitro-4-(pyrrolidin-3-ylamino)benzenesulfonamide (440 mg) in N,N-dimethylformamide (10 mL) was added sodium carbonate (132 mg) and l-bromo-2-(2- methoxyethoxy)ethane (0.155 mL). The reaction mixture was heated at 60°C for 18 hours and after an aqueous workup, the crude product was purified on silica gel with a 2.5 - 10% methanol in methylene chloride gradient to provide the title compound.
EXAMPLE 254D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({(3R)-l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yl-oxy)benzamide
The title compound was prepared by substituting EXAMPLE 254C for EXAMPLE 130C in EXAMPLE 130D. IH NMR (500 MHz, pyridine-d5) δ 12.96 (m, IH), 9.25 (m, IH), 8.57 (d, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.11 (d, IH), 7.66 (t, IH) 7.64 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.82 (d, IH), 6.76 (dd, IH), 6.55 (m, IH), 6.47 (m, IH), 5.26 (br s, IH), 4.02 (m, IH), 3.63 (m, 4H), 3.53 (m, 2H), 3.28 (s, 3H), 3.07 (m, 4H), 2.89 - 2.81 (m, 2H), 2.78 (s, 2H), 2.75 - 2.66 (m, 3H), 2.37 (m, IH), 2.26 (m, 2H), 2.24 - 2.18 (m, IH), 2.15 (m, 4H), 1.97 (s, 2H), 1.65 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 255
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 255A
(R)-4-( 1 -(2-(dimethylamino)acetyl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesufonamide The title compound was prepared by substituting 2-(dimethylamino)acetyl chloride, hydrochloric acid for l-bromo-2-(2-methoxyethoxy)ethane in EXAMPLE 254C except the reaction was stirred at ambient temperature for 18 hours. EXAMPLE 255B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 255 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500 MHz, pyridine - d5) δ 13.01 (d, IH), 9.26 (m, IH), 8.46 - 8.33 (m, 3H), 8.14 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 7.01 - 6.89 (m, IH), 6.76 (dd, IH), 6.55 (m, IH), 6.48 (m, IH), 5.32 (br s, IH), 4.27 - 4.14 (m, IH), 4.05- 3.95 (m, IH), 3.82 - 3.62 (m, 3H), 3.27 - 3.15 (m, 2H), 3.07 (m, 4H), 2.77 (s, 2H), 2.34 (2, 3H), 2.32 (s, 3H), 2.30 - 2.20 (m, 3H), 2.15 (m, 4H), 1.97 (s, 2H), 1.87 - 1.81 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 256
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[l-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
EXAMPLE 256A
tert-butyl 3-(2-nitro-4-sulfamoylphenylamino)azetidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl 3-aminoazetidine-l- carboxylate for 4-methylpiperazin-l -amine dihydrochloride in EXAMPLE 6A.
EXAMPLE 256B
4-(azetidin-3 -ylamino)-3 -nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 256 A for (S)-l -tert- butyl 2-methyl 4,4-difluoropyrrolidine-l,2-dicarboxylate in EXAMPLE 168 A.
EXAMPLE 256C
3 -nitro-4-( 1 -(oxetan-3 -yl)azetidin-3 -ylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 256B for tert-butyl piperazine-1 -carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A. EXAMPLE 256D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- nitro-4-{[l-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 256C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.04 (s, IH), 9.27 (d, IH), 8.62 (d, IH), 8.42 (d, IH), 8.35 (dd, IH), 8.09 (d, IH), 7.67 (m, IH), 7.63 (d, IH), 7.44 (m, 2H), 7.07 (m, 2H), 6.76 (dd, IH), 6.67 (d, IH), 6.55 (d, IH), 6.48 (dd, IH), 4.66 (t, 2H), 4.58 (m, 2H), 4.23 (m, IH), 3.71 (m, 3H), 3.12 (dd, 2H), 3.07 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (t, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 257
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 257A
tert-butyl 4-((3 -chloro-5 -sulfamoylpyridin-2-yloxy)methyl)-4-fluoropiperidine- 1 -carboxylate
The title compound was prepared by substituting EXAMPLE 126 A for (tetrahydro- 2H-pyran-4-yl)methanol and EXAMPLE 40 A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 257B
5 -chloro-6-((4-fluoropiperidin-4-yl)methoxy)pyridine-3 -sulfonamide ditrifluoroacetic acid The title compound was prepared by substituting EXAMPLE 257 A for EXAMPLE 39A in EXAMPLE 39B.
EXAMPLE 257C
5 -chloro-6-(( 1 -(cyanomethyl)-4-fluoropiperidin-4-yl)methoxy)pyridine-3 -sulfonamide EXAMPLE 257B (0.166 g) in acetonitrile (3 mL) was treated with 2- chloroacetonitrile (0.027 g) and sodium carbonate (0.064 g), heated at 60°C overnight, cooled to room temperature and chromatographed on silica gel with 0 to 3% methanol in CH2CI2 as the eluent. The obtained solid was slurried in water, filtered, rinsed with water and diethyl ether, and dried in a vacuum oven at 80°C.
EXAMPLE 257D
N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 257C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400 MHz, pyridine- d5) δ 13.05 (s, 1H), 9.12 (d, 1H), 8.72 (d, 1H), 8.41 (d, 1H), 8.10 (d, 1H), 7.66 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.75 (dd, 1H), 6.50 (m, 2H), 4.49 (d, 2H), 3.72 (s, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.73 (m, 4H), 2.26 (t, 2H), 2.13 (m, 4H), 2.07 (m, 2H), 1.90 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 258
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 258 A
(S)-tert-butyl 2-(tosyloxymethyl)morpholine-4-carboxylate To a solution of (S)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (1 g) in dichloromethane (50 mL) was added triethylamine (1.604 mL) and 4-methylbenzene-l- sulfonyl chloride (1.097 g). The mixture was stirred at ambient temperature under nitrogen for 72 hours. The reaction was diluted with methylene chloride (50 mL) and brine (100 mL). The brine layer was extracted with methylene chloride (75 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude material was purified on a silica gel column eluting with a 15-65 % ethyl acetate in hexane gradient to provide the title compound. EXAMPLE 258B
(S)-tert-butyl 2-(azidomethyl)morpholine-4-carboxylate A solution of EXAMPLE 258 A (1.66 g) and sodium azide (0.581 g) in anhydrous N,N-dimethylformamide (10 mL) was stirred at 90 °C for 4 hours. The mixture was cooled and concentrated to dryness. The residue was taken up in 5% aqueous sodium carbonate solution and extracted with methylene chloride. The organic solution was dried (MgS04), filtered and concentrated to give a solid.
EXAMPLE 258C
(R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate
This compound was obtained by hydrogenation of EXAMPLE 258B under 60 psi of hydrogen over 10% palladium on carbon in methanol for 24 hours, followed by filtration and evaporation of the solvent. EXAMPLE 258D
(Pv)-tert-butyl 2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 258C for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 258E
(S)-4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 258D for EXAMPLE 113A in EXAMPLE 134A. EXAMPLE 258F
(R)-4-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methylamino)-3- nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 258E for EXAMPLE 134A and 2-(dimethylamino)acetyl chloride hydrochloride for methyl iodide in EXAMPLE 134B. EXAMPLE 258G
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 258F for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.27 (d, IH), 8.87 (bs, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.10 (dd, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (dd, IH), 6.75 (d, IH), 6.54 (s, IH), 6.48 (s, IH), 4.55 (dd, IH), 4.20 (dd, IH), 3.95-3.76 (m, 2H),3.60-3.40 (m, 3H),3.32 (dd, IH), 3.25-3.12 (m, 2H), 3.07 (m, 4H), 2.80 (m, IH), 2.77 (s, 2H), 2.26 (s, 6H), 2.23 (s, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 259
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(^,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]su
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 259A
(Pv)-tert-butyl 2-(tosyloxymethyl)morpholine-4-carboxylate The title compound was prepared by substituting (R)-tert-butyl 2- (hydroxymethyl)morpholine-4-carboxylate for (S)-tert-butyl 2-(hydroxymethyl)morpholine- 4-carboxylate in EXAMPLE 258 A.
EXAMPLE 259B
(R)-tert-butyl 2-(azidomethyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 259 A for EXAMPLE in EXAMPLE 258B.
EXAMPLE 259C
(S)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 259B for EXAMPLE in EXAMPLE 258C. EXAMPLE 259D
(S)-tert-butyl 2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 259C for
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 259E
(R)-4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 259D for EXAMPLE 113 A in EXAMPLE 134A.
EXAMPLE 259F
(S)-4-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methylamino)-3- nitrobenzenesulfonamide
The title compound was prepared by substituting EXAMPLE 259E for EXAMPLE
134A and 2-(dimethylamino)acetyl chloride hydrochloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 259G
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 259F for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.27 (d, IH), 8.87 (bs, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.10 (dd, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (dd, IH), 6.75 (d, IH), 6.54 (s, IH), 6.48 (s, IH), 4.55 (dd, IH), 4.20 (dd, IH), 3.95-3.76 (m, 2H),3.60-3.40 (m, 3H),3.32 (dd, IH), 3.25-3.12 (m, 2H), 3.07 (m, 4H), 2.80 (m, IH), 2.77 (s, 2H), 2.26 (s, 6H), 2.23 (s, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 260
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 260A
5 -chloro-6-(( 1 -(2-(dimethylamino)acetyl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide EXAMPLE 253B (0.061 g), 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.061 g), and sodium carbonate (0.032 g) were combined in a 4-mL vial with N,N- dimethylformamide (2 mL). The mixture was stirred at ambient temperature for 3 days.
Additional 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.037 g), sodium carbonate (0.032 g) and Ν,Ν-dimethylformamide (1 mL) were added and stirring was continued for 24 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 0 to 20% methanol in CH2CI2 as the eluent.
EXAMPLE 260B
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 260A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 12.91 (s, IH), 9.16 (d, IH), 8.75 (d, IH), 8.51 (d, IH), 8.33 (d, IH), 7.70 (d, IH), 7.62 (d, IH), 7.45 (m, 2H), 7.09 (m, 2H), 6.77 (dd, IH), 6.60 (d, IH), 6.45 (d, IH), 4.81 (d, IH), 4.15 (m, 3H), 3.24 (m, 2H), 3.04 (m, 4H), 2.89 (m, IH), 2.79 (s, 2H), 2.53 (m, IH), 2.29 (m, 6H), 2.26 (m, 2H), 2.18 (m, 4H), 1.98 (m, 2H), 1.91 (m, IH), 1.71 (m, 2H), 1.39 (t, 2H), 1.25 (m, 2H), 0.94 (s, 6H).
EXAMPLE 261
N-[(5-chloro-6-{[(3R)-l-(2,2-difiuoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 261 A
(R)-tert-Butyl 3 -(3 -chloro-5 -sulfamoylpyridin-2-yloxy pyrrolidine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and (R)-tert-butyl 3 -hydroxypyrrolidine-1 -carboxylate for
(tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 26 IB
(R)-5-Chloro-6-(pyrrolidin-3-yloxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 261 A for tert-butyl (4- (l,3-difluoropropan-2-yl)morpholin-2-yl)methylcarbamate in EXAMPLE 252B.
EXAMPLE 261C
(R)-5-chloro-6-(l-(2,2-difluoroethyl)pyrrolidin-3-yloxy)pyridine-3-sulfonamide A mixture of EXAMPLE 261B (353 mg), 1, l-difhioro-2-iodoethane (268 mg), sodium carbonate (283 mg) in Ν,Ν-dimethylformamide (lOmL) was heated at 80°C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water, brine, dried over magnesium sulfate, filtered, and concentrated. The residue was loaded onto silica gel column and eluted using a gradient of 0.5 to 3 % methanol in dichloromethane to provide the title compound.
EXAMPLE 26 ID
N-[(5-chloro-6-{[(3R)-l-(2,2-difiuoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 261C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.55 (s, 1 H), 8.04 (s, 1 H), 7.95 (d, 1 H), 7.58 (d, 1 H), 7.44 (t, 1 H), 7.35 (m, 3 H), 7.05 (d, 2 H), 6.64 (dd, 1 H), 6.33 (m, 1 H), 6.24 (d, 1 H), 6.25-5.97 (m, 1 H), 5.39 (m, 1 H), 2.98 (m, 6 H), 2.86 (m, 6 H), 2.55 (m, 2 H), 2.24 (m, 7 H), 1.96 (s, 2 H), 1.83 (m, 1 H), 1.39 (t, 2 H), 0.93 (s, 6 H)
EXAMPLE 262
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 262A
(R)-4-( 1 -(cyanomethyl)pyrrolidin-3 -ylamino)-3 -nitrobenzenesufonamide The title compound was prepared by substituting 2-bromoacetonitrile for l-bromo-2- (2-methoxyethoxy)ethane in EXAMPLE 254C. EXAMPLE 262B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(3R)- 1 -(cyanomethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 262A for EXAMPLE 130C in EXAMPLE 130D. IH NMR (400 MHz, pyridine - d5) δ 13.03 (s, IH), 9.27 (d, IH), 8.53 (d, IH), 8.43 (d, IH), 8.35 (dd, IH), 8.10 (d, IH), 7.67 - 7.64 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.81 (d, IH), 6.76 (dd, IH), 6.54 (m, IH), 6.48 (m, IH), 5.15 (br s, IH), 4.10 (m, IH), 3.89 (s, 2H), 3.07 (m, 4H), 2.93 - 2.86 (m, 2H), 2.80 - 2.77 (m, 3H), 2.61 - 2.53 (m, IH), 2.31 - 2.21 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.75 - 1.68 (m, IH), 1.39 (t, 2H), 0.94 (m, 6H).
EXAMPLE 263
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 263A
tert-butyl 1 -oxa-6-azaspiro[2.5]octane-6-carboxylate Sodium hydride (6.63 g, 60% in mineral oil) was added to trimethylsulfoxonium iodide (36.5 g) in dimethyl sulfoxide (150 mL) and tetrahydrofuran (150 mL), was and stirred for 30 minutes. tert-Butyl 4-oxopiperidine-l-carboxylate (25.4 g) was added and the reaction was stirred for 3 hours. The reaction was poured into water (800 mL) and extracted three times with ether. The combined extracts were washed three times with water, and brine, dried over Na2S04, filtered, and concentrated to yield the crude product which was used without further purification.
EXAMPLE 263B
tert-butyl 4-(2-(benzyloxy)benzyl)-4-hydroxypiperidine- 1 -carboxylate (2-(Benzyloxy)phenyl)magnesium bromide (33.8 mL, 1M) was added to a solution of EXAMPLE 263A (6.0 g) and Cul (1.07 g) in tetrahydrofuran (220 mL) at 0°C over 10 minutes. The reaction was quenched with pH 7 buffer (20 mL), extracted twice with ether, and the combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 2-20% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 263C
tert-butyl 4-hydroxy-4-(2-hydroxybenzyl)piperidine- 1 -carboxylate
EXAMPLE 263B (11.5 g) and methanol (120 mL) were added to Raney Nickel (1.150 g) in a 250 mL SS pressure bottle and stirred for 1 hour at 30 psi under hydrogen. The mixture was filtered through a nylon membrane and the solution was concentrated to yield the title compound.
EXAMPLE 263D
tert-butyl 4-hydroxy-4-(2-(trifluoromethylsulfonyloxy)benzyl)piperidine- 1 -carboxylate A mixture of EXAMPLE 263C (4.6 g), N-phenylbis(trifluoromethanesulfonimide) (5.88 g), and Hunig's base (2.88 mL) in dichloromethane (100 mL) was stirred for 24 hours. The mixture was concentrated and chromatographed on silica gel using 5-50% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 263E
tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)-4-hydroxypiperidine- 1 -carboxylate A mixture of EXAMPLE 263D (4.3 g), 4-chlorophenylboronic acid (1.84 g), K3P04 (2.91 g), and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.36 g) in 2- methyltetrahydrofuran (50 mL) was stirred at 70°C for 24 hours. The reaction was cooled and quenched with water (50 mL), extracted twice with ether, and the combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 5-30% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 263F
tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)-4-methoxypiperidine- 1 -carboxylate Sodium hydride (0.36 g, 60% in mineral oil) was added to EXAMPLE 263E (4.3 g), in tetrahydrofuran (40 mL) and the reaction was stirred for 10 minutes.
Hexamethylphosphoramide (5 mL) and CH3I (2.34 mL) were added and the reaction was stirred at 50°C for 18 hours. The reaction was cooled and quenched with water (50 mL), extracted twice with ether, and the combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 5-25% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 263G
4-((4'-chlorobiphenyl-2-yl)methyl)-4-methoxypiperidine The title compound was prepared by substituting EXAMPLE 263F for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 263H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)-4- methoxypiperidin- 1 -yl)benzoate
A solution of EXAMPLE 263G (1.4 g), EXAMPLE 3H (1.06 g) and Hunig's base (0.75 mL) in dimethylsulfoxide (20 mL) was stirred at 120°C for 18 hours. The reaction was cooled and quenched with water (200 mL), extracted three times with ether, and the combined extracts were washed three times with water, and brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 5-50%> ethyl acetate in hexanes to provide the title compound.
EXAMPLE 2631
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)-4- methoxypiperidin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 263H for EXAMPLE 31 in EXAMPLE 3 J.
EXAMPLE 263J
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 2631 for EXAMPLE IE and EXAMPLE 96A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.71 (s, IH), 11.58 (br s, IH), 8.58 (d, IH), 8.28 (d, IH), 8.05 (d, IH), 7.56 (d, IH), 7.52 (m, IH), 7.46 (d, IH), 7.44 (d, 2H), 7.28 (m, 5H), 7.11 (dd, IH), 6.62 (dd, IH), 6.41 (dd, IH), 6.11 (d, IH), 4.54 (d, 2H), 3.75 (m, 2H), 3.59 (m, 2H), 3.20 (m, 2H), 2.97 (s, 3H), 2.81 (m, 2H), 2.74 (m, 2H), 1.89 (m, 2H), 1.83 (m, 2H), 1.36 (m, 2H), 1.09 (m, 2H).
EXAMPLE 264
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin- 1 -yl} -N-( {3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 2631 for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.71 (s, IH), 11.40 (br s, IH), 8.62 (t, IH), 8.58 (d, IH), 8.03 (d, IH), 7.81 (dd, IH), 7.54 (m, 2H), 7.44 (m, 3H), 7.28 (m, 5H), 7.13 (dd, IH), 6.62 (dd, IH), 6.41 (dd, IH), 6.11 (d, IH), 3.85 (dd, 2H), 3.31 (m, 4H), 3.20 (m, 2H), 2.97 (s, 3H), 2.81 (m, 2H), 2.73 (m, 2H), 1.89 (m, IH), 1.62 (m, 2H), 1.38 (m, 2H), 1.25 (m, 2H), 1.09 (m, 2H).
EXAMPLE 265
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 265A
benzyl 4-(piperidin- 1 -ylmethylene)piperidine- 1 -carboxylate To a solution of benzyl 4-formylpiperidine-l -carboxylate (12.5g) in toluene (120 mL) was added piperidine (6.46g). The mixture was stirred at reflux under a Dean-Stark trap overnight. The mixture was then concentrated under vacuum and the residue was used directly in the next step.
EXAMPLE 265B
benzyl 9-oxo-3-azaspiro[5.5]undec-7-ene-3-carboxylate To a solution of EXAMPLE 265A (15.88g) in ethanol (300 mL) was added but-3- enone (3.89 g). The mixture was stirred at reflux overnight. Then acetic acid (30 mL) was added to the mixture which was stirred at reflux again overnight. The mixture was then concentrated under vacuum and the residue was diluted with ethyl acetate (400 mL) and washed with water and brine and dried over Na2S04. After filtration and evaporation of the solvent, column purification gave the title compound.
EXAMPLE 265C
benzyl 9-hydroxy-3-azaspiro[5.5]undecane-3-carboxylate
EXAMPLE 265B (21 g) and tetrahydrofuran (160 mL) were added to 5% Pt-C wet (3.15 g) in a 250 mL pressure bottle and stirred for 1 hour at 30 psi and room temperature. The mixture was filtered though a nylon membrane and the filtrate was concentrated under vacuum to provide the title compound.
EXAMPLE 265D
benzyl 9-oxo-3-azaspiro[5.5]undecane-3-carboxylate To a solution of EXAMPLE 265C (8.0 g) in dichloromethane (200 mL) was added Dess-Martin Periodinane (11.2 g). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (400 mL) and washed with 2N aqueous NaOH, water, and brine. After drying over Na2S04 and filtration, concentration of the solvent gave the crude product which was used directly in the next reaction without further purification.
EXAMPLE 265E
benzyl 9-chloro-8-formyl-3-azaspiro[5.5]undec-8-ene-3-carboxylate
Phosphorus oxychloride (2.33 mL) was added dropwise to a cooled (0°C) solution of EXAMPLE 265D (7.5 g) in N,N-dimethylformamide (10 mL) and dichloromethane (30 mL). The mixture was then stirred overnight before it was diluted with ethyl acetate (300 mL) and washed with aqueous sodium acetate, water (3x), and brine and dried over Na2S04. After filtration and concentration, the crude product was used directly in the next reaction without further purification.
EXAMPLE 265F
benzyl 9-(4-chlorophenyl)-8-formyl-3-azaspiro[5.5]undec-8-ene-3-carboxylate To a mixture of 4-chlorophenylboronic acid (5.94 g), EXAMPLE 265E (11.01 g), palladium(II) acetate (142 mg), K2CO3 (13.2 g) and tetrabutylammonium bromide (10.2 g) was added water (120 mL). The mixture was stirred at 50°C overnight. The mixture was diluted with ethyl acetate (400 mL) and washed with water (3x) and brine and dried over Na2S04. After filtration and concentration, the residue was loaded on a column and eluted with 5 to 20% ethyl acetate in hexane to provide the title compound.
EXAMPLE 265G
benzyl 8-((4-(3-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(methoxycarbonyl)phenyl)piperazin-l- yl)methyl)-9-(4-chlorophenyl)-3-azaspiro[5.5]undec-8-ene-3-carboxylate To a solution of EXAMPLE 15F (1.37 g) and EXAMPLE 265F (1.65 g) in dichloromethane (20 mL) was added sodium triacetoxyborohydride (1.24 g). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with 2N aqueous NaOH, water and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 265H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin- l-yl)benzoate
EXAMPLE 265G (2 g) and tetrahydrofuran (10 mL) were added to 20% Pd(OH)2-C, wet (0.400 g) in a 50 mL pressure bottle and stirred for 16 hours at 30 psi and room temperature. The mixture was filtered though a nylon membrane and evaporation of the solvent gave the title compound.
EXAMPLE 2651
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-(l,3- difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin- 1 -yl)benzoate To a solution of EXAMPLE 265H (320 mg) in dichloromethane (5 mL) was added 1, 3-difluoroacetone (139 mg) and sodium triacetoxyborohydride (157 mg). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with 2N aqueous NaOH, water and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated under vacuum to provide the title compound. EXAMPLE 265J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)- 3-azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-l-yl)benzoic acid To a solution of EXAMPLE 2651 (320 mg) in tetrahydrofuran (4 mL) and methanol (2 mL) was added LiOH H20 (120 mg) and the solution was stirred overnight. The reaction was cooled, carefully neutralized with IN aqueous HCl and extracted with dichloromethane (3x 50 mL). The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered and concentrated under vacuum to provide the title compound. EXAMPLE 265K
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 265 J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.61 (s, 1 H), 8.49 (d, 2 H), 7.72 (m, 1 H), 7.49 (m, 2 H), 7.32 (d, 2 H), 7.07 (m, 3 H), 6.65 (dd, 1 H), 6.35 (d, 1 H), 6.20 (m, 1 H), 4.66 (m, 2 H), 4.50 (m, 2 H), 3.84 (m, 2 H), 3.04 (m, 5 H), 2.70 (m, 6 H), 2.23 (m, 6 H), 2.00 (m, 4 H), 1.35 (m, 12 H). EXAMPLE 266
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 266A
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-isopropyl-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-l-yl)benzoate To a solution of EXAMPLE 265H (320 mg) in dichloromethane (5 mL) was added acetone (143 mg) and sodium triacetoxyborohydride (157 mg). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with 2N aqueous NaOH, water and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 266B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-isopropyl-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 266A for EXAMPLE 2651 in EXAMPLE 265J. EXAMPLE 266C
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 266B for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.54 (s, 1 H), 8.38 (m, 2 H), 7.93 (d, 1 H), 7.60 (m, 3 H), 7.39 (m, 4 H), 7.09 (d, 2 H), 6.85 (d, 1 H), 6.63 (dd, 1 H), 6.27 (dd, 2 H), 3.84 (m, 3 H), 3.08 (m, 8 H), 2.71 (s, 3 H), 2.15 (m, 8 H), 1.71 (m, 9 H), 1.24 (m, 11 H)
EXAMPLE 267
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 265 J for EXAMPLE IE and EXAMPLE 40B for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.56 (s, 1 H), 8.38 (s, 1 H), 8.06 (m, 1 H), 7.57 (d, 1 H), 7.38 (m, 5 H), 7.07 (m, 3 H), 6.64 (dd, 1 H), 6.33 (d, 1 H), 6.23 (m, 1 H), 4.68 (d, 2 H), 4.52 (d, 2 H), 4.21 (d, 2 H), 3.86 (dd, 2 H), 3.08 (m, 8 H), 2.71 (m, 6 H), 2.10 (m, 12 H), 1.42 (m, 7 H).
EXAMPLE 268
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 266B for EXAMPLE IE and EXAMPLE 40B for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.49 (s, 1 H), 8.28 (d, 1 H), 7.94 (dd, 2 H), 7.60 (d, 1 H), 7.35 (m, 4 H), 7.08 (m, 2 H), 6.61 (dd, 1 H), 6.28 (dd, 2 H), 4.18 (d, 2 H), 3.85 (m, 2 H), 3.05 (m, 7 H), 2.71 (s, 3 H), 2.25 (m, 6 H), 2.02 (m, 2 H), 1.63 (m, 8 H), 1.30 (m, 9 H). EXAMPLE 269
N-( {5-chloro-6-[(4-fluoro-l -methylp^
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 269A
5 -chloro-6-((4-fluoro- 1 -methylpiperidin-4-yl)methoxy)pyridine-3 -sulfonamide EXAMPLE 257B (0.131 g) in N,N-dimethylformamide (3.0 mL) was treated with iodomethane (0.043 g) and sodium carbonate (0.079 g) and stirred at ambient temperature for 3 days. The Ν,Ν-dimethylformamide was removed on high vacuum and the concentrate was chromatographed on amine functionalized silica gel with 0 to 2% methanol in CH2CI2 as the eluent.
EXAMPLE 269B
N-({5-chloro-6-[(4-fluoro-l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 269A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.01 (s, IH), 9.11 (d, IH), 8.71 (d, IH), 8.44 (d, IH), 8.16 (d, IH), 7.66 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.76 (dd, IH), 6.54 (d, IH), 6.49 (dd, IH), 4.49 (d, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.68 (m, 2H), 2.38 (m, 2H), 2.26 (m, 5H), 2.14 (t, 4H), 1.97 (m, 6H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 270
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 270A
5-chloro-6-((l-(2-(dimethylamino)acetyl)-4-fluoropiperidin-4-yl)methoxy)pyridine-3- sulfonamide
EXAMPLE 257B (0.131 g), 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.139 g), and sodium carbonate (0.048 g) were combined in a 5-mL vial with N,N- dimethylformamide (3.0 mL) and stirred overnight at ambient temperature. Additional sodium carbonate (0.048 g) was added followed by 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.139 g) and stirring was continued over a second night. The reaction mixture was concentrated under high vacuum, slurried in CH2C12, filtered, concentrated and chromatographed on amine functionalized silica gel with 0 to 4% methanol in CH2C12 as the eluent.
EXAMPLE 270B
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 270A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.04 (s, 1H), 9.12 (d, 1H), 8.73 (d, 1H), 8.42 (d, 1H), 8.11 (d, 1H), 7.66 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.76 (dd, 1H), 6.52 (d, 1H), 6.49 (dd, 1H), 4.66 (d, 1H), 4.52 (dd, 2H), 4.07 (d, 1H), 3.46 (m, 1H), 3.40 (m, 1H), 3.30 (m, 1H), 3.11 (m, 1H), 3.06 (m, 4H), 2.77 (s, 2H), 2.35 (s, 6H), 2.26 (t, 2H), 2.14 (m, 4H), 2.05 (m, 2H), 1.97 (s, 2H), 1.81 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 271
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-({3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 271 A
tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)-4-fluoropiperidine- 1 -carboxylate
A solution of EXAMPLE 263E (2.0 g) and diethylaminosulfur trifluoride (1.39 mL) in dichloromethane (40 mL) was stirred for 24 hours. The reaction was quenched with water (30 mL), extracted twice with ether, and the combined extracts were washed with water, and brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 5% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 27 IB
4-((4'-chlorobiphenyl-2-yl)methyl)-4-fluoropiperidine The title compound was prepared by substituting EXAMPLE 271 A for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 271C
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)-4- fluoropiperidin-l-yl)benzoate
The title compound was prepared by substituting EXAMPLE 27 IB for EXAMPLE 263G in EXAMPLE 263H.
EXAMPLE 27 ID
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)-4- fluoropiperidin-l-yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 271C for EXAMPLE 31 in EXAMPLE 3 J. EXAMPLE 27 IE
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-({3-nitro-4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 27 ID for EXAMPLE IE EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 11.46 (br s, IH), 8.62 (t, IH), 8.56 (d, IH), 8.03 (d, IH), 7.81 (dd, IH), 7.52 (m, 3H), 7.44 (d, 2H), 7.28 (m, 5H), 7.14 (m, IH), 6.68 (dd, IH), 6.40 (dd, IH), 6.19 (d, IH), 3.84 (dd, 2H), 3.31 (m, 9H), 2.95 (d, 2H), 2.81 (m, 2H), 1.91 (m, IH), 1.62 (m, 2H), 1.45 (m, 2H), 1.29 (m, 2H). EXAMPLE 272
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-( {5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 27 ID for EXAMPLE IE and EXAMPLE 96A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 11.64 (br s, IH), 8.58 (m, IH), 8.25 (m, IH), 8.03 (d, IH), 7.70 (dd, IH), 7.50 (m, 4H), 7.43 (m, 3H), 7.28 (m, 4H), 7.15 (m, IH), 6.68 (dd, IH), 6.40 (dd, 1H), 6.19 (d, 1H), 4.54 (d, 2H), 4.04 (m, 1H), 3.75 (m, 2H), 3.58 (m, 2H), 2.95 (d, 2H), 2.80 (m, 2H), 1.88 (m, 2H), 1.82 (m, 2H), 1.48 (m, 2H), 1.28 (m, 2H), 0.85 (m, 2H).
EXAMPLE 273
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l- yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino] -3 -
(trifluoromethyl)phenyl}sulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 266B for EXAMPLE IE and EXAMPLE 42A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.57 (s, 1 H), 7.97 (d, 1 H), 7.77 (s, 1 H), 7.55 (m, 2 H), 7.45 (m, 1 H), 7.36 (m, 3 H), 7.08 (d, 2 H), 6.62 (dd, 2 H), 6.35 (dd, 1 H), 6.21 (d, 1 H), 3.82 (m, 3 H), 3.06 (m, 9 H), 2.72 (m, 3 H), 2.25 (m, 8 H), 2.09 (m, 2 H), 1.56 (m, 9 H), 1.20 (m, 10 H).
EXAMPLE 274
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 274A
(R)-5-chloro-6-(l-(3-fluoro-2-(fluoromethyl)propyl)pyrrolidin-3-yloxy)pyridine-3- sulfonamide
The title compound was prepared by substituting l,3-difluoropropan-2-one for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 26 IB for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A.
EXAMPLE 274B
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 274 A for EXAMPLE
1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.52 (s, 1 H), 8.32 (d, 1 H), 8.01 (d, 1 H), 7.93 (d, 1 H), 7.59 (d, 1 H), 7.42 (m, 1 H), 7.33 (m, 3 H), 7.05 (d, 2 H), 6.63 (dd, 1 H), 6.31 (dd, 1 H), 6.25 (d, 1 H), 5.38 (m, 1 H), 4.65 (t, 2 H), 4.53 (t, 2 H), 3.02 (s, 4 H), 2.94 (m, 5 H), 2.75 (s, 2 H), 2.66 (m, 1 H), 2.23 (m, 7 H), 1.96 (s, 2 H), 1.82 (m, 1 H), 1.39 (t, 2 H), 0.93 (s, 6 H).
EXAMPLE 275
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 275A
3 -(2-(benzyloxy)ethoxy)tetrahydrofuran
Tetrahydrofuran-3-ol (0.881 g) in tetrahydrofuran (15 mL) was treated with 60% sodium hydride (0.8 g). After 10 minutes, ((2-bromoethoxy)methyl)benzene (3.23 g) was added. The solution was stirred for 16 hours. The reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was separated, and was extracted with additional ethyl acetate twice. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with 1 : 1 ethyl acetate: hexane to provide the title compound.
EXAMPLE 275B
2-(tetrahydrofuran-3 -y loxy)ethanol
EXAMPLE 275A (0.85 g) and 5% palladium on carbon (0.1 g) in ethanol (10 mL) was treated with a balloon of hydrogen. The reaction was stirred overnight. The solid was filtered off, and the filtrate was concentrated to give the title compound. EXAMPLE 275C
3-nitro-4-(2-(tetrahydrofuran-3-yloxy)ethoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 275B for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 275D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 275 C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.65 (s, 1H), 8.32 (s, 1H), 8.00-8.02 (m, 2H), 7.49-7.52 (m, 2H), 7.39-7.41 (m, 1H), 7.38 (d, 2H), 7.04 (d, 2H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.21 (d, 1H), 4.33-4.35 (m, 2H), 4.18-4.21 (m, 1H), 3.62-3.67 (m, 4H), 3.09 (s, 4H), 2.83 (s, 2H), 2.26 (s, 2H), 2.15 (s, 2H), 1.96 (s, 2H), 1.85-1.94 (m, 2H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 276
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 276A
trans-4-(aminomethyl)cyclohexanecarbonitrile
To a solution of tert-butyl (trans-4-(cyanomethyl)cyclohexyl)methylcarbamate (500 mg) in dichloromethane (10 mL) was slowly added trifluoroacetic acid (2 mL) at 0°C. The reaction mixture was warmed to room temperature, stirred for 1 hour and concentrated to provide the title compound.
EXAMPLE 276B
4-((trans-4-cyanocyclohexyl)methylamino)-3-nitrobenzenesulfonamide A mixture of 4-fluoro-3-nitrobenzenesulfonamide (347 mg) and EXAMPLE 276A (300 mg) in tetrahydrofuran (20 mL) was treated with triethylamine (1.4 mL) overnight and concentrated. The residue was triturated with ethyl acetate to provide the title compound.
EXAMPLE 276C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-cyanocyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 276B in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1 H), 11.36 (s, 1 H), 8.60 (t, 1 H), 8.56 (d, 1 H), 8.04 (d, 1 H), 7.79 (dd, 1 H), 7.47 - 7.54 (m, 3 H), 7.34 (d, 2 H), 7.01 - 7.09 (m, 3 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.25 (t, 2 H), 3.07 (s, 4 H), 2.76 (s, 2 H), 2.57 - 2.68 (m, 1 H), 2.17 (d, 6 H), 1.92 - 2.06 (m, 4 H), 1.78 (d, 2 H), 1.66 (s, 1 H), 1.35 - 1.53 (m, 4 H), 0.96 - 1.10 (m, 2 H), 0.92 (s, 6 H).
EXAMPLE 277
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 277A
methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate
To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoroacetic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product.
EXAMPLE 277B
methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarboxylate EXAMPLE 277A (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2: 1 dimethoxy ethane /methanol (600 mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product.
EXAMPLE 277C
(2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 277B (53.8 g) and ether (400 mL), was added methanol (25 mL) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN HCl with ice-cooling. The mixture was diluted with water and extracted with ether (3x 100 mL). The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 277D
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine- 1 - carboxylate
Mesyl Chloride (7.5 mL) was added via syringe to EXAMPLE 277C (29.3 g) and triethylamine (30 mL) in CH2CI2 (500 mL) at 0°C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE 277E
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine EXAMPLE 277D (1 g) was stirred in dichloromethane (10 mL), trifluoroacetic acid (10 mL), and triethylsilane (1 mL) for 1 hour. The mixture was concentrated, taken up in a mixture of dichloromethane (100 mL) and saturated aqueous Na2C03 solution (20 mL) and stirred for 10 minutes. The layers were separated, and the organic layer was dried over Na2S04, filtered, and concentrated to give the product.
EXAMPLE 277F
5-bromo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine To a mixture of 5-bromo-lH-pyrrolo[2,3-b]pyridine (15.4 g) in tetrahydrofuran (250 mL) was added 1M lithium hexamethyldisilazide in tetrahydrofuran (86 mL), and after 10 minutes, TIPS-Cl (triisopropylchlorosilane ) (18.2 mL) was added. The mixture was stirred at room temperature for 24 hours. The reaction was diluted with ether, and the resulting solution was washed twice with water. The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10% ethyl acetate/hexanes.
EXAMPLE 277G
l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-5-ol
To a mixture of EXAMPLE 277F (24.3 g) in tetrahydrofuran (500 mL) at -78°C was added 2.5M BuLi (30.3 mL). After 2 minutes, trimethylborate (11.5 mL) was added, and the mixture was allowed to warm to room temperature over 1 hour. The reaction was poured into water, extracted thee times with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was taken up in tetrahydrofuran (200 mL) at 0°C, and 1M NaOH (69 mL) was added, followed by 30% H202 (8.43 mL), and the solution was stirred for 1 hour. Na2S203 (10 g) was added, and the pH was adjusted to 4-5 with concentrated HCl and solid NaH2P04. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2S04), filtered, and
concentrated. The crude product was chromatographed on silica gel with 5-25% ethyl acetate/hexanes.
EXAMPLE 277H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 277G (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and
K3P04 (9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes.
EXAMPLE 2771
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate A mixture of EXAMPLE 277H (1.55 g), EXAMPLE 277E (2.42 g), and HK2P04 (1.42 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed three times with 1M NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50%) ethyl acetate/hexanes. EXAMPLE 277J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
EXAMPLE 2771 (200 mg) in dioxane (10 mL) and 1M NaOH (6 mL) at 50°C was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product. EXAMPLE 277K
5, 6-dichloropyridine-3 -sulfonamide
To a solution of 5,6-dichloropyridine-3-sulfonyl chloride (32.16 g) in isopropyl alcohol (300 mL) at 0 °C was added a 30% aqueous solution of NH4OH (50.8 mL). After stirring overnight, the solvent was reduced to 1/3 of the original volume. It was then partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was chromatographed on silica gel. The material was then slurried in 1 :9 ethyl acetate/hexanes, filtered and dried under vacuum to give the title compound.
EXAMPLE 277L
tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine- 1 -carboxylate 1-Tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.0 g) in tetrahydrofuran (5 mL) was treated with 1.0 N LiAlH4 in tetrahydrofuran (2.54 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. Water (0.6 mL) was added to the reaction mixture drop-wise, followed by 2 N aqueous NaOH (0.2 mL). The reaction was stirred for another 1 hour. The solid was removed by filtration via a pack of diatomaceous earth and washed with ethyl acetate. The filtrate was washed with brine, dried over MgS04, filtered, and concentrated to give the product.
EXAMPLE 277M
tert-butyl 4-((3 -chloro-5 -sulfamoylpyridin-2-yloxy)methyl)-4-fluoropiperidine- 1 -carboxylate To a solution of EXAMPLE 277L (1 g) in tetrahydrofurab (15 mL) was added NaH (60%) dispersion in mineral oil, 685 mg), and the solution was stirred for 10 minutes.
EXAMPLE 227K (1 g) was added and the reaction stirred for 24 hours. The mixture was poured into water, neutralized with 10% HCl, and extracted with ethyl acetate thee times. The combined organic layers were washed with brine, dried over MgS04, filtered, and
concentrated. The residue was purified with flash column chromatography on silica gel eluting with 30% ethyl acetate in hexanes.
EXAMPLE 277N
5 -chloro-6-((4-fluoropiperidin-4-yl)methoxy)pyridine-3 -sulfonamide ditrifluoroacetic acid EXAMPLE 277M (13 mL) was treated with trifluoroacetic acid (2.363 mL), stirred at ambient temperature for 2 hours, concentrated and dried to give the title compound.
EXAMPLE 2770
5 -chloro-6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide
EXAMPLE 277N (0.088 g) and oxetan-3-one (0.014 g) were combined in
dichloromethane (2.0 mL) and dimethylformamide (1.0 mL) and stirred at ambient temperature for 45 minutes. Sodium triacetoxyborohydride (0.064 g) was added in portions. Stirring was continued overnight at ambient temperature. Additional oxetan-3-one (0.014 g) was added and stirring was continued for 30 minutes at ambient temperature before more sodium triacetoxyborohydride (0.064 g) was added. The reaction mixture was stirred for 72 hours at ambient temperature, concentrated, chromatographed on silica gel with 0 to 5% methanol in dichloromethane as the eluent, and dried in a vacuum oven at 80 °C to give the title compound.
EXAMPLE 277P
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 277J (0.063 g), EXAMPLE 2770 (0.042 g), l-ethyl-3-[3-
(dimethylamino)propyl]-carbodiimide hydrochloride (0.032 g), and 4-dimethylaminopyridine (0.027 g) were combined in a 4-mL vial with dichloromethane (1.0 mL) and stirred overnight at ambient temperature. The reaction mixture was chromatographed directly without aqueous workup on silica gel with 0-4% methanol in dichloromethane as the eluent. Fractions containing the desired product were concentrated, slurried in acetonitrile, concentrated and dried overnight in a vacuum oven at 80 °C to give the title compound. 1H NMR (500 MHz, pyridine-d5) δ 13.05 (s, 1H), 9.13 (d, 1H), 8.72 (d, 1H), 8.41 (d, 1H), 8.10 (d, 1H), 7.67 (m, 1H), 7.66 (d, 1H), 7.44 (m, 2H), 7.07 (m, 2H), 6.76 (dd, 1H), 6.51 (m, 2H), 4.63 (m, 4H), 4.53 (d, 2H), 3.39 (m, 1H), 3.07 (m, 4H), 2.77 (s, 2H), 2.51 (m, 2H), 2.25 (m, 2H), 2.18 (m, 2H), 2.13 (m, 4H), 2.06 (t, 2H), 1.97 (s, 2H), 1.89 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 278
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 278A
5-bromo-6-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting 2-(tetrahydro-2H-pyran-4-yl)ethanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 36B .
EXAMPLE 278B
5-cyano-6-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 278A for EXAMPLE 36B in EXAMPLE 36C.
EXAMPLE 278C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- cyano-6- [2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3 -yl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 278B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.60 (s, IH), 8.70 (s, IH), 8.48 (s, IH), 7.96 (d, IH), 7.56 (d, IH), 7.45-7.47 (m, IH), 7.40 (s, IH), 7.36 (d, 2H), 7.06 (d, 2H), 6.67 (dd, IH), 6.34 (dd, IH), 6.25 (d, IH), 4.47 (d, 2H), 3.80-3.84 (m, 2H), 3.24-3.28 (m, 2H), 3.12 (s, 2H), 2.16 (s, 2H), 1.97 (s, 2H), 1.61-1.71 (m, 4H), 1.40 (t, 2H), 1.21-1.25 (m, 2H), 0.93 (s, 6H).
EXAMPLE 279
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 279A
4-(furan-3 -ylmethoxy)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting furan-3-ylmethanol for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 279B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3- furylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 279A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 8.34 (s, 1H), 8.03-8.06 (m, 2H), 7.83 (s, 1H), 7.69 (t, 1H), 7.51-7.53 (m, 4H), 7.34-7.36 (m, 2H), 7.04-7.06 (m, 2H), 6.68 (dd, 1H), 6.57 (s, 1H), 6.40 (dd, 1H), 6.20 (d, 1H), 5.23 (s, 2H), 3.10 (s, 4H), 2.83 (s, 2H), 2.15-2.32 (m, 6H), 1.39 (t, 2H), 0.92 (s, 6H).
EXAMPLE 280
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 280A
(R)-tert-butyl 3 -((3 -chloro-5 -sulfamoylpyridin-2-yloxy)methyl)pyrrolidine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and (R)-tert-butyl 3 -(hydroxymethyl)pyrrolidine-l -carboxylate for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 280B
(R)-5 -chloro-6-(pyrrolidin-3 -ylmethoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 280A for tert-butyl (4- (l,3-difluoropropan-2-yl)morpholin-2-yl)methylcarbamate in EXAMPLE 252B.
EXAMPLE 280C
(R)-5 -chloro-6-(( 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yl)methoxy)pyridine-3 -sulfonamide
The title compound was prepared by substituting l,3-difluoropropan-2-one for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 280B for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A. EXAMPLE 280D
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 280C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.57 (s, 1 H), 8.38 (d, 1 H), 8.07 (d, 1 H), 7.96 (d, 1 H), 7.57 (d, 1 H), 7.44 (m, 1 H), 7.35 (m, 3 H), 7.05 (d, 2 H), 6.64 (dd, 1 H), 6.33 (dd, 1 H), 6.23 (d, 1 H), 4.65 (d, 2 H), 4.53 (dd, 2 H), 2.92 (m, 8 H), 2.75 (m, 4 H), 2.58 (m, 2 H), 2.20 (m, 6 H), 1.96 (m, 4 H), 1.53 (m, 1 H), 1.39 (t, 2 H), 0.89 (s, 6 H).
EXAMPLE 281
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfo^ 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 281 A
(R)-5 -chloro-6-(( 1 -(2,2-difluoroethyl)pyrrolidin-3 -yl)methoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 280B for EXAMPLE 261B in EXAMPLE 261C.
EXAMPLE 28 IB
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 281 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.59 (s, 1 H), 8.41 (d, 1 H), 8.10 (d, 1 H), 7.98 (d, 1 H), 7.56 (d, 1 H), 7.46 (m, 1 H), 7.41 (d, 1 H), 7.34 (d, 2 H), 7.04 (d, 2 H), 6.65 (dd, 1 H), 6.35 (dd, 1 H), 6.23 (m, 1 H), 6.03 (m, 1 H), 3.06 (s, 4 H), 2.84 (m, 6 H), 2.63 (m, 4 H), 2.20 (m, 6 H), 1.94 (m, 3 H), 1.53 (m, 1 H), 1.39 (t, 2 H), 0.91 (s, 6 H). EXAMPLE 282
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 282A
5-chloro-6-((l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl)methoxy)pyridine-3- sulfonamide
EXAMPLE 257B (0.088 g) and l,3-difluoropropan-2-one (0.028 g) were combined in dichloromethane (2 mL) and N,N-dimethylformamide (0.500 mL) and stirred at ambient temperature for 45 minutes. Sodium triacetoxyborohydride (0.064 g) was added in portions and then the reaction mixture was stirred overnight at ambient temperature. Additional 1,3- difluoropropan-2-one (0.028 g) was added, followed 30 minutes later by the addition of more sodium triacetoxyborohydride (0.064 g). The reaction mixture was stirred at ambient temperature for 72 hours. Additional l,3-difluoropropan-2-one (0.028 g) was again added, followed 30 minutes later by the addition of more sodium triacetoxyborohydride (0.064 g). The reaction mixture was stirred overnight at ambient temperature. Additional 1,3- difluoropropan-2-one (0.028 g) was again added, followed 30 minutes later by the addition of more sodium triacetoxyborohydride (0.064 g). The reaction mixture was stirred overnight at ambient temperature. The reaction mixture was concentrated under high vacuum to remove Ν,Ν-dimethylformamide and then chromatographed on silica gel with 0 to 4% methanol in CH2CI2 as the eluent.
EXAMPLE 282B
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 282A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.05 (s, 1H), 9.12 (t, 1H), 8.72 (d, 1H), 8.41 (d, 1H), 8.10 (d, 1H), 7.66 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.75 (dd, 1H), 6.50 (m, 2H), 4.77 (dd, 1H), 4.65 (dd, 1H), 4.52 (dd, 2H), 3.06 (m, 4H), 2.93 (t, 1H), 2.80 (m, 5H), 2.52 (m, 1H), 2.26 (t, 2H), 2.13 (m, 4H), 2.04 (m, 2H), 1.97 (s, 2H), 1.85 (m, 2H), 1.39 (t, 2H), 1.28 (m, 2H), 0.93 (s, 6H). EXAMPLE 283
N-({3-chloro-4-[(4-fluoro-l-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
EXAMPLE 283A
3 -chloro-4-((4-fluoro- 1 -methylpiperidin-4-yl)methoxy)benzenesulfonamide
To a solution of (4-fluoro-l-methylpiperidin-4-yl)methanol (0.265 g) in
tetrahydrofuran (2 mL) was added sodium hydride (0.288 g). After 15 minutes, 3-chloro-4- fluorobenzenesulfonamide (0.377 g) was added as a solution in tetrahydrofuran (1 mL). The reaction was stirred for 2 hours, quenched with water (5 mL), adjusted to pH~7 with IN aqueous HC1, and extracted with dichloromethane (2 x 25 mL). The organic layer was washed with brine (25 mL), dried over magnesium sulfate, filtered and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 0.1% to 10% methanol containing 2N NH3/dichloromethane over 30 minutes gave the title compound.
EXAMPLE 283B
N-({3-chloro-4-[(4-fluoro-l-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 283A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.60 (s, 1H), 10.68 - 9.84 (m, 1H), 7.99 (d, 1H), 7.79 (d, 1H), 7.63 (t, 1H), 7.54 (d, 1H), 7.50 - 7.38 (m, 2H), 7.34 (d, 2H), 7.04 (d, 3H), 6.64 (dd, 1H), 6.36 (dd, 1H), 6.22 (s, 1H), 4.23 (d, 2H), 3.03 (s, 6H), 2.71 (m, 4H), 2.07 (m, 12H), 1.38 (s, 3H), 1.24 (s, 2H), 0.92 (s, 6H).
EXAMPLE 284
4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide EXAMPLE 284A
3-cyano-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide To a solution of (tetrahydro-2H-pyran-4-yl)methanol (0.258 g) in tetrahydrofuran (5 mL) was added sodium hydride (0.355 g) and the reaction stirred at room temperature for 15 minutes. EXAMPLE 52A (0.400 g) was added and the reaction stirred for an additional 1 hour. The reaction was poured into ethyl acetate (50 mL) and IN aqueous HCl (35 mL). The organic layer was washed with brine (35 mL) dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 10% to 100% ethyl acetate/hexanes over 30 minutes gave the title compound.
EXAMPLE 284B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 284A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.69 (s, 1H), 11.60 - 11.16 (m, 1H), 8.15 (s, 1H), 8.08 - 8.01 (m, 2H), 7.58 - 7.46 (m, 3H), 7.35 (d, J= 8.4, 2H), 7.29 (d, 1H), 7.04 (d, 2H), 6.68 (d, 1H), 6.40 (dd, 1H), 6.20 (s, 1H), 4.05 (d, 2H), 3.89 (d, 2H), 3.37 (d, 4H), 3.09 (s, 4H), 2.81 (s, 2H), 2.21 (d, 7H), 1.96 (s, 2H), 1.67 (d, 2H), 1.39 (s, 2H), 0.92 (s, 6H).
EXAMPLE 285
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 285A
5-chloro-6-((l-(2,2-difluoroethyl)-4-fiuoropiperidin-4-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 257B (0.263 g), l,l-difluoro-2-iodoethane (0.23 g), and sodium carbonate (0.254 g) were combined in a 20-mL vial with N,N-dimethylformamide (6 ml) and stirred at 70 °C overnight. The reaction mixture was concentrated under high vacuum and then chromatographed on silica gel with 0 to 5% methanol in CH2CI2 as the eluent. EXAMPLE 285B
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 285A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.05 (s, IH), 9.12 (d, IH), 8.72 (d, IH), 8.41 (d, IH), 8.10 (d, IH), 7.66 (m, 2H), 7.43 (m, 2H), 7.06 (m, 2H), 6.75 (dd, IH), 6.50 (m, 2H), 6.18 (tt, 2H), 4.51 (d, 2H), 3.07 (m, 4H), 2.80 (m, 6H), 2.60 (td, 2H), 2.25 (t, 2H), 2.13 (m, 4H), 2.03 (t, 2H), 1.97 (s, 2H), 1.93 (m, IH), 1.85 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 286
N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 286A
3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 37C for (4-fluoro-l- methylpiperidin-4-yl)methanol in EXAMPLE 283A.
EXAMPLE 286B
N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 286A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.71 (s, IH), 11.56 - 11.16 (m, IH), 8.06 (d, IH), 7.90 (d, IH), 7.81 (d, IH), 7.64 - 7.45 (m, 3H), 7.34 (d, 2H), 7.26 (d, IH), 7.04 (d, 2H), 6.68 (d, IH), 6.42 (dd, IH), 6.18 (s, IH), 4.28 (d, 2H), 3.78 (d, 2H), 3.61 (dd, 2H), 3.07 (s, 4H), 2.76 (s, 2H), 2.17 (d, 6H), 1.87 (dd, 6H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 287
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 287A
(4,4-difluorocyclohexyl)methanol
Ethyl 4,4-difluorocyclohexanecarboxylate (1.0 g, 5.20 mmol) in diethyl ether (2 mL) was added dropwise to lithium aluminium hydride (0.24 g) in diethyl ether (15 mL), and heated under reflux for 4 hours. The reaction was then cooled to 0°C, and water was added (0.24 mL), followed by 5N aqueous NaOH (0.24 mL) and water (0.72 mL). Then Na2S04 and more diethyl ether (40 mL) were added, and the mixture was stirred for 30 minutes, then filtered through celite. After concentration, the residue was diluted with CH2C12 and Na2S04 was added, and the mixture was filtered and concentrated to provide the title compound.
EXAMPLE 287B
5-chloro-6-((4,4-difluorocyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 287A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 287C
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 287B for EXAMPLE
1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.63 (s, IH), 8.46 (d, IH), 8.14 (d, IH), 8.00 (d, IH), 7.56 (d, IH), 7.47 (m, 2H), 7.35 (d, 2H), 7.03 (d, 2H), 6.66 (dd, IH), 6.37 (m, IH), 6.21 (d, IH), 4.25 (d, 2H), 3.07 (br m, 4H), 2.82 (br s, 2H), 2.30 (br m, 4H), 2.16 (br m, 2H), 2.00, 1.95, 1.85 (all m, total 9H), 1.40 (t, 2H), 1.37 (m, 2H), 0.92 (s, 6H). EXAMPLE 288
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- {[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidm^
yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 288A
5 -Nitro-3 -(trifluoromethyl)pyridin-2-ol
3-(Trifluoromethyl)pyridin-2-ol (2.3 g) was added to concentrated sulfuric acid (15 mL) at 0 °C. The mixture was stirred at 0°C for 5 minutes. To this solution was added fuming nitric acid (6 mL) dropwise over 5 minutes. The reaction mixture was stirred at room temperature for 2 hours, and then heated at 50°C for 3 hours. After cooling, the reaction mixture was poured onto ice (200 g), and the mixture was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure to provide the title compound.
EXAMPLE 288B
2-Chloro-5 -nitro-3 -(trifluoromethyl)pyridine
A mixture of EXAMPLE 288A (1.69 g), phosphorus pentachloride (2.03 g), and phosphoryl trichloride (0.97 mL) was heated at 90°C for 3 hours. After cooling, the reaction mixture was poured into ice, and extracted with ethyl acetate three times. The extract was washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 288C
6-Chloro-5 -(trifluoromethyl)pyridin-3 -amine
A mixture of iron (1.5 g) and ammonium chloride (2.38 g) in water (40 mL) was stirred at room temperature for 5 minutes. To this suspension was added EXAMPLE 288B in methanol (40 mL). The reaction mixture was stirred at room temperature for 1 hour. More iron (1.8 g) was added to the reaction mixture, and it was stirred for another 3 hours. The solid from the reaction mixture was filtered off, and the filtrate was partitioned between water and ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 20% ethyl acetate in hexanes to provide the title compound. EXAMPLE 288D
6-chloro-5 -(trifluoromethyl)pyridine-3 -sulfonyl chloride Under ice-cooling, thionyl chloride (4 mL) was added dropwise over 20 minutes to water (27 mL). The mixture was stirred overnight for 12 hours to give a S02 containing solution. Separately, EXAMPLE 288C (1.14 g) in dioxane (5 mL) was added to concentrated HC1 (20 mL) at 0°C. The solution was stirred for 5 minutes. To this suspension/solution was added sodium nitrite (0.44 g) in water (6 mL) dropwise at 0°C. The solution was stirred at 0°C for 3 hours. During this time, any solid formed was crushed with a glass rod to make sure that EXAMPLE 288C was completely reacted. To the S02 containing solution was added copper(I) chloride (0.115 g). Then, to this solution was added the diazotized EXAMPLE 288C at 0°C. The solution was stirred for 30 minutes. The reaction mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 5% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 288E
6-chloro-5 -(trifluoromethyl)pyridine-3 -sulfonamide EXAMPLE 288D (2.03 g) in dioxane (20 mL) solution was cooled to 0°C.
Ammonium hydroxide solution was added dropwise. The reaction mixture was stirred at 0°C for 2 hours followed by room temperature over night. The solvent was partially removed, and the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 0-3% methanol in dichloromethane to afford the title compound.
EXAMPLE 288F
tert-butyl 4-fluoro-4-((5 -sulfamoyl-3 -(trifluoromethyl)pyridin-2-yloxy)methyl)piperidine- 1 carboxylate
The title compound was prepared by substituting EXAMPLE 288E for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 322A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 288G
6-((4-fluoropiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonami
The title compound was prepared by substituting EXAMPLE 288F for tert-butyl (4- (l,3-difluoropropan-2-yl)morpholin-2-yl)methylcarbamate in EXAMPLE 252B.
EXAMPLE 288H
6-((l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyri
3 -sulfonamide
The title compound was prepared by substituting l,3-difluoropropan-2-one for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 288G for tert-butyl piperazine-1- carboxylate in EXAMPLE 1 A.
EXAMPLE 2881
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [6- {[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3- yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 288H for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.50 (s, 1 H), 8.57 (s, 1 H), 8.27 (d, 1 H), 7.91 (d, 1 H), 7.58 (d, 1 H), 7.40 (m, 1 H), 7.35 (d, 2 H), 7.28 (d, 1 H), 7.05 (d, 2 H), 6.61 (dd, 1 H), 6.29 (dd, 1 H), 6.24 (d, 1 H), 4.67 (d, 2 H), 4.55 (d, 2 H), 4.50 (s, 1 H), 4.44 (s, 1 H), 3.06 (m, 5 H), 2.73 (m, 6 H), 2.19 (d, 6 H), 1.90 (m, 7 H), 1.39 (t, 2 H), 0.93 (s, 6 H).
EXAMPLE 289
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydroi iran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 289A
5-chloro-6-(2-(tetrahydrofuran-2-yl)ethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting 2-(tetrahydro-2H-pyran-4-yl)ethanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 40 A for EXAMPLE 36A in
EXAMPLE 36B. EXAMPLE 289B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- chloro-6-[2-(tetrahydromran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 289A for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1H), 8.52 (d, 1H), 8.18 (s, 1H), 8.02 (s, 1H), 7.50-7.55 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, 1H), 6.38 (dd, 1H), 6.21 (d, 1H), 4.39-4.51 (m, 4H), 3.87-3.94 (m, 1H), 3.73-3.78 (m, 1H), 3.57-3.62 (m, 1H), 3.11 (s, 4H), 2.89 (s, 2H), 2.33 (s, 4H), 2.15 (s, 2H), 1.77-2.01 (m, 7H), 1.45-1.54 (m, 1H), 1.40 (t, 2H), 0.93 (s, 6H).
EXAMPLE 290
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3-methylpiperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 290A
2-chloro-4,4-dimethylcyclohex- 1 -enecarbaldehyde
Into a 250 ml round-bottomed flask was added N,N-dimethylformamide (3.5 mL) in dichloromethane (30 mL). The mixture was cooled to -10°C, and phosphoryl trichloride (4 mL) was added dropwise. The solution was warmed up to room temperature and 3,3- dimethylcyclohexanone (5.5 mL) was added slowly. The mixture was heated to reflux overnight. The reaction mixture was quenched by 0°C solution of sodium acetate (25 g in 50 mL water). The aqueous layer was extracted with ether (3 x 200 mL). The organic layers were combined, dried over Na2S04, filtered, and dried under vacuum.
EXAMPLE 290B
2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarbaldehyde Into a 1 L round-bottomed flask was added EXAMPLE 290 A (6.8 g), 4- chlorophenylboronic acid (6.5 g) and palladium(II) acetate (0.2 g) in water (100 mL) to give a suspension. Potassium carbonate (15 g) and tetrabutylammonium bromide (10 g) were added. After degassing after subjecting to vacuum and nitrogen, the mixture was stirred at 45°C for 4 hours. After filtering through silica gel, diethyl ether (4x 200 mL) was used to extract the product. The combined organic layers were dried over Na2S04 and filtered. The filtrate was concentrated and purified by flash chromatography on silica with 0-10% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 290C
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)-3-methylpiperazine-
1-carboxylate
To a solution of tert-butyl 3-methylpiperazine-l-carboxylate (0.256 g) and
EXAMPLE 290B (0.350 g) in dichloromethane (2 mL) was added sodium
triacetoxyborohydride (0.406 g) and the reaction was stirred at room temperature overnight. The reaction was quenched with NaHC03 solution (50 mL) and extracted with
dichloromethane (50 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 0.5% to 2.5% methanol/dichloromethane gave the title compound.
EXAMPLE 290D
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)-2-methylpiperazine A solution of EXAMPLE 290C (0.298 g) and HC1 (4.0M in dioxane, 2 mL) were stirred for 1 hour. The reaction was concentrated and partioned between dichloromethane (100 mL) and NaHC03 (100 mL). The organic layer was washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated to provide the title compound.
EXAMPLE 290E
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)-3 -methylpiperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 290D for EXAMPLE 3E in EXAMPLE 31.
EXAMPLE 290F
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- eny l)methyl)-3 -methylpiperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 290E for EXAMPLE 15G in EXAMPLE 15H. EXAMPLE 290G
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3-methylpiperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 290F for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.66 (s, IH), 11.54 - 11.30 (m, IH), 8.62 - 8.53 (m, 2H), 8.03 (d, IH), 7.78 (d, IH), 7.48 (d, 3H), 7.34 (d, 2H), 7.06 (t, 3H), 6.68 (d, IH), 6.38 (dd, IH), 6.21 (s, IH), 3.84 (d, 2H), 3.23 (s, 4H), 2.75 (s, 4H), 1.64 (s, 8H), 1.62 (d, 2H), 1.42 - 1.17 (m, 6H), 0.92 (s, 6H), 0.87 (s, 3H).
EXAMPLE 291
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(cyclopropylamino)propyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
EXAMPLE 291 A
tert-butyl 2-cyanoethyl(cyclopropyl)carbamate
To a solution of 3-(cyclopropylamino)propanenitrile (5.0g) in tetrahydrofuran (30 mL) was added di-tert-butyl dicarbonate (9.9 lg) and a catalytic amount of 4- dimethylaminopyridine. The mixture was stirred overnight. The mixture was diluted with ethyl acetate (400 mL) and washed with 5% aqueous HC1, water and brine. After drying over Na2S04, the mixture was filtered, and the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 29 IB
tert-butyl 3 -aminopropyl(cyclopropyl)carbamate
EXAMPLE 291 A (9.75 g) and 7M NH3-methanol (25 mL) were added to a Ra-Ni 2800, water slurry (19.50 g, 332 mmol) in a 250 mL pressure bottle and stirred for 2 hours at 30 psi and room temperature. The mixture was filtered though a nylon membrane and evaporation of the solvent gave the title compound.
EXAMPLE 291C
tert-butyl cyclopropyl(3-(2-nitro-4-sulfamoylphenylamino)propyl)carbamate To a solution of 4-chloro-3-nitrobenzenesulfonamide (2.5 g), and EXAMPLE 291B (2.26 g) in dioxane (20 mL) was added N,N-diisopropylethylamine (5 mL). The mixture was stirred at reflux overnight. The mixture was diluted with ethyl acetate (400 mL) and washed with water and brine. After drying over Na2S04, the mixture was filtered, and the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 29 ID
tert-butyl 3-(4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)propyl(cyclopropyl)carbamate
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 291C for EXAMPLE IF in EXAMPLE 1G.
EXAMPLE 29 IE
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [3 -(cyclopropylamino)propyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-
5 -yloxy)benzamide
To a solution of EXAMPLE 291D (2.56 g) in dichloromethane (10 mL) was added trifluoroacetic acid(10 mL). The mixture was stirred for 2 hours. The mixture was concentrated under vacuum and the residue was dissolved in dichloromethane (300 mL) and washed with aqueous NaHC03, water, and brine and dried over Na2S04. Filtration and evaporation of the solvent gave the crude product. The title compound was obtained by dissolving 200 mg of the crude material in dimethylsulfoxide/methanol (1 : 1, 10 mL) and loaded on Gilson, C18(100A) 250x121.2 mm(lOmicron), eluting with 30% acetonitrile to 65% acetonitrile over 40 minutes. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.54 (s, 1 H), 8.43 (m, 2 H), 7.94 (d, 1 H), 7.71 (dd, 1 H), 7.57 (d, 1 H), 7.43 (m, 1 H), 7.34 (m, 3 H), 7.05 (d, 2 H), 6.90 (d, 1 H), 6.63 (dd, 1 H), 6.29 (d, 2 H), 3.43 (m, 2 H), 2.96 (m, 6 H), 2.73 (m, 2 H), 2.22 (m, 7 H), 1.87 (m, 4 H), 1.38 (m, 3 H), 0.94 (m, 6 H), 0.62 (m, 4 H). EXAMPLE 292
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide EXAMPLE 292A
5 -chloro-6-(2-methoxyethoxy)pyridine-3 -sulfonamide
The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and 2-methoxyethanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 292B
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 292A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.63 (s, IH), 8.48 (d, IH), 8.17 (d, IH), 8.01 (d, IH), 7.56 (d, IH), 7.49 (m, 2H), 7.35 (d, 2H), 7.04 (d, 2H), 6.66 (dd, IH), 6.37 (m, IH), 6.21 (d, IH), 4.52 (m, 2H), 3.70 (m, 2H), 3.28 (s, 3H), 3.13 (br m, 4H), 2.88 (br s, 2H), 2.34 (br m, 4H), 2.16 (br m, 2H), 1.97 (s, 2H), 1.40 (t, 2H), 0.92 (s, 6H).
EXAMPLE 293
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
EXAMPLE 293A
The title compound was prepared by substituting 5-bromo-2,3-difluoropyridine for 4- fluoro-3 -nitrobenzenesulfonamide in EXAMPLE 24 A.
EXAMPLE 293B
tert-butyl 5 -fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-3 -ylcarbamate The title compound was prepared by substituting EXAMPLE 293 A for EXAMPLE 248A in EXAMPLE 248B.
EXAMPLE 293C
5 -fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3 -sulfonyl chloride The title compound was prepared by substituting EXAMPLE 293B for EXAMPLE 248B in EXAMPLE 248C.
EXAMPLE 293D
5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 293 C for EXAMPLE 248C in EXAMPLE 248D.
EXAMPLE 293E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 293D for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.07 (s, IH), 9.05 (d, IH), 8.44 (dd, IH), 8.41 (d, IH), 8.09 (d, IH), 7.67 (t, IH), 7.65 (d, IH), 7.44 (m, 2H), 7.07 (m, 2H), 6.76 (dd, IH), 6.53 (d, IH), 6.49 (dd, IH), 4.21 (d, 2H), 3.96 (dd, 2H), 3.31 (td, 2H), 3.07 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (m, 3H), 1.58 (dd, 2H), 1.38 (m, 4H), 0.94 (s, 6H).
EXAMPLE 294
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 294A
tert-butyl 4-((2-chloro-4-sulfamoylphenoxy)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting tert-butyl-4- (hydroxymethyl)piperidine-l -carboxylate for (4-fluoro-l-methylpiperidin-4-yl)methanol in EXAMPLE 283A.
EXAMPLE 294B
tert-butyl 4-((4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- chlorophenoxy)methyl)piperidine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 294A for EXAMPLE IF in EXAMPLE 1G.
EXAMPLE 294C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(3-chloro-4-(piperidin-4- ylmethoxy)phenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzamide
To EXAMPLE 294B (0.286 g) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL) and the reaction stirred at room temperature. After 3 hours the reaction was concentrated to provide the title compound.
EXAMPLE 294D
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
To EXAMPLE 294C (0.75 g) as a solution in dichloromethane (1 mL) was added N,N-diisopropylethylamine (0.055 mL) followed by 2-methoxyacetyl chloride (6 μΐ). After stirring for 10 minutes the reaction was loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.5% to 3.5% methanol/dichloromethane over 30 minutes (flow = 40 mL/minutes) to provide the title compound. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.71 (s, IH), 11.55 - 11.24 (m, IH), 8.06 (d, IH), 7.88 (d, IH), 7.78 (d, IH), 7.57 (s, IH), 7.51 (s, IH), 7.48 (d, IH), 7.34 (d, 2H), 7.21 (d, IH), 7.04 (d, 2H), 6.67 (d, IH), 6.42 (dd, IH), 6.18 (s, IH), 4.42 - 4.32 (m, IH), 4.03 (dd, 4H), 3.86 - 3.74 (m, IH), 3.28 (s, 3H), 3.07 (s, 5H), 2.77 (s, 3H), 2.30 - 1.92 (m, 9H), 1.77 (s, 2H), 1.31 (d, 4H), 0.92 (s, 6H).
EXAMPLE 295
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting 2-(dimethylamino)acetyl chloride for 2-methoxyacetyl chloride in EXAMPLE 294D. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.58 (s, IH), 10.35 - 9.94 (m, IH), 7.96 (d, IH), 7.74 (d, IH), 7.55 (d, 2H), 7.45 (s, IH), 7.41 - 7.29 (m, 3H), 7.05 (d, 3H), 6.63 (d, IH), 6.37 - 6.32 (m, IH), 6.22 (d, IH), 4.39 (d, 1H), 3.94 (s, 6H), 3.01 (s, 6H), 2.73 (m, 4H), 2.55 (m, 5H), 2.19 (s, 6H), 1.95 (m, 2H), 1.82 (m, 2H), 1.38 (s, 4H), 0.93 (s, 6H).
EXAMPLE 296
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 296A
tert-butyl 4-((4,4-dimethyl-2-oxocyclohexyl)methyl)piperidine- 1 -carboxylate 3,3-Dimethylcyclohexanone (5.60 mL) was added to sodium bis(trimethylsilyl)amide (45.3 mL, 1M in tetrahydrofuran), and the reaction was stirred for 1 hour. tert-Butyl 4- (bromomethyl)piperidine-l -carboxylate (11.1 g) in dimethylsulfoxide (30 mL) was added, and the reaction was stirred at 50°C for 24 hours. The reaction was cooled, poured into water (300 mL), extracted three times with ether, and the combined extracts were washed three times with water, and brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 5-20% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 296B
tert-butyl 4-((2-(4-chlorophenyl)-2-hydroxy-4,4-dimethylcyclohexyl)methyl)piperidine- 1 - carboxylate
(4-Chlorophenyl)magnesium bromide (14.1 mL, 1M in ether) was added to
EXAMPLE 296A (3.25 g) in tetrahydrofuran (40 mL) at -78°C, and the reaction was stirred for 20 minutes, and then allowed to warm to room temperature overnight. The reaction was quenched with pH 7 buffer (20 mL), extracted with 2x ether, and the combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The crude product was chromatographed on silica gel using 1-20% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 296C
trans-4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexyl)methyl)piperidine The title compound was prepared by substituting EXAMPLE 296B for EXAMPLE 1A in EXAMPLE IB. EXMAPLE 296D
Trans-methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethy lcyclohexyl)methyl)piperidin- 1 -yl)benzoate
The title compound was prepared by substituting EXAMPLE 296C for EXAMPLE 263G in EXAMPLE 263H.
EXAMPLE 296E
Trans-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohexyl)methyl)piperidin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 296D for EXAMPLE 31 in EXAMPLE 3 J.
EXAMPLE 296F
Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 296E for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.36 (br s, IH), 8.60 (t, IH), 8.55 (d, IH), 8.03 (d, IH), 7.78 (dd, IH), 7.52 (m, 3H), 7.27 (d, 2H), 7.16 (d, 2H), 7.09 (m, IH), 6.63 (dd, IH), 6.38 (dd, IH), 6.11 (d, IH), 3.83 (dd, 2H), 3.52 (m, 2H), 3.26 (m, 4H), 2.61 (m, 2H), 2.35 (m, IH), 1.89 (m, 2H), 1.76 (m, IH), 1.62 (m, 2H), 1.38 (m, 4H), 1.25 (m, 6H), 1.12 (m, 2H), 0.95 (m, 2H), 0.94 (s, 3H), 0.88 (s, 3H).
EXAMPLE 297
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3 -yl] sulfonyl} benzamide
EXAMPLE 297A
6-((tetrahydro-2H-pyran-4-yl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 288E for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A. EXAMPLE 297B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 -
(trifluoromethyl)pyridin-3 -yl] sulfonyl} benzamide
The title compound was prepared by substituting EXAMPLE 297A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.49 (s, 1 H), 8.56 (d, 1 H), 8.23 (d, 1 H), 7.90 (d, 1 H), 7.58 (d, 1 H), 7.40 (m, 1 H), 7.34 (m, 2 H), 7.26 (d, 1 H), 7.05 (d, 2 H), 6.61 (dd, 1 H), 6.28 (dd, 1 H), 6.24 (d, 1 H), 4.24 (d, 2 H), 3.86 (dd, 2 H), 3.30 (m, 4 H), 3.00 (s, 4 H), 2.73 (s, 2 H), 2.16 (m, 6 H), 1.97 (m, 2 H), 1.61 (dd, 2 H), 1.33 (m, 4 H), 0.93 (s, 6 H).
EXAMPLE 298
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 298A
6-((trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)methoxy)-5-chloropyridine-3-sulfonamide
The title compound was prepared by substituting (trans-4-(tert- butyldimethylsilyloxy)cyclohexyl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 40A for EXAMPLE 36A in EXAMPLE 36B.
EXAMPLE 298B
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 298A for
EXAMPLE 1 IB in EXAMPLE 1 ID. After the reaction was over, the solvent was removed, and the residue was treated with 1 : 1 trifluoroacetic acid/dichloromethane for two hours. The solvents were removed, and the residue was purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 μ, CI 8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrle in water with 0.1% trifluoroacetic acid to provide the title compound.1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.65 (s, 1H), 8.47 (s, 1H), 8.15 (s, 1H), 8.01 (d, 1H), 7.54 (d, 1H), 7.48-7.49 (m, 1H), 7.35 (d, 2H), 7.05 (d, 2H), 6.67 (dd, 1H), 6.37 (d, 1H), 6.21 (s, 1H), 4.53 (t, 1H), 4.18 (d, 2H), 3.08 (s, 4H), 2.84 (s, 2H), 2.29 (s, 4H), 2.15 (s, 2H), 1.96 (s, 2H), 1.79-1.83 (m, 5H), 1.39 (t, 2H), 1.08-1.13 (m, 5H), 0.93 (s, 6H).
EXAMPLE 299
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 299A
3-cyano-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 37C for (tetrahydro-2H- pyran-4-yl)methanol in EXAMPLE 284A.
EXAMPLE 299B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 299A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.72 (s, 1H), 10.24 - 9.27 (m, 1H), 8.21 (d, 1H), 8.12 (dd, 1H), 8.05 (d, 1H), 7.63 - 7.46 (m, 3H), 7.45 - 7.31 (m, 3H), 7.07 (d, 2H), 6.70 (dd, 1H), 6.42 (s, 1H), 6.23 (s, 1H), 4.38 (d, 2H), 3.91 - 3.73 (m, 2H), 3.68 - 3.51 (m, 2H), 3.22 - 2.96 (m, 10H), 2.31 - 2.12 (m, 2H), 1.99 (s, 6H), 1.43 (t, 2H), 0.93 (s, 6H).
EXAMPLE 300
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 300A
6-((trans-4-methoxycyclohexyl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 288E for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 121 A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 300B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(trans-4-methoxycyclohexyl)methoxy] -5 -(trifluoromethyl)pyridin-3 -yl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 300 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.50 (s, 1 H), 8.56 (d, 1 H), 8.23 (d, 1 H), 7.90 (d, 1 H), 7.58 (d, 1 H), 7.40 (m, 1 H), 7.35 (d, 2 H), 7.27 (d, 1 H), 7.05 (d, , 2 H), 6.61 (dd, 1 H), 6.28 (dd, 1 H), 6.24 (d, 1 H), 4.20 (d, 2 H), 3.23 (s, 3 H), 3.03 (m, 5 H), 2.73 (s, 2 H), 2.18 (m, 6 H), 1.98 (m, 5 H), 1.80 (m, 3 H), 1.39 (t, 2 H), 1.09 (m, 4 H), 0.93 (s, 6 H).
EXAMPLE 301
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 301 A
6-((cis-4-methoxycyclohexyl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 288E for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 121 A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 301B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {6- [(cis-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 301 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.49 (m, 1 H), 8.54 (m, 1 H), 8.23 (d, 1 H), 7.91 (d, 1 H), 7.59 (d, 1 H), 7.40 (m, 1 H), 7.34 (m, 2 H), 7.27 (d, 1 H), 7.04 (d, 2 H), 6.61 (dd, 1 H), 6.29 (dd, 1 H), 6.24 (d, 1 H), 4.20 (d, 2 H), 3.37 (m, 2 H), 3.19 (s, 3 H), 3.00 (s, 4 H), 2.73 (s, 2 H), 2.18 (m, 6 H), 1.96 (s, 2 H), 1.80 (m, 3 H), 1.50 (dd, 2 H), 1.37 (m, 6 H), 0.93 (s, 6 H).
EXAMPLE 302
N-( {5-chloro-6-[(4,4-difluoro- 1 -hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperidin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 302A
4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperidine EXAMPLE 296B (1.0 g) was stirred in dichloromethane (15 mL) and trifluoroacetic acid (15 mL) at 35°C for 48 hours. The mixture was concentrated, taken up in
dichloromethane (100 mL), and stirred, and saturated Na2C03 solution (20 mL) was added slowly. The solution was separated and the organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 302B
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperidin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 302 A for EXAMPLE 263G in EXAMPLE 263H.
EXAMPLE 302C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperidin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 302B for EXAMPLE 31 in EXAMPLE 3 J.
EXAMPLE 302D
1 , 1 -difluoro4-methylenecyclohexane
Butyllithium (12.32 mL, 2.5 M solution in hexanes) was added to a solution of methyltriphenylphosphonium chloride (9.63 g) in tetrahydrofuran (50 mL) at 0°C, and the reaction was stirred for 5 minutes. 4,4-Difluorocycleohexanone (3.76 g) in dioxane (150 mL)was then added, and the reaction was stirred for 30 minutes. Water (3 mL) was added, and then hexane (150 mL) was slowly added, the reaction was filtered, and the solution carried on.
EXAMPLE 302E
4,4-difluoro- 1 -(hydroxymethyl)cyclohexanol
To the solution from EXAMPLE 302D was added water (75 mL), then N- metthylmorpholine-N-oxide (6.4 mL, 50% solution in water) and Os04 (14.2 g, 2.5 wt % solution in tert-butanol) were added, and the reaction was stirred for 96 hours at 50°C. The solution was cooled to room temperature, treated with saturated aqueous Na2S203 solution (100 mL) for 30 minutes, and then acidified with concentrated aqueous HCl. The solution was then extracted three times with ethyl acetate, and the organic layers were combined, washed with 1M HCl, and brine, and concentrated. The crude mixture was chromatographed on silica gel using 10-100% ethyl acetate in hexanes, and then 5% methanol in ethyl acetate to give the product.
EXAMPLE 302F
5-chloro-6-((4,4-difluoro-l-hydroxycyclohexyl)methoxy)pyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 302E for tetrahydro-2H- pyran-4-yl)methanol and EXAMPLE 40 A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 302G
N-( {5-chloro-6-[(4,4-difluoro- 1 -hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperidin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 302C for EXAMPLE IE and EXAMPLE 302F for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.65 (br s, 2H), 8.51 (s, 1H), 8.18 (s, 1H), 8.02 (d, 1H), 7.53 (m, 3H), 7.35 (d, 2H), 7.04 (d, 2H), 6.69 (dd, 1H), 6.39 (dd, 1H), 6.21 (d, 1H), 4.88 (s, 1H), 4.27 (s, 2H), 3.10 (m, 4H), 2.88 (m, 1H), 2.33 (m, 2H), 2.15 (m, 4H), 1.97 (s, 2H), 1.91 (m, 2H), 1.73 (m, 4H), 1.52 (m, 1H), 1.40 (m, 2H), 1.31 (m, 1H), 0.93 (s, 3H), 0.91 (m, 2H). EXAMPLE 303
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 303A
trans-4-morpholinocyclohexyl)methanol
To tert-butyl trans-4-(hydroxymethyl)cyclohexylcarbamate (0.500 g) was added hydrogen chloride (4.0M in dioxane, 2.2 mL) and the reaction was stirred for 1 hour and concentrated. The resulting solid was dissolved in acetonitrile (4 mL) and treated with N,N- diisopropylethylamine (1.523 mL) followed by l-bromo-2-(2-bromoethoxy)ethane (0.556 g) and heated to 60°C. After stirring overnight the reaction was concentrated, loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 1% to 10% methanol/dichloromethane over 30 minutes (flow = 40 mL/min) to provide the title compound.
EXAMPLE 303B
3-chloro-4-(((lr,4r)-4-morpholinocyclohexyl)methoxy)benzenesulfonamide
The title compound was prepared by substituting EXAMPLE 303 A for (4-fluoro-l- methylpiperidin-4-yl)methanol in EXAMPLE 283A.
EXAMPLE 303C
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 303B for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.65 (s, IH), 10.96 - 10.59 (m, IH), 8.02 (d, IH), 7.82 (d, IH), 7.69 (s, IH), 7.50 (dd, 3H), 7.38 - 7.30 (m, 2H), 7.15 - 6.99 (m, 3H), 6.65 (dd, IH), 6.39 (dd, IH), 6.20 (d, IH), 3.91 (d, 2H), 3.64 (s, 4H), 3.04 (s, 4H), 2.73 (s, 7H), 2.18 (s, 6H), 1.93 (m, 6H), 1.80 - 1.65 (m, IH), 1.32 (m, 6H), 0.92 (s, 6H).
EXAMPLE 304
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide To a solution of EXAMPLE 29 IE (95 mg) in dichloromethane (2 mL) and acetic acid (0.5 mL) was added thiazole-5-carbaldehyde (13 mg) followed by sodium
triacetoxyborohydride (35 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHC03, water, and brine and dried over Na2S04. Filtration and evaporation of the solvent gave crude product which was dissolved in dimethylsulfoxide/methanol (6 mL, 1 : 1) and loaded on Gilson, C18(100A) 250x121.2 mm(lOmicron), with 30% acetonitrile to 65% acetonitrile over 40 minutes. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1 H), 8.95 (s, 1 H), 8.57 (m, 2 H), 8.03 (d, 1 H), 7.78 (m, 2 H), 7.49 (m, 3 H), 7.35 (m, 2 H), 7.02 (m, 3 H), 6.67 (dd, 1 H), 6.38 (dd, 1 H), 6.19 (d, 1 H), 4.00 (s, 2 H), 3.05 (d, 4 H), 2.73 (m, 2 H), 2.60 (m, 2 H), 2.18 (m, 7 H), 1.95 (s, 2 H), 1.79 (m, 3 H), 1.37 (m, 3 H), 0.92 (s, 6 H), 0.45 (m, 4 H).
EXAMPLE 305
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 305A
3-chloro-4-((trans-4-hydroxycyclohexyl)methoxy)benzenesulfonamide (Trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)methanol (275 mg, prepared according to a procedures in WO 2008/124878) and 3-chloro-4-fluorobenzenesulfonamide (259 mg) in tetrahydrofuran (15 mL) were treated with sodium hydride (180 mg, 60%>) overnight. The reaction was quenched with water (1 mL) and trifluoroacetic acid (4 mL) was added. The resulting mixture was stirred for 1 hour and concentrated. The residue was triturated with water and methanol to provide the title compound.
EXAMPLE 305B
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 305A in place of EXAMPLE 1 IB. 1H NMR (500 MHz, dimethylsulfoxide-d 6) δ 11.71 (s, 1 H), 11.38 (s, 1 H), 8.06 (d, 1 H), 7.87 (d, 1 H), 7.76 (dd, 1 H), 7.57 (d, 1 H), 7.51 - 7.55 (m, 1 H), 7.49 (d, 1 H), 7.34 (d, 2 H), 7.18 (d, 1 H), 7.04 (d, 2 H), 6.67 (dd, 1 H), 6.42 (dd, 1 H), 6.18 (d, 1 H), 4.54 (d, 1 H), 3.91 (d, 2 H), 3.07 (s, 4 H), 2.75 (s, 2 H), 2.17 (d, 6 H), 1.95 (s, 2 H), 1.78 - 1.90 (m, 4 H), 1.63 - 1.75 (m, 1 H), 1.38 (t, 2 H), 1.00 - 1.25 (m, 4 H), 0.92 (s, 6 H).
EXAMPLE 306
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 306A
3-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3- chlorobenzenesulfonamide for 4-chloro-3-nitrobenzenesulfonamide, (tetrahydro-2H-pyran-4- yl)methanamine for 4-methylpiperazin-l -amine dihydrochloride and Hunig's base for N1,N1,N2,N2-tetramethylethane-l,2-diamine in EXAMPLE 6A.
EXAMPLE 306B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 306 A for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (400MHz, dimethylsulfoxide-d6) δ 11.80 (s, IH), 11.17 (br s, IH), 8.09 (d, IH), 7.71 (d, IH), 7.63 (d, IH), 7.58 (dd, IH), 7.53 (dd, IH), 7.50 (d, IH), 7.34 (d, 2H), 7.03 (d, 2H), 6.74 (d, IH), 6.66 (dd, IH), 6.42 (m, IH), 6.40 (t, IH), 6.16 (d, IH), 3.83 (m, 2H), 3.24 (m, 2H), 3.10 (m, 2H), 3.06 (br m, 4H), 2.72 (s, 2H), 2.17 (br m, 6H), 1.95 (s, 2H), 1.83 (m, IH), 1.59 (br m, 2H), 1.38 (t, 2H), 1.20 (ddd, 2H), 0.92 (s, 6H).
EXAMPLE 307
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 307A
4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-(trifluoromethyl)benzenesulfonamid The title compound was prepared by substituting 4-fluoro-3- (trifluoromethyl)benzenesulfonamide for 4-fluoro-3-nitrobenzenesulfonamide and
EXAMPLE 37C for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24 A.
EXAMPLE 307B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 307A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400 MHz, pyridine- d5) δ 13.07 (s, IH), 8.78 (d, IH), 8.58 (dd, IH), 8.42 (d, IH), 8.09 (d, IH), 7.67 (t, IH), 7.65 (d, IH), 7.43 (m, 2H), 7.16 (d, IH), 7.06 (m, 2H), 6.74 (dd, IH), 6.51 (m, 2H), 4.21 (d, 2H), 3.87 (m, 2H), 3.78 (td, 2H), 3.06 (m, 4H), 2.76 (s, 2H), 2.25 (t, 2H), 2.13 (m, 4H), 1.95 (m, 6H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 308
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 308A
4-(3 -(cyclopropylamino)propylamino)-3 -nitrobenzenesulfonamide To a solution of EXAMPLE 291C (4.14 g) in dichloromethane (10 mL) was added trifluoroacetic acid(10 mL). The mixture was stirred for 2 hours. The mixture was concentrated under vacuum and the residue was dissolved in dichloromethane (300 mL) and washed with aqueous NaHC03, water, and brine and dried over Na2S04. Filtration and evaporation of solvent gave the title compound. EXAMPLE 308B
4-(3-(cyclopropyl(2,2,2-trifluoroethyl)amino)propylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 308A (314 mg) in dichloromethane (6 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (255 mg) and N,N-diisopropylethylamine (258 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHC03, water, brine and dried over Na2S04. Filtration and evaporation of solvent gave the title compound. EXAMPLE 308C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 308B for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.67 (s, 1 H), 11.38 (m, 1 H), 8.55 (d, 2 H), 8.03 (d, 1 H), 7.81 (dd, 1 H), 7.50 (m, 3 H), 7.34 (d, 2 H), 7.05 (m, 3 H), 6.67 (dd, 1 H), 6.38 (dd, 1 H), 6.19 (d, 1 H), 3.07 (m, 4 H), 2.82 (m, 4 H), 2.18 (m, 7 H), 1.38 (m, 2 H), 0.92 (s, 6 H), 0.44 (m, 4 H). EXAMPLE 309
N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
To a solution of EXAMPLE 294B (0.150 g) in dichloromethane (2 mL) was added trifluoro acetic acid (1 mL). After stirring for 1 hour the reaction was concentrated and dried under high vacuum. The residue was dissolved in dichloromethane (2 mL) and treated with sodium triacetoxyborohydride (0.050 g) and oxetan-3-one (0.017 g) and stirred overnight at room temperature. The reaction was quenched with saturated aqueous NaHC03 (20 mL) and extracted into dichloromethane (50 mL). The organic layer was separated, washed with brine (25 mL), dried over Na2S04, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 0.5% to 5% methanol/dichloromethane over 30 minutes (flow = 40 mL/min) provided the title compound. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.70 (s, IH), 11.21 (s, IH), 8.05 (d, IH), 7.87 (dlH), 7.75 (dd, IH), 7.61 - 7.42 (m, 3H), 7.42 - 7.26 (m, 2H), 7.18 (d, IH), 7.14 - 6.97 (m, 2H), 6.67 (dd, IH), 6.41 (dd, IH), 6.18 (d, IH), 4.51 (dt, 4H), 3.99 (d, 2H), 3.56 - 3.32 (m, IH), 3.06 (s, 4H), 2.89 - 2.68 (m, 4H), 2.16 (d, 6H), 2.01 - 1.69 (m, 7H), 1.50 - 1.07 (m, 4H), 0.92 (s, 6H). EXAMPLE 310
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 31 OA
3,5-difluoro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide EXAMPLE 37C (0.423 g) in tetrahydrofuran (30 niL) was treated with NaH (60% oil dispersion) (0.480 g), stirred 20 minutes at ambient temperature, treated with 3,4,5- trifluorobenzenesulfonamide (0.633 g) and stirred 30 minutes. N,N-Dimethylacetamide (15 mL) was added to increase solubility of the reactants and stirring was continued overnight at ambient temperature. Additional NaH (60% oil dispersion) (0.480 g) and N,N- dimethylacetamide (15 mL) were added and the mixture was heated overnight at 50°C. The reaction was quenched with saturated aqueous NH4C1 solution and then partitioned between saturated aqueous NH4C1 solution and ethyl acetate. The organic layer was washed with water and brine, dried (MgS04), filtered and concentrated. The concentrate was
chromatographed on amine functionalized silica gel with 0 to 2% methanol in CH2CI2 as the eluent. The residue was further purified by reverse phase HPLC on a CI 8 column using a gradient of 10-70% acetonitrile/0.1% trifluoroacetic acid in water to provide the title compound.
EXAMPLE 310B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,5- difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 310A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (500 MHz, pyridine- d5) δ 13.06 (s, 1H), 8.41 (d, 1H), 8.11 (m, 2H), 8.08 (d, 1H), 7.66 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.75 (dd, 1H), 6.52 (d, 1H), 6.50 (dd, 1H), 4.26 (d, 2H), 3.85 (dd, 1H), 3.83 (dd, 1H), 3.74 (m, 2H), 3.07 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.87 (m, 4H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 311
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {3 - [cyclopropyl(oxetan-3 -yl)amino]propyl } amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 311A
4-(3 -(cyclopropyl(oxetan-3 -yl)amino)propylamino)-3 -nitrobenzenesulfonamide To a solution of EXAMPLE 308A (314 mg) in dichloromethane (5 mL) was added oxetan-3-one (72 mg) followed by sodium triacetoxyborohydride (318 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHC03, water and brine and dried over Na2S04. After filtration, evaporation of the solvent gave the crude title compound.
EXAMPLE 31 IB
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {3 - [cyclopropyl(oxetan-3 -yl)amino]propyl } amino)-3 -nitrophenyljsulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 311 A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz,
dimethylsulfoxide-de) δ 11.65 (s, 1 H), 11.37 (s, 1 H), 8.68 (s, 1 H), 8.54 (d, 1 H), 8.02 (d, 1 H), 7.79 (d, 1 H), 7.49 (m, 3 H), 7.34 (d, 2 H), 7.03 (m, 3 H), 6.67 (dd, 1 H), 6.38 (dd, 1 H), 6.19 (d, 1 H), 4.62 (m, 2 H), 4.48 (t, 2 H), 3.98 (m, 1 H), 3.37 (m, 2 H), 3.06 (m, 4 H), 2.73 (d, 2 H), 2.59 (m, 2 H), 2.23 (m, 6 H), 1.95 (s, 2 H), 1.74 (m, 3 H), 1.38 (t, 2 H), 0.92 (s, 6 H), 0.41 (m, 4 H).
EXAMPLE 312
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
To EXAMPLE 294B (0.065 g) was added hydrogen chloride (4.0M in dioxane, 0.339 mL) and a few drops of methanol. After 30 minutes, the reaction was concentrated, and (S)- l-methylpyrrolidine-2-carboxylic acid (0.013 g), N1-((ethylimino)methylene)-N3,N3- dimethylpropane-l,3-diamine hydrochloride (0.026 g), suspended in dichloromethane (0.5 mL) were added followed by diisopropylethylamine (0.036 mL). The mixture stirred at room temperature. After stirring overnight, the reaction mixture was loaded onto silica gel (Reveleris 40g) and eluted using a gradient of 1% to 10% methanol (containing IN
NH3)/dichloromethane over 30 minutes (flow = 40 mL/minutes) to provide the title compound. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.51 (s, IH), 10.00 - 9.22 (m, IH), 7.92 (d, IH), 7.68 (d, IH), 7.57 (d, IH), 7.47 (dd, IH), 7.44 - 7.38 (m, IH), 7.38 - 7.31 (m, 2H), 7.29 (d, IH), 7.12 - 7.01 (m, 2H), 6.90 (d, IH), 6.61 (dd, IH), 6.31 (dd, IH), 6.25 (d, IH), 5.85 (d, IH), 4.40 (s, IH), 3.92 (s, 4H), 3.17 - 2.89 (m, 8H), 2.73 (s, 4H), 2.38 (s, 3H), 2.18 (m, 6H), 1.96 (s, 2H), 1.80 (m, 2H), 1.57 (s, 2H), 1.39 (s, 2H), 1.22 (m, 2H), 0.96 (m, 6H).
EXAMPLE 313
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 313A
3,4-difluoro-5-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was obtained as a side product in EXAMPLE 310A.
EXAMPLE 313B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3 ,4- difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 313A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (400 MHz, pyridine- d5) δ 13.05 (s, IH), 8.41 (d, IH), 8.10 (d, IH), 7.98 (m, 2H), 7.66 (m, IH), 7.63 (d, IH), 7.44 (m, 2H), 7.07 (m, 2H), 6.77 (dd, IH), 6.54 (d, IH), 6.48 (dd, IH), 4.12 (d, 2H), 3.83 (m, 2H), 3.75 (m, 2H), 3.08 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.15 (m, 4H), 1.97 (s, 2H), 1.82 (m, 4H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 314
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 314A
(S)-5-chloro-6-((4-cyclopropylmorpholin-2-yl)methoxy)pyridine-3-sulfonamide A solution of EXAMPLE 244B (250 mg), anhydrous methanol (6 mL), (1- ethoxycyclopropoxy)trimethylsilane (0.474 mL), and acetic acid (0.509 mL) was heated at 70 °C for 30 minutes. After cooling to ambient temperature, sodium cyanoborohydride (1 12 mg) was added and the mixture was stirred for 18 hours. Additional sodium cyanoborohydride (75 mg) was added and stirring was continued 18 hours. The reaction was concentrated and the residue was partitioned between methylene chloride and saturated sodium bicarbonate solution. The crude product was isolated from the dried methylene chloride layer and was purified on silica gel and was eluted with a 1, 2.5, 5, 10% methanol in methylene chloride step gradient to provide the title compound.
EXAMPLE 314B
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 314A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine- d5) δ 12.98 (s, IH), 9.09 (d, IH), 8.69 (d, IH), 8.41 (d, IH), 8.11 (d, IH), 7.66 - 7.64 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.75 (dd, IH), 6.53 (m, IH), 6.48 (m, IH), 5.72 (br s, IH), 4.62 - 4.57 (m, IH), 4.51 - 4.47 (m, IH), 3.99 (m, IH), 3.85 (m, IH), 3.57 (m, IH), 3.08 - 3.01 (m, 5H), 2.77 (s, 2H), 2.69 (m, IH), 2.39 - 2.24 (m, 4H), 2.14 (m, 4H), 1.97 (s, 2H), 1.57 (m, IH), 1.39 (t, 2H), 0.94 (m, 6H), 0.48 - 0.3 (m, 4H). EXAMPLE 315
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 302C for EXAMPLE IE and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300MHz,
dimethylsulfoxide-d6) δ 11.70 (s, IH), 11.35 (br s, IH), 8.61 (m, IH), 8.57 (d, IH), 8.04 (d, IH), 7.82 (dd, IH), 7.45-7.57 (m, 3H), 7.33 (d, 2H), 7.15 (d, IH), 7.01 (d, 2H), 6.65 (dd, IH), 6.40 (dd, IH), 6.11 (d, IH), 3.85 (dd, 2H), 3.53 (m, 2H), 3.27 (m, 4H), 2.63 (m, 2H), 2.04 (m, 2H), 1.91 (s, 2H), 1.77 (m, 2H), 1.62 (m, 4H), 1.45 (m, 2H), 1.38 (m, 2H), 1.27 (m, IH), 1.23 (m, 4H), 0.92 (s, 6H).
EXAMPLE 316
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N- { [3- chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
EXAMPLE 316A
3-chloro-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting (tetrahydro-2H-pyran-4-yl)methanol for (4-fluoro-l-methylpiperidin-4-yl)methanol in EXAMPLE 283 A.
EXAMPLE 316B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N- { [3- chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-
5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 302C for EXAMPLE IE and EXAMPLE 316A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300MHz, dimethylsulfoxide-d6) δ 11.77 (s, IH), 11.35 (br s, IH), 8.06 (m, IH), 7.88 (d, IH), 7.79 (dd, IH), 7.58 (s, IH), 7.53 (t, IH), 7.46 (d, IH), 7.34 (d, 2H), 7.22 (d, IH), 7.01 (d, 2H), 6.66 (dd, IH), 6.42 (dd, IH), 6.11 (d, IH), 3.99 (d, 2H), 3.88 (dd, 2H), 3.52 (m, 2H), 3.34 (m, 4H), 2.62 (m, 2H), 2.04 (m, 4H), 1.76 (m, 2H), 1.68 (m, 2H), 1.46 (m, 2H), 1.38 (m, 4H), 0.92 (s, 6H), 0.75 (m, 2H). EXAMPLE 317
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate
EXAMPLE 317A
methyl 2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting methyl chloroformate for methyl iodide in EXAMPLE 134B.
EXAMPLE 317B
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl}morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 317A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.84 (t, IH), 8.43 (d, IH), 8.35 (d, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (bs, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.29-4.03 (m, 1H),3.89-3.70 (m, 3H), 3.71 (s, 3H), 3..55-3.38 (m, 3H), 3.07 (m, 4H), 2.96 (dt, IH), 2.86 (dd, IH), 2.77 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 318
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N- ethyl-N-methylmorpholine-4-carboxamide
EXAMPLE 318A
N-ethyl-N-methyl-2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxamide The title compound was prepared by substituting N-methyl-N-ethyl carbamyl chloride for methyl iodide in EXAMPLE 134B. EXAMPLE 318B
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N- ethyl-N-methylmorpholine-4-carboxamide
The title compound was prepared by substituting EXAMPLE 318 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.86 (t, IH), 8.44 (d, IH), 8.33 (dd, IH), 8.12 (d, IH), 7.67 (t, IH), 7.64 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.91 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.92-3.85 (m, 2H), 3.75 (d, IH), 3.62 (dt, IH), 3.55-3.48 (m, IH), 3.45-3.39 (m, 2H), 3.21 (q, 2H), 3.07 (m, 4H), 2.99 (dt, IH), 2.90 (dd, IH), 2.77 (s, 2H), 2.76 (s, 3H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 1.06 (t, 3H), 0.93 (s, 6H).
EXAMPLE 319
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 319A
4-((4-(methylsulfonyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide
The title compound was prepared by substituting methanesulfonyl chloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 319B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 319A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.25 (d, IH), 8.84 (t, IH), 8.43 (d, IH), 8.32 (dd, IH), 8.13 (d, IH), 7.67 (t, IH), 7.65 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.92 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.99 (m, 1Η),3.92-3.88 (m, 2H), 3.64 (m, 2H), 3.56 (m, IH), 3.50 (m, IH), 3.07 (m, 4H), 3.04 (s, 3H), 2.95-2.88 (m, 2H), 2.77 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 320
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 320A
4-(3-(cyclobutyl(cyclopropyl)amino)propylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 308A (314 mg) in dichloromethane (5 mL) was added cyclobutanone (70 mg) followed by sodium triacetoxyborohydride (318 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHC03, water and brine and dried over Na2S04. After filtration, evaporation of solvent gave the title compound.
EXAMPLE 320B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 320A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.65 (s, 1 H), 8.70 (m, 1 H), 8.54 (d, 1 H), 8.02 (d, 1 H), 7.79 (dd, 1 H), 7.49 (m, 3 H), 7.34 (d, 2 H), 7.03 (m, 3 H), 6.66 (dd, 1 H), 6.38 (dd, 1 H), 6.19 (d, 1 H), 3.37 (q, 2 H), 3.06 (m, 4 H), 2.73 (s, 2 H), 2.63 (m, 2 H), 2.21 (m, 8 H), 1.82 (m, 3 H), 1.53 (m, 2 H), 1.38 (t, 2 H), 0.94 (m, 6 H), 0.41 (m, 4 H).
EXAMPLE 321
4-(4- { [2-(4-chlorophenyl)-5 ,5-difluorocyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 321 A
ethyl 5,5-difluoro-2-oxocyclohexanecarboxylate
To a solution of diethyl 4,4-difluoroheptanedioate (4.3 g) in toluene (50 mL) was added potassium 2-methylpropan-2-olate (2.87 g) and the reaction stirred overnight at room temperature. The reaction was quenched with IN aqueous HC1 (100 mL) and extracted with diethyl ether (150 mL). The ether layer was washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 5% ethyl acetate/hexanes gave the title compound.
EXAMPLE 32 IB
ethyl 5 ,5 -difluoro-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate To a solution of EXAMPLE 321 A (2.37 g) in dichloromethane (40 mL) at 0°C was added N,N-diisopropylethylamine (5.02 mL) followed by trifluoromethanesulfonic anhydride (2.33 mL) and the reaction was allowed to slowly warm to room temperature. After stirring overnight the reaction was quenched with 10 ml of water then IN aqueous HC1 (100 mL). The reaction was extracted with dichloromethane (3 x 75 mL), and the combined organics were washed with brine (50 mL) and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 25% ethyl acetate/hexanes gave the title compound.
EXAMPLE 321C
ethyl 2-(4-chlorophenyl)-5,5-difluorocyclohex-l -enecarboxylate A solution of EXAMPLE 32 IB (3.47 g), 4-chlorophenylboronic acid (1.925 g) and cesium fluoride (3.43 g) in 30 ml of 1 ,2-dimethoxyethane and 15 ml of ethanol was degassed with nitrogen for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.237 g) was added and the reaction was heated to 70°C. The reaction was diluted with ether (200 mL) and washed with IN aqueous HC1 (100 mL) and brine (100 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 8% ethyl acetate/hexanes over 40 minutes gave the title compound.
EXAMPLE 32 ID
(2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methanol To a solution of EXAMPLE 321C (1.84 g) in diethyl ether (25 mL) at 0°C was added lithium aluminum hydride (1.0M, 4.28 mL). The reaction was quenched with the dropwise addition of water, then IN aqueous HC1 (50 mL) was added and the reaction diluted with diethyl ether (100 mL). The organic layer was separated, washed with brine (50 mL) dried over magnesium sulfate, filtered and concentrated to provide the title compound. EXAMPLE 32 IE
2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enecarbaldehyde To a solution of EXAMPLE 32 ID (1.38 g) in dichloromethane (25 mL) was added Dess-Martin periodinane (2.489 g) and the reaction stirred for 1 hour at room temperature. The reaction was quenched with IN aqueous NaOH solution (75 mL) and the product was extracted into dichloromethane (2 x 100 mL). The combined organics were washed with brine (75 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveris 80 g) eluting with a gradient of 1% to 10% ethyl acetate/hexanes over 40 minutes gave the title compound.
EXAMPLE 32 IF
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- difluorocyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 32 IE for EXAMPLE 15E in EXAMPLE 15G.
EXAMPLE 321G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 32 IF for EXAMPLE
15G in EXAMPLE 15H.
EXAMPLE 321H
4-(4- { [2-(4-chlorophenyl)-5 ,5-difluorocyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 321G for EXAMPLE IE and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G.. 1H NMR (300 MHz, dimethylsulfoxide- de) δ 11.74 - 11.63 (m, 1H), 11.53 - 11.29 (m, 1H), 8.57 (d, 2H), 8.05 (d, 1H), 7.85 - 7.77 (m, 1H), 7.49 (d, 3H), 7.38 (d, 2H), 7.16 - 7.06 (m, 3H), 6.73 - 6.64 (m, 1H), 6.43 - 6.36 (m, 1H), 6.21 - 6.14 (m, 1H), 3.93 - 3.77 (m, 2H), 3.29 (d, 4H), 3.07 (s, 4H), 2.79 - 2.57 (m, 4H), 2.45 (dd, 2H), 2.19 (s, 6H), 1.99 - 1.80 (m, 1H), 1.70 - 1.54 (m, 2H), 1.38 - 1.13 (m, 2H). EXAMPLE 322
N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 322A
tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine- 1 -carboxylate 1-Tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (2 g) was taken up in tetrahydrofuran (20 ml) and cooled in an ice bath. Lithium aluminum hydride (1.0M in dioxane, 5.09 mL) was added dropwise. The reaction was stirred at room temperature for 2 hours. The reaction was quenched with water and with 1M aqueous NaOH solution and then stirred another 1 hour at room temperature. The mixture was extracted with ethyl acetate, and the extracts were combined and washed with water and with brine, dried over MgS04, filtered and concentrated under vacuum. The crude product was used without further purification.
EXAMPLE 322B
tert-butyl 4-((2-chloro-4-sulfamoylphenoxy)methyl)-4-fluoropiperidine- 1 -carboxylate The title compound was prepared by substituting EXAMPLE 322A for (tetrahydro- 2H-pyran-4-yl)methanol and 3-chloro-4-fluorobenzenesulfonamide for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 322C
3-chloro-4-((4-fluoropiperidin-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 322B for EXAMPLE 1A in EXAMPLE IB.
EXAMPLE 322D
3-chloro-4-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)benzenesulfonamide To a solution of EXAMPLE 322C (830 mg) in tetrahydrofuran (15 mL) and acetic acid (5 mL) was added oxetan-3-one (163 mg) and MP-cyanoborohydride (2.38 mmol/g, 1.9 g). The mixture was stirred at room temperature overnight. The reaction was then filtered and the filtrate was concentrated under vacuum. The residue was slurried in ether and the solid product was collected by filtration.
EXAMPLE 322E
N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 322D for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.71 (s, IH), 8.06 (d, IH), 7.89 (d, IH), 7.79 (m, IH), 7.58 (d, IH), 7.52 (t, IH), 7.49 (d, IH), 7.34 (d, 2H), 7.25 (d, IH), 7.04 (d, 2H), 6.67 (dd, IH), 6.42 (m, IH), 6.18 (d, IH), 4.55 (t, 2H), 4.44(t, 2H), 4.24 (d, 2H), 3.44 (m, 2H), 3.07 (br s, 4H), 2.74 (m, 2H), 2.59 (m, 2H), 2.14 (m, 7H), 1.95 (m, 4H), 1.78 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H).
EXAMPLE 323
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
EXAMPLE 323A
3 -chloro-4-((tetrahydrofuran-3 -yl)methoxy)benzenesulfonamide
The title compound was prepared by substituting 4-fluoro-3- chlorobenzenesulfonamide for 4-fluoro-3-nitrobenzenesulfonamide and (tetrahydrofuran-3 - yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A, except here, dimethylformamide was used in place of tetrahydrofuran and the reaction was heated at 70° C for two days.
EXAMPLE 323B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 323A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.73 (s, IH), 8.07 (d, IH), 7.89 (d, IH), 7.80 (dd, IH), 7.59 (d, IH), 7.51 (dd, IH), 7.49 (d, IH), 7.34 (d, 2H), 7.23 (d, IH), 7.03 (d, 2H), 6.66 (dd, IH), 6.42 (m, IH), 6.19 (d, IH), 4.07 (m, 2H), 3.80 (m, 2H), 3.68 (m, IH) 3.56 (m, IH), 3.10 (br m, 4H), 2.85 (br s, 2H), 2.69 (m, IH), 2.32 (br m, 4H), 2.17 (br m, 2H), 2.02 (m, IH), 1.96 (s, 2H), 1.69 (m, IH), 1.40 (t, 2H), 0.92 (s, 6H).
EXAMPLE 324 4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxycyclohexyl)methyl]amino } -3 - nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-¾]pyridin-5-yloxy)benzamide
EXAMPLE 324A
4-((trans-4-hydroxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 120 A for EXAMPLE 39B in EXAMPLE 39C.
EXAMPLE 324B
4-(4- { [2-(4-chlorophenyl)-5 ,5-difluorocyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxycyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -
¾]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 321G for EXAMPLE IE and EXAMPLE 324A for EXAMPLE lFin EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 1 1.69 (s, IH), 1 1.41 (s, IH), 8.65 - 8.50 (m, 2H), 8.05 (d, IH), 7.80 (dd, IH), 7.60 - 7.44 (m, 3H), 7.41 - 7.34 (m, 2H), 7.14 - 7.02 (m, 3H), 6.68 (dd, IH), 6.39 (dd, IH), 6.17 (d, IH), 4.50 (d, IH), 3.23 (t, 2H), 3.06 (s, 4H), 2.70 (d4H), 2.44 (s, 2H), 2.33 1.94 (m, 6H), 1.78 (dd, 4H), 1.51 (d, 2H), 1.23 (s, 2H), 1.16 - 0.92 (m, 2H).
EXAMPLE 325
N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [9-(4- chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-2-(lH pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 325A
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-(oxetan-3-yl)-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting oxetan-3-one for 1 ,3- difluoropropan-2-one in EXAMPLE 265G. EXAMPLE 325B
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-(oxetan-3-yl)-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 325A for EXAMPLE 15G in EXAMPLE 15H.
EXAMPLE 325C
N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [9-(4- chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 325B for EXAMPLE IE and EXAMPLE 286A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.67 (s, 1H), 11.13 (s, 1H), 8.05 (d, 1H), 7.87 (d, 1H), 7.80 - 7.70 (m, 1H), 7.59 - 7.46 (m, 3H), 7.34 (d, 2H), 7.21 (d, 1H), 7.11 - 7.03 (m, 2H), 6.66 (d, 1H), 6.41 (dd, 1H), 6.18 (d, 1H), 4.50 (dd, 4H), 4.26 (d, 2H), 3.85 - 3.69 (m, 2H), 3.61 (d, 3H), 3.05 (s, 4H), 2.69 (s, 2H), 2.37 (s, 4H), 2.17 (s, 6H), 2.04 (s, 2H), 1.87 (d, 4H), 1.49 (d, 6H).
EXAMPLE 326
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 326A
(R)-4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 258E for EXAMPLE 173 A in EXAMPLE 173B.
EXAMPLE 326B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [(2R)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 326A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, 1H), 9.26 (d, 1H), 8.88 (t, IH), 8.44 (d, IH), 8.34 (dd, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.88 (d, IH), 3.84-3.81 (m, 1H),3.59 (dt, IH), 3.50-3.40 (m, 2H), 3.07 (m, 4H), 2.93 (d, IH), 2.77 (s, 2H), 2.69 (d, IH), 2.34 (dt, IH), 2.26 (m, 2H), 2.21 (t, IH), 2.14 (m, 4H), 1.97 (s, 2H), 1.58 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.45-0.39 (m, 4H).
EXAMPLE 327
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 327A
(S)-4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 259E for EXAMPLE in EXAMPLE 173B.
EXAMPLE 327B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 327A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.88 (t, IH), 8.44 (d, IH), 8.34 (dd, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.94 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.88 (d, IH), 3.84-3.81 (m, 1H),3.59 (dt, IH), 3.50-3.40 (m, 2H), 3.07 (m, 4H), 2.93 (d, IH), 2.77 (s, 2H), 2.69 (d, IH), 2.34 (dt, IH), 2.26 (m, 2H), 2.21 (t, IH), 2.14 (m, 4H), 1.97 (s, 2H), 1.58 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.45-0.39 (m, 4H).
EXAMPLE 328
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide EXAMPLE 328A
spiro[2.5]octan-5-one
To a solution of 3-ethoxycyclohex-2-enone (48.1 mL) in ether (1000 mL) was added titanium(IV) isopropoxide (110 mL) followed by addition of ethylmagnesium bromide (357 mL) at ambient temperature. The reaction mixture was stirred for 2 hours at ambient temperature and was then quenched with water (500 mL). The organic layer was separated (decanted) and the water layer was extracted with ether (3 x 300 mL). The combined extracts were partially concentrated to approximately 300 mL. p-Toluenesulfonic acid monohydrate (3.0 g) was added and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was then washed with saturated aqueous NaHC03 solution., dried (MgS04), filtered and concentrated. The concentrate was purified by fractional distillation (1st fraction b.p. 27°C at 23 torr (not product), 2nd fraction (product) b.p. 75°C at 8 torr).
EXAMPLE 328B
5-chlorospiro[2.5]oct-5-ene-6-carbaldehyde
N,N-dimethylformamide (2.1 mL) in dichloromethane (3.2 ml) at -5 °C was treated slowly with POCl3 (2.33 ml) keeping the bath temperature less than 0°C. The cooling bath was removed and the mixture was stirred at ambient temperature for 30 minutes. The reaction mixture was returned to the cooling bath and EXAMPLE 328A (2.484 g) in dichloromethane (4 mL) was added slowly to the reaction mixture. The reaction mixture was heated at 45°C for 15 hours, cooled to room temperature and then poured into a mixture of ice and saturated aqueous sodium acetate solution. After the ice melted, the mixture was extracted with diethyl ether. The combined extracts were washed with saturated aqueous NaHC03 solution and brine, dried (MgS04), filtered and concentrated. The concentrate was chromatographed with 0 to 10% CH2CI2 in hexanes, then 25% CH2CI2 in hexanes and then 100% CH2CI2 as the eluents.
EXAMPLE 328C
5 -(4-chlorophenyl)spiro [2.5 ]oct-5 -ene-6-carbaldehyde EXAMPLE 328B (2.9 g), 4-chlorophenylboronic acid (2.87 g), palladium(II) acetate (0.103 g), K2C03 (5.28 g) and tetrabutylammonium bromide (4.93 g) were combined in a 100-mL round bottomed flask with water (17.0 mL). The flask was flushed with nitrogen and stirred at 45°C for 14 hours. The reaction mixture was partitioned between brine and diethyl ether. The organic layer was washed with brine, dried (MgS04), filtered through a plug of celite, concentrated and chromatographed on silica gel with 0 to 2% ethyl acetate in hexanes as the eluent.
EXAMPLE 328D
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((5-(4-chlorophenyl)spiro[2.5]oct-5-en-6- yl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared by substituting EXAMPLE 15F for tert-butyl piperazine carboxylate and EXAMPLE 328C for 4-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 328E
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((5-(4-chlorophenyl)spiro[2.5]oct-5-en-6- yl)methyl)piperazin-l-yl)benzoic acid hydrochloride EXAMPLE 328D (0.85 g) in a mixture of tetrahydrofuran (4.8 mL), methanol (2.4 mL) and water (2.4 mL) was treated with LiOH»H20 (0.184 g) and heated overnight at 50°C. The reaction mixture was cooled to room temperature, concentrated to remove
tetrahydrofuran and methanol and acidified with 1 N aqueous HCl causing precipitation of the product. The solid was collected by filtration, rinsed with water and dried overnight in a vacuum oven at 80°C to provide the title compound. EXAMPLE 328F
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 328E for EXAMPLE IE in EXAMPLE 1G. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.32 (d, IH), 8.68 (t, IH), 8.44 (d, IH), 8.38 (dd, IH), 8.10 (d, IH), 7.68 (m, IH), 7.66 (d, IH), 7.43 (m, 2H), 7.10 (m, 2H), 6.91 (d, IH), 6.75 (dd, IH), 6.51 (m, 2H), 3.97 (dd, 2H), 3.30 (td, 2H), 3.16 (t, 2H), 3.06 (m, 4H), 2.81 (s, 2H), 2.37 (t, 2H), 2.16 (m, 4H), 2.11 (s, 2H), 1.81 (m, IH), 1.58 (dd, 2H), 1.45 (t, 2H), 1.32 (qd, 2H), 0.38 (s, 4H). EXAMPLE 329
N- { [5 -chloro-6-( {4- [cyclopropyl(oxetan-3 -yl)amino] cyclohexyl} methoxy)pyridin-3 - yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 329A
ethyl 4-(cyclopropylamino)cyclohexanecarboxylate
To a solution of ethyl 4-oxocyclohexanecarboxylate (3.4 g) in dichloromethane (30 mL) was added cyclopropanamine (1.14 g) followed by sodium triacetoxyborohydride (4.24 g). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with 2N NaOH, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 329B
ethyl 4-(cyclopropyl(oxetan-3-yl)amino)cyclohexanecarboxylate
To a solution of EXAMPLE 329A (1.05g) in dichloromethane (10 mL) was added oxetan-3-one (0.358 g) followed by sodium triacetoxyborohydride (1.05 g). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with 2N aqueous NaOH, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 329C
(4-(cyclopropyl(oxetan-3-yl)amino)cyclohexyl)methanol To a solution of EXAMPLE 329B (1.2 g) in tetrahydrofuran (20 mL) was added lithium aluminum hydride (0.681 g). The mixture was stirred overnight. 2N aqueous NaOH solution was added dropwise to the reaction mixture. The mixture was then diluted with ethyl acetate (300 mL) and washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound. EXAMPLE 329D
5 -chloro-6-((4-(cyclopropyl(oxetan-3-yl)amino)cyclohexyl)methoxy)pyridine-3 -sulfonamide
To a solution of EXAMPLE 329C (706 mg) in N,N-dimethylformamide (6 mL) was added NaH (60% in mineral oil, 300 mg) . The mixture was stirred for 30 minutes, and then 5,6-dichloropyridine-3-sulfonamide (706 mg) was added. The mixture was stirred overnight. The mixture was poured over aqueous NH4C1 and extracted with ethyl acetate (3x 200 mL). The combined organic layers were washed with water, brine and dried over Na2SC"4. After filtration and evaporation of the solvent the residue was loaded on a silica gel cartridge and eluted with 5 to 10% 7N NH3 in methanol in dichloromethane to provide the title compound.
EXAMPLE 329E
N- { [5 -chloro-6-( {4- [cyclopropyl(oxetan-3 -yl)amino] cyclohexyl} methoxy)pyridin-3 - yl]sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 329D for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.64 (s, 1 H), 8.50 (m, 1 H), 8.16 (s, 1 H), 8.02 (d, 1 H), 7.51 (m, 3 H), 7.35 (d, 2 H), 7.04 (d, 2 H), 6.67 (dd, 1 H), 6.38 (m, 1 H), 6.21 (s, 1 H), 4.70 (m, 2 H), 4.43 (t, 3 H), 4.19 (m, 2 H), 3.12 (m, 4 H), 2.84 (m, 2 H), 2.19 (m, 6 H), 1.96 (s, 3 H), 1.77 (m, 3 H), 1.38 (m, 7 H), 0.93 (s, 6 H), 0.44 (m, 4 H).
EXAMPLE 330
4-(4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 328E for EXAMPLE 3 J and EXAMPLE 218A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.01 (s, IH), 9.26 (d, IH), 8.88 (t, IH), 8.43 (d, IH), 8.34 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.42 (m, 2H), 7.09 (m, 2H), 6.95 (d, IH), 6.75 (dd, IH), 6.53 (d, IH), 6.49 (dd, IH), 3.84 (m, 2H), 3.58 (td, IH), 3.45 (m, 2H), 3.06 (m, 4H), 2.93 (d, IH), 2.81 (s, 2H), 2.69 (d, IH), 2.35 (m, 3H), 2.19 (m, 5H), 2.11 (s, 2H), 1.58 (m, IH), 1.45 (t, 2H), 0.42 (m, 8H). EXAMPLE 331
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 331 A
tert-butyl 2-((2-chloro-4-sulfamoylphenoxy)methyl)morpholine-4-carboxylate To a solution of tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (0.478 g) in anhydrous N,N-dimethylformamide (5 mL) was added sodium hydride (0.280 g). The mixture was stirred at room temperature for 30 minutes, followed by addition of 3-chloro-4- fluorobenzenesulfonamide (0.419 g). The mixture was stirred at 40°C overnight. The reaction was quenched with water (10 mL), and the mixture was adjusted to ~pH 7 and extracted with ethyl acetate. The crude product was purified on a silica gel column eluting with 60% ethyl acetate in hexane to provide the title compound.
EXAMPLE 33 IB
3-chloro-4-(morpholin-2-ylmethoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 331 A for EXAMPLE 113 A in EXAMPLE 134A.
EXAMPLE 331C
3-chloro-4-((4-cyclopropylmorpholin-2-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 33 IB for EXAMPLE in EXAMPLE 173B.
EXAMPLE 33 ID
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 331C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.04 (s, IH), 8.54 (d, IH), 8.43 (d, IH), 8.27 (dd, IH), 8.09 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 7.05 (d, IH), 6.75 (dd, IH), 6.52 (d, IH), 6.50 (m, IH), 4.20 (dd, IH), 4.10 (dd, IH), 3.94 (m, IH), 3.86 (d, IH), 3.58 (dt, IH), 3.06 (m, 5H), 2.77 (s, 2H), 2.69 (d, IH), 2.40-2.20 (m, 4H), 2.14 (m, 4H), 1.97 (s, 2H), 1.60 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.41 (m, 4H). EXAMPLE 332
N-[(3-chloro-4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 332A
tert-butyl 2-((2-chloro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate A solution of 3-chloro-4-fluorobenzenesulfonamide (1.0 g), tert-butyl 2- (aminomethyl)morpholine-4-carboxylate (1.135 g) and N-ethyl-N-isopropylpropan-2-amine (1.246 mL) in dimethylsulfoxide (15 mL) was stirred at 115°C for 72 hours. The mixture was concentrated, and the residue was purified on a silica gel column eluting with 60% ethyl acetate to provide the title compound.
EXAMPLE 332B
3 -chloro-4-(morpholin-2-ylmethylamino)benzenesulfonamide
The title compound was prepared by substituting EXAMPLE 332A for EXAMPLE 113A in EXAMPLE 134A.
EXAMPLE 332C
The title compound was prepared by substituting EXAMPLE 332B for EXAMPLE in EXAMPLE 173B.
EXAMPLE 332D
N-[(3-chloro-4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 332C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.05 (s, IH), 8.45 (m, 2H), 8.21 (dd, IH), 8.12 (d, IH), 7.69 (d, IH), 7.67 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.78 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.50 (m, IH), 6.37 (m, IH), 3.84 (d, IH), 3.77 (m, IH), 3.54 (dt, IH), 3.35 (m, 2H), 3.05 (m, 4H), 2.94 (d, IH), 2.77 (s, 2H), 2.68 (d, IH), 2.32 (dt, IH), 2.26 (m, 2H), 2.18-2.12 (m, 5H), 1.97 (s, 2H), 1.55 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.41 (m, 4H). EXAMPLE 333
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide
EXAMPLE 333A
2-((2-chloro-4-sulfamoylphenylamino)m
The title compound was prepared by substituting EXAMPLE 332B for EXAMPLE 134A and N-methyl-N-ethyl carbamyl chloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 333B
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide
The title compound was prepared by substituting EXAMPLE 333 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.05 (s, IH), 8.46 (s, IH), 8.45 (s, IH), 8.20 (dd, IH), 8.10 (d, IH), 7.69 (d, IH), 7.67 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.79 (d, IH), 6.73 (dd, IH), 6.52 (dd, IH), 6.49 (d, IH), 6.43 (m, IH), 3.83 (d, 2H),3.73 (d, IH), 3.59 (dt, IH), 3.41-3.35 (m, 3H), 3.20 (q, 2H), 3.05 (m, 4H), 2.95 (t, IH), 2.84 (dd, IH), 2.76 (s, 2H), 2.73 (s, 3H), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 1.04 (t, 3H), 0.94 (s, 6H).
EXAMPLE 334
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide
EXAMPLE 334A
(S)-2-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)-N-ethyl-N-methylmorpholine-4- carboxamide The title compound was prepared by substituting EXAMPLE 244B for EXAMPLE 134A and N-methyl-N-ethyl carbamyl chloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 334B
(2S)-2 - { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide The title compound was prepared by substituting EXAMPLE 334A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.98 (s, IH), 9.08 (d, IH), 8.70 (d, IH), 8.42 (d, IH), 8.11 (d, IH), 7.67 (t, IH), 7.64 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.75 (dd, IH), 6.53 (d, IH), 6.48 (m, IH), 4.58 (dd, 1H),4.47 (dd, IH), 4.03 (m, IH), 3.84 (m, 2H), 3.63 (dt, IH), 3.45 (d, IH), 3.22 (q, 2H), 3.07 (m, 4H), 3.05-2.95 (m, 2H), 2.78 (s, 3H), 2.77 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 1.07 (t, 3H), 0.94 (s, 6H).
EXAMPLE 335
N-[(5-chloro-6-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 335A
tert-butyl 2-((3-chloro-5-sulfamoylpyridin-2-ylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and tert-butyl 2-(aminomethyl)morpholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 335B
5 -chloro-6-(morpholin-2-ylmethylamino)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 335 A for EXAMPLE 113A in EXAMPLE 134A.
EXAMPLE 335C
5-chloro-6-((4-cyclopropylmorpholin-2-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 335B for EXAMPLE 173 A in EXAMPLE 173B.
EXAMPLE 335D
N-[(5-chloro-6-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 335C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 9.15 (d, IH), 8.49 (d, IH), 8.43 (d, IH), 8.11 (d, IH), 7.80 (t, IH), 7.69 (d, IH), 7.65 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.73 (dd, IH), 6.52 (m, IH), 6.49 (d, IH), 3.92 (m, 1H),3.84 (m, 2H), 3.70 (m, IH), 3.54 (dt, IH), 3.05 (m, 4H), 2.99 (d, IH), 2.76 (s, 2H), 2.68 (d, IH), 2.32 (dt, IH), 2.25 (m, 2H), 2.12 (m, 5H), 1.97 (s, 2H), 1.53 (m, IH), 1.39 (t, 2H), 0.93 (s, 6H), 0.40 (m, 4H).
EXAMPLE 336
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide
EXAMPLE 336A
2-((3-chloro-5-sulfamoylpyridin-2-ylamino)methyl)-N-ethyl-N-methylmorpholine-4- carboxamide
The title compound was prepared by substituting EXAMPLE 335B for EXAMPLE 134A and N-methyl-N-ethyl carbamyl chloride for methyl iodide in EXAMPLE 134B.
EXAMPLE 336B
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]sulfamoyl} pyridin- 2-yl)amino]methyl} -N-ethyl-N-methylmorpholine-4-carboxamide
The title compound was prepared by substituting EXAMPLE 336A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.03 (s, IH), 9.14 (d, IH), 8.51 (d, IH), 8.43 (d, IH), 8.11 (d, IH), 7.89 (m, IH), 7.69 (d, IH), 7.66 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.74 (dd, 1H), 6.51 (m, 1H), 6.48 (d, 1H), 3.96 (m, 1Η),3.90-3.70 (m, 4H), 3.59 (dt, 1H), 3.43 (d, 1H), 3.17 (q, 2H), 3.05 (m, 4H), 2.95 (dt, 1H), 2.81 (dd, 1H), 2.76 (s, 2H), 2.72 (s, 3H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 1.03 (t, 3H), 0.93 (s, 6H).
EXAMPLE 337
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 337A
methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoroacetic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product.
EXAMPLE 337B
methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarboxylate EXAMPLE 337A (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2: 1 dimethoxy ethane /methanol (600 mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product.
EXAMPLE 337C
(2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 337B (53.8 g) and ether (400 mL), was added methanol (25 mL) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN HCl with ice-cooling. The mixture was diluted with water and extracted with ether (3x 100 mL). The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 337D
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine- 1 - carboxylate
Mesyl Chloride (7.5 mL) was added via syringe to EXAMPLE 337C (29.3 g) and triethylamine (30 mL) in CH2CI2 (500 mL) at 0°C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE 337E
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine EXAMPLE 337D (1 g) was stirred in dichloromethane (10 mL), trifluoroacetic acid (10 mL), and triethylsilane (1 mL) for 1 hour. The mixture was concentrated, taken up in a mixture of dichloromethane (100 mL) and saturated aqueous Na2C03 solution (20 mL) and stirred for 10 minutes. The layers were separated, and the organic layer was dried over Na2S04, and concentrated to give the product.
EXAMPLE 337F
5-bromo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine To a mixture of 5-bromo-lH-pyrrolo[2,3-b]pyridine (15.4 g) in tetrahydrofuran (250 mL) was added 1M lithium hexamethyldisilazide in tetrahydrofuran (86 mL), and after 10 minutes, TIPS-Cl (triisopropylchlorosilane ) (18.2 mL) was added. The mixture was stirred at room temperature for 24 hours. The reaction was diluted with ether, and the resulting solution was washed twice with water. The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10% ethyl acetate/hexanes.
EXAMPLE 337G
l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-5-ol
To a mixture of EXAMPLE 337F (24.3 g) in tetrahydrofuran (500 mL) at -78°C was added 2.5M BuLi (30.3 mL). After 2 minutes, trimethylborate (11.5 mL) was added, and the mixture was allowed to warm to room temperature over 1 hour. The reaction was poured into water, extracted thee times with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was taken up in tetrahydrofuran (200 mL) at 0 C, and 1M aqueous NaOH (69 mL) was added, followed by 30% aqueous H202 (8.43 mL), and the solution was stirred for 1 hour. Na2S203 (10 g) was added, and the pH was adjusted to 4-5 with concentrated HC1 and solid NaH2P04. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 5-25% ethyl acetate/hexanes.
EXAMPLE 337H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate
A mixture of EXAMPLE 337G (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and K3P04 (9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and
concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes .
EXAMPLE 3371
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate A mixture of EXAMPLE 337H (1.55 g), EXAMPLE 337E (2.42 g), and HK2P04 (1.42 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed three times with 1M aqueous NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50%) ethyl acetate/hexanes.
EXAMPLE 337J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
EXAMPLE 3371 (200 mg) in dioxane (10 mL) and 1M aqueous NaOH (6 mL) at 50°C was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product. EXAMPLE 337K
tert-butyl (4-hydroxy-4-methylcyclohexyl)methylcarbamate To a vigorous stirring solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (1.7 g) in tetrahydrofuran (40 mL) at -78°C was dropwise added 1.6 M methyllithium (14.02 mL) in ether. After completion of the addition, the mixture was stirred at -78°C for 1.2 hours and poured into a cold NH4C1 aqueous solution. The resulting mixture was extracted with dichloromethane (100 ml, three times) and the organic layer was dried over Na2S04, filtered, and concentrated. The residue was dissolved in dichloromethane and loaded onto an
Analogix purification system, and it was eluted with 0 - 50% ethyl acetate in
dichloromethane to provide the title compound.
EXAMPLE 337L
4-(aminomethyl)- 1 -methylcyclohexanol
EXAMPLE 337K (1.3 g) in dichloromethane (5 mL) at 0°C was treated with trifluoroacetic acid (2.1 mL) and a few drops of water for 1 hour. The reaction mixture was concentrated and the residue was directly used for next step.
EXAMPLE 337M
4-((trans-4-hydroxy-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 337L (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (1.1 g) in tetrahydrofuran (15 mL) was treated with triethylamine overnight. The reaction mixture, was concentrated and the residue was purified by a reverse phase chromatography, eluting with 30% - 50% acetonitrile in 0.1% trifluoroacetic acid water solution to isolate the title compound.
EXAMPLE 337N
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
A mixture of EXAMPLE 337J (3.0 g), EXAMPLE 337M (1.98 g), N, N- dimethylpyridin-4-amine (1.93 g) and N1-((ethylimino)methylene)-N3,N3-dimethylpropane- 1,3-diamine hydrochloride (1.31 g) in dichloromethane (50 ml) was stirred overnight and concentrated. The residue was purified by reverse chromatography, eluted with 40%>-70%> acetonitrile in 0.1% TFA water. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHC03 and extracted with dichloromethane. The organic layer was dried over Na2S04, concentrated and dried to provide the title compound. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.68 (s, 1 H), 8.52 - 8.58 (m, 2 H), 8.04 (d, 1 H), 7.79 (dd, 1 H), 7.53 (d, 1 H), 7.47 - 7.52 (m, 2 H), 7.30 - 7.37 (m, 2 H), 7.07 (d, 1 H), 7.01 - 7.06 (m, 2 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 4.25 (s, 1 H), 3.25 - 3.32 (m, 4 H), 3.07 (s, 4 H), 2.75 (s, 2 H), 2.09 - 2.24 (m, 6 H), 1.95 (s, 2 H), 1.50 - 1.73 (m, 5 H), 1.28 - 1.43 (m, 4 H), 1.06 - 1.18 (m, 5 H), 0.92 (s, 6 H). EXAMPLE 338
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methy lcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 338A
methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- 1 -enecarboxylate To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifiuoroacetic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product.
EXAMPLE 338B
methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enecarboxylate
EXAMPLE 338A (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2: 1 dimethoxy ethane /methanol (600 mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product.
EXAMPLE 338C
(2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 338B (53.8 g) and ether (400 mL), was added methanol (25 mL) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN aqueous HC1 with ice-cooling. The mixture was diluted with water and extracted with ether (3x 100 mL). The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes.
EXAMPLE 338D
tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine- 1 - carboxylate
Mesyl Chloride (7.5 mL) was added via syringe to EXAMPLE 338C (29.3 g) and triethylamine (30 mL) in CH2C12 (500 mL) at 0°C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes.
EXAMPLE 338E
1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazine EXAMPLE 338D (1 g) was stirred in dichloromethane (10 mL), trifluoroacetic acid
(10 mL), and triethylsilane (1 mL) for 1 hour. The mixture was concentrated, taken up in a mixture of dichloromethane (100 mL) and saturated aqueous Na2C03 solution (20 mL) and stirred for 10 minutes. The layers were separated, and the organic layer was dried over Na2S04, filtered, and concentrated to give the product.
EXAMPLE 338F
5-bromo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine To a mixture of 5-bromo-lH-pyrrolo[2,3-b]pyridine (15.4 g) in tetrahydrofuran (250 mL) was added 1M lithium hexamethyldisilazide in tetrahydrofuran (86 mL), and after 10 minutes, TIPS-Cl (triisopropylchlorosilane ) (18.2 mL) was added. The mixture was stirred at room temperature for 24 hours. The reaction was diluted with ether, and the resulting solution was washed twice with water. The extracts were dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 338G
l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-5-ol To a mixture of EXAMPLE 338F (24.3 g) in tetrahydrofuran (500 mL) at -78°C was added 2.5M BuLi (30.3 mL). After 2 minutes, trimethylborate (11.5 mL) was added, and the mixture was allowed to warm to room temperature over 1 hour. The reaction was poured into water, extracted thee times with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was taken up in tetrahydrofuran (200 mL) at 0°C, and 1M aqueous NaOH (69 mL) was added, followed by 30% aqueous H202 (8.43 mL), and the solution was stirred for 1 hour. Na2S203 (10 g) was added, and the pH was adjusted to 4-5 with concentrated HC1 and solid NaH2P04. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2S04), filtered, and concentrated. The crude product was chromatographed on silica gel with 5-25%> ethyl acetate/hexanes .
EXAMPLE 338H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 338G (8.5 g), methyl 2,4-difluorobenzoate (7.05 g), and K3P04 (9.32 g) in diglyme (40 mL) at 115°C was stirred for 24 hours. The reaction was cooled, diluted with ether (600 mL), and washed twice with water, and brine, and
concentrated. The crude product was chromatographed on silica gel with 2-50% ethyl acetate/hexanes. EXAMPLE 3381
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate A mixture of EXAMPLE 338H (1.55 g), EXAMPLE 338E (2.42 g), and HK2P04 (1.42 g) in dimethylsulfoxide (20 mL) at 135°C was stirred for 24 hours. The reaction was cooled, diluted with ether (400 mL), and washed three times with 1M aqueous NaOH, and brine, and concentrated. The crude product was chromatographed on silica gel with 10-50%) ethyl acetate/hexanes. EXAMPLE 338J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
EXAMPLE 3381 (200 mg) in dioxane (10 mL) and 1M NaOH (6 mL) at 50°C was stirred for 24 hours. The reaction was cooled, added to NaH2P04 solution, and extracted thee times with ethyl acetate. The combined extracts were washed with brine, and concentrated to give the pure product.
EXAMPLE 338K
tert-butyl (4-hydroxy-4-methylcyclohexyl)methylcarbamate To a vigorous stirring solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (1.7 g) in tetrahydrofuran (40 mL) at -78°C was dropwise added 1.6 M methyllithium (14.02 mL) in ether. After completion of the addition, the mixture was stirred at -78°C for 1.2 hours and poured into a cold NH4C1 aqueous solution. The resulting mixture was extracted with dichloromethane (100 ml, three times) and the organic layer was dried over Na2S04, filtered, and concentrated. The residue was dissolved in dichloromethane and loaded onto an
Analogix purification system, and it was eluted with 0 - 50% ethyl acetate in
dichloromethane to provide the title compound.
EXAMPLE 338L
4-(aminomethyl)- 1 -methylcyclohexanol
EXAMPLE 338K (1.3 g) in dichloromethane (5 mL) at 0°C was treated with trifluoroacetic acid (2.1 mL) and a few drops of water for 1 hour. The reaction mixture was concentrated and the residue was directly used for next step.
EXAMPLE 338M
4-((cis-4-hydroxy-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 338L (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (1.1 g) in tetrahydrofuran (15 mL) was treated with triethylamine overnight. The reaction mixture, was concentrated and the residue was purified by a reverse phase chromatography, eluting with 30% - 50% acetonitrile in 0.1% trifluoroacetic acid water solution to isolate the title compound. EXAMPLE 338N
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4-methy lcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
A mixture of EXAMPLE 338J (144 mg), EXAMPLE 338M (95 mg), N, N- dimethylpyridin-4-amine (123 mg) and N1-((ethylimino)methylene)-N3,N3-dimethylpropane- 1,3-diamine hydrochloride (62.7 mg) in dichloromethane (7 ml) was stirred overnight and concentrated. The residue was purified by reverse chromatography, eluted with 40%-70% acetonitrile in 0.1% TFA water. The desired fractions were concentrated, neutralized with NaHCC"3 and extracted with dichloromethane. The organic layer was dried over Na2SC"4, filtered, concentrated and dried to provide the title compound. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.69 (s, 1 H), 11.38 (s, 1 H), 8.59 (t, 1 H), 8.55 (d, 1 H), 8.04 (d, 1 H), 7.79 (dd, 1 H), 7.54 (d, 1 H), 7.46 - 7.52 (m, 2 H), 7.30 - 7.38 (m, 2 H), 7.00 - 7.10 (m, 3 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.95 (s, 1 H), 3.25 (t, 4 H), 3.07 (s, 4 H), 2.75 (s, 2 H), 2.10 - 2.26 (m, 6 H), 1.95 (s, 2 H), 1.29 - 1.62 (m, 8 H), 1.16 - 1.30 (m, 2 H), 1.08 (s, 3 H), 0.92 (s, 6 H).
EXAMPLE 339
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 339A
(lR,4S)-methyl spiro[bicyclo[2.2.1]heptane-2,2'-[l,3]dioxolane]-5-carboxylate A reaction mixture of l,4-dioxaspiro[4.4]non-6-ene (5 g), methyl acrylate (10.24 g), and hydroquinone (0.13 g) was heated at 100 ° C in acetonitrile (12 mL) for three days. After cooling, the solvent was removed, and residue was purified by flash chromatography on silica gel eluting with 4:1 hexane/ethyl acetate to provide the title compound as a mixture of two isomers.
EXAMPLE 339B
(lR,4S)-spiro[bicyclo[2.2.1]heptane-2,2'-[l,3]dioxolane]-5-ylmethanol EXAMPLE 339A (1.0 g) in tetrahydrofuran was cooled to 0°C. To this solution was added 1.0 N lithium aluminum hydride (2.8 mL) dropwise. The reaction mixture was stirred for 2 hours. Water (0.4 mL) was added followed by 2 N aqueous NaOH (0.2 mL). The solid was filtered off, and the filtrate was concentrated. Toluene was added, and it was then distilled to remove any trace amount of water. The title compound was used for the next reaction without further purification.
EXAMPLE 339C
5-chloro-6-(((l S,2R,4R)-5-oxobicyclo[2.2.1 ]heptan-2-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 339B for (tetrahydro-
2H-pyran-4-yl)methanol and EXAMPLE 40A for EXAMPLE 36A in EXAMPLE 36B. The two stereoisomers at the 5 position were isolated by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 μ, CI 8(2), 250X21.20 mm, 5 A) eluting with 20- 80% acetonitrle in water with 0.1% trifluoroacetic acid. The desired fractions were collected, and the solvents were removed under reduced vacuum at 60°C. During this process, a lot of solid formed. It was then partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered and concentrated to give the title compound.
EXAMPLE 339D
5-chloro-6-(((lS,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]heptan-2- yl)methoxy)pyridine-3-sulfonamide
EXAMPLE 339C (0.44 g) in tetrahydrofuran (15 mL) was treated with 3.0 M methylmagnesium bromide (5.3 mL) at 0 °C. The solution was stirred for 16 hours. The reaction mixture was then partitioned between ethyl acetate and 0.05 N aqueous HC1 (20 mL). The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 10-50% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 339E
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 339D for
EXAMPLE 1 IB in EXAMPLE 1 ID H NMR (500MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1H), 8.50 (s, 1H), 8.16 (s, 1H), 8.02 (d,lH), 7.49-7.55 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H), 6.67 (dd, 1H), 6.38 (dd, 1H), 6.20 (s, 1H), 4.40-4.48 (m, 2H), 4.31 (s, 1H), 3.09 (s, 4H), 2.83 (s, 2H), 2.15-2.33 (m, 7H), 1.96 (s, 2H), 1.87 (d, 1H), 1.65-1.69 (m, 1H), 1.54-1.56 (m, 2H), 1.36-1.47 (m, 6H), 1.26-1.30 (m, 1H), 1.19 (s, 3H), 0.93 (s, 6H).
EXAMPLE 340
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 340A
4-(l,4-dioxaspiro[4.5]decan-8-ylamino)-3-nitrobenzenesulfonamide To a solution of 4-fluoro-3-nitrobenzenesulfonamide (1.4 g) in tetrahydrofuran (30 mL) was added l,4-dioxaspiro[4.5]decan-8-amine (1.0 g) and diisopropylethylamine (5 mL) . The mixture was stirred overnight. The mixture was diluted with ethyl acetate (300 mL) and washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 340B
N-(4-(l,4-dioxaspiro[4.5]decan-8-ylamino)-3-nitrophenylsulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin- l-yl)benzamide
To a solution of EXAMPLE 3 J (617 mg) and EXAMPLE 340A (386 mg) in dichloromethane (10 mL) was added l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (288 mg) and 4-(dimethylamino)pyridine (183 mg). The mixture was stirred overnight. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHCOs, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound. EXAMPLE 340C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-(4-oxocyclohexylamino)phenylsulfonyl)benzamide To a solution of EXAMPLE 340B (386 mg) in acetone (10 mL) and water (5 mL) was added para-toluenesulfonic acid monohydrate (50 mg). The mixture was stirred at 120°C in a Biotage Initiator microwave reactor for 30 minutes. The mixture was diluted with
dichloromethane (300 mL) and washed with aqueous NaHC03, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 340D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
To a solution of EXAMPLE 340C (240 mg) and 3-(cyclopropylamino)propanenitrile (62 mg) in tetrahydrofuran (10 mL) was added acetic acid (2 mL) and MP-cyanoborohydride (300 mg, 2.15mmol/g). The mixture was stirred overnight. The mixture was filtered and concentrated under vacuum and the residue was dissolved in dimethylsulfoxide/methanol (1 : 1, 10 mL) and loaded on Gilson, C18(100A) 250x121.2 mm(10 micron), with 30% acetonitrile to 65% acetonitrile over 40 minutes.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.66 (s, 1 H), 8.55 (dd, 1 H), 8.17 (d, 1 H), 8.03 (d, 1 H), 7.79 (d, 1 H), 7.49 (m, 3 H), 7.34 (d, 2 H), 7.11 (m, 1 H), 7.04 (d, 2 H), 6.67 (dd, 1 H), 6.38 (d, 1 H), 6.19 (d, 1 H), 4.01 (m, 1 H), 3.56 (m, 1 H), 3.06 (m, 4 H), 2.88 (t, 2 H), 2.65 (m, 6 H), 2.19 (m, 6 H), 2.00 (m, 7 H), 1.51 (m, 6 H), 0.92 (s, 6 H), 0.42 (m, 4 H).
EXAMPLE 341
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 341 A
ethyl 1 ,4-dioxaspiro[4.5]decane-8-carboxylate
To a solution of ethyl 4-oxocyclohexanecarboxylate (31.8 g) in toluene (100 mL) was added ethylene glycol (36.5 mL) and p-toluenesulfonic acid monohydrate (0.426 g). The two phase mixture was stirred rapidly at ambient temperature for 72 hours. The reaction was diluted with water (900 mL) and extracted with ether (900 mL). The organic layer was washed with saturated sodium bicarbonate solution and brine, and then dried over anhydrous sodium sulfate. After filtration, the title compound was obtained by concentration under high vacuum.
EXAMPLE 34 IB
1 ,4-dioxaspiro [4.5] decan-8-ylmethanol
To a suspension of lithium aluminum hydride (8.19 g) in tetrahydrofuran (400 mL) was added dropwise a solution of EXAMPLE 341A (37.8 g) in tetrahydrofuran (75 mL). The mixture was then heated at reflux for 2 hours. The reaction mixture was cooled in an ice bath and quenched very slowly with water (8 mL). Then added sequentially were 4N sodium hydroxide (8 mL), ether (200 mL), water (24 mL), ether (500 mL) and anhydrous sodium sulfate (250 g). The resulting mixture was stirred rapidly for 2 hours and was filtered. The title compound was isolated by concentration of the filtrate.
EXAMPLE 341C
8-(benzyloxymethyl)- 1 ,4-dioxaspiro[4.5]decane
To a suspension of sodium hydride (60% oil dispersion, 8.86 g) in tetrahydrofuran (170 mL) was added a solution of EXAMPLE 341B (30.52 g) in tetrahydrofuran (100 mL). This mixture was stirred for 30 minutes and benzyl bromide (24 mL) was added. After stirring for 72 hours, the reaction was quenched with saturated ammonium chloride solution (400 mL) and diluted with ether (500 mL). The layers were separated and the aqueous layer was extracted with ether (2 X 150 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel eluting with a 0, 10, 15, 75 % ethyl acetate in hexanes step gradient to provide the title compound.
EXAMPLE 34 ID
4-(benzyloxymethyl)cyclohexanone
To a solution of EXAMPLE 341C (43.02 g) in dioxane (500 mL) was added water (125 mL) and 2M hydrochloric acid (90 mL). The mixture was heated at 85°C for 18 hours. Upon cooling, the reaction mixture was diluted with brine (1500 ml), saturated sodium bicarbonate solution (300 mL) and ether (1000 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel eluting with a 5- 50% ethyl acetate in hexanes step gradient to provide the title compound. EXAMPLE 34 IE
trans-4-(benzyloxymethyl)- 1 -methylcyclohexanol To 2,6-di-t-butyl-4-methylphenol (83.4 g) in toluene (1100 mL) was added 2.0M (in hexanes) trimethylaluminum (95 mL) somewhat carefully to control methane evolution and a small exotherm. The reaction mixture was stirred at ambient temperature under N2 for 75 minutes and was then cooled to -77° C. A solution of EXAMPLE 341D (14 g) in toluene (15 mL) was added dropwise, keeping the temperature below -74 °C. Methyllithium (1.6M in diethyl ether, 120 mL) was then added dropwise, keeping the temperature below -65 °C. The resulting mixture was stirred at -77 °C under N2 for 2 hours. The reaction mixture was then poured into IN aqueous HC1 (1600 mL), rinsing the flask with toluene. The organic layer was washed with brine and the combined aqueous layers were extracted with diethyl ether. The combined organic layers were dried (Na2S04), filtered and concentrated. The concentrate was chromatographed on 650 g of spherical silica gel using 2.5 L of 80/20 hexanes/ethyl acetate, then 3.0 L of 75/25 hexanes/ethyl acetate, and finally 4.0 L of 70/30 hexanes/ethyl acetate as the eluents to provide the title compound.
EXAMPLE 34 IF
Trans-4-(hydroxymethyl)- 1 -methylcyclohexanol
EXAMPLE 341E (12.6 g) and ethanol (120 ml) were added to 20% Pd(OH)2/C, wet
(1.260 g) in a 500 mL SS pressure bottle. The reaction mixture was stirred at ambient temperature under 30 psi hydrogen gas. Hydrogen uptake ceased at 5 minutes. The mixture was filtered through a nylon membrane rinsing with ethanol. The filtrate was concentrated and then azeotroped with toluene (100 mL) to remove any remaining ethanol. The concentrate was dried under high vacuum for 40 minutes to provide the title compound.
EXAMPLE 341G
5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 34 IF for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 34 IH
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 328E for EXAMPLE 3 J and EXAMPLE 341G for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.09 (s, IH), 9.18 (d, IH), 8.74 (d, IH), 8.41 (d, IH), 8.09 (d, IH), 7.67 (m, 2H), 7.42 (m, 2H), 7.09 (m, 2H), 6.74 (dd, IH), 6.52 (dd, IH), 6.49 (d, IH), 4.29 (d, 2H), 3.05 (m, 4H), 2.80 (s, 2H), 2.37 (t, 2H), 2.15 (m, 4H), 2.11 (s, 2H), 1.89 (m, 6H), 1.75 (m, 2H), 1.45 (t, 2H), 1.41 (s, 3H), 1.32 (m, 2H), 0.37 (m, 4H).
EXAMPLE 342
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 342A
methyl 5,6,7,8-tetrahydroimidazo[l ,2-a]pyridine-6-carboxylate To a 50 ml pressure bottle were placed methyl imidazo[l,2-a]pyridine-6-carboxylate (0.26 g ), acetic acid (10 ml), and wet 5% palladium on carbon (0.052 g ). The reaction mixture was stirred for 16 hours at 30 psi and 50 °C. The solid was filtered off, and the filtrate was concentrated. The residue was taken up in ethyl acetate. It was then washed with saturated sodium bicarbonate, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel using 10-100% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 342B
(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-yl)methanol The title compound was prepared by substituting EXAMPLE 342A for EXAMPLE in EXAMPLE 339B.
EXAMPLE 342C
5-chloro-6-((5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 342B for (tetrahydro- 2H-pyran-4-yl)methanol and EXAMPLE 40A for EXAMPLE 36A in EXAMPLE 36B.
EXAMPLE 342D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 342C for
EXAMPLE 1 IB in EXAMPLE 1 ID H NMR (500MHz, dimethylsulfoxide-d6) δ 11.54 (s, IH), 8.36 (s, IH), 8.06 (s, IH), 7.93 (s, IH), 7.58 (d, IH), 7.41-7.44 (m, 2H), 7.2-7.36 (m, 4H), 7.05 (d, 2H), 6.63 (dd, IH), 6.32 (dd, IH), 6.24 (d, IH), 4.42-4.51 (m, IH), 4.37-4.40 (m, IH), 4.29 (dd, IH), 3.91 (dd, IH), 3.03 (s, 4H), 2.90-2.95 (m, 2H), 2.77 (s, 2H), 2.51-2.52 (m, IH), 2.07-2.23 (m, 7H), 1.96 (s, 2H), 1.76-1.82 (m, IH), 1.65-1.69 (m, 2H), 1.54-1.56 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 343
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 343A
5 -chloro-6-((( 1 S ,2S,4R)-5 -oxobicyclo [2.2.1 ]heptan-2-yl)methoxy)pyridine-3 -sulfonamide The title compound was isolated as another isomer in EXAMPLE 339C.
EXAMPLE 343B
5-chloro-6-(((lS,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]heptan-2-yl)methoxy)pyridine-
3 -sulfonamide
The title compound was prepared by substituting EXAMPLE 343A for EXAMPLE 339B in EXAMPLE 339C. EXAMPLE 343C
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 343B for EXAMPLE 1 IB in EXAMPLE 1 ID H NMR (500MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1H), 8.51 (s, 1H), 8.17 (s, 1H), 8.03 (s, 1H), 7.49-7.55 (m, 3H), 7.35 (d, 2H), 7.05 (d, 2H), 6.67 (dd, 1H), 6.39 (dd, 1H), 6.20 (d, 1H), 4.27 (s, 1H), 4.11-4.19 (m, 2H), 3.11 (s, 4H), 2.87 (s, 2H), 1.96-2.23 (m, 10H), 1.88 (d, 1H), 1.50 (dd, 1H), 1.33-1.44 (m, 2H), 1.13-1.19 (m, 4H), 0.88-0.93 (m, 8H).
EXAMPLE 344
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
EXAMPLE 344A
4-((cis-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide
EXAMPLE 347A (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (1.2 g) in tetrahydrofuran (40 mL) were treated with 60% sodium hydride (1.6 g) for 3 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by a reverse phase chromatography, eluting with 30-50%) CH3CN in 0.1 %> trifluoroacetic acid water to provide the title compound as a single enantiomer.
EXAMPLE 344B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 344A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.34 (d, IH), 8.04 (m, 2H), 7.52 (m, 3H), 7.40 (d, IH), 7.35 (d, 2H), 7.04 (d, 2H), 6.68 (dd, IH), 6.40 (m, IH), 6.20 (d, IH), 4.02 (d, 2H), 3.96 (s, IH), 3.10 (br s, 4H), 2.85 (m, 2H), 2.29 (m, 3H), 2.15 (t, 2H), 1.96 (br s, 2H), 1.68 (m, IH), 1.55(m, 4H),1.42 (m, 4H), 1.27 (m, 2H), 1.10 (s, 3H), 0.92 (s, 6H).
EXAMPLE 345
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4^ (4-{[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 328E for EXAMPLE 3 J and EXAMPLE 2770 for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.13 (d, IH), 8.41 (d, IH), 8.09 (d, IH), 7.68 (t, IH), 7.66 (d, IH), 7.42 (m, 2H), 7.09 (m, 2H), 6.75 (dd, IH), 6.51 (m, 2H), 4.64 (d, 4H), 4.53 (d, 2H), 3.39 (m, IH), 3.06 (m, 4H), 2.81 (s, 2H), 2.51 (m, 2H), 2.37 (m, 2H), 2.12 (m, 10H), 1.90 (m, 2H), 1.45 (t, 2H), 0.38 (s, 4H).
EXAMPLE 346
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting 3,3-difluoropyrrolidine
hydrochloride for 3-(cyclopropylamino)propanenitrile in EXAMPLE 340D. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.68 (s, 1 H), 11.38 (m, 1 H), 8.55 (m, 1 H), 8.36 (d, 1 H), 8.03 (d, 1 H), 7.80 (m, 1 H), 7.50 (m, 3 H), 7.34 (d, 2 H), 7.13 (d, 1 H), 7.04 (d, 2 H), 6.83 (m, 1 H), 6.68 (m, 1 H), 6.38 (d, 1 H), 6.19 (s, 1 H), 4.02 (s, 1 H), 3.83 (m, 1 H), 3.06 (m, 4 H), 2.96 (m, 2 H), 2.73 (m, 4 H), 2.26 (m, 8 H), 1.97 (m, 4 H), 1.68 (m, 4 H), 1.37 (m, 2 H), 0.92 (s, 6 H).
EXAMPLE 347
N-( {5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 347A
4-(hydroxymethyl)- 1 -methylcyclohexanol
4-(Hydroxymethyl)cyclohexanone (800 mg) in tetrahydrofuran (15 mL) was treated with 3 M methylmagnesium chloride in tetrahydrofuran (6.24 mL) at 0°C. The reaction was warmed to room temperature over 2 hours and quenched with methanol and water. The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The precipitates were filtered off and the filtrate was concentrated. The residue was purified by chromatography, eluting with 0-100% ethyl acetate in hexane to provide the title compound. EXAMPLE 347B
5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide
EXAMPLE 347A (970 mg) and EXAMPLE 40A (1.6 g) in N,N-dimethylformamide (8 mL) were treated with sodium hydride (1.8 g, 60%>) at room temperature for 2 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HC1, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by a reverse phase chromatography, eluting with 30-45% acetonitrile in 0.1% trifluoroacetic acid water to isolate the title compound.
EXAMPLE 347C
5 -chloro-6-((cis-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3 -sulfonamide
The title compound was prepared and isolated as described in Example 347B.
EXAMPLE 347D
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 347B in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d 6) δ 11.67 (s, 1 H), 8.51 (d, 1 H), 8.18 (d, 1 H), 8.03 (d, 1 H), 7.48 - 7.56 (m, 3 H), 7.35 (d, 2 H), 7.05 (d, 2 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.21 (d, 1 H), 4.17 - 4.34 (m, 3 H), 3.11 (s, 4 H), 2.89 (s, 2 H), 2.24 - 2.42 (m, 4 H), 2.15 (s, 2 H), 1.96 (s, 2 H), 1.66 - 1.82 (m, 3 H), 1.55 (d, 2 H), 1.31 - 1.44 (m, 4 H), 1.12 - 1.27 (m, 2 H), 1.10 (s, 3 H), 0.93 (s, 6 H). EXAMPLE 348
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE
347C in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d 6) δ 11.67 (s, 1 H), 8.51 (d, 1 H), 8.18 (d, 1 H), 8.03 (d, 1 H), 7.47 - 7.58 (m, 3 H), 7.35 (d, 2 H), 7.05 (d, 2 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.21 (d, 1 H), 4.21 (d, 2 H), 3.95 (s, 1 H), 3.11 (s, 4 H), 2.89 (s, 2 H), 2.33 (d, 4 H), 2.15 (s, 2 H), 1.96 (s, 2 H), 1.63 - 1.77 (m, 1 H), 1.48 - 1.60 (m, 4 H), 1.35 - 1.48 (m, 4 H), 1.20 - 1.33 (m, 2 H), 1.09 (s, 3 H), 0.93 (s, 6 H).
EXAMPLE 349
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting 2,2-difluorocyclopropanamine hydrochloride for 3-(cyclopropylamino)propanenitrile in EXAMPLE 340D. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.60 (s, 1 H), 8.47 (m, 2 H), 8.12 (m, 1 H), 7.98 (m, 1 H), 7.72 (m, 2 H), 7.47 (m, 3 H), 7.34 (m, 3 H), 7.05 (m, 3 H), 6.65 (dd, 1 H), 6.35 (m, 1 H), 6.22 (d, 1 H), 3.54 (m, 2 H), 3.08 (m, 4 H), 2.74 (m, 4 H), 2.25 (m, 4 H), 2.01 (m, 4 H), 1.38 (m, 4 H), 0.92 (s, 6 H).
EXAMPLE 350
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 350A
ethyl spiro[benzo[d] [ 1 ,3]dioxole-2, 1 '-cyclohexane]-4'-carboxylate To a solution of ethyl 4-oxocyclohexanecarboxylate (22.75 g) and pyrocatechol (14.75 g) in toluene (200 mL) was added catalytic amount of para-toluenesulfonic acid monohydrate and the mixture was stirred under reflux and a Dean-Stark trap overnight. The mixture was diluted with diethyl ether (600 mL) and washed with aqueous NaHC03, water and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated under vacuum to provide the title compound.
EXAMPLE 350B
ethyl 4'-fluorospiro[benzo[d][ 1 ,3]dioxole-2, 1 '-cyclohexane]-4'-carboxylate
A solution of EXAMPLE 350A (5.25g) in tetrahydrofuran (40 mL) was added dropwise to a solution of lithium diisopropylamide (12 mL, 2.0M in
tetrahydrofuran/heptane/ethylbenzene) at 0°C. The solution was stirred at 0°C for 30 minutes, and then was transferred by cannula to a pre-cooled (0°C) stirring solution of N- fluorobenzenesulfonnimide (7.89g) in dry tetrahydrofuran (20 mL). The reaction mixture was stirred at 0°C for 30 minutes, and then at 20°C for 18 hours. The reaction mixture was poured over aqueous NH4C1 and extracted with diethyl ether (3x200 mL). The combined organic layers were washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the crude product.
EXAMPLE 350C
(4'-fluorospiro[benzo[d][ 1 ,3]dioxole-2, 1 '-cyclohexane]-4'-yl)methanol To a solution of EXAMPLE 350B (23 g) in tetrahydrofuran (150 mL) was added lithium aluminum hydride (3.11 g). The mixture was stirred overnight. Aqueous 2N NaOH solution was added dropwise to the reaction mixture. The mixture was then diluted with ethyl acetate (600 mL) and washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the crude product which was loaded on a 600 g analogies column and eluted with 10% to 20% ethyl acetate in hexane to provide the title compound.
EXAMPLE 350D
5-chloro-6-((4'-fluorospiro[benzo[d] [ 1 ,3]dioxole-2, 1 '-cyclohexane]-4'-yl)methoxy)pyridine-
3 -sulfonamide
To a solution of EXAMPLE 350C (89 mg) in N,N-dimethylformamide (3 mL) was added NaH (65% in mineral oil, 36 mg) . The mixture was stirred for 30 minutes, and then 5, 6-dichloropyridine-3-sulfonamide (85 mg) was added. The mixture was stirred overnight.
The mixture was poured over aqueous NH4CI and extracted with ethyl acetate (100 mL). The combined organic layers were washed with water, brine and dried over Na2S04. After filtration and evaporation of the solvent, the residue was loaded on a silica gel cartridge and eluted with 30% ethyl acetate in hexane to provide the title compound. EXAMPLE 350E
5-chloro-6-((l-fluoro-4-oxocyclohexyl)methoxy)pyridine-3-sulfonamide To a solution of EXAMPLE 350D (1.6g) and pyridinium p-toluenesulfonate (1.2 g) in acetone (10 mL) was added water (2 mL) and the mixture was stirred under microwave irradiation at 100°C for 10 minutes. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHC03, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 350F
5-chloro-6-((cis- 1 -fluoro-4-hydroxycyclohexyl)methoxy)pyridine-3 -sulfonamide
To a solution of EXAMPLE 350E (336 mg) in tetrahydrofuran(10 mL) was added NaBH4 (75 mg). The mixture was stirred for 45 minutes. The mixture was diluted with ethyl acetate (300 mL) and washed with 2N aqueous NaOH, water, and brine. After drying over Na2S04, the mixture was filtered and the solvent was evaporated to give the crude product.
EXAMPLE 350G
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 350F for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.63 (s, 1 H), 8.48 (s, 1 H), 8.18 (s, 1 H), 8.01 (d, 1 H), 7.50 (m, 3 H), 7.35 (d, 2 H), 7.05 (d, 2 H), 6.67 (dd, 1 H), 6.37 (dd, 1 H), 6.21 (d, 1 H), 4.62 (d, 1 H), 4.47 (s, 1 H), 4.40 (s, 1 H), 3.46 (m, 1 H), 3.06 (m, 4 H), 2.88 (m, 1 H), 2.25 (m, 6 H), 1.99 (m, 4 H), 1.58 (m, 8 H), 0.93 (s, 6 H).
EXAMPLE 351
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 351 A
diethyl 1 ,4-dioxaspiro[4.5]decane-8,8-dicarboxylate A 500 mL round-bottomed flask was charged with diisopropylamine (16 mL) and tetrahydrofuran (311 mL). The solution was cooled to -78 °C under N2 and n-BuLi (2.5 M in hexanes, 44.8 mL)) was added. The reaction was stirred for 30 minutes at -78°C and ethyl l,4-dioxaspiro[4.5]decane-8-carboxylate (20 g) was added as a tetrahydrofuran solution (ca. 10 mL). The solution was stirred at -78°C for 1 hour and ethyl chloro formate (9 mL) was added neat. After stirring at -78°C for 10 minutes, the reaction was warmed to room temperature over 2 hours. The reaction was quenched with saturated aqueous NH4C1 and was diluted with diethyl ether. The layers were separated, the aqueous layer was extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-65% hexanes / ethyl acetate).
EXAMPLE 35 IB
1 ,4-dioxaspiro [4.5] decane-8 , 8-diyldimethanol
To a 1 L round-bottomed flask was added EXAMPLE 351 A (26.6 g) and
tetrahydrofuran (310 mL) to give a colorless solution. The solution was cooled to 0 °C and lithium aluminum hydride (2M in tetrahydrofuran, 62 mL) was added via syringe. The reaction was allowed to warm to room temperature and stirred overnight. The mixture was cooled back down to 0 °C and quenched slowly with 4.7 mL water, 4.7 mL 10% aqueous NaOH and 14 mL water. The mixture was allowed to stir until salts were formed and was then filtered through a Supelco 90 mm silica gel Buchner funnel. The filtrate was
concentrated by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-80% hexanes / ethyl acetate). EXAMPLE 351C
2,8,11 -trioxa-dispiro [3.2.4]tridecane
To a 1 L round-bottomed flask was added EXAMPLE 351B (13 g) in tetrahydrofuran
(321 mL). The solution was cooled to -78 °C under N2 and n-BuLi (25.7 mL) was added dropwise via syringe. After addition was complete, the mixture stirred for 30 minutes and a tetrahydrofuran solution of 4-toluenesulfonyl chloride (12.25 g) was added via addition funnel. The reaction was allowed to stir overnight, and gradually warm to room temperature. The reaction mixture was cooled to -78 °C and n-BuLi (25.7mL) was added. The mixture was warmed to room temperature and stirred for 3 hours. The reaction was quenched with sat aqueous NH4C1 and diluted with diethyl ether. The layers were separated, the aqueous layers extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-20% acetone / hexanes).
EXAMPLE 35 ID
2-oxaspiro[3.5]nonan-7-one
To a 500 mL round-bottomed flask was added EXAMPLE 351C (11 g) in 80 % aqueous acetic acid (200 mL). The reaction was heated to 65°C and stirred for about 4 hours. Most of the acetic acid and water were removed by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-65 % hexanes/ethyl acetate).
EXAMPLE 35 IE
7-methylene-2-oxaspiro [3.5 Jnonane
To a 250 mL round-bottomed flask was added methyltriphenylphosphonium iodide
(4.33 g) in tetrahydrofuran (35.7 mL) to give a suspension. The suspension was cooled to -15 °C. n-BuLi (2.5 M in hexanes, 4.28 mL) was added dropwise and the mixture was stirred at - 15 °C for 40 minutes and EXAMPLE 35 ID (1 g) was added as a tetrahydrofuran (ca. 5 mL) solution. The mixture was stirred at -15 °C for about 15 minutes and warmed to room temperature. After 1.5 hours, the reaction was complete and was quenched with saturated aqueous NH4C1 and diluted with diethyl ether. The layers were separated and the aqueous layer was extracted (2x) with diethyl ether. The combined organics were washed with brine, dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase chromatography (Analogix, 80 g Grace silica gel column, 0-50% hexanes/ethyl acetate).
EXAMPLE 35 IF
2-oxaspiro [3.5 ]nonan-7-ylmethanol
To a 25 mL round-bottomed flask was added EXAMPLE 35 IE (568 mg) and EXAMPLE 35 IF tetrahydrofuran (4.11 mL) to give a colorless solution. 9- Borabicyclo[3.3.1]nonane (0.5 M in tetrahydrofuran, 24.7 mL) was added and the reaction was allowed to stir for 2 hours at room temperature. Ethanol (11 mL) was added followed by aqueous NaOH (5M, 4.11 mL) and then hydrogen peroxide (2.1 mL) was added. The reaction was heated at 50 °C for 2 hours. The mixture was concentrated by rotary evaporation, and diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (3x) and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column
chromatography (Analogix, 80 g Grace, 0-70 % hexanes / ethyl acetate).
EXAMPLE 351G
4-(2-oxaspiro[3.5]nonan-7-ylmethoxy)-3-nitrobenzenesulfonamide EXAMPLE 351G was prepared substituting EXAMPLE 35 IF for (tetrahydro-2H- pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 351H
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-(2-oxaspiro[3.5]nonan-7-ylmethoxy)-3- nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 351G for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1 H) 8.34 (s, 1 H) 8.03 (d, 2 H) 7.45 - 7.57 (m, 3 H) 7.30 - 7.40 (m, 3 H) 7.04 (d, 2 H) 6.67 (dd, 1 H) 6.39 (dd, 1 H) 6.17 - 6.23 (m, 1 H) 4.29 (s, 2 H) 4.20 (s, 2 H) 4.00 (d, 2 H) 3.08 (s, 4 H) 2.73 - 2.90 (m, 2 H) 2.72 (s, 1 H) 2.01 - 2.32 (m, 6 H) 1.96 (s, 2 H) 1.64 - 1.78 (m, 4 H) 1.33 - 1.50 (m, 6 H) 0.96 - 1.15 (m, 2 H) 0.92 (s, 6 H).
EXAMPLE 352
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide
EXAMPLE 352A
4-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 34 IF for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24 A.
EXAMPLE 352B 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 352A for EXAMPLE IF and EXAMPLE 3 J for EXAMPLE lEin EXAMPLE 1G. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.66 (s, 1H), 8.31 (br s, 1H), 8.01 (m, 2H), 7.49 (m, 3H), 7.33 (m, 3H), 7.03 (m, 2H), 6.66 (dd, 1H), 6.37 (m, 1H), 6.19 (d, 1H), 4.27 (s, 1H), 4.05 (d, 2H), 3.40 (m, 2H), 3.17 (s, 1H), 3.07 (m, 3H), 2.79 (m, 1H), 2.24 (m, 3H), 2.14 (m, 2H), 1.94 (m, 2H), 1.71 (m, 3H), 1.52 (m, 2H), 1.38 (m, 4H), 1.22 (m, 2H), 1.09 (s, 3H), 0.91 (s, 6H).
EXAMPLE 353
4-(4- { [2-(4-chlorophenyl)-5 ,5 -bis(fluoromethyl)cyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 353A
l,4-dioxaspiro[4.5]decane-8,8-diylbis(methylene) bis(4-methylbenzenesulfonate) To a 500 mL round-bottomed flask was added EXAMPLE 35 IB (10 g) and dichloromethane (165 mL) to give a colorless solution. Triethylamine (24.1 mL) and toluene-2-sulfonyl chloride (19.8 g) were added followed by 4-dimethylaminopyridine (0.604 g). The reaction was refluxed overnight. Saturated aqueous NH4C1 was added followed by dilution with water and additional dichloromethane. The aqueous layer was extracted with dichloromethane (2x) and the combined organics were dried (MgS04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-55% hexanes / ethyl acetate).
EXAMPLE 353B
8 , 8 -bis(fluoromethy 1)- 1 ,4-dioxaspiro [4.5] decane
To a 500 mL round-bottomed flask was added EXAMPLE 353 A (20 g). tetra-n- Butylammonium fluoride (1M in tetrahydrofuran, 200 mL) was added and the resulting solution was refluxed for 6 days. The reaction was cooled, diluted with diethyl ether and washed with water (3x). The organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-30% hexanes / ethyl acetate).
EXAMPLE 353C
4,4-bis(fluoromethyl)cyclohexanone
To a 250 mL round bottom flask was added EXAMPLE 353B (1.1 g) and 80% aqueous acetic acid (50 mL). The reaction was heated at 65 °C for 3 hours, cooled and concentrated by rotary evaporation to remove most of the acetic acid and water. The residue was purified by regular phase flash column chromatography (Analogix, 0-50% hexanes / ethyl acetate).
EXAMPLE 353D
2-chloro-5 ,5-bis(fluoromethyl)cyclohex- 1 -enecarbaldehyde To a 100 mL pear flask was added N,N-dimethylformamide (498 μΐ) and
dichloromethane (8.9 mL) to give a colorless solution. The solution was cooled to 0 °C and POCl3 (550 μΐ) was added dropwise and then the mixture was warmed to room temperature for 30 minutes. In the meantime, to a 100 mL pear shaped flask was added EXAMPLE 353C (870 mg, 5.36 mmol) in dichloromethane (8941 μΐ) to give a colorless solution. The
Vilsmeier reagent was then taken up in a syringe and added dropwise to the 4,4- bis(fluoromethyl)cyclohexanone (870 mg) solution at room temperature. The resulting solution was stirred overnight. The reaction was poured into saturated aqueous NaHC03 and ice, warmed to room temperature and extracted with dichloromethane (3 x 30 mL). The organics were combined, dried over MgS04, filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix (0-60% hexanes / ethyl acetate).
EXAMPLE 353E
2-(4-chlorophenyl)-5,5-bis(fluoromethyl)cyclohex-l -enecarbaldehyde To a 20 mL vial was added EXAMPLE 353D (460 mg), 4-chlorophenylboronic acid (414 mg), potassium carbonate (762 mg), tetrabutylammonium bromide (711 mg), palladium (II) acetate (14.85 mg) and water (2450 μΐ) to give a suspension which was degassed with N2 for 2 minutes. The reaction was stirred at 45 °C overnight, cooled, and poured over a Supelco silica gel Buchner funnel, washing with ethyl acetate several times. The filtrate was concentrated by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-60% hexanes / ethyl acetate).
EXAMPLE 353F
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- bis(fiuoromethyl)cyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate To a 20 mL vial was added EXAMPLE 353E (240 mg), EXAMPLE 15F (297 mg) and dichloromethane (4.2 mL). Sodium triacetoxyborohydride (268 mg) was added and the reaction was stirred overnight at room temperature. The reaction was loaded directly onto silica gel and purified by regular phase flash column chromatography (Analogix, 0-80% hexanes / ethyl acetate).
EXAMPLE 353G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- bis(fiuoromethyl)cyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 353F for EXAMPLE 15G in EXAMPLE 15 H.
EXAMPLE 353H
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5- bis(fiuoromethyl)cyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-((tetrahydro-2H- pyran-4-yl)methylamino)phenylsulfonyl)benzamide EXAMPLE 353H was prepared by replacing EXAMPLE 3J with EXAMPLE 353G and EXAMPLE 1 IB with EXAMPLE IF in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-de) 511.69 (s, 1 H) 11.44 (s, 1 H) 8.48 - 8.70 (m, 1 H) 8.05 (d, 2 H) 7.81 (dd, 1 H) 7.46 - 7.59 (m, 3 H) 7.35 (d, 2 H) 7.12 (d, 2 H) 6.68 (dd, 1 H) 6.40 (dd, 1 H) 6.16 (d, 1 H) 4.39 - 4.49 (m, 2 H) 4.23 - 4.35 (m, 2 H) 3.85 (dd, J=l 1.87, 2.71 Hz, 2 H) 3.20 - 3.30 (m, 4 H) 2.98 - 3.10 (m, 4 H) 2.66 - 2.77 (m, 2 H) 2.11 - 2.30 (m, 6 H) 2.02 - 2.12 (m, 3 H) 1.99 (s, 1 H) 1.82 - 1.97 (m, 1 H) 1.54 - 1.67 (m, 4 H) 1.20 - 1.34 (m, 2 H). EXAMPLE 354
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 354A
tert-butyl 2-((2-nitro-4-sulfamoylphenoxy)methyl)morpholine-4-carboxylate The title compound was prepared by substituting tert-butyl 2-(hydroxymethyl)- morpholine-4-carboxylate fortetrahydro-2H-pyran-4-yl-methanol EXAMPLE 24A.
EXAMPLE 354B
4-(morpholin-2-ylmethoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 354A for EXAMPLE 113A in EXAMPLE 134A.
EXAMPLE 354C
4-((4-cyclopropylmorpholin-2-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 354B for EXAMPLE 173 A in EXAMPLE 173B.
EXAMPLE 354D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4- [(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 354C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.98 (s, IH), 9.06 (d, IH), 8.50 (dd, IH), 8.41 (d, IH), 8.09 (d, IH), 7.66 (t, IH), 7.62 (d, IH), 7.44 (d, 2H), 7.26 (d, IH), 7.07 (d, 2H), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.31 (dd, 1H),4.22 (dd, IH), 3.92 (m, IH), 3.83 (d, IH), 3.56 (dt, IH), 3.07 (m, 5H), 2.77 (s, 2H), 2.68 (d, IH), 2.35 (m, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.59 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.40 (m, 4H). EXAMPLE 355
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 355A
5 -chloro-6-((trans- 1 -fluoro-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3 -sulfonamide
To a cooled (0°C) solution of EXAMPLE 350E (1.2 g) in tetrahydrofuran (30 mL) was added dropwise a solution of methylmagnesium bromide (5 mL, 3.0M in ether). Upon addition, the reaction mixture solidified. More tetrahydrofuran (10 mL) was added to the mixture and stirring was continued for 1 hour. The mixture was poured over aqueous NH4C1 and extracted with ethyl acetate (3x 150 mL). The combined organic layers were washed with water, brine and dried over Na2S04. The mixture was filtered and concentrated. The residue was dissolved in dimethylsulfoxide/methanol (20 mL, 1 : 1) and loaded on loaded on Gilson, C18(100A) 250x121.2 mm (10 micron), with 30% acetonitrile to 65% acetonitrile over 40 minutes to separate the two isomers and isolate the title compound.
EXAMPLE 355B
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 355A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.63 (s, 1 H), 8.47 (s, 1 H), 8.17 (s, 1 H), 7.54 (d, 1 H), 7.48 (m, 2 H), 7.35 (d, 2 H), 7.05 (d, 2 H), 6.67 (dd, 1 H), 6.37 (d, 1 H), 6.22 (d, 1 H), 4.49 (s, 1 H), 4.42 (s, 1 H), 4.15 (s, 1 H), 3.06 (m, 4 H), 2.84 (m, 1 H), 2.25 (m, 6 H), 1.96 (s, 3 H), 1.83 (m, 4 H), 1.44 (m, 6 H), 1.14 (s, 3 H), 0.93 (s, 6 H).
EXAMPLE 356
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide EXAMPLE 356A
5 -chloro-6-((cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3 -sulfonamide The title compound was prepared as described in EXAMPLE 355 A. EXAMPLE 356B
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 356A for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.65 (s, 1 H), 8.52 (s, 1 H), 8.20 (s, 1 H), 8.03 (d, 1 H), 7.51 (m, 3 H), 7.35 (d, 2 H), 7.05 (d, 2 H), 6.67 (dd, 1 H), 6.39 (dd, 1 H), 6.21 (d, 1 H), 4.55 (s, 1 H), 4.48 (s, 1 H), 4.34 (s, 1 H), 3.08 (m, 4 H), 2.89 (d, 2 H), 2.27 (m, 5 H), 1.93 (m, 4 H), 1.66 (m, 4 H), 1.43 (m, 4 H), 1.11 (s, 3 H), 0.93 (s, 6 H).
EXAMPLE 357
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 357A
ethyl 4-fluoro- 1 -(oxetan-3-yl)piperidine-4-carboxylate To 1-tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.000 g) was added HC1 (4.0M in dioxane, 4.54 mL). After 1 hour the reaction was concentrated and dried under high vacuum. The resulting solid was dissolved in dichloromethane (5 mL) and treated with sodium triacetoxyborohydride (1.155 g) and oxetan-3-one (0.262 g) and stirred overnight. The reaction was quenched with saturated NaHCC"3 solution (20 mL) and extracted into dichloromethane (2 x 25 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with a gradient of 0.5% to 3.75% methanol/dichloromethane over 40 minutes (flow = 30mL/min) gave the title compound.
EXAMPLE 357B
(4-fluoro- 1 -(oxetan-3-yl)piperidin-4-yl)methanol To a solution of EXAMPLE 357A (0.59 g) in tetrahydrofuran (5 mL) was added lithium aluminum hydride (1.80 mL) at 0°C. The reaction was removed from the ice bath and allowed to warm to room temperature. The reaction was quenched by the dropwise addition of 0.6 ml of water followed by 0.2 ml of 2N aqueous NaOH. The reaction was filtered through celite and rinsed with ethyl acetate (50 mL). The mixture and the residue was loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.75% to 7.5% methanol/dichloromethane over 30 minutes (flow = 40 mL/minutes) to provide the title compound.
EXAMPLE 357C
3-cyano-4-((4-f uoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 357B for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 284A.
EXAMPLE 357D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 357C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide- d6) δ 11.67 (s, 1H), 11.49 - 11.14 (m, 1H), 8.17 (d, 1H), 8.03 (d, 2H), 7.51 (dd, 3H), 7.43 - 7.26 (m, 3H), 7.12 - 6.96 (m, 2H), 6.67 (dd, 1H), 6.40 (dd, 1H), 6.20 (d, 1H), 4.55 (t, 2H), 4.45 (t, 2H), 4.34 (d, 2H), 3.49 (s, 1H), 3.09 (s, 8H), 2.39 - 1.66 (m, 14H), 1.39 (s, 2H), 0.92 (s, 6H).
EXAMPLE 358
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 358A
benzyl (4-ethyl-4-hydroxycyclohexyl)methylcarbamate To a vigorous stirring solution of benzyl (4-oxocyclohexyl)methylcarbamate (1 g) in tetrahydrofuran (20 mL) at -78°C was slowly added 1 M ethylmagnesium bromide (11.48 ml, 11.48 mmol) in ether. After completion of the addition, the mixture was stirred at -78°C for 2 hours and was warmed to 0°C, and stirred in an ice bath for 30 minutes. The reaction was quenched with a cold NH4C1 aqueous solution. The precipitates were filtered off and washed with ethyl acetate. The filtrate was concentrated. The residue was dissolved in
dichloromethane and loaded onto Analogix purification system, and was eluted with 0 - 50% ethyl acetate in dichloromethane to provide the title compound.
EXAMPLE 358B
4-(aminomethyl)- 1 -ethylcyclohexanol
A mixture of EXAMPLE 358 A (500 mg) and 10% Pd/C (100 mg) in tetrahydrofuran (15 mL) was stirred under H2 for 3 hours. The insoluble material was removed by filtration, and the filtrate was concentrated to provide the title compound.
EXAMPLE 358C
4-((trans-4-ethyl-4-hydroxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide
EXAMPLE 358B (270 mg) and 4-fluoro-3-nitrobenzenesulfonamide (417 mg) in tetrahydrofuran were treated with triethylamine (0.8 mL) overnight. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by a reverse phase chromatography, eluting with 40- 55% acetonitrile in 0.1% trifluoroacetic acid water to isolate the title compound.
EXAMPLE 358D
4-((cis-4-ethyl-4-hydroxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared and isolated as described in Example 358C.
EXAMPLE 358E
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 358C in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d 6) δ 11.69 (s, 1 H), 11.35 (s, 1 H), 8.56 (d, 2 H), 8.05 (d, 1 H), 7.80 (dd, 1 H), 7.45 - 7.57 (m, 3 H), 7.34 (d, 2 H), 7.00 - 7.10 (m, 3 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.98 (s, 1 H), 3.24 - 3.31 (m, 4 H), 3.07 (s, 4 H), 2.75 (s, 2 H), 2.17 (d, 6 H), 1.95 (s, 2 H), 1.54 - 1.73 (m, 5 H), 1.35 - 1.47 (m, 4 H), 1.20 - 1.32 (m, 2 H), 1.03 - 1.18 (m, 2 H), 0.92 (s, 6 H), 0.81 (t, 3 H). EXAMPLE 359
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 358D in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d 6) δ 11.69 (s, 1 H), 11.34 (s, 1 H), 8.60 (t, 1 H), 8.56 (d, 1 H), 8.05 (d, 1 H), 7.80 (dd, 1 H), 7.54 (d, 1 H), 7.47 - 7.52 (m, 2 H), 7.34 (d, 2 H), 7.01 - 7.10 (m, 3 H), 6.68 (dd, 1 H), 6.39 (dd, 1 H), 6.19 (d, 1 H), 3.77 (s, 1 H), 3.26 (t, 2 H), 3.07 (s, 4 H), 2.76 (s, 2 H), 2.10 - 2.26 (m, 6 H), 1.95 (s, 2 H), 1.46 - 1.61 (m, 5 H), 1.28 - 1.46 (m, 6 H), 1.12 - 1.24 (m, 2 H), 0.92 (s, 6 H), 0.82 (t, 3 H).
EXAMPLE 360
4-(4- {[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 360A
ethyl 8-methyl- 1 ,4-dioxaspiro[4.5]decane-8-carboxylate Into a 500 mL round-bottomed flask was added diisopropylamine (7.98 mL) in tetrahydrofuran (233 mL) to give a colorless solution. The mixture was cooled to -78 °C under N2 and n-BuLi (2.5 M in hexanes, 22.40 mL) was added. The reaction was stirred for 30 minutes and ethyl l,4-dioxaspiro[4.5]decane-8-carboxylate (10 g) was added. The reaction was allowed to stir for 1.5 hours upon which time CH3I (4.38 mL) was added. The reaction was allowed to warm to room temperature overnight with stirring. Water was added and the aqueous layer was extracted with ethyl acetate. The combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by normal phase flash column chromatography (Analogix, 0-50% hexanes / ethyl acetate). EXAMPLE 360B
(8-methyl-l,4-dioxaspiro[4.5]decan-8-yl)methanol
In a 500 mL round-bottomed flask was lithium aluminum hydride (1.772 g) in tetrahydrofuran (234 mL) to give a suspension. This suspension was cooled to 0 °C and ethyl 8-methyl-l,4-dioxaspiro[4.5]decane-8-carboxylate (10.66 g) was added via addition funnel. The reaction was stirred overnight at room temperature and then cooled back down to 0 °C. The excess lithium aluminum hydride was slowly quenched with 1.8 mL water, 1.8 mL aqueous NaOH (5N) and 5.6 mL water. The suspension was stirred until the salts turned white and was then filtered through a plug of silica gel. The filtrate was concentrated by rotary evaporation and the residue was purified by regular phase flash column
chromatography (Analogix, 0-75% hexanes / ethyl acetate).
EXAMPLE 360C
8-(methoxymethyl)-8-methyl-l,4-dioxaspiro[4.5]decane To a 250 mL round-bottomed flask was added NaH (0.902 g) and tetrahydrofuran
(37.6 mL) to give a suspension. EXAMPLE 360B was added as a tetrahydrofuran solution at room temperature. The suspension was stirred for 30 minutes and then CH3I (0.611 mL) was added. The reaction was stirred under N2 overnight, carefully quenched with brine and diluted with water and ether. The aqueous layer was extracted with ether (2x) and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation.
The residue was purified by flash column chromatography (Analogix, 0-60% hexanes / ethyl acetate).
EXAMPLE 360D
4-(methoxymethyl)-4-methylcyclohexanone
The title compound was prepared by substituting EXAMPLE 360C for EXAMPLE
353B in EXAMPLE 353C.
EXAMPLE 360E
2-chloro-5-(methoxymethyl)-5-methylcyclohex- 1 -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 360D for EXAMPLE
353C in EXAMPLE 353D.
EXAMPLE 360F
2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 360E for EXAMPLE 353D in EXAMPLE 353E.
EXAMPLE 360G
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)- 5 -methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 360F for EXAMPLE 353E in EXAMPLE 353F.
EXAMPLE 360H
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 360G for EXAMPLE 15G in EXAMPLE 15H.
EXAMPLE 3601
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by replacing EXAMPLE 3J with EXAMPLE 360H and EXAMPLE 1 IB with EXAMPLE IF in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.68 (s, 1 H) 11.43 (s, 1 H) 8.45 - 8.72 (m, 2 H) 8.04 (d,l H) 7.80 (dd,l H) 7.44 - 7.61 (m, 3 H) 7.34 (d, 2 H) 6.99 - 7.20 (m, 3 H) 6.68 (dd, 1 H) 6.39 (dd, 1 H) 6.18 (d, 1 H) 3.85 (dd, 2 H) 3.25 - 3.30 (m, 4 H) 3.24 (s, 3 H) 3.02 - 3.17 (m, 6 H) 2.72 (dd, 2 H) 2.18 (s, 5 H) 2.03 - 2.13 (m, 2 H) 1.81 - 1.93 (m, 2 H) 1.57 - 1.67 (m, 2 H) 1.47 - 1.56 (m, 1 H) 1.17 - 1.41 (m, 3 H) 0.91 (s, 3 H).
EXAMPLE 361
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 361 A
(S)-3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 259E for tert-butyl piperazine-l-carboxylate and 3-oxetanone for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE 1A.
EXAMPLE 361B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 361 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.00 (s, IH), 9.26 (d, IH), 8.87 (t, IH), 8.43 (d, IH), 8.35 (dd, IH), 8.11 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.96 (d, IH), 6.75 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 4.64 (m, 4H), 3.93 (m, 1H),3.89 (d, IH), 3.68 (dt, IH), 3.53-3.35 (m, 3H), 3.07 (m, 4H), 2.77 (s, 2H), 2.72 (d, IH), 2.44 (d, IH), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.85 (t, IH), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 362
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 362A
3-chloro-4-(((lr, 4r)-4-hydroxy-4-methylcyclohexyl)methoxy)benzenesulfonamide To a solution of EXAMPLE 341F (300 mg) in N,N-dimethylformamide (10 mL) was added sodium hydride (416 mg) portionwise. The resulting suspension was stirred for 15 minutes. 3-Chloro-4-fluorobenzenesulfonamide (425 mg) was added and stirring was continued for 72 hours. The reaction was quenched with water and the pH was adjusted to ca. 7. The mixture was diluted with brine (75 mL) and extracted with methylene chloride. The crude product was isolated from the dried methylene chloride layer by concentration and was purified on silica gel eluted with a 10, 25, 50 % ethyl acetate in methylene chloride step gradient to provide the title compound. EXAMPLE 362B
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 362 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine- d5) δ 13.07 (m, IH), 8.58 (d, IH), 8.45 (d, IH), 8.31 (dd, IH), 8.11 (d, IH), 7.69 - 7.67 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.97 (d, IH), 6.74 (dd, IH), 6.52 (m, 2H), 5.34 (br s, 2H), 3.82 (d, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 - 1.85 (m, 7H), 1.82 - 1.73 (m, 2H), 1.44 - 1.32 (m, 7H), 0.94 (m, 6H).
EXAMPLE 363
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 363A
4-((4'-fluorospiro[benzo[d][l,3]dioxole-2, -cyclohexane]-4'-yl)methoxy)-3- nitrobenzenesulfonamide
To a solution of EXAMPLE 350C (495 mg) in N,N-dimethylformamide (6 mL) was added NaH (65% in mineral oil, 320 mg). The mixture was stirred for 30 minutes, and then 4- fluoro-3-nitrobenzenesulfonamide (457 mg) was added. The mixture was stirred overnight. The mixture was poured over aqueous NH4C1 and extracted with ethyl acetate (300 mL). The combined organic layers were washed with water, brine and dried over Na2S04. After filtration and evaporation of the solvent, the residue was loaded on a silica gel cartridge and was eluted with 30% ethyl acetate in hexane to provide the title compound.
EXAMPLE 363B
4-((l-fluoro-4-oxocyclohexyl)methoxy)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 363 A (860 mg) in ethanol (30 mL) was added concentrated HC1 (10 mL) and the mixture was stirred at 100°C for 3 hours. The mixture was neutralized with solid Na2C03 and extracted with dichloromethane (300 mL) and washed with aqueous NaHCC , water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 363C
4-((4-((2-cyanoethyl)(cyclopropyl)amino)-l-fluorocyclohexyl)methoxy)-3- nitrobenzenesulfonamide
To a solution of EXAMPLE 363B (200 mg) in dichloromethane (6 mL) was added 3- (cyclopropylamino)propanenitrile (64 mg) followed by sodium triacetoxyborohydride (184 mg). The mixture was stirred overnight. The reaction mixture was diluted with
dichloromethane (400 mL) and washed with 2N aqueous NaOH, water, and brine. After drying over Na2S04, the mixture was filtered and evaporation of the solvent gave the title compound.
EXAMPLE 363D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( {4-[(2-cyanoethyl)(cyclopropyl)amino]- 1 -fluorocyclohexyl}methoxy)-3- nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 363C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.66 (s, 1 H), 8.35 (s, 1 H), 8.02 (d, 2 H), 7.51 (m, 3 H), 7.40 (m, 1 H), 7.35 (d, 2 H), 7.04 (d, 2 H), 6.67 (dd, 1 H), 6.39 (d, 1 H), 6.20 (s, 1 H), 4.27 (d, 2 H), 3.13 (m, 4 H), 2.88 (m, 3 H), 2.67 (m, 4 H), 2.09 (m, 10 H), 1.49 (m, 9 H), 0.93 (s, 6 H), 0.45 (m, 4 H). EXAMPLE 364
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 364A
6-amino-5 -nitropyridine-3 -sulfonic acid
6- Aminopyridine-3 -sulfonic acid (20 g) in concentrated H2S04 (80 mL) was heated at 50°C until it was completely dissolved. To this solution was added fuming HNO3 slowly over 20 minutes, so the internal temperature did not exceed 55 °C. After the addition was complete, the reaction mixture was heated at 50°C for 1 hour. After it was cooled to room temperature, it was poured into 150 g of ice. The mixture was stirred for another hour. The flask was cooled to 0°C, and was kept at 0°C for another 2 hours. The solid was collected by filtration, and washed with cold 1 : 1 water/ethanol (20 mL), followed by diethyl ether (10 mL). The solid was dried in a vacuum oven overnight to provide the title compound.
EXAMPLE 364B
6-hydroxy-5 -nitropyridine-3 -sulfonic acid
EXAMPLE 364A (4.0 g) in aqueous HC1 (37%, 12 mL) and water (50 mL) was treated with sodium nitrite ( 1.19 g) in water (8 mL) dropwise at 0°C . After the addition was complete, the reaction mixture was stirred at 0°C for 1 hour. The mixture was heated at reflux for 2 hours. Water was distilled off to give a dry residue. After the residue was cooled to room temperature, a solution of 1 : 1 ethano/water (20 mL) was added. The resulting suspension was cooled to 0°C, and kept at 0°C for 1 hour. The solid was collected by filtration to provide the title compound.
EXAMPLE 364C
6-chloro-5 -nitropyridine-3 -sulfonyl chloride
A mixture of EXAMPLE 364B (2.6 g), PC15 (5.91 g), and POCl3 (10 mL) was heated at 120 °C for 4 hours. The initial suspension became a clear solution. The excess of POCl3 was distilled off. After it was cooled to room temperature, the residue was poured into 50 g of crushed ice. The solid was extracted into ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated to give crude product that was used in the next step without further purification.
EXAMPLE 364D
6-chloro-5 -nitropyridine-3 -sulfonamide
EXAMPLE 364C in tetrahydrofuran ( 10 mL) was cooled to - 10 °C . To this solution was added concentrated ammonium hydroxide (0.82 mL) dropwise. The solution was stirred at -10 °C for 10 minutes. The solvent was removed under pressure at room temperature. The residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column
chromatography on silica gel using 5-50% ethyl acetate in hexanes to provide the title compound.
EXAMPLE 364E
5-nitro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide
The title compound was prepared by substituting EXAMPLE 364D for 4-fluoro-3- nitrobenzenesulfonamide and (tetrahydro-2H-pyran-4-yl)methanamine for (4- fluorotetrahydro-2H-pyran-4-yl)methanamine in EXAMPLE 138D.
EXAMPLE 364F
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {5- nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 364E for
EXAMPLE 1 IB in EXAMPLE 1 ID H NMR (500MHz, dimethylsulfoxide-d6) δ 11.63 (s, IH), 8.93 (s, IH), 8.73 (d, IH), 8.69 (d, IH), 8.00 (d, IH), 7.54 (d, IH), 7.47-7.48 (m, 2H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, IH), 6.35 (dd, IH), 6.22 (d, IH), 3.83 (dd, 2H), 3.51 (t, 2H), 3.21-3.27 (m, 2H), 3.10 (s, 4H), 2.83 (s, 2H), 1.90-2.27 (m, 12H), 1.58 (dd, 2H), 1.39 (t, 2H), 1.18-1.28 (m, 2H), 0.88-0.93 (m, 8H).
EXAMPLE 365
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3- nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 365A
7-(azidomethyl)-2-oxaspiro [3.5 Jnonane
To a 250 mL round-bottomed flask was EXAMPLE 35 IF (350 mg) in tetrahydrofuran (75.0 mL) to give a colorless solution. The solution was cooled to 0 °C, triphenylphosphine (2.94 g), diisopropyl azodicarboxylate (2.18 mL) and diphenyl phosphorazidate (2.32 mL) were added and the reaction was stirred for 30 minutes at room temperature. The mixture was concentrated and purified the residue by regular phase flash column chromatography (Analogix, 0-20% hexanes / ethyl acetate).
EXAMPLE 365B
2-oxaspiro[3.5]nonan-7-ylmethanamine
To a 50 mL round-bottomed flask was added 10% palladium on carbon (58.7 mg). The flask was flushed with N2 and EXAMPLE 365 A (400 mg) was added as a methanol solution (10.5 mL). The flask was then flushed several times with H2 (via balloon) and heated to 45 °C for 2 hours. The reaction was cooled to room temperature, filtered through celite and the filtrate was concentrated by rotary evaporation. The residue was used in the next step without further purification.
EXAMPLE 365C
4-(2-oxaspiro [3.5 ]nonan-7-y lmethylamino)-3 -nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 365B for 1-
(tetrahydropyran-4-yl)methylamine in EXAMPLE IF.
EXAMPLE 365D
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-(2-oxaspiro[3.5]nonan-7-ylmethylamino)-3- nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 - enyl)methyl)piperazin- 1 -yl)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 365C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.67 (s, 1 H) 11.25 - 11.49 (m, 1 H) 8.48 - 8.66 (m, 2 H) 8.03 (d, 1 H) 7.79 (dd, 1 H) 7.41 - 7.61 (m, 3 H) 7.27 - 7.40 (m, 2 H) 7.05 (t, 3 H) 6.67 (dd, 1 H) 6.39 (dd, 1 H) 6.18 (d, 1 H) 4.29 (s, 2 H) 4.19 (s, 2 H) 3.17 - 3.27 (m, 2 H) 2.99 - 3.14 (m, 4 H) 2.69 - 2.79 (m, 2 H) 2.09 - 2.28 (m, 6 H) 2.04 (d, 2 H) 1.95 (s, 2 H) 1.66 (d, 2 H) 1.49 - 1.61 (m, 1 H) 1.29 - 1.45 (m, 4 H) 0.93 - 1.05 (m, 2 H) 0.92 (s, 6 H). EXAMPLE 366
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide EXAMPLE 366A
tert-butyl (4-cyano-4-methylcyclohexyl)methylcarbamate
To a cooled (-78°C) solution of tert-butyl (4-cyanocyclohexyl)methylcarbamate (500 mg) in tetrahydrofuran (10 mL) was added lithium diisopropylamide (2.0 mL, 2M in heptane). The mixture was stirred at -78°C for 30 minutes before the addition of CH3I (1 mL). The mixture was then stirred and the temperature was allowed to warm to room temperature. The reaction was quenched with aqueous NH4CI and the mixture was extracted with ethyl acetate (300 mL) and washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent and silica gel chomatography (40% ethyl acetate in hexane) of the crude material gave the title compound.
EXAMPLE 366B
4-(aminomethyl)- 1 -methylcyclohexanecarbonitrile
To a solution of EXAMPLE 366A (480 mg) in dichloromethane (10 mL) was added trifluoroacetic acid (10 mL). The mixture was stirred for 3 hours. The mixture was then concentrated under vacuum and was used directly in the next reaction without further purification. EXAMPLE 366C
4-((4-cyano-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide
To a solution of 4-fluoro-3-nitrobenzenesulfonamide (362 mg) in tetrahydrofuran (10 mL) was added EXAMPLE 366B (250 mg) and N,N-diisopropylethylamine (2 mL) . The mixture was stirred overnight. The mixture was diluted with ethyl acetate (300 mL) and washed with water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the title compound.
EXAMPLE 366D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(4-cyano-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3- b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 366C for EXAMPLE IF in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.67 (s, 1 H), 11.37 (m, 1 H), 8.59 (m, 2 H), 8.04 (d, 1 H), 7.80 (d, 1 H), 7.51 (m, 3 H), 7.34 (d, 2 H), 7.10 (d, 1 H), 7.04 (d, 2 H), 6.68 (dd, 1 H), 6.39 (m, 1 H), 6.19 (s, 1 H), 3.07 (m, 4 H), 2.75 (m, 2 H), 2.17 (m, 7 H), 1.76 (m, 9 H), 1.32 (m, 9 H), 0.92 (s, 6 H).
EXAMPLE 367
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl} sulfonyl)amino} methyl pivalate
This example was prepared by substituting chloromethyl pivalate for chloromethyl butyrate in EXAMPLE 368. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.72 (s, IH), 8.43 (d, IH), 8.22 (dd, IH), 8.01 (d, IH), 7.55 (m, 3H), 7.36 (m, 3H), 7.03 (d, 2H), 6.68 (dd, IH), 6.41 (m, IH), 6.17 (d, IH), 5.83 (s, 2H), 4.40 (d, 2H), 3.78 (m, 2H), 3.59 (m, 2H), 3.08 (br m, 4H), 2.73 (br s, 2H), 2.18 (br m, 6H), 1.96 (s, 2H), 1.84 (m, 4H), 1.39 (m, 2H), 1.00 (s, 9H), 0.92 (s, 6H).
EXAMPLE 368
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl]( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl }sulfonyl)amino} methyl butyrate
EXAMPLE 37E (500 mg) was dissolved in acetonitrile (3.7 mL) and chloromethyl butyrate (77 mg) and Hunig's base (73 mg) were added. The reaction was heated under reflux for one day. After cooling and dilution with dimethylsulfoxide (4 mL) the reaction was purified by preparative HPLC using a 250 x 50 mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (6 ml) and washed with 50% aqueous NaHC03. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to provide the title compound. 1H NMR (400 MHz, dimethylsulfoxide-de) δ 11.72 (s, IH), 8.43 (d, IH), 8.22 (dd, IH), 8.01 (d, IH), 7.55 (m, 3H), 7.36 (m, 3H), 7.03 (d, 2H), 6.68 (dd, IH), 6.41 (m, IH), 6.17 (d, IH), 5.83 (s, 2H), 4.40 (d, 2H), 3.78 (m, 2H), 3.59 (m, 2H), 3.08 (br m, 4H), 2.73 (br s, 2H), 2.18 (m, 8H), 1.96 (s, 2H), 1.84 (m, 4H), 1.39 (m, 4H), 0.92 (s, 6H), 0.75 (t, 3H). EXAMPLE 369
4-[4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} (2Hg)piperazin- 1 -yl]-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-
¾]pyridin-5 -yloxy)benzamide
EXAMPLE 369A
methyl 4-[(2,2,3,3,5,5,6,6-2H8)piperazin-l-yl]-2-(lH-pyrrolo[2,3-¾]pyridin-5-yloxy)benzoate
Into a 40 mL vial were added EXAMPLE 3H (1.55 g) and piperazine-dg (2.040 g) in dimethylsulfoxide (13 mL). The solution was heated to 85°C for 2.5 hours, and was then allowed to cool to room temperature overnight. The mixture was transferred to a 120 mL flask and was cooled to 5-10 °C. Dichloromethane (30 mL) was added, then water (10 mL) was added via syringe over 5 minutes maintaining temp at no more than 15°C. The layers were separated and the organic layer was washed with water (4x 10-15 mL) until pH of aqueous layer was 8-9. The organic layer was filtered through Na2S04 and rinsed with dichloromethane (5 mL), and concentrated to provide the title compound.
EXAMPLE 369B
methyl 4-[4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} (2Hg)piperazin- 1 - yl]-2-(lH-pyrrolo[2,3-£]pyridin-5-yloxy)benzoate
In a 100 mL round-bottomed flask, EXAMPLE 369A (3.4 g), EXAMPLE 290B
(1.321 g) and dichloromethane (3 mL) were added to a 100 mL round bottom flask at room temperature. To a separate 50 mL 3 neck round bottom flask, sodium triacetoxyborohydride (1.330 g) and dichloromethane (12 mL) were added to give a slurry. After cooling the 50 mL round bottom flask to 18-20 °C, the piperazine adduct/aldehyde solution was added via syringe over 5 minutes. The triacetoxyborohydride gradually dissolved to give a clear solution after ~5 minutes. After an additional 10 minutes, the solution became hazy. After 16 hours, the reaction was cooled to 5-10 °C. Saturated aqueous NaHC03 (12 mL) was added over 5 minutes maintaining the temperature at no more than 10 °C. The layers were separated and the organic layer was washed with saturated aqueous NaHC03, and 10% NaCl (12 mL), and then filtered through Na2S04 and rinsed with dichloromethane (4 mL). The solution was concentrated on a rotovap, and chase concentrated with methanol (40 mL). The resulting solution was cooled to 5-10 °C, and the product precipitated. The solution was mixed at room temperature for 30 minutes, then filtered and rinsed with methanol (5 mL), and the product was air dried. EXAMPLE 369C
4-[4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} (2Hg)piperazin- 1 -yl]-2- (lH-pyrrolo[2,3-£]pyridin-5-yloxy)benzoic acid
The title compound was prepared by substituting EXAMPLE 369B for EXAMPLE 15G in EXAMPLE 15H.
EXAMPLE 369D
4-[4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} (2Hg)piperazin- 1 - yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -£]pyridin-5 -yloxy)benzamide
To a mixture of EXAMPLE 369C (2.0g), EXAMPLE IF (l . lg) and N,N- dimethylpyridin-4-amine (0.7 g) in dichloromethane (20 mL) was added l-ethyl-3-[3- (dimethylamino)propyl]-carbodiimide hydrochloride (0.8 g). The reaction mixture was stirred at room temperature overnight. The reaction was quenched with N,N-dimethylethane- 1 ,2-diamine (0.6g) and stirred at room temperature for 3 hours. The mixture was extracted with 20% aqueous acetic acid and washed with 5% aqueous NaCl. Methanol (2 mL) and ethyl acetate (18 mL) were added and the precipitate was collected by filtration to provide the title compound. 1H NMR (400 MHz, dimethylsulfoxide -de) δ 1 1.71 (s, 1H), 1 1.37 (s, br, 1H), 8.60 (t, 1H), 8.55 (d, 1H), 8.04 (d, 1H), 7.80 (dd, 1H), 7.47 - 7.54 (m, 3H), 7.31 - 7.34 (m, 2H), 7.09 (d, 1H), 7.01 - 7.03 (m, 2H), 6.67 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 3.83 (dd, 2H), 3.21 - 3.30 (m, 4H), 3.00 - 3.10 (s, 4H), 2.75 (s, 2H), 2.05 - 2.24 (m, 6H), 1.95 (s, 2H), 1.80 - 1.93 (m, 1H), 1.55 - 1.64 (m, 2H), 1.37 (t, 2H), 1.18 - 1.31 (m, 2H), 0.90 (s, 6H).
EXAMPLE 370
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2
pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [3 -(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l ,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide
EXAMPLE 370A
5-amino-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide A mixture of EXAMPLE 364E (0.16 g) and 5% palladium on carbon (0.025 g) in ethanol (5 mL) was treated with a balloon of hydrogen. The reaction mixture was stirred overnight. The solid was filtered off. The filtrate was concentrated. The residue was purified by flash chromatography on silica gel to give the title compound.
EXAMPLE 370B
3-((tetrahydro-2H-pyran-4-yl)methyl)-3H-[ 1 ,2,3]triazolo[4,5-b]pyridine-6-sulfonamide
EXAMPLE 370A (0.085 g) in water (10 mL) was treated with concentrated H2S04 (0.5 mL). The solution was cooled to 0 °C. To this solution was added NaN02 (0.023 g) in water (1 mL) dropwise. The solution was stirred for 1 hour at 0 °C. The reaction mixture was poured into saturated NaHC03 solution, and extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and
concentrated to give the title compound.
EXAMPLE 370C
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(3-((tetrahydro-2H-pyran-4-yl)methyl)-3H-[l,2,3]triazolo[4,5- b]pyridin-6-ylsulfonyl)benzamide
This example was prepared by substituting EXAMPLE 370B for EXAMPLE 1 IB in EXAMPLE 1 ID H NMR (500MHZ, dimethylsulfoxide-d6) δ 11.60 (s, 1H), 9.11 (s, 1H), 8.92 (d, 1H), 7.96 (d, 1H), 7.55 (d, 1H), 7.45-7.46 (m, 1H), 7.42 (s, 1H), 7.36 (d, 2H), 7.05 (d, 2H), 6.66 (dd, 1H), 6.32 (s, 1H), 6.22 (s, 1H), 4.63 (d, 2H), 3.80 (dd, 2H), 3.21-3.30 (m, 2H), 3.16 (s, 4H), 2.83 (s, 2H), 2.19-2.29 (m, 6H), 1.97 (s, 2H), 1.33-1.41 (m, 6H), 0.93 (s, 2H).
EXAMPLE 371
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 371 A
6-((trans-4-hydroxy-4-methylcyclohexyl)methylamino)-5-nitropyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 364D for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 376B for EXAMPLE 138C in EXAMPLE 138D. The title compound was isolated by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 μ, CI 8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% TFA.
EXAMPLE 371B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 -yl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 371 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.63 (s, 1H), 11.53 - 10.99 (m, 1H), 8.91 (s, 1H), 8.71 (dd, 2H), 8.01 (d, 1H), 7.61 - 7.44 (m, 3H), 7.44 - 7.28 (m, 2H), 7.12 - 6.97 (m, 2H), 6.76 - 6.61 (m, 1H), 6.36 (dd, 1H), 6.21 (d, 1H), 3.92 (s, 1H), 3.48 (t, 2H), 3.10 (s, 4H), 2.83 (s, 2H), 2.24 (dd, 6H), 1.96 (s, 2H), 1.37 (ddd, 11H), 1.07 (s, 3H), 0.93 (s, 6H). EXAMPLE 372
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 372A
ethyl 4-fluoro- 1 -(oxetan-3-yl)piperidine-4-carboxylate To 1-tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.00 g) was added HC1 (4.0M in dioxane, 4.54 mL). After 1 hour the reaction was concentrated and dried under high vacuum. The resulting solid was dissolved in dichloromethane (5 ml) and treated with sodium triacetoxyborohydride (1.155 g) and oxetan-3-one (0.262 g) and stirred overnight. The reaction was quenched with saturated NaHC03 solution (20 mL) and extracted into dichloromethane (2 x 25 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with a gradient of 0.5% to 3.75% methanol/dichloromethane over 40 minutes (flow = 30 mL/minute) gave the title compound.
EXAMPLE 372B
(4-fluoro- 1 -(oxetan-3-yl)piperidin-4-yl)methanol To a solution of EXAMPLE 372A (0.59 g) in tetrahydrofuran (5 mL) was added lithium aluminum hydride (1.80 mL) at 0°C. The reaction was removed from the ice bath and allowed to warm to room temperature. The reaction was quenched by the dropwise addition of 0.6 mL of water followed by 0.2 ml of 2N aqueous NaOH. The reaction was filtered through diatomaceous earth and rinsed with ethyl acetate (50 mL). The organics were concentrated and loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.75% to 7.5% methanol/dichloromethane over 30 minute (flow = 40 mL/minutes) to give the title compound.
EXAMPLE 372C
5 -bromo-6-((4-fluoro- 1 -(oxetan-3 -yl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide This example was prepared by substituting EXAMPLE 372B for (tetrahydro-2H- pyran-4-yl)methanol and EXAMPLE 36A for 4-f uoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 372D
5 -cyano-6-((4-fluoro-l -(oxetan-3 -yl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide This example was prepared by substituting EXAMPLE 372C for EXAMPLE 36B in EXAMPLE 36C.
EXAMPLE 372E
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(5-cyano-6-((4-fluoro- 1 -(oxetan-3 -yl)piperidin-4- yl)methoxy)pyridin-3-ylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 372D for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (300 MHz, dimethylsulfoxide-d6) 5 11.58 (s, 1H), 8.71 (s, 1H), 8.52 (s, 1H), 7.96 (d, 1H), 7.57 (d, 1H), 7.48 - 7.30 (m, 4H), 7.06 (d, 2H), 6.68 (d, 1H), 6.37 - 6.22 (m, 2H), 4.65 - 4.40 (m, 6H), 3.58 (s, 1H), 3.12 (s, 6H), 2.84 - 2.59 (m, 4H), 2.17 (s, 6H), 1.96 (d, 6H), 1.41 (s, 2H), 0.93 (s, 6H).
EXAMPLE 373
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] sulfamoyl} -2-nitrophenyl)morpholine-4- carboxamide EXAMPLE 373A
morpholine-4-carboxamide
A solution of morpholine-4-carbonyl chloride (2.0 g) in methanol (10 mL) and 7 N N¾ in methanol (5 mL) was stirred at 45 °C overnight. The mixture was concentrated to give a solid, which was dried under vacuum.
EXAMPLE 373B
N-(2-nitro-4-sulfamoylphenyl)morpholine-4-carboxamide This example was prepared by substituting EXAMPLE 373 A for (tetrahydro pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 373C
N-(4-(N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoyl)sulfamoyl)-2- nitrophenyl)morpholine-4-carboxamide
This example was prepared by substituting EXAMPLE 373B for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 10.41 (s, IH), 9.27 (d, IH), 8.81 (d, IH), 8.50 (dd, IH), 8.40 (d, IH), 8.09 (d, IH), 7.65 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.76 (dd, IH), 6.54 (d, IH), 6.48 (m, IH), 3.67 (m, 4H),3.58 (m, 4H), 3.07 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 374
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 374A
(4,4-diethoxycyclohexyl)methanol
Ethyl 4, 4-diethoxycyclohexanecarboxylate (6.67 g) synthesized according to a literature procedure (European Journal of Organic Chemistry, 2008, 5, 895) in
tetrahydrofuran (60 mL) was treated with 2 M lithium aluminum hydride in tetrahydrofuran (14.5 mL) at 0°C for 1 hour. Water (3 mL) was slowly added to quench the reaction. The precipitates were filtered off and washed with ethyl acetate. The filtrate was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 374B
1,1 -diethoxy-4-(methoxymethyl)cyclohexane
EXAMPLE 374 A (665 mg) in tetrahydrofuran (20 mL) was treated with NaH (394 mg) for 30 minutes and then CH3I (0.267 mL) was slowly added. The resulting mixture was stirred overnight and the reaction was quenched with a few drops of water. The mixture was concentrated and the residue was suspended in water and extracted with dichloromethane. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography, and was eluted with 0-15% ethyl acetate in
dichloromethane to provide the title compound.
EXAMPLE 374C
4-(methoxymethyl)cyclohexanone
EXAMPLE 374B (2.2 g) in a mixture of water (3 mL) and acetic acid (12 mL) was heated at 65°C for 2 hours. The reaction mixture was concentrated. The residue was mixed with water and saturated aqueous NaHC03 and extracted with dichloromethane. The dichloromethane layer was dried over Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 374D
4-(methoxymethyl)cyclohexanecarbonitrile
To a cold (-10°C) solution of EXAMPLE 374C (1.18 g) and toluenesulfonylmethyl isocyanide (2.268 g) in dimethoxyethane (3 mL) and absolute ethanol (0.1 mL) was added (in small portions) potassium tert-butoxide (2.235 g). The reaction mixture was continued to stir at <5°C for 30 minutes, warmed to room temperature, heated at 35°C for 30 minutes and then at room temperature for 2 hours. The reaction mixture was concentrated and the residue was dissolved in water-brine, and extracted with dichloromethane. The dichloromethane layer was purified by flash chromatography, and was eluted with 5% ethyl acetate in
dichloromethane to provide the title compound.
EXAMPLE 374E
(4-(methoxymethyl)cyclohexyl)methanamine To a solution of EXAMPLE 374D (460 mg) in tetrahydrofuran (15 mL) was added 2M lithium aluminum hydride in tetrahydrofuran (2.252 mL) slowly. The reaction mixture was stirred at room temperature for 1 hour, refluxed for 1 hour and cooled. 2 ml of 2M aqueous NaOH and water (5 mL) was added. The solid was filtered off and washed with ether. The filtrate was concentrated. The residue was mixed with dichloromethane (50 mL) and the resulting mixture was dried over Na2SC"4 and concentrated to provide the title compound.
EXAMPLE 374F
4-((4-(methoxymethyl)cyclohexyl)methylamino)-3 -nitrobenzenesulfonamide
EXAMPLE 374E (450 mg) and 4-fluoro-3 -nitrobenzenesulfonamide (693 mg) in tetrahydrofuran (10 mL) were stirred overnight. The reaction mixture was concentrated and the residue was suspended in a mixture of CH3CN, methanol and water. The precipitates were collected, washed with water and dried to give the title compound.
EXAMPLE 374G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- eny l)methyl)piperazin- 1 -yl)-N-(4-((4-(methoxymethyl)cyclohexyl)methylamino)-3 - nitrophenylsulfonyl)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE
374F in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 11.40 (s, 1H), 8.53 - 8.61 (m, 2H), 8.04 (d, 1H), 7.77 - 7.82 (m, 1H), 7.47 - 7.55 (m, 3H), 7.34 (d, 2H), 7.02 - 7.09 (m, 3H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 3.18 - 3.27 (m, 5H), 3.04 - 3.14 (m, 5H), 2.75 (s, 2H), 2.11 - 2.24 (m, 6H), 1.95 (s, 2H), 1.69 - 1.84 (m, 3H), 1.33 - 1.63 (m, 7H), 0.84 - 1.05 (m, 9H).
EXAMPLE 375
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 375A
methyl 1 -(thiazol-2-yl)piperidine-4-carboxylate A mixture of methyl piperidine-4-carboxylate (2.045 g), 2-bromothiazole (1.64 g), and CS2CO3 (5.86 g) in dimethylformamide (15 mL) was heated at 100 °C overnight. After it cooled to room temperature, the reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compound.
EXAMPLE 375B
( 1 -(thiazol-2-yl)piperidin-4-yl)methanol
This example was prepared by substituting EXAMPLE 375 A for EXAMPLE 339A in EXAMPLE 339B.
EXAMPLE 375C
5 -chloro-6-((l-(thiazol-2-yl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide This example was prepared by substituting EXAMPLE 375B for (tetrahydro-2H- pyran-4-yl)methanol and EXAMPLE 40A for EXAMPLE 36A in EXAMPLE 36B.
EXAMPLE 375D
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(5-chloro-6-((l-(thiazol-2-yl)piperidin-4- yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzamide
This example was prepared by substituting EXAMPLE 375C for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.65 (s, IH), 8.49 (s, IH), 8.17 (s, IH), 8.01 (d, IH), 7.54 (d, IH), 7.48-7.49 (m, 2H), 7.35 (d, 2H), 7.14 (d, IH), 7.05 (d, 2H), 6.80 (d, IH), 6.67 (dd, IH), 6.38 (dd, IH), 6.21 (d, IH), 4.28 (d, 2H), 3.92 (d, 2H), 2.98-3.10 (m, 6H), 2.86 (s, 2H), 2.30 (m, 4H), 2.03-2.15 (m, 3H), 1.96 (s, 2H), 1.96 (s, 2H), 1.82-1.86 (m, 2H), 1.33-1.44 (m, 4H), 0.93 (s, 6H).
EXAMPLE 376
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 376A
tert-butyl (4-hydroxy-4-methylcyclohexyl)methylcarbamate A solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (1.00 g) was dissolved in tetrahydrofuran (20 mL) and cooled to -78°C. Methylmagnesium bromide (4.40 mL) was added dropwise. The reaction was stirred for 2 hours at -78°C then allowed to warm to 0°C and stirred for 30 minutes. The resulting suspension was quenched with water (10 mL), diluted with ether (50 mL), washed with ammonium chloride (25 mL), washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting using a gradient of 5% to 50% ethyl acetate/dichloromethane over 30 minutes (flow = 60 mL/min) gave the title compound as a ~2: 1 mixture of cis and trans isomers.
EXAMPLE 376B
4-(aminomethyl)- 1 -methylcyclohexanol
To a solution of EXAMPLE 376A (0.75 g) in dichloromethane (3 mL) was added a few drops of water followed by trifluoroacetic acid (1.19 mL) and the reaction stirred at room temperature. After stirring for 2h added added additional trifluoroacetic acid (0.5 mL). After an additional 4 h the reaction was concentrated and dried under high vacuum. The resulting oily solid was triturated with diethyl ether with sonication. Filtration and washing with diethyl ether gave the title compound as a trifluoroacetic acid salt and a mixture of cis and trans isomers.
EXAMPLE 376C
6-((cis-4-hydroxy-4-methylcyclohexyl)methylamino)-5-nitropyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 364D for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 376B for (4-fluorotetrahydro-2H-pyran-4- yl)methanamine in EXAMPLE 138D. The title compound was isolated by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 μ, CI 8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% TFA. EXAMPLE 376D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(6- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridin-3-yl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
This example was prepared by substituting EXAMPLE 376C for EXAMPLE 11B in EXAMPLE 11D. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.64 (s, IH), 8.91 (s, IH), 8.72 (d, IH), 8.70 (d, IH), 8.01 (d, IH), 7.47-7.54 (m, 3H), 7.35 (d, 2H), 7.04 (d, 2H), 6.68 (dd, IH), 6.36 (dd, IH), 6.21 (d, IH), 3.93 (s, IH), 3.48 (t, 2H), 3.10 (s, 4H), 2.83 (s, 2H), 2.15-2.33 (m, 6H), 1.96 (s, IH), 1.34-1.59 (m, 9H), 1.17-1.24 (m, 2H), 1.07 (s, 2H), 0.92 (s, 6H).
EXAMPLE 377
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)- N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 378D for EXAMPLE IE and EXAMPLE 337D for EXAMPLE IF in EXAMPLE 1G. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.31 (d, IH), 8.68 (t, IH), 8.44 (d, IH), 8.37 (dd, IH), 8.10 (d, IH), 7.68 (m, IH), 7.66 (d, IH), 7.41 (m, 2H), 7.09 (m, 2H), 6.92 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.50 (dd, IH), 3.20 (m, 5H), 3.06 (t, 4H), 2.77 (m, 2H), 2.57 (d, IH), 2.49 (m, IH), 2.17 (m, 6H), 1.86 (m, 5H), 1.69 (m, 4H), 1.40 (s, 3H), 1.23 (m, 5H).
EXAMPLE 378
4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 378A
2-chloro-5-methoxy-5-methylcyclohex- 1 -enecarbaldehyde Dimethylformamide (1.298 mL) in dichloromethane (2.0 mL) at -10 °C was treated dropwise with POCI3 (1.426 mL) to give a colorless solution. The mixture was stirred 5 minutes and then warmed to room temperature and stirred 30 minutes. The solution was cooled to -10 °C, treated dropwise with a solution of 4-methoxy-4-methylcyclohexanone (1.74 g) in dichloromethane (2.5 mL), and stirred for 4 hours at ambient temperature. The reaction mixture was poured over a mixture of ice and 25% aqueous sodium acetate solution. After the ice melted, the reaction mixture was poured into a separatory funnel and extracted with diethyl ether (4 x 125 mL). The diethyl ether extracts were washed with NaHC03 solution and brine, dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 0 to 5%ethyl acetate in hexanes as the eluent.
EXAMPLE 378B
2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -enecarbaldehyde EXAMPLE 378A (1.55 g), 4-chlorophenylboronic acid (1.542 g), PdOAc2 (0.055 g),
K2C03 (2.84 g) and tetrabuylammonium bromide (2.65 g) were combined in a 50-mL round- bottomed flask equipped with a magnetic stir bar. Water (9.13 mL) was added. The vial was flushed with nitrogen, capped and stirred at 45 °C for 14 hours. The reaction mixture was cooled to room temperature and partitioned between brine and diethyl ether. The organic layer was washed with brine, dried (MgS04), filtered through a plug of celite, concentrated and chromatographed on silica gel with 5 to 20% ethyl acetate in hexanes as the eluent.
EXAMPLE 378C
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-methoxy-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared by substituting EXAMPLE 378B for 4'- chlorobiphenyl-2-carboxaldehyde and EXAMPLE 15F for tert-butyl piperazine-1- carboxylate in EXAMPLE 1A except that a small amount of DMSO was added to the reaction mixture.
EXAMPLE 378D
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-methoxy-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 378C for EXAMPLE 15G in EXAMPLE 15H. EXAMPLE 378E
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5-methoxy-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 378D for EXAMPLE IE in EXAMPLE 1G. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.31 (d, IH), 8.68 (t, IH), 8.43 (d, IH), 8.37 (dd, IH), 8.09 (d, IH), 7.68 (m, IH), 7.66 (d, IH), 7.41 (m, 2H), 7.09 (m, 2H), 6.90 (d, IH), 6.74 (dd, IH), 6.52 (d, IH), 6.50 (dd, IH), 3.97 (dd, 2H), 3.30 (td, 2H), 3.21 (s, 3H), 3.15 (m, 2H), 3.06 (t, 4H), 2.77 (m, 2H), 2.57 (d, IH), 2.50 (m, IH), 2.16 (m, 6H), 1.81 (m, 2H), 1.63 (m, IH), 1.57 (dd, 2H), 1.32 (m, 2H), 1.21 (s, 3H).
EXAMPLE 379
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylate
EXAMPLE 379A
trans-methyl 4-((2-nitro-4-sulfamoylphenylamino)methyl)cyclohexanecarboxylate To 4-fluoro-3-nitrobenzenesulfonamide (0.265 g) and trans-methyl 4- (aminomethyl)cyclohexanecarboxylate hydrochloride in tetrahydrofuran (5 mL) was added N,N-diisopropylethylamine (0.526 mL) and the reaction was stirred at room temperature. After stirring overnight the reaction was loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.5% to 3.5% methanol/dichloromethane over 30 minutes to provide the title compound.
EXAMPLE 379B
methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylate
The title compound was prepared by substituting EXAMPLE 379 A for EXAMPLE IF and EXAMPLE 3J for EXAMPLE IE in EXAMPLE 1G. 1H NMR (300 MHz, dimethylsulfoxide-de) δ 11.68 (s, IH), 11.37 (s, IH), 8.57 (dd, 2H), 8.04 (d, IH), 7.79 (dd, IH), 7.50 (s, 3H), 7.34 (d, 2H), 7.04 (d, 3H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.58 (s, 3H), 3.25 (t, 2H), 3.07 (s, 4H), 2.75 (s, 2H), 2.36 - 2.09 (m, 7H), 1.95 (s, 6H), 1.63 (s, 1.46 - 1.19 (m, 4H), 1.15 - 0.95 (m, 2H), 0.92 (s, 6H).
EXAMPLE 380
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} cyclohexanecarboxylic acid To a solution of EXAMPLE 379B (0.162 g) in tetrahydrofuran (2 mL) and methanol (0.5 mL) was added 1.0 M aqueous LiOH (0.596 mL) and the reaction heated to 50°C for 1 hour. The reaction was cooled, diluted with dichloromethane (30 mL) and water (5 mL), and quenched with aqueous HCl (1.0 M, 0.6 mL). The aqueous layer was diluted with saturated NH4C1 solution (5 mL) and removed. The organic layer was dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 0.5% to 5% methanol/dichloromethane over 30 minutes (flow = 40 mL/minute) provided the title compound. 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 12.00 (s, 1H), 11.68 (s, 1H), 11.38 (s, 1H), 8.55 (d, 2H), 8.04 (d, 1H), 7.79 (dd, 1H), 7.59 - 7.43 (m, 3H), 7.34 (d, 2H), 7.05 (t, 3H), 6.68 (dd, 1H), 6.39 (dd, 1H), 6.19 (d, 1H), 3.25 (s, 2H), 3.07 (s, 4H), 2.75 (s, 2H), 2.17 (d, 7H), 1.95 (s, 6H), 1.62 (s, 1H), 1.38 (s, 4H), 1.03 (dd, 2H), 0.92 (s, 6H). EXAMPLE 381
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide
EXAMPLE 381 A
4-cyanopiperidine- 1 -carboxamide
A round bottom flask containing phosgene (20% wt in toluene, 3.16 mL) and dichloromethane (10 mL) was cooled with an ice bath. A solution of N-ethyl-N- isopropylpropan-2-amine (1.385 mL) and piperidine-4-carbonitrile (0.441 g) in
dichloromethane (5 mL) was added via a syringe dropwise. The mixture was stirred overnight and then concentrated to dryness. The residue was dissolved in methanol (10 mL) and 2 ml of 7 N N¾ in methanol. The mixture was stirred at 50 °C overnight. The mixture was concentrated and the residual solid was mixed with brine (5 mL) and extracted with ethyl acetate (8x25 mL). The organic solution was dried (MgS04), filtered and concentrated. The crude material was purified on a silica gel column eluting with 5% and 10% methanol in CH2CI2 to provide the title compound.
EXAMPLE 38 IB
4-cyano-N-(2-nitro-4-sulfamoylphenyl)piperidine- 1 -carboxamide The title compound was prepared by substituting EXAMPLE 381 A for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 381C
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l- carboxamide
The title compound was prepared by substituting EXAMPLE 38 IB for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 10.46 (s, IH), 9.26 (d, IH), 8.67 (d, IH), 8.50 (dd, IH), 8.40 (d, IH), 8.09 (d, IH), 7.65 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.76 (dd, IH), 6.53 (s, IH), 6.48 (m, IH), 3.80 (m, 2H),3.46 (m, 2H), 3.07 (m, 4H), 2.99 (m, lh), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.85 (m, 2H), 1.79 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 382
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 382 A
4-((cis-4-(methoxymethyl)cyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was obtained through a SFC chiral separation of EXAMPLE 374F. The separation was performed on a Berger SFC system using a gradient of 10-50%) methanol in C02 over 20 minutes, and a Chiral Pak AD-H 21 x 250 mm column. EXAMPLE 382B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ( { [cis-4-(methoxymethyl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 382A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH), 11.39 (s, IH), 8.47 - 8.61 (m, 2H), 8.04 (d, IH), 7.80 (dd, IH), 7.46 - 7.56 (m, 3H), 7.34 (d, 2H), 7.00 - 7.11 (m, 3H), 6.67 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.22 - 3.26 (m, 5H), 3.07 (s, 4H), 2.75 (s, 2H), 2.10 - 2.24 (m, 6H), 1.95 (s, 2H), 1.67 - 1.87 (m, 2H), 1.33 - 1.54 (m, 10H), 0.92 (s, 6H).
EXAMPLE 383
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 383 A
4-((trans-4-(methoxymethyl)cyclohexyl)methylamino)-3-nitrobenzenesulfonamide
The title compound was obtained through a SFC chiral separation of EXAMPLE 374F. The separation was performed on a Berger SFC system using a gradient of 10-50% methanol in C02 over 20 minutes, and a Chiral Pak AD-H 21 x 250 mm column.
EXAMPLE 383B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4- ({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared as described in EXAMPLE 1 ID using EXAMPLE 383A in place of EXAMPLE 1 IB. 1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 11.38 (s, IH), 8.51 - 8.64 (m, 2H), 8.04 (d, IH), 7.79 (dd, IH), 7.46 - 7.58 (m, 3H), 7.32 - 7.38 (m, 2H), 7.00 - 7.10 (m, 3H), 6.68 (dd, IH), 6.39 (dd, IH), 6.19 (d, IH), 3.22 - 3.28 (m, 2H), 3.21 (s, 3H), 3.12 (d, 2H), 3.07 (s, 4H), 2.75 (s, 2H), 2.10 - 2.25 (m, 6H), 1.95 (s, 2H), 1.76 (t, 4H), 1.45 - 1.63 (m, 2H), 1.38 (t, 2H), 0.85 - 1.05 (m, 10H). EXAMPLE 384
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide
EXAMPLE 384 A
3-amino-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE IF for EXAMPLE 364E in EXAMPLE 370A.
EXAMPLE 384B
The title compound was prepared by substituting EXAMPLE 384 A for EXAMPLE 370A in EXAMPLE 370B. EXAMPLE 384C
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-benzotriazol-5 - yl] sulfonyl} benzamide
The title compound was prepared by substituting EXAMPLE 384B for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.69 (s, IH), 8.59 (s, IH), 7.97-8.04 (m, 3H), 7.47-7.55 (m, 3H), 7.34 (d, 2H), 7.03 (d, 2H), 6.66 (dd, IH), 6.39 (dd, IH), 6.17 (d, IH), 4.66 (d, 2H), 3.79-3.82 (m, 2H), 3.19-3.23 (m, 2H), 3.16 (s, 4H), 2.76 (s, 2H), 2.14-2.20 (m, 8H), 1.95 (s, 2H), 1.31-1.40 (m, 6H), 0.92 (s, 2H). EXAMPLE 385
N-( {5 -chloro-6- [(2-oxo- 1 -oxa-3 -azaspiro [4.5] dec-8-yl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 385A
l-(aminomethyl)-4-(benzyloxymethyl)cyclohexanol A suspension of EXAMPLE 341D (5 g), zinc iodide (0.183 g) and anhydrous ether (50 mL) was cooled in an ice bath and trimethylsilanecarbonitrile (3.45 mL) was added dropwise. The reaction was allowed to warm to ambient temperature with stirring continued 45 minutes. The reaction mixture was added via a syringe to a suspension of lithium aluminum hydride (2.78 g) in ether (75 mL) dropwise and the reaction mixture was then heated at reflux for 2 hours. The reaction was cooled in an ice bath and quenched very slowly by careful addition of water (2.8 mL), keeping the temperature below 5 °C. Ether (100 mL) was added, followed by 4N aqueous sodium hydroxide (2.8 mL) and water (8.4 mL). The mixture was further diluted with ether (150 mL) and anhydrous sodium sulfate (70 g) was added. The resulting suspension was stirred for 18 hours and filtered. The solids were washed with ether (4 x 150 mL). The combined organics were dried with Na2S04, filtered, and concentrated to provide the title compound.
EXAMPLE 385B
8-(benzyloxymethyl)- 1 -oxa-3-azaspiro[4.5]decan-2-one A mixture of EXAMPLE 385 A (475 mg) and potassium hydroxide (641 mg) in toluene (10 mL) and water (25 mL) was cooled in an ice bath and phosgene (20% in toluene, 2.178 mL) was added dropwise maintaining the temperature below 3 °C. The reaction was stirred rapidly at ambient temperature for 3 hours while warming to ambient temperature. The reaction mixture was partitioned between brine (100 mL) and ethyl acetate (100 mL). The organics were dried over sodium sulfate, filtered, and concentrated to provide the title compound.
EXAMPLE 385C
8-(hydroxymethyl)- 1 -oxa-3-azaspiro[4.5]decan-2-one A solution of EXAMPLE 385B (500 mg) in ethanol was added to wet 20% palladium hydroxide on carbon (2500 mg) in a 50 ml pressure bottle. The mixture was stirred at ambient temperature for 3 hours under hydrogen at 30 psi. The mixture was filtered and concentrated to provide the title compound.
EXAMPLE 385D
5 -chloro-6-((2-oxo- 1 -oxa-3 -azaspiro[4.5 ]decan-8-yl)methoxy)pyridine-3 -sulfonamide To a solution of EXAMPLE 385C (325 mg, 1.755 mmol) in a mixture of
tetrahydrofuran (16 mL) and N,N-dimethylformamide (8 mL) was added sodium hydride (281 mg, 7.02 mmol) and the mixture was stirred for 30 minutes. 5,6-Dichloropyridine-3- sulfonamide (389 mg) was added and the reaction was stirred for 42 hours. The reaction was quenched with water (5 mL) and concentrated. The residue was diluted with 75% brine (200 mL) and extracted with methylene chloride (3 x 200 mL). The organics were dried over sodium sulfate, filtered, and concentrated. The residue was purified on silica gel and eluted with a 1, 5, and 10 % methanol in methylene chloride step gradient to provide the title compound.
EXAMPLE 385E
N-( {5 -chloro-6- [(2-oxo- 1 -oxa-3 -azaspiro [4.5] dec-8-yl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 385D for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine-d5) δ 13.07 (m, 1H), 9.16 (d, 1H), 8.74 (m, 1H), 8.58 (s, 1H), 8.42 (d, 1H), 8.12 (d, 1H), 7.67 (d, 2H), 7.45 (d, 2H), 7.07 (d, 2H), 6.75 (dd, 1H), 6.51 (m, 2H), 5.17 (br s, 1H), 4.19 (m, 2H), 3.41 (s, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 2.01 - 1.88 (m, 4H), 1.84 - 1.68 (m, 5H), 1.39 (m, 2H),1.13 (m, 2H), 0.94 (m, 6H).
EXAMPLE 386
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl} piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-
1-carboxamide
EXAMPLE 386A
4-methoxypiperidine- 1 -carboxamide
The title compound was prepared by substituting 4-methoxy-piperidine for piperidine- 4-carbonitrile in EXAMPLE 381 A.
EXAMPLE 386B
4-methoxy-N-(2-nitro-4-sulfamoylphenyl)piperidine-l -carboxamide The title compound was prepared by substituting EXAMPLE 386A for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A. EXAMPLE 386C
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-
1-carboxamide
The title compound was prepared by substituting EXAMPLE 386B for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.03 (s, 1H), 10.47 (s, 1H), 9.28 (d, 1H), 8.79 (d, 1H), 8.48 (dd, 1H), 8.40 (d, 1H), 8.08 (d, 1H), 7.65 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.76 (dd, 1H), 6.53 (s, 1H), 6.48 (m, 1H), 3.82 (m, 2H),3.38 (m, 2H), 3.36 (m, 1H), 3.23 (s, 3H), 3.07 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.80 (m, 2H), 1.61 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 387
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 387A
ethyl 3-bromo-4-oxocyclohexanecarboxylate
Ethyl 4-oxocyclohexanecarboxylate (3.0 g) in dichloromethane (20 mL) was treated with bromine (2.82 g) in dichloromethane (10 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed, and the product was used without further purification.
EXAMPLE 387B
ethyl 2-methyl-4,5,6,7-tetrahydrobenzo[d]thiazole-6-carboxylate
A mixture of EXAMPLE 387A (4.4 g) and ethanethioamide (1.33 g) in N,N- dimethylformamide (50 mL) was heated at 140 °C for 20 hours. After it cooled to room temperature, the reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica to give the title compound. EXAMPLE 387C
(2-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)methanol The title compound was prepared by substituting EXAMPLE 387B for EXAMPLE 339A in EXAMPLE 339B.
EXAMPLE 387D
5-chloro-6-((2-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)methoxy)pyridine-3- sulfonamide
The title compound was prepared by substituting EXAMPLE 40 A for 4-fluoro-3- nitrobenzenesulfonamide and EXAMPLE 387C for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 24A.
EXAMPLE 387E
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 387D for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.66 (s, IH), 8.50 (s, IH), 8.10 (s, IH), 8.02 (d, IH), 7.54 (d, IH), 7.48-7.49 (m, 2H), 7.35 (d, 2H), 7.05 (d, 2H), 6.68 (dd, IH), 6.38 (dd, Hz, IH), 6.21 (d, IH), 4.39 (dd, Hz, 2H), 3.11 (s, 4H), 2.89-2.93 (m, 2H), 2.65-2.77 (m, 2H), 2.56 (s, 3H), 2.32-2.36 (m, 4H), 2.15 (s, 2H), 2.02- 2.05 (m, IH), 1.95 (s, 2H), 1.60-1.63 (m, IH), 1.40 (t, 2H), 0.93 (s, 2H).
EXAMPLE 388
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-pyrrolo[2,3- b]pyridin-5-yl]sulfonyl}benzamide
EXAMPLE 388A
5-bromo-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 36A for 4-fluoro-3- nitrobenzenesulfonamide in EXAMPLE IF. EXAMPLE 388B
(E)-5-(2-ethoxyvinyl)-6-((tetrahydro
A mixture of EXAMPLE 388A (0.65 g), (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (0.735 g), palladium acetate (0.013 g), dicyclohexyl(2',6'- dimethoxybiphenyl-2-yl)phosphine (0.057 g), and potassium phosphate (0.788 g) in CH3CN (9 ml) and water (6 mL) was heated at reflux overnight. After it cooled to room temperature, the reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica to give the title compound.
EXAMPLE 388C
l-((tetrahydro-2H-pyran-4-yl)methyl)-lH-pyrrolo[2,3-b]pyridine-5-sulfonamide EXAMPLE 388B (0.57 g) in acetic acid (15 mL) was heated at 90 °C for 2 hours. The solvent was removed, and the residue was dissolved in ethyl acetate. The mixture was washed with brine, dried over MgS04, filtered, and concentrated. The residue was treated with 1 : 1 ethyl acetate and hexanes and filtered to give the title compound.
EXAMPLE 388D
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-pyrrolo[2,3- b]pyridin-5-yl]sulfonyl}benzamide
The title compound was prepared by substituting EXAMPLE 388C for
EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.72 (s, 1H), 8.74 (d, 1H), 8.50 (d, 1H), 8.06 (d, 1H), 7.74 (d, 1H), 7.60 (d, 1H), 7.52-7.53 (m, 1H), 7.48 (d, 1H), 7.34 (d, 2H), 7.03 (d, 2H), 6.66 (d, 1H), 6.64 (d, 1H), 6.41 (dd, 1H), 6.15 (d, 1H), 4.19 (d, 2H), 3.79 (dd, 2H), 3.18-3.23 (m, 2H), 3.06 (s, 4H), 2.73 (s, 2H), 2.13-2.17 (m, 6H), 1.94 (s, 2H), 1.25-1.39 (m, 6H), 0.92 (s, 2H). EXAMPLE 389
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-pyrrolo[2,3-b]pyridin-5-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide EXAMPLE 389A
3 -chloro- 1 -((tetrahydro-2H-pyran-4-yl)methyl)- 1 H-pyrrolo [2,3 -b]pyridine-5 -sulfonamide A mixture of EXAMPLE 388C (0.15 g) and N-chlorosuccinimide (0.081 g) in CH3CN (8 mL) was heated at 90 °C for 16 hours. The solvent was removed, and the residue was purified by flash column chromatography on silica to give the title compound.
EXAMPLE 389B
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3- chloro-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-pyrrolo[2,3-b]pyridin-5-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 389A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H), 8.80 (d, 1H), 8.43 (d, 1H), 8.04 (d, 1H), 8.02 (s, 1H), 7.54 (d, 1H), 7.48-7.51 (m, 2H), 7.34 (d, 2H), 7.03 (d, 2H), 6.65 (dd, 1H), 6.40 (dd, 1H), 6.15 (d, 1H), 4.18 (d, 2H), 3.80 (dd, 2H), 3.20- 3.22 (m, 2H), 3.06 (s, 4H), 2.76 (s, 2H), 2.14-2.21 (m, 6H), 1.95 (s, 2H), 1.23-1.39 (m, 6H), 0.92 (s, 2H).
EXAMPLE 390
4-(4- { [2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex- 1 -en- 1 - yljmethyl} piperazin- 1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
EXAMPLE 390A
methyl 1 ,4-dioxaspiro[4.5]decane-7-carboxylate
Methyl 3-oxocyclohexanecarboxylate (930 mg) and pyridinium /?-toluenesulfonate (299 mg) were combined in toluene (29.8 mL) to give a colorless solution. Ethylene glycol (0.996 mL) was added and the reaction was refluxed under Dean-Stark conditions for 2 days. The reaction was cooled to room temperature, triethylamine was added, and then the mixture was concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix 0-40% hexane/ethyl acetate). EXAMPLE 390B
methyl 7-methyl- 1 ,4-dioxaspiro[4.5]decane-7-carboxylate The title compound was prepared by substituting EXAMPLE 390 A for ethyl 1,4- dioxaspiro[4.5]decane-8-carboxylate in EXAMPLE 360A.
EXAMPLE 390C
(7-methyl- l,4-dioxaspiro[4.5]decan-7-yl)methanol The title compound was prepared by substituting EXAMPLE 390B for ethyl 8- methyl-l,4-dioxaspiro[4.5]decane-8-carboxylate in EXAMPLE 360B.
EXAMPLE 390D
7-(methoxymethyl)-7-methyl-l,4-dioxaspiro[4.5]decane The title compound was prepared by substituting EXAMPLE 390C for EXAMPLE 360B in EXAMPLE 360C.
EXAMPLE 390E
3 -(methoxymethyl)-3 -methylcyclohexanone
The title compound was prepared by substituting EXAMPLE 390D for EXAMPLE 353B in EXAMPLE 353C.
EXAMPLE 390F
2-chloro-4-(methoxymethyl)-4-methylcyclohex- 1 -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 390E for EXAMPLE 353C in EXAMPLE 353D.
EXAMPLE 390G
2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex-l -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 390F for EXAMPLE 353D in EXAMPLE 353E.
EXAMPLE 390H
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4-(methoxymethyl)- 4-methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 390G for EXAMPLE 353E in EXAMPLE 353F.
EXAMPLE 3901
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4-(methoxymethyl)-4- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 390H for EXAMPLE 15G in EXAMPLE 15H. EXAMPLE 390 J
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4-(methoxymethyl)-4- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by replacing EXAMPLE 3J with EXAMPLE 3901 and EXAMPLE 1 IB with EXAMPLE IF in EXAMPLE 1 ID. In this example, the crude product was purified using regular phase flash column chromatography (Analogix, 0.4 - 4% methanol in dichloromethane). 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.68 (s, IH) 11.22 - 11.49 (m, IH) 8.60 (t, IH) 8.56 (d,lH) 8.04 (d, IH) 7.80 (dd, IH) 7.53 (d, IH) 7.49 - 7.52 (m, IH) 7.48 (s, IH) 7.34 (d, IH) 7.11 (d, IH) 7.04 (d, 2H) 6.68 (dd, IH) 6.37 - 6.41 (m, IH) 6.19 (d, IH) 3.80 - 3.90 (m, 2H) 3.24 - 3.30 (m, 4H) 3.22 - 3.25 (m, 3H) 3.04 - 3.14 (m, 6H) 2.70 - 2.79 (m, 2H) 2.04 - 2.29 (m, 7H) 1.77 - 1.94 (m, 2H) 1.56 - 1.67 (m, 2H) 1.45 - 1.56 (m, IH) 1.30 - 1.42 (m, IH) 1.17 - 1.30 (m, 2H) 0.91 (s, 3H).
EXAMPLE 391
N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide
EXAMPLE 391 A
methyl 4-(hydroxymethyl)cyclohexanecarboxylate
To a cooled (0 °C ) solution of 4-(hydroxymethyl)cyclohexanecarboxylic acid (40 g) in methanol (632 mL) was added thionyl chloride (22.15 mL) dropwise via an addition funnel. The reaction was slowly warmed to room temperature, stirred for 1 hour, concentrated by rotary evaporation, and the residue was purified by regular phase flash column chromatography (Analogix, 0-100% hexanes / ethyl acetate).
EXAMPLE 391B
methyl 4-((tert-butyldimethylsilyloxy)methyl)cyclohexanecarboxylate To a solution of EXAMPLE 391 A (43.6 g) and triethylamine (42.3 mL) in dichloromethane (633 mL) was added tert-butyldimethylsilyl chloride (38.1 g) and 4- dimethylaminopyridine (3.09 g) and the reaction was stirred overnight at room temperature. A saturated solution of aqueous NH4C1 was added and the layers were separated. The organic layer was washed with water and brine, dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-40% hexanes / ethyl acetate.
EXAMPLE 391C
dimethyl 4-((tert-butyldimethylsilyloxy)methyl)cyclohexane- 1 , 1 -dicarboxylate The title compound was prepared by substituting EXAMPLE 39 IB for ethyl 1,4- dioxaspiro[4.5]decane-8-carboxylate and methyl chloroformate for ethyl chloroformate in
EXAMPLE 351 A.
EXAMPLE 391D
(4-((tert-butyldimethylsilyloxy)methyl)cyclohexane- 1 , 1 -diyl)dimethanol The title compound was prepared by substituting EXAMPLE 391C for EXAMPLE 351 A in EXAMPLE 35 IB.
EXAMPLE 391E
(3,3-dimethyl-2,4-dioxaspiro[5.5]undecan-9-yl)methanol To a solution of EXAMPLE 391D (1 g) and 2,2-dimethoxypropane (1.276 mL) in N,N-dimethylformamide (6.93 mL) was added para-toluenesulfonic acid monohydrate (1.451 g). The reaction was stirred for 4 hours at room temperature, triethylamine was added and the solution was concentrated by rotary evaporation. The residue was placed under high vacuum overnight to remove Ν,Ν-dimethylformamide. The residue was purified by regular phase flash column chromatography (Analogix - 0-100% hexanes / ethyl acetate). EXAMPLE 391F
4-((3,3-dimethyl-2,4-dioxaspiro[5.5]undecan-9-yl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 39 IE for (tetrahydro- 2H-pyran-4-yl)methanol in EXAMPLE 24A.
EXAMPLE 391G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(4-((3,3-dimethyl-2,4-dioxaspiro[5.5]undecan-9-yl)methoxy)-
3 -nitrophenylsulfonyl)benzamide
The title compound was prepared by substituting EXAMPLE 3 J for EXAMPLE IE and EXAMPLE 391F for EXAMPLE IF in EXAMPLE 1G. In this example, the crude product was purified by regular phase flash column chromatography (Analogix, 0.4 - 4% methanol in dichloromethane).
EXAMPLE 391H
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-(4-((4,4-bis(hydroxymethyl)cyclohexyl)methoxy)-3- nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin- 1 -yl)benzamide
To a solution of EXAMPLE 391G (680 mg) in dichloromethane (3514 μΐ) was added para-toluenesulfonic acid monohydrate (535 mg) and the reaction was allowed to stir for 3 hours. Triethylamine (490 μΐ) was added and the reaction was concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix 0.5-5% dichloromethane / methanol). 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11.69 (s, 1H) 8.35 (s, 1H) 8.03 (d, 2H) 7.46 - 7.58 (m, 3H) 7.29 - 7.42 (m, 3H) 7.04 (d, 2H) 6.68 (dd, 1H) 6.39 (d, 1H) 6.20 (s, 1H) 4.19 - 4.35 (m, 2H) 4.05 (d, 2H) 3.37 (d, 2H) 3.17 (d, 2H) 3.09 (bs, 4H) 2.10 - 2.31 (m, 6H) 1.96 (bs, 2H) 1.62 - 1.75 (m, 1H) 1.46 - 1.62 (m, 4H) 1.39 (t, 2H) 1.05 - 1.32 (m, 4H) 0.93 (s, 6H).
EXAMPLE 392
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-methoxypiperidine- 1 -carboxamide EXAMPLE 392A
3-chloro-4-isocyanatobenzenesulfonamide
In a round bottom flask containing a solution of phosgene (1.573 mL) in
dichloromethane (5 mL) was added 4-amino-3-chlorobenzenesulfonamide (0.206 g) and N- ethyl-N-isopropylpropan-2-amine (0.521 mL). The resulting clear solution was stirred at room temperature overnight. The mixture was concentrated and further dried under vacuum to provide the title compound.
EXAMPLE 392B
N-(2-chloro-4-sulfamoylphenyl)-4-methoxypiperidine- 1 -carboxamide
To a solution of EXAMPLE 392 A in anhydrous tetrahydrofuran (6 mL) was added 4- methoxypiperidine (451 mg). The mixture was stirred at 60 °C for 3 hours. The mixture was cooled, mixed with methanol (20 mL) and silica gel (6 g) and concentrated. The material was purified on a silica gel column and was eluted with 10% methanol in dichloromethane to provide the title compound.
EXAMPLE 392C
N-(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)- 4-methoxypiperidine- 1 -carboxamide
The title compound was prepared by substituting EXAMPLE 392B for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.03 (s, IH), 8.58 (s, IH), 8.57 (d, IH), 8.43 (d, IH), 8.28 (m, 2H), 8.08 (d, IH), 7.68 (d, IH), 7.65 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.72 (dd, IH), 6.51 (m, 2H), 3.87 (m, 2H),3.34 (m, 3H), 3.24 (s, 3H), 3.05 (m, 4H), 2.76 (s, 2H), 2.25 (t, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.81 (m, 2H), 1.60 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 393
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-cyanopiperidine- 1 -carboxamide EXAMPLE 393A
N-(2-chloro-4-sulfamoylphenyl)-4-cyanopiperidine-l-carboxamide The title compound was prepared by substituting piperidine-4-carbonitrile for 4- methoxy-piperidine in EXAMPLE 392B.
EXAMPLE 393B
N-(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-cyanopiperidine- 1 -carboxamide
The title compound was prepared by substituting EXAMPLE 393 A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 12.98 (s, IH), 8.55 (s, IH), 8.46 (m, 3H), 8.28 (d, IH), 8.11 (d, IH), 7.68 (d, IH), 7.65 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.72 (dd, IH), 6.51 (m, 2H), 3.84 (m, 2H),3.43 (m, 2H), 3.05 (m, 4H), 2.94 (m, IH), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.86-1.73 (m, 4H), 1.39 (t, 2H), 0.93 (s, 6H).
EXAMPLE 394
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-hydroxy-4-methylpiperidine- 1 -carboxamide
EXAMPLE 394A
N-(2-chloro-4-sulfamoylphenyl)-4-hydroxy-4-methylpiperidine-l -carboxamide The title compound was prepared by substituting 4-hydroxy-4-methylpiperidine for 4- methoxy-piperidine in EXAMPLE 392B.
EXAMPLE 394B
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-hydroxy-4-methylpiperidine- 1 -carboxamide
The title compound was prepared by substituting EXAMPLE 394 A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.01 (s, IH), 8.64 (d, IH), 8.57 (d, IH), 8.45 (d, IH), 8.28 (dd, IH), 8.19 (s, IH), 8.14 (d, IH), 7.69 (d, IH), 7.65 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.73 (dd, IH), 6.52 (d, IH), 6.50 (dd, IH), 4.05 (m, 2H),3.68 (m, 2H), 3.05 (m, 4H), 2.77 (s, 2H), 2.26 (t, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.79 (m, 2H), 1.69 (dt, 2H), 1.39 (t, 2H), 1.36 (s, 3H), 0.94 (s, 6H).
EXAMPLE 395
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-(methoxymethyl)piperidine- 1 -carboxamide
EXAMPLE 395A
N-(2-chloro-4-sulfamoylphenyl)-4-(methoxymethyl)piperidine-l -carboxamide The title compound was prepared by substituting 4-methoxymethylpiperidine for 4- methoxy-piperidine in EXAMPLE 392B.
EXAMPLE 395B
N-(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-(methoxymethyl)piperidine- 1 -carboxamide
The title compound was prepared by substituting EXAMPLE 395 A for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 8.59 (d, IH), 8.56 (d, IH), 8.45 (d, IH), 8.28 (dd, IH), 8.16 (s, IH), 8.12 (d, IH), 7.69 (d, IH), 7.65 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.73 (dd, IH), 6.51 (m, 2H), 4.28 (bd, 2H), 3.23 (s, 3H), 3.12 (d, 2H), 3.05 (m, 4H), 2.84 (dt, 2H), 2.77 (s, 2H), 2.26 (t, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.79-1.65 (m, 3H), 1.39 (t, 2H), 1.25 (m, 2H), 0.94 (s, 6H).
EXAMPLE 396
N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 396A
Trans-8-(benzyloxymethyl)- 1 -oxa-3 -azaspiro [4.5] decan-2-one A mixture of EXAMPLE 385A (5.56 g) and potassium hydroxide (7.51 g) in toluene (120 mL) and water (300 mL) was cooled in an ice bath and phosgene (20% in toluene, 25.5 mL) was added dropwise, maintaining the temperature below 3 °C. The reaction was stirred rapidly at ambient temperature for 3 hours while warming to ambient temperature. The reaction mixture was partitioned between brine (100 mL) and ethyl acetate (100 mL). The organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 50, 75, 100 % ethyl acetate in hexane step gradient to provide the title compound.
EXAMPLE 396B
trans-8-(hydroxymethyl)- 1 -oxa-3 -azaspiro [4.5 ]decan-2-one The title compound was prepared by substituting EXAMPLE 396 A for EXAMPLE 385B in EXAMPLE 385C.
EXAMPLE 396C
5-chloro-6-((trans-2-oxo-l-oxa-3-azaspiro[4.5]decan-8-yl)methoxy)pyridine-3-sulfonamide
The title compound was prepared by substituting EXAMPLE 396B for EXAMPLE 385C in EXAMPLE 385D.
EXAMPLE 396D
N-[(5-chloro-6-{[trans-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 396C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine- d5) δ 13.05 (m, 1H), 9.16 (d, 1H), 8.74 (m, 1H), 8.58 (s, 1H), 8.42 (d, 1H), 8.10 (d, 1H), 7.67 (m, 2H), 7.45 (d, 2H), 7.07 (d, 2H), 6.75 (dd, 1H), 6.51 (m, 2H), 5.21 (br s, 1H), 4.19 (d, 2H), 3.41 (s, 2H), 3.06 (m, 4H),
2.77 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.92 (d, 2H), 1.84 - 1.68 (m, 5H), 1.39 (m, 2H),1.13 (m, 2H), 0.93 (m, 6H).
EXAMPLE 397
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide EXAMPLE 397A
Cis-8-(benzyloxymethyl)-l-oxa-3-azaspiro[4.5]decan-2-one A mixture of EXAMPLE 385A (5.56 g) and potassium hydroxide (7.51 g) in toluene (120 mL) and water (300 mL) was cooled in an ice bath and phosgene (20% in toluene, 25.5 mL) was added dropwise maintaining the temperature below 3 °C. The reaction was stirred rapidly at ambient temperature for 3 hours while warming to ambient temperature. The reaction mixture was partitioned between brine (100 mL) and ethyl acetate (100 mL). The organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 50, 75, 100 % ethyl acetate in hexane step gradient to provide the title compound.
EXAMPLE 397B
Cis-8-(hydroxymethyl)- 1 -oxa-3-azaspiro[4.5]decan-2-one The title compound was prepared by substituting EXAMPLE 397 A for EXAMPLE in EXAMPLE 385C.
EXAMPLE 397C
5 -chloro-6-((cis-2-oxo- 1 -oxa-3 -azaspiro [4.5] decan-8-yl)methoxy)pyridine-3 -sulfonamide The title compound was prepared by substituting EXAMPLE 397B for EXAMPLE 385C in EXAMPLE 385D.
EXAMPLE 397D
N- [(5 -chloro-6- { [cis-2-oxo- 1 -oxa-3-azaspiro [4.5 ]dec-8-yl]methoxy } pyridin-3 -yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 397C for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine- d5) δ 13.06 (m, 1H), 9.15 (d, 1H), 8.72 (m, 1H), 8.50 (s, 1H), 8.42 (d, 1H), 8.10 (d, 1H), 7.67 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.75 (dd, 1H), 6.51 (m, 2H), 5.36 (br s, 1H), 4.21 (d, 2H), 3.25 (s, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.13 (m, 4H), 2.02 - 1.96 (m, 4H), 1.86 - 1.77 (m, 1H), 1.76 - 1.71 (m, 2H),1.64 - 1.52 (m, 2H), 1.39 (m, 4H), 0.94 (m, 6H). EXAMPLE 398
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-(morpholin-4-yl)piperidine- 1 -carboxamide
EXAMPLE 398A
N-(2-chloro-4-sulfamoylphenyl)-4-morpholinopiperidine-l -carboxamide The title compound was prepared by substituting 4-(piperidin-4-yl)morpholine for 4- methoxy-piperidine in EXAMPLE 392B.
EXAMPLE 398B
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}phenyl)-
4-(morpholin-4-yl)piperidine- 1 -carboxamide
The title compound was prepared by substituting EXAMPLE 398A for EXAMPLE
130C in EXAMPLE 130D. 1H NMR (500MHz, pyridine-d5) δ 13.02 (s, IH), 8.59 (d, IH), 8.57 (d, IH), 8.44 (d, IH), 8.28 (m, 2H), 8.10 (d, IH), 7.69 (d, IH), 7.66 (t, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.72 (dd, IH), 6.51 (m, 2H), 4.28-4.24 (m, 2H), 3.71 (m, 4H), 3.05 (m, 4H), 2.92 (dt, 2H), 2.76 (s, 2H), 2.44 (m, 4H), 2.30-2.24 (m, 3H), 2.13 (m, 4H), 1.97 (s, 2H), 1.75 (m, 2H), 1.48 (dq, 2H), 1.39 (t, 2H), 0.94 (s, 6H).
EXAMPLE 399
N-[(5-chloro-6-{[trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 399A
(((4-methylenecyclohexyl)methoxy)methyl)benzene
A mixture of methyltriphenylphosphonium bromide (12.27 g) and anhydrous tetrahydrofuran (60.0 mL) was cooled to -78 °C. A suspension of potassium t-butoxide (4.37 g) in tetrahydrofuran (60.0 mL) was added dropwise. The mixture was stirred at 0 °C for 1 hour and then for 1 hour as the reaction warmed to ambient temperature. The reaction mixture was cooled to -40 °C and a solution of EXAMPLE 341D (5 g,) in tetrahydrofuran (35 mL) was added dropwise. After stirring 18 hours at ambient temperature, the reaction was quenched by the careful addition of 33% brine (150 mL) and diluted with ether (150 mL). The layers were separated and the aqueous layer was extracted with ether (2 x 75 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 0, 10, 15, 25 % ethyl acetate in hexane step gradient to provide the title compound.
EXAMPLE 399B
4-(benzyloxymethyl)- 1 -(hydroxymethyl)cyclohexanol To a solution of EXAMPLE 399A (4.77 g) and 4-methylmorpholine 4-oxide hydrate (3.28 g), in a mixture of tetrahydrofuran (90 mL) and water (13.50 mL) was added potassium dioxidodioxoosmium dihydrate (0.325 g) and the resulting suspension was stirred rapidly 18 hours. Sodium sulfite (12.51 g) and water (90 mL) were added and stirring was continued for 1 hour. The reaction was diluted with water (300 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 50, 100 % ethyl acetate in hexane step gradient to provide the title compound.
EXAMPLE 399C
Trans-4-(benzyloxymethyl)- 1 -(methoxymethyl)cyclohexanol To a solution of EXAMPLE 399B (1 g) in anhydrous tetrahydrofuran (50 mL) was added sodium hydride (0.192 g) and the suspension was stirred for 20 minutes. lodomethane (0.274 mL) was added and stirring was continued for 72 hours. The reaction was quenched with brine (150 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 25, 50 % ethyl acetate in hexane step gradient to provide the title compound.
EXAMPLE 399D
Trans-4-(hydroxymethyl)- 1 -(methoxymethyl)cyclohexanol The title compound was prepared by substituting EXAMPLE 399C for EXAMPLE 385B in EXAMPLE 385C. EXAMPLE 399E
5-chloro-6-((trans-4-hydroxy-4-methoxyme
The title compound was prepared by substituting EXAMPLE 399D for EXAMPLE 385C in EXAMPLE 385D.
EXAMPLE 399F
N-[(5-chloro-6-{[trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 399E for EXAMPLE 130C in EXAMPLE 130D. 1H NMR (400 MHz, pyridine- d5) δ 13.06 (m, 1H), 9.16 (d, 1H), 8.75 (m, 1H), 8.42 (d, 1H), 8.10 (d, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.74 (dd, 1H), 6.51 (m, 2H), 5.51 (br s, 2H), 4.31 (d, 2H), 3.51 (s, 2H), 3.37 (s, 3H), 3.06 (m, 4H), 2.77 (s, 2H), 2.25 (m, 2H), 2.15 - 2.07 (m, 6H), 1.99 - 1.91 (m, 5H), 1.71 - 1.63 (m, 2H), 1.39 (m, 4H), 0.93 (m, 6H).
EXAMPLE 400
N-[(5-chloro-6-{[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 400A
Cis-8-(benzyloxymethyl)-2,2-dimethyl-l,3-dioxaspiro[4.5]decane A solution of EXAMPLE 399B (1250 mg), 4-methylbenzenesulfonic acid hydrate (95 mg) and 2,2-dimethoxypropane (624 mg) in acetone (100 mL) was stirred for 18 hours. The reaction was quenched with saturated sodium bicarbonate solution (50 mL) and the resulting suspension was concentrated. The aqueous residue was diluted with saturated sodium bicarbonate solution (75 mL) and water (125 mL) and was extracted with ethyl acetate (2 x 200 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 0 - 20 % ethyl acetate in hexane gradient to provide the title compound. EXAMPLE 400B
(cis-2 ,2-dimethy 1- 1 , 3 -dioxaspiro [4.5 ] decan- 8 -y l)methanol The title compound was prepared by substituting EXAMPLE 400A for EXAMPLE 385B in EXAMPLE 385C.
EXAMPLE 400C
5-chloro-6-((cis-2,2-dimethyl-l ,3-dioxaspiro[4.5]decan-8-yl)methoxy)pyridine-3- sulfonamide
The title compound was prepared by substituting EXAMPLE 400B for EXAMPLE 385C in EXAMPLE 385D.
EXAMPLE 400D
2-(lH-pyrrolo[2,3-¾]pyridin-5-yloxy)-N-(5-chloro-6-((cis-2,2-dimethyl-l ,3- dioxaspiro[4.5]decan-8-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperizin- 1 -yl)benzamide
The title compound was prepared by substituting EXAMPLE 400C for EXAMPLE 130C in EXAMPLE 130D.
EXAMPLE 400E
N-[(5-chloro-6- {[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide To a solution of EXAMPLE 400D (123 mg) in dioxane (2.0 mL) was added water (0.25 mL) and 2M hydrochloric acid (0.261 mL). The mixture was heated at 85 °C for 18 hours. Upon cooling, the reaction was quenched with saturated sodium bicarbonate (60 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified by reverse phase chromatography and eluted with an acetonitrile in ammonium acetate buffer gradient to provide the title compound. 1H NMR (400 MHz, pyridine- d5) δ 13.02 (m, 1H), 9.14 (d, 1H), 8.71 (m, 1H), 8.42 (d, 1H), 8.12 (d, 1H), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.74 (dd, 1H), 6.50 (m, 2H), 5.32 (br s, 3H), 4.31 (d, 2H), 3.82 (s, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.22 - 2.1 1 (m, 5H), 2.05 (d, 2H), 1.97 (s, 2H), 1.94 - 1.82 (m, 4H), 1.71 - 1.61 (m, 2H), 1.39 (m, 2H), 0.93 (m, 6H). EXAMPLE 401
N-[(5-chloro-6-{[trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
EXAMPLE 401 A
Trans-8-(benzyloxymethyl)-2,2-dimethyl-l ,3-dioxaspiro[4.5]decane A solution of EXAMPLE 399B (1250 mg), 4-methylbenzenesulfonic acid hydrate (95 mg) and 2,2-dimethoxypropane (624 mg) in acetone (100 mL) was stirred 18 hours. The reaction mixture was quenched with saturated sodium bicarbonate solution (50 mL) and the resulting suspension was concentrated. The aqueous residue was diluted with saturated sodium bicarbonate solution (75 mL) and water (125 mL) and was extracted with ethyl acetate (2 x 200 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was purified on silica gel and eluted with a 0 - 20 % ethyl acetate in hexane gradient to provide the title compound.
EXAMPLE 40 IB
(trans-2,2-dimethyl-l ,3-dioxaspiro[4.5]decan-8-yl)methanol The title compound was prepared by substituting EXAMPLE 401 A for EXAMPLE 385B in EXAMPLE 385C.
EXAMPLE 401C
5 -chloro-6-((trans-2,2-dimethyl- 1 ,3 -dioxaspiro [4.5] decan-8-yl)methoxy)pyridine-3 - sulfonamide
The title compound was prepared by substituting EXAMPLE 40 IB for EXAMPLE 385C in EXAMPLE 385D.
EXAMPLE 40 ID
2-(lH-pyrrolo[2,3-¾]pyridin-5-yloxy)-N-(5-chloro-6-((trans-2,2-dimethyl-l ,3- dioxaspiro[4.5]decan-8-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperizin- 1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 401C for EXAMPLE 130C in EXAMPLE 130D. EXAMPLE 40 IE
N-[(5-chloro-6-{[trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 40 ID for EXAMPLE 400D in EXAMPLE 400E. 1H NMR (400 MHz, pyridine- d5) δ 13.02 (m, IH), 9.14 (d, IH), 8.71 (m, IH), 8.42 (d, IH), 8.12 (d, IH), 7.66 (m, 2H), 7.44 (d, 2H), 7.07 (d, 2H), 6.74 (dd, IH), 6.50 (m, 2H), 5.31 (br s, 3H), 4.31 (d, 2H), 3.95 (s, 2H), 3.06 (m, 4H), 2.77 (s, 2H), 2.28 - 2.18 (m, 4H), 2.13 (m, 4H), 2.02 - 1.91 (m, 5H), 1.79 - 1.70 (m, 2H), 1.49 - 1.36 (m, 4H), 0.93 (m, 6H).
EXAMPLE 402
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 378D for EXAMPLE 3J and EXAMPLE 277A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (400 MHz, pyridine-d5) δ 13.04 (s, IH), 9.12 (d, IH), 8.72 (m, IH), 8.41 (d, IH), 8.09 (d, IH), 7.67 (m, 2H), 7.41 (d, 2H), 7.09 (d, 2H), 6.74 (dd, IH), 6.51 (m, 2H), 4.64 (m, 4H), 4.53 (d, 2H), 3.39 (m, IH), 3.22 (s, 3H), 3.06 (t, 4H), 2.77 (m, 2H), 2.52 (m, 4H), 2.13 (m, 10H), 1.90 (m, 3H), 1.64 (m, IH), 1.21 (s, 3H).
EXAMPLE 403
4-(4- { [2-(4-chlorophenyl)cyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {3 -nitro-4-
[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide
EXAMPLE 403A
2-chlorocyclohex-l-enecarbaldehyde
The title compound was prepared by substituting cyclohexanone for EXAMPLE 353C in EXAMPLE 353D. EXAMPLE 403B
2-(4-chlorophenyl)cyclohex- 1 -enecarbaldehyde
The title compound was prepared by substituting EXAMPLE 403 A for EXAMPLE 353D in EXAMPLE 353E.
EXAMPLE 403C
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoate
The title compound was prepared by substituting EXAMPLE 403B for EXAMPLE 353E in EXAMPLE 353F.
EXAMPLE 403D
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l- enyl)methyl)piperazin- 1 -yl)benzoic acid
The title compound was prepared by substituting EXAMPLE 403 C for EXAMPLE
15G in EXAMPLE 15H.
EXAMPLE 403E
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l- enyl)methyl)piperazin- 1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonyl)benzamide
The title compound was prepared by replacing EXAMPLE 3 J with EXAMPLE 403D and EXAMPLE 1 IB with EXAMPLE IF in EXAMPLE 1 ID. In this example, the crude product was purified using regular phase flash column chromatography (Analogix, 0.4 - 4% methanol in dichloromethane). 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 1 1.68 (s, IH) 8.52 - 8.64 (m, 2H) 8.04 (d, IH) 7.80 (dd, IH) 7.54 (d, IH) 7.45 - 7.53 (m, 2H) 7.29 - 7.38 (m, 2H) 7.12 (s, IH) 7.04 - 7.1 1 (m, 2H) 6.68 (dd, IH) 6.39 (dd, IH) 6.17 (d, IH) 3.85 (dd, 2H) 3.19 - 3.30 (m, 5H) 3.01 - 3.1 1 (m, 4H) 2.67 - 2.78 (m, 2H) 2.07 - 2.31 (m, 8H) 1.79 - 1.96 (m, IH) 1.53 - 1.70 (m, 6H) 1.14 - 1.34 (m, 2H). EXAMPLE 404
4-(4-chlorophenyl)-l-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)carbamoyl]-3 -( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)phenyl}piperazin- 1 -yl)methyl]cyclohex-3-ene- 1 -carboxylic acid
EXAMPLE 404A
tert-butyl 1 ,4-dioxaspiro[4.5]decane-8-carboxylate The title compound was prepared by substituting tert-butyl 4- oxocyclohexanecarboxylate for methyl 3-oxocyclohexanecarboxylate in EXAMPLE 390A. In this example, the reaction was refluxed under Dean-Stark conditions for 8 hours.
EXAMPLE 404B
tert-butyl 8-methyl- 1 ,4-dioxaspiro[4.5]decane-8-carboxylate The title compound was prepared by substituting EXAMPLE 404A for ethyl 1 ,4- dioxaspiro[4.5]decane-8-carboxylate in EXAMPLE 360A.
EXAMPLE 404C
tert-butyl 1 -methyl-4-oxocyclohexanecarboxylate The title compound was prepared by substituting EXAMPLE 404B for EXAMPLE 353B in EXAMPLE 353C.
EXAMPLE 404D
tert-butyl 4-chloro-3 -formyl- 1 -methylcyclohex-3 -enecarboxylate The title compound was prepared by substituting EXAMPLE 404C for EXAMPLE 353C in EXAMPLE 353D.
EXAMPLE 404E
tert-butyl 4-(4-chlorophenyl)-3 -formyl- 1 -methylcyclohex-3 -enecarboxylate The title compound was prepared by substituting EXAMPLE 404D for EXAMPLE 353D in EXAMPLE 353E.
EXAMPLE 404F
methyl 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((5-(tert-butoxycarbonyl)-2-(4- chlorophenyl)-5 -methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 404E for EXAMPLE 353E in EXAMPLE 353F.
EXAMPLE 404G
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((5-(tert-butoxycarbonyl)-2-(4-chlorophenyl)-5- methylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 404F for EXAMPLE 15G in EXAMPLE 15H. EXAMPLE 404H
tert-butyl 3-((4-(3-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonylcarbamoyl)phenyl)piperazin-l-yl)methyl)-4-(4- chlorophenyl)- 1 -methylcyclohex-3-enecarboxylate
The title compound was prepared by replacing EXAMPLE 3 J with EXAMPLE 404G and EXAMPLE 1 IB with EXAMPLE IF in EXAMPLE 1 ID. In this example, the crude product was purified using regular phase flash column chromatography (Analogix, 0.4 - 4% methanol in dichloromethane).
EXAMPLE 4041
3-((4-(3-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonylcarbamoyl)phenyl)piperazin-l-yl)methyl)-4-(4- chlorophenyl)- 1 -methylcyclohex-3 -enecarboxylic acid EXAMPLE 404H (236 mg) was taken up in dichloromethane (824 μΐ) and
trifluoroacetic acid (82 μΐ) was added. The reaction was stirred until LC/MS indicated complete consumption of starting material (ca. IH). An excess of triethylamine was added and the volatiles were removed by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0.5 - 5% methanol in dichloromethane). 1H NMR (300 MHz, dimethylsulfoxide-d6) δ 12.20 - 12.53 (m, IH) 11.70 (s, IH) 8.51 - 8.67 (m, 2H) 8.04 (d, IH) 7.81 (dd, IH) 7.46 - 7.64 (m, 3H) 7.38 (d, 2H) 7.13 (d, IH) 7.05 (d, 2H) 6.71 (d, IH) 6.40 (dd, IH) 6.23 (s, IH) 3.85 (dd, 2H) 3.22 - 3.43 (m, 7H) 2.97 - 3.19 (m, 6H) 2.55 - 2.74 (m, 2H) 2.27 (dd, 2H) 1.78 - 2.11 (m, 3H) 1.61 (d, 3H) 1.21 - 1.37 (m, 5H). EXAMPLE 405
N-[(5-chloro-6- {[ 1 -(oxetan-3-yl)piperi
chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl}piperazin- 1 -yl)-2-(lH-pyrrolo[2,3-
¾]pyridin-5 -yloxy)benzamide
EXAMPLE 405A
5 -chloro-6-((l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridine-3 -sulfonamide
Sodium cyanoborohydride resin (1.334 g) was added to a mixture of EXAMPLE
253B (0.534 g) in tetrahydrofuran (11.72 mL) and acetic acid (3.91 mL). Oxetan-3-one (0.108 g) was added and the mixture was stirred at room temperature for 46 hours.
Additional oxetan-3-one (0.108 g) was added and stirring was continued for another 2.5 days.
The reaction mixture was set aside without stirring for 16 weeks and was then filtered to remove the resin. The resin was rinsed with methanol and tetrahydrofuran. The filtrate was concentrated, taken up in dichloromethane, washed with saturated NaHC03 solution and brine, dried (MgS04), filtered and concentrated. The concentrate was slurried in methanol and filtered. The solid was then slurried in CH3CN and filtered. The solid was collected and dried in a vacuum oven at 80 °C to provide the title compound.
EXAMPLE 405B
N-[(5-chloro-6-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1H- pyrrolo [2,3 -£]pyridin-5 -yloxy)benzamide
The title compound was prepared by substituting EXAMPLE 405 A for EXAMPLE 1 IB in EXAMPLE 1 ID. 1H NMR (500 MHz, pyridine-d5) δ 13.07 (s, IH), 9.16 (d, IH), 8.42 (d, IH), 8.09 (d, IH), 7.67 (m, 2H), 7.44 (m, 2H), 7.07 (m, 2H), 6.75 (dd, IH), 6.51 (m, 2H), 4.62 (m, 4H), 4.23 (d, 2H), 3.31 (m, IH), 3.06 (m, 4H), 2.77 (s, 2H), 2.65 (d, 2H), 2.26 (t, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.76 (m, 3H), 1.66 (m, 2H), 1.42 (m, 4H), 0.93 (s, 6H).

Claims

WHAT IS CLAIMED IS:
1. A compound havin Formula (I)
Figure imgf000668_0001
A1 is N or C(A2);
NHR1, N(R1)2,
Figure imgf000668_0002
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1,
Figure imgf000668_0003
NHS02NHR1, NHS02N(R1)2, NR^NHR1, NR^O^R1^, C(0)NHNOH, C(0)NHNOR1, C(0)NHS02R1, C(NH)NH2,
Figure imgf000668_0004
C(NH)N(R1)2
Figure imgf000668_0005
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000668_0006
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, H,
Figure imgf000668_0007
Figure imgf000668_0008
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; N(R1)2,
Figure imgf000668_0009
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1, H,
Figure imgf000668_0010
Figure imgf000668_0011
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; NHR1, N(R1)2,
Figure imgf000669_0001
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1,
NR1S02R1,
, C(0)NHNOH,
Figure imgf000669_0002
NH)N(R1)2
Figure imgf000669_0003
NHS02N(CH3)R1,_N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000669_0004
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^,
Figure imgf000669_0005
C(NH)N(R1)2
Figure imgf000669_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or
C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000669_0007
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^,
Figure imgf000669_0008
C(NH)N(R1)2
Figure imgf000669_0009
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or
heterocycloalkene; and
Figure imgf000670_0001
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^,
Figure imgf000670_0002
C(NH)N(R1)2
Figure imgf000670_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or
C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or
heterocycloalkene; and
Figure imgf000670_0004
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SO^HR1, SO^R1^,
C(NH)N(R1)2
Figure imgf000670_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or
C(0)OR1A;
G1 is H, or C(0)OR;
R is alkyl;
R1 is R2, R3, R4 or R5;
R1A is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2,
NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,
NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin- 1 -yl, azetidin- 1 -yl, pyrrolidin- 1 -yl or piperidin- 1 -yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
R 8 is phenyl, which is unfused or fused with R 8A ; R 8A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12, NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12,
NHC(0)NH2, NHC(0)NHR12, NHC(0)N(R12)2, NR12C(0)NHR12, NR12C(0)N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
18 18A 18 A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22,
NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
23 23A 23A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R24 is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R .25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; z s R26 or R27;
Z2 is R28, R29 or R30;
Z1A and Z2A are both absent or are taken together to form CH2, CH2CH2 or r l2A.
Z is C2-C6-alkylene having one or two CH2 moieties replaced by NH,
N(CH3), S, S(O) or S02;
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R37, OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH, S02NHR37, C(N)NH, or C(N)NHR37;
R26 is phenylene, which is unfused or fused with R26A; R26A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 27 is heteroarylene, which is unfused or fused with R 27A ; R 27A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or
heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R 37B , OR 37B , SR 37B , S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2, NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B,
NHC(0)OR37B, NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; Z3 is R38, R39 or R40;
R 38 is phenyl, which is unfused or fused with R 38A ; R 38 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R40A; R40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the moieties represented by R26 and R27 are substituted (i.e., if Z1A and Z2A are absent) or further substituted (i.e., if Z1A and Z2A are present) with R41, OR41 , SR41, S(0)R41, S02R41, C(0)R41, CO(0)R41, OC(0)R41, OC(0)OR41, NHR41, N(R41)2, NHC(0)R41, NR41C(0)R41, NHS(0)2R41, NR41S(0)2R41, NHC(0)OR41, NR41C(0)OR41, NHC(0)NHR41, NHC(0)N(R41)2, NR41C(0)NHR41,
NR41C(0)N(R41)2, C(0)NHR41, C(0)N(R41)2, C(0)NHOR41, C(0)NHS02R41, C(0)NR41S02R41, S02NHR41, S02N(R41)2, C(N)NHR41, or C(N)N(R41)2;
R41 is heteroaryl, which is fused with R43A; R43A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; which is unfused or fused with benzene, heteroarene or R43B; R43B is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6,
D 6C D 8 8A D D 9A D 10 D 10A D 13 D 13A D 14 D 14A D 1 5 D 15A D 18 D 18A D 19 D 19A , , , , , , , , , , , , , , , , , 20 D 20A D 23 D 23A D 24 D 24A D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A , , , , , , , , , , , , , , , ,
R30, R30A, R37B, R38, R38A, R39, R39A, R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57,
NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57, C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R57A is spiroalkyl, or spiroheteroalkyl; R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62, NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62,
NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NR62S02R62, S02NH2, S02NHR62, S02N(R62)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R65 is cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67,
NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67, S02N(R67)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
wherein the cyclic moieties represented by R57A, R58, R59, R60, R63, R64, R65, and R67 are unsubstituted or substituted with one or two or three or four of independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68,
NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2,
NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68, NR68C(0)N(R68)2, C(0)NH2, C(0)NHR68, C(0)N(R68)2, C(0)NHOH, C(0)NHOR68, C(0)NHS02R68,
C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72;
R69 is phenyl, which is unfused or fused with R69A; R69A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73 C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73, NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73,
NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73) C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH: C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
2. A compound having Formula (II)
Figure imgf000677_0001
or a therapeutically acceptable salt thereof, wherein
R is as described for substituents on
n is 0, 1, 2, or 3;
A1 is N or C(A2);
NHR1, N(R1)2,
NR1C(
Figure imgf000677_0002
1, NR1C(0)N(R1)2, SO2NH2, SO2NHR1, SOzNiR^z, NHSO2R1, NR^OzR1,
NHSO2NHR1, NHS02N(R1)2, NR1S02NHR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1, C(0)NHS02R1, C(NH)NH2,
Figure imgf000677_0003
C(NH)N(R1)2
NHSO2NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
NR1C(
Figure imgf000677_0004
1, NR1C(0)N(R1)2, SO2NH2, SO2NHR1, SOzNiR^z, NHSO2R1, NR^OzR1,
NHSO2NHR1, NHS02N(R1)2, NR1S02NHR1, NR1S02N(R1)2, C(0)NHNOH, C(0)NHNOR1, C(0)NHS02R1, C(NH)NH2,
Figure imgf000677_0005
C(NH)N(R1)2
NHSO2NHR1, NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; NHR1, N(R1)2,
Figure imgf000678_0001
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1,
NR1S02R1,
, C(0)NHNOH,
Figure imgf000678_0002
NH)N(R1)2
Figure imgf000678_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
NHR1, N(R1)2,
Figure imgf000678_0004
NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1, NHC(0)N(R1)2, NR1C(0)NHR1,
NR1S02R1,
, C(0)NHNOH,
Figure imgf000678_0005
NH)N(R1)2
Figure imgf000678_0006
NHS02N(CH3)R1,_N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02 N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; and
Y1 is H, CN, N02, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)OR17, SR17, S02R17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 or NHS02R17; or
E1 and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000678_0007
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^, NHSOzR1,
C(0)NHN
Figure imgf000678_0008
C(NH)N(R1)2
Figure imgf000678_0009
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
Y1 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000679_0001
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SO^HR1, SO^R1^,
Figure imgf000679_0002
C(0)NHNOH, C(0)NHNOR1, C(0)NHS02R1, C(NH)NH2, C(NH)NHR1,
C(NH)N(R1)2
Figure imgf000679_0003
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000679_0004
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SO^HR1, SO^R1^,
Figure imgf000679_0005
C(NH)N(R1)2
Figure imgf000679_0006
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A; or
A2 and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and
Figure imgf000679_0007
NR1C(0)R1, NHC(0)OR1, NR1C(0)OR1, NHC(0)NH2, NHC(0)NHR1,
NHC(0)N(R1)2, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NH2, SOzNHR1, SO^R1^,
Figure imgf000679_0008
C(NH)N(R1)2
Figure imgf000679_0009
NHS02N(CH3)R1, N(CH3)S02N(CH3)R1, F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR1A;
R1 is R2, R3, R4 or R5; R is cycloalkyl, cycloalkenyl or cycloalkynyl;
R2 is phenyl, which is unfused or fused with R2A; R2A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R3 is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, C(0)N(R7)2,
NHC(0)R7, NR7C(0)R7, NHS02R7, NHC(0)OR7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,
NHC(0)CH(CH3)NHC(0)CH(CH3)NHR7, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I;
R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2;
R6A and R6B are independently selected alkyl or, together with the N to which they are attached, R6C;
R6C is aziridin- 1 -yl, azetidin- 1 -yl, pyrrolidin- 1 -yl or piperidin- 1 -yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), S02 or NH;
R7 is R8, R9, R10 or Ru;
8 8A 8A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R9 is heteroaryl, which is unfused or fused with R9A; R9A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R10 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R10A; R10A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R12, OR12, SR12, S(0)R12, S02R12, C(0)R12, CO(0)R12, OC(0)R12, OC(0)OR12, NH2, NHR12, N(R12)2, NHC(0)R12, NR12C(0)R12, NHS(0)2R12, NR12S(0)2R12, NHC(0)OR12, NR12C(0)OR12, NHC(0)NH2, NHC(0)NHR , NHC(0)N(R1 )2, NR1 C(0)NHR , NR1 C(0)N(R1 )2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, C(0)NHOH, C(0)NHOR12, C(0)NHS02R12, C(0)NR12S02R12, S02NH2, S02NHR12, S02N(R12)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R12 is R13, R14, R15 or R16;
R13 is phenyl, which is unfused or fused with R13A; R13A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R14 is heteroaryl, which is unfused or fused with R14A; R14A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R15 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R16 is alkyl, alkenyl or alkynyl;
R17 is R18, R19, R20 or R21;
R 18 is phenyl, which is unfused or fused with R 18A ; R 18 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R19 is heteroaryl, which is unfused or fused with R19A; R19A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R20 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with R20A; R20A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R22, OR22, SR22, S(0)R22, S02R22, C(0)R22, CO(0)R22, OC(0)R22, OC(0)OR22, NH2, NHR22, N(R22)2, NHC(0)R22, NR22C(0)R22, NHS(0)2R22, NR22S(0)2R22, NHC(0)OR22, NR22C(0)OR22,
NHC(0)NH2, NHC(0)NHR22, NHC(0)N(R22)2, NR22C(0)NHR22, NR22C(0)N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, C(0)NHOH, C(0)NHOR22, C(0)NHS02R22, C(0)NR22S02R22, S02NH2, S02NHR22, S02N(R22)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R22 is R23, R24 or R25;
R 23 is phenyl, which is unfused or fused with R 23A ; R 23A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is heteroarene, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R25 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R25A; R25A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
Z2 is R28, R29 or R30;
37
L1 is a R37, OR37, SR37, S(0)R37, S02R37, C(0)R37, CO(0)R37, OC(0)R OC(0)OR37, NHR37, C(0)NH, C(0)NR37, C(0)NHOR37, C(0)NHS02R37, S02NH, S02NHR37, C(N)NH, or C(N)NHR37;
R 28 is phenylene, which is unfused or fused with R 28 A ; R 28A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R29 is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R30 is cycloalkylene, cycloalkenylene, heterocycloalkylene or
heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R37 is a bond or R37A;
R37Ais alkylene, alkenylene, or alkynylene, each of which is unsubstituted or
37B 37B 37B substituted with one or two or three independently selected R , OR , SR , S(0)R37B, S02R37B, C(0)R37B, CO(0)R37B, OC(0)R37B, OC(0)OR37B, NH2, NHR37B, N(R37B)2, NHC(0)R37B, NR37BC(0)R37B, NHS(0)2R37B, NR37BS(0)2R37B,
NHC(0)OR37B, NR37BC(0)OR37B, NHC(0)NH2, NHC(0)NHR37B, NHC(0)N(R37B)2, NR37BC(0)NHR37B, NR37BC(0)N(R37B)2, C(0)NH2, C(0)NHR37B, C(0)N(R37B)2, C(0)NHOH, C(0)NHOR37B, C(0)NHS02R37B, C(0)NR37BS02R37B, S02NH2, S02NHR37B, S02N(R37B)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents;
R37B is alkyl, alkenyl, alkynyl, or R37C;
R is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;
Z3 is R38, R39 or R40;
38 38A 38 A
R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R39 is heteroaryl, which is unfused or fused with R39A; R39A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R40 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R40A; R40A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
wherein the cyclic moieties represented by E1 and Y1 together, Y1 and B1 together, A2 and B1 together, A2 and D1 together, R1A, R2, R2A, R3, R3A, R4, R4A, R6,
D 6C D 8 8A D 9A D 10 D 10A D 13 D 13A D 14 D 14A D 15 D 15A D 18 D 18A D 19 D 19A , , , , , , , , , , , , , , , , ,
Tj 20 D 20A D 23 D 23A D 24 D 24A D 25 D 25A D 26 D 26A D 27 D 27A D 28 D 28A D 29 D 29A , , , , , , , , , , , , , , , , R30, R30A, R37B, R38, R38A, R39, R39A, R40,and R40A are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R57A, R57, OR57, SR57, S(0)R57, S02R57, C(0)R57, CO(0)R57, OC(0)R57, OC(0)OR57, NH2, NHR57, N(R57)2, NHC(0)R57, NR57C(0)R57, NHS(0)2R57, NR57S(0)2R57, NHC(0)OR57, NR57C(0)OR57,
NHC(0)NH2, NHC(0)NHR57, NHC(0)N(R57)2, NR57C(0)NHR57, NR57C(0)N(R57)2, C(0)NH2, C(0)NHR57, C(0)N(R57)2, C(0)NHOH, C(0)NHOR57, C(0)NHS02R57, C(0)NR57S02R57, S02NH2, S02NHR57, S02N(R57)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R57A is spiroalkyl or heterospiroalkyl;
R57 is R58, R59, R60 or R61;
R 58 is phenyl, which is unfused or fused with R 58A ; R 58 A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R59 is heteroaryl, which is unfused or fused with R59A; R59A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R60 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R60A; R60A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R61 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R62, OR62, SR62, S(0)R62, S02R62, C(0)R62, CO(0)R62, OC(0)R62, OC(0)OR62, NH2, NHR62, N(R62)2, NHC(0)R62, NR62C(0)R62, NHS(0)2R62, NR62S(0)2R62, NHC(0)OR62, NR62C(0)OR62,
NHC(0)NH2, NHC(0)NHR62, NHC(0)N(R62)2, NR62C(0)NHR62, NR62C(0)N(R62)2, C(0)NH2, C(0)NHR62, C(0)N(R62)2, C(0)NHOH, C(0)NHOR62, C(0)NHS02R62, C(0)NRb S02R , S02NH2, S02NHR , S02N(R<")2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R62 is R63, R64, R65 or R66;
R63 is phenyl, which is unfused or fused with R63A; R63A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R64 is heteroaryl, which is unfused or fused with R64A; R64A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R65 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R65A; R65A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R66 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R67, OR67, SR67, S(0)R67, S02R67, C(0)R67, CO(0)R67, OC(0)R67, OC(0)OR67, NH2, NHR67, N(R67)2, NHC(0)R67, NR67C(0)R67, NHS(0)2R67, NR67S(0)2R67, NHC(0)OR67, NR67C(0)OR67,
NHC(0)NH2, NHC(0)NHR67, NHC(0)N(R67)2, NR67C(0)NHR67, NR67C(0)N(R67)2, C(0)NH2, C(0)NHR67, C(0)N(R67)2, C(0)NHOH, C(0)NHOR67, C(0)NHS02R67, C(0)NR67S02R67, S02NH2, S02NHR67, S02N(R67)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents;
R67 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;
wherein the cyclic moieties represented by R57A, R58, R59, R60, R63, R64, R65, and R67 are unsubstituted or substituted with one or two or three or four of
independently selected R68, OR68, SR68, S(0)R68, S02R68, C(0)R68, CO(0)R68, OC(0)R68, OC(0)OR68, NH2, NHR68, N(R68)2, NHC(0)R68, NR68C(0)R68,
NHS(0)2R68, NR68S(0)2R68, NHC(0)OR68, NR68C(0)OR68, NHC(0)NH2,
NHC(0)NHR68, NHC(0)N(R68)2, NR68C(0)NHR68, NR68C(0)N(R68)2, C(0)NH2, C(0)NHR68, C(0)N(R68)2, C(0)NHOH, C(0)NHOR68, C(0)NHS02R68,
C(0)NR68S02R68, S02NH2, S02NHR68, S02N(R68)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R68 is R69, R70, R71 or R72; R is phenyl, which is unfused or fused with R ; R is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R70 is heteroaryl, which is unfused or fused with R70A; R70A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R71 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R71A; R71A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
R72 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R73, OR73, SR73, S(0)R73, S02R73, C(0)R73, CO(0)R73, OC(0)R73, OC(0)OR73, NH2, NHR73, N(R73)2, NHC(0)R73, NR73C(0)R73, NHS(0)2R73, NR73S(0)2R73, NHC(0)OR73, NR73C(0)OR73,
NHC(0)NH2, NHC(0)NHR73, NHC(0)N(R73)2, NR73C(0)NHR73, NR73C(0)N(R73)2, C(0)NH2, C(0)NHR73, C(0)N(R73)2, C(0)NHOH, C(0)NHOR73, C(0)NHS02R73, C(0)NR73S02R73, S02NH2, S02NHR73, S02N(R73)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I;
R73 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and
wherein the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, S02NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I.
The compound of claim 1 , wherein
G1 is H;
A1 is N or C(A2); and
A2 is H.
The compound of claim 1 , wherein
G1 is H;
A1 is N or C(A2);
A2 is H; and
B1 is NHR1.
5. The compound of claim 1, wherein
G1 is H;
A1 is N or C(A2);
A2 is H;
B1 is NHR1; and
D1 is H.
The compound of claim 1 , wherein
G1 is H;
A1 is N or C(A2);
A2 is H;
B1 is NHR1;
D1 is H; and
E1 is H.
The compound of claim 1 , wherein
G1 is H;
A1 is N or C(A2);
A2 is H;
B1 is NHR1;
D1 is H;
E1 is H; and
Y1 is N02. 8. A compound of claim 1 or claim 2, wherein the compound is chosen from:
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4- {4-[(4'-chloro- 1 , 1 '-biphenyl-2-yl)methyl]piperazin- 1 -y 1 } -N-( {4-[(3 -morpholin-4- ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(4-methylpiperazin- 1 -yl)amino]-3-nitrophenyl} sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(3R)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- (2-naphthylsulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-
3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;
4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl} sulfonyl)-2-(l H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-
3- yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4- ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl} piperazin- 1 -yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [4- [(tetrahydro- 2H-pyran-4-ylmethyl)amino] -3 -(trifluoromethyl)phenyl] sulfonyl} benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; Trans-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin- 1 -yl)-N-( {4-[(l -methylpiperidin-4-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
5-({[4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 - yl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] amino } sulfonyl)-2-(tetrahydro-2H- pyran-4-ylmethoxy Nicotinamide;
N-({5-bromo-6-[(l-methylpiperidin-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-{[5-bromo-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-5-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [5 -cyano-6-(2-morpholin-4-ylethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-( {5 -bromo-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3 - yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3- nitrophenyl] sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [( 1 -methylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(morpholin-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-methylpiperazin-l -yl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Cis-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yljmethyl} piperazin- 1 -yl)-N- [(4- { [(4-methoxycyclohexyl)methyl]amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({4-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N- [(4- { [(4-methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
tert-butyl 3 - { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(morpholin-3 -ylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4-{[8-(4-chlorophenyl)spiro[4.5]dec-7-en-7-yl]methyl}piperazin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(4- { [ 1 -(methylsulfonyl)piperidin-4-yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
( {4-[( 1 , 1 -dioxidotetrahydro-2H-thiopyran-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [ 1 -(2,2,2-trifluoroethyl)piperidin-4-yl] amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {5-cyano-6-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-isopropyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
and therapeutically acceptable salts, and metabolites thereof. 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl} amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yl
oxy)benzamide;
N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [ 1 -(2,2-difluoroethyl)piperidin-4-yl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[( 1 -eye lopropylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [( 1 -morpholin-4-ylcyclohexyl)methyl]amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(dicyclopropylamino)cyclohexyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-6,6-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-bromo-6-[(4-ethylmorpholin-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(4-ethylmorpholin-3 -yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3-nitro-4-[(4-tetrahydro-2H-pyran-4-ylmorpholin-3-yl)methoxy]phenyl} sulfonyl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpiperidin-3 -yljamino } phenyl)sulfonyl]- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[( 1 , 1 -dioxidothiomorpholin-4-yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N-({5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [( 1 S ,3R)-3 -morpholin-4-ylcyclopentyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(lR,3S)-3-morpholin-4-ylcyclopentyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(morpholin-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3 -nitro-4- [(tetrahydrofuran-3 -ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-( { 1 -[cis-3-fluorotetrahydro-2H-pyran-4-yl]piperidin-4-yl} amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3 -nitro-4- [( 1 -tetrahydro-2H-pyran-4-ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3 -nitro-4- [( 1 -tetrahydrofuran-3 -ylazetidin-3 -yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(4-((trans-4- hydroxycyclohexyl)methoxy)-3-nitrophenylsulfonyl)benzamide;
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -enyl)methyl)piperazin- 1 -yl)-N-(4-((cis-4- methoxycyclohexyl)methoxy)-3 -nitrophenylsulfonyl)benzamide;
Cis-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 - yl)-N- [(4- { [4-(cyclopropylamino)cyclohexyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N- [(3 -nitro-4- {[4-(tetrahy dro-2H-pyran-4- ylamino)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
Trans-N-({5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
tert-butyl 4- { [4-( { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] amino} sulfonyl)-2-nitrophenoxy]methyl} -4-fluoropiperidine- 1 - carboxylate; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(4-tetrahydro-2H-pyran-4-ylpiperazin- 1 - yl)cyclohexyl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(3 -nitro-4- { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- {[(3R)- 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl] amino } phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3 S)- 1 -(2,2-dimethy ltetrahydro-2H-pyran-4-yl)pyrrolidin-3 -y 1] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[4-(2-methoxyethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [trans-4-(fluoromethyl)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethoxy } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-cyclobutylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [ 1 -(2,2-dimethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(3S)-l-cyclopropylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3 -nitro-4- [( 1 -tetrahydrofuran-3 -ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(3R)-l-cyclopropylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [(3 S)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [ 1 -(methylsulfonyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpiperidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-3 ,3-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { 1 - [2-fluoro- 1 -(fluoromethyl)ethyl] azetidin-3 -yl} amino)-3 - nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-ylo
xy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [ 1 -(methylsulfonyl)pyrrolidin-3 -yljmethyl} amino)-3 -nitropheny 1] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N- [(4- { [( 1 -acetylpyrrolidin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4-(4- { [2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(4-{[(3R)-l-acetylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [( 1 R,3R)-3 -hydroxy eye lopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [( 1 S ,3 S)-3 -hydroxy eye lopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[(lS,3R)-3-hydroxycyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [( 1 R,3 S)-3 -hydroxy cyclopentyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]azetidin-3-yl}methyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [( 1 -oxetan-3 -ylazetidin-3 -yl)methyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [( 1 -oxetan-3 -ylpiperidin-4-yl)methyl]amino } phenyl)sulfonyl]-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [( 1 -cyclopropylpiperidin-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [4-(2-fiuoroethyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({4-[(4-fluoro-l-oxetan-3-ylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(4- {[(2S)-4,4-difiuoro- 1 -oxetan-3-ylpyrrolidin-2-yl]methoxy} -3- nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(3 -nitro-4- { [(4-tetrahydro-2H-pyran-4-ylmorpholin-3 - yl)methyl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
[(4- { [(4-cyclobutylmorpholin-3 -yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(4-tetrahydrofuran-3 -ylmorpholin-3 -yl)methyl] amino } phenyl)sulfonyl] - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[( { 1 -[2-fluoro- 1 -(fluoromethyl)ethyl]piperidin-4-yl}methyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [3 -(trifluoromethoxy)benzyl] amino } phenyl)sulfonyl]-2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(3 -methoxybenzyl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(difluoromethoxy)benzyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-(l,4-dioxaspiro[4.5]dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
Trans-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3 S)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(3S)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3R)- 1 -(2-fluoroethyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]methoxy}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [3 -(difluoromethoxy)benzyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[cis-3-morpholin-4-ylcyclopentyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-( {4-[(methylsulfonyl)amino]cyclohexyl} amino)-3-nitrophenyl]sulfonyl} - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-cyclopropylpiperidin-4-yl)amino]-3-
[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(l-oxetan-3-ylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(4-fluoro- 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)methoxy]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(4-fluoro- 1 -tetrahydrofuran-3-ylpiperidin-4-yl)methoxy]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- {[4-fluoro-l-(methylsulfonyl)piperidin-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3-nitro-4-( {[(3R)- 1 -oxetan-3-ylpyrrolidin-3-yl]methyl} amino)phenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( {4- [3 -(dimethylamino)propoxy]benzyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(2-morpholin-4-ylethoxy)benzyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [(E)-4-hydroxy- 1 -adamantyljmethyl} amino)-3-nitrophenyl]sulfonyl} -2-(l H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [(2 )-4-hydroxy- 1 -adamantyljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({4-[(l S,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[( 1 -methyl-5 -oxopyrrolidin-3 -yl)amino] -3 -nitrophenyl} sulfonyl)-2-( 1 H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- {[(lR,4R,5R,6S)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3- nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(lR,4R,5S,6R)-5,6-dihydroxybicyclo[2.2.1]hept-2-yl]methoxy}-3- nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexa-l,3-dien-l-yl]methyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3- yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [(3 S)- 1 -oxetan-3 -ylpyrrolidin-3 -yljmethyl} amino)phenyl] sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Cis-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[(3S)-l-oxetan-3-ylpyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3- nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2 ,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [4-(N,N-dimethylglycyl)morpholin-2-yl]methyl} amino)-3 - nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
(2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}- 2-nitrophenyl)amino]methyl}morpholin-4-yl)acetic acid;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [4-(oxetan-3 -yl)morpholin-2-yl]methyl} amino)phenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-(methylsulfonyl)-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
ethyl 4-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}- 2-nitrophenyl)piperazine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[4-(morpholin-4-yl)piperidin-l-yl]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[(3R)-l-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]amino} -3- [(trifluoromethyl)sulfonyl]phenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(l-isopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [ 1 -(2-methoxyethyl)piperidin-3-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [ 1 -(cyanomethyl)piperidin-3 -yljmethyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy] -3 -
[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N- [(5 -chloro-6- { [(3R)- 1 -( 1 ,3 -difluoropropan-2-yl)pyrrolidin-3 -yl] amino } pyridin-3 - yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
tert-butyl 4-[(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-
2-nitrophenyl)amino]piperazine- 1 -carboxylate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({3-(pentafluoro- 6-sulfanyl)-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- {[(3R)- 1 -(1 ,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy} -3-nitrophenyl)sulfonyl]- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[4-(oxetan-3-yl)piperazin-l-yl]amino}phenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [4-(tetrahydro-2H-pyran-4-yl)piperazin- 1 -yljamino } phenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {3 -nitro-4- [(3R)-tetrahydrofuran-3 -ylamino]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4,4-difluorocyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({4-[(l-tert-butylpiperidin-4-yl)amino]-3-
[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin-l -yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ( {4-( { [4-(oxetan-3 -yl)morpholin-2-yl]methyl} amino)-3 - [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide;
N- [(5 -chloro-6- { [(4-fluorotetrahydro-2H-pyran-4-yl)methy 1] amino } pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[(2R)-4-(N ,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-( {5 -chloro-6- [3 -hydroxy-2-(hydroxymethy l)-2-methylpropoxy]pyridin-3 - yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[4-(l,3-difluoropropan-2-yl)morpholin-2-yl]methyl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({(3R)-l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3R)- 1 -(N,N-dimethylglycyl)pyrrolidin-3 -y 1] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-nitro-4-{[l-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[1 -(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl} amino)-3 - nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methyl} amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(3R)-l-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidin-l-yl}-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[9-(4-chlorophenyl)-3-(l,3-difluoropropan-2-yl)-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4- ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8- yljmethyl} piperazin- 1 -yl)-N- { [5 -chloro-6-(tetrahydro-2H-pyran-4- ylmethoxy)pyridin-3 -yl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-( {5-chloro-6-[(4-fluoro- 1 -methylpipe
(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin-l-yl}-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4- {4-[(4'-chlorobiphenyl-2-yl)methyl]-4-fluoropiperidin- 1 -yl} -N-({5-chloro-6-[(4- fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl} sulfonyl)benzamide;
N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(trans-4-cyanocy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-cyano-6-[2-(tetrahydro-2H-pyran-4-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-(3 -furylmethoxy)-3 -nitrophenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-( {3-chloro-4-[(4-fluoro- 1 -methylpiperidin-4-yl)methoxy]phenyl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3-cyano-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[6- {[ 1 -(1 ,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl]methoxy} -5- (trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} -3- methylpiperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [3 -(cyclopropylamino)propyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(methoxyacetyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(N,N-dimethylglycyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [6-(tetrahydro-2H-pyran-4-ylmethoxy)-5 - (trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;
N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({6-[(trans-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3- yl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({6-[(cis-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-
2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-({5-chloro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[trans-4-(morpholin-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclopropyl(l,3-thiazol-5-ylmethyl)amino]propyl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-chloro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-
(trifluoromethyl)phenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(3-chloro-4-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-
(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-
({3,5-difluoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-
( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[l-(l-methyl-L-prolyl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3,4-difluoro-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperidin- 1 -yl)-N- {[3-chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
methyl 2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcy clohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}- 2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;
2- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-
2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -chloro-4-(tetrahydrofuran-3 -ylmethoxy)phenyl] sulfonyl} -2-( 1 H-pyrrolo [2,3 - b]pyridin-5 -yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-5 ,5 -difluorocyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl]-2-( 1H- pyrrolo [2,3 -£]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4- {[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-en-8- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[(2R)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-({3-nitro- 4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide;
N- {[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3- yl] sulfonyl} -4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[5-(4-chlorophenyl)spiro[2.5]oct-5-en-6-yl]methyl}piperazin-l-yl)-N-[(4-{[(4- cyclopropylmorpholin-2-yl)methyl]amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(4-cyclopropylmorpholin-2-yl)methoxy]phenyl}sulfonyl)-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(3-chloro-4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
2- { [(2-chloro-4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] sulfamoyl } phenyl)amino]methyl} -N-ethyl-N-methylmorpholine-4- carboxamide;
(2S)-2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}pyridin-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholine-4- carboxamide;
N- [(5 -chloro-6- { [(4-cyclopropylmorpholin-2-yl)methyl] amino } pyridin-3 - yl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
2- { [(3 -chloro-5 - { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] sulfamoyl } pyridin-2-yl)amino]methyl} -N-ethyl-N-methylmorpholine- 4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitropheny l)sulfonyl] -2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [5 -(4-chlorophenyl)spiro [2.5 ]oct-5 -en-6-yl]methyl} piperazin- 1 - yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[5-chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3- yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3- yl)sulfonyl] -4-(4- { [5 -(4-chlorophenyl)spiro [2.5 ]oct-5 -en-6-yl]methyl} piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [4-(3 ,3 -difluoropyrrolidin- 1 -yl)cyclohexyl]amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({4-[(2,2-difluorocyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)- 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3-nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 ,5 -bis(fluoromethyl)cyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-cyclopropylmorpholin-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3-cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(trans-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(cis-4-ethyl-4-hydroxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl}amino)phenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-({3-chloro-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-l-fluorocyclohexyl}methoxy)-3- nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({5-nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(4-cyano-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzoyl] ( {4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]-3-nitrophenyl} sulfonyl)amino} methyl pivalate;
{ [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]({4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]-3-nitrophenyl} sulfonyl)amino} methyl butyrate;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)-N-{[3-(tetrahydro-2H-pyran-4-ylmethyl)-3H- [l,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(6- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -5 -nitropyridin-3 - yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(5-cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)morpholine-4-carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [4-( { [4-(methoxymethyl)cyclohexyl]methyl} amino)-3 -nitrophenyl] sulfonyl} -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(5-chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -5 -nitropyridin-3 - yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 - nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide; methyl trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}- 2-nitrophenyl)amino]methyl}cyclohexanecarboxylate;
trans-4- { [(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-
2- nitrophenyl)amino]methyl} cyclohexanecarboxylic acid;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4- cyanopiperidine- 1 -carboxamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[cis-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({[trans-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}- 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H- benzotriazol-5-yl]sulfonyl}benzamide;
N-({5-chloro-6-[(2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(4- { [4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4- methoxypiperidine- 1 -carboxamide;
N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-l,3-benzothiazol-5-yl)methoxy]pyridin-
3- yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)-N- { [ 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H- pyrrolo[2,3-b]pyridin-5-yl]sulfonyl}benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -chloro- 1 -(tetrahydro-2H-pyran-4-ylmethyl)- 1 H-pyrrolo [2,3 -b]pyridin-5 - yl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N-[(4-{[4,4-bis(hydroxymethyl)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)-4-methoxypiperidine-l-carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl]sulfamoyl}phenyl)-4-cyanopiperidine-l-carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] sulfamoyl } phenyl)-4-hydroxy-4-methylpiperidine- 1 -carboxamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] sulfamoyl } phenyl)-4-(methoxymethyl)piperidine- 1 -carboxamide; N-[(5-chloro-6-{[(5r,8r)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[(5s,8s)-2-oxo-l-oxa-3-azaspiro[4.5]dec-8-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-(2-chloro-4- { [4-(4- { [2-(4-chloropheny l)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzoyl] sulfamoyl } phenyl)-4-(morpholin-4-yl)piperidine- 1 -carboxamide; N- [(5 -chloro-6- { [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(5 -chloro-6- { [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]methoxy } pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N- [(5 -chloro-6- {[4-fluoro-l -(oxetan-3-yl)piperidin-4-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- {[2-(4-chlorophenyl)cyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3- b]pyridin-5 -yloxy)benzamide;
4-(4-chlorophenyl)-l-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)carbamoyl] -3 -( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)phenyl} piperazin- 1 -yl)methyl] cyclohex-3 -ene- 1 -carboxylic acid;
N-[(5-chloro-6-{[l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-(lH- pyrrolo[2,3-£]pyridin-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites thereof.
9. The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
10. The compound Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide or a pharmaceutically acceptable salt thereof.
11. The compound Cis-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(4-methoxycyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
12. The compound Trans-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-[(4- { [(4- methoxycyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
13. The compound 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
14. The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(trans-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
15. The compound 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
16. The compound N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-
1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2-( 1 H-pyrrolo[2,3 -b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
17. The compound N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin- 4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
18. The compound 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- {[(3R)- 1 -(methylsulfonyl)pyrro lidin-3-yl] amino } -
3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
19. The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [4-( {3 - [cyclopropyl(oxetan-3 - yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;or a pharmaceutically acceptable salt thereof.
20. The compound 4-(4-{[2-(4-chlorophenyl)-5-methoxy-5- methylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
21. A compound of claim 1 or claim 2, wherein the compound is chosen from:
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N- [(4- { [(3R)- 1 - (methylsulfonyl)pyrrolidin-3 -yljamino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [4-( {3 - [cyclopropyl(oxetan-3 - yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
22. A compound of claim 1 or claim 2, wherein the compound is chosen from:
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
23. A compound of claim 1 or claim 2, wherein the compound is chosen from: 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(trans-4-hydroxy-4-methylcyclohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] - 2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N-[(4- { [(cis-4-hydroxy-4- methy Icy clohexyl)methyl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H-pyrrolo [2,3 - b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.
24. The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1 -yljmethyl} piperazin- 1 -yl)-N- { [4-( {3 - [cyclopropyl(oxetan-3 - yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamide;
or a pharmaceutically acceptable salt thereof.
25. A compound of claim 1 or claim 2, wherein the compound is chosen from:
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yljmethyl} amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
26. A compound of claim 1 or claim 2, wherein the compound is chosen from:
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(3 -nitro-4- { [(3 S)-tetrahydro-2H-pyran-3 -ylmethyl] amino } phenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin- 5 -yloxy)benzamide;
N-( {5 -bromo-6- [( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3 - yl} sulfonyl)-4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 - yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- { [3 -nitro-4-( { [(3R)- 1 -tetrahydro-2H-pyran-4-ylpyrrolidin-3 - yl]methyl}amino)phenyl]sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(4- { [(3R)- 1 -(methylsulfonyl)pyrrolidin-3 -yl] amino } -3 -nitrophenyl)sulfonyl] -2-( 1 H- pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- ({4-[(4-methoxytetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- {[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2- ( 1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
N-[(5-chloro-6-{[(lR,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-N- [(6- { [(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino } -5 -nitropyridin-3 - yl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;
4-(4- { [2-(4-chlorophenyl)-5 -methoxy-5 -methylcyclohex- 1 -en- 1 -yljmethyl} piperazin- l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- (1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy)benzamide;
or a pharmaceutically acceptable salt thereof.
27. The compound N-[(5-chloro-6-{[l-(cyanomethyl)piperidin-4- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; or a pharmaceutically acceptable salt thereof.
28. A compound of claim 1 or claim 2, wherein the compound is chosen from:
N- [(4- { [(4-aminotetrahydro-2H-pyran-4-yl)methyl] amino } -3 -nitrophenyl)sulfonyl] -4- (4- { [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- 1 -yl]methyl}piperazin- 1 -yl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1 -en- 1 -yljmethyl} piperazin- 1 -yl)-N-( {4- [(4-methoxytetrahydro- 2H-pyran-4-yl)methoxy] -3 -nitrophenyl} sulfonyl)-2-( 1 H-pyrrolo [2,3 -b]pyridin-5 - yloxy)benzamide; or a pharmaceutically acceptable salt thereof. 29. The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(4-methoxytetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof. 30. A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma,
myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a
therapeutically effective amount of a compound of claim 1 or claim 2.
31. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic
lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a
therapeutically effective amount of a compound of claim lor claim 2.
32. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic
lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient
therapeutically effective amount of the compound of claim 1 or claim 2 and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
PCT/US2010/057587 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases WO2011149492A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
MX2012013708A MX350726B (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
EP10784398.9A EP2576546B1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES10784398.9T ES2546135T3 (en) 2010-05-26 2010-11-22 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
DK10784398.9T DK2576546T3 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SI201031000T SI2576546T1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2012156844/04A RU2554346C2 (en) 2010-05-26 2010-11-22 Apoptosis-inducing medications for treating cancer and immune and autoimmune diseases
PL10784398T PL2576546T3 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR1020127033726A KR101725114B1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UAA201214904A UA107706C2 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG2012084745A SG185638A1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
BR112012029923A BR112012029923A2 (en) 2010-05-26 2010-11-22 apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ603463A NZ603463A (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2799280A CA2799280A1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2010354083A AU2010354083B2 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MEP-2015-156A ME02215B (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN201080068177.5A CN103153993B (en) 2010-05-26 2010-11-22 The apoptosis induction medicament for the treatment of cancer and immunity and autoimmune disease
RS20150643A RS54289B1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2013512589A JP5667695B2 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL223070A IL223070A (en) 2010-05-26 2012-11-15 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ZA2012/08832A ZA201208832B (en) 2010-05-26 2012-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HK13111276.7A HK1183866A1 (en) 2010-05-26 2013-10-03 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HRP20150925TT HRP20150925T1 (en) 2010-05-26 2015-09-03 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SM201600015T SMT201600015B (en) 2010-05-26 2016-01-15 APOPTOSE INDUCING AGENTS FOR CANCER AND IMMUNE AND AUTOIMMUNE DISEASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/787,682 US8546399B2 (en) 2009-05-26 2010-05-26 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US12/787,682 2010-05-26

Publications (1)

Publication Number Publication Date
WO2011149492A1 true WO2011149492A1 (en) 2011-12-01

Family

ID=43836533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/057587 WO2011149492A1 (en) 2010-05-26 2010-11-22 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Country Status (37)

Country Link
US (10) US8546399B2 (en)
EP (1) EP2576546B1 (en)
JP (1) JP5667695B2 (en)
KR (1) KR101725114B1 (en)
CN (1) CN103153993B (en)
AR (1) AR079124A1 (en)
AU (1) AU2010354083B2 (en)
BR (1) BR112012029923A2 (en)
CA (1) CA2799280A1 (en)
CL (1) CL2012003286A1 (en)
CO (1) CO6640274A2 (en)
CR (1) CR20120631A (en)
CY (1) CY1116728T1 (en)
DK (1) DK2576546T3 (en)
DO (1) DOP2012000297A (en)
EC (1) ECSP12012349A (en)
ES (1) ES2546135T3 (en)
GT (1) GT201200314A (en)
HK (1) HK1183866A1 (en)
HR (1) HRP20150925T1 (en)
IL (1) IL223070A (en)
ME (1) ME02215B (en)
MX (1) MX350726B (en)
MY (1) MY160994A (en)
NZ (1) NZ603463A (en)
PE (1) PE20131044A1 (en)
PL (1) PL2576546T3 (en)
PT (1) PT2576546E (en)
RS (1) RS54289B1 (en)
RU (1) RU2554346C2 (en)
SG (1) SG185638A1 (en)
SI (1) SI2576546T1 (en)
SM (1) SMT201600015B (en)
TW (1) TWI501966B (en)
UA (1) UA107706C2 (en)
WO (1) WO2011149492A1 (en)
ZA (1) ZA201208832B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580794B2 (en) 2009-05-26 2013-11-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9018381B2 (en) 2010-08-06 2015-04-28 Astrazeneca Ab Chemical compounds
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
JP2018138571A (en) * 2013-03-13 2018-09-06 アッヴィ・インコーポレイテッド Process for the preparation of apoptosis-inducing agent
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US10221174B2 (en) 2016-08-05 2019-03-05 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors
US10314920B2 (en) 2017-02-22 2019-06-11 Astrazeneca Ab Therapeutic dendrimers
WO2019210828A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 INHIBITORS
WO2020003272A1 (en) 2018-06-29 2020-01-02 Fresenius Kabi Oncology Ltd. An improved process for the preparation of venetoclax
WO2021009770A1 (en) * 2019-07-12 2021-01-21 Natco Pharma Limited A process for the preparation of venetoclax and its polymorphs thereof
WO2021074769A1 (en) 2019-10-14 2021-04-22 Astrazeneca Ab Combination therapy for treating a hematological malignancy
CN113727719A (en) * 2020-07-17 2021-11-30 德尔塔菲制药股份有限公司 Novel therapeutic method and novel therapeutic agent for leukemia
US11279711B2 (en) 2017-08-23 2022-03-22 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US11478470B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
RU2782469C2 (en) * 2017-04-18 2022-10-27 Шанхай Фокон Фармасьютикал Ко., Лтд. Apoptosis-inducing agents
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
IT202100025976A1 (en) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combination of active substances for the treatment of acute myeloid leukemia (AML) with nucleophosmin (NPM1) mutation
US11813260B1 (en) 2018-01-10 2023-11-14 Recurium Ip Holdings, Llc Benzamide compounds
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
RU2539587C2 (en) * 2009-01-19 2015-01-20 Эббви Инк. Apoptosis-inducing agents for treating cancer and immune and autoimmune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (en) * 2009-06-08 2016-07-01 亞培公司 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
JP5779591B2 (en) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド ABT-263 capsule
TWI520960B (en) 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CN103958508B (en) 2011-10-14 2019-02-12 艾伯维公司 For treating cancer and the immune cell death inducer with autoimmune disease
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
JP6408993B2 (en) 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド Type II anti-CD20 antibody and selective Bcl-2 inhibitor combination therapy
US9006438B2 (en) 2013-03-13 2015-04-14 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US20160168155A1 (en) 2013-07-30 2016-06-16 Gilead Connecticut, Inc. Polymorph of syk inhibitors
UY35898A (en) 2013-12-23 2015-07-31 Gilead Sciences Inc ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?.
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
JP6310144B2 (en) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド Combinations for treating cancer
PL3179991T3 (en) * 2014-08-11 2022-02-14 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
TW201639573A (en) 2015-02-03 2016-11-16 吉李德科學股份有限公司 Combination therapies for treating cancers
SI3319995T1 (en) 2015-07-07 2019-07-31 F. Hoffmann-La Roche Ag Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
CN108601839B (en) 2015-11-03 2021-10-26 基因泰克公司 Bcl-2 inhibitor and MEK inhibitor combination for the treatment of cancer
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
EP3426655A1 (en) 2016-03-10 2019-01-16 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
WO2018029711A2 (en) 2016-08-12 2018-02-15 Mylan Laboratories Limited Process for the preparation of venetoclax
WO2018041248A1 (en) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2 selective inhibitor and preparation and use thereof
US10800777B2 (en) 2016-10-14 2020-10-13 Mylan Laboratories Limited Polymorphic forms of VENCLEXTA
RS62036B1 (en) 2016-10-28 2021-07-30 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
WO2018200841A1 (en) * 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
HUE063119T2 (en) 2017-05-31 2024-01-28 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
EP3412666A1 (en) 2017-06-07 2018-12-12 Albany Molecular Research, Inc. Process and intermediates for the preparation of bcl-2 inhibitors including venetoclax through reductive amination
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
JP7374496B2 (en) * 2017-06-26 2023-11-07 深▲チェン▼市塔吉瑞生物医薬有限公司 N-benzenesulfonylbenzamide compounds, compositions and uses thereof for inhibiting Bcl-2 protein
KR20200031127A (en) * 2017-07-25 2020-03-23 헤파진 테라퓨틱스, 인크. Apoptosis protein dimer peptide inhibitor
CN115028640A (en) 2017-08-25 2022-09-09 吉利德科学公司 Polymorphic forms of a SYK inhibitor
WO2019135253A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Polymorphic forms of venetoclax
AU2019374142A1 (en) 2018-11-01 2021-05-27 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
TW202038958A (en) 2018-12-18 2020-11-01 比利時商阿根思公司 Cd70 combination therapy
JP2022521413A (en) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Solid form of condensed pyrazine as a SYK inhibitor
EP3705109A1 (en) 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
JP2022532519A (en) 2019-05-03 2022-07-15 モルフォシス・アーゲー Anti-CD19 therapy in patients with a limited number of NK cells
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
US20220339141A1 (en) 2019-09-18 2022-10-27 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
CN112661751A (en) * 2019-10-16 2021-04-16 南京天印健华医药科技有限公司 Heterocyclic compounds as BCL-2 inhibitors
KR20220103947A (en) 2019-10-21 2022-07-25 노파르티스 아게 Combination Therapy with Venetoclax and TIM-3 Inhibitors
BR112022007179A2 (en) 2019-10-21 2022-08-23 Novartis Ag TIM-3 INHIBITORS AND USES THEREOF
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
US20230183236A1 (en) 2020-04-10 2023-06-15 Abbvie Inc. Crystalline forms of an apoptosis-inducing agent
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic
CN113880834B (en) * 2020-07-01 2023-01-20 苏州亚盛药业有限公司 Synthesis method of N- (phenylsulfonyl) benzamide compound and intermediate thereof
CN114057728A (en) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 Heterocyclic compounds as BCL-2 inhibitors
AU2021334165A1 (en) 2020-08-29 2023-03-02 The Regents Of The University Of Colorado, A Body Corporate Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CA3211639A1 (en) * 2021-03-19 2022-09-22 Volodymyr KYSIL Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117616023A (en) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 BCL-2 or BCL-2/BCL-XL modulators and uses thereof
TW202345849A (en) 2022-03-04 2023-12-01 日商大塚製藥股份有限公司 Methods of treating cancer with iap antagonist compounds and combination therapies
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
WO2023215471A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215482A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2007002325A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
RU2387653C2 (en) * 2005-05-16 2010-04-27 Айрм Ллк Compounds and compositions as protein kinase inhibitors
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (en) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (IMIDAZOLYL-4) PIPERIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
CZ141795A3 (en) 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (en) 1995-09-15 2004-10-07 Upjohn Co AMINOARYL OXAZOLIDINONE N-OXIDES
WO1999018099A1 (en) 1997-10-03 1999-04-15 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CO5170498A1 (en) 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
MXPA02006474A (en) * 1999-12-28 2002-11-29 Eisai Co Ltd Heterocyclic compounds having sulfonamide groups.
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002237014A (en) 2001-02-09 2002-08-23 Tdk Corp Suspension, head gimbals assembly and method for manufacturing the head gimbals assembly
DE60213810T2 (en) 2001-06-06 2007-02-01 Eli Lilly And Co., Indianapolis BENZOYL SULPHONAMIDES AND SULPHONYL BENZIDIDES FOR USE AS ANTITUMOR AGENTS
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (en) 2002-03-11 2008-03-14 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
DE602004009344T2 (en) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad A NEW METHOD FOR THE PRODUCTION OF LINEZOLID AND RELATED COMPOUNDS
BRPI0511070A (en) * 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compounds and processes for inhibiting the interaction of bcl proteins with binding partners
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2006039164A2 (en) * 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
PT1888550E (en) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) * 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090105388A1 (en) * 2006-06-07 2009-04-23 Sumitomo Chemical Company, Limited Epoxy Resin Composition and Cured Epoxy Resin
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
KR101335845B1 (en) * 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 2-aminooxazolines as taar1 ligands
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
US7528131B2 (en) * 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) * 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) * 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) * 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2011005922A (en) * 2008-12-05 2011-06-16 Abbott Lab Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases.
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
RU2539587C2 (en) 2009-01-19 2015-01-20 Эббви Инк. Apoptosis-inducing agents for treating cancer and immune and autoimmune diseases
CN104945311A (en) 2009-01-19 2015-09-30 Abbvie公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2568611C2 (en) 2010-03-25 2015-11-20 Эббви Инк. Apoptosis inducing agents for treating cancer, immune and autoimmune diseases
TWI520960B (en) * 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
RU2387653C2 (en) * 2005-05-16 2010-04-27 Айрм Ллк Compounds and compositions as protein kinase inhibitors
WO2007002325A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580794B2 (en) 2009-05-26 2013-11-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9045475B2 (en) 2009-05-26 2015-06-02 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9174982B2 (en) 2009-05-26 2015-11-03 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9018381B2 (en) 2010-08-06 2015-04-28 Astrazeneca Ab Chemical compounds
US9248140B2 (en) 2010-08-06 2016-02-02 Astrazeneca Ab Chemical compounds
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9840502B2 (en) 2010-11-23 2017-12-12 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9238649B2 (en) 2010-11-23 2016-01-19 Abbvie Inc. Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
US10730873B2 (en) 2010-11-23 2020-08-04 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
JP2018138571A (en) * 2013-03-13 2018-09-06 アッヴィ・インコーポレイテッド Process for the preparation of apoptosis-inducing agent
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2021167330A (en) * 2013-03-14 2021-10-21 アッヴィ・インコーポレイテッド Apoptosis-inducing agents for treatment of cancer and immune and autoimmune diseases
JP2019038820A (en) * 2013-03-14 2019-03-14 アッヴィ・インコーポレイテッド Apoptosis-inducing agents for treatment of cancer and immune and autoimmune diseases
JP2020180145A (en) * 2013-03-14 2020-11-05 アッヴィ・インコーポレイテッド Apoptosis-inducing agents for treatment of cancer and immune and autoimmune diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10426788B2 (en) 2015-03-13 2019-10-01 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
US11718613B2 (en) 2016-08-05 2023-08-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
US10221174B2 (en) 2016-08-05 2019-03-05 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
US11717574B2 (en) 2017-02-22 2023-08-08 Astrazeneca Ab Therapeutic dendrimers
US10314920B2 (en) 2017-02-22 2019-06-11 Astrazeneca Ab Therapeutic dendrimers
US10888624B2 (en) 2017-02-22 2021-01-12 Astrazeneca Ab Therapeutic dendrimers
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
KR20190140910A (en) * 2017-04-18 2019-12-20 상하이 포천 파마슈티컬 씨오 엘티디 Apoptosis-Inducing Agents
US11091478B2 (en) 2017-04-18 2021-08-17 Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
KR102630069B1 (en) 2017-04-18 2024-01-26 포천 파마슈티컬즈, 엘티디. Apoptosis-inducing agent
EP4119560A1 (en) 2017-04-18 2023-01-18 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
RU2782469C2 (en) * 2017-04-18 2022-10-27 Шанхай Фокон Фармасьютикал Ко., Лтд. Apoptosis-inducing agents
AU2018255621B2 (en) * 2017-04-18 2022-03-10 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
US11680072B2 (en) 2017-08-23 2023-06-20 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11279711B2 (en) 2017-08-23 2022-03-22 Newave Pharmaceutical Inc. Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11365206B2 (en) 2017-08-23 2022-06-21 Newave Pharmaceutical Inc. BCL-2 inhibitors
TWI829664B (en) * 2018-01-10 2024-01-21 美商瑞卡瑞恩Ｉｐ控股有限責任公司 Benzamide compounds
US11813260B1 (en) 2018-01-10 2023-11-14 Recurium Ip Holdings, Llc Benzamide compounds
US11813259B2 (en) 2018-01-10 2023-11-14 Recurium Ip Holdings, Llc Benzamide compounds
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
EP3788042A4 (en) * 2018-04-29 2022-01-26 BeiGene, Ltd. Bcl-2 inhibitors
WO2019210828A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 INHIBITORS
WO2020003272A1 (en) 2018-06-29 2020-01-02 Fresenius Kabi Oncology Ltd. An improved process for the preparation of venetoclax
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
US11478470B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
US11478469B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2021009770A1 (en) * 2019-07-12 2021-01-21 Natco Pharma Limited A process for the preparation of venetoclax and its polymorphs thereof
WO2021074769A1 (en) 2019-10-14 2021-04-22 Astrazeneca Ab Combination therapy for treating a hematological malignancy
CN113727719A (en) * 2020-07-17 2021-11-30 德尔塔菲制药股份有限公司 Novel therapeutic method and novel therapeutic agent for leukemia
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer
IT202100025976A1 (en) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combination of active substances for the treatment of acute myeloid leukemia (AML) with nucleophosmin (NPM1) mutation

Also Published As

Publication number Publication date
ECSP12012349A (en) 2013-09-30
SG185638A1 (en) 2012-12-28
JP5667695B2 (en) 2015-02-12
PE20131044A1 (en) 2013-10-20
KR20130116002A (en) 2013-10-22
KR101725114B1 (en) 2017-04-10
PT2576546E (en) 2015-10-28
HK1183866A1 (en) 2014-01-10
DK2576546T3 (en) 2015-11-02
SMT201600015B (en) 2016-02-25
EP2576546B1 (en) 2015-07-22
IL223070A (en) 2016-02-29
US20120190688A1 (en) 2012-07-26
CR20120631A (en) 2013-03-19
NZ603463A (en) 2014-11-28
US20170158666A1 (en) 2017-06-08
ES2546135T3 (en) 2015-09-18
EP2576546A1 (en) 2013-04-10
TW201141860A (en) 2011-12-01
AU2010354083A1 (en) 2012-11-29
UA107706C2 (en) 2015-02-10
IL223070A0 (en) 2013-02-03
US9174982B2 (en) 2015-11-03
PL2576546T3 (en) 2015-12-31
SI2576546T1 (en) 2015-10-30
CA2799280A1 (en) 2011-12-01
MX2012013708A (en) 2013-02-26
CO6640274A2 (en) 2013-03-22
MX350726B (en) 2017-09-14
RU2554346C2 (en) 2015-06-27
US20150329541A1 (en) 2015-11-19
US20140113910A1 (en) 2014-04-24
CL2012003286A1 (en) 2014-02-21
US20130267534A1 (en) 2013-10-10
RS54289B1 (en) 2016-02-29
US20200231566A1 (en) 2020-07-23
US9045475B2 (en) 2015-06-02
TWI501966B (en) 2015-10-01
AU2010354083B2 (en) 2015-02-12
ME02215B (en) 2016-02-20
AR079124A1 (en) 2011-12-28
RU2012156844A (en) 2014-07-10
ZA201208832B (en) 2013-07-31
US20210221789A1 (en) 2021-07-22
JP2013527202A (en) 2013-06-27
CY1116728T1 (en) 2017-03-15
US20140094471A1 (en) 2014-04-03
CN103153993A (en) 2013-06-12
BR112012029923A2 (en) 2017-02-21
CN103153993B (en) 2016-06-01
US20190119247A1 (en) 2019-04-25
US8546399B2 (en) 2013-10-01
DOP2012000297A (en) 2013-01-15
HRP20150925T1 (en) 2015-10-09
US20100305122A1 (en) 2010-12-02
GT201200314A (en) 2014-03-14
MY160994A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
US9174982B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580794B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2016277708B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080068177.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784398

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2799280

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 223070

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10067/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2013512589

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201006121

Country of ref document: TH

Ref document number: 002218-2012

Country of ref document: PE

Ref document number: MX/A/2012/013708

Country of ref document: MX

Ref document number: 2010784398

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010354083

Country of ref document: AU

Date of ref document: 20101122

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CR2012-000631

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12226068

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20127033726

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012156844

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-2015/0643

Country of ref document: RS

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012029923

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012029923

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121123